<SEC-DOCUMENT>0001558370-23-019732.txt : 20231212
<SEC-HEADER>0001558370-23-019732.hdr.sgml : 20231212
<ACCEPTANCE-DATETIME>20231212070053
ACCESSION NUMBER:		0001558370-23-019732
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231212
DATE AS OF CHANGE:		20231212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		231479929

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tmb-20230930x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.5.0.8 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 12/12/2023 2:45:11 AM -->
      <!-- iXBRL Library version: 1.0.8703.18788 -->
      <!-- iXBRL Service Job ID: a881bfd5-ce93-493c-9616-7ced80752e9a -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:epix="http://www.essapharma.com/20230930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" sign="-" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_TrZ4lBb27E2A0GuACyi-aw">0.60</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" sign="-" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_a4Wdv5GQfE61kqdTxTzn1w">0.80</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_7TlkU0AO20-Mh4JJyOiT2w">44089557</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_P17FVeHfbECjABoFyv6khQ">44038241</ix:nonFraction><ix:nonNumeric contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_ap4efqCYWU2Hbn9_bqvWYg">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden_lmzlcV9vjEWol2ZaLP303g">1600</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" sign="-" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden_hGtoKtsILUiP3lfxWLcxPg">111821</ix:nonFraction><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityCentralIndexKey" id="Tc_iGTcOO9sPUezKHfYpeV3Bg_2_1">0001633932</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:DocumentFiscalPeriodFocus" id="Tc_C3ds3pMhaUqBEvelJWWc6g_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:AmendmentFlag" id="Tc_jDhp5s_xEECqj_5wP52BIg_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" id="Hidden_MqSGdzQPEkKOh8Gi7K9I_Q">http://fasb.org/us-gaap/2022#ShortTermInvestments</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" id="Hidden_Kk5qrfMvTE2vUhXl6Q4JEQ">http://fasb.org/us-gaap/2022#ShortTermInvestments</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_89-NsoVFH0O_N3itcj9uow">44073076</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_HkEK9MjWyUuH6gbj3DHx6g">44100838</ix:nonFraction><ix:nonNumeric contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthSanFranciscoOfficeMember_q8gTrDswH0qfe_-3oLWeuA" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Hidden_7lRLzzwpXE2PixIFHj_goQ">P8M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_ilqp4H9x3UeeSj7zg-kL4w">0.00</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_uPwaofhXOUatr_NRDuquTg">0.00</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JDmOjRguN0Kdzie1u0Eb5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAmkRE0UfkGBBqBYDyrB1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1GvOZDpc9kurwGwIRX7X8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cE_1p24JbUqJ-xoUjPgBNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_u3RWCPRxEkqwJwigyugqLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dSbYsOwpaE63kePh-8jz7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_33a8zsLaSk-B2UKpI6UonA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_95yfEfIrOESDv0CcRLcCrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iAza1BQ9g06mhs6rTWFHOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YGXbKtAO4kKDSY4O_EsLzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0AhVVm9dOU2bAEoDagZNuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U1nHSjU-9kq6alVsVAiXcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GZadl9A4R0-GCOCxiuNSXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_XLCr0Xj6H0aNDrwxKDqxqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_pWlgE-YtkE6a1ceHbsbCoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_1IKX4UL6x02-V0ZkVdX6ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_9BP0mMLtwUiCKPlTHk1SXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwelveInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_x5J0Bj22GkOSTsuWEuiR0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_iM029G27tEWSaBRh7eMCuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThirteenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_BVOK3SHXX0WbRyp5MK4RKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_KjLjZYnxOUW1bHNr8qUGxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_nTVq80JJdEeConndZT7hnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7PhtjQKMu0GtgpMqe-anoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_eNYFrBUgOkyeap6Drvlcbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_Z8RH8VRQakCIZEbIjDEjqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_39z0JsHALEOoxiU3ve-ryw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourteenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_KJWT3GdVH0q0Ytfdkc7bPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_H2lt2rM4EkuRKpzFCmU7bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_r_BXr9FtnkCrKXKU8xDMqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_r5PTgGJDcU29voLTSfqxHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceElevenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_cFCRxahqm0OO2m5OxSVtkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_NQ4IZZb2JUG6Ggr4NZOxqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice3.05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_tqxeOLNwukiNCCAewkMiEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.97Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_nFQt8T1RlESSnCiqvgcN4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.91Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_b7SS3eXxTkaoqtw4IRnCyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_leH9ftDSCk-54cm_qblTEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.70Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_bjAYITQVzEWC4LdXfX0KSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_oph37iD120e84jRRKFEFfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_sGuewVdd5Ei7shCy53nuBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwelveInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_tvAsNHy91UG6aiTxFG9cZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_NJOZ1OzFSkq8Ovbj3UzvyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThirteenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_CiW6XcCB7EaHNCJu_Aq1Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_BBOSnkAiwUSXe9gvqshK1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hvdIRMII4U2RBEiyYCqbEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_lVjeFiQ6Ekm7fjJ6XoNSrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_FP7VhhSK3kiyjwb8KXwCug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_arlI8eyiaUyFxwbf3MAH1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_Pvirta9m-0q0bvKX6IdX9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourteenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_1m2P4O_uf06H8eYherHW9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_ovkHbXBRKkiZP-tc8tH0CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_Mju67xWeg0qPdkvGo74miQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_m_PpxKgTgEO101iOVrfx0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceElevenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_45YEp4T3rkaRbQZc8sGXeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_O7Jrtq6Zy0mI4nNJSzPGZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice3.05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_vIjORgSPqUiUIc9dMJFfFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.97Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_zjWTpjhz5Emw7U-GDyTvbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.91Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_x4LeuRkg3EeVAWxunWBKlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_sRBNs2Bp202TAd85J0t1Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.70Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2021_To_9_30_2023_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_us-gaap_PlanNameAxis_epix_LegacyOptionPlanAndRsuPlanMember_V6OYcw6z4ky5o49UbZ6MnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionsAndRsuPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:LegacyOptionPlanAndRsuPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-25</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_12_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hSCrc4kh-k-gCOK-G9Yn7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_n0-uTgmcUUGkCdF3R77kgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kJCtEN0KwUq7roKlGrzIaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionExercisedTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oXvRvCbUM0iIVSZ_bqCa7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionExercisedOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_MIfdcUdEqkGqK0TtOwu9JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ngnJEUWVhEOlVoIyubYBdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_jv1GtGcpZ0q7yIrUUj3bGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_KbenI4q0-UCApoqCAIKAKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthSanFranciscoOfficeMember_q8gTrDswH0qfe_-3oLWeuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">epix:SouthSanFranciscoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember__JFKnEKGe0C4wTHeLj8ODQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_sSMbCtSnJkqpJVr-Lf7Pqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_HocJtCQ_y0aiW3Uavtqtkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:EssaPharmaceuticalsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_S2NPPkKazEK7p8VCK-q5Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_diQtzC8i2UykHgFa4IJSIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_oBr_-pywIkaEsKV63Ewtww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ZDv0kj75JkKg3GXnXPe5gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_48y5HKDd8Ue6FoNx1ErTJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_THqCoUiZjkanSO4NpVc-KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_cJ--xfd0e0C0p7RyafiWnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LeaseOnUsOfficeSpacesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LeaseOnCdnOfficeSpacesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ilrzsfU4sEeAns69HPYjLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e_uffl0eK0idHCR6gU0Cig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9cT9Z1eluEyoPr8TmVwHZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AeJ9w5KQP0qIzR5IqHQARw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_FyoK9yWXWUCxMbtsqkJzCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionsAndRsuPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6mUYISo1eEmc_-LnuL2s_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6XCUQP7JO0WguT4GQ8sEbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OlXqQixrvUur2aI9T8N3gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_i33tUz0BdkGB-UPAxwqTtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_b-IPqnYNFUuNriL48L7_JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_M3oeDgOQYE6eQpxPLzjyHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_o2_4N6z4yU-LaC4B4CfAIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_eK7QF44Iy0SInRW3V5Ougw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_2u163Nw1DkebtudqKBTvFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_aDqpgEkao0qTgIxFls48UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_iovEoELo8UyztRr2wxqLXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_wcftaJxSUUSWCXQKbpxAPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NNI3v2338EuRZLbwXgovnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_-Af7YkvMXkif21idoG044w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4qyYlMrwq0e0DG3Br4Mq3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:EssaPharmaceuticalsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_EfgTWfcorki7QNu4wkVtZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">epix:FinancingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_sF7fPbMdqUqvbTzfsfT_8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">epix:FinancingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_uQe42TT11ESmRCITPgf7Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:TenPercentChangeInForeignExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_S5AnpSsXtEG3ZBTgeWIHtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_pgfyxr43aUaS7J3E2ObeeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_11_2023_mMbu45hweUOoQXPnULm7xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_z0MYX-vw9EWUytYjOXmUkg"><xbrli:measure>epix:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_4JNQuy2SFUWBUQBeaKqunQ"><xbrli:measure>epix:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_CAD_shares_Mjvk30bxUEexejOIshQtIg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55368cd4_4db7_4a46_a2f9_62ff33b8f863"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:DocumentType" id="Narr_FeNMywVaU02dNGLmtpc0Iw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:DocumentAnnualReport" id="Narr_KPrpPx0j7kiMbOUnQCCZ2Q"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9746;</span></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:DocumentPeriodEndDate" id="Narr_a61tDkpvj0WuWKcGAN-w7A"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:CurrentFiscalYearEndDate" id="Narr_RwmOim86aEikJSf8rVHAhg"><b style="font-size:8pt;font-weight:bold;">September 30</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:DocumentFiscalYearFocus" id="Narr_nOg9PYe5WkOsg95rbKRBOg"><b style="font-size:8pt;font-weight:bold;">2023</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:DocumentTransitionReport" id="Narr_NlVmUSP54UiDWq42wdGGrA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">For the transition period from</b><span style="display:inline-block;width:4.46pt;"></span><b style="font-weight:bold;">to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityFileNumber" id="Narr_w5kEHuaBKkySzXlr9Nv4Kw"><b style="font-size:8pt;font-weight:bold;">001-37410</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityRegistrantName" id="Narr_o3KvpwbapkKSybNWmCMydw"><b style="font-weight:bold;">ESSA Pharma&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_aa9e82d9_a7e4_4720_a10a_d5a278cfc3de"></a><a id="Tc_onD1glQ20UiaUNDFZZorvA_1_0"></a><a id="Tc_5L2WR_FzlEy6WHG_QuzJTg_2_0"></a><a id="Tc_lLmgBajSgkasxePFrQw5QQ_2_1"></a><a id="Tc_uVIVU9oAKU-KrNtiXsiitw_3_0"></a><a id="Tc_lSWa4omelkKPl3gLQk9oeA_3_1"></a><a id="Tc_uN8HdMjd3kmDZIhH5Y3jPA_4_0"></a><a id="Tc_c7GhTG4-QkKwwgW6VxSQsA_5_0"></a><a id="Tc_g67Jt2fxuEaiT_UR7e8b0w_6_0"></a><a id="Tc_vfdUARE2cUi6LsttQ4fdqw_7_0"></a><a id="Tc_pjRgZdX1fU28WH40cJRW1g_8_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityIncorporationStateCountryCode" id="Narr_SsczzQXtPUKbWRRT1nQlzQ"><b style="font-size:8pt;font-weight:bold;">British Columbia</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityAddressCountry" id="Narr_zPxJX4JaN0yCcYkiUdp20w"><b style="font-size:8pt;font-weight:bold;">Canada</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityTaxIdentificationNumber" id="Tc_gzY5SJFfqUCe8pA1cZyDCA_1_1"><b style="font-size:8pt;font-weight:bold;">98-1250703</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification Number)</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityAddressAddressLine1" id="Narr_kcE2MGqqoEKAlOmOzVujdw"><b style="font-size:8pt;font-weight:bold;">Suite 720</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityAddressAddressLine2" id="Narr_KDkxsiXrQkCEqAbmO841lQ"><b style="font-size:8pt;font-weight:bold;">999 West Broadway</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityAddressCityOrTown" id="Narr_Uj3sUdyA40-5T99lf4M8yg"><b style="font-size:8pt;font-weight:bold;">Vancouver</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityAddressStateOrProvince" id="Narr_uBy7OwduaE-i9_JtASx3PA"><b style="font-size:8pt;font-weight:bold;">BC</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityAddressPostalZipCode" id="Narr_WLrFF7JCkEWWdGbWB2FtjQ"><b style="font-size:8pt;font-weight:bold;">V5Z 1K5</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including zip code)</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:CityAreaCode" id="Narr_KcBtkjHAGke4H574ugoljg"><b style="font-size:8pt;font-weight:bold;">778</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:LocalPhoneNumber" id="Narr_wxbkbv9tNUGzqVuD_-I7Og"><b style="font-size:8pt;font-weight:bold;">331-0962</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_f7a99698_79f1_42e9_a214_33bce7640f37"></a><a id="Tc_z1TkvlArmkWOuDUGuOzE-g_1_0"></a><a id="Tc_8721PtEFVkuIRR9I43JUqQ_1_2"></a><a id="Tc_8TFd5axsx0yTSyPRrbAN3Q_1_4"></a><a id="Tc_VPf6TY53zEi3u-ZxhLP2QQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:34.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:30.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:Security12bTitle" id="Tc_6vxGaOnYSUSH6ta6BzYXSQ_2_0"><b style="font-size:8pt;font-weight:bold;">Common Shares</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:TradingSymbol" id="Tc_wOcr4wspfUaN09ItbdcstA_2_2"><b style="font-size:8pt;font-weight:bold;">EPIX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:SecurityExchangeName" id="Narr_LYocaDNPV0KQGGS2SHvqzA"><b style="font-size:8pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> Capital Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_5XF9FtYMbUOeO2dlB4sZ8w"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityVoluntaryFilers" id="Narr_RMUe0IlqkUS-jqJr8fEnhA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityCurrentReportingStatus" id="Narr_pAQLpFRpn0atzZl-3gvMUw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> </span><span style="font-size:8pt;">No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityInteractiveDataCurrent" id="Narr_-1CTEsKHRkeZYVbReclWXw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> </span><span style="font-size:8pt;">No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_64fddc81_a108_4818_8135_01cf3842b9f7"></a><a id="Tc_7iQ2g2bz-k6mcOUYkxJaTA_1_0"></a><a id="Tc_7sr196dyc0a4F5WSHr7mzQ_1_1"></a><a id="Tc_Oh6SMtMP_UOTgLhXy0rljQ_1_3"></a><a id="Tc_cc699PVHbECmNs-R5aHjDQ_1_4"></a><a id="Tc_b2vDxndIT0ilASLQaiygNw_2_1"></a><a id="Tc_X0LKv272YEO-4EhvDZDFuw_2_3"></a><a id="Tc_f6c2ZVrQVk2spmxgLycHvA_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityFilerCategory" id="Tc_dwMcQls1WU-oBf_V_fk7Bw_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntitySmallBusiness" id="Tc_1CwGW9LLYUCSuqGpQbOTqA_2_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:EntityEmergingGrowthCompany" id="Tc_9CPSQfESyk-9LTGTxG9A-A_3_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:IcfrAuditorAttestationFlag" id="Narr_zlDx2_-NmEGBUx-by2JRUQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="epix:DocumentFinancialStatementErrorCorrectionFlag" id="Narr_J9EpuGVQF0izlXXHXiORyA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Securities Exchange Act of 1934). Yes </span><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="Narr_XAEErQF8gkqhTk4cbYL1yg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-size:8pt;">No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">The aggregate market value of the voting and non-voting Common Shares held by non-affiliates of the registrant, based on the closing sale price of the registrant&#8217;s Common Shares on the last business day of its most recently completed second fiscal quarter, as reported on the Nasdaq was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_3_31_2023_pgfyxr43aUaS7J3E2ObeeA" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="Narr_Vb_tDBGNrEKco1CxGnn4_Q">78.8</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">The number of outstanding Common Shares of the registrant, no par value per share, as of December 11, 2023, was <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_12_11_2023_mMbu45hweUOoQXPnULm7xQ" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Narr_ny9gWW7yVUG_whLBiziAsA">44,142,088</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a046859d_1437_4c6c_8fc3_d559836e00fe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DOCUMENTS INCORPORATED BY REFERENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Portions of the registrant&#8217;s definitive proxy statement in connection with the registrant&#8217;s 2024 annual meeting of shareholders, which will be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) subsequent to the date hereof, are incorporated by reference into Part&#160;III of this Form&#160;10-K. Such proxy statement will be filed with the SEC not later than 120&#160;days following the end of the registrant&#8217;s fiscal&#160;year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_24a8df43_254d_4dba_a476_ee533aebe8fa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ESSA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORM&#160;10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">For the Fiscal&#160;Year Ended September 30, 2023</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI_971828"><span style="font-style:normal;font-weight:normal;">PART I</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_294150"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_294150"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1A"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1A"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1B"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1B"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Item 1C</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII"><span style="font-style:normal;font-weight:normal;">PART II</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span></a>s</p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7A"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7A"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:AuditorFirmId" id="Narr_cxVphLD7j0SOYExZRM2gWA">731</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_577277"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OPERATIONSANDCOMPREHENSIVELOSS_841542"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CASHFLOWS_242138"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CHANGESINSHAREHOLDERSEQUITY_787925"><span style="font-style:normal;font-weight:normal;">Consolidated Statement of Changes In Shareholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">87</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a1NATUREOFOPERATIONS_101323"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9A"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9A"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9B"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9B"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII"><span style="font-style:normal;font-weight:normal;">PART III</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIV"><span style="font-style:normal;font-weight:normal;">PART IV</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">106</p></td></tr><tr><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_3a4e2dfb_9480_4aaf_909b_57a2f636094e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;text-indent:0pt;text-transform:uppercase;margin:0pt 0pt 6pt 0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">This Annual Report on Form 10-K includes &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and &#8220;forward-looking information&#8221; within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements can often be identified by the use of terminology such as &#8220;subject to&#8221;, &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;hope,&#8221; &#8220;can,&#8221; the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Examples of such forward looking statements include, but are not limited to statements related to:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to advance our product candidate and potential future product candidates through, and successfully complete, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit sufficient numbers of patients for future clinical trials, and the benefits expected therefrom;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain relationships with collaborators with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain funding for operations, including research funding, and the timing and potential sources of such funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, timing, cost, location, progress and success of, strategy and plans with respect to our research and development programs (including research programs and related milestones with regards to next-generation drug candidates and compounds), preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the therapeutic benefits, properties, effectiveness, pharmacokinetic profile and safety of our product candidate and potential future product candidates, if any, including the expected benefits, properties, effectiveness, pharmacokinetic profile and safety of our next-generation Aniten compounds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry, including the success of competing therapies that are or may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the grant (&#8220;CPRIT Grant&#8221;) under the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) and payments thereunder, including any residual obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our Common Shares, no par value (the &#8220;Common Shares&#8221;) under the Open Market Sale Agreement</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> between the Company and Jefferies LLC, effective November 3, 2023 (the &#8220;ATM Sales Agreement&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intended use of proceeds from past and future offerings of our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the implementation of our business model and strategic plans, including strategic plans with respect to patent applications and strategic collaborations and partnerships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify, develop and commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding federal, state, provincial and foreign regulatory requirements, including our plans with respect to anticipated regulatory filings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will receive, and the timing and costs of obtaining, regulatory approvals in the United States, Canada and other jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our product candidate and potential future product candidates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain operations, development programs, preclinical studies, clinical trials and raise capital as a result of global macroeconomic factors including inflation, supply chain issues and any current or future impact related to widespread health concerns, pandemics, or epidemic, and other outbreaks of illness;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance and clinical utility of our potential future product candidates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and our ability and our collaborators&#8217; ability, if any, to obtain and maintain regulatory approvals for our product candidate and potential future product candidates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding market risk, including inflation, interest rate changes and foreign currency fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to engage and retain the employees required to grow our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the compensation that is expected to be paid to our employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our future financial performance and projected expenditures; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates of our financial condition, expenses, future revenue, capital requirements and our need for additional financing and potential sources of capital and funding.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">Such statements reflect our current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including those described under &#8220;Risk Factors&#8221;. All forward-looking statements included in this Annual Report on Form 10-K, are based upon our current expectations and various assumptions. Certain assumptions made in preparing the forward-looking statements include, but are not limited to:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to conduct clinical studies involving our product candidate and to identify any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain regulatory and other approvals to commence clinical trials involving any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain positive results from research and development activities, including clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of sufficient financing on reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain required regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to protect patents and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully out-license or sell future products, if any, and in-license and develop new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the absence of material adverse changes in our industry or the global economy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our continued compliance with third-party license terms and non-infringement of third-party intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain good business relationships with our strategic partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to understand and predict market competition.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">We believe there is a reasonable basis for our current expectations, views and assumptions, but they are inherently uncertain. We may not realize our expectations, and our views and assumptions may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. &#160;In evaluating forward-looking statements, investors should specifically consider the following uncertainties and factors, among others (including those set forth under the heading &#8220;Risk Factors&#8221; within this document), that could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;text-indent:0pt;text-transform:uppercase;margin:6pt 0pt 6pt 0pt;">RISK FACTOR SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">Below is a summary of material factors that make an investment in our Common Shares speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report. The below summary is qualified in its entirety by those more complete discussions of such risks and uncertainties. You should consider carefully the risks and uncertainties described under Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report as part of your evaluation of an investment in our Common Shares. Important factors that could cause such differences include, among other things, the following:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to clinical trial development and our ability to conduct the clinical trial of our product candidate and the predictive value of our current or planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our future success being dependent primarily on identification through preclinical studies, clinical studies, regulatory approval for commercialization of a single product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our license agreement with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainty related to our ability to obtain required regulatory approvals for our proposed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the Company&#8217;s ability to conduct a clinical trial or submit a future NDA/NDS or IND/CTA (each, as defined herein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to successfully commercialize future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the possibility that our product candidate and potential future product candidates, if any, may have undesirable side effects when used alone or in combination with other drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to enroll subjects in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks that the FDA may not accept data from trials conducted in locations outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ongoing obligations and continued regulatory review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to potential administrative or judicial sanctions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk of increased costs associated with prolonged, delayed or terminated clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to clinical trials being conducted by third parties under collaboration and clinical supply agreements, including combination studies, using the Company&#8217;s product candidate, studies which the Company may not control, and ensuing reputational risk related to clinical trial results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that third parties may not carry out their contractual duties or terminate the relationship;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our lack of experience manufacturing product candidates on a large clinical or commercial scale and our lack of manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks inherent in foreign operations, including related to foreign sourced raw materials, manufacturing or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to disruptions in domestic and foreign supply chains that the Company relies on for the production and shipment of raw materials and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our failure to obtain regulatory approval in international jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to recently enacted and future legislation in the United States and internationally that may increase the difficulty and cost for us to obtain marketing approval of, and commercialize, our product candidate and potential future products, if any, and affect the prices we may obtain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to new legislation, new regulatory requirements, and the continuing efforts of governmental and third-party payors to contain or reduce the costs of healthcare;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainty as to our ability to raise additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to raise additional capital on favorable terms and the impact of dilution from incremental financing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks of a deemed default on any residual obligations of the agreement providing for the CPRIT Grant and having to reimburse all of the CPRIT Grant, if such deemed default is not waived by CPRIT;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our incurrence of significant losses in every quarter since inception and our anticipation that it will continue to incur significant losses in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our limited operating history;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our reliance on proprietary technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to protect our intellectual property rights throughout the world;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to claims by third parties asserting that we, or our employees, contractors or consultants have misappropriated their intellectual property, or claiming ownership of what we regard as our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to comply with governmental patent agency requirements in order to maintain patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to computer system failures or security breaches and increasing cyber threats;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to business disruptions that could seriously harm our future revenues and financial condition and increase our costs and expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to attract and maintain highly qualified personnel;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks relating to the possibility that third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to potential conflicts of interest between us and our directors and officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to competition from other biotechnology and pharmaceutical companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to movements in foreign currency exchange rates, interest rates and rate of inflation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to convince public payors and hospitals to include our product candidate and potential future products, if any, on their approved formulary lists;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to manage growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to achieve or maintain expected levels of market acceptance for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to realize benefits from acquired businesses or products or form strategic alliances in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to collaborations with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks that employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to product liability lawsuits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to compulsory licensing and/or generic competition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the costs of and management time devoted to operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to being a smaller reporting company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the possibility that laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and Canada and require us to develop and implement costly compliance programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to laws that govern fraud and abuse and patients&#8217; rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to comply with environmental, health and safety laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to us being a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;passive foreign investment company&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to United States investors&#8217; ability to effect service of process or enforcement of actions against us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to market price and trading volume volatility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our dividend policy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with future sales of our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to maintain an active trading market for the Company&#39;s Common Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to widespread health concerns, pandemics, or epidemics and other outbreaks of illness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our ability to implement and maintain effective internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to provisions in our charter documents and Canadian law affecting corporate governance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to analyst coverage.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">If one or more of these risks or uncertainties or a risk that is not currently known to us, materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from those expressed or implied by forward-looking statements. The forward-looking statements represent our expectations, plans, estimates and views as of the date of this document. We do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events, except as required by law. &#160;Investors are cautioned that we cannot guarantee future results, events, levels of activity, performance or achievements and that forward-looking statements are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. We advise you that these cautionary remarks expressly qualify in their entirely all forward-looking statements attributable to us or persons acting on our behalf.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">We express all amounts in this Annual Report on Form 10-K in U.S. dollars, except where otherwise indicated. References to &#8220;$&#8221; and &#8220;US$&#8221; are to U.S. dollars and references to &#8220;C$&#8221; are to Canadian dollars. Except as otherwise indicated, references in this Annual Report on Form 10-K to &#8220;ESSA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ESSA Pharma Inc. and its subsidiary.</p><a id="_Toc75278512"></a><a id="_77d017e3_880c_45c6_ae27_22b18da583dc"></a><a id="PARTI_971828"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART I</p><a id="_Toc75278513"></a><a id="Item1Business_294150"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Item 1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Business</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">ESSA is a clinical stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer with a primary focus on patients whose disease is still predominantly driven by the androgen axis. ESSA&#8217;s development of proprietary small molecule inhibitors of the N-terminal domain (&#8220;NTD&#8221;) of the androgen receptor (&#8220;AR&#8221;) is focused on the treatment of these patients in combination with second-generation antiandrogen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. The Company believes its latest series of investigational compounds, including its product candidate masofaniten (formerly known as EPI-7386), have the potential to significantly expand the interval of time in which patients with earlier stage prostate cancer can benefit from anti-hormone-based therapies. Specifically, the compounds are designed to disrupt the androgen receptor AR signaling pathway, the primary pathway that drives prostate cancer growth and prevent AR activation through selective binding to the NTD of the AR. In this respect, the Company&#8217;s compounds differ mechanistically from classical non-steroid antiandrogens. These classic antiandrogens interfere either with androgen synthesis (i.e., abiraterone), or with the binding of androgens to the ligand-binding domain (&#8220;LBD&#8221;), located at the opposite end of the receptor from the NTD (i.e., &#8220;lutamides&#8221;). A functional NTD is essential for the functionality of the AR; blocking the NTD inhibits AR-driven transcription and therefore androgen-driven biology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">The Company believes that the transcription inhibition mechanism of its preclinical compounds is unique and has the potential advantage of bypassing several of the identified mechanisms of resistance to the antiandrogens currently used in the treatment of castration-resistant prostate cancer (&#8220;CRPC&#8221;). The Company has been granted by the United States Adopted Names (&#8220;USAN&#8221;) Council a unique USAN stem &#8220;-Aniten&#8221; to recognize this new first-in-class mechanistic class. The Company refers to this series of proprietary investigational compounds as the &#8220;Aniten&#8221; series. In preclinical studies, blocking the NTD has demonstrated the capability to prevent AR-driven gene expression. A previously completed Phase 1 clinical trial of ESSA&#8217;s first-generation agent, ralaniten acetate (&#8220;EPI-506&#8221;) administered to patients with metastatic CRPC (&#8220;mCRPC&#8221;) refractory to current standard of care therapies demonstrated prostate-specific antigen (&#8220;PSA&#8221;) declines, a sign of inhibition of AR-driven biology. This inhibition, however, was neither deep nor sustained enough to confer clinical benefit and the Company made the decision to develop a more potent next generation drug which would also have a longer half-life. &#160;The Company has done so and is now in clinical trial with this next generation Aniten, masofaniten (EPI-7386), focusing on the treatment of earlier stage, more homogeneously androgen-driven tumors, in combination with one or another of the current latest generation classic antiandrogens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">According to the American Cancer Society, in the United States, prostate cancer is the second most frequently diagnosed cancer among men, behind skin cancer. Approximately one-third of all prostate cancer patients who have been treated for local disease with curative intent will subsequently have rising serum levels of PSA, which is an indication of recurrent &#160;disease with or without development of distant metastasis. Patients with recurrent disease as indicated by rising PSA or nodal or bone metastasis usually undergo initial androgen ablation therapy using analogues of luteinizing hormone releasing hormone or surgical castration; this approach is termed &#8220;androgen deprivation therapy&#8221; (&#8220;ADT&#8221;). Most of these patients initially respond to ADT; however, many experience a recurrence in tumor growth despite the reduction of testosterone to castrate levels, and at that point are considered to have CRPC. Following diagnosis of CRPC, patients have been generally treated with antiandrogens that block the binding of androgens (enzalutamide) to the AR, or inhibit synthesis of androgens (abiraterone). More recently, significant improvements in progression free survival and overall survival have been achieved by utilizing this latest generation of antiandrogens in combination with ADT earlier in the disease natural history (i.e., metastatic hormone-sensitive prostate cancer (&#8220;mHSPC&#8221;) and non-metastatic castration-resistant prostate cancer (&#8220;nmCRPC&#8221;)).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since the mid-20th century, it has been recognized that the growth of prostate tumors is in large part mediated by an activated AR. Generally, there are three means of activating the AR. First, androgens, such as dihydrotestosterone can activate AR by binding to its LBD. Second, CRPC can be driven by variants of AR that lack an LBD, are constitutively activated, and consequently do not require androgen for activation. A third mechanism, of less certain clinical significance, may involve certain signaling pathways that activate AR independent of androgen activity. &#160;Generally, current drugs for the treatment of prostate cancer are directed against the first mechanism by either (i) interfering with the production of androgen, or (ii) preventing androgen from binding to the LBD. Over time, these approaches eventually fail due to mechanisms of resistance which involve the LBD end of the receptor, whether at the DNA (AR amplification or LBD mutations) or RNA level (emergence of AR splice variants). With respect to the development of alternative pathway mechanisms of AR activation, tumors may also become insensitive to antiandrogen activity. Finally, in patients who have been treated for years with various antiandrogen therapies, genomic changes may lead to additional, non-AR-related oncogenic drivers, also insensitive to inhibition of AR biology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company believes that through their potential to block androgen-driven gene transcription by using a unique mechanism involving the NTD and thereby bypassing these known mechanisms of resistance to current antiandrogens, the Aniten series of compounds hold the potential to be effective in cases where LBD-based mechanisms of resistance to second generation antiandrogens in otherwise AR-driven disease are operating. The results from both extensive preclinical studies and the initial clinical experience support the Company&#8217;s belief. In preclinical studies, the Aniten series of compounds has been observed to shrink AR-dependent prostate cancer xenografts, including tumors both sensitive and resistant to the second-generation antiandrogens, such as enzalutamide. Plasma PSA level declines and increases in PSA doubling time as well as declines in circulating tumor DNA and decreases in radiographic tumor measurements were observed in a subset of patients enrolled in the Phase 1 study of masofaniten (EPI-7386) as described below. &#160;Importantly with respect to the potential clinical application of NTD inhibition during the natural history of the disease, recent studies by the Company and its collaborators have also suggested the potential advantage for combinations of the Company&#8217;s Aniten compounds with currently approved antiandrogens to inhibit AR-driven biology more completely than AR inhibition from either end of the receptor alone. This hypothesis is supported by the clinical trial results obtained in recent years of the superior overall survival obtained in the hormone-sensitive prostate cancer (&#8220;HSPC&#8221;) setting by combining ADT and latest generation antiandrogens earlier in the course of the disease versus the administration of these two therapies sequentially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the potential importance of the NTD as a drug target has been appreciated for more than two decades, for technical reasons this has been a difficult target for therapeutic agent development.&#160; The NTD of the AR is flexible with a high degree of intrinsic disorder making it difficult for use in classic crystal structure-based drug design. The Company is not currently aware of any clinical-stage NTD AR inhibitors that are in development by other drug development companies. The nature of the highly specific binding of the Aniten compounds to the NTD, and the biological consequences of that binding, have been defined in scientific studies. The selectivity of the binding, based on <i style="font-style:italic;">in vivo</i> imaging as well as <i style="font-style:italic;">in vitro</i> studies, has been consistent with the favorable toxicological results observed in preclinical studies of the first-generation EPI-506 and the subsequent safety results observed in the Phase 1 trial of EPI-506.&#160; Subsequent to this trial and following the decision to pursue masofaniten (EPI-7386) as the Company&#8217;s lead product candidate, the Company completed a series of biophysical and biological studies revealing the interaction and binding of masofaniten (EPI-7386) to the NTD of the AR and presented these findings at several medical conferences in 2021.&#160; See &#8220;Completed Phase 1 Clinical Study of EPI-506&#8221; and &#8220;Next generation Aniten molecules&#8221; below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The incidence of both metastatic and non-metastatic CRPC continues to rise. Using a dynamic progression model, Scher et al.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> projected a 2020 incidence of 546,955 and prevalence of 3,072,480. The Company believes that the Aniten series of compounds could ultimately hold potential benefit for many of those patients. In its early clinical development, the Company focused on patients who have failed second-generation antiandrogen therapies (i.e. abiraterone and/or lutamides) for the following reasons:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CRPC treatment remains a prostate cancer market segment with an apparent and significant unmet therapeutic need and is a potentially large market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company believes that the unique mechanism of action of its Aniten compounds is well suited to treat those patients who have failed AR LBD focused therapies and whose biological characterization reveals that their tumors are still largely driven by AR biology; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company expects that the relatively large number of patients with an apparent unmet therapeutic need in this area will facilitate timely enrollment in its clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company believes that the demonstration of favorable safety and tolerability in the initial Aniten Phase 1 clinical trial, together with the compelling preclinical rationale, enabled and emphasized the importance of the study of the combination of masofaniten (EPI-7386) with second-generation antiandrogens. Furthermore, the Company believes that this application of two independent, complementary mechanisms of AR transcription inhibition may result in greater suppression of androgen activity and the delay or prevention of drug resistance. Recent progress in the clinical treatment of prostate cancer has resulted from the earlier utilization of antiandrogens in combination with classic ADT, consistent with the premise that more effective androgen suppression may yield clinical benefit. The Company believes that the introduction of NTD inhibitors, such as masofaniten (EPI-7386), therefore has the potential to improve androgen suppression, delay the emergence of resistance, and result in improved clinical benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Completed Phase 1 Clinical Study of EPI-506</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company conducted an initial proof-of-concept Phase 1 clinical study utilizing the first-generation Aniten compound, EPI-506 from 2015 to 2017. The objective of the EPI-506 Phase 1 clinical trial was to explore the safety, tolerability, maximum tolerated dose and pharmacokinetics of EPI-506, in addition to anti-tumor activity in asymptomatic or minimally symptomatic patients with mCRPC who were no longer responding to either abiraterone or enzalutamide treatments, or both. Efficacy endpoints, such as PSA reduction, and other disease progression criteria were evaluated. Details relating to the design of the Phase 1/2 clinical trial of EPI-506 are available on the U.S. National Institutes of Health clinical trials website (see https://clinicaltrials.gov under identifier NCT02606123).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Investigational New Drug (&#8220; IND&#8221;) application to the FDA for EPI-506, to begin a Phase 1 clinical trial was allowed in September&#160;2015, with the first clinical patient enrolled in November&#160;2015. The Company&#8217;s Clinical Trial Application (&#8220;CTA&#8221;) submission to Health Canada was subsequently also cleared. Based on allometric scaling, an initial dose level of EPI-506 of 80 mg was determined. However, following the enrollment of the initial cohorts, it became apparent that EPI-506 exposure was much lower in humans than projected. EPI-506 dosing was escalated aggressively to allow patients in the clinical study greater exposure to the drug. The highest dose patients ultimately received was 3600 mg of EPI-506, administered in a single dose or split into two doses daily. The initial data from the Phase 1 clinical trial was presented at the European Society of Medical Oncology meeting in September&#160;2017.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup><span style="display:inline-block;width:14.75pt;"></span>Scher HI, Solo K, Valant J, Todd MB, Mehra M (2015) Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE 10(10): e0139440. doi:10.1371/journal.pone.013944</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Conducted at five sites in the United States and Canada, the open-label, single-arm, dose-escalation study evaluated the safety, pharmacokinetics, maximum-tolerated dose and anti-tumor activity of EPI-506 in men with end-stage mCRPC who had progressed after prior enzalutamide and/or abiraterone treatment and who may have received one prior line of chemotherapy. Twenty-eight patients were available for analysis, with each patient having received four or more prior therapies for prostate cancer at the time of study entry. Patients self-administered oral doses of EPI-506 ranging from 80 mg to 3600 mg, with a mean drug exposure of 85&#160;days (range of eight to 535&#160;days). Four patients underwent prolonged treatment (with a median of 318&#160;days, and a range of 219 to 535&#160;days at data cut-off), following intra-patient dose escalation. PSA declines, a measure of potential efficacy, ranging from 4% to 37% were observed in five patients, which occurred predominantly in the higher dose cohorts (&#8805;1280 mg).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">EPI-506 was generally well-tolerated with favorable safety results observed across all doses up to 2400 mg. At a dose of 3600 mg, gastrointestinal adverse events (nausea, vomiting and abdominal pain) were observed in two patients: one patient in the once-daily (&#8220;QD&#8221;) dosing cohort and one patient in the 1800 mg twice-daily dosing cohort, leading to study discontinuation and a dose-limiting toxicity (&#8220;DLT&#8221;) due to more than 25% of doses being missed in the 28-day safety reporting period. A separate patient in the 3600 mg QD cohort experienced a transient Grade 3 increase in liver enzymes (AST/ALT), which also constituted a DLT, and enrollment was consequently concluded in this cohort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that the safety results and possible signs of anti-tumor activity observed at higher dose levels support the concept that inhibiting the AR-NTD may provide a clinical benefit to mCRPC patients, the pharmacokinetic and metabolic studies revealed the limitations of the first generation agent EPI-506. &#160;Through its discovery research, the Company had concluded that it should be feasible to develop a next generation of NTD inhibitor which would demonstrate greater potency, reduced metabolism and other improved pharmaceutical properties. As a result, the Company announced on September&#160;11, 2017, its decision to discontinue the further clinical development of EPI-506 and to implement a corporate restructuring plan to focus research and development resources on its next-generation Anitens targeting the AR-NTD. This next generation aniten compound includes significantly more potent drugs designed to exhibit increased resistance to metabolism and therefore a longer predicted circulating half-life. The Company&#8217;s lead product candidate masofaniten (EPI-7386) has demonstrated these and other favorable characteristics in extensive preclinical characterization and clinical studies which the Company has presented in a series of poster presentations at scientific meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Next generation Aniten molecules</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s family of next-generation investigational Aniten compounds incorporate multiple chemical scaffold changes to the first-generation drugs which in preclinical studies retain NTD inhibition of the AR. In addition, they have shown improvement in a range of attributes when compared to the first-generation compound, EPI-506, in preclinical studies. In <i style="font-style:italic;">in vitro</i> assays measuring inhibition of AR transcriptional activity, these product candidates demonstrated 20 times higher potency than EPI-506 or its active metabolite, EPI-002. In addition, the compounds have demonstrated increased metabolic stability in preclinical studies, suggesting the potential for longer half-lives in humans. Lastly, the compounds have demonstrated more favorable pharmaceutical properties relative to EPI-506. The Company believes that these product candidates, if successfully developed and approved, may offer advancements in ease and cost of large-scale manufacture, drug product stability, and suitability for commercialization globally. Of these next-generation anitens, masofaniten (EPI-7386) was selected for IND filing and a Phase 1 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In developing possible therapeutics that involve binding to the NTD, the Company&#8217;s strategic approach involves:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">combining aniten compounds with second generation antiandrogens in earlier lines of therapy. The Company, with industry partners, has been conducting clinical trials of combinations of masofaniten (EPI-7386) and second-generation antiandrogens in patients with nmCRPC, mCRPC, mHSPC and neo-adjuvant prostate cancer surgical therapy in earlier lines of treatment; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing the initial Phase 1 clinical development of masofaniten (EPI-7386) as a monotherapy treatment for patients with mCRPC, who are resistant to the current standard of care, to demonstrate the drug&#8217;s characteristics </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as a single agent as completely as possible, with regards to safety, tolerability, and efficacy together with detailed pharmacological and biological studies. The Company&#8217;s assessment of this clinical data will determine the Company&#8217;s clinical development of masofaniten (EPI-7386) as a single agent therapy and also as a combination therapy, whilst considering the impact of such treatment against the size of the patient population whose tumors have progressed and are prevalently driven by the AR pathway despite heavy pre-treatment of the latest generation antiandrogens; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing preclinical studies, including work on other Aniten molecules, NTD degraders and other potential applications for AR NTD inhibitors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The identification and characteristics of masofaniten (EPI-7386)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The purpose of the next-generation program has been to identify drug candidates with increased potency, reduced metabolic susceptibility and superior pharmaceutical properties compared to ESSA&#8217;s first-generation compounds. Structure-activity relation studies conducted on the chemical scaffold of ESSA&#8217;s first-generation compounds have resulted in the generation of a new series of compounds that have demonstrated higher potency and predicted longer half-lives. Multiple changes in the chemical scaffold have also been incorporated with the goal of improving ADME (absorption, distribution, metabolism, and excretion) and pharmaceutical properties of the chemical class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Several next-generation Aniten molecules met prespecified preclinical target product profile goals regarding potency, stability, selectivity and pharmaceutical properties. On March&#160;26, 2019, the Company announced the nomination of masofaniten (EPI-7386) as its lead clinical candidate for the treatment of mCRPC through inhibition of the NTD of the androgen receptor. In preclinical studies, masofaniten (EPI-7386) has displayed activity <i style="font-style:italic;">in vitro</i> in numerous AR-dependent prostate cancer models including models where second-generation antiandrogens are inactive. In addition, masofaniten (EPI-7386) is significantly more potent, metabolically stable and more effective in preclinical studies compared to ESSA&#8217;s first-generation compound, EPI-506. Lastly, masofaniten (EPI-7386) has demonstrated a favorable tolerability profile in all animal studies of the compound conducted to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From this series of next-generation compounds, masofaniten (EPI-7386) was selected as the lead candidate for the initial clinical development in mCRPC. An IND was submitted to the FDA on March 30, 2020, and was allowed by the FDA on April 30, 2020. A CTA was filed with Health Canada in April 2020 and clearance was subsequently received. Clinical testing of masofaniten (EPI-7386) commenced in July 2020, allowing for accommodations to the planned timeline as a result of the impact of COVID-19 at clinical trial sites (see &#8220;Risk Factors&#160;&#8211; Widespread health concerns, pandemics or epidemics, and other outbreaks of illness may negatively affect the Company&#8217;s ability to maintain operations and execute its business plan&#8221; in this Annual report on Form 10-K).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:204pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Advancing masofaniten (EPI-7386) through clinical development </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is advancing masofaniten (EPI-7386) through two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010. The clinical trial of EPI-7386-CS-001 has two arms that each represent a monotherapy and combination component of the study schema, as outlined below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20230930x10k002.jpg" alt="Graphic" style="display:inline-block;height:203.75pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:455.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Notes: &#8220;mCRPC&#8221; means metastatic castration-resistant prostate cancer; &#8220;AAP&#8221; means abiraterone acetate/prednisone; &#8220;mHSPC&#8221; means metastatic hormone-sensitive prostate; &#8220;nmCRPC&#8221; means non-metastatic castration-resistant prostate cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The clinical trial of EPI-7386-CS-010 is a combination trial with enzalutamide with a Phase 1 dose equilibration component and Phase 2 head-to-head comparison component, as outlined in the study schema below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><img src="tmb-20230930x10k003.jpg" alt="Graphic" style="display:inline-block;height:144.2pt;width:463.55pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;">Notes: &#8220;ENZ&#8221; means enzalutamide</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Phase 1 Clinical Trial - EPI-7386-CS-001- Monotherapy Treatment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Phase 1 clinical trial of masofaniten (EPI-7386) &#8220;Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer (EPI-7386)&#8221; is currently actively enrolling nmCRPC patients na&#239;ve to second generation antiandrogens and mCRPC patients who are refractory to standard of care treatments at clinical sites in the U.S. and Canada (www.clinicaltrials.gov under identifier NCT04421222). In September 2021, the Company amended the protocol to allow testing in the Phase 1a for a 800 mg/day and 1200 mg/day dosages, administered as either 400 mg or 600 mg dosed twice daily (&#8220;BID&#8221;), respectively. In addition, the protocol amendment focused further monotherapy development in less heavily pretreated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">patients with mCRPC, i.e., patients who have received a maximum of three prior approved systemic therapies for mCRPC, including at least one second-generation antiandrogen and excluded patients with visceral metastasis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Part A Monotherapy - Phase 1a &#8211; Dose Escalation </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The open-label, dose-escalation Phase 1a clinical trial was designed to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose and/or a recommended Phase 2 range of doses in line with the FDA&#8217;s Project Optimus, and to access preliminary anti-tumor activity of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The design of the Phase 1 clinical trial included the standard 3+3 design per dose cohort for the Part 1a dose escalation phase, with subjects receiving a daily oral dose of masofaniten (EPI-7386) once a day QD until there is objective evidence of clinical disease progression, and or occurrence of an unacceptable toxicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The dose escalation Part 1a of the study has completed enrollment. Patients enrolled in the Part 1a of the study were selected clinically, on the basis of having progressive mCRPC as exemplified by rising PSA values and/or radiological disease progression despite latest generation antiandrogen treatment. However, all patients were also retrospectively biologically characterized for underlying tumor genomic characteristics, for evidence of AR pathway activation as well as non-AR oncogenic pathways and during the conduct of the trial, for dose-related biological, pharmacological and pharmacodynamic effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The protocol amendments filed with the FDA in September 2021 and July 2022 allow for monotherapy development in less heavily pretreated patients (as described above) in whom the androgen receptor pathway is more likely to be the primary driver of tumor growth. The Company&#8217;s goal has been to establish, one or more doses/schedules to be tested in the expansion Phase 1b study in alignment with the FDA Project Optimus guidance, based on multiple inputs, including pharmacokinetic and biological observations, in addition to clinical experience. Two dose levels have been advanced to Phase 1b dose expansion testing: 600 mg QD and 600 mg BID. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">Part A Monotherapy &#8211; Phase 1b  &#8211; Dose Expansion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The primary objective of Phase 1b is to further evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity (as measured by changes in tumor burden measured by imaging and changes in PSA levels over time) of masofaniten (EPI-7386) at 600 mg BID and 600 mg QD in a patient population enrolled under eligibility criteria similar to the one adopted for the Phase 1a with a focus on chemo-na&#239;ve mCRPC patients whose diseases have progressed after two lines of treatment including at least one line of second-generation antiandrogens. The 600 mg BID cohort of 12 patients has been fully enrolled and the 600 mg QD cohort of 12 patients is enrolling. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Demonstration of the favorable safety and tolerability profile of masofaniten (EPI-7386) in the Phase 1a, together with clinical evidence for its mechanism of action and efficacy, were necessary to enable the study of patient populations with less advanced and less heavily pre-treated prostate cancer. The experience in the initial Phase 1a trial provided evidence for both an antiandrogen biological effect as well as some level of clinically relevant anti-tumor activity. The biological characterization of these patients also demonstrated favorable safety profiles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s preclinical data and other evidence suggest earlier patient populations are more homogeneously AR-driven, and the favorable safety profile demonstrated in the Phase 1a dose escalation trial justified the study of the combination of masofaniten (EPI-7386) with classic antiandrogens. As a result the Company, together with its collaborators, are conducting a series of clinical trials in this regard. The first Phase 1/2 study involves masofaniten (EPI-7386) evaluated in combination with enzalutamide in patients with mCRPC na&#239;ve to second generation antiandrogens. Additional clinical trials involving the combination of masofaniten (EPI-7386) with apalutamide, abiraterone acetate, or darolutamide are in various stages of implementation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Combination studies &#8211; developing a new standard of care for the treatment of prostate cancer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An activated AR is required for the growth and survival of most prostate cancer. Unlike current antiandrogen therapies which can only inhibit full-length AR, NTD inhibition of AR-directed biology occurs both in full length AR and splice </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">variant ARs. Therefore, the Company believes that the AR-NTD is an ideal target for next-generation antiandrogen hormone therapy. If masofaniten (EPI-7386) is successful in treating CRPC patients, it is reasonable to expect that such clinical candidate may be effective in treating earlier stage patients. Preclinical studies suggest particular value to the use of Anitens in combination with the currently widely used second-generation antiandrogens. The Company is conducting clinical trials in line with this strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Clinical Trial &#8211; EPI-7386-CS-010 &#8211; Combination Treatment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has been running a Phase 1/2 study of masofaniten (EPI-7386) in combination with enzalutamide compared with enzalutamide alone in patients with mCRPC. Phase 1 of the study is a single-arm dose escalation study of masofaniten (EPI-7386) in combination with a fixed dose of enzalutamide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A collaboration and supply agreement with Astellas Pharma Inc. (&#8220;Astellas&#8221;) to evaluate masofaniten (EPI-7386) in combination with Astellas and Pfizer Inc.&#8217;s (&#8220;Pfizer&#8221;) AR inhibitor, enzalutamide, in patients with mCRPC was announced on February 24, 2021. ESSA is paying for and is operationally conducting this trial, with an initial Phase 1 dose equilibration followed by a randomized Phase 2 trial involving a planned 120 patients. The enzalutamide for this trial is supplied by Astellas. The first patient in this Phase 1/2 study was dosed in January 2022 and the safety, tolerability, pharmacokinetics, and initial PSA responses were originally reported in the June 2022 clinical update in poster presentations at the Prostate Cancer Foundation Retreat in October 2022 and the American Society of Clinical Oncology Genitourinary Cancers Symposium in February 2023. The clinical trial is a two part study: a Phase 1 dose equilibration stage followed by a Phase 2 open label randomized study. Masofaniten (EPI-7386) is being evaluated at escalating dose levels including 600 mg QD, 800 mg QD and 600 mg BID in combination with 120 mg and 160 mg enzalutamide in patients with mCRPC na&#239;ve to second generation antiandrogens. The Phase 1 part of the study has completed enrollment and the recommended Phase 2 combination doses for the Phase 2 randomized phase is 600 mg BID masofaniten (EPI-7386) with 160 mg enzalutamide (the highest dose levels tested).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Clinical Trial &#8211; EPI-7386-CS-001 &#8211; Combination Treatment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first collaboration, with Janssen Research &amp; Development, LLC (&#8220;Janssen&#8221;), to study in clinical trials the safety and potential benefit of the combination of masofaniten (EPI-7386) with abiraterone acetate with prednisone as well as the combination of masofaniten (EPI-7386) with apalutamide in patients with mCRPC, was announced on January 13, 2021. Under the collaboration agreement with Janssen, Janssen would pay for and conduct a clinical trial with masofaniten (EPI-7386) and in separate cohorts each of their antiandrogens, apalutamide and abiraterone acetate. This combination trial was initiated in March 2022. Enrollment was suspended by Janssen in October 2022 due to operational recruitment challenges. On April 12, 2023, ESSA announced that it had entered into a clinical trial support agreement with Janssen, with ESSA paying for and conducting a study of the combinations, in an earlier patient population, and with Janssen supplying apalutamide and abiraterone acetate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s most recent protocol amendment in June 2023, modifies the protocol design of this study by adding combination treatment with second-generation antiandrogens. Specifically, the amended protocol consists of two parts: a Part A Monotherapy study and a Part B Combination study. Part A has two phases: a Phase 1a Dose Escalation and a Phase 1b Dose Expansion, as discussed above, with Part B conducted in two cohorts, Cohort 1 evaluating masofaniten (EPI-7386) in combination with abiraterone acetate/prednisone for patients with mHSPC or mCRPC who receive abiraterone acetate/prednisone as part of their standard of care treatment and Cohort 2, previously the &#8220;window of opportunity cohort&#8221;, evaluating single agent masofaniten (EPI-7386) for 12 weeks in patients with nmCRPC before apalutamide is added.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Part B Combination &#8211; Cohort 1 &#8211; Combination with abiraterone acetate/prednisone</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company will evaluate the combination of masofaniten (EPI-7386) with abiraterone acetate/prednisone (AAP) in patients with mHSPC or mCRPC. AAP will be provided by Janssen under a clinical trial support agreement as described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Part B Combination - Cohort 2 &#8211; Window of opportunity with clinical endpoints followed by combination with apalutamide </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The primary objective of Cohort 2 is to assess the anti-tumor activity (as measured by changes of PSA over time) of masofaniten (EPI-7386) administered at 600 mg BID for a limited window of time (up to 12 weeks before patients start standard of care therapy) in nmCRPC patients whose disease is unperturbed by previous second-generation antiandrogen therapies or chemotherapy. Following the dosage of masofaniten (EPI-7386) as a single agent after the 12-week window, the Company will evaluate the combination of masofaniten (EPI-7386) with apalutamide. Apalutamide will be provided by Janssen under the same clinical trial support agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the agreements announced with Pfizer, and Janssen, a third collaboration has been announced with Bayer. Bayer will pay for and conduct a Phase 1/2 clinical trial with masofaniten (EPI-7386) to evaluate masofaniten (EPI-7386) in combination with darolutamide in earlier line mCRPC patients. ESSA will provide masofaniten (EPI-7386) for the combination trial. This clinical trial has not yet been initiated. The Company continues to evaluate potential collaborations that could enhance the value of its prostate cancer program and allow it to leverage the expertise of such strategic collaborators such as those with Janssen, Astellas, and Bayer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Preclinical Development of Anitens, Degraders, and other indications</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of the continued preclinical work on Aniten compounds, the Company has also studied NTD degraders and presented data for its first generation of AR ANITAC NTD degraders at the AACR annual meeting on April 10, 2022, in a poster titled &#8220;Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models&#8221;. The Company continues preclinical work on other emerging potential clinical applications for NTD inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has presented preclinical and clinical scientific data relative to masofaniten (EPI-7386) in a number of presentations at scientific meetings and other forums. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">2023</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 26-28, 2023<i style="font-style:italic;">, </i>the Company presented updated dose escalation data from its Phase 1/2 study evaluating masofaniten (EPI-7386) in combination with enzalutamide at the 30th Annual Prostate Cancer Foundation Scientific Retreat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The data presented were from the four cohorts of patients in the Phase 1 dose escalation portion of the study. The data indicated that masofaniten (EPI-7386) had no effect on enzalutamide exposure, thus allowing the use of full dose per label (160mg) of enzalutamide in combination. It also indicated that enzalutamide reduces masofaniten (EPI-7386) exposure but twice daily dosing of masofaniten (EPI-7386) appears to mitigate the reduction and maintains clinically relevant drug exposures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In patients evaluable for safety (n=18), masofaniten (EPI-7386) combined with enzalutamide, was well-tolerated at the doses tested through 21 cycles of dosing in some patients. The most frequent adverse events were Grade 1 and 2, related to either AR inhibition or gastrointestinal tract irritation. In Cohort 4, one patient experienced a Grade 3 rash, which was observed immediately following administration of masofaniten (EPI-7386) combined with enzalutamide and deemed probably related.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the patients evaluable for efficacy (n=16), rapid, deep and durable reductions in PSA were observed, regardless of previous chemotherapy status, including in patients who received lower than the full dose of enzalutamide (120 mg). In the first three cohorts, 90% of patients (9 of 10) achieved PSA50 and PSA90, 80% of patients (8 of 10) achieved PSA90 in less than 90 days, and 70% of patients (7 of 10) achieved PSA &lt;0.2ng/mL. Across all dose cohorts including patients in the recently enrolled Cohort 4, 88% of patients (14 of 16) achieved PSA50, 81% of patients (13 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 days, and 56% of patients (9 of 16) achieved PSA &lt;0.2ng/mL. The randomized Phase 2 dose expansion portion of the study was reported to be enrolling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 20-24, 2023, the Company presented the same updated dose escalation data from its Phase 1/2 study evaluating masofaniten (EPI-7386) in combination with enzalutamide at the European Society of Medical Oncology (ESMO) 2023 Congress. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 3, 2023, the Company filed a prospectus supplement to its registration statement on Form S-3, including a base prospectus, with the SEC. Further to this, on November 6, 2023, the Company announced that it had entered into the ATM Sales Agreement with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may, within the period that the ATM Sales Agreement is in effect, sell its Common Shares from time to time for up to US$50.0 million in aggregate sales proceeds. No offers or sales of Common Shares will be made in Canada, to anyone known by Jefferies LLC to be a resident of Canada or on or through the facilities of any stock exchange or trading markets in Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, the Company announced the initiation of the Phase 2 portion of its Phase 1/2 study evaluating its lead candidate, masofaniten (EPI-7386), in combination with Astellas and Pfizer&#39;s enzalutamide in patients with mCRPC na&#239;ve to second-generation antiandrogens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 31, 2023, the Company announced the establishment of Automatic Securities Disposition Plans for its President and Chief Executive Officer, David R. Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 6, 2023, the Company appointed Lauren Merendino to its Board of Directors (the &#8220;Board&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On April 12, 2023, the Company announced it had entered into a clinical trial support agreement with Janssen. ESSA will sponsor and conduct a Phase 1 clinical trial evaluating the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of masofaniten (EPI-7386) when administered in combination with either apalutamide or abiraterone acetate plus prednisone. Janssen will supply apalutamide and abiraterone acetate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 16-19, 2023, the Company presented analyses of initial clinical data from two Phase 1 studies of masofaniten (EPI-7386) in patients with mCRPC at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The Company presented an update to the Phase 1 monotherapy study demonstrating that masofaniten (EPI-7386) single agent showed a favorable safety profile and was well tolerated up to a daily dose of 1200 mg (600 mg BID), achieved target clinical exposures and showed preliminary signals of anti-tumor activity in heavily pretreated mCRPC patients. The second poster presented preliminary results to the Phase 1/2 trial of masofaniten (EPI-7386) in combination with Astellas and Pfizer&#8217;s AR inhibitor, enzalutamide. Ten patients had been enrolled in the first three cohorts: three in cohort 1 (600 mg QD masofaniten (EPI-7386) and 120 mg QD enzalutamide), four in cohort 2 (800 mg QD masofaniten (EPI-7386) and 120 mg QD enzalutamide) and three in cohort 3 (600 mg BID masofaniten (EPI-7386) and 120 mg QD enzalutamide). At that time, the DLT period had not cleared for cohort 3. For the first 2 cohorts that cleared the DLT period, no DLTs were observed, and the safety profile was consistent with second-generation antiandrogens (e.g., Grade 1 or 2 AEs of fatigue and hot flushes). Pharmacokinetic results from cohorts 1 and 2 had demonstrated that enzalutamide exposure was minimally impacted by masofaniten (EPI-7386), while, as expected, masofaniten (EPI-7386) exposure was reduced by approximately 60% by enzalutamide (a well established CYP3A4 inducer). The observed masofaniten (EPI-7386) exposures remained in the clinically relevant range suggested by pre-clinical xenograph studies. Five out of six evaluable patients enrolled in the first two cohorts showed a PSA decrease &gt;90% regardless of the patients previous chemotherapy status, and four out of six evaluable patients PSA levels reached &lt; 0.2 ng/mL. All five patients that experienced biochemical responses showed stable disease by imaging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">2022</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 31, 2022, the Company announced that Janssen Research and Development is suspending enrollment into the Phase 1 clinical study of masofaniten (EPI-7386) with apalutamide and masofaniten (EPI-7386) with abiraterone acetate plus prednisone in mCRPC patients as a result of operational recruitment challenges. Initial clinical activity was observed in some patients, with two of the three patients achieving a PSA reduction of 90% (&#8220;PSA90&#8221;) within 12 weeks. The Company is in discussions with Janssen to supply abiraterone acetate and apalutamide for an ESSA-sponsored combination study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 26, 2022, the Company announced the presentation of preclinical data for its lead first generation AR ANITen bAsed Chimera (&#8220;ANITAC&#8221;&#8482;) NTD degrader in a poster session at the 34th EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 26, 2022, the Company announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA&#39;s lead candidate masofaniten (EPI-7386) in combination with enzalutamide at the 2022 Prostate Cancer Foundation Scientific Retreat. In the multicenter, open-label Phase 1/2 dose escalation study, seven mCRPC patients na&#239;ve to second generation antiandrogens were enrolled in the first two cohorts, with escalating doses of masofaniten (EPI-7386) and a fixed 120 mg once a day QD dose of enzalutamide. The study permitted one prior line of chemotherapy. Pharmacokinetic results from these first two cohorts demonstrated that enzalutamide exposure was minimally impacted by masofaniten (EPI-7386) while exposures of masofaniten (EPI-7386) were reduced by coadministration with enzalutamide, but remained in the clinically relevant range as suggested by preclinical xenograft studies. The safety of the combination was favorable with a safety profile consistent with second-generation antiandrogens and no dose limiting toxicities were observed. One of the patients in the first cohort discontinued after one cycle of dosing due to a strong CYP3A inducer concomitant medication which lowered exposures to both masofaniten (EPI-7386) and enzalutamide and was therefore not evaluable for efficacy. Anti-tumor activity in the remaining six patients enrolled demonstrated that four of six of these patients achieved a PSA90 by 12 weeks of dosing and five of six patients to date have achieved a PSA90.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company appointed Philip Kantoff to its Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 30, 2022, the Company announced the establishment of Automatic Securities Disposition Plans for its President and Chief Executive Officer, David R. Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 27, 2022, the Company presented, by conference call and webcast, a clinical update on masofaniten (EPI-7386) monotherapy and combination therapy clinical development. The update on the Phase 1a dose escalation study showed initial data from 36 patients that demonstrated that masofaniten (EPI-7386) was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients. The Company believes the favorable safety and tolerability profile, good pharmaceutical characteristics together with both antiandrogen biological and anti-tumor activity support the Company&#8217;s decision to move into earlier lines of therapy and study masofaniten (EPI-7386) in combination with second-generation antiandrogens. The update also noted that ctDNA molecular analysis in the heavily pretreated population has provided a detailed profile of genetic alterations, which reveals the biological complexity of late-stage mCRPC patients and also allows for the continued refinement of the population of prostate cancer patients whose tumors are still primarily driven by the androgen receptor, and therefore most likely to respond to an androgen receptor inhibitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The update detailed that in the multi-center, open-label Phase 1a dose escalation study, 31 patients received masofaniten (EPI-7386) as oral tablets once a day QD in cohorts with 200 milligram increments from 200 milligrams up to 1000 milligrams. Patients in this QD group were heavily pretreated, with a median of seven lines of prior therapy for prostate cancer and four lines of therapy for mCRPC. Almost 60% of patients had been treated with prior chemotherapy. Patients entered the trial with rapidly progressive disease, as evidenced by a median PSA doubling time of only 2.1 months and a median ctDNA percent of 29%. Almost a third of the patients had lung, liver, or brain metastases, and an overlapping third of patients had overt neuroendocrine differentiation. The ctDNA analysis revealed that tumors in these patients had extensive non-AR associated genomic changes denoting the presence of multiple non-AR oncogenic drivers associated with late-stage prostate cancer. Subsequent to a protocol amendment, the experience was also presented for the five initial patients enrolled in a twice daily dose regimen in 400 mg and 600 mg BID cohorts. The amendment excluded patients who had been treated with more than three prior lines of therapy, excluded patients with visceral metastases, and permitted only one prior line of chemotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The key safety results from both QD and BID patients, as of June 1, 2022, showed that masofaniten (EPI-7386) was safe and well-tolerated at all dose levels and schedules tested, with no dose-limiting toxicities, treatment related adverse events were limited to Grade 1 or Grade 2, with one Grade 3 occurrence of anemia ultimately deemed unlikely to be treatment related, and that there was no apparent dose dependency in any of the side effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Antiandrogen response was assessed by changes in circulating PSA levels, changes in ctDNA levels, and radiographic changes in disease burden measured by both traditional RECIST criteria as well as by total lesion volumetric quantification using the AIQ Solutions platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The key response findings in both QD and BID patients, as of June 1, 2022, demonstrated that tumor volume decreased in five patients out of 10 patients who had measurable disease and were on therapy for more than 12 weeks. PSA decrease or PSA stabilization was observed in a clinical subset of patients with no visceral disease, fewer DNA genomic aberrations in non-AR oncogenic pathways, and fewer than 3 lines of therapy. This provides further information to support refining the monotherapy development program patient population. In 17 patients with measurable ctDNA levels at baseline, ctDNA declines were observed in patients harboring AR point mutations, AR gain/amplification and AR truncations, suggesting masofaniten&#8217;s (EPI-7386) potential activity against these tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The update also described the planned Phase 1b study, the planned window of opportunity cohort and the status of the combination study of masofaniten (EPI-7386) with enzalutamide. The Phase 1b study will evaluate a patient population of mCRPC similar to the one treated under the Phase 1a BID cohort but with the additional exclusion of prior chemotherapy. Up to 12 patients per each dose/schedule (600 mg QD and either 400 mg or 600 mg BID) will be evaluated to gain additional information about safety, tolerability, exposure and anti-tumor activity of masofaniten (EPI-7386) in a less heavily pretreated patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The update also described the planned window of opportunity cohort as part of the Phase 1b expansion in which a separate group of non-metastatic CRPC will be enrolled into a 12-week study with a clinical endpoint (i.e., PSA changes) to assess the anti-tumor activity of masofaniten (EPI-7386) in a patient population in which the disease is mainly AR-driven and the tumor biology has not been affected by second-generation antiandrogen therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The clinical update also provided the status of the combination studies evaluating masofaniten (EPI-7386) in earlier lines of therapy in Phase 1/2 trials which combine masofaniten (EPI-7386) with approved second-generation antiandrogens. In the Phase 1/2 study being conducted by the Company of masofaniten (EPI-7386) in combination with Astellas Pharma Inc.&#39;s and Pfizer Inc.&#39;s AR inhibitor, enzalutamide, in patients with mCRPC who have not been treated with second-generation antiandrogens, the first cohort had cleared the 28-day DLT period with no safety issues and when reported the trial was currently enrolling the second cohort of patients. The preliminary data from the first cohort in the Phase 1/2 combination trial with enzalutamide suggests that the drugs can be combined safely and based upon clinical and preclinical data predicted to be active. The early data, in addition to preclinical studies, support masofaniten&#8217;s (EPI-7386) potential in combination with second-generation antiandrogens to suppress androgen receptor biology and induce a potent anti-tumor response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company also described the anticipated initiation later in 2022 of a Phase 2 investigator-sponsored neoadjuvant study which will evaluate darolutamide compared to masofaniten (EPI-7386) + darolutamide in patients undergoing prostatectomy for high-risk localized prostate cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At the AACR annual meeting on April 10, 2022, in a poster titled &#8220;Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models,&#8221; the Company presented preclinical data for its first generation of androgen receptor (AR) ANITen bAsed Chimera (ANITAC&#8482;) N-terminal domain (NTD) degraders. The preclinical data demonstrated the potential of ESSA&#8217;s ANITAC degraders as a new approach to AR pathway inhibition. The intrinsically disordered nature of the NTD region of the AR has meant it has generally been considered undruggable. The preclinical studies have shown that through their unique ability to bind to the NTD of AR, ANITACs have the ability to inhibit NTD-mediated AR transcription while also degrading AR protein including resistant forms of AR which are commonly associated with CRPC. The preclinical results demonstrate that ANITAC degraders utilize the ubiquitin proteasome system and can degrade many forms of AR including full length, mutant, and splice variants which are often expressed in CRPC patients. Specifically, the ANITAC degraders show robust potency in inhibiting AR transcriptional activity driven by AR-FL, AR-V7, or AR-V567es. In addition, the orally bioavailable ANITAC degraders exhibit high potency in inhibiting AR-dependent transcription and reducing viability of AR-dependent prostate cancer cells. The Company continues to design and test ANITAC degraders with a focus on improving selectivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 19, 2022, the Company announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA&#8217;s lead product candidate, masofaniten (EPI-7386), a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas and Pfizer Inc.&#8217;s ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with mCRPC. This combination trial investigates the potential clinical benefit of inhibiting the androgen receptor through two independent pathways in the treatment of patients with mCRPC who have not yet received treatment with a second-generation antiandrogen drug. In preclinical models, the combination of masofaniten (EPI-7386) with lutamides by simultaneously targeting both ends of the AR resulted in deeper and broader inhibition of androgen biology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Phase 1/2 clinical trial (NCT05075577) is a two part study. Phase 1 evaluates the safety and tolerability of the drug combination to establish the recommended Phase 2 range of doses for masofaniten (EPI-7386) and enzalutamide when dosed in combination. This Phase of the study is expected to enroll up to 30 mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. As described below on June 27, 2022, the results of the initial experience with the first cohort were presented, demonstrating the safety and tolerability of the combination in this first cohort, along with the accompanying pharmacokinetic and PSA reduction information. In Phase 2, single agent enzalutamide is compared to the combination of enzalutamide and masofaniten (EPI-7386) in the same patient population. The goal of Phase 2 is to evaluate the safety, tolerability and anti-tumor activity of masofaniten (EPI-7386) in combination with a fixed dose of enzalutamide compared with enzalutamide as a single agent. This part of the study is expected to enroll 120 mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">2021</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2021, the company disclosed the development of a collaboration with Caris Life Sciences, involving the incorporation of Caris&#8217; newly developed cNAS (&#8220;circulating nucleic acid sequencing&#8221;) assay in the characterization of patients receiving masofaniten (EPI-7386). The Company believes that the characterization of real time individual patient biology will contribute significantly to understanding the extent to which individual patient&#8217;s tumors are still AR driven and what mechanisms of resistance exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At the October AACR, National Cancer Institute, and European Organisation for Research and Treatment of Cancer Virtual International Conference on Molecular Targets and Cancer Therapeutics, the Company presented preclinical data characterizing the mechanism of action of masofaniten (EPI-7386), including the results of NMR studies which confirm the binding of the compound to the NTD of the AR, a region not currently targeted by other antiandrogen therapies. The data also demonstrated that the combination of masofaniten (EPI-7386) with enzalutamide results in complete inhibition of genome-wide androgen-induced AR binding, supporting the rationale for Phase 1 / 2 combination trials of masofaniten (EPI-7386) with approved antiandrogens in patients with mCRPC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 11, 2021, the Company presented preclinical and clinical pharmacology data from ESSA&#8217;s Phase 1 clinical trial of masofaniten (EPI-7386) for the treatment of patients with mCRPC at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium in an oral poster presentation titled, &#8220;Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.&#8221; The poster is available on the Company website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Data on the poster included a comparison of preclinical projections of masofaniten (EPI-7386) clinical pharmacokinetic parameters to the pharmacokinetic, safety and preliminary clinical data from the initial 200 mg cohort of patients enrolled in ESSA&#8217;s multi-center, open-label, ascending multiple-dose Phase 1 study of masofaniten (EPI-7386) to treat patients with mCRPC who have become resistant to standard of care treatments. Patients participating in this trial have progressed on two or more approved systemic therapies for mCRPC, including at least one second generation antiandrogen therapy not necessarily in the metastatic disease setting. In this initial cohort of patients receiving the 200 mg once-daily dose, masofaniten (EPI-7386) was well-tolerated with no significant adverse effects observed. The results from this cohort support ESSA&#8217;s preclinical projections regarding the pharmacologic properties of masofaniten (EPI-7386) in humans. masofaniten (EPI-7386) was well-absorbed, demonstrated high exposure levels and was confirmed to have a long half-life of at least 24 hours. The predicted exposures of masofaniten (EPI-7386) in patients at that 200 mg dose level were similar to the Company&#8217;s modeled projections and were still below optimal target exposures of masofaniten (EPI-7386) associated with anti-tumor activity in animal models. Although the 200 mg dose exposure was suboptimal, one out of three patients who completed 12 weeks of therapy experienced a PSA decline of more than 50 percent after three cycles of masofaniten (EPI-7386) therapy (12 weeks) with ongoing continued PSA declines continuing through seventeen cycles of therapy, despite previously having failed enzalutamide and abiraterone acetate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At the 2021 American Association of Cancer Research (&#8220;AACR&#8221;) Annual Meeting, which took place virtually April 10-15, 2021, ESSA presented an e-poster presentation titled, &#8220;Comprehensive <i style="font-style:italic;">in vitro </i>characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal inhibitor.&#8221; The content of this poster added to previously presented data that masofaniten (EPI-7386) binds to the full-length androgen receptor, inhibits the transcription of AR-regulated genes, and physically interacts with the splice variant form AR-V7, by demonstrating that masofaniten (EPI-7386) can prevent the androgen receptor from binding to genomic DNA and is active against additional androgen receptor splice variants, including AR-v567es. These preclinical data suggest masofaniten (EPI-7386) can potentially inhibit AR related transcription, a key driver of &#160;prostate cancer, and further supports the ongoing Phase 1 dose escalation study. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The data also showed that masofaniten (EPI-7386), in combination with enzalutamide, may result in broader and deeper inhibition of the AR pathway, underscoring the potential clinical benefit of combining masofaniten (EPI-7386) with current standard of care antiandrogen therapies for prostate cancer patients at earlier stages of the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Future Clinical Development Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 2/3 Clinical Trial Design for treating CRPC patients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Combination Therapy Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The wealth of preclinical data developed by the Company, as well as the continued emergence of evidence that while earlier stages of prostate cancer are more homogeneously AR pathway driven, the later stages of the disease are much more biologically complex. The Company is conducting the combination of masofaniten (EPI-7386) with current antiandrogens in earlier patients. This is the current priority for the Company&#8217;s clinical development, reflected in the several clinical trial collaborations established with leading pharmaceutical companies. Following demonstration of the practical ability to combine masofaniten (EPI-7386) with each of these antiandrogens, further clinical development will require conduct of randomized clinical trials in earlier patient populations (potentially ranging from newly-diagnosed through non-metastatic and metastatic hormone-sensitive or pre-latest generation antiandrogen CRPC populations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Single Agent Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depending on the results of the Phase 1 study, a Phase 2 single arm clinical trial evaluating the activity of masofaniten (EPI-7386) single agent in a larger group of biologically-characterized mCRPC patients might be conducted. While the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">decision as to whether or not to conduct such a trial has not been formally reached, embarking on the conduct of such a trial will depend on several considerations. The considerations related to the decision to conduct such a trial relate to the company&#8217;s ability to identify those patients who, having progressed on one or another late generation antiandrogen, have tumors which are still predominantly AR-driven, as well as the size of that patient population. Our experience during the conduct of the Phase 1 dose escalation trial has revealed that many such patients will have tumors driven predominantly by other oncogenic drivers. Those patients whose tumors remain predominantly AR-driven are the population most likely to benefit clinically from Aniten therapy, and the size of this population will weigh in the decision as to whether or not to pursue a single agent registration strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In order to ultimately obtain full single agent regulatory approval, the Company expects that at least one Phase 3 clinical trial would be required, most likely in patients similar to the population of mCRPC patients who will have been enrolled in the planned Phase 1/2 clinical trial. However, the results of the Phase 1/2 clinical trial may also suggest modification of the initial patient population based on anti-tumor response and biomarker assessment. In a Phase 3 clinical trial, the key end-point is expected to be progression-free survival or overall survival relative to patients receiving the standard of care. It is expected that such a Phase 3 clinical trial would be conducted at numerous sites around the world. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The competition in the prostate cancer market is very high, many of the companies against which we compete or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Several pharmaceutical therapies already have approved and many new molecules are being tested for their effect in this patient population. In addition, generic forms of Zytiga (abiraterone acetate) are now approved and commercially available in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currently approved therapies include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">GENERIC/PROGRAM</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">NAME</b></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BRAND NAME</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPANY NAME(S)</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STAGE</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Enzalutamide</p></td><td style="vertical-align:top;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xtandi</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Astellas and Pfizer</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abiraterone acetate</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Zytiga</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Johnson&#160;&amp; Johnson</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sipuleucel-T</p></td><td style="vertical-align:top;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provenge</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valeant</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Docetaxel</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">n/a</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sanofi and various</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cabazitaxel</p></td><td style="vertical-align:top;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jevtana</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sanofi</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Radium-233</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xofigo</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bayer</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Apalutamide (ARN-509)</p></td><td style="vertical-align:top;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Erleada</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Johnson&#160;&amp; Johnson</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Darolutamide</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nubeqa</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bayer</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pembrolizumab</p></td><td style="vertical-align:top;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Keytruda</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merck</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Olaparib</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lynparza</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AstraZeneca</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rucaparib</p></td><td style="vertical-align:top;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rubraca</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clovis Oncology</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vipivotide tetraxetan</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pluvicto</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this market, ESSA believes that its competitive position is strong because its product candidate, if successful, involves a mechanistically unique, differentiated approach to prostate cancer treatment involving the therapeutic modality that has been shown to make the biggest difference to the survival of recurrent prostate cancer patients: blocking AR activation. Since Anitens have been shown to directly bind to AR-NTD and prevent AR-mediated transcription, they have the potential to bypass the AR-dependent resistance pathways (discussed above) that may develop as a result of treatment with current hormone-related therapies that target the AR LBD. If successful, ESSA believes this could represent a significant step forward in the treatment of prostate cancer. To ESSA&#8217;s knowledge, no other antagonist to the AR-NTD is currently undergoing clinical trials for prostate cancer or any other indication. Other approaches to interfering with AR signaling include potentially complementary strategies to degrade the AR such as that being pursued by Arvinas, Inc.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patents and Proprietary Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">License Agreement with UBC and the BCCA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA has in-licensed intellectual property embodied in issued patents, pending patents applications and know-how relating to compounds that modulate AR activity. ESSA refers to these intellectual property rights as the &#8220;Licensed IP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is party to a license agreement with the British Columbia Cancer Agency and the University of British Columbia (the &#8220;Licensors&#8221;) dated December 22, 2010, as amended on February 10, 2011, May 27, 2014, and May 25, 2021 (the &#8220;License Agreement&#8221;), which provides the Company with exclusive world-wide rights to develop and commercialize products based on the Licensed IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA paid a minimum annual royalty of C$85,000 in 2017, 2018, and 2019 and must continue to pay a minimum of C$85,000 for each year thereafter. For a First Compound entering clinical development, an additional C$50,000 and C$900,000 must be paid upon enrollment of a patient in a Phase 2 and Phase 3 clinical trial, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Licensors may terminate the License Agreement upon ESSA&#8217;s insolvency, or the License Agreement may be terminated by either party for certain material breaches by the other party. ESSA has already spent more than C$5,000,000 in connection with the commercialization of products relating directly to the Licensed IP, as required under the License Agreement. ESSA is required to allocate reasonable time to the development and commercialization of the Licensed IP and to use reasonable efforts to promote, market and sell products covered by the Licensed IP. The terms of the License Agreement required ESSA to issue to the Licensors, 1,000,034 pre-Consolidation Common Shares, in lieu of payment of an initial license fee. If ESSA develops products covered by the Licensed IP in the future, it will be required to pay certain development and regulatory milestone payments up to an aggregate of C$2.4 million for the first drug product developed under the license and up to an aggregate of C$510,000 for each subsequent product. ESSA must also pay the Licensors low single-digit royalties based on aggregate worldwide net sales of products covered by the Licensed IP and a percentage of sublicensing revenue in the low teens. The License Agreement will expire on the later of 20 years after the date of the License Agreement or the expiry of the last issued patent included in the Licensed IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ESSA&#8217;s Intellectual Property Strategy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company currently retains all commercial rights for its Aniten series drug portfolio and believes it has developed a strong and defensive intellectual property position for the Aniten structural classes. ESSA has licensed certain patent rights, with respect to some of its compounds that modulate AR activity, from the Licensors. ESSA has the right to acquire ownership of the licensed patents and patent applications upon specified payment to the Licensors, and providing that payments required under the License Agreement continue to be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 2023, ESSA owns rights to a patent portfolio that includes 71 issued patents, including 19 issued U.S. patents, that are in force and cover multiple EPI- and Aniten structural classes of compounds with different structural motifs/analogues. Patent applications are also pending in the United States and in contracting states to the Patent Cooperation Treaty for Aniten next-generation NTD inhibitors, with expected expiration dates between 2036 to 2043.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent portfolio includes issued patents that are in force and pending patent applications that cover the masofaniten (EPI-7386) compound, pharmaceutical compositions comprising the masofaniten (EPI-7386) compound, or its methods of use, and are expected to provide protection until the expiration dates, ranging from 2036 to 2043.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Both ESSA and the broader pharmaceutical industry attach significant importance to patents for the protection of new technologies, products and processes. Accordingly, ESSA&#8217;s success depends, in part, on its ability to obtain patents or rights thereto, to protect commercial secrets and carry on activities without infringing the rights of third parties. Disputes may arise as to the inventorship of and/or ownership interest in the Company&#8217;s or the Licensors&#8217; patents, including for example, former or current employees of the Company or the Licensors pursuing ownership rights of patents owned by or licensed to the Company. The Company may have limited ability to impact any internal disputes between the Licensors and their employees or former employees. See &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. Where appropriate, and consistent with management&#8217;s objectives, ESSA will continue to seek patents in relation to components or concepts of its technology that it perceives to be important.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Environment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The production and manufacture of ESSA&#8217;s product candidate and potential future product candidates and its R&amp;D activities are subject to regulation for safety, efficacy, quality and ethics by various governmental authorities around the world. In the United States, drugs and biological products are subject to regulation by the FDA. In Canada, these activities are regulated by the Food and Drugs Act and the rules and regulations thereunder, which are enforced by the TPD. Drug approval laws require registration of manufacturing facilities, carefully controlled research and testing of product candidates, government review and approval of experimental results prior to giving approval to sell drug products. Regulators also require that rigorous and specific standards such as cGMP, good laboratory practices (&#8220;GLP&#8221;) and current good clinical practices (&#8220;GCP&#8221;) are followed in the manufacture, testing and clinical development respectively of any drug product. See &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process of obtaining regulatory approvals and the corresponding compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Drug Products Development Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of extensive nonclinical, sometimes referred to as preclinical laboratory tests, and preclinical animal trials in compliance with applicable requirements for the humane use of laboratory animals and formulation studies, including GLPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must take effect before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as GCP regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed drug product for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">review of the product by an FDA advisory committee, where appropriate or if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees and securing FDA approval of the NDA; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) and post-approval studies required by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical studies are conducted <i style="font-style:italic;">in vitro</i> and in animals to evaluate pharmacokinetics, metabolism and possible toxic effects to provide evidence of the safety of the product candidate prior to its administration to humans in clinical studies and throughout development. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Initiation of Human Testing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. In Canada, this application is called a CTA. An IND/CTA application must be filed and accepted by the FDA or TPD, as applicable, before human clinical trials may begin. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Two key factors influencing the rate of progression of clinical trials are the rate at which patients can be enrolled to participate in the research program and whether effective treatments are currently available for the disease that the drug is intended to treat. Patient enrollment is largely dependent upon the incidence and severity of the disease, the treatments available and the potential side effects of the drug to be tested and any restrictions for enrollment that may be imposed by regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1 Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Phase 1 clinical trials for cancer therapeutics are typically conducted on a small number of patients to evaluate safety, dose limiting toxicities, tolerability, pharmacokinetics and to determine the dose for Phase 2 clinical trials in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 2 Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Phase 2 clinical trials typically involve a larger patient population than Phase 1 clinical trials and are conducted to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of a product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 3 Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Phase 3 clinical trials typically involve testing an experimental drug on a much larger population of patients suffering from the targeted condition or disease&#160;&#8211; in ESSA&#8217;s case, CRPC. These studies involve testing the experimental drug in an expanded patient population at geographically dispersed test sites (multi-center trials) to establish clinical safety and effectiveness. These trials also generate information from which the overall risk-benefit relationship relating to the drug can be determined.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In most cases FDA requires two adequate and well controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient in rare instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">New Drug Application</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA, or the TPD as part of a New Drug Submission (&#8220;NDS&#8221;), requesting approval to market the drug product for one or more indications. The NDS or NDA is then reviewed by the applicable regulatory body for approval to market the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of an NDA within 60&#160;days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten&#160;months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within nine&#160;months of filing. The review process may be extended by the FDA for three additional&#160;months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections cover all facilities associated with an NDA submission, including drug component manufacturing (such as Active Pharmaceutical Ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2,500,000 and the manufacturer or sponsor under an approved new drug application are also subject to significant annual program and establishment user fees. These fees are typically increased annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or nine&#160;months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, significant changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Designation and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA may, in the future, seek orphan drug designation for its product candidates. Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven&#160;years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Government Regulation Outside of the United States and Canada</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition to regulations in the United States and Canada, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical study development may proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The requirements and process governing the conduct of clinical studies, product licensing, coverage, pricing and reimbursement vary from country to country. In all cases, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">As of the date of this Annual Report, ESSA has a total of approximately 50 employees and consultants on a full-time or part-time basis. ESSA has in the past, and may in the future, retain additional expert consultants on an ad-hoc basis if required in connection with the Company&#8217;s development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">We believe that our future success will depend, in part, on our ability to continue to attract, hire, and retain qualified personnel. We continue to seek additions to our science and technical staff. Through our experience with technological innovation, we appreciate the importance of retention, growth and development of our employees. We believe we offer competitive compensation (including salary, incentive bonus, and equity) and benefits packages. None of our employees is represented by a labor union, and we have never experienced a work stoppage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Corporate Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company was incorporated under the name &#8220;ESSA Pharma Inc.&#8221; pursuant to the Business Corporations Act (British Columbia) on January 6, 2009. The Company&#8217;s registered and records office is located at Suite 3500, The Stack, 1133 Melville Street, Vancouver, British Columbia, Canada V6E 4E5. The Company&#8217;s head office is located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Since July 9, 2015, the Company&#8217;s Common Shares have traded on the Nasdaq under the symbol &#8220;EPIX.&#8221; The Company&#8217;s Common Shares traded under the symbol &#8220;EPI&#8221; on the Toronto Stock Exchange (the &#8220;TSX&#8221;) from July 28, 2015, until November 24, 2017. On November 27, 2017, the Company delisted its Common Shares from the TSX and began trading on the TSX-V under the same symbol, &#8220;EPI.&#8221; On October 26, 2020, the Company announced its decision to voluntarily delist its Common Shares from the TSX-V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company has one wholly owned subsidiary:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ESSA Pharmaceuticals Corp. (&#8220;ESSA Texas&#8221;), existing under the laws of the State of Texas. The head office of ESSA Texas is located at Suite 1300, 700 Milam Street, Houston, Texas, USA 77002.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This Annual Report on Form 10-K, our quarterly reports on Form 10-Q or Form 6-K, our current reports on Form 8-K or Form 6-K, and any amendments to these reports are filed, or will be filed, as appropriate, with the SEC and the Canadian Securities Administrators (&#8220;CSA&#8221;). These reports are available free of charge on our website, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.essapharma.com</span>, as soon as reasonably practicable after we electronically file such reports with or furnish such reports to the SEC and the Canadian regulatory authorities. Information contained on, or accessible through, our website or any other website referenced herein is not a part of this Annual Report on Form 10-K, and the inclusion of our website address or any other website address in this document is an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, our filings with the SEC may be accessed through the SEC&#8217;s website at <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.sec.gov</span> and our filings with the CSA may be accessed through SEDAR+ at <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.sedarplus.com</span>. Our annual report on Form 10-K from the year ended September 30, 2022, which includes a full discussion of the general development of our business, can be found at https://www.sec.gov/Archives/edgar/data/1633932/000155837022018570/tmb-20220930x10k.htm.<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b4cd0fad_4d82_4475_bc9f_0a74da5bb460"></a><a id="Item1A"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Item 1A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Risk Factors </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Risk Factor Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">We are providing the following summary of the risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures. This summary does not address all the risks &#160;that we face. We encourage you to carefully review the full risk factors contained in this Annual Report on Form 10-K in their entirety, together with our other filings with the SEC, for additional information regarding the material factors that make an investment in our securities speculative or risky, and before making an investment decision regarding our Common Shares. These risks and uncertainties include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future success is dependent primarily on the regulatory approval for commercialization of a single product candidate, which is in the clinical development stage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to obtain required regulatory approvals for our proposed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to successfully commercialize our Aniten series of compounds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidate and potential future product candidates may have undesirable side effects when used alone or in combination with other drugs, that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we obtain marketing approval for any product candidate and potential future products, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may fail to comply with applicable legal and regulatory requirements, which may result in administrative or judicial sanctions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or terminate the relationship, this could substantially harm our business because we may not be able to obtain regulatory approval for or commercialize product candidates in a timely manner or at all;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited experience manufacturing product candidates on a large clinical or commercial scale and have no manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business may be materially adversely affected by new legislation, new regulatory requirements and the continuing efforts of governmental and third-party payors to contain or reduce the costs of healthcare through various means;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will have significant additional future capital needs for future clinical trials and there are uncertainties as to the Company&#8217;s ability to raise additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to raise additional capital on favorable terms, which may result in dilution to our existing shareholders, restrictions on our operations or the requirement for us to relinquish rights to technologies or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses in every quarter since our inception and anticipate that we will continue to incur significant losses in the future and may never generate profits from operations or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on proprietary technology, the protection of which can be unpredictable and costly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to protect our intellectual property rights throughout the world;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to claims by third parties asserting that we, or our employees, contractors or consultants have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business and operations would suffer in the event of computer system failures or security breaches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face intense competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have never marketed a drug before, and if we are unable to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements, we may be unable to generate any revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidate and potential future products may, if approved for sale, not achieve or maintain expected levels of market acceptance, which could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our securities to decline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and Canada and require us to develop and implement costly compliance programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a smaller reporting company and a non-accelerated filer and the reduced disclosure requirements available to us may make our Common Shares less attractive to investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are and there is a risk that we may continue to be a &#8220;passive foreign investment company,&#8221; which would likely result in materially adverse U.S. federal income tax consequences for U.S. investors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price and trading volume of our Common Shares may be volatile, which could result in rapid and substantial losses for our shareholders or securities litigation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Widespread health concerns, pandemics or epidemics, and other outbreaks of illness may negatively affect our ability to maintain operations and execute our business plan.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">ESSA&#8217;s Product Candidate and Regulatory Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results and ESSA&#8217;s product candidate and potential future product candidates may not have favorable results in later trials or in the commercial setting or satisfy the requirements of the FDA or non-US regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. ESSA&#8217;s planned clinical trials may produce negative or inconclusive results, and ESSA or any of its current and future collaborators may decide, or regulators may require ESSA, to conduct additional clinical or preclinical testing. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Preclinical tests and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials does not ensure that later </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">large-scale efficacy trials will be successful nor does it predict final results. Favorable results in early trials may not be repeated in later trials. The Company cannot assure you that the FDA, TPD or EMA or other similar government bodies will view the results as the Company does, or that any future trials of ESSA&#8217;s proposed products for other indications will achieve positive results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Any current or future clinical trial results for ESSA&#8217;s proposed products may not be successful. Similarly, preclinical interim results of a clinical trial do not necessarily predict final results. A number of factors could contribute to a lack of favorable safety and efficacy results for ESSA&#8217;s proposed products for other indications. For example, such trials could result in increased variability due to varying site characteristics, such as local standards of care, differences in evaluation period and due to varying patient characteristics including demographic factors and health status. There can be no assurance that the Company&#8217;s clinical trials will demonstrate sufficient safety and efficacy for the FDA, TPD or EMA or other similar government bodies to approve ESSA&#8217;s potential products for the treatment of CRPC, or any other indication that the Company may consider in any additional NDA or NDS submissions for ESSA&#8217;s potential products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company will be required to demonstrate through large scale clinical trials that any product candidate and potential future product candidate is safe and effective for use in a diverse population before ESSA can seek regulatory approvals for its commercial sale. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical and post-approval trials. If ESSA&#8217;s potential products fail to demonstrate sufficient safety and efficacy in ongoing or future clinical trials, the Company could experience potentially significant delays in, or be required to abandon development of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition, clinical trials and nonclinical studies performed by research organizations and other independent third parties may yield negative or inconclusive results regarding the effect of ESSA&#8217;s potential products on CRPC, either in absolute terms or relative to other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">ESSA&#8217;s future success is dependent primarily on the regulatory approval for commercialization of a single product candidate, which is in the clinical development stage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company does not have any products that have obtained regulatory approval for commercialization. Currently, ESSA is engaged in the clinical testing of a product candidate, masofaniten (EPI-7386), to take forward from its Aniten series of compounds through clinical development to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and potential therapeutic benefits of such candidate in patients with CRPC, and to ultimately receive regulatory approval. As a result, the Company&#8217;s near-term prospects, including its ability to finance its operations and generate revenue, are substantially dependent on its ability to develop, obtain regulatory approval for, and, if approved, to successfully commercialize a product candidate in a timely manner. ESSA cannot commercialize its product candidates in the United States without first conducting multiple preclinical and clinical trials to establish the product&#8217;s safety and efficacy and obtaining regulatory approval for the product from the FDA; similarly, ESSA cannot commercialize its product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. The FDA development and review process typically varies in time and may take years to complete and approval is not guaranteed. Developing, obtaining regulatory approval for and successfully commercializing ESSA&#8217;s product candidates will depend on many factors, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully completing formulation and process development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing multiple clinical trials that demonstrate the efficacy and safety of ESSA&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receiving marketing approval from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales, marketing and distribution operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of ESSA&#8217;s product candidates by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing effectively with other therapies, including with respect to the sales and marketing of ESSA&#8217;s product candidates, if approved.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Many of these factors are wholly or partially beyond ESSA&#8217;s control, including clinical development, the regulatory submission process and changes in the competitive landscape. If ESSA does not achieve one or more of these factors in a timely manner, it could experience significant delays or an inability to develop ESSA&#8217;s product candidates at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Further, disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could also hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified product candidates from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact the Company&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If the Company breaches any of the agreements under which the Company licenses rights to its technology from third parties, the Company could lose license rights that are important to ESSA&#8217;s business. ESSA&#8217;s current license agreement may not provide an adequate remedy for its breach by the licensor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA entered into a License Agreement with UBC and the BC Cancer Agency that covers certain Aniten compound candidates. The Company is subject to a number of risks associated with the Company&#8217;s collaboration with UBC and the BC Cancer Agency, including the risk that UBC or the BC Cancer Agency may terminate the License Agreement upon the occurrence of certain specified events. ESSA&#8217;s License Agreement requires, among other things, that the Company make certain payments and use reasonable commercial efforts to meet certain clinical and regulatory milestones. See &#8220;Patents and Proprietary Rights&#8221; in Item 4 of this Annual Report. If ESSA fails to comply with any of these obligations or otherwise breaches this or similar agreements, UBC, the BC Cancer Agency or any future licensors may have the right to terminate the license. ESSA could also suffer the consequences of non-compliance or breaches by licensors in connection with ESSA&#8217;s license agreements. Such non-compliance or breaches by such third parties could in turn result in ESSA&#8217;s breaches or defaults under the Company&#8217;s agreements with the Company&#8217;s other collaboration partners, and the Company could be found liable for damages or lose certain rights, including rights to develop and/or commercialize a product or product candidate. Loss of ESSA&#8217;s rights to the Licensed IP or any similar license granted to ESSA in the future, or the exclusivity rights provided therein, could harm ESSA&#8217;s financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may not be able to obtain required regulatory approvals for the Company&#8217;s proposed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The research, testing, manufacturing, labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of drug products developed by ESSA or ESSA&#8217;s future collaborative partners, if any, is subject to extensive regulation by federal, provincial, state and local governmental authorities and those regulations differ from country to country. ESSA&#8217;s product candidate and potential future product candidates will be principally regulated in the United States by the FDA, in the European Union by the EMA and the regulators in the individual European Union member countries, in Canada by the TPD, and by other similar regulatory authorities in Japan and other jurisdictions. Government regulation substantially increases the cost and risk of researching, developing, manufacturing and selling products. Following several widely publicized issues in recent years, the FDA and similar regulatory authorities in other jurisdictions have become increasingly focused on product safety. This development has led to requests for more clinical trial data, for the inclusion of a significantly higher number of patients in clinical trials and for more detailed analysis of trial results. Consequently, the process of obtaining regulatory approvals, particularly from the FDA, is time-consuming and has become more costly than in the past. Any product developed by ESSA or ESSA&#8217;s future collaborative partners, if any, must receive all relevant regulatory approvals or clearances from the applicable regulatory authorities before it may be marketed and sold in a particular country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">ESSA will not be permitted to market any potential products in the United States, Europe, Japan, Canada or in other countries where ESSA intends to market its product candidate and potential future product candidates until such product candidate receives approval of a NDA from the FDA or similar approval in other countries as restrictions apply. In the United States, the FDA generally requires the completion of preclinical testing and clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before an NDA is approved. This process takes many years and requires the expenditure of substantial resources and may include post-marketing studies and surveillance. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs in development, only a small percentage result in the submission of an NDA to the FDA and even fewer are approved for commercialization. Other than the INDs submitted for EPI-506 and EPI-7386, the Company has not submitted an IND or an NDA to date for any of the Company&#8217;s potential products to the FDA or comparable applications to other regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">authorities. If the Company&#8217;s development efforts for potential products are not successful for the treatment of CRPC and regulatory approval is not obtained in a timely fashion or at all, the Company&#8217;s business will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The receipt of required regulatory approvals for the Company&#8217;s product candidate and potential future product candidate(s) is uncertain and subject to a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, IRBs or comparable foreign regulatory authorities may disagree with the design or implementation of the Company&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company may not be able to provide acceptable evidence of the safety, efficacy or quality of its potential products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of the Company&#8217;s clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign regulatory authorities for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the dosing of the Company&#8217;s potential products in a particular clinical trial may not be at an optimal level;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients in the Company&#8217;s clinical trials may suffer adverse effects for reasons that may or may not be related to the Company&#8217;s potential products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from the Company&#8217;s clinical trials may not be sufficient to support the submission of an NDA for the Company&#8217;s potential products or to obtain regulatory approval in the United States, Europe, Japan, Canada, or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which the Company contracts for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering the Company&#8217;s clinical data insufficient for approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The FDA and other comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that the Company&#8217;s data is insufficient for approval and require additional clinical trials, or other studies. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent regulatory approval of the Company&#8217;s potential products. ESSA, or ESSA&#8217;s future collaborative partner, if any, must obtain and maintain regulatory authorization to conduct clinical trials. ESSA&#8217;s preclinical research is subject to good laboratory practice, or GLP and other requirements and ESSA&#8217;s clinical research is subject to good clinical practice, or GCP and other requirements. Failure to adhere to these requirements could invalidate ESSA&#8217;s data. In addition, the relevant regulatory authority or independent review board may modify, suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits. Further, the process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among other things, the type, complexity and novelty of the prescription product candidates involved, the jurisdiction in which regulatory approval is sought and the substantial discretion of the regulatory authorities. If regulatory approval is obtained in one jurisdiction, it does not necessarily mean that ESSA&#8217;s potential products will receive regulatory approval in all jurisdictions in which the Company may seek approval, or any regulatory approval obtained may not be as broad as what was obtained in other jurisdictions. However, the failure to obtain approval for ESSA&#8217;s potential products in one or more jurisdictions may negatively impact the Company&#8217;s ability to obtain approval in a different jurisdiction. Accordingly, despite ESSA&#8217;s expenditures and investment of time and effort, it may be unable to receive required regulatory approvals for product candidates developed by it. If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful, ESSA&#8217;s business, financial condition and results of operations may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company will also need to obtain FDA approval for any proposed product candidate names, and any failure or delay associated with such approval may adversely affect the business. The FDA typically conducts a review of proposed product candidate names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies certain medical claims or contributes to an overstatement of efficacy. If the FDA objects to any product candidate names, ESSA may be required to adopt an alternative name for product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">As an organization, ESSA has never submitted an NDA/NDS and may be unable to do so for any future products ESSA develops.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA is currently undergoing a Phase 1 clinical trial for masofaniten (EPI-7386). ESSA will need to conduct Phase 2 and Phase 3 clinical trials, which it has not previously undertaken. The conduct of Phase 3 clinical trials and the submission of a successful IND or CTA and NDA or NDS is a complicated process. As an organization, ESSA has limited experience in preparing, submitting and prosecuting regulatory filings and has not submitted an NDA or NDS. ESSA&#8217;s interactions with the FDA to date have been limited to the completed EPI-506 clinical trial and the initiation of the Phase 1 clinical trial for masofaniten (EPI-7386). Consequently, even if ESSA&#8217;s initial clinical trials are successful, the Company may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to NDA or NDS submission and approval of ESSA&#8217;s proposed products or any other future product candidate ESSA may develop. The Company may require more time and incur greater costs than competitors and may not succeed in obtaining regulatory approvals of products that the Company develops. Failure to commence or complete, or delays in, ESSA&#8217;s planned clinical trials, would prevent ESSA from or delay ESSA in commercializing proposed products or any other future product candidate ESSA develops.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA may not be able to successfully commercialize its Aniten series of compounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Even if a candidate from ESSA&#8217;s Aniten series were to be successfully developed and obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, may be subject to burdensome post-approval study or risk management requirements, or may be limited to a subset of CRPC patients with limited commercial value. If ESSA is unable to obtain regulatory approval in one or more jurisdictions, or any approval contains significant limitations, ESSA may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other future product candidates that ESSA may discover, in-license, develop or acquire in the future. Also, any regulatory approval of any future product candidates, once obtained, may be withdrawn. Furthermore, even if ESSA obtains regulatory approval for a product candidate, the commercial success of such product candidate will depend on a number of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development of a commercial organization or establishment of a commercial collaboration with a commercial infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of commercially viable pricing and approval for adequate reimbursement from third-party and government payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of ESSA&#8217;s third-party manufacturers to manufacture quantities of the compound using commercially efficient processes and at a scale sufficient to meet anticipated demand and enable ESSA to reduce its cost of manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ESSA&#8217;s success in educating physicians and patients about the benefits, administration and use of the compound;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of ESSA&#8217;s own or its potential strategic collaborators&#8217; marketing, sales and distribution strategy and operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product candidate as safe and effective by patients and the medical community; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile of a product candidate following approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Many of these factors are beyond ESSA&#8217;s control. If ESSA, or its potential commercialization collaborators, are unable to successfully commercialize a product candidate, ESSA may not be able to earn sufficient revenues to continue the Company&#8217;s business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">The Company&#8217;s product candidate and potential future product candidates may have undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Although any future product candidates will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of ESSA&#8217;s product candidate and potential future product candidates when used alone or in combination with other approved products or investigational new drugs could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. The results of any future clinical trials may show a product candidate causes undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings, limited patient populations or potential product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Patients in ESSA&#8217;s planned clinical trials may in the future suffer significant adverse events or other side effects not observed in ESSA&#8217;s nonclinical studies or previous clinical trials. If significant adverse events or other side effects are observed in any of ESSA&#8217;s current or future clinical trials, ESSA may have difficulty recruiting patients to the clinical trials, patients may drop out of ESSA&#8217;s trials, or ESSA may be required to abandon the trials or the Company&#8217;s development efforts of that product candidate altogether or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In addition, if masofaniten (EPI-7386) or any future product candidates ESSA may develop, are used in combination with other approved products, masofaniten (EPI-7386) or any future product candidates ESSA may develop may exacerbate adverse events associated with the approved product and it may not be possible to determine whether it was caused by ESSA&#8217;s product or the one with which it was combined. Patients treated with masofaniten (EPI-7386) or any future candidates ESSA may develop, may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to masofaniten (EPI-7386) or any future product candidates ESSA may develop, but may still impact the success of ESSA&#8217;s clinical trials. The inclusion of critically ill patients in ESSA&#8217;s clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If any of ESSA&#8217;s product candidate and potential future product candidates receive marketing approval and it or others later identify undesirable or unacceptable side effects caused by such products:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require us to take ESSA&#8217;s approved product off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it may be subject to limitations on how it may promote or distribute the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of the product may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it may be subject to litigation or product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ESSA&#8217;s reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Any of these events could prevent ESSA or its future collaborative partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent ESSA from generating significant revenue from the sale of ESSA&#8217;s products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If ESSA, or any of ESSA&#8217;s partners are unable to enroll and/or maintain subjects in clinical trials, ESSA will be unable to complete its clinical development activities on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of ESSA&#8217;s or ESSA&#8217;s partners clinical trials depends, in part, on the speed at which ESSA or ESSA&#8217;s partners can recruit patients to participate in its trials, as well as completion of required follow-up periods. The Company or its partners may not be able to initiate or continue clinical trials for masofaniten (EPI-7386), or any future product candidate it may develop, if the Company or its partners are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA, or other comparable foreign regulatory authorities. Additionally, certain clinical trials for future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower enrollment than the Company or the Company&#8217;s partners anticipate. The eligibility criteria of ESSA or ESSA&#8217;s partners clinical trials, once established, may further limit the pool of available trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Enrollment of patients in ESSA or ESSA&#8217;s partners clinical trials and maintaining patients in its ongoing clinical trials may be delayed or limited in the future if the Company or the Company&#8217;s partners clinical trial sites have to limit their onsite staff or temporarily close as a result of the widespread health concerns, pandemics or epidemics, or other outbreaks of illness. In addition, patients may not be able to visit clinical trial sites for dosing or data collection purposes due to limitations on travel and physical distancing imposed or recommended by federal or state governments or patients&#8217; reluctance to visit the clinical trial sites during any such event. These factors could delay the anticipated readouts from the Company&#8217;s or the Company&#8217;s partners clinical trials and ultimately delay future regulatory submissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Patient enrollment may also be affected if ESSA&#8217;s or ESSA&#8217;s partners or competitors have ongoing clinical trials for product candidates that are under development for the same indications as masofaniten (EPI-7386), or any future product candidate the Company or the Company&#8217;s partners or competitors may develop, and patients who would otherwise be eligible for ESSA&#8217;s or ESSA&#8217;s partners clinical trials instead enroll in clinical trials of a competitors&#8217; product candidates. Patient enrollment for any of the Company&#8217;s or the Company&#8217;s partners clinical trials may be affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved drugs for the disease under investigation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient eligibility criteria for the trial in question as defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications ESSA is investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued enrollment of prospective patients by clinical trial sites; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Furthermore, ESSA&#8217;s or ESSA&#8217;s partners&#8217; plans to rely on clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites to ensure the proper and timely conduct of the Company&#8217;s or the Company&#8217;s partners clinical trials, and while the Company has agreements governing their committed activities, the Company has limited influence over their actual performance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If ESSA experiences delays in the completion or termination of any clinical trial of any future product candidates, the commercial prospects of product candidates will be harmed, and ESSA&#8217;s or ESSA&#8217;s partners ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing ESSA&#8217;s or ESSA&#8217;s partners&#8217; clinical trials will increase costs, slow down product candidate development and approval process and could shorten any periods during which ESSA or ESSA&#8217;s partners may have the exclusive right to commercialize product candidates or allow competitors to bring products to market before ESSA or ESSA&#8217;s partners does, and jeopardize ESSA&#8217;s or ESSA&#8217;s partners ability to commence product sales, which would impair ESSA&#8217;s or ESSA&#8217;s partners ability to generate revenues and may harm ESSA&#8217;s or ESSA&#8217;s partners business, results of operations, financial condition and cash flows and future prospects. In addition, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of ESSA&#8217;s or ESSA&#8217;s partners proposed products or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA may conduct trials for future product candidates at sites outside the United States and the FDA may not accept data from trials conducted in such locations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA may in the future choose to conduct more clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators of recognized competence and pursuant to GCP requirements. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. The FDA must be able to validate the data through an on-site inspection or other appropriate means. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA chooses to not accept data collected outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt the development of the Company&#8217;s proposed products or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Even if the Company obtains marketing approval for any product candidate and potential future products, the Company will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Even if the Company obtains U.S., Canadian or European regulatory approval for a future product candidate, which would not occur until the Company successfully completes multiple clinical trials, including Phase 3 clinical trials, the FDA, TPD or EMA may still impose significant restrictions on its indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming post-approval studies, including Phase 4 clinical trials or clinical outcome studies and post-market surveillance to monitor the safety and efficacy of ESSA&#8217;s potential products. Even if the Company secures U.S., Canadian or European regulatory approval, the Company would continue to be subject to ongoing regulatory requirements governing manufacturing, labeling, packaging, storage, quality assurance, distribution, import, export, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information. These requirements include registration with the FDA, as well as continued compliance with GCP obligations, for any clinical trials that the Company conducts post approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">With respect to any product candidates for which ESSA obtains regulatory approval, ESSA will be subject to post-marketing regulatory obligations, including the requirements by the FDA, EMA and similar agencies in other jurisdictions to maintain records regarding product safety and to report to regulatory authorities serious or unexpected adverse events. Compliance with extensive post-marketing record keeping and reporting requirements requires a significant commitment of time and funds, which may limit ESSA&#8217;s ability to successfully commercialize approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In addition, manufacturing of approved drug products must comply with extensive regulations governing cGMP. Manufacturers and their facilities are subject to continual review and periodic inspections. As ESSA will be dependent on third parties for manufacturing, ESSA will have limited ability to ensure that any entity manufacturing products on its behalf is doing so in compliance with applicable cGMP requirements. Failure or delay by any manufacturer of ESSA&#8217;s </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">products to comply with cGMP regulations or to satisfy regulatory inspections could have a material adverse effect on ESSA, including potentially preventing ESSA from being able to supply products for clinical trials or commercial sales. In addition, manufacturers may need to obtain approval from regulatory authorities for product, manufacturing, or labeling changes, which requires time and money to obtain and can cause delays in product availability. ESSA is also required to comply with good distribution practices such as maintenance of storage and shipping conditions, as well as security of products, in order to ensure product quality determined by cGMP is maintained throughout the distribution network. In addition, ESSA is subject to regulations governing the import and export of its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Sales and marketing of pharmaceutical products are subject to extensive federal and state or other laws governing on-label and off-label advertising, scientific/educational grants, gifts, consulting and pricing and are also subject to consumer protection and unfair competition laws. Compliance with these extensive regulatory requirements will require training and monitoring of any future sales force, which will impose a substantial cost on ESSA and ESSA&#8217;s collaborators. To the extent any future ESSA products are marketed by collaborators, ESSA&#8217;s ability to ensure their compliance with applicable regulations will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Failure to comply with applicable legal and regulatory requirements may result in administrative or judicial sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If the Company or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, lack of efficacy, problems with the facility where the product is manufactured, or the Company or its manufacturers fail to comply with applicable regulatory requirements, the Company may be subject to the following administrative or judicial sanctions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance of warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties or monetary fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications filed by the Company, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the product from the market and product recalls; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention or refusal to permit the import or export of product.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The occurrence of any event or penalty described above may inhibit the Company&#8217;s ability to commercialize potential products and generate revenue. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase the Company&#8217;s product liability exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In the future, the regulatory climate might change due to changes in the FDA and other regulatory authorities&#8217; staffing, policies or regulations and such changes could impose additional post-marketing obligations or restrictions and related costs. While it is impossible to predict future legislative or administrative action, if the Company is not able to maintain regulatory compliance, the Company will not be able to market its drugs and its business could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If clinical trials for ESSA&#8217;s product candidate and potential future product candidates are prolonged, delayed or stopped, ESSA may be unable to obtain regulatory approval and commercialize such product candidates on a timely basis, or at all, which would require ESSA to incur additional costs and delay receipt of any product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA may experience delays in any future preclinical studies or clinical trials, and ESSA does not know whether future preclinical studies or clinical trials will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. The commencement of these planned clinical trials could be substantially delayed or prevented by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussions with the FDA or other regulatory agencies regarding the scope or design of ESSA&#8217;s clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limited number of, and competition for, suitable sites to conduct ESSA&#8217;s clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as ESSA&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects choosing an alternative treatment for the indication for which ESSA is developing masofaniten (EPI-7386), or participating in competing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain sufficient funds required for a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure to manufacture sufficient supplies of the product candidate or obtaining sufficient quantities of combination therapies for ESSA&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure to obtain IRB approval to conduct a clinical trial at a prospective site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The completion of ESSA&#8217;s clinical trials, once started, could also be substantially delayed or prevented by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of patient recruitment and enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of patients to complete the clinical trial or to return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically significant treatment effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of efficacy during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination of ESSA&#8217;s clinical trials by one or more clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of patients or clinical investigators to follow ESSA&#8217;s anticipated schedule or ESSA&#8217;s clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to monitor patients adequately during or after treatment by ESSA and/or ESSA&#8217;s CROs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ESSA&#8217;s CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual obligations to ESSA in a timely manner, or at all, deviating from the protocol or dropping out of a study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to produce or obtain sufficient quantities of the product candidate to complete clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to scale up manufacture of the product candidate into a commercially acceptable formulation at reasonable cost;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to address any noncompliance with regulatory requirements or safety concerns that arise during the course of a clinical trial; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Changes in regulatory requirements, policies and guidelines may also occur and ESSA may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Such changes may require ESSA to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. ESSA&#8217;s clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of ESSA&#8217;s clinical trial sites with respect to that site, or ESSA, due to a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to conduct the clinical trial in accordance with regulatory requirements or ESSA&#8217;s clinical protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of ESSA&#8217;s product candidates.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Product development costs for any of ESSA&#8217;s potential products will increase if it has delays in testing or approval or if the Company needs to perform more or larger clinical studies than planned. Any delays in completing the Company&#8217;s future clinical trials will increase its costs, slow down its development and approval process and jeopardize its ability to generate revenues. Any of these occurrences may have a material adverse effect on the Company&#8217;s business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ESSA relies on third parties to conduct its preclinical studies and clinical trials, and has entered into collaboration agreements with companies related to combination studies, in addition to the combination study the Company controls. If these third parties do not successfully carry out their contractual duties, fail to meet expected deadlines, or if unfavorable results related to combination studies are announced, this could have a negative impact on ESSA&#8217;s reputation and substantially harm ESSA&#8217;s business because it may not be able to obtain regulatory approval for or commercialize product candidates in a timely manner or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA has extensively relied upon and plans to continue to extensively rely upon entities outside of its control, including independent clinical investigators, CROs and academic institutions, to monitor and manage data for its ongoing preclinical and clinical programs. ESSA relies on these parties for execution of its preclinical studies and clinical trials, and it controls only some aspects of their activities. Nevertheless, ESSA is responsible for ensuring that each of its studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and ESSA&#8217;s reliance on CROs and academic institutions does not relieve it of these responsibilities. ESSA also relies on third parties to assist in conducting its preclinical studies in accordance with GLP and the Animal Welfare Act requirements. ESSA and the third parties that it relies on are required to comply with federal regulations and current GCP, which are international standards meant to protect the rights and health of patients that are enforced by the FDA and comparable foreign regulatory authorities for all of ESSA&#8217;s products in clinical development. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If ESSA or any of the third parties it relies on fail to comply with applicable GCP, the clinical data generated in ESSA&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require ESSA to perform additional clinical trials before approving ESSA&#8217;s marketing applications. ESSA cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of its clinical trials comply with GCP requirements. In addition, ESSA&#8217;s clinical trials must be conducted with product produced under cGMP requirements. Failure to comply with these regulations may require ESSA to repeat preclinical studies and clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA has ongoing combination studies with Astellas and Pfizer, Janssen, and Bayer, not all of which are under ESSA&#8217;s control. These combination studies involve additional risks due to their reliance on circumstances outside of ESSA&#8217;s control, such as those relating to the availability and marketability of the third-party product in the study. In addition, because we have established collaborations with leading biotechnology and pharmaceutical companies, we may be subject to greater reputational risk depending on the outcomes of the combination studies conducted through these collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The third parties that ESSA relies upon are not its employees, and except for remedies available to the Company under its agreements with such third parties, ESSA cannot control whether or not they devote sufficient time and resources to the Company&#8217;s ongoing clinical, nonclinical and preclinical programs. Academic institutions may not operate under the same commercial standards as other third-party CROs that undertake such work and may not be able to devote adequate time and resources to preclinical studies. These third parties may also have relationships with other commercial entities, including ESSA&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on ESSA&#8217;s behalf. Switching or adding additional CROs or academic institutions would involve additional cost and would require management time and focus. The CROs and academic institutions that ESSA relies on have the right to terminate their agreements with the Company in the event of an uncured material breach. If any of ESSA&#8217;s relationships with CROs and academic institutions terminate, the Company could experience a significant delay in identifying, qualifying and managing performance of a comparable third-party service provider, which could adversely affect its development programs. In addition, there is a natural transition period when a new CRO or academic institution commences work and the new CRO or academic institution may not provide the same type or level of services as the original provider. ESSA may not be able to enter into arrangements with alternative CROs or academic institutions or be able to do so on commercially reasonable terms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If independent clinical investigators, CROs or academic institutions do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, ESSA&#8217;s preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize future product candidates. As a result, ESSA&#8217;s results of operations and the commercial prospects for its future product candidates would be harmed, its costs could increase and its ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Because ESSA has relied on third parties, its internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to ESSA&#8217;s standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires ESSA to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. ESSA currently has a small number of employees, which limits the internal resources we have available to identify and monitor third-party providers. To the extent ESSA is unable to identify and successfully manage the performance of third-party service providers in the future, its business may be adversely affected. Though ESSA carefully manages its relationships with CROs and academic institutions, there can be no assurance that it will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on ESSA&#8217;s business, results of operations, financial condition and cash flows and future prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA has limited experience manufacturing product candidates on a large clinical or commercial scale and has no manufacturing facility. As a result, ESSA may in the future be dependent on third-party manufacturers for the manufacture of product candidates as well as on third parties for ESSA&#8217;s supply chain, and if ESSA experiences problems with any future third parties, the manufacturing of ESSA&#8217;s product candidates or products could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA does not own or operate facilities for the manufacture of future potential product candidates. ESSA currently has no plans to build internal clinical or commercial scale manufacturing capabilities. ESSA relies on collaborators either directly or through third-party contract manufacturing organizations, or CMOs, for the manufacture of active pharmaceutical ingredients for ESSA&#8217;s product candidates for preclinical testing and clinical trials and intends to do so for the future commercial manufacturing of its products. Also, ESSA may potentially rely on other CMOs for the production of the final product formulation. To meet ESSA&#8217;s projected potential needs for clinical supplies to support its activities through regulatory approval and commercial manufacturing, the CMOs with whom ESSA works and may potentially work will need to increase the scale of production. ESSA may need to identify additional CMOs for continued production of supply for product candidates in the event the current potential CMOs ESSA chooses to utilize are unable to scale production, or if ESSA otherwise experiences any problems with them. Although alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it could be expensive and take a significant amount of time to arrange for alternative suppliers. ESSA may encounter technical difficulties or delays in the transfer of any future potential product manufacturing on a commercial scale to additional third-party manufacturers. ESSA may be unable to enter into agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms. If ESSA is unable to arrange for alternative third-party manufacturing sources or to do so on commercially reasonable terms or in a timely manner, ESSA may not be able to complete development of its potential product candidates, market or distribute them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Reliance on third-party manufacturers entails risks to which ESSA would not be subject if ESSA manufactured product candidates or products ourselves, including reliance on the third-party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third-party because of factors beyond ESSA&#8217;s control, including a failure to synthesize and manufacture product candidates or any products ESSA may eventually commercialize in accordance with ESSA&#8217;s specifications and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to ESSA. In addition, the FDA and other regulatory authorities require that ESSA&#8217;s product candidates and any products that ESSA may eventually commercialize be manufactured according to cGMP and similar foreign standards. Any failure by ESSA&#8217;s third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of ESSA&#8217;s potential product candidates and could cause ESSA to incur higher costs and prevent ESSA from commercializing product candidates successfully. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to ESSA, or take other regulatory or legal action, including recall or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">seizure of outside supplies of the product candidate, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Any significant disruption in ESSA&#8217;s supplier relationships could harm the Company&#8217;s business. Any significant delay in the supply of a product candidate or its key materials for a potential ongoing clinical study could considerably delay completion of ESSA&#8217;s potential clinical trials, product testing and regulatory approval of ESSA&#8217;s potential product candidates. If ESSA&#8217;s manufacturers or ESSA is unable to purchase these key materials after regulatory approval has been obtained for ESSA&#8217;s product candidates, the commercial launch of ESSA&#8217;s product candidates would be delayed or there would be a shortage in supply, which would impair ESSA&#8217;s ability to generate revenues from the sale of its product candidates. It may take several years to establish an alternative source of supply for ESSA&#8217;s product candidates and to have any such new source approved by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Failure to obtain regulatory approval in international jurisdictions would prevent any product candidates from being marketed outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In order to market and sell ESSA&#8217;s products in the European Union and many other jurisdictions, it must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for ESSA and could delay or prevent the introduction of its potential products in certain countries. ESSA may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. A failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. ESSA may not be able to file for marketing approvals and may not receive necessary approvals to commercialize its potential products in any market. If ESSA is unable to obtain approval of any of its future product candidates by regulatory authorities in the European Union or another jurisdiction, the commercial prospects of that product candidate may be significantly diminished and its business prospects could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recently enacted and future legislation may increase the difficulty and cost for the Company to obtain marketing approval of, and commercialize, its products and affect the prices the Company may obtain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In the United States and internationally there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for ESSA&#8217;s products, restrict or regulate post-approval activities and affect the Company&#8217;s ability to profitably sell products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. The Company does not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of ESSA&#8217;s products, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject the Company to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In recent years, the U.S. Congress has considered reductions in Medicare reimbursement levels for drugs administered by physicians. CMS also has authority to revise Medicare reimbursement rates and to implement Medicare coverage restrictions for some drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products, which in turn would affect the price ESSA can receive for those products, if approved. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In March 2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was signed into law. This law, which was intended to broaden access to health insurance, significantly impacted the pharmaceutical industry. Among other things, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">the ACA imposed an annual fee on manufacturers of branded prescription drugs, increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; expanded the healthcare fraud and abuse laws, implemented a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer discounts off negotiated prices; expanded the eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program; and imposed a number of substantial new compliance provisions related to pharmaceutical companies&#8217; interactions with healthcare practitioners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act, signed into law by President Trump in 2017, effectively repealed the individual health insurance mandate, which is considered a key component of the ACA. In November 2020, the United States Supreme Court heard oral argument in a case regarding the constitutionality of the ACA and the individual mandate. The ongoing challenges to the ACA and new legislative proposals have resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health care market. These reforms could have an adverse effect on anticipated revenue from product candidates that ESSA may successfully develop and for which ESSA may obtain marketing approval and may affect ESSA&#8217;s overall financial condition and ability to develop or commercialize product candidates. For example, it is possible that efforts to repeal the ACA, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. The scope of potential future legislation to repeal and replace the ACA provisions is highly uncertain in many respects, as is the effect of such future legislation on ESSA&#8217;s business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. Beginning April 1, 2013, Medicare payments for all items and services, including drugs and biologics, were reduced by 2% under the sequestration (i.e., automatic spending reductions) required by the Budget Control Act of 2011. Although Medicare sequestration will remain in effect through 2027 unless additional Congressional action is taken, the Coronavirus Aid, Relief, and Economic Security (CARES) Act passed in March 2020 temporarily suspended Medicare sequestration from May 1, 2020, through December 31, 2020. Separately, in January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect future customer demand and affordability for any future our products, if approved and, accordingly, the results of our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Further, the FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. In response to the global COVID-19 pandemic, in March 2020 the FDA announced its intention to postpone most domestic and foreign inspections of manufacturing facilities, and regulatory authorities outside the United States adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. Although the FDA resumed domestic on-site inspections in July 2021, inspections are being scheduled based upon each state&#8217;s phase of reopening and the current intensity and risk of COVID-19 infections in a geographic region, and foreign inspections have not resumed. This or other decreases in FDA inspection or regulatory activity could delay regulatory approval of our product candidates. Changes to the FDA&#8217;s policies and regulations may also impact our product candidates. For example, in December 2016, the 21st Century Cures Act (&#8220;Cures Act&#8221;) was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. In addition, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (&#8220;Right to Try Act&#8221;) was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. ESSA cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on its product candidates, if any, may be.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action in the United States. For example, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set and advertise prices for their marketed products, which have resulted in several Congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries, and bulk purchasing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Further, on September 9, 2021, the Biden Administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The United States Department of Health and Human Services ( &#8220;HHS&#8221;) plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. These initiatives recently culminated in the enactment of the Inflation Reduction Act (the &#8220;IRA&#8221;) in August 2022, which will, among other things, allow the HHS to negotiate the selling price of certain drugs and biologics that the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price beginning in October 2023, penalize drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidates we successfully develop or additional pricing pressures. These and other potential reforms could have a significant impact on the pharmaceutical industry and on the development and potential future pricing of ESSA&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Further, governments and regulatory authorities in Europe and other markets in which ESSA intends to sell its products may propose and adopt new legislation and regulatory requirements relating to pharmaceutical approval criteria and manufacturing requirements. Such legislation or regulatory requirements, or the failure to comply with such, could adversely impact ESSA&#8217;s operations and could have a material adverse effect on ESSA&#8217;s business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In recent years, national, federal, provincial, state, and local officials and legislators have proposed, or are reportedly considering proposing, a variety of price-based reforms to the healthcare systems in the European Union, the United States and other countries. Some proposals include measures that would limit or eliminate payments for certain medical procedures and treatments or subject the pricing of pharmaceuticals to government control. Furthermore, in certain foreign markets, the pricing or profitability of healthcare products is subject to government controls and other measures that have been prepared by legislators and government officials. While ESSA cannot predict whether any such legislative or regulatory proposals or reforms will be adopted, the adoption of any such proposals or reforms could adversely affect the commercial viability of the Company&#8217;s existing and potential products. Significant changes in the healthcare system in the European Union and other countries may have a substantial impact on the manner in which ESSA conducts its business. Such changes could also have a material adverse effect on ESSA&#8217;s business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Risks Related to ESSA&#8217;s Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA will have significant additional future capital needs for future clinical trials and there are uncertainties as to the Company&#8217;s ability to raise additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Management has forecasted that ESSA&#8217;s working capital will be sufficient to execute its planned operating expenses and capital expenditures for the coming fiscal year. On current plans, ESSA believes it has sufficient capital resources to fund its current and planned operations through 2025. The Company recognizes that despite a decreased cash outflow that may occur as a result of delays to clinical trials, general and administrative and other expenses will continue to be incurred which may impact the Company&#8217;s cash runway. ESSA has based this estimate on assumptions that may prove to be wrong, and ESSA could use its capital resources sooner than it currently expects. Advancing ESSA&#8217;s novel and proprietary therapies, or the acquisition and the development of any new products or product candidates will require considerable resources and additional access to capital. In addition, ESSA&#8217;s future cash requirements may vary materially from those now expected. For example, ESSA&#8217;s future capital requirements may increase if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company experiences setbacks in its progress with non-clinical studies or if ongoing or future clinical trials are delayed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company is required to perform additional non-clinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company elects to develop, acquire or license new technologies, products or businesses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company experiences competition from other life sciences companies or in more markets than anticipated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company experiences delays or unexpected increases in connection with obtaining regulatory approvals in the various markets where ESSA hopes to sell its products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company experiences unexpected or increased costs relating to preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, or other lawsuits, brought by either ESSA or ESSA&#8217;s competition; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company experiences scientific progress sooner than expected in its discovery and R&amp;D projects, if ESSA expands the magnitude and scope of these activities, or if ESSA changes its focus as a result of ESSA&#8217;s discoveries.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA could potentially seek additional funding through strategic collaborations, alliances and licensing arrangements, through public or private equity or debt financing, or through other transactions. However, if future sales are slow to increase or if capital market conditions in general, or with respect to life sciences companies such as ESSA&#8217;s, are unfavorable, ESSA&#8217;s ability to obtain significant additional funding on acceptable terms, if at all, will be negatively affected. There is no certainty that any such financing will be provided or provided on favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If sufficient capital is not available, ESSA may be required to delay or abandon its business expansion or R&amp;D projects, either of which could have a material adverse effect on ESSA&#8217;s business, financial condition, prospects or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA may not be able to raise additional capital on favorable terms, which may result in dilution to ESSA&#8217;s existing shareholders, restrictions on ESSA&#8217;s operations or the requirement for ESSA to relinquish rights to technologies or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Until the Company can generate substantial revenue from product sales, if ever, the Company expects to finance future cash needs through a combination of private and public equity offerings, debt financings, strategic collaborations and alliances and licensing arrangements. Additional financing that the Company may pursue may involve the sale of its Common Shares or financial instruments that are exchangeable for, or convertible into, its Common Shares, which could result in significant dilution to ESSA&#8217;s shareholders and the terms may include liquidation or other preferences that adversely affect the rights of existing shareholders. Additional capital may not be available on reasonable terms, if at all. Furthermore, these securities may have rights senior to those of ESSA&#8217;s Common Shares and could contain covenants that include restrictive covenants limiting ESSA&#8217;s ability to take important actions and potentially impair ESSA&#8217;s competitiveness, such as limitations on ESSA&#8217;s ability to incur additional debt, make capital expenditures, acquire, sell or license intellectual property rights or declare dividends. If ESSA raises additional funds through strategic collaborations and alliances or licensing arrangements with third parties, ESSA may have to relinquish valuable rights to technologies or future product candidates, or grant licenses on terms that are not favorable to ESSA. If the Company is unable to raise additional funds when needed, the Company may be required to delay, limit, reduce or terminate its product development </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">or commercialization efforts or grant rights to develop and market product candidates that ESSA would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company was subject to the restrictions and conditions of the CPRIT Agreement for a period of time after receipt of the last grant payment. Failure to have complied with the CPRIT Agreement may materially and adversely affect ESSA&#8217;s financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA relied on the CPRIT Grant to fund a portion of its preclinical and Phase 1 clinical development costs of clinical candidate EPI-506, which ceased development in September 2017. The total of the CPRIT Grant was US$12 million. The CPRIT Grant was subject to various requirements, including ESSA&#8217;s compliance with the scope of work outlined in the CPRIT Agreement. &#160;If ESSA was found not to have complied with the terms of the CPRIT Agreement, or found to have used any grant proceeds for purposes other than intended, or found to have failed to maintain the required level of operations in the State of Texas for three years following the final payment of grant funds, CPRIT could determine that ESSA was in default of its obligations under the CPRIT Agreement and could, among other things, seek reimbursement of all proceeds of the CPRIT Grant received by ESSA. ESSA received and responded to a request in October 2018 for information from CPRIT regarding the nature and extent of the Company&#8217;s operations in Texas. Although the Company believes it has at all times acted in compliance with the CPRIT Agreement and believes its response to CPRIT&#8217;s request for information was satisfactory, there can be no assurance that CPRIT will agree with ESSA&#8217;s determination. If ESSA is found to be in default under the CPRIT Agreement and such default is not waived by CPRIT, the Company could be required to reimburse a portion or all of the CPRIT Grant. Being required to reimburse a portion or all of the CPRIT Grant would impact ESSA&#8217;s ongoing operations, which could materially and adversely affect its financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has incurred significant losses in every quarter since its inception and anticipates that it will continue to incur significant losses in the future and may never generate profits from operations or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA is a clinical stage pharmaceutical company with a limited operating history. Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. ESSA does not have any products approved by regulatory authorities for marketing or commercial sale and has not generated any revenue from product sales, or otherwise, to date. Furthermore, ESSA continues to incur significant research, development and other expenses related to its ongoing operations. As a result, ESSA is not profitable and has incurred losses in every reporting period since inception in 2009. For the years ended September 30, 2023 and September 30, 2022, ESSA reported net losses of $26,567,596 and $35,161,917, respectively. As of September 30, 2023, ESSA had an accumulated deficit since inception of $179,461,359.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company expects to continue to incur significant expenses and operating losses for the foreseeable future. ESSA anticipates these losses will increase as it continues the research and development of, and seeks regulatory approvals for, its product candidate and any of its potential future product candidates and potentially begins to commercialize any products that may achieve regulatory approval. ESSA may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect its financial condition. ESSA expects its financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond ESSA&#8217;s control. The size of ESSA&#8217;s future net losses will depend, in part, on the rate of future growth of ESSA&#8217;s expenses and ESSA&#8217;s ability to generate revenues. The Company&#8217;s prior losses and expected future losses have had and will continue to have an adverse effect on the Company&#8217;s financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Even if the Company is able to commercialize any product candidate, there can be no assurance that the Company will generate significant revenues or ever achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company expects to continue to incur substantial losses for the foreseeable future, and these losses may be increasing. The Company is uncertain about when or if it will be able to achieve or sustain profitability. If the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. Failure to become and remain profitable would impair the Company&#8217;s ability to sustain operations and adversely affect the price of the Common Shares and its ability to raise capital.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA has a limited operating history, which may make it difficult for you to evaluate the success of ESSA&#8217;s business to date and to assess ESSA&#8217;s future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company commenced operations in 2009, and its operations have been primarily limited to organizing and staffing ESSA, business planning, raising capital, establishing relationships with consultants and contract vendors with relevant expertise, acquiring the in-licensing of intellectual property, filing patent applications, discovering and developing novel small molecule product candidates, conducting preliminary preclinical research, preparing for and conducting early-stage clinical trials. ESSA is a development stage company with limited operating history and no revenue. As a development stage company ESSA may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors. If the Company&#8217;s trials are successful, ESSA will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. ESSA may not be successful in such a transition. ESSA has identified a product candidate, masofaniten (EPI-7386), to advance through clinical development but does not have any products ready for commercialization. Consequently, evaluating ESSA&#8217;s performance, viability or future success will be more difficult than if ESSA had a longer operating history or approved products on the market. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Risks Related to ESSA&#8217;s Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA relies on proprietary technology, the protection of which can be unpredictable and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s activities depend, in part, on its ability to (i) obtain and maintain patents, trade secret protection and operate without infringing the intellectual proprietary rights of third parties, (ii) successfully defend these patents (including patents owned by or licensed to the Company) against third-party challenges and (iii) successfully enforce these patents against third-party competitors. There is no assurance that the Company will be granted such patents or proprietary technology or that such granted patents or proprietary technology will not be circumvented through the adoption of a competitive, though non-infringing, process or product. Failure to protect the Company&#8217;s existing and future intellectual property rights could seriously harm its business and prospects and may result in the loss of its ability to exclude others from using the Company&#8217;s technology or its own right to use the technologies. If the Company does not adequately ensure the right to use certain technologies, it may have to pay others for the right to use their intellectual property, pay damages for infringement or misappropriation or be enjoined from using such intellectual property. The Company&#8217;s patents do not guarantee the right to use the technologies if other parties own intellectual property rights that are necessary in order to use such technologies. The Company&#8217;s patent position is subject to complex factual and legal issues that may give rise to uncertainty as to the validity, scope and enforceability of a particular patent. The Company&#8217;s and the Company&#8217;s licensors&#8217; patents and patent applications, if issued, may be challenged, invalidated or circumvented by third parties. U.S. patents and patent applications may also be subject to interference proceedings, re-examination proceedings, derivation proceedings, post-grant review or inter partes review in the United States Patent and Trademark Office (&#8220;USPTO&#8221;), challenging the Company&#8217;s or the Company&#8217;s licensors&#8217; patent rights. Foreign patents may be subject also to opposition or comparable proceedings in the corresponding foreign patent office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">For example, in patent litigation in the United States and in some other jurisdictions, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness, written description, indefiniteness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or third party could challenge the Company&#8217;s patents on this basis even if the Company believes that it conducted its patent prosecution in accordance with the duty of candor and in good faith. The outcome following such a challenge is unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In addition, it is possible that the Company or its licensors do not perfect ownership of all patents, patent applications or other intellectual property. This possibility includes the risk that the Company or its licensors does not identify all inventors, or identifies incorrect inventors, or that third parties pursue an ownership interest in the Company&#8217;s patents, which may lead to claims disputing inventorship or ownership of ESSA&#8217;s patents, patent applications or other intellectual property by former employees or other third parties. If ESSA fails in prosecuting or defending any such claims, in addition to paying monetary damages, ESSA may lose valuable intellectual property rights or personnel or sustain damages. ESSA may lose exclusive rights to their intellectual property rights and ESSA could be required to obtain a license from such third-party to commercialize ESSA&#8217;s technology or products. Such a license may not be available on commercially reasonable terms </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">or at all. Even if ESSA is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If a defendant were to prevail on a legal assertion of invalidity, sole or joint ownership, and/or unenforceability, the Company would lose at least part, or perhaps all, of the patent protection on a product candidate. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, the Company&#8217;s patent claims may be construed in a manner that would limit its ability to enforce such claims against the defendant and others. The cost of defending such a challenge, and any resulting loss of patent protection, could have a material adverse impact on one or more of the Company&#8217;s product candidates and its business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Certain of ESSA&#8217;s current or former employees, contractors or consultants, including senior management, were previously employed, or continue to be employed, at universities or other public institutions, or at other biotechnology or pharmaceutical companies, including ESSA&#8217;s competitors or potential competitors. Some of these employees may have executed proprietary rights, nondisclosure and noncompetition agreements, in connection with such previous employment. ESSA may be subject to claims that ESSA, or these employees, have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition, there is a risk that improved versions of ESSA&#8217;s own product developed by third parties will be granted patent protection and compete with ESSA&#8217;s products. For example, any patents ESSA obtains may not be sufficiently broad to prevent others from utilizing its technologies or from developing competing products and technologies. Third parties may attempt to circumvent ESSA&#8217;s patents by means of alternative designs and processes or may independently develop similar products, duplicate any of ESSA&#8217;s products not under patent protection, or design around the inventions ESSA claims in any of its existing patents, existing patent applications or future patents or patent applications. The actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of ESSA&#8217;s coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patents. It is impossible to anticipate the breadth or degree of protection that patents will afford products developed by ESSA or their underlying technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In any case, there can be no assurance that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any rights under U.S., Canadian, or foreign patents owned by the Company or other patents that third parties license to the Company will not be curtailed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company was the first inventor of inventions covered by its issued patents or pending applications or that the Company was the first to file patent applications for such inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s pending or future patent applications will be issued with the breadth of claim coverage sought by the Company, or be issued at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s competitors will not independently develop or patent technologies that are substantially equivalent or superior to the Company&#8217;s technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties will not attempt to circumvent ESSA&#8217;s patents by means of alternative designs and processes or that third parties will not also independently develop similar products, duplicate any of ESSA&#8217;s products not under patent protection, or design around the inventions ESSA claims in any of the Company&#8217;s existing patents, existing patent applications or future patents or patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of the Company&#8217;s trade secrets will not be learned independently by its competitors; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the steps the Company takes to protect its intellectual property will be adequate.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition, effective patent, trademark, copyright and trade secret protection may be unavailable, limited or not sought in certain foreign countries. Further, countries ESSA may sell to may not protect its intellectual property to the same extent as the laws of the United States, Canada or Europe, and may lack rules and procedures required for defending ESSA&#8217;s patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">There is a risk that any patents issued relating to ESSA&#8217;s products or any patents licensed to ESSA may be successfully challenged or that the practice of its products might infringe the patents of third parties. If the practice of ESSA&#8217;s products infringes the patents of third parties, the Company may be required to design around such patents, potentially causing increased costs and delays in product development and introduction or precluding ESSA from developing, manufacturing or selling its planned products. In addition, disputes may arise as to the rights to know-how and inventions among ESSA&#8217;s </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">employees and consultants who use intellectual property owned by others for the work performed for the Company. The scope and validity of patents which may be obtained by third parties, the extent to which ESSA may wish or need to obtain patent licenses and the cost and availability of such licenses are currently unknown. If such licenses are obtained, it is likely they would be royalty bearing, which could reduce ESSA&#8217;s income. If licenses cannot be obtained on an economical basis, delays in market introduction of its planned products could occur or introduction could be prevented, in some cases causing the expenditure of substantial funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In certain instances, ESSA may elect not to seek patent protection but instead rely on the protection of the Company&#8217;s technology through confidentiality agreements or trade secrets. There can be no assurance that these agreements will not be breached, that the Company will have adequate remedies for any breach or that such persons or institutions will not assert rights to intellectual property arising out of these relationships. The value of ESSA&#8217;s assets could also be reduced to the extent that third parties are able to obtain patent protection with respect to aspects of ESSA&#8217;s technology or products or that confidential measures ESSA has in place to protect the Company&#8217;s proprietary technology are breached or become unenforceable. However, third parties may independently develop or obtain similar technology and such third parties may be able to market competing products and obtain regulatory approval through a showing of equivalency to one of ESSA&#8217;s products which has obtained regulatory approval, without being required to undertake the same lengthy and expensive clinical studies that ESSA would have already completed. The cost of enforcing the Company&#8217;s patent rights or defending rights against infringement charges by other patent holders may be significant and could limit operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Litigation may also be necessary to enforce patents issued or licensed to ESSA or to determine the scope and validity of a third party&#8217;s proprietary rights. ESSA could incur substantial costs if the Company is required to defend itself in patent suits brought by third parties, if ESSA participates in patent suits brought against or initiated by ESSA&#8217;s corporate collaborators or if ESSA initiates such suits. The Company may not have the necessary resources to participate in or defend any such activities or litigation. Even if ESSA did have the resources to vigorously pursue its interests in litigation, because of the complexity of the subject matter, it is impossible to predict whether ESSA would prevail in any such action. Any claims of patent infringement asserted by third parties may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">divert the time and attention of the Company&#8217;s technical personnel and management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cause product development or commercialization delays;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the Company to cease or modify its use of the technology and/or develop non-infringing technology; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the Company to enter into royalty or licensing agreements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If third parties successfully assert their intellectual property rights against ESSA, ESSA might be barred from using certain aspects of its intellectual property portfolio or barred from developing and commercializing certain products. Prohibitions against using certain technologies or prohibitions against commercializing certain products could be imposed by a court or by a settlement agreement between the Company and a plaintiff. In addition, if ESSA is unsuccessful in defending against allegations that it has infringed, misappropriated or otherwise violated patent or other intellectual property rights of others, the Company may be forced to pay substantial damage awards to a plaintiff. If litigation leads to an outcome unfavorable to the Company or in order to avoid or settle potential claims, the Company may choose or be required to seek a license from a third-party and be required to pay license fees or royalties or both, which could be substantial, in order to continue the Company&#8217;s development or to commercialize any resulting product. It is possible that the necessary license will not be available to the Company on commercially acceptable terms, or at all. These licenses may not be available on acceptable terms, or at all. Even if the Company or any future collaborators were able to obtain a license, the rights may be nonexclusive, which could result in the Company&#8217;s competitors gaining access to the same intellectual property. Ultimately, the Company could be prevented from commercializing a product, or be forced, by court order or otherwise, to cease some or all aspects of its business operations, if, as a result of actual or threatened patent or other intellectual property claims, we are unable to enter into licenses on acceptable terms. Alternatively, the Company may be required to modify or redesign its current or future products, if any, in order to avoid infringing or otherwise violating third-party intellectual property rights. This may not be technically or commercially feasible, may render those products less competitive, or may delay or prevent the entry of those products to the market. Further, the Company could be found liable for significant monetary damages as a result of claims of intellectual property infringement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">An adverse outcome in litigation, or interference or derivation proceeding to determine priority or other proceeding in a court or patent or selling office could subject ESSA to significant liabilities, require disputed rights to be licensed from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">third parties or require ESSA to cease using certain technology or products, any of which may have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA may not be able to protect its intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Filing, prosecuting and defending patents on ESSA&#8217;s product candidate and potential future product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States or federal and provincial laws in Canada. Consequently, ESSA may not be able to prevent third parties from practicing its inventions in all countries outside the United States or Canada, or from selling or importing products made using its inventions in and into the United States, Canada or other jurisdictions. Competitors may use ESSA&#8217;s technologies in jurisdictions where it has not obtained patent protection to develop their own products and may export otherwise infringing products to territories where ESSA has patent protection, but where enforcement is not as strong as that in the United States or Canada. These products may compete with ESSA&#8217;s products in jurisdictions where it does not have any issued patents and its patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for ESSA to stop the infringement, misappropriation or violation of its patents or ESSA&#8217;s licensors patents, or marketing of competing products in violation of its proprietary rights generally. Proceedings to enforce ESSA&#8217;s patent rights in foreign jurisdictions could result in substantial cost and divert its efforts and attention from other aspects of its business, could put ESSA&#8217;s patents or the patents of ESSA&#8217;s licensors at risk of being invalidated or interpreted narrowly, could put ESSA&#8217;s patent applications or the patent applications of ESSA&#8217;s licensors at risk of not issuing and could provoke third parties to assert claims against ESSA. ESSA may not prevail in any lawsuits that it initiates and the damages or other remedies awarded, if any, may not be commercially meaningful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval of a drug and its patent status. Furthermore, generic or biosimilar drug manufacturers or other competitors may challenge the scope, validity or enforceability of ESSA&#8217;s patents, requiring it to engage in complex, lengthy and costly litigation or other proceedings. Generic or biosimilar drug manufacturers may develop, seek approval for, and launch biosimilar versions of ESSA&#8217;s products. In addition to India, certain countries in Europe and developing countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, ESSA may have limited remedies if patents are infringed or if it is compelled to grant a license to a third-party, which could materially diminish the value of those patents. This could limit ESSA&#8217;s potential revenue opportunities. Accordingly, ESSA&#8217;s efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that it owns or licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Obtaining and maintaining ESSA&#8217;s patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and ESSA&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and other foreign patent agencies in several stages over the lifetime of ESSA&#8217;s patents and/or applications. ESSA has systems in place to remind the Company to pay these fees. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. ESSA employs reputable law firms to help the Company comply, and in many cases, an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules to the relevant jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If ESSA or its future potential licensors fail to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">maintain the patents and patent applications covering product candidates, ESSA&#8217;s competitive position would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Depending upon the timing, duration and conditions of FDA marketing approval of ESSA&#8217;s product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, the Company may not receive an extension if it fails to apply within applicable deadlines, fails to apply prior to expiration of relevant patents or otherwise fails to satisfy applicable requirements. Moreover, the length of the extension could be less than the Company requests. If the Company is unable to obtain patent term extension or the term of any such extension is less than it requests, the period during which the Company can enforce its patent rights for that product will be shortened and the Company&#8217;s competitors may obtain approval to market competing products sooner. As a result, the Company&#8217;s revenue from applicable products could be reduced, possibly materially. Further, if this occurs, ESSA&#8217;s competitors may take advantage of the Company&#8217;s investment in development and trials by referencing the Company&#8217;s clinical and preclinical data and launch their product earlier than might otherwise be the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Confidentiality Agreements with employees and third parties may not prevent unauthorized disclosure of Company proprietary information, which would harm ESSA&#8217;s competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition to patents, ESSA relies on technical know-how and proprietary information concerning the Company&#8217;s, business strategy and product candidates in order to protect its competitive position. ESSA&#8217;s employees are required to sign agreements which protect the Company&#8217;s proprietary information and intellectual property rights. In the course of ESSA&#8217;s research and development activities and its business activities and operations, the Company relies on confidentiality and service agreements with its third-party service providers, consultants and contractors, to protect its proprietary information and intellectual property rights. Such assignment agreements may be breached, and the Company may be forced to bring claims against third parties, or defend claims that third parties may bring against the Company. In addition, the Company&#8217;s employees, consultants, contractors, business partners or outside scientific collaborators may intentionally or inadvertently disclose the Company&#8217;s proprietary information in breach of these agreements. Third parties working collaboratively with ESSA may have certain rights to publish data and may fail to notify ESSA of such publication and ESSA in turn may fail to apply for patent protection prior to such disclosure. It is possible that a competitor may make use of such information disclosure, and that ESSA&#8217;s competitive position could be compromised. Enforcing a claim that a third party illegally obtained and is using any of ESSA&#8217;s proprietary information is expensive and time consuming, and the outcome may be unpredictable. In addition, courts outside the U.S. sometimes may be less willing than U.S. courts to protect proprietary information and know-how. Moreover, the Company&#8217;s competitors may independently develop equivalent knowledge, methods and know-how. If the Company cannot maintain the confidentiality of its proprietary technology and other confidential information, then the Company&#8217;s ability to obtain patent protection could be jeopardized, which could adversely affect ESSA&#8217;s competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If ESSA&#8217;s trademarks and trade names are not adequately protected, the Company may not be able to build name recognition in its markets of interest and its business, financial condition, results of operations and prospects could be significantly harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">ESSA intends to use registered or unregistered trademarks or trade names to brand and market itself and its products. The Company&#8217;s trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. The Company may not be able to protect its rights to these trademarks and trade names, which it needs to build name recognition among potential partners or customers in its markets of interest. At times, competitors may adopt trade names or trademarks similar to ESSA&#8217;s, thereby impeding its ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of the Company&#8217;s registered or unregistered trademarks or trade names. Over the long term, if the Company is unable to establish name recognition based on its trademarks and trade names, then the Company may not be able to compete effectively, and its business, financial condition, results of operations and prospects may be significantly harmed. The Company&#8217;s efforts to enforce or protect its proprietary rights related to trademarks, trade names, domain names, copyrights or other intellectual </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">property may be ineffective and could result in substantial costs and diversion of resources and could significantly harm its business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Intellectual property litigation may lead to unfavorable publicity that harms ESSA&#8217;s reputation and causes the market price of its Common Shares to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in such litigation. If securities analysts or investors regard these announcements as negative, the perceived value of the Company&#8217;s existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of the Company&#8217;s Common Shares may decline. Such announcements could also harm ESSA&#8217;s reputation or the market for the Company&#8217;s future products, which could significantly harm the Company&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ESSA&#8217;s intellectual property rights may not necessarily provide the Company with competitive advantages and its patent terms may be inadequate to protect the Company&#8217;s competitive position on its product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The degree of future protection afforded by the Company&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect the Company&#8217;s business, or permit the Company to maintain its competitive advantage. The following examples are illustrative: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make compounds that are similar to the Company&#8217;s product candidates but that are not covered by the claims of the patents that the Company or the Company&#8217;s strategic partners own or have exclusively licensed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies without infringing the Company&#8217;s intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that the Company owns or has exclusively licensed may not provide the Company&#8217;s with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by the Company&#8217;s competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company may obtain patents for certain compounds many years before it obtains marketing approval for products containing such compounds, and because patents have a limited term, the term may run close to the commercial sale of the related product, the commercial value of the Company&#8217;s patents may be limited;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company may fail to develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the laws of certain countries may not protect the Company&#8217;s intellectual property rights to the same extent as the laws of the United States, or the Company may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which it operates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party patents may have an adverse effect on the Company&#8217;s business, for example by preventing the Company from marketing one or more of its product candidates for one or more indications.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Any of the aforementioned threats to the Company&#8217;s competitive advantage could have a material adverse effect on its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In addition, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various patent term extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering the Company&#8217;s product candidates are obtained, once the patent life has expired, the Company may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, the Company&#8217;s owned and licensed patents may not provide the Company with sufficient rights to exclude others from commercializing products similar or identical to the Company&#8217;s.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing ESSA&#8217;s ability to protect its products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of the Company&#8217;s intellectual property. The Company cannot predict the breadth of claims that may be allowed or found to be enforceable in its patents (including patents owned by or licensed to the Company), in the Company&#8217;s strategic partners&#8217; patents or in third-party patents. Recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to the Company&#8217;s ability to obtain patents in the future, this has created uncertainty with respect to the validity, scope and value of patents, once obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2011, the Leahy-Smith America Invents Act, also known as the America Invents Act (&#8220;AIA&#8221;), was signed into law. An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a first inventor to file system for deciding which party should be granted a patent when two or more patent applications are filed by different parties disclosing or claiming the same invention. A third party that has filed, or files a patent application in the USPTO after March 16, 2013, but before the Company&#8217;s, could be awarded a patent covering a given invention, even if the Company had made the invention before it was made by the third party. This requires the Company to be cognizant of the time from invention to filing of a patent application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that may weaken the Company&#8217;s and the Company&#8217;s licensors&#8217; ability to obtain new patents or to enforce existing patents the Company and the Company&#8217;s licensors or partners may obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent protection and patent prosecution for some of ESSA&#8217;s product candidates may be dependent on, and the ability to assert patents and defend them against claims of invalidity may be maintained by, third parties. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">There may be times in the future when certain patents that relate to the Company&#8217;s product candidates or any approved products are controlled by the Company&#8217;s licensees or licensors. Although the Company may, under such arrangements, have rights to consult with the Company&#8217;s strategic partners on actions taken as well as back-up rights of prosecution and enforcement, the Company may relinquish rights to prosecute and maintain patents and patent applications within the Company&#8217;s portfolio as well as the ability to assert such patents against infringers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If any current or future licensee or licensor with rights to prosecute, assert or defend patents related to the Company&#8217;s product candidates fails to appropriately prosecute and maintain patent protection for patents covering any of the Company&#8217;s product candidates, or if patents covering any of the Company&#8217;s product candidates are asserted against infringers or defended against claims of invalidity or unenforceability in a manner that adversely affects such coverage, the Company&#8217;s ability to develop and commercialize any such product candidate may be adversely affected and the Company may not be able to prevent competitors from making, using and selling competing products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Risks Related to ESSA&#8217;s Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s business and operations would suffer in the event of computer system failures or security breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In the ordinary course of ESSA&#8217;s business, the Company collects, stores and transmits confidential information, including intellectual property, proprietary business information and personal information. Despite the implementation of security measures, ESSA&#8217;s internal computer systems, and those of other third parties on which the Company relies, including, but not limited to, ESSA&#8217;s CROs, collaborators, contractors or consultants, are vulnerable to damage from computer viruses, unauthorized access, cyberattacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. Cyberattacks are increasing in their frequency, sophistication and intensity. Cyberattacks could include the deployment of harmful malware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Significant disruptions of ESSA&#8217;s information technology systems or security breaches could adversely affect ESSA&#8217;s business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and could result in financial, legal, business and reputational harm to the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If ESSA fails to maintain or protect ESSA&#8217;s information systems and data integrity effectively, ESSA could lose or have difficulty attracting customers, have difficulty preventing, detecting and controlling fraud, experience increases in operating expenses, incur expenses or lose revenues, or suffer other adverse consequences as a result of a data privacy breach. If such disruptions were to occur and cause interruptions in ESSA&#8217;s operations or result in the unauthorized acquisition of ESSA&#8217;s access to personally identifiable information or individually identifiable health information (violating certain privacy laws, as applicable, such as HIPAA, CCPA, HITECH and GDPR), it could result in a material disruption of ESSA&#8217;s drug development program and ESSA could be subject to significant fines or penalties for any non-compliance with certain state and/or international privacy and security laws. Further, the loss of preclinical study or clinical trial data from completed, ongoing or planned preclinical studies or clinical trials could result in delays in ESSA&#8217;s efforts to identify and develop product candidates and significantly increase its costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of, or damage to, ESSA&#8217;s data or applications, or inappropriate disclosure of confidential or proprietary information, the Company could incur liability and the further development of its product candidate and the Company&#8217;s potential future product candidates could be delayed. ESSA&#8217;s insurance policies may not be adequate to compensate ESSA for the potential loss arising from such disruptions, failure or security breach. In addition, such insurance may not be available to ESSA in the future on economically reasonable terms, or at all. Further ESSA&#8217;s insurance may not cover all claims made against ESSA and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. While ESSA has invested in the protection of data and information technology, there can be no assurance that ESSA&#8217;s efforts, or those of ESSA&#8217;s third-party collaborators, if any, to implement adequate security and quality control measures for data processing would be sufficient to protect against data deterioration or loss in the event of a system malfunction, or to prevent data from being stolen or corrupted in the event of a security breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Business disruptions could seriously harm ESSA&#8217;s future revenues and financial condition and increase costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA&#8217;s operations and the operations of third parties whom ESSA depend upon, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which ESSA is predominantly self-insured. Although ESSA carries insurance for earthquakes and other natural disasters, ESSA may not carry sufficient business interruption insurance to compensate the Company for all losses that may occur. The disaster recovery and business continuity plans ESSA has in place may not be adequate in the event of a serious disaster or similar event. ESSA does not carry insurance for all categories of risk that ESSA&#8217;s business may encounter. The occurrence of any of these business disruptions could seriously harm ESSA&#8217;s operations and financial condition and increase costs and expenses. Further, any significant uninsured liability may require ESSA to pay substantial amounts, which would adversely affect ESSA&#8217;s business, results of operations, financial condition and cash flows from future prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If the Company is not successful in attracting and retaining highly qualified personnel, the Company may not be able to successfully implement its business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s ability to compete in the highly competitive biotechnology and pharmaceutical industries depends in large part upon its ability to attract and retain highly qualified managerial, scientific and medical personnel. Competition affects the Company&#8217;s ability to hire and retain highly qualified personnel on acceptable terms. The Company is highly dependent on its management, scientific and medical personnel. The Company&#8217;s management team has substantial knowledge in many different aspects of drug development and commercialization. Despite the Company&#8217;s efforts to retain valuable employees, members of its management, scientific and medical teams may terminate their employment with the Company on short notice or, potentially, without any notice at all. The Company does not maintain &#8220;key person&#8221; insurance for any of its executives or employees. The loss of the services of any of the Company&#8217;s executive officers or other key employees could potentially harm its business, operating results or financial condition. The Company&#8217;s success may also depend on its ability to attract, retain and motivate highly skilled junior, mid-level, and senior managers and scientific personnel. Other pharmaceutical companies with which the Company competes for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than the Company does. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what the Company has to offer. The Company relies on consultants and advisors, including scientific and clinical advisors, to assist ESSA in its research and development strategy. The Company&#8217;s consultants and advisors may be employed by employers other than ESSA and may have commitments under consulting or advisory contracts with other entities that may limit their availability to the Company. If the Company is unable to continue to attract and retain high-quality personnel, the rate and success at which the Company can develop and commercialize product candidates would be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain the Company&#8217;s future revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In many of the markets ESSA hopes to sell future products in, successful commercialization of any product candidate will depend, in part, on the extent to which coverage and reimbursement for such product candidates and related treatments will be available from government healthcare programs, private health insurers, managed care plans and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy for coverage and reimbursement for products exists among third -party payors in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require ESSA to provide scientific and clinical support for the use of ESSA&#8217;s products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">A primary trend in the U.S. healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. ESSA cannot be sure that coverage and reimbursement will be available for any product candidates that it or any future collaborator commercialize and, if reimbursement is available, the level of reimbursement. In addition, coverage and reimbursement may impact the demand for, or the price of, any product candidate for which ESSA or a collaborator obtains marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, ESSA or its collaborators may not be able to successfully commercialize any product candidate for which marketing approval is obtained.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the TPD, FDA or other regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers ESSA&#8217;s costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover ESSA&#8217;s and any collaborator&#8217;s costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. ESSA&#8217;s or any collaborator&#8217;s inability to promptly obtain coverage and profitable payment rates from both government-funded and private payers for any approved products that ESSA or its collaborators develop could have a material adverse effect on ESSA&#8217;s operating results, ability to raise capital needed to commercialize product candidates and overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The directors and officers of ESSA may be subject to conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Some of the directors and officers are engaged and will continue to be engaged in the search for additional business opportunities on behalf of other corporations and situations may arise where these directors and officers will be in direct competition with the Company. Not all of the Company&#8217;s directors or officers are subject to non-competition agreements. Some of the directors and officers of the Company are or may become directors or officers of the other companies engaged in other business ventures whose operations may, from time to time, be in direct competition with ESSA&#8217;s operations. Conflicts, if any, will be dealt with in accordance with the relevant provisions of the Business Corporations Act (British Columbia) and under the Company&#8217;s articles of incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company faces intense competition from other biotechnology and pharmaceutical companies and its operating results will suffer if the Company fails to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change with a strong emphasis on proprietary and novel products and product candidates. ESSA&#8217;s competitors may develop products, product candidates and processes competitive to ESSA&#8217;s masofaniten (EPI-7386). The Company&#8217;s potential competitors in the United States and globally include large, multi-national pharmaceutical companies, established biotechnology companies, specialty pharmaceutical sales and marketing companies, specialized cancer treatment companies, emerging and start-up companies, universities and other research institutions. Many companies, as well as research organizations, currently engage in, or have in the past engaged in, efforts related to the development of products in the same therapeutic areas as ESSA does. Due to the size of the prostate cancer treatment market and the large unmet medical need for products that treat CRPC, a number of the world&#8217;s largest pharmaceutical companies are developing, or could potentially develop, products that could compete with the Company&#8217;s future product candidates. Products ESSA may develop in the future are also likely to face competition from other product therapies, some of which ESSA may not be currently aware. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Many of the companies developing competing technologies and products in ESSA&#8217;s field have significantly greater financial resources and expertise in discovery, R&amp;D, manufacturing, preclinical studies and clinical testing, obtaining regulatory approvals and marketing than ESSA does. These companies may also have products that have been approved or are in late stages of development in our target markets. Other smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for discovery, research, clinical development and marketing of products similar to ESSA&#8217;s. There is a risk that one or more of ESSA&#8217;s competitors may develop more effective or more affordable products and that such competitors will commercialize products that will render its product candidates obsolete. ESSA faces competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent positions of others. In addition, these companies and institutions also compete with ESSA in recruiting and retaining qualified personnel, and in seeking and entering into new strategic partnerships. ESSA also competes with these companies and institutions in establishing clinical trial sites and enrolling subjects for clinical trials. If the Company </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">is not able to compete effectively against its current and future competitors, its business will not grow and its financial condition and operations will suffer materially adverse effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may face exposure to adverse movements in foreign currency exchange rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA&#8217;s business may expand internationally and as a result, a significant portion of its revenues, expenses, current assets and current liabilities may be preliminary denominated in foreign currencies, while its financial statements are expressed in U.S. dollars. A decrease in the value of such foreign currencies relative to the U.S. dollar could result in losses in revenues from currency exchange rate fluctuations. To date, ESSA has not hedged against risks associated with foreign exchange rate exposure. ESSA cannot be sure that any hedging techniques it may implement in the future will be successful or that its business, financial condition, and results of operations will not be materially adversely affected by exchange rate fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If ESSA is not able to convince public payors and hospitals to include ESSA&#8217;s products on their approved formulary lists, revenues may not meet expectations and ESSA&#8217;s business, results of operations and financial condition may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Hospitals establish formularies, which are lists of drugs approved for use in the hospital. If a drug is not included on the hospital&#8217;s formulary, the ability to promote and sell ESSA&#8217;s products may be limited or denied. If ESSA fails to secure and maintain formulary inclusion for products on favorable terms or are significantly delayed in doing so, ESSA may have difficulty achieving market acceptance of products and ESSA&#8217;s business, results of operations and financial condition could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has never marketed a drug before, and if the Company is unable to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements, the Company may be unable to generate any revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA does not currently have, and has never had, an infrastructure for the sales, marketing and distribution of pharmaceutical drug products. The cost of establishing and maintaining such an infrastructure may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities, ESSA must build its sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. Establishing such an infrastructure will be expensive and time-consuming and will require significant attention of ESSA&#8217;s executive officers to manage and could delay any product launch of ESSA&#8217;s lead product candidate and potential future product candidates. If ESSA is unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, ESSA may not be able to generate product revenue and may not become profitable. If ESSA chooses to collaborate, either globally or on a territory-by territory basis, with third parties that have direct sales forces and established distribution systems, either to augment ESSA&#8217;s own sales force and distribution systems or in lieu of ESSA&#8217;s own sales force and distribution systems, ESSA will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If ESSA is unable to enter into such arrangements when needed, on acceptable terms, or at all, ESSA may not be able to successfully commercialize its lead product candidate and potential future product candidates, or any such commercialization&#8217;s may experience delays or limitations. ESSA will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, ESSA may be unable to compete successfully against these more established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company will need to expand the size of its organization and the Company may experience difficulties in managing this growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">As the Company&#8217;s development and commercialization plans and strategies develop, and if clinical trials are successful, the Company expects that it will need to expand the size of its employee base for managerial, operational, sales, marketing, financial and other resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. In addition, the Company&#8217;s management may have to divert </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">a disproportionate amount of its attention away from the Company&#8217;s day-to-day activities and devote a substantial amount of time to managing these growth activities. The Company&#8217;s future financial performance and its ability to commercialize its potential products and any other future product candidates and its ability to compete effectively will depend, in part, on the Company&#8217;s ability to effectively manage any future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA&#8217;s product candidate and potential future products may, if approved for sale, not achieve or maintain expected levels of market acceptance, which could have a material adverse effect on its business, financial condition and results of operations and could cause the market value of its securities to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Even if ESSA is able to obtain regulatory approvals for its product candidates, the success of those products is dependent upon achieving and maintaining market acceptance. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial success. Levels of market acceptance for ESSA&#8217;s products could be impacted by several factors, many of which are not within ESSA&#8217;s control, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of clinical safety and efficacy of ESSA&#8217;s potential products and other possible AR-NTD inhibitors generally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety, efficacy, convenience and cost-effectiveness of ESSA&#8217;s products compared to products of its competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any adverse side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scope of approved uses and marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in FDA-approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market approvals and market entry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to prescribe ESSA&#8217;s potential products and of the target patient population to try new therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inclusion of AR-NTD inhibitor products in applicable treatment guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new procedures or methods of treatment that may reduce the incidences of any of the indications for which ESSA&#8217;s potential products shows utility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in, or excessive costs to, manufacture;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringement or alleged infringement of the patents or intellectual property rights of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of any new products, including generic AR-NTD inhibitor products, that may in the future become available to treat indications for which ESSA&#8217;s potential product may be approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of alternative products from ESSA&#8217;s competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the price of ESSA&#8217;s products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to market ESSA&#8217;s products effectively at the retail level.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition, the success of any new product will depend on ESSA&#8217;s ability to either successfully build its in-house sales capabilities or to secure new, or to realize the benefits of existing arrangements with third-party marketing or distribution partners. Seeking out, evaluating and negotiating marketing or distribution agreements may involve the commitment of substantial time and effort and may not ultimately result in an agreement. In addition, the third-party marketing or distribution partners may not be as successful in promoting ESSA&#8217;s products as it had anticipated. If ESSA is unable to commercialize new products successfully, whether through a failure to achieve market acceptance, a failure to build its own in-house sales capabilities, a failure to secure new marketing partners or to realize the benefits of ESSA&#8217;s arrangements with existing marketing partners, there may be a material adverse effect on ESSA&#8217;s business, financial condition and results of operations and it could cause the market value of ESSA&#8217;s securities to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition, by the time any products are ready to be commercialized, what ESSA believes to be the market for these products may have changed. The Company&#8217;s estimates of the number of patients who have received or might have been candidates to use a specific product may not accurately reflect the true market or market prices for such products or the extent to which such products, if successfully developed, will actually be used by patients. If ESSA&#8217;s projections are inaccurate, the market opportunities for any of its product candidates could be significantly diminished. ESSA&#8217;s failure to successfully introduce and market its products that are under development would have a material adverse effect on its business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may acquire businesses or products or form strategic alliances in the future and the Company may not realize the benefits of such acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that the Company believes will complement or augment its existing business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If the Company acquires businesses in the future, it may not be able to realize the benefit of acquiring such businesses if the Company is unable to successfully integrate them with its existing operations and company culture. The Company may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent the Company from realizing their expected benefits. The potential failure of the due diligence processes to identify significant problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, revenue recognition or other accounting practices, taxes, corporate governance and internal controls, regulatory compliance, employee, customer or partner disputes or issues and other legal and financial contingencies could decrease or eliminate the anticipated benefits and synergies of any acquisition and could negatively affect ESSA&#8217;s future business and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">As part of ESSA&#8217;s business strategy, it may also continue to acquire additional companies, products or technologies principally related to, or complementary to, ESSA&#8217;s current operations. Any such acquisitions will be accompanied by certain risks including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities of acquired companies and the unknown issues with any associated technologies or research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than anticipated acquisition costs and expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the difficulty and expense of integrating operations, systems and personnel of acquired companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of ESSA&#8217;s ongoing business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to retain key customers, distributors, vendors and other business partners of the acquired company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s time and attention; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible dilution to shareholders.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Also, the anticipated benefit of any joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of ESSA&#8217;s equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm ESSA&#8217;s financial condition. ESSA cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on its operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA may not be able to successfully overcome these risks and other problems associated with acquisitions and this may adversely affect ESSA&#8217;s business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA has entered into collaborations with third parties for the development and commercialization of its lead product candidate. If those collaborations are not successful, ESSA may not be able to capitalize on the market potential of its lead product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company has third-party collaborators for development and commercialization of its lead product candidate. ESSA&#8217;s likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical and biotechnology companies. ESSA has and will likely continue to have limited control over the amount and timing of resources that its collaborators dedicate to the development or commercialization of its lead product candidate. The Company&#8217;s ability to generate revenues from these arrangements will depend on its collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Collaborations involving ESSA&#8217;s product candidates would pose numerous risks to ESSA including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of ESSA&#8217;s product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with ESSA&#8217;s products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ESSA&#8217;s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of ESSA&#8217;s product relative to other products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain, defend or enforce ESSA&#8217;s intellectual property rights or may use ESSA&#8217;s proprietary information in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate ESSA&#8217;s intellectual property or proprietary information or expose ESSA to potential litigation or other intellectual property related proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose ESSA to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and ESSA that result in the delay or termination of the research, development or commercialization of ESSA&#8217;s products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ESSA&#8217;s were to be involved in a business combination, the continued pursuit and emphasis on ESSA&#8217;s product development or commercialization program could be delayed, diminished or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for ESSA and harm ESSA&#8217;s reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards ESSA has established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to ESSA. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to ESSA&#8217;s reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions ESSA takes to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses in protecting ESSA from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against ESSA and ESSA is not successful in defending itself or asserting ESSA&#8217;s rights, those actions could have a significant impact on ESSA&#8217;s business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment and restructuring of the Company&#8217;s operations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If product liability lawsuits are brought against the Company or its strategic partners, it may incur substantial liabilities and may be required to cease or limit the sale, marketing and distribution of its product candidate and potential future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company or its strategic partners could face a potential risk of product liability as a result of its potential sales, marketing and distribution activities relating to any future commercialization of any future product. For example, the Company may be sued if any product it develops allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under U.S. state or Canadian provincial or other foreign consumer protection legislation. If the Company cannot successfully defend itself against product liability claims, it may incur substantial liabilities or be required to cease or limit the sale, marketing and distribution of its products. Even successful defense against product liability claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any future products that the Company may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to the Company&#8217;s reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and the Company&#8217;s resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to consumers, trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to continue the sale, marketing and distribution of ESSA&#8217;s product candidate and potential future products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in the price of the Common Shares or other outstanding securities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company currently maintains insurance that it believes has sufficient coverage to protect against the liability risks discussed above and the Company believes this coverage is consistent with industry norms for companies at a similar stage of development. However, if the Company is unable to obtain and retain sufficient product liability insurance in the future at an acceptable cost to protect against potential product liability claims, the commercialization of products it develops could be hindered or prevented.</p><a id="_Hlk84962185"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Compulsory licensing or generic competition may affect the Company&#8217;s business in certain countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In a number of countries, governmental authorities and other groups have suggested that companies which manufacture medical products (e.g., pharmaceuticals) should make products available at a low cost. In some cases, governmental authorities have held that where a pharmaceutical company does not do so, its patents might not be enforceable to prevent generic competition. Alternatively, some governmental authorities could require that ESSA grant compulsory licenses to allow competitors to manufacture and sell their own versions of ESSA&#8217;s products, thereby reducing ESSA&#8217;s sales or the sales of ESSA&#8217;s licensee(s). In all of these situations, the results of future operations in these countries if any, could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA incurs significantly increased costs and devotes substantial management time as a result of operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">As a public company, ESSA incurs significant legal, accounting and other expenses. For example, ESSA is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act and the listing requirements of the Nasdaq Stock Market LLC, as well as rules and regulations subsequently implemented by the SEC and including the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. ESSA&#8217;s continued compliance with these requirements increase its legal and financial compliance costs and make some activities more time consuming and costly. In addition, ESSA&#8217;s management and other personnel need to divert attention from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">operational and other business matters to devote substantial time to these public company requirements. In particular, ESSA may or in the future incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of Sarbanes-Oxley, which involves annual assessments of a company&#8217;s internal controls over financial reporting. ESSA may in the future need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and may need to establish an internal audit function. ESSA cannot always predict or estimate the amount of additional costs incurred as a result of being a public company or the timing of such costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA is a smaller reporting company and a non-accelerated filer, and the reduced disclosure requirements available to ESSA may make ESSA&#8217;s Common Shares less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Under the SEC rules, smaller reporting companies (&#8220;SRCs&#8221;) may choose to comply with scaled financial and non-financial disclosure requirements in their annual and quarterly reports and registration statements relative to non-SRCs. In addition, companies that are not &#8220;accelerated filers&#8221; can take advantage of additional regulatory relief. Whether a company is an accelerated filer or a SRC is determined on an annual basis. For so long as ESSA qualifies as a non-accelerated filer and/or a SRC, ESSA will be permitted to and intends to rely on some or all of the accommodations available to such companies. These accommodations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to provide an auditor&#8217;s attestation of management&#8217;s assessment of internal control over financial reporting required by Section 404(b) of the Sarbanes-Oxley Act of 2002;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced financial disclosure obligations, including that SRCs need only provide two years of financial statements rather than three years; a maximum of two years of acquiree financial statements are required rather than three years; fewer circumstances under which pro forma financial statements are required; and less stringent age of financial statements requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced non-financial disclosure obligations, including regarding the description of their business, management&#8217;s discussion and analysis of financial condition and results of operations, market risk, executive compensation, transactions with related persons, and corporate governance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">later deadlines for the filing of annual and quarterly reports compared to accelerated filers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA will continue to qualify as a SRC and non-accelerated filer for so long as (a) ESSA&#8217;s public float is less than $75 million as of the last day of its most recently completed second fiscal quarter or (b) ESSA&#8217;s public float is $75 million or more but less than $700 million and it reported annual revenues of less than $100 million for its most recently completed fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA may choose to take advantage of some, but not all, of the available accommodations. ESSA cannot predict whether investors will find ESSA&#8217;s Common Shares less attractive if ESSA relies on these accommodations. If some investors find ESSA&#8217;s Common Shares less attractive as a result, there may be a less active trading market for ESSA&#8217;s Common Shares and the price of ESSA&#8217;s Common Shares may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Risks Related to Additional Legal Compliance and Regulatory Matters </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA is subject to risks inherent in foreign operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA intends to pursue international market growth opportunities, such that international sales may account for a significant portion of its revenue. ESSA is subject to a number of risks associated with its potential international business operations, sales and marketing activities that may increase liability, costs, lengthen sales cycles and require significant management attention. These risks include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with the laws of the United States, Canada, the European Union and other jurisdictions where ESSA may conduct business, including import and export legislation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased reliance on third parties to establish and maintain foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the complexities and expenses of administering a business abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complications in compliance with, and unexpected changes in, foreign regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">instability in economic or political conditions, including inflation, recession and actual or anticipated military conflicts, social upheaval or political uncertainty;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign exchange controls and cash repatriation restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tariffs and other trade barriers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in collecting accounts receivable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing tax structures and related potential adverse tax consequences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties of laws and enforcement relating to the protection of intellectual property or secured technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation in foreign court systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unauthorized copying or use of ESSA&#8217;s intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cultural and language differences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in managing a geographically dispersed workforce in compliance with local laws and customs that vary from country to country; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other factors, depending upon the country involved.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that the policies and procedures ESSA implements to address or mitigate these risks will be successful, that ESSA&#8217;s personnel will comply with them or that ESSA will not experience these factors in the future or that they will not have a material adverse effect on ESSA&#8217;s business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Laws and regulations governing international operations may preclude ESSA from developing, manufacturing and selling certain product candidates outside of the United States and Canada and require ESSA to develop and implement costly compliance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA must comply with numerous laws and regulations in each jurisdiction in which ESSA plans to operate. ESSA must also comply with U.S. laws applicable to the foreign operations of U.S. individuals, such as the Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), and Canadian laws applicable to the foreign operations of Canadian businesses and individuals, such as the Corruption of Foreign Public Officials Act (&#8220;CFPOA&#8221;). The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The CFPOA prohibits Canadian businesses and individuals from giving or offering to give a benefit of any kind to a foreign public official, or any other person for the benefit of the foreign public official, where the ultimate purpose is to obtain or retain a business advantage. Furthermore, a company may be found liable for violations by not only its employees, but also by its third-party agents. Any failure to comply with the CFPOA, as well as applicable laws and regulations in foreign jurisdictions, could result in substantial penalties or restrictions on ESSA&#8217;s ability to conduct business in certain foreign jurisdictions, which may have a material adverse impact on ESSA and its share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring ESSA to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical studies and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of ESSA&#8217;s failure to satisfy any of its obligations under laws governing international </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">business practices would have a negative impact on its operations and harm its reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA&#8217;s employees or other agents may, without the Company&#8217;s knowledge and despite the Company&#8217;s efforts, engage in prohibited conduct under its policies and procedures and the CFPOA, FCPA or other anti-bribery laws that ESSA may be subject to for which it may be held responsible. If ESSA&#8217;s employees or other agents are found to have engaged in such practices, it could suffer severe penalties and other consequences that may have a material adverse effect on its business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If ESSA expands its presence outside of the United States in the future, it will be required to dedicate additional resources to comply with these laws, and these laws may preclude ESSA from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit ESSA&#8217;s growth potential and increase development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA is subject to U.S. laws relating to fraud and abuse and patients&#8217; rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">As a pharmaceutical company, even though ESSA does not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to ESSA&#8217;s future arrangements with third-party payors and customers who are in a position to purchase, recommend and/or prescribe ESSA&#8217;s product candidates for which the Company obtains marketing approval. These broadly applicable fraud and abuse and other healthcare laws and regulations may constrain ESSA&#8217;s future business or financial arrangements and relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors and other entities, including ESSA&#8217;s marketing practices, educational programs and pricing policies. Restrictions under applicable federal and state healthcare laws and regulations that may affect ESSA&#8217;s ability to operate include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Anti-Kickback Statute, among other things, prohibits persons from knowingly and willfully soliciting, offering, receiving or providing paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil and criminal false claims laws and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, among other things, prohibits individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Efforts to ensure that ESSA&#8217;s business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that ESSA&#8217;s business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If ESSA&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to ESSA, the Company may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings, and the curtailment or restructuring of ESSA&#8217;s operations. If any physicians or other healthcare providers or entities with whom ESSA expects to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Moreover, ESSA expects there will continue to be federal and state laws and regulations, proposed and implemented, that could impact ESSA&#8217;s operations and business. The extent to which future legislation or regulations, if any, relating to healthcare fraud abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on ESSA&#8217;s business remains uncertain.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If ESSA fails to comply with environmental, health and safety laws and regulations, ESSA could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of ESSA&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA is subject to numerous environmental, health and safety laws and regulations in the United States and in Canada, and may in the future involve, the handling, use, storage, treatment and disposal of hazardous materials and wastes. ESSA&#8217;s operations could involve the use of hazardous and flammable materials, including chemicals and biological materials. ESSA&#8217;s operations could also produce hazardous waste products. The Company&#8217;s general practice would be to contract with third parties for the disposal of such materials and wastes. ESSA cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from ESSA&#8217;s use of hazardous materials, it could be held liable for any resulting damages, and any liability could exceed its resources. ESSA also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Although ESSA maintains workers&#8217; compensation insurance to cover for costs and expenses ESSA may incur due to injuries to employees resulting from the use of any hazardous materials, this insurance may not provide adequate coverage against potential liabilities. ESSA does not maintain insurance for environmental liability or toxic tort claims that may be asserted against it in connection with its storage or disposal of biological or hazardous materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In addition, ESSA may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair ESSA&#8217;s research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA is and there is a risk that ESSA may continue to be a &#8220;passive foreign investment company&#8221; which would likely result in materially adverse U.S. federal income tax consequences for U.S. investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) for the taxable year ending September 30, 2023 and believes it may be classified as a PFIC for the current taxable year and in future taxable years. However, the determination as to whether ESSA is a PFIC for any taxable year is based on the application of complex U.S. federal income tax rules that are subject to differing interpretations. If ESSA is a PFIC for any taxable year during which a U.S. Holder (as defined under &#8220;United States Income Tax Considerations&#8221;) holds the Common Shares, it would likely result in adverse U.S. federal income tax consequences for such U.S. Holder. U.S. Holders should carefully read &#8220;United States Income Tax Considerations&#8212;Passive Foreign Investment Company Rules&#8221; for more information and consult their own tax advisors regarding the consequences of ESSA being treated as a PFIC for U.S. federal income tax purposes, including the advisability of making a qualified electing fund (&#8220;QEF&#8221;) election (including a protective election), which may mitigate certain possible adverse U.S. federal income tax consequences but may result in an inclusion in gross income without receipt of such income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">It may be difficult for United States investors to effect services of process or enforcement of actions against the Company or certain of its directors and officers under U.S. federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company is incorporated under the laws of the Province of British Columbia, Canada. Its directors and officers reside in Canada or the United States. Because a number of these persons and a substantial portion of the assets of the Company are located outside the United States, it will be difficult for United States investors to effect service of process in the United States upon the Company and its directors and officers, or to enforce judgements obtained against the Company or such persons in United States courts, in any action, including actions predicated upon the civil liability provisions of the United States federal securities laws or any other United States laws. Additionally, rights predicated solely upon civil liability provisions of United States federal securities laws or any other laws of the United States may not be enforceable in original actions, or actions to enforce judgments obtained in United States courts, brought in a Canadian court including courts in the Province of British Columbia.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Risks Relating to ESSA&#8217;s Common Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The market price and trading volume of ESSA&#8217;s Common Shares may be volatile, which could result in rapid and substantial losses for its shareholders or securities litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The market price of ESSA&#8217;s Common Shares may be highly volatile and could be subject to wide fluctuations, in response to various factors, some of which ESSA cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of ESSA&#8217;s common stock, regardless of ESSA&#8217;s actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual report, these factors include: &#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarterly variations in operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating results that vary from the expectations of securities analysts and investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change in valuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in ESSA&#8217;s operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses ESSA incurs related to future research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in the demand for ESSA&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the industry in which ESSA operates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by ESSA or other companies of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures, capital commitments, plans, prospects, service offerings or operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical studies of our product candidates, including our combination studies, or those of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future sales of ESSA&#8217;s securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading of ESSA&#8217;s securities by a large shareholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risk factors discussed herein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other unforeseen events.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Stock markets in the United States and Canada have experienced extreme price and volume fluctuations. Market fluctuations, as well as general political and economic conditions, such as acts of terrorism, prolonged economic uncertainty, a recession or interest rate or currency rate fluctuations, could adversely affect the market price of ESSA&#8217;s Common Shares resulting in substantial losses for shareholders. Also, in the past, companies that have experienced volatility in the market price of their Common Shares have been subject to securities litigation. ESSA may be the target of this type of litigation in the future. Securities litigation against ESSA could result in substantial costs and divert management&#8217;s attention from other business concerns, which could materially harm ESSA&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has never declared dividends and may not do so in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA has not declared or paid any cash dividends on Common Shares to date. The payment of dividends in the future will be dependent on ESSA&#8217;s earnings and financial condition and on such other factors as ESSA&#8217;s Board considers appropriate. Unless and until ESSA pays dividends, shareholders may not receive a return on their shares. There is no present intention by the Board to pay dividends on the Common Shares.</p><a id="_Hlk84962211"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may experience future sales or issue additional securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The market price of the Company&#8217;s equity securities could decline as a result of issuances of securities by the Company or sales by the Company&#8217;s existing shareholders of Common Shares in the market, or the perception that such sales could occur. Sales of Common Shares by shareholders might also make it more difficulty for the Company to sell equity securities at a time and price that the Company deems appropriate. Sales or issuances of substantial numbers of Common Shares, or the perception that such sales could occur, may adversely affect the prevailing market prices of the Common Shares. With any additional sale or issuance of Common Shares, investors will suffer dilution to their voting power and the Company may experience dilution in its earnings per share.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Additionally, as of September 30, 2023, there are 2,920,000 pre-funded warrants outstanding, which are exercisable into Common Shares at a nominal exercise price. If holders of these pre-funded warrants exercise these securities, existing shareholders will suffer dilution to their voting power and the Company may experience dilution in its earnings per share, as well as a negative impact on its share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">An active trading market for the Common Shares may not be sustained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Although ESSA has listed the Common Shares on the Nasdaq, an active trading market for the Common Shares may not be sustained. If an active trading market for the Common Shares is not maintained, the liquidity of the Common Shares and the prices that may be obtained for the Common Shares will be adversely affected. As of September 30, 2023, ESSA&#8217;s public float, which is defined as Common Shares outstanding minus Common Shares held by officers, directors, or beneficial holders of greater than 10% of ESSA&#8217;s outstanding Common Shares, represented approximately 60.17% of ESSA&#8217;s outstanding Common Shares. In addition, the Company is aware of a number of significant shareholders, defined as a holding greater than 5%, who have participated in recent financings. The average number of shares traded in any given day over the past year has been relatively small compared to the public float. Thus, the actions of a few shareholders either buying or selling ESSA&#8217;s Common Shares may adversely affect the price of the Common Shares. Historically, securities similar to ESSA&#8217;s Common Shares have experienced extreme price and volume fluctuations that do not necessarily relate to operating performance and could result in rapid and substantial losses for shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Widespread health concerns, pandemics or epidemics, and other outbreaks of illness may negatively affect the Company&#8217;s ability to maintain operations and execute its business plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Widespread health concerns, pandemics, and other outbreaks of illness, particularly in North America but also globally, can have evolving and uncertain impacts on our business. In March 2020, the Company made the decision to transition employees to primarily remote working arrangements. This continues to the present, but the Company has taken steps to maintain internal communication, and operations have thus far continued on schedule and with minimal interruption. Although COVID-19 has not yet had any material adverse impact on the Company&#8217;s operations or financial condition, there can be no assurances that it, widespread health concerns, or other outbreaks of illness will not have an impact on the Company&#8217;s business, operations or financial condition going forward. The Company has experienced significant delays in enrolling patients in its clinical trials, directly or indirectly related to COVID-19, resulting in resource constraints at clinical trial sites, as well as competition for patients with other studies being pursued by other entities. As a result of any widespread health concern, pandemic, or other outbreaks of illness, including the COVID-19 pandemic, the Company has and may continue to experience disruptions that severely impact our business, commercialization, third party vendor operations, including foreign and domestic supply chains, or delays in clinical trial activities, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in initiating clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in enrolling patients in our current and potential future clinical trials of masofaniten (EPI-7386);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption to and delays in preclinical research and analysis activities due to an extended temporary closure of contract lab facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions in supply, logistics or other activities related to the procurement of materials, which could have a negative impact on the Company&#8217;s ability to conduct preclinical studies, initiate or complete clinical trials or commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from conducting clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key preclinical studies and clinical trial activities, due to limitations on travel imposed or recommended by federal, state, provincial or municipal governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in resources that would otherwise be focused on the conduct of the Company&#8217;s business or current or planned preclinical studies or clinical trials, including due to sickness, restrictions on travel, prolonged stay-at-home or shelter-in-place orders and other COVID-19 related concerns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulations as part of a response to the COVID-19 outbreak which may require the Company to change the ways in which the preclinical studies and clinical trials are conducted and incur unexpected costs, or requires the Company to discontinue our preclinical research or clinical trials altogether;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or furlough of government or contractor personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations on the Company&#8217;s ability to recruit preclinical research, clinical, regulatory and other professional staff on the timeframe required to support research and development programs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Government and health authority intervention in the face of a widespread health concern, pandemic, or other outbreak of illness may vary greatly in the various geographic regions in which we operate. The extent to which a widespread health concern may impact our business, commercialization, pre-clinical studies, and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If ESSA is unable to implement and maintain effective internal control over financial reporting in the future, ESSA may not be able to report financial results accurately or prevent fraud. In that case, investors may lose confidence in the accuracy and completeness of ESSA&#8217;s financial reports and the market price of ESSA&#8217;s Common Shares may be negatively affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Maintaining effective internal control over financial reporting is necessary for ESSA to produce reliable financial reports and is important in helping to prevent financial fraud. If ESSA is unable to maintain adequate internal controls, ESSA&#8217;s business and operating results could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Pursuant to Section 404(a) of the Sarbanes-Oxley Act and the related rules of the SEC, ESSA&#8217;s management is required to, among other things, assess annually the effectiveness of its internal control over financial reporting and certify that it has established effective disclosure controls and procedures and internal controls over financial reporting for the period ended September 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Preparing ESSA&#8217;s consolidated financial statements involves a number of complex manual and automated processes which are dependent on individual data input or review and require significant management judgment. One or more of these elements may result in errors that may not be detected and could result in a material misstatement of ESSA&#8217;s consolidated financial statements. Management&#8217;s significant estimates and judgements with respect to financial reporting are discussed and disclosed in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The process of designing and implementing effective internal controls and procedures, and expanding ESSA&#8217;s internal accounting capabilities, is a continuous effort that requires ESSA to anticipate and react to changes in ESSA&#8217;s business and the economic and regulatory environments and expend significant resources to establish and maintain a system of internal controls that is adequate to satisfy ESSA&#8217;s reporting obligations as a public company. The standards that must be met for management to assess the internal control over financial reporting as effective are complex, and require significant documentation, testing and possible remediation to meet the detailed standards. ESSA cannot be certain at this time whether the Company will be able to successfully complete the continuing implementation of controls and procedures or the certification and attestation requirements of Section 404(a) of Sarbanes-Oxley on a continuous basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If a material misstatement occurs in the future, ESSA may fail to meet its future reporting obligations, it may need to restate its financial results and the price of its Common Shares may decline. Any failure of ESSA&#8217;s internal controls could also adversely affect the results of the periodic management evaluations and any future annual independent registered public accounting firm attestation reports regarding the effectiveness of ESSA&#8217;s internal control over financial reporting that may be required when Section 404 of Sarbanes-Oxley becomes fully applicable to ESSA. Effective internal controls are necessary for ESSA to produce reliable financial reports and are important to helping prevent financial fraud. If ESSA cannot provide reliable financial reports or prevent fraud, ESSA&#8217;s business and results of operations could be harmed, investors could lose confidence in ESSA&#8217;s reported financial information, and the trading price of ESSA&#8217;s Common Shares could drop significantly.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Provisions in ESSA&#39;s corporate charter documents and Canadian law could make an acquisition of the Company, which may be beneficial to ESSA&#39;s shareholders, more difficult and may prevent attempts by the shareholders to replace or remove ESSA&#39;s current management and/or limit the market price of the Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Provisions in ESSA&#39;s articles, as well as certain provisions under the Business Corporations Act (British Columbia) or applicable Canadian securities laws may discourage, delay or prevent a merger, acquisition or other change in control of ESSA that shareholders may consider favorable, including transactions in which they might otherwise receive a premium for their Common Shares. These provisions could also limit the price that investors might be willing to pay in the future for ESSA&#8217;s Common Shares, thereby depressing the market price of ESSA&#8217;s Common Shares. In addition, because the Board is responsible for appointing the members of the Company&#39;s management team, these provisions may frustrate or prevent any attempts by ESSA&#39;s shareholders to replace or remove current management by making it more difficult for shareholders to replace members of the Board. Among other things, these provisions include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shareholders cannot amend ESSA&#39;s articles unless such amendment is approved by shareholders holding at least two-thirds of the votes cast on the proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Board may, without shareholder approval, issue preferred shares having any terms, conditions, rights, preferences and privileges as the Board may determine; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shareholders must give advance notice to nominate directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applicable Canadian securities laws generally require, subject to certain exceptions, a tender offer to remain open for a minimum of 105 days and that more than 50% of the outstanding securities not owned by the offeror be tendered before the offeror may take up the securities subject to the tender offer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about ESSA&#8217;s business, its stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The trading market for ESSA&#8217;s Common Shares depends in part on the research and reports that securities or industry analysts publish about it, or its business. If one or more of the securities or industry analysts who cover ESSA downgrade its Common Shares or publish inaccurate or unfavorable research about its business, its stock price would likely decline. If one or more of these analysts cease coverage of ESSA or fail to publish reports on it regularly, demand for ESSA&#8217;s stock could decrease, which might cause its stock price and trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b1cad291_25a2_42eb_a192_d0e7f3b9d6bc"></a><a id="Item1B"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1B.&#160;&#160;&#160;&#160;&#160;Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7d89f646_75a0_4dca_a866_8b7d050cdf87"></a><a id="Item1C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1C. </b><b style="font-weight:bold;">Cybersecurity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d95e7a9f_75d2_464f_8b6b_a1d5bd4f6bc3"></a><a id="Item2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Our headquarters are located in Vancouver, British Columbia, where we rent office space on a short-term lease. Our U.S. offices are located in South San Francisco, California. In March 2018, we entered into a lease for the South San Francisco office that expired on March 31, 2021, and which we have extended to May 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">We believe that our existing facilities are adequate for our immediate needs and can accommodate our anticipated growth. We believe that, should it be needed, additional space can be leased to accommodate any future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b157505d_b7ce_4825_84a8_c13c9c122d21"></a><a id="Item3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. As of September 30, 2023, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_0f8b5c7f_e7a7_4c16_9ff6_2239cf0999ae"></a><a id="Item4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">Not applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_149fde9d_3ca5_4310_a448_c27540ffea84"></a><a id="PARTII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our Common Shares began trading on the Nasdaq under the symbol &#8220;EPIX&#8221; on July&#160;9, 2015. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nasdaq</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">High</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Low</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quarter Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.58</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.56</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.63</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.45</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.16</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.40</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.66</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.03</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.13</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14.88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.00</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14.78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.54</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 8, 2023, the last reported sale price of our Common Shares on the Nasdaq was $5.46 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As at December 8, 2023, there were approximately 346 holders of record of ESSA&#8217;s Common Shares. This number does not include beneficial owners whose shares are held in &#8220;street name&#8221; by banks, brokers, and other financial institutions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never paid any dividends on our Common Shares or any of our other securities. We currently intend to retain any future earnings to finance the growth and development of our business, and we do not anticipate that we will declare or pay any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board and will be dependent upon our financial condition, results of operations, capital requirements, restrictions under any future indebtedness and other factors the Board deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Certain Canadian Federal Income Tax Considerations for United States Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following generally summarizes certain Canadian federal income tax consequences generally applicable under the Income Tax Act (Canada) and the regulations enacted thereunder (collectively, the &#8220;Canadian Tax Act&#8221;) and the Canada-United States Tax Convention (1980) (the &#8220;Convention&#8221;) to the holding and disposition of Common Shares. Comment is restricted to holders of Common Shares each of whom, at all material times for the purposes of the Canadian Tax Act and the Convention, (i) is resident solely in the United States for tax purposes, (ii) is a &#8220;qualifying person&#8221; under, and entitled to the benefits of, the Convention, (iii) holds all Common Shares as capital property, (iv) holds no Common Shares that are &#8220;taxable Canadian property&#8221; (as defined in the Canadian Tax Act) of the holder, (v) deals at arm&#8217;s length with and is not affiliated with ESSA, (vi) does not and is not deemed to use or hold any Common Shares in a business carried on in Canada, (vii) is not an insurer that carries on business in Canada and elsewhere, and (viii) is not an &#8220;authorized foreign bank&#8221; (as defined in the Canadian Tax Act) (each such holder, a &#8220;U.S. Resident Holder&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain U.S.-resident entities that are fiscally transparent for United States federal income tax purposes (including certain limited liability companies) may not in all circumstances be entitled to the benefits of the Convention. Members of or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">holders of an interest in such an entity that holds Common Shares should consult their own tax advisers regarding the extent, if any, to which the benefits of the Convention will apply to the entity in respect of its Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Generally, a U.S. Resident Holder&#8217;s Common Shares will be considered to be capital property of such holder provided that the U.S. Resident Holder is not a trader or dealer in securities, did not acquire, hold, or dispose of the Common Shares in one or more transactions considered to be an adventure or concern in the nature of trade, and does not hold the Common Shares in the course of carrying on a business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This summary is based on the information contained in this Form 10-K, the current provisions of the Canadian Tax Act and the Convention in effect on the date hereof, all specific proposals to amend the Canadian Tax Act and Convention publicly announced by or on behalf of the Minister of Finance (Canada) on or before the date hereof, and the current published administrative and assessing policies of the Canada Revenue Agency (the &#8220;CRA&#8221;). It is assumed that all such amendments will be enacted as currently proposed, and that there will be no other material change to any applicable law or administrative or assessing practice, whether by way of judicial, legislative or governmental decision or action, although no assurance can be given in these respects. Except as otherwise expressly provided, this summary does not take into account any provincial, territorial, or foreign tax considerations, which may differ materially from those set out herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations, and is not intended to be and should not be construed as legal or tax advice to any particular U.S. Resident Holder. U.S. Resident Holders are urged to consult their own tax advisers for advice with respect to their particular circumstances. The discussion below is qualified accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Generally, a U.S. Resident Holder&#8217;s Common Shares will not constitute &#8220;taxable Canadian property&#8221; of such holder at a particular time provided the Common Shares are listed on a &#8220;designated stock exchange&#8221; (which currently includes the TSX and Nasdaq) unless both of the following conditions are concurrently met:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>at any time during the 60-month period that ends at the particular time, 25% or more of the issued shares of any class of the capital stock of ESSA were owned by or belonged to one or any combination of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A.</span></span>the U.S. Resident Holder,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">B.</span></span>persons with whom the U.S. Resident Holder did not deal at arm&#8217;s length, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">C.</span></span>partnerships in which the U.S. Resident Holder or a person referred to in clause (B) above holds a membership interest directly or indirectly through one or more partnerships, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>at any time during the 60-month period that ends at the particular time, more than 50% of the fair market value of the Common Shares was derived, directly or indirectly, from one or any combination of (a) real or immovable property situated in Canada; (b) &#8220;Canadian resource properties&#8221; (as defined in the Canadian Tax Act); (c) &#8220;timber resource properties&#8221; (as defined in the Canadian Tax Act); or (d) options in respect of, interests in, or civil law rights in, such properties, whether or not the property exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Common Shares may also be deemed to be &#8220;taxable Canadian property&#8221; in certain circumstances set out in the Canadian Tax Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A U.S. Resident Holder who disposes or is deemed to dispose of one or more Common Shares generally should not thereby incur any liability for Canadian federal income tax in respect of any capital gain arising as a consequence of the disposition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A U.S. Resident Holder to whom ESSA pays or credits or is deemed to pay or credit a dividend on such holder&#8217;s Common Shares will generally be subject to Canadian withholding tax, and ESSA will be required to withhold the tax from the dividend and remit it to the CRA for the holder&#8217;s account. The rate of withholding tax under the Canadian Tax Act is 25% of the gross amount of the dividend, but should generally be reduced under the Convention to 15% (or, if the U.S. Resident Holder is a company which is the beneficial owner of at least 10% of the voting stock of ESSA, 5%) of the gross amount of the dividend. For this purpose, a company that is a resident of the United States for purposes of the Convention and is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">entitled to the benefits of the Convention shall be considered to own the voting stock of ESSA owned by an entity that is considered fiscally transparent under the laws of the United States and that is not a resident of Canada, in proportion to such company&#8217;s ownership interest in that entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">United States Income Tax Considerations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following is a summary of the anticipated U.S. federal income tax consequences generally applicable to U.S. Holders (as defined below) of the ownership and disposition of the Company&#8217;s Common Shares. This summary addresses only holders who acquire and hold the Common Shares as &#8220;capital assets&#8221; (generally, assets held for investment purposes).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following summary does not purport to address all U.S. federal income tax consequences that may be relevant to a U.S. Holder (as defined below) as a result of the ownership and disposition of the Common Shares, nor does it take into account the specific circumstances of any particular holder, some of which may be subject to special tax rules (including, but not limited to, brokers, dealers in securities or currencies, traders in securities that elect to use a mark-to-market method of accounting for securities holdings, tax-exempt organizations, insurance companies, banks, thrifts and other financial institutions, persons liable for alternative minimum tax, persons that hold an interest in an entity that holds the Common Shares, persons that will own, or will have owned, directly, indirectly or constructively 10% or more (by vote or value) of our stock, persons that hold the Common Shares as part of a hedging, integration, conversion or constructive sale transaction or a straddle, former citizens or permanent residents of the United States, or persons whose functional currency is not the U.S. dollar).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This summary is based on the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), U.S. Treasury regulations, administrative pronouncements and rulings of the United States Internal Revenue Service (the &#8220;IRS&#8221;), judicial decisions and the Canada-United States Income Tax Convention (1980), as amended, all as in effect on the date hereof, and all of which are subject to change (possibly with retroactive effect) and to differing interpretations. Except as specifically set forth below, this summary does not discuss applicable income tax reporting requirements. This summary does not describe any state, local or foreign tax law considerations, or any aspect of U.S. federal tax law other than income taxation (e.g., estate or gift tax or the Medicare contribution tax). U.S. Holders (as defined below) should consult their own tax advisers regarding such matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No legal opinion from U.S. legal counsel or ruling from the IRS has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the ownership or disposition of the Common Shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to different interpretations, the IRS and U.S. courts could disagree with one or more of the positions taken in this summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As used in this summary, a &#8220;U.S. Holder&#8221; is a beneficial owner of the Common Shares who, for U.S. federal income tax purposes, is (i) a citizen or individual resident of the United States, (ii) a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States, any State thereof or the District of Columbia, (iii) an estate whose income is subject to U.S. federal income tax regardless of its source, or (iv) a trust if (A) a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons are authorized to control all substantial decisions of the trust, or (B) the trust has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The tax treatment of a partner in a partnership (or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) that holds the Common Shares may depend on both the partnership&#8217;s and the partner&#8217;s status and the activities of the partnership. Partnerships (or other entities or arrangements classified as a partnership for U.S. federal income tax purposes) that are beneficial owners of the Common Shares, and their partners and other owners, should consult their own tax advisers regarding the tax consequences of the ownership and disposition of the Common Shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Passive Foreign Investment Company Rules</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A foreign corporation will be considered a PFIC for any taxable year in which (1) 75% or more of its gross income is &#8220;passive income&#8221; under the PFIC rules or (2) 50% or more of the average quarterly value of its assets produce (or are held for the production of) &#8220;passive income.&#8221; For this purpose, &#8220;passive income&#8221; generally includes interest, dividends, certain rents and royalties, and certain gains. Moreover, for purposes of determining if the foreign corporation is a PFIC, if the foreign corporation owns, directly or indirectly, at least 25%, by value, of the shares of another corporation, it will be treated as if it holds directly its proportionate share of the assets and receives directly its proportionate share of the income of such other corporation. If a corporation is treated as a PFIC with respect to a U.S. Holder for any taxable year, the corporation will continue to be treated as a PFIC with respect to that U.S. Holder in all succeeding taxable years, regardless of whether the corporation continues to meet the PFIC requirements in such years, unless certain elections are made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The determination as to whether a foreign corporation is a PFIC is based on the application of complex U.S. federal income tax rules, which are subject to differing interpretations, and the determination will depend on the composition of the income, expenses and assets of the foreign corporation from time to time and the nature of the activities performed by its officers and employees. ESSA believes that it was classified as a PFIC for the taxable year ending September 30, 2023, and ESSA believes that it may be classified as a PFIC for the current taxable year and in future taxable years. However, our actual PFIC status for the current or any future taxable year is uncertain and cannot be determined until after the end of such taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are classified as a PFIC, a U.S. Holder that does not make any of the elections described below would be required to report any gain on the disposition of Common Shares as ordinary income, rather than as capital gain, and to compute the tax liability on the gain and any &#8220;Excess Distribution&#8221; (as defined below) received in respect of Common Shares as if such items had been earned ratably over each day in the U.S. Holder&#8217;s holding period (or a portion thereof) for the Common Shares. The amounts allocated to the taxable year during which the gain is realized or distribution is made, and to any taxable years in such U.S. Holder&#8217;s holding period that are before the first taxable year in which we are treated as a PFIC with respect to the U.S. Holder, would be included in the U.S. Holder&#8217;s gross income as ordinary income for the taxable year of the gain or distribution. The amount allocated to each other taxable year would be taxed as ordinary income in the taxable year during which the gain is realized or distribution is made at the highest tax rate in effect for the U.S. Holder in that other taxable year and would be subject to an interest charge as if the income tax liabilities had been due with respect to each such prior year. For purposes of these rules, gifts, exchanges pursuant to corporate reorganizations and use of Common Shares as security for a loan may be treated as a taxable disposition of the Common Shares. An &#8220;Excess Distribution&#8221; is the amount by which distributions during a taxable year in respect of a Common Share exceed 125% of the average amount of distributions in respect thereof during the three preceding taxable years (or, if shorter, the U.S. Holder&#8217;s holding period for the Common Shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain additional adverse tax rules will apply to a U.S. Holder for any taxable year in which we are treated as a PFIC with respect to such U.S. Holder and any of our subsidiaries is also treated as a PFIC (a &#8220;Subsidiary PFIC&#8221;). In such a case, the U.S. Holder will generally be deemed to own its proportionate interest (by value) in any Subsidiary PFIC and be subject to the PFIC rules described above with respect to the Subsidiary PFIC regardless of such U.S. Holder&#8217;s percentage ownership in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The adverse tax consequences described above may be mitigated if a U.S. Holder makes a timely &#8220;qualified electing fund&#8221; election (a &#8220;QEF election&#8221;) with respect to its interest in the PFIC. Consequently, if we are classified as a PFIC, it may be advantageous for a U.S. Holder to elect to treat us as a &#8220;qualified electing fund&#8221; with respect to such U.S. Holder in the first year in which it holds Common Shares. If a U.S. Holder makes a timely QEF election with respect to ESSA, the electing U.S. Holder would be required in each taxable year that we are considered a PFIC to include in gross income (i) as ordinary income, the U.S. Holder&#8217;s pro rata share of the ordinary earnings of ESSA and (ii) as capital gain, the U.S. Holder&#8217;s pro rata share of the net capital gain (if any) of ESSA, whether or not the ordinary earnings or net capital gain are distributed. An electing U.S. Holder&#8217;s basis in Common Shares will be increased to reflect the amount of any taxed but undistributed income. Distributions of income that had previously been taxed will result in a corresponding reduction of basis in the Common Shares and will not be taxed again as distributions to the U.S. Holder.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A QEF election made with respect to ESSA will not apply to any Subsidiary PFIC; a QEF election must be made separately for each Subsidiary PFIC (in which case the treatment described above would apply to such Subsidiary PFIC). If a U.S. Holder makes a timely QEF election with respect to a Subsidiary PFIC, it would be required in each taxable year to include in gross income its pro rata share of the ordinary earnings and net capital gain of such Subsidiary PFIC, but may not receive a distribution of such income. Such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge (which would not be deductible for U.S. federal income tax purposes if the U.S. Holder were an individual).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we determine that we, and any subsidiary in which we own, directly or indirectly, more than 50% of such subsidiary&#8217;s total aggregate voting power, is likely a PFIC in any taxable year, we intend to make available to U.S. Holders, upon request and in accordance with applicable procedures, a &#8220;PFIC Annual Information Statement&#8221; with respect to ESSA and any such subsidiary for such taxable year. The &#8220;PFIC Annual Information Statement&#8221; may be used by U.S. Holders for purposes of complying with the reporting requirements applicable to a QEF election with respect to ESSA and any Subsidiary PFIC. The U.S. federal income tax on any gain from the disposition of Common Shares or from the receipt of Excess Distributions may be greater than the tax if a timely QEF election is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Alternatively, if we were to be classified as a PFIC, a U.S. Holder could also avoid certain of the rules described above by making a mark-to-market election (instead of a QEF election), provided the Common Shares are treated as regularly traded on a qualified exchange or other market within the meaning of the applicable U.S. Treasury Regulations. However, a U.S. Holder will not be permitted to make a mark-to-market election with respect to a Subsidiary PFIC. U.S. Holders should consult their own tax advisers regarding the potential availability and consequences of a mark-to-market election, as well as the advisability of making a protective QEF election in case we are classified as a PFIC in any taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During any taxable year in which we or any Subsidiary PFIC is treated as a PFIC with respect to a U.S. Holder, that U.S. Holder generally must file IRS Form 8621. U.S. Holders should consult their own tax advisers concerning annual filing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Common Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Distributions on the Common Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In general, subject to the passive foreign investment company rules discussed above, the gross amount of any distribution received by a U.S. Holder with respect to the Common Shares (including amounts withheld to pay Canadian withholding taxes) will be included in the gross income of the U.S. Holder as a dividend to the extent attributable to our current and accumulated earnings and profits, as determined under U.S. federal income tax principles. We may not calculate our earnings and profits for each year under U.S. federal income tax rules. Accordingly, U.S. Holders should expect that a distribution generally will be treated as a dividend for U.S. federal income tax purposes. Subject to the passive foreign investment company rules discussed above, distributions on the Common Shares to certain non-corporate U.S. Holders that are treated as dividends may be taxed at preferential rates provided we are not treated as a PFIC for the taxable year of the distribution or the preceding taxable year. Such dividends will not be eligible for the &#8220;dividends received&#8221; deduction ordinarily allowed to corporate shareholders with respect to dividends received from U.S. corporations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The amount of any dividend paid in Canadian dollars (including amounts withheld to pay Canadian withholding taxes) will equal the U.S. dollar value of the Canadian dollars calculated by reference to the exchange rate in effect on the date the dividend is received by the U.S. Holder, regardless of whether the Canadian dollars are converted into U.S. dollars. A U.S. Holder will have a tax basis in the Canadian dollars equal to their U.S. dollar value on the date of receipt. If the Canadian dollars received are converted into U.S. dollars on the date of receipt, the U.S. Holder should generally not be required to recognize foreign currency gain or loss in respect of the distribution. If the Canadian dollars received are not converted into U.S. dollars on the date of receipt, a U.S. Holder may recognize foreign currency gain or loss on a subsequent conversion or other disposition of the Canadian dollars. Such gain or loss will be treated as U.S. source ordinary income or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Distributions on the Common Shares that are treated as dividends generally will constitute income from sources outside the United States and generally will be categorized for U.S. foreign tax credit purposes as &#8220;passive category income.&#8221; A </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">U.S. Holder may be eligible to elect to claim a U.S. foreign tax credit against its U.S. federal income tax liability, subject to applicable limitations and holding period requirements, for Canadian tax withheld, if any, from distributions received in respect of the Common Shares. A U.S. Holder that does not elect to claim a U.S. foreign tax credit may instead claim a deduction for Canadian tax withheld, but only for a taxable year in which the U.S. Holder elects to do so with respect to all foreign income taxes paid or accrued in such taxable year. The rules relating to U.S. foreign tax credits are complex, and each U.S. Holder should consult its own tax adviser regarding the application of such rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sale, Exchange or Other Taxable Disposition of the Common Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A U.S. Holder generally will recognize gain or loss on the sale, exchange or other taxable disposition of Common Shares in an amount equal to the difference, if any, between the amount realized on the sale, exchange or other taxable disposition and the U.S. Holder&#8217;s adjusted tax basis in the Common Shares exchanged therefor. Subject to the passive foreign investment company rules discussed above, such gain or loss will be capital gain or loss and will be long-term capital gain (currently taxable at a reduced rate for non-corporate U.S. Holders) or loss if, on the date of the sale, exchange or other taxable disposition, the Common Shares have been held by such U.S. Holder for more than one year. The deductibility of capital losses is subject to limitations. Such gain or loss generally will be sourced within the United States for U.S. foreign tax credit purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Required Disclosure with Respect to Foreign Financial Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Certain U.S. Holders are required to report information relating to an interest in the Common Shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain financial institutions), by attaching a completed IRS Form 8938, Statement of Specified Foreign Financial Assets, with their tax return for each year in which they hold an interest in Common Shares. U.S. Holders should consult their own tax advisers regarding information reporting requirements relating to their ownership of the Common Shares.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Repurchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26446a1e_158c_447e_aa64_17d067001c69"></a><a id="Item6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;&#160;&#160;[Reserved.]</p><a id="Reserved_971843"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk56170122"></a><a id="_66687e01_826a_40af_b8dd_cc536ead7821"></a><a id="Item7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">The following discussion should be read in conjunction with the attached financial statements and notes thereto. This Annual Report on Form 10-K, including the following sections, contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K. We caution the reader not to place undue reliance on these forward -looking statements, which reflect management&#8217;s analysis only as of the date of this Annual Report on Form 10-K. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report on Form 10-K. Throughout this discussion, unless the context specifies or implies otherwise, the terms &#8220;ESSA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ESSA Pharma Inc. and its subsidiaries. For a discussion regarding our financial condition and results of operations for fiscal 2022 as compared to fiscals 2021 and 2020 see Item 7 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, filed with the SEC on December 13, 2022.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA is a clinical stage pharmaceutical company, focused on developing novel and proprietary therapies for the treatment of prostate cancer with an initial focus on patients whose disease is progressing despite treatment with current standard of care therapies, including second-generation antiandrogen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. The Company believes its latest series of investigational compounds, including its product candidate masofaniten (EPI-7386), have the potential to significantly expand the interval of time in which patients with castration-resistant prostate cancer can benefit from anti-hormone-based therapies. Specifically, the compounds are designed to disrupt the androgen receptor signaling pathway, the primary pathway that drives prostate cancer growth and prevent AR activation through selective binding to the N-terminal domain of the AR. In this respect, the Company&#8217;s compounds are designed to differ from classical non-steroid antiandrogens. These antiandrogens interfere either with androgen synthesis (i.e., abiraterone), or with the binding of androgens to the ligand-binding domain, located at the opposite end of the receptor from the NTD (i.e., lutamides). A functional NTD is essential for activation of the AR; blocking the NTD inhibits AR-driven transcription and therefore androgen-driven biology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">General Development of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Significant Business Developments for the Year Ended September 30, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 26-28, 2023<i style="font-style:italic;">, </i>the Company presented updated dose escalation data from its Phase 1/2 study evaluating masofaniten (EPI-7386) in combination with enzalutamide at the 30th Annual Prostate Cancer Foundation Scientific Retreat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The data presented were from the first four cohorts of patients in the Phase 1 dose escalation portion of the study. The data indicated that masofaniten (EPI-7386) had no effect on enzalutamide exposure, thus allowing the use of full dose per label (160mg) of enzalutamide in combination. It also indicated that enzalutamide reduces masofaniten (EPI-7386) exposure but twice daily dosing of masofaniten (EPI-7386) appears to mitigate the reduction and maintains clinically relevant drug exposures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In patients evaluable for safety (n=18), masofaniten (EPI-7386) combined with enzalutamide, was well-tolerated at the doses tested through 21 cycles of dosing in some patients. The most frequent adverse events were Grade 1 and 2, related to either AR inhibition or gastrointestinal tract irritation. In Cohort 4, one patient experienced a Grade 3 rash, which was observed immediately following administration of masofaniten (EPI-7386) combined with enzalutamide and deemed probably related.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the patients evaluable for efficacy (n=16), rapid, deep and durable reductions in PSA were observed, regardless of previous chemotherapy status, including in patients who received lower than the full dose of enzalutamide (120 mg). In the first three cohorts, 90% of patients (9 of 10) achieved PSA50 and PSA90, 80% of patients (8 of 10) achieved PSA90 in less than 90 days, and 70% of patients (7 of 10) achieved PSA &lt;0.2ng/mL. Across all dose cohorts including patients in the recently enrolled Cohort 4, 88% of patients (14 of 16) achieved PSA50, 81% of patients (13 of 16) achieved PSA90, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">69% of patients (11 of 16) achieved PSA90 in less than 90 days, and 56% of patients (9 of 16) achieved PSA &lt;0.2ng/mL. The randomized Phase 2 dose expansion portion of the study was reported to be enrolling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 20-24, 2023, the Company presented the same updated dose escalation data from its Phase 1/2 study evaluating masofaniten (EPI-7386) in combination with enzalutamide at the European Society of Medical Oncology (ESMO) 2023 Congress. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 3, 2023, the Company filed a prospectus supplement to its registration statement on Form S-3, including a base prospectus, with the SEC. Further to this, on November 6, 2023, the Company announced that it had entered into the ATM Sales Agreement with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may, within the period that the ATM Sales Agreement is in effect, sell its Common Shares from time to time for up to US$50.0 million in aggregate sales proceeds. No offers or sales of Common Shares will be made in Canada, to anyone known by Jefferies LLC to be a resident of Canada or on or through the facilities of any stock exchange or trading markets in Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, the Company announced the initiation of the Phase 2 portion of its Phase 1/2 study evaluating its lead candidate, masofaniten (EPI-7386) in combination with Astellas and Pfizer&#39;s enzalutamide in patients with mCRPC na&#239;ve to second-generation antiandrogens</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 31, 2023, the Company announced the establishment of Automatic Securities Disposition Plans for its President and Chief Executive Officer, David R. Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 6, 2023, the Company appointed Lauren Merendino to its Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On April 12, 2023, the Company announced it had entered into a clinical trial support agreement with Janssen. ESSA will sponsor and conduct a Phase 1 clinical trial evaluating the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of masofaniten (EPI-7386) when administered in combination with either apalutamide or abiraterone acetate plus prednisone. Janssen will supply apalutamide and abiraterone acetate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 16-19, 2023, the Company presented analyses of initial clinical data from two Phase 1 studies of masofaniten (EPI-7386) in patients with mCRPC at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The Company presented an update to the Phase 1 monotherapy study demonstrating that masofaniten (EPI-7386) single agent showed a favorable safety profile and was well tolerated up to a daily dose of 1200 mg (600 mg BID), achieved target clinical exposures and showed preliminary signals of anti-tumor activity in heavily pretreated mCRPC patients. The second poster presented preliminary results to the Phase 1/2 trial of masofaniten (EPI-7386) in combination with Astellas and Pfizer&#8217;s AR inhibitor, enzalutamide. Ten patients had been enrolled in the first three cohorts: three in cohort 1 (600 mg QD masofaniten (EPI-7386) and 120 mg QD enzalutamide), four in cohort 2 (800 mg QD masofaniten (EPI-7386) and 120 mg QD enzalutamide) and three in cohort 3 (600 mg BID masofaniten (EPI-7386) and 120 mg QD enzalutamide). At that time, the DLT period had not cleared for cohort 3. For the first 2 cohorts that cleared the DLT period, no DLTs were observed, and the safety profile was consistent with second-generation antiandrogens (e.g., Grade 1 or 2 AEs of fatigue and hot flushes). Pharmacokinetic results from cohorts 1 and 2 had demonstrated that enzalutamide exposure was minimally impacted by masofaniten (EPI-7386), while, as expected, masofaniten (EPI-7386) exposure was reduced by approximately 60% by enzalutamide (a well established CYP3A4 inducer). The observed masofaniten (EPI-7386) exposures remained in the clinically relevant range suggested by pre-clinical xenograph studies. Five out of six evaluable patients enrolled in the first two cohorts showed a PSA decrease &gt;90% regardless of the patients previous chemotherapy status, and four out of six evaluable patients PSA levels reached &lt; 0.2 ng/mL. All five patients that experienced biochemical responses showed stable disease by imaging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 12pt 0pt;">Financing and Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 6, 2023, the Company announced that it had entered into the ATM Sales Agreement with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may, within the period that the ATM Sales Agreement is in effect, sell its Common Shares from time to time for up to US$50.0 million in aggregate sales proceeds.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No offers or sales of Common Shares will be made in Canada, to anyone known by Jefferies LLC to be a resident of Canada or on or through the facilities of any stock exchange or trading markets in Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA has never been profitable and has incurred net losses since inception. ESSA&#8217;s net losses were $26,567,596 and $35,161,917 for the years ended September 30, 2023 and 2022, respectively. ESSA expects to incur losses for the foreseeable future, and it expects these losses to increase as it continues the development of, and seek regulatory approvals for, its product candidate. Because of the numerous risks and uncertainties associated with product development, ESSA is unable to predict the timing or amount of increased expenses or when, or if, it will be able to achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth ESSA&#8217;s consolidated statements of financial position and consolidated statements of loss and comprehensive loss as at and for the fiscal&#160;years ended September 30, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(US$)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Income Statement Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,322,530</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,415,246</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,942</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,746</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administration, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,811,574</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,544,760</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,141,046)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,973,752)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26,582,343)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35,103,251)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss and comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26,567,596)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35,161,917)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,701,912</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57,076,475</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaids and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 115,094,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 111,982,866</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 257,245</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 259,455</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,008</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 186,499</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 149,122,131</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 169,505,295</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,414,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,176,565</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,328</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 210,252</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shareholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 145,627,060</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 167,118,478</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and shareholders&#8217; equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 149,122,131</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 169,505,295</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations for the Fiscal&#160;Years Ended September 30, 2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There was no revenue in any of the fiscal&#160;years as reported. The Company incurred a comprehensive loss of $26,567,596 for the&#160;year ended September 30, 2023 compared to a comprehensive loss of $35,161,917 for the&#160;year ended September 30, 2022. Variations in ESSA&#8217;s expenses and net loss for the periods resulted primarily from the following factors described below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenditures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D expense included the following major expenses by nature:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical and data analysis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,081,575</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,134,161</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,780,660</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,872,268</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,712,168</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,073,188</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,627,505</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,322,844</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,356,472</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,946,412</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal patents and license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 919,859</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,123,319</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 430,260</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 511,590</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 213,972</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 204,334</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Travel and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 137,285</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144,645</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 62,774</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,485</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,322,530</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,415,246</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The overall R&amp;D expense for the&#160;year ended September 30, 2023 was $21,322,530 compared to $24,415,246 for the&#160;year ended September 30, 2022 and includes non-cash expense related to share-based payments expense of $2,627,505 (2022 - $4,322,844). R&amp;D expense in 2023 reflects the ongoing clinical trial of masofaniten (EPI-7386).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical costs of $6,081,575 (2022 - $8,134,161) were generated in relation to expenditures for pharmacokinetic data analysis on data from the clinical trial related to the Phase 1 study and work on preclinical pipeline and Anitac compounds. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical costs of $5,780,660 (2022 - $4,872,268) were generated in relation to expenditures associated with the Company&#8217;s clinical research organizations conducting the Phase 1 clinical trial of masofaniten (EPI-7386). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Salaries and benefits, related to preclinical and clinical staff, have increased to $2,712,168 (2022 - $2,073,188) as a result of an increased number of preclinical and clinical staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The share-based payments expense of $2,627,505 (2022 - $4,322,844), which is a non-cash expense, relates to the value assigned to stock options and employee share purchase rights granted to key management personnel and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing costs of $2,356,472 (2022 - $2,946,412) for the&#160;year ended September 30, 2023 includes amount for cGMP manufacturing of masofaniten (EPI-7386) drug supply to support the ongoing clinical trial as well as costs incurred in formulation and chemistry work around the Company&#8217;s pharmaceutical characteristics of masofaniten (EPI-7386). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Legal patents and license fees decreased to $919,859 (2022 - $1,123,319). The Company has adopted a tiered patent strategy to protect its intellectual property as the pharmaceutical industry places significant importance on patents for the protection of new technologies, products and processes. The costs reflect that ongoing investment and the timing of associated maintenance costs. The Company anticipates that there will be continued investment into patent applications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Consulting costs decreased to $430,260 (2022 - $511,590) for the&#160;year ended September 30, 2023 primarily resulting from contract project management services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administration Expenditures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative expenses include the following major expenses by nature:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:49.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,303,570</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,710,999</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,379,965</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,565,241</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,724,746</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,088,637</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,019,989</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 901,282</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor relations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 602,645</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 577,350</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office, insurance, IT and communications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 529,301</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 554,255</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 392,667</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 343,083</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory fees and transfer agent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 202,525</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 197,877</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Travel and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 179,302</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 146,603</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,567</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,443</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting and subcontractor fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 185,292</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization/(Accretion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (554,403)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 264,698</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,811,574</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,544,760</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administration expenses decreased to $10,811,574 for the&#160;year ended September 30, 2023 from $12,544,760 in the&#160;year ended September 30, 2022 and included non-cash expense related to share-based payments of $2,379,965 (2022 - $3,565,241). This non-cash expense relates to the value assigned to stock options and employee share purchase rights granted to key management and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.</p><a id="_Hlk56180972"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Salaries and benefits expense increased to $4,303,570 (2022 - $3,710,999) reflecting merit related salary adjustment and bonuses paid to employees and additional support staff costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Insurance expense of $1,724,746 (2022 - $2,088,637) decreased in the current year following lower insurance renewal premiums relative to the Company&#8217;s activities, risk mitigation choices and insurance market pricing trends. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Professional fees of $1,019,989 (2022 - $901,282) were incurred for legal and accounting services in conjunction with ongoing corporate activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Consulting and subcontractor fees of $8,700 (2022 - $185,292) decreased following the termination of a support services contract in late fiscal 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization/(Accretion) recognized varies relative to the Company&#8217;s investment holdings and market conditions for expected investment returns. Over the periods presented, the Company had a larger investment holding and had benefited from higher interest rates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA is a clinical stage company and does not currently generate revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As at September 30, 2023, the Company had working capital of $145,301,807 (2022 - $166,748,942). Operational activities during the year ended September 30, 2023 were financed mainly by proceeds from financings in July 2020 and February 2021. At September 30, 2023, the Company had available cash reserves and short-term investments of $148,076,401 (2022 - $167,237,504) to settle current liabilities of $3,495,071 (2022 - $2,310,399). At September 30, 2023, the Company believed that it had sufficient capital to satisfy its obligations as they became due and execute its planned expenditures for more than twelve months. The Company expects its current cash runway to fund its operations and ESSA-sponsored clinical programs through 2025, including under Clinical Trial &#8211; EPI-7386-CS-001, the Part B Combination &#8211; Cohort 1 &#8211; Combination with abiraterone acetate/prednisone and the Part B Combination &#8211; Cohort 2 &#8211; Window of opportunity with clinical endpoints followed by combination with apalutamide study, also under Clinical Trial &#8211; EPI-7386-CS-010, the Phase 2 combination study with enzalutamide, and an investigator-sponsored study of masofaniten (EPI-7386) and darolutamide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA&#8217;s future cash requirements may vary materially from those now expected due to a number of factors, including the costs associated with future preclinical work and to take advantage of strategic opportunities, such as partnering collaborations or mergers and acquisitions activities. In the future, it may be necessary to raise additional funds. These funds may come from sources such as entering into strategic collaboration arrangements, the issuance of shares from treasury, or alternative sources of financing. However, there can be no assurance that ESSA will successfully raise funds to continue its operational activities. See &#8220;Risk Factors&#8221; in Item&#160;1A. elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made that relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based payments and compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date of grant and the cost is recorded when the Company receives the goods or services.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The fair value of the underlying Common Shares is assessed as the most recent issuance price per common share for cash proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trend Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA is a clinical stage pharmaceutical company and does not currently generate revenue. The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain Licensed IP. As at the date of this Annual Report, no products are in commercial production or use. The Company&#8217;s financial success will be dependent upon its ability to continue development of its compounds through preclinical and clinical stages to commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Safe Harbor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements&#8221; in the introduction to this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Toc75278523"></a><a id="Item7A"></a><a id="_302df660_dc8d_48c8_af44_97fb4e0694f9"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Item 7A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Quantitative and Qualitative Disclosures About Market Risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 6pt 0pt;"><span style="margin-bottom:10pt;margin-top:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:180.02pt;"><a id="_45baf27b_1db7_4697_b3bb_3399a38c0fdb"></a><a id="Item8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ESSA Pharma&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20230930x10k004.jpg" alt="Graphic" style="display:inline-block;height:179.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:467.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Expressed in United States dollars)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOR THE&#160;YEARS ENDED SEPTEMBER 30, 2023 and 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:628.5pt;"><a id="_b09cf731_4997_4c38_bb83_1d708d2ed24b"></a><div style="height:628.5pt;position:absolute;right:50%;top:0pt;transform:translateX(50%);width:486pt;z-index:-9223372036603117568;"><div style="height:628.05pt;left:0pt;padding-bottom:0.45pt;position:relative;width:485.3pt;"><img src="tmb-20230930x10k005.jpg" alt="Graphic" style="height:628.05pt;width:485.3pt;" /></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-transform:uppercase;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;">To the Shareholders and Directors of</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;">ESSA Pharma Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Consolidated Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of ESSA Pharma Inc. (the &#8220;Company&#8221;) as of September&#160;30,&#160;2023 and 2022, and the related consolidated statements of operations and comprehensive loss, cash flows, and changes in shareholders&#8217; equity for the years ended September 30, 2023 and 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2023 and 2022, and the results of its operations and its cash flows for the years ended September&#160;30, 2023 and 2022 in conformity with accounting principles generally accepted in the United States of America. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have not identified any critical audit matters for the years ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as the Company&#8217;s auditor since 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">/s/ </b><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:AuditorName" id="Narr_Lk0_bpU6fUGyrXJY9J6bTw"><b style="font-weight:bold;">DAVIDSON &amp; COMPANY LLP</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="dei:AuditorLocation" id="Narr_fxytQ5hE8Eii3lc_3jWtZw">Vancouver, Canada</ix:nonNumeric> &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Chartered Professional Accountants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">December 12, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_acf267df_61cc_4143_a1b7_14355699980f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><a id="CONSOLIDATEDBALANCESHEETS_577277"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">AS AT SEPTEMBER&#160;30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d1178942_a09a_4f3f_86c6_6f076c275fd9"></a><a id="OLE_LINK1"></a><a id="Tc_kFXuC0Gt0UioIrbUjuSuRQ_1_2"></a><a id="Tc_1PhnaQOnv0qVpde7lOe4Zg_1_5"></a><a id="Tc_mAA4-bIifka-8lhocu__uA_3_0"></a><a id="Tc__Ng3Pd1i602_B3LXYQUnzA_5_0"></a><a id="Tc_lS5wSTKse0qcXtn_Wrq6vQ_6_0"></a><a id="Tc_yayzqVsnOkinCAzfINymZQ_6_2"></a><a id="Tc_-X0whQsTsU2bT_ANrYsPmg_6_5"></a><a id="Tc_kMxEgM0-50S7rPZyqU8XwQ_7_0"></a><a id="Tc_9igEaXKGkk6AKU6x64SQZw_8_0"></a><a id="Tc_sVFdCL7FTkKQdx28HMk9ZA_9_0"></a><a id="Tc_8ThGPyz14USPtzUVcFZCVw_13_0"></a><a id="Tc_Uy8cC_PyjECH975h_Kio7A_14_0"></a><a id="Tc_O3VJaPbMjEKCnSrJFHfVog_16_0"></a><a id="Tc_vxqpIj4Pj02RFoaFLUxS4w_16_2"></a><a id="Tc_XASb8M8L_EySjCBfuOTx6g_16_5"></a><a id="Tc_QuBtVL835U2UDwXFh9QVZQ_18_0"></a><a id="Tc_NurPFU1l90WWHYro2bpKDg_20_0"></a><a id="Tc_yRA7jP0SG0KzKb4dDdCWTQ_21_0"></a><a id="Tc_eF6nyPyByk2Sn_aKY4VD9A_21_2"></a><a id="Tc_DzObL5Jd5UmV39cmWHUc1w_21_5"></a><a id="Tc_jjN6Dr99FkumyW77bLEMEA_22_0"></a><a id="Tc_VNNx_j0vgU-AC1n_sDkOAA_26_0"></a><a id="Tc_zjyc0myt50SH7Es4NgOaaQ_28_0"></a><a id="Tc_lAMzoLiGSE2UeIFCVtTv9w_30_0"></a><a id="Tc_QRJ4Zfm86EWZgQYrOU2CLA_31_0"></a><a id="Tc_JjvdB0tWQkyigCQDmdQPcg_32_0"></a><a id="Tc_heTOSPZmOUak7Hdiq4Aquw_33_0"></a><a id="Tc_V9SySeid5EeuWWicCpRGOg_34_0"></a><a id="Tc_wbbYlhMJq0GZ5hmKvPWScA_35_0"></a><a id="Tc_oYggF8sk50e4sNPmzV3UWQ_36_0"></a><a id="Tc_ZiFVimR4fEmc1-ybm-PvcA_37_0"></a><a id="Tc_OjJGuhUmX0CliSbl3icihA_41_0"></a><a id="Tc_6RQg0yrd80GFzqTVhERIeQ_41_2"></a><a id="Tc_r1ZE0nty4EOUidLkjzwRKQ_41_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_YV-MX1Mgzk2Lgf5mmho-UQ_6_3">33,701,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_OXlE5PRwW0m3tkKJn6r4-w_6_6">57,076,475</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Short-term investments (Note 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="Tc_3N1e6JKxiE671c6BiTjsiw_7_3">114,374,489</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="Tc_Ocq-uV0gc0aJDKltWGsaLQ_7_6">110,161,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="Tc_MWkZN8Jqg0as9RJ_so_3pg_8_3">135,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="Tc_PfyM3KLqFk27IheWUUczKw_8_6">6,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Prepaids (Note&#160;5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_IrmTvOiqj02O0BpoEtu8KA_9_3">585,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_KE8boZugkU6gFjYs4RQ3GQ_9_6">1,815,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_NZtxxy-BhkiwQPY46PTrfg_11_3">148,796,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_nwKrue5gdkiHxvsRTKnmWg_11_6">169,059,341</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Deposits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" id="Tc_tBSkTOAPhkOmsRsB4s7j0g_13_3">257,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" id="Tc_13sTB0pS1EaWwij3E_vw7g_13_6">259,455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Operating lease right-of-use assets (Note&#160;7)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_Nfyn0qt2rEyLWnEEji_ELQ_14_3">68,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_GHXAv5htXkWqGBw7jWPLDA_14_6">186,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_d_9cevuiFEiKvpoECy57_w_16_3">149,122,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_2RW4F9JznEKyRCyozj9woQ_16_6">169,505,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued liabilities (Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_usZN87ebFU2FsLGZ-6lbEg_21_3">3,414,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_Nj0L6aO_hEWk_T7AOxsOOQ_21_6">2,176,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Current portion of operating lease liabilities (Note&#160;7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_CamQWktOSk2Vuw74VYHfCg_22_3">80,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_KAs-gijJT0egH4z5cGtbjA_22_6">133,834</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_16bAMyICzESASw-PkUJdyg_24_3">3,495,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_4x9wUaKjZEam3ALJfggrPw_24_6">2,310,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Operating lease liabilities (Note 7)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_OI6GR2uXsUSj5R2uMlI1-w_26_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_7pJz5GB2NUGvxTJlXtSSFw_26_6">76,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_94Z54OS8WkOqXo1j0gGiPw_28_3">3,495,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_fxrMCMcxe0GHqil7QclgBA_28_6">2,386,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Authorized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Unlimited common shares, without par value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Unlimited preferred shares, without par value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;">Common shares </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Y5c6UrmTckOIcy-CpW331w">44,100,838</ix:nonFraction></span><span style="font-size:9pt;"> </span><span style="-sec-ix-hidden:Hidden_89-NsoVFH0O_N3itcj9uow;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_HkEK9MjWyUuH6gbj3DHx6g;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> (September 30, 2022&#160;&#8211; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_xP2Uk8sZz0GNrhmznECnuQ">44,073,076</ix:nonFraction></span><span style="font-size:9pt;">) (Note&#160;9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_H2Yb9yilfEWTKyZ0BswYAg_34_3">278,161,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_M2inwYoj-UKbdw-1RHmN6A_34_6">278,089,136</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital (Note&#160;9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_7LIoU0HbFEiETSZDavULyQ_35_3">49,047,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_T1_mgO0u1k-wb2TmCC2wxQ_35_6">44,043,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_9x6oeiNS4k-CY12GN25OiA_36_3">2,120,398</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_q585CLcb3kanl5IWijiohQ_36_6">2,135,145</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_OcRDsUVrrUKUWwCWC9ALcQ_37_3">179,461,359</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_JL8-G5HjREWrPttmkFTivw_37_6">152,879,016</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_0LfhJLzNxEKViK1-o5nYzQ_39_3">145,627,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ja8mE5o0jkeAunVH40IxBw_39_6">167,118,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total liabilities and shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_eydg7AsmH0qzTJIObRg2sQ_41_3">149,122,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_9aG7_YTKgUCJStwXGDZiug_41_6">169,505,295</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><b style="font-style:normal;font-weight:bold;">Nature of operations (Note&#160;1)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><b style="font-style:normal;font-weight:bold;">Commitments (Note&#160;15)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><b style="font-style:normal;font-weight:bold;">Subsequent events (Note&#160;16)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_7d479132_5d94_4c4b_a570_814dd99c3276"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><a id="OPERATIONSANDCOMPREHENSIVELOSS_841542"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">FOR THE&#160;YEARS ENDED SEPTEMBER&#160;30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_715e4f5a_3581_435d_a75f_2f92582742ec"></a><a id="Tc_nPXRiAQXa0ao0E5lPT4MUQ_1_2"></a><a id="Tc_pbMlT4gEakSbY3wul0p6Pw_1_5"></a><a id="Tc_uTIzPXE4CESqftebIgFryQ_3_0"></a><a id="Tc_-BMfLvz3TUy4h_bVmDTQWQ_4_0"></a><a id="Tc_Ky-mU4174EKE16qCnutlzw_4_2"></a><a id="Tc_Xdbw1btmJUuryMej6Upjmg_4_5"></a><a id="Tc_SHm29JLUBkqzg5cKWvDWKQ_5_0"></a><a id="Tc_9Fk_0jShpEO3I1e-l2aRZQ_6_0"></a><a id="Tc_-415qRy9ekmVbE3dae2nCQ_8_0"></a><a id="Tc_LIrJHu_Vd0yncrBV45kUZg_10_0"></a><a id="Tc_rmPf0acVrEKohW-4dGUlTw_11_0"></a><a id="Tc_zk9Op0Epu06i1arJuJbJVw_12_0"></a><a id="Tc_pud7WEgCSE6WoEmGH6Zriw_14_0"></a><a id="Tc_4JMHGh5g1kSBvtCpLGRGnQ_16_0"></a><a id="Tc_73OKFgMU70mrR2oudF5Ifg_18_0"></a><a id="Tc_UwNmgmFkQUmALd3yiRcnBA_20_0"></a><a id="Tc_6tA80eHjF0CoH60xVJy7QQ_21_0"></a><a id="Tc_e50zEHC9XEucRTW8x33MTw_23_0"></a><a id="Tc_2p5m3CZfqE-jkQMcKbfubg_23_2"></a><a id="Tc_9YBffx8510e39YpJjpBN-w_23_5"></a><a id="Tc_P7MM4FZqFEa6k7hDQ3YXHw_25_0"></a><a id="Tc_lAJVUJCNnEafa21nQtvhDA_27_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OPERATING EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_MRHKsU2joEKV3UpcGdBBlg_4_3">21,322,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_9MJPviGEuEWvkvBshuU0mw_4_6">24,415,246</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing costs (Note&#160;7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="epix:FinancingCosts" scale="0" id="Tc_OAyDhZ6-60SZ_rYBoTVbPQ_5_3">6,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="epix:FinancingCosts" scale="0" id="Tc_PmHy29vyB0m845rQnifSWQ_5_6">13,746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administration </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_hhCLTx9uNEaMUWEVDykSkA_6_3">10,811,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_Dl0X33kcJE-ySEpy1G6CIg_6_6">12,544,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_V3ttyup_Sk2xT9UhYO_RWw_8_3">32,141,046</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_Tek0vLzNm0Oe_fvEToslJg_8_6">36,973,752</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_Th_Nbs86zUuUrSuW9RRSSA_10_3">6,529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc__ogGLm31DUODdcWdMATV5A_10_6">1,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="0" id="Tc_9nh9cIm0akS1xg6u4Y_nUw_11_3">5,553,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="0" id="Tc_ZUHbWV-QqUmd79PP74289Q_11_6">1,736,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Derivative liability gain (Note 8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_BAG7TqwahUCmBEZYJPrR3g_12_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_GwyDgYJKp0Cqa5WdOD12KQ_12_6">20,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Loss for the&#160;year before taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_MI5B0BzB-k6cGNXjL64icg_14_3">26,580,743</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_xKkUP_DAGE2awb6CHZ-0zw_14_6">35,215,072</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax recovery (expense) (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_ZI6s_uWBJka7BmciDFYI4w_16_3">1,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_f4JBZ1KdU0m6W20EJI13tQ_16_6">111,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_fXrxH61XwkWAzx3DnWKy1Q_18_3">26,582,343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_lBFWaOddS0WfqVPNO0e8lQ_18_6">35,103,251</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OTHER COMPREHENSIVE LOSS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain (loss) on short-term investments (Note 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="0" id="Tc_PVLFlgqNCEegj3A9cotbQQ_21_3">14,747</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="0" id="Tc_TydcJWEHYESTfPuavKB54A_21_6">58,666</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Loss and comprehensive loss for the&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_90fEJk6JEUuCLT7mCRlheQ_23_3">26,567,596</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_ZeAMWuLOREGXluDIAGb1PA_23_6">35,161,917</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Basic and diluted loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TrZ4lBb27E2A0GuACyi-aw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_4w46MuRmO0a8CQ87GQlmRQ_25_3">0.60</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_a4Wdv5GQfE61kqdTxTzn1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_aPfYoRbUOkiH_2ihwQXn-Q_25_6">0.80</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Weighted average number of common shares outstanding &#8211; basic and diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_gxRKiiMpkE6lbCVCSLHyLQ_27_3">44,089,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_h0uMJHH5fUqP2U-Iiqpv9w_27_6">44,038,241</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_d438a73d_2442_4527_9997_b3d7d319bc2b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><a id="CASHFLOWS_242138"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">FOR THE&#160;YEARS ENDED SEPTEMBER&#160;30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f173c36d_c41d_4235_915c_f2474f8b5fe9"></a><a id="Tc_uESkFxQBRk2jclgDk7vPHA_1_2"></a><a id="Tc_iW1nKjjtj0y7T_wl8ZdPrg_1_5"></a><a id="Tc_RqQQUu7R10625RokUO70Ww_3_0"></a><a id="Tc_c-hU6stO0UmUHeY4Q1r8rw_4_0"></a><a id="Tc_tkf1Pdt2_Uq6lO5upB4FCQ_4_2"></a><a id="Tc_9wksSXdGMkSzHgnJdX7phw_4_5"></a><a id="Tc_utlR7wHIxk2ZCFuhcFrPeQ_5_0"></a><a id="Tc_3JLYnn6kpEunZ-wxlkh6LQ_6_0"></a><a id="Tc_JllPqI1V30yyI62J-A8lEg_7_0"></a><a id="Tc_t9ej6_VzPkG5cA5oARpKng_8_0"></a><a id="Tc_Pc7EnxMQIUykzETWR47TWw_9_0"></a><a id="Tc_8G6-DdCrKUmGqyHwvGwkGA_10_0"></a><a id="Tc_nq1Sqfme2E-9deLvjv8jsA_11_0"></a><a id="Tc_3kwykwz3u0WJIyO5L8H6yA_12_0"></a><a id="Tc_mQdG1WYlkkGuO9mcM-wz6A_14_0"></a><a id="Tc_UHwyU7Zn_EmG1Pe40DwBxg_15_0"></a><a id="Tc_uqpaLINGgUi0NtgXf7Sb0Q_16_0"></a><a id="Tc_G0JOfbaFsESLVhg2y40enA_17_0"></a><a id="Tc_sdSPo8aTREucgYthMZM96g_19_0"></a><a id="Tc_DT-XAYydVEqzSsmwl253Og_21_0"></a><a id="Tc_NINWEeOK0USZHF-Q_z1ljA_22_0"></a><a id="Tc_Vt-DnpgGMEmoPCSvlg-JcQ_23_0"></a><a id="Tc_O2s14ZjCOUCUwPALnjU2LQ_25_0"></a><a id="Tc_w662h_FybUeAzkDmtjWN_A_27_0"></a><a id="Tc_wsvhX-KZ7EGEmUFRZyWv-g_28_0"></a><a id="Tc__inoU1vErEq5HBOsQwWV3g_29_0"></a><a id="Tc_PCODpXRuC0qWrDRCQTRkqA_30_0"></a><a id="Tc_L7bAlR_s6EyfwOTTFW30Gg_32_0"></a><a id="Tc_J7vwpjJQwkSTVJPGuIYPHA_34_0"></a><a id="Tc_zCMQKFy_Y0KTBoP2BWAWUg_35_0"></a><a id="Tc_k9IMHGk9wUqAczoN1gtsLg_36_0"></a><a id="Tc_a912vYjl5E6LCWiCYUZ7yw_38_0"></a><a id="Tc_-41Syw1u80ytOCtyqlvyUg_38_2"></a><a id="Tc_yYsp9KZRf0im8qhSXrZKzQ_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss for the&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_BS0fXrTH8ka7KjQq3J9PjQ_4_3">26,582,343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_WXZzPhW5pUmGNKJGbQ66hg_4_6">35,103,251</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Items not affecting cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_YiDcw_5g3E-j-kvr0oYjTg_6_3">118,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_4PpwNfm9qU-zssvv3U_X-g_6_6">121,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization/(Accretion) of premiums/discounts on short-term investments, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="0" id="Tc_cKVRb5bWVkOfhNPFWi3Xkg_7_3">671,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" sign="-" scale="0" id="Tc_DD8FIfESu0uSdWYPYF8GNw_7_6">69,653</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accretion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionExpense" scale="0" id="Tc_J6w_BPuso06HkqKyZTWYlw_8_3">6,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionExpense" scale="0" id="Tc_FC0VKoqHiE-IEu8kPGkYjw_8_6">13,305</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Derivative liability gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_yoZvg57Ro0mm4w65hb41rQ_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_IxWaBw9G5UWoOyZzf52JIA_9_6">20,352</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accrued Investment income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" sign="-" scale="0" id="Tc_yBS9LHAEkkenWUi3CWR8rw_10_3">374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="0" id="Tc_p7lRLMRPKkeo1LHkuPIY6g_10_6">189,213</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Unrealized foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="0" id="Tc_GJuN_5prDECc1WaP3PMBig_11_3">528</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="0" id="Tc_IhF-cLnh7kyeQGqJAiSxhA_11_6">845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_BDMfg08dlEq4WEtzbqXG2A_12_3">5,007,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_f38NexbgREaWzlFu_FBFAQ_12_6">7,888,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Changes in non-cash working capital items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" id="Tc_u2Qy5q-Fs0qY0xyfethm4Q_15_3">128,846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" sign="-" scale="0" id="Tc_48qv4cvtxkOptLqihPz7Ew_15_6">482,801</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_A-3XTftIwEWJbGepoRy5wQ_16_3">1,232,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_8_b7kS14IUqpycAAAS5kHQ_16_6">366,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_VCVKrbCl50KT3ptKsMwgZA_17_3">1,235,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_SNIoqeNhtkeP4hvubq0mZA_17_6">1,629,065</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_zi9GDModREeE3K_B0P6F7A_19_3">19,781,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_Zjxpt251yUe0eoLdRPyfwA_19_6">27,999,149</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Purchase of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_Nsb_tHpok0yQhyU2Se_JRQ_22_3">365,203,691</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_y2KterSFoEOLB7G_HHV3sg_22_6">296,012,498</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from short-term investments sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc_2myFDCbJ4U2VRTeYB7MQ-Q_23_3">361,676,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc_2i9RSYRKLk-YTeiqhvpzsA_23_6">242,959,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_k5qxQ5xZ2EWB93OtwhhZtg_25_3">3,527,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_biubL-Yt9km7qGCvupJQGw_25_6">53,053,414</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_gy-Dd77I0kKwksuGVHBOtg_28_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_CXG5j8tSRkyVgUgETCztrw_28_6">319,832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Shares purchased through employee share purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="0" id="Tc_NybsPnBvCE-zgt0cNis-GA_29_3">68,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="0" id="Tc_7Mc4jVIaIEW857wcQNmfZQ_29_6">66,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeasePaymentsFinancingActivities" scale="0" id="Tc_3Y0-yDyyWUOQglpTqYlobQ_30_3">136,866</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeasePaymentsFinancingActivities" scale="0" id="Tc_25qRWifvyU2GG3Xt3eGPAw_30_6">134,023</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net cash (used) provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="0" id="Tc_Or1fQscaYE6XkK0Bj4PWug_32_3">68,157</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_zTd67CF8V0emeA-ztgkCIg_32_6">252,735</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Effect of foreign exchange on cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_dtJTXEhETE2QP0u_lPjtrA_34_3">2,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_ctjKFyu2QkCcTi85BE8EBQ_34_6">51,279</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Change in cash and cash equivalents for the&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_TbiX-0sxwEiKcUSMfJXwmw_35_3">23,374,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_t8jxsW72K0Spr61ezeyjDA_35_6">80,748,549</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, beginning of&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_kadmN7tBrUevWp-mDCzdQw_36_3">57,076,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_teZHVglkjUmn-3utxQWf2g_36_6">137,825,024</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_9IW6e8Om4kKuSqAkcLTsPw_38_3">33,701,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_XxQq0GXFuEmQKq1m1MNoIA_38_6">57,076,475</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Supplemental Disclosure with respect to Cash Flows (Note&#160;12)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The accompanying</span> <span style="font-style:normal;">notes are an integral part of these consolidated</span> <span style="font-style:normal;">financial statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_26bfcc0d_3fb2_429e_af3e_462b34ad1b2b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><a id="CHANGESINSHAREHOLDERSEQUITY_787925"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bd3e3538_aee1_4a0f_935d_38ca7aaea23f"></a><a id="Tc_mnKrTYbLQEyDNTTpRzDS9w_1_10"></a><a id="Tc_8I93730LBkGyeNT1JOvuFA_2_7"></a><a id="Tc_-zT8nAU5AkSR1ZlWTTi0Dg_2_10"></a><a id="Tc_0OtDE1iVBUy02XDxd59KNw_3_2"></a><a id="Tc_zfcBM3xhLkCP90jYYVhmGQ_3_4"></a><a id="Tc_LpiNK4zh60WzVs0Qusx2bQ_3_7"></a><a id="Tc_1stEZbvWOEuSv_J0KxZnTg_3_10"></a><a id="Tc_yPb6gvdca0Gd0LmB0PI44g_4_2"></a><a id="Tc_F0E-vF6gH0mJI52-JSUbRw_4_4"></a><a id="Tc_1Om323nyaEujg8W84B5T-w_4_7"></a><a id="Tc_mBf7vhxUMU-v2t7sWW2oag_4_10"></a><a id="Tc_whMmBTsZ-UGkR3_gJ94QNA_4_13"></a><a id="Tc_aW75SQ2xiE6Z0u5x0rLcWA_4_16"></a><a id="Tc_Zb9UEnJk-kKaJlYoj3IPOA_7_0"></a><a id="Tc_1BaZIje7VE6HEPk5JIvBXQ_7_4"></a><a id="Tc_HFYIql85IU2R4EA8AMqbOA_7_7"></a><a id="Tc_NoEXcmQtFUyWcRccOUA_GQ_7_10"></a><a id="Tc_YBVQMd1u8kS6izGWvnqcpA_7_13"></a><a id="Tc_wafcWQCK50W2yRnfOGOgQA_7_16"></a><a id="Tc_i6vRVNwRZ0aeB3pUHSsihA_8_0"></a><a id="Tc_A5Y3rBZ8wUOF5jMZYGA1TA_8_11"></a><a id="Tc_MVJC33JovkaQiGWS9UkSiw_8_14"></a><a id="Tc_yuR1AWya-USUf6wcXsBPkA_9_0"></a><a id="Tc_CswUZzlr-0iyCqyCp-lzPw_9_11"></a><a id="Tc_ZIkHz1l1u02cNqM6xnWr8g_9_14"></a><a id="Tc_fzkBzvGM1kqkmw7jD09kZw_10_0"></a><a id="Tc_dPIkP_QMfUG3PAla_5maWw_10_2"></a><a id="Tc_-Bv8qklKZ0eCNXRPZWSg0Q_10_5"></a><a id="Tc_DoWolqtHOkOgffEzcerHcQ_10_11"></a><a id="Tc_PkqywOrEQ02xykbN-6I53g_10_14"></a><a id="Tc_hBvCpFc1aUK8byTPpDA-1g_11_0"></a><a id="Tc_uqVXNTL12UCVjz3rUNkYzQ_11_2"></a><a id="Tc_0bnOadH420exgNIVfstZ9A_11_5"></a><a id="Tc_k-Kj816Mgk-I8y3IfqSBQA_11_8"></a><a id="Tc_y8VGoC-T8kWNl7JIFUDmew_13_0"></a><a id="Tc_zoXKctXRbEqQaezCTUpsPg_13_4"></a><a id="Tc_eXqsVZc-0066UhmFYxtp6A_13_7"></a><a id="Tc_lohM-yKpZ0SzDomfJykBSQ_13_10"></a><a id="Tc_c7IDvZ-PdkajiwBOid1elg_13_13"></a><a id="Tc_y-WANhzSO0-KbKEquw44Yw_13_16"></a><a id="Tc_CMyH1JVSO0yr_4-thndDYA_14_0"></a><a id="Tc_05hKB9owHUOla8W_-SgW-A_14_11"></a><a id="Tc_Y-ehuuooLkSe5fiKINf0EA_14_14"></a><a id="Tc_fXX1NK9nqkOyk7YG41YTTw_15_0"></a><a id="Tc_j0rKUCxpwkyMiDlQ_JriMQ_15_2"></a><a id="Tc_v1Nd4e1tWUyRWqRWUePfFQ_15_5"></a><a id="Tc_aAfxYeCW20q2x3eG49rXJQ_15_11"></a><a id="Tc_Cajkza0Lt0OELFiNVQDYkA_15_14"></a><a id="Tc_dtaiic0u7kOgBv3cdvcmRA_16_0"></a><a id="Tc_m7h1PfapX0W9iWqSAgSWaQ_16_2"></a><a id="Tc_LwY9m-odfE-cF7PinOB9tQ_16_5"></a><a id="Tc_tvnWMQFc20KUjWw8WgMbQg_16_8"></a><a id="Tc_0r5Y5GFWh0mLLyH1lxIetQ_18_0"></a><a id="Tc_p0A5_DeqlUeZS2fjUppZWQ_18_4"></a><a id="Tc_NJ9NIHY1s0y9-JNQvV_QLQ_18_7"></a><a id="Tc_N_Zav_0mdEmbBkBcI5dx4A_18_10"></a><a id="Tc_6PpjitfurkK3qaHX-pi9FA_18_13"></a><a id="Tc_BT2SQRsTY0KNR-NPliBzMw_18_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance, September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_eiEJeqNHx0y9uYJilRoiTw_7_2">43,984,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_BfGzXkcwckenEpjgcNbDsA_7_5">277,415,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YGXbKtAO4kKDSY4O_EsLzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_udFjEXUpcU6OB6X42J4s7Q_7_8">36,442,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0AhVVm9dOU2bAEoDagZNuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_b4s0Apwzm0eBuB9ro5ohlg_7_11">2,076,479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iAza1BQ9g06mhs6rTWFHOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_LlU-H19vJUW1ReCMWhWb5g_7_14">117,775,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_lrWROCa6gk-Ihvp4BbnSJQ_7_17">194,005,552</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_aYfU9jGkSEKLu6o16PUlqg_8_2">72,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_0ZF_lodnMU-sSjLLbGEeJw_8_5">568,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_ZvS2hHtdb0CQdimX61WwHA_8_8">249,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_QNKcoJKH4Uino4bLN87zaA_8_17">319,832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Shares issued through employee share purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_-wge2VCcDkaROlWRg71a3A_9_2">15,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_uVl93BT3PUuEUJbaGyWpyA_9_5">105,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" sign="-" scale="0" id="Tc_SHqejMynYE2tsPhXx_0ZPw_9_8">38,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_TCRq0D9oZU6KEHIlXocMWA_9_17">66,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_o_Chc6-LVU24LO9c-0Mksw_10_8">7,888,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_6yGpMixCBUu74VLQ5g8WGQ_10_17">7,888,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loss and comprehensive loss for the&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AeJ9w5KQP0qIzR5IqHQARw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_5vyJ3Jzpa0GqPsLnEUDgSw_11_11">58,666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9cT9Z1eluEyoPr8TmVwHZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_959gJ2HXokiH-1PFSgoVEA_11_14">35,103,251</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_TZ9O9RITCEq42VsuzEHI2w_11_17">35,161,917</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance, September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GZadl9A4R0-GCOCxiuNSXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_b1zPhlEQeEeAWScqa3Xf1w_13_2">44,073,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GZadl9A4R0-GCOCxiuNSXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_kNLH49lJJUm_l3y1HCMfxg_13_5">278,089,136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_33a8zsLaSk-B2UKpI6UonA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jkwjO-9vrE-AOrZrvwyJSg_13_8">44,043,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_95yfEfIrOESDv0CcRLcCrw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ZBtMO0UJTU6_-p95lvebnA_13_11">2,135,145</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dSbYsOwpaE63kePh-8jz7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_T--6oiEWVEODf8Z9lAfPWQ_13_14">152,879,016</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gyLXYUcZeUShzxxR12kBSA_13_17">167,118,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Shares issued through employee share purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAmkRE0UfkGBBqBYDyrB1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_sG_YX5fjBk2WycGwYnOKvw_14_2">27,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAmkRE0UfkGBBqBYDyrB1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_ZkOjciVM3UCylF_nYVOwyA_14_5">72,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NNI3v2338EuRZLbwXgovnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" sign="-" scale="0" id="Tc_GU70K3JjfkW1MvPf-hxDDw_14_8">3,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_pKB-jN_9P0qi4xFlEsfZ2Q_14_17">68,709</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NNI3v2338EuRZLbwXgovnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_CR7HBUCGyU2VuSOpSK9W7w_15_8">5,007,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_HVlFF5CACki91_N_l8i4MQ_15_17">5,007,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loss and comprehensive loss for the&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e_uffl0eK0idHCR6gU0Cig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="Tc_q8nKvHnYWk6NK2a66te2ng_16_11">14,747</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ilrzsfU4sEeAns69HPYjLg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_pf3kofbntkmm46czM-9odw_16_14">26,582,343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_52WYt9rQ50Kenx-Qs1-fmw_16_17">26,567,596</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance, September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U1nHSjU-9kq6alVsVAiXcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_nnEZDofevU--oCVrUKZp4A_18_2">44,100,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U1nHSjU-9kq6alVsVAiXcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_y3htFFlfKkKK00Y93Y1oNw_18_5">278,161,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cE_1p24JbUqJ-xoUjPgBNg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_azCoVoCRlUiYiJ6kndtLTg_18_8">49,047,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_u3RWCPRxEkqwJwigyugqLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_MtHrLddplkiUr5H9mBqNBg_18_11">2,120,398</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1GvOZDpc9kurwGwIRX7X8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_xDeWVxhC2UaqblXb3Rq3nQ_18_14">179,461,359</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_l2z-WHppYEmLoMVP8O1gsg_18_17">145,627,060</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="a1NATUREOFOPERATIONS_101323"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:NatureOfOperations" id="Tb_kPHJHrSS30mD_v6ZYEjtwQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA Pharma&#160;Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the Province of British Columbia on January&#160;6, 2009. The Company&#8217;s head office address is Suite&#160;720&#160;&#8211; 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5. The registered and records office address is Suite 3500, The Stack, 1133 Melville Street, Vancouver, British Columbia, V6E 4E5. The Company is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;EPIX&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has a license to certain patents (the &#8220;NTD Technology&#8221;) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2023, no products are in commercial production or use.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_a5YqqooP80OWFccJb80a8w_1_2"></a><a id="Tc_nknEkURdMkqw3TuCg08O0w_1_4"></a><a id="Tc_Q1PnZLtkrUSXguVgzr51OA_1_6"></a><a id="Tc_UGLneABZok2KGHq-yBtIrA_2_2"></a><a id="Tc_GFwuj621QkmjmnMucS1VAg_2_4"></a><a id="Tc_CS_30dB-x02Gnt2XdK4Zzw_2_6"></a><a id="Tc_uBlpLg2TMki5ZMd07K4VLw_4_0"></a><a id="Tc_b2eni5DDREmdLB1Z-ZGSMg_4_2"></a><a id="Tc_1EP6r21Z0EeifdUvbozp7w_4_4"></a><a id="Tc_RgsoXvFoQUGKUCVVSloFVA_4_6"></a><a id="Tc_1ZAP0rYLqkqfdnw9T77l3Q_5_0"></a><a id="Tc_EYojeXMFEU2kFJgAMNTayg_5_2"></a><a id="Tc_Td0imjIh9E6eArjU_psnWQ_5_5"></a><a id="Tc_eChgMK1G7UiBZYETRc3dkg_5_6"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_OyCICzZzEUOI3PVjH0dMCg" continuedAt="Tb_OyCICzZzEUOI3PVjH0dMCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;BASIS OF PRESENTATION</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_w3W-gUfGrkOmf9wQ2yxZLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) on a going concern basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value using the accrual basis of accounting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#8220;$&#8221; are to United States dollars and references to &#8220;C$&#8221; are to Canadian dollars.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_o4kjATVRo0Gx5JunlG3RSg" continuedAt="Tb_o4kjATVRo0Gx5JunlG3RSg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Consolidation and Functional Currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Functional Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The functional currency of an entity is the currency of the primary economic environment in which the entity operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The functional currency of the Company and its subsidiary have been determined as follows:</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" id="Tb_8cZGhVDv8U2md8nw6p4YJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA" decimals="2" format="ixt:numdotdecimal" name="epix:PercentageOfEffectiveInterestInSubsidiaries" scale="-2" id="Tc_6cgVQF8-eUONqE9hxBQBYQ_5_4">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The liquidation and dissolution process for Realm Therapeutics plc and Realm Therapeutics Inc. were completed as at September 30, 2022. The consolidated financial statements also include the operations of Realm Therapeutics plc and Realm Therapeutics Inc. to the date of dissolution.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OyCICzZzEUOI3PVjH0dMCg_cont1"><ix:continuation id="Tb_o4kjATVRo0Gx5JunlG3RSg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:UseOfEstimates" id="Tb_1wbXOug6gkuUMlZQXVoIgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and income taxes. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;9.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Vxmp6MCsJ0qFIMyInZbHAg" continuedAt="Tb_Vxmp6MCsJ0qFIMyInZbHAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_6e4IOMAamE-N2hdoasB5Rw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:InvestmentPolicyTextBlock" id="Tb_p0urKmUSnU-h9ZAvNW5Zuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-term investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s short-term investments consist of guaranteed investment certificates, U.S. treasury securities, corporate debt securities, commercial paper and term deposits with original maturities exceeding three months and less than one year. The investments are carried at fair value plus accrued interest.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_MqpsySlwmUq43moaxlznuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign exchange</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_Gv0dYHpII0WPvKGvWco0Dw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_ZCSxY6ewQ02mMbFteSkaGQ" continuedAt="Tb_ZCSxY6ewQ02mMbFteSkaGQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#8217;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8211; quoted prices (unadjusted) in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8211; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;">directly (i.e., as prices) or indirectly (i.e., derived from prices); and</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Vxmp6MCsJ0qFIMyInZbHAg_cont1" continuedAt="Tb_Vxmp6MCsJ0qFIMyInZbHAg_cont2"><ix:continuation id="Tb_ZCSxY6ewQ02mMbFteSkaGQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8211; inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using level 3 inputs (Note 8).</p></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_un7TBWw9ukSAsypovBSCwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company grants stock options to acquire Common Shares of the Company to directors, officers, employees and consultants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_cKsgn3k1RUuZNPnwQXJMbA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of Common Shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_LIEGY1Y4k0qBRF9AkOTQXw" continuedAt="Tb_LIEGY1Y4k0qBRF9AkOTQXw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Vxmp6MCsJ0qFIMyInZbHAg_cont2"><ix:continuation id="Tb_LIEGY1Y4k0qBRF9AkOTQXw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">The Company elected the short-term lease exemption for all leases that qualify; as a result, we will not recognize right-of-use assets or lease liabilities for leases with a term of less than 12 months at inception.</p></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_22-3WaosPEaj8PHseQ1ZqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration. &#160;The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_XXU9IvXumUid63YwUh_LUQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="Tb_QbzhiosBIkOQ6-_yQsaEvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Change in presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, the Company identified a presentation item that required adjustments to be recorded in the historical consolidated statements of cash flows to conform to the presentation required under U.S. GAAP. Interest from short-term investments of $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingInterestIncomeOfShortTermInvestments" scale="0" id="Narr_uRhwmLNUSkGcomBtGjNEaw">705,020</ix:nonFraction> for the year ended September 30, 2022 has been reclassified from investing activities to operating activities. There were <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NetIncomeLoss" scale="0" id="Narr_KTv1wIvkbki44-wmiqoEOA">no</ix:nonFraction> changes to net loss of the Company or <span style="-sec-ix-hidden:Hidden_ilqp4H9x3UeeSj7zg-kL4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">earnings</span></span> per <span style="-sec-ix-hidden:Hidden_uPwaofhXOUatr_NRDuquTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share</span></span> in the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company believes this reclassification and presentation change in the historical consolidated statement of cash flow for the year ended September 30, 2022 is not material and has reflected this reclassification and presentation change in the comparative period included within these consolidated financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_vLpObSylzEyRQFsZr6veKA_1_3"></a><a id="Tc_F0PDxXEvmU6ickBF-qhKvw_2_3"></a><a id="Tc_6z8w0VJstEOXSrPvZh9BCw_2_5"></a><a id="Tc_xwfHKlV0gEe4TEYih-sq7A_2_15"></a><a id="Tc_DHu3MFNXTkS4cQBdi_3q_Q_3_3"></a><a id="Tc_7FDLqT5kOkasO4VNFOq0eg_3_6"></a><a id="Tc_IkGMjOyjJUWtrQqToAh4Jw_3_9"></a><a id="Tc_AQDhTUcFSUGNZoWFpsDvrQ_3_12"></a><a id="Tc_V3N8XYX9DkmBpFd4H4LYRA_3_15"></a><a id="Tc_SBN-W79S6UqCDskLLXHm9g_5_0"></a><a id="Tc_mkBy4KwD50eHe_z808CHIw_5_2"></a><a id="Tc_GPGWr5VXuEuhmPQbpBWeoQ_5_5"></a><a id="Tc_Zd57UBEyb0qVITnhyGLjLg_5_6"></a><a id="Tc_uWNG_-v_OEewwgVtt-H6Ew_5_8"></a><a id="Tc_5EnUykmja0eNjyXuGRyS9Q_5_11"></a><a id="Tc_rZSwwGsjHkG6_F28RgbGfw_5_14"></a><a id="Tc_S3FLcOAn7kmucBeGV8v14w_6_0"></a><a id="Tc_trDcOOznTU-Bw8jYVjlyQQ_6_6"></a><a id="Tc_j1nZrPVtj0WG1_rB8kvDyQ_6_9"></a><a id="Tc_0hATVTsRSUOUbI_cpz348g_7_0"></a><a id="Tc_JOo1qglw4ke0TjcEGt4iYg_7_3"></a><a id="Tc_KgV5Tk6Pk0yfutCyaAZpdw_7_6"></a><a id="Tc_nq7QTm6egE2KUREJeWB2vQ_7_9"></a><a id="Tc_aXWzONC9V0aWbhR7oscpew_7_12"></a><a id="Tc_BBi0D21ZZ0GGa9g74qABTA_7_15"></a><a id="Tc_LkWL3X2c7E2xXbhjHpQizQ_9_0"></a><a id="Tc_n3EaQvAsTUipQU83JEMfxA_9_2"></a><a id="Tc_I1oHeC2NGEedWJg72e5qgg_9_5"></a><a id="Tc_6NvFp7C5F0-uzlFeu0ONEw_9_6"></a><a id="Tc_2V7L419f0EOi3cpSeYuriA_9_8"></a><a id="Tc_ITgdwYlPtkSz4yV3l1fnHw_9_11"></a><a id="Tc_30iO3T-NVkeu_bw7psCFHA_9_14"></a><a id="Tc_VKjPs6KZ8Ua_9LgCV7e-6g_11_3"></a><a id="Tc_FETt3_UmVECWDecG2hplng_12_3"></a><a id="Tc_aHkA3ZKM5U6RZnjjX1yMQA_12_5"></a><a id="Tc_RnUgErvAwUWj_vpFqSq--Q_12_15"></a><a id="Tc_La2BJwYMTkqIwCWRH-DepA_13_3"></a><a id="Tc_j6Gw_htU6U-NZn82s9srfQ_13_6"></a><a id="Tc_TS-PvldrhEK3m3vQKR_JHw_13_9"></a><a id="Tc_CK8jbLDJc0S-uDryyz_YQw_13_12"></a><a id="Tc_gVhHz7XiXkS7I__-X-eYQA_13_15"></a><a id="Tc_GoWY-KiX3EyP2-29pYBBQA_15_0"></a><a id="Tc__2gbVLvFkk-nzFg2qB8UAg_15_2"></a><a id="Tc_Rn3iMOblMkmR6cg-gGk4og_15_5"></a><a id="Tc_SlcZK-86SEqnTMpePjdx2A_15_6"></a><a id="Tc_RFsbWC2-OkO6J5Zx-ACNpg_15_8"></a><a id="Tc_nRu5djLjlEyC0gbxZR2pqQ_15_9"></a><a id="Tc_pjAYlyWiP0-LIpq34Oz-Bw_15_11"></a><a id="Tc_ero8GvAU3UKFpDoJLeoz9Q_15_14"></a><a id="Tc_ssD2Crm1mECZq-8GB_K7BA_16_0"></a><a id="Tc_mBT4KWV-L0SwWqa59NKB_g_16_6"></a><a id="Tc_wETWk6fke063BEuRPtltxw_17_0"></a><a id="Tc_YbClrRuCvkas6UGGtGqNPQ_17_6"></a><a id="Tc_aG2j_cYdBUOUfOoiQj7NrA_18_0"></a><a id="Tc_hQKRTyQem0am-rccxUf-sQ_18_6"></a><a id="Tc_QFa_vUB2RU61ttKNQ2qZ2Q_18_9"></a><a id="Tc_ZG4_kkDjUUaXSRB2N0OjiQ_18_12"></a><a id="Tc_MTYgo5w4sEma3F0mrmx3FQ_20_0"></a><a id="Tc_r-I8P1HOyUi6s51p4t9BaA_20_2"></a><a id="Tc_LciB5j8Q9EW8JiEzbAAdCw_20_5"></a><a id="Tc_MYXEns8kkkesTuG_8Vfx_w_20_6"></a><a id="Tc_qsb-Dz86gUOc6BqThtMdqw_20_8"></a><a id="Tc_1rQBonuQUU6tSNXvPUEDAA_20_11"></a><a id="Tc_VJkFIcHfF0K0LP_8D8q0rg_20_14"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="Tb_zhK3T0rqmU69zudV7htsiA" continuedAt="Tb_zhK3T0rqmU69zudV7htsiA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4</b><b style="font-weight:bold;">.&#160;&#160;&#160;&#160;&#160;SHORT-TERM INVESTMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Short-term investments consist of guaranteed investment certificates (&#8220;GICs&#8221;) held at financial institutions purchased in accordance with the Company&#8217;s treasury policy. These GICs and term deposits bear interest at </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember__JFKnEKGe0C4wTHeLj8ODQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:InvestmentInterestRate" scale="-2" id="Narr_fo_0ShIS60S4iKFiX3cAzA">5.15</ix:nonFraction>%</span><span style="font-size:10pt;">-</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_sSMbCtSnJkqpJVr-Lf7Pqg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:InvestmentInterestRate" scale="-2" id="Narr_ca4HkK2TOEizyi7oWKnE7A">5.40</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum and have maturities of up to </span><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_-Af7YkvMXkif21idoG044w" format="ixt-sec:durwordsen" name="epix:ShortTermInvestmentsMaturityTerm" id="Narr_XkIE_XX0nkSA10ZVQDrvhg"><span style="font-size:10pt;">12 months</span></ix:nonNumeric><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Short-term investments also consist of U.S. treasury securities, corporate debt securities and commercial paper. The Company has classified these investments as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investment securities as current assets. Those investments with maturity dates of three months or less at the date of purchase are presented as cash equivalents in the accompanying balance sheets. Short-term investments are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss as a component of shareholders&#8217; equity until realized. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income.</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_FNtG0uoJxUifVfzNCok-Iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_MqSGdzQPEkKOh8Gi7K9I_Q;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;">Accrued</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc__gBOlPSHKkeLcyyHeLPYAw_5_3">72,802,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="Tc_3l3C1-AObEGKW-6QMtNjjQ_5_9">43,248</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="0" id="Tc_MDv0p2au9EWTp0RhWraHNQ_5_12">301,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_4vAw7zxqIkKmw9BERiSvzA_5_15">73,061,021</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GICs and Term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc_pIgYPIPp80eEfF9D5g9rDA_6_3">41,141,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="0" id="Tc_jOedparnV0apV7coupqVSA_6_12">172,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_sZZcuVg7X0OeiqRJZ2vLwA_6_15">41,313,468</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc_UxfxTzro9EKnvpJPSvFevg_9_3">113,943,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="Tc_oZa83lMmikqwirxRqSE0yg_9_9">43,248</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="0" id="Tc_bGRmg4LSQkaVp3NQxaw_3Q_9_12">473,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_K9thhLvMO0OkpO36dYXNUQ_9_15">114,374,489</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Kk5qrfMvTE2vUhXl6Q4JEQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;">Accrued</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GICs and Term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc_rzqjkTJmREaYcPpSqBhwCg_15_3">89,688,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="0" id="Tc_NWHeT44KGEagJ5UlcEUgPQ_15_12">316,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_vHHJNedNCEKyq-Bh6fQvSQ_15_15">90,005,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc_UHgii78ICUy-laoKa0XrCA_16_3">11,149,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="Tc_urzh27YYUU6YVmMPj7yAEQ_16_9">39,590</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="0" id="Tc_hvD3ZfVImkOgfGSYNyA5oQ_16_12">39,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_JmjZ_Ip2dU2h1m3bfx581A_16_15">11,149,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc_sNjUg210CEKz6uoh86jEkw_17_3">3,034,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="Tc_u7niG12RN02k2eJN_MmcVw_17_9">19,076</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="0" id="Tc_TPOkXy5jdUqGXfoOtovLlA_17_12">29,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_7QpCKgnIr0eZmuUA1PBVrg_17_15">3,044,599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_i33tUz0BdkGB-UPAxwqTtA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc_vw0h5NpBvUWoh_dQt-H1Dw_18_3">5,961,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_i33tUz0BdkGB-UPAxwqTtA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_PsPuNjP4tUWEUkniAj8QWQ_18_15">5,961,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="Tc_PGD02kLZSUKSOwsJwa4oEA_20_3">109,833,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="Tc_qxyniVNvLUOFmgaeKBx90Q_20_9">58,666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" scale="0" id="Tc_QKCxqtWxAEWkOkhi8C4MGA_20_12">385,938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Tc_LyOGq7YDDk2ZaaJMdJJKwA_20_15">110,161,029</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">As of September 30, 2023, short-term investments have an aggregate fair market value of </span><span style="font-size:9.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="Narr_CV9MRI4cRkGxyxoY9T6-0g">114.4</ix:nonFraction></span><span style="font-size:9.5pt;"> million (2022 &#8211; </span><span style="font-size:9.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="Narr_ZrcS4j_ESkCNz6JXv-wVhw">110.2</ix:nonFraction></span><span style="font-size:9.5pt;"> million) were in an aggregate gross unrealized loss position of </span><span style="font-size:9.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="Narr_Bpq1Rx08zkW84OARGc6few">43,248</ix:nonFraction></span><span style="font-size:9.5pt;"> (2022 - </span><span style="font-size:9.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="Narr_8h7BBi8aF0WusldNbKZt3g">58,666</ix:nonFraction></span><span style="font-size:9.5pt;">). The Company considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. These particular investments have been in an unrealized loss position for less than 12 months and it is not more likely than not that the Company will be required to sell any of its securities prior to maturity. Accordingly, </span><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="Narr_pUoPKatc5kOhXoSrww0gUQ">no</ix:nonFraction></span><span style="font-size:9.5pt;"> allowance for credit losses has been recorded as of September 30, 2023, and </span><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnSaleOfInvestments" scale="0" id="Narr_GUnmvDJ1nkSmzBbehH2gLQ">no</ix:nonFraction></span><span style="font-size:9.5pt;"> realized gains or losses on sales of short-term investments have been recorded through September 30, 2023.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zhK3T0rqmU69zudV7htsiA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Tc_LG3htRaKbEG56k82YX5Xeg_1_3"></a><a id="Tc_N2J5fKZd-02Bny3qsPbWlg_1_6"></a><a id="Tc_1jtjwwFu4k2GJcICYsA6wA_2_2"></a><a id="Tc_BayP0gG4cE6NX2l52xT-sg_2_5"></a><a id="Tc_dBcb_sbrhESRjhU4oYX7Kw_4_0"></a><a id="Tc_LSBpP0WaHkKwXHFPycG6ZQ_4_2"></a><a id="Tc_vjfOIcYbR0aS0O347MWGyw_4_5"></a><a id="Tc_4zKZDjYWQ0Wt6rh2fn7MoA_5_0"></a><a id="Tc_5OnzXRNcX0KsHNjSqZ9x_Q_6_0"></a><a id="Tc_xR4S6X46eku4S2t_X2XFeA_8_0"></a><a id="Tc_YPg7faa5hUSsLNFA6glYJw_8_2"></a><a id="Tc_FOj1pimIg0iLUsAGRioXFA_8_5"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="epix:PrepaidExpensesTextBlock" id="Tb_3Ya-sycOB0ylaArmrU1W6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;PREPAIDS</b></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="epix:ScheduleOfPrepaidExpensesTableTextBlock" id="Tb_hJPbnFEQKUKo-YjjJFk_nQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_IFjUoANkH0W6Z1tugWtHbQ_4_3">24,839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_0MQH8k6XdES_q7vPtn61Pw_4_6">1,611,516</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid CMC and clinical expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits" scale="0" id="Tc_vhH5P0DoWk2p6MtQ7GNwRQ_5_3">181,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits" scale="0" id="Tc_GT6pZhfp_EizDRrGU7Xt3Q_5_6">181,835</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other deposits and prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" id="Tc_L7xvUQq5sEaEF5tLyQyaUA_6_3">378,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" id="Tc_QyOVxTJPl0KRS_DRqDQG9A_6_6">22,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_NYp5l2m3akW3PY-JmF8nnw_8_3">585,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_FO24ISbv9061wt_5SOQe0g_8_6">1,815,626</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_g8391Pl0I02rS_QBuuhrIQ_1_3"></a><a id="Tc_o5pVh8C5kkKNQWnwAZPGWQ_1_6"></a><a id="Tc_7KdWl2Ka2kW27eQ2TX9vPA_2_2"></a><a id="Tc_kAxVXZPOtkOhWeMk3xtBAQ_2_5"></a><a id="Tc_plYmjTJ0-kW40U8DxE4KHw_4_0"></a><a id="Tc_EVeUbUPrOUGCBJvRJeZCoA_4_2"></a><a id="Tc_fpfQK3LmOUivBf8BZ7NJNA_4_5"></a><a id="Tc_lc4W9z5lREewkPpYXjaqVw_5_0"></a><a id="Tc_InEMDvQkV0SCvPumCKz7mQ_6_0"></a><a id="Tc_DaLTK2jpxUikuCgl2TbPlA_8_0"></a><a id="Tc_oyNYyHUsh0am8nq2WSMx0Q_8_2"></a><a id="Tc_rlfr6zAUjU2dVwQx1gvb0w_8_5"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_5yR5mQBX4kSCc2oUKtPg5w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_W7hCmDuTjEuTlWbGvHurqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_Wg2tqy9mskWax00c0ZYqhg_4_3">2,028,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_2TRvc-byhE6uzG2WDQHixQ_4_6">954,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_0rsyOocRC0uP8rxJjqKWrA_5_3">845,730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_CcIpfPaR6UyVFgNGHJL35Q_5_6">807,484</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="0" id="Tc_snNCeqN-pEOo4iHdIqJrYg_6_3">540,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="0" id="Tc_Csl7YAs5GUCRLDG1WZdQ0w_6_6">414,483</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_JbYmu1JJR0KumYz0XMFh5Q_8_3">3,414,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_9q4qTby8rEObhtH5E6l-JQ_8_6">2,176,565</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_fHuounwCq0SZ5wVT7FoNmg_1_0"></a><a id="Tc_d8fqylbXL0KWlWp5xrp5jQ_2_0"></a><a id="Tc_bNmykmRFhEa4D_dCMOLqIw_2_2"></a><a id="Tc_At8h3W1I8UOItWiNLKcaOw_3_0"></a><a id="Tc_ULohCBmV00KR9vWR1QCs3g_5_0"></a><a id="Tc_OCLaxFI9o0anZVOqW-goBA_5_2"></a><a id="Tc_zRgbwAGOkUWg5HetQQfXfA_7_0"></a><a id="Tc_vguEWTdbTUWfg0DCQfINiA_9_0"></a><a id="Tc_PQfh7oOkW0K3R-aJsJVkdw_9_2"></a><a id="Tc_ADnwKQSnika3s1r9mderAw_11_0"></a><a id="Tc_ZmRtYNvWTEmWKLnb8z1Xtg_12_0"></a><a id="Tc_MkrmhL4TDkafCvSGLpZnSg_12_2"></a><a id="Tc_2GA-6JGGt0mDQNncXBbicw_13_0"></a><a id="Tc_l34ZVRMw80Or-8--fSzyVw_14_0"></a><a id="Tc_EBNtl28-3kSWFh2Uqoj-Jg_16_0"></a><a id="Tc_TkIKsUpSGUa2BUNiKK8YnA_16_2"></a><a id="Tc_9Dp_V4qFWUSxFPEHisDPeA_18_0"></a><a id="Tc_5YkrSe9pN0ioJfrUfQ4L9w_19_0"></a><a id="Tc_Bi1C48tCD0eA_9C72z1G3Q_21_2"></a><a id="Tc_5aCxRhkNRkyigpjqBFHgaw_23_0"></a><a id="Tc_wIugfzIyX0WiiB1oR3cm5A_23_2"></a><a id="Tc_IzWIKsB_S0GcGcalWxtDcQ_24_0"></a><a id="Tc_GDJe62kZ7EGuxWshgBnSZQ_24_2"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_Zar8_jbJJUOxrqgGSm161w" continuedAt="Tb_Zar8_jbJJUOxrqgGSm161w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;OPERATING LEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s operating leases included on the balance sheet are as follows:</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" id="Tb_sE3wvdbPx0iXQZGHHheoUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_21EIvpzflEu9u-kFRAJSrg_2_3">308,286</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_DOJWruuDqUaGVAYIFjkzuA_3_3">121,787</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_awymHugWfkiEFXlzY7lVzQ_5_3">186,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_deKwvJdG1UOi-yThvjrjJg_7_3">118,491</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_Ioiwks6rm0CatoRPxR_SJw_9_3">68,008</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_98vv7IAKrECwF3hCe-IVhw_12_3">330,970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Tc_2ltSlSiPn0GbLdE7S5jV1w_13_3">13,305</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_4-T2t9hbaECFOUBNhWKH_Q_14_3">134,023</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_Nbfm_H_49EKFrF4jEmHExA_16_3">210,252</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Tc_95N2kt0Rr06v4CaYYYZDSQ_18_3">6,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_Z3_WuSIhiE2DLLzQfUpl-A_19_3">136,866</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ap4efqCYWU2Hbn9_bqvWYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Balance, September&#160;30,&#160;2023</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc__Kbzn_XMEUOXKpKB2ZoQxA_21_3">80,328</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities with expected life of less than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_EsAwY1RapEibhKtOw_-Xag_23_3">80,328</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities with expected life greater than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_-OtlciBwxkiB97Idvjkxeg_24_3">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zar8_jbJJUOxrqgGSm161w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company&#8217;s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. At September 30, 2023, the Company&#8217;s incremental borrowing rate was <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_qln_1kbV1kmYNNXLpbkyJg">5.0</ix:nonFraction>% and the remaining lease term for the South Francisco office was <span style="-sec-ix-hidden:Hidden_7lRLzzwpXE2PixIFHj_goQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8&#160;months</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion expense of $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_EfgTWfcorki7QNu4wkVtZg" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Narr_yRpmiPxtGkCsYiVqzosyYw">6,942</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_sF7fPbMdqUqvbTzfsfT_8w" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Narr_ayeonbhTUEGOYlzA4PCEOw">13,305</ix:nonFraction>) have been recorded in &#8220;financing costs&#8221; in the statement of operations and comprehensive loss.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7bc0ae10_9de1_4d4d_bbf8_f82693e00a74"></a><a id="Tc_VXvDJDES5kuDmIvS_PG4UQ_2_3"></a><a id="Tc_-E0rFGcbaU-yyqcDCMBYhw_3_3"></a><a id="Tc_DkRDfOjJg0uWupDMR6mzdQ_5_0"></a><a id="Tc_edKG7tdJB0Sk4SMxWrGi1w_5_4"></a><a id="Tc_DDthZiEc306FkcNrqC-Ryw_6_0"></a><a id="Tc_Yb7EhDrxX0qj5pplB8tqzg_6_4"></a><a id="Tc_se-r5TNhFk-PGWXdlMsIrQ_7_0"></a><a id="Tc_bLniARhwp0SvI82PKh-XBQ_7_4"></a><a id="Tc_4izN-adOeEOk4nw6ZZZ8XQ_8_0"></a><a id="Tc_fxjpauwlZ0mdNCZwHQbYKA_9_0"></a><a id="Tc_8PU5jsLHlk24n-WRPj0sxg_9_4"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Tb_AO3M0kkhv0e5zVcyfdgIhw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;DERIVATIVE LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January&#160;2016, the Company issued, pursuant to a financing, <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JDmOjRguN0Kdzie1u0Eb5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ueKZjFfcD0CVgvitEXAVmA">227,273</ix:nonFraction> warrants (&#8220;Warrants&#8221;) having an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OlXqQixrvUur2aI9T8N3gg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_wLjHU4MZpUqIgnvULyX87Q">66.00</ix:nonFraction> per common share. The holders of the Warrants had the ability to receive a variable number of shares pursuant to exercise terms or receive cash settlement under certain conditions. Pursuant to these conditions, the Warrants were treated as financial liabilities measured at fair value through profit or loss. The Warrants expired unexercised in the year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valuation</i></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_jnG08khI0ECvXNkNYZ8bgg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_oBr_-pywIkaEsKV63Ewtww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_l0ywcv8fAUSf3AEznf1tiA_5_3">3.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_z0MYX-vw9EWUytYjOXmUkg" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_48y5HKDd8Ue6FoNx1ErTJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_m7y-_2AyOUGs3Ox1lzBiyg_6_3">0.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ZDv0kj75JkKg3GXnXPe5gQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_wMeOMhFZvEWXeNjyjJ-R1Q_7_3">73.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_THqCoUiZjkanSO4NpVc-KQ" decimals="4" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_usMr6f1OUkyzHbXrIideCw_8_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liquidity discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_cJ--xfd0e0C0p7RyafiWnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_T3U7fCNd70q4eO-cCcBGUw_9_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_0oReTK33YkyuMuX7UCnYuw" continuedAt="Tb_0oReTK33YkyuMuX7UCnYuw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Authorized</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited common shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited preferred shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Omnibus incentive plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 25, 2021, the Company adopted an omnibus incentive plan (&#8220;Omnibus Plan&#8221;) consistent with the policies and rules of Nasdaq. Pursuant to the Omnibus Plan, the Company may issue stock options, share appreciation rights, restricted shares, restricted share units and other share-based awards. As of September 30, 2023, the Company has not issued any instruments other than stock options under the Omnibus Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Prior to the adoption of the Omnibus Plan, the Company issued equity compensation pursuant to the Company&#8217;s amended and restated stock option plan (the &#8220;Legacy Option Plan&#8221;), Amended and Restated Restricted Share Unit Plan (the &#8220;RSU Plan&#8221;) and Employee Stock Purchase Plan. Since the adoption of the Omnibus Plan, <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_2_25_2021_To_9_30_2023_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_us-gaap_PlanNameAxis_epix_LegacyOptionPlanAndRsuPlanMember_V6OYcw6z4ky5o49UbZ6MnA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_KP3TXfxJJ0ieGM1HqNu6YA">no</ix:nonFraction> further grants have been made under the Legacy Option Plan or RSU Plan, though existing grants under the Legacy Option Plan will continue in effect in accordance with their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f461ef82_1a44_47b6_8a61_7de5bb959f2a"></a><a id="Tc_wiO8fDkR5EmnUiS6loyc2A_1_2"></a><a id="Tc_OfmTVjp8h0Oq9K7jQY9ozA_2_2"></a><a id="Tc_Goz8k6B90UyHAvr3heHj7g_3_2"></a><a id="Tc_VexbkNMnGEe1VWPAZpMj7A_3_6"></a><a id="Tc_ztzSU6Fin0ifPRflPQ2FiQ_5_0"></a><a id="Tc_x29T7Q4Z5UeDag169reyjQ_5_2"></a><a id="Tc_A6YUL0rcMk2d69AnrT-BFA_5_5"></a><a id="Tc_YYdeUaOxC0evp4y1S8YgZg_6_0"></a><a id="Tc_-HGoacEGykG2Ol_BRAtTlw_7_2"></a><a id="Tc_CjPhj2Sm8UmAtuo9YCwA_Q_7_5"></a><a id="_4484d52d_f4fc_4db9_bb8b_de31826e6c52"></a><a id="Tc_T24vOY_6_UevFfmmpKE0Hw_1_2"></a><a id="Tc_PfWmj6_iOkOR-tWV0oibuQ_1_4"></a><a id="Tc_CApr5uoiB0iH0lLkerdQMg_3_0"></a><a id="Tc_M6KbkFBroEmZskXDPYvipw_3_3"></a><a id="Tc_QV0M-T1daUqrJ3UgfWhHhQ_3_5"></a><a id="Tc_Ejum9eVgOkKcj28sQuKiqg_4_0"></a><a id="Tc_BqEuNxzLX0i-obLnO_Tkyw_5_0"></a><a id="Tc_v5-jsWTe5Ee25YLDq6xD6Q_5_3"></a><a id="Tc_WC5MOrpQwkikTZ8LXmcrOg_5_5"></a><a id="Tc_nGu7aFg5fk-Fp8FI75eZkQ_6_0"></a><ix:continuation id="Tb_0oReTK33YkyuMuX7UCnYuw_cont1" continuedAt="Tb_0oReTK33YkyuMuX7UCnYuw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As of September 30, 2023, the Omnibus Plan has a maximum of </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_FyoK9yWXWUCxMbtsqkJzCA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_5KyUU90E1ESw7-8LLnK4Kw">8,410,907</ix:nonFraction></span><span style="font-weight:normal;"> Common Shares which may be reserved for issuance. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Employee Share Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has adopted an Employee Share Purchase Plan (&#8220;ESPP&#8221;) under which qualifying employees may be granted purchase rights (&#8220;Purchase Rights&#8221;) to the Company&#8217;s Common Shares at not less of <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_XLCr0Xj6H0aNDrwxKDqxqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_A5PMsOMbgUy9ZL1JdPgs3w">85</ix:nonFraction>% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of <ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" format="ixt-sec:durwordsen" name="epix:PurchaseRightsOfferingTerm" id="Narr_WtQ9Lpboq0a2D1JII6If5A">six-month</ix:nonNumeric> periods commencing on January&#160;1 and July&#160;1 and ending on June&#160;30 and December&#160;31 of each calendar&#160;year. As at September 30, 2023, the ESPP has a maximum of <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6mUYISo1eEmc_-LnuL2s_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_FTd3ziBhZESi3eN2fmWGpg">208,836</ix:nonFraction> (2022&#160;&#8211;<ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6XCUQP7JO0WguT4GQ8sEbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_nevKEuYXYUaaKCuSusEhTg">236,598</ix:nonFraction>) Common Shares reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Eligible employees are able to contribute up to <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_S5AnpSsXtEG3ZBTgeWIHtg" decimals="2" format="ixt:numdotdecimal" name="epix:ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" scale="-2" id="Narr_6LAjL7UCzk-3rPwwhHo3nA">15</ix:nonFraction>% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" decimals="0" format="ixt:numdotdecimal" name="epix:MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" scale="0" id="Narr_hjR_jGUn9EemHJ1mOAWy5w">25,000</ix:nonFraction> worth of the Company&#8217;s Common Shares (determined using the lesser of (i)&#160;the market price of a common share on the first day of an applicable purchase period and (ii)&#160;the market price of a common share on the purchase date) for each calendar&#160;year in which a purchase right is outstanding.</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_A2V56cDu_EmX03MkIvvWaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the&#160;year ended September 30, 2023, the Company issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Ft1nVoqcvk-VWT9s1oXOAA">27,762</ix:nonFraction> (2022&#160;&#8211;<ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rlX8Utw-0EC06meFCoTdpA">15,820</ix:nonFraction>) Common Shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_M3oeDgOQYE6eQpxPLzjyHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_5k3RtfR8kUuuMX9TxrA6-w_5_3">4,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_aDqpgEkao0qTgIxFls48UQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_6aru2227rUmkUXtwp0jCuw_5_6">16,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_eK7QF44Iy0SInRW3V5Ougw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_2DkfN0MD1UG3FIa2WOlX8Q_6_3">7,031</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_wcftaJxSUUSWCXQKbpxAPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_dNnKnXlNNkqMkZAT2LpErQ_6_6">13,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_0DhuixKAWkW_UEkhY6FNWQ_7_3">11,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_i_f7RyklvUWqvFmo68cdhg_7_6">29,943</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_cJtYMD8VrEezBFk1B3riJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_fq3wtrUlSEutQQK75TqVuQ_3_2">4.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_blyslfZrkUqVYxAE6PqdtQ_3_4">0.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of share purchase rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_r81roVf8ykSiG9nUmsfOoQ_4_2">6&#160;months</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_XGZorc4tAE2XXs60o4rpOg_4_4">6&#160;months</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_M2EbSVDHHk24C_qBoaXpyA_5_2">72.45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_CtXOxluRT0O9oG_cVzc0Nw_5_4">89.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_niIdvMBtzUOFYbqhLL83ug_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_o-WQqGE0CU6xBYycl0GoLA_6_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Legacy Option Plan and Omnibus Plan, options were previously or may be granted, respectively, with expiry terms of up to <ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_n0-uTgmcUUGkCdF3R77kgA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_zBxJfBQmnkKRfld459LbyA">10 years</ix:nonNumeric>, and vesting criteria and periods are approved by the Board at its discretion. The options issued under the Legacy Option Plan and Omnibus Plan are accounted for as equity-settled share-based payments.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_dd1ab335_d4db_40f6_9032_6077b9d5c63b"></a><a id="Tc_iYDgMtzPTEKZrnGf8dmdfg_1_4"></a><a id="Tc_Fcgi7U9CPEGMkEhz7vDKGA_2_2"></a><a id="Tc_bVPprkkzz0eAPoUhZ83Omg_2_4"></a><a id="Tc_kTdSzOoRPUaX3dF6NT3CXA_3_2"></a><a id="Tc_LsVJ_cJBjE6YbpLJu0F2Jw_3_4"></a><a id="Tc_vabM4lJRBE6Vy2IPklxVCA_5_0"></a><a id="Tc_4x7Yw3_3AUu0Jo-eOcFkvA_5_4"></a><a id="Tc_YBzWeFns7k6QnZIprvGI5A_6_0"></a><a id="Tc_SsNGWKqLjEWijwU_iCbtTQ_7_0"></a><a id="Tc_jV9EnmgnXEiPzJHqGi1NVg_8_0"></a><a id="Tc_tYGNdjSZcUawJ-43_MKIuA_10_0"></a><a id="Tc_LWw9uWvmh0igTnKrapDobg_10_4"></a><a id="Tc_ZuoNpev0X0C7ev88WhTOIA_11_0"></a><a id="Tc_pybEkwE9nECDIN1dO90Kog_12_0"></a><a id="Tc_I_vH5P9icEytqeMoC5Ry1Q_14_0"></a><a id="Tc_MlwwliJh4keCL2yiswPfew_14_4"></a><a id="Tc_6AWx4crDC0mH2OkYEnHdZw_15_0"></a><a id="Tc_p717Fd4YsEmRG7VAeFp2fA_15_4"></a><a id="_1b06176e_15eb_41ad_b723_1da293d851cf"></a><a id="Tc_wiQqRXxzoE2EOEOYvu_hgQ_1_5"></a><a id="Tc_yNsYfuwlLke04miVSStdkw_2_1"></a><a id="Tc_9QOTkhZv9UmZbaotCpV7RQ_2_3"></a><a id="Tc_bjIxSHO_qUan3rIik5UaQQ_2_5"></a><a id="Tc_zHHB7_4rYUmbLPF-0jWQEA_4_0"></a><a id="Tc_qx5spxGWl0GIc4Q6liPDXg_5_0"></a><a id="Tc_NoFuaYIf7keemf62_250WA_6_0"></a><a id="Tc_Tmr4XdvN5UeWhjYeTYLJLw_7_0"></a><a id="Tc_5AQsftWPxUefFXwZbusSRQ_8_0"></a><a id="Tc_54_03YjDRUK1IRaHNxBxWw_9_0"></a><a id="Tc__lsP8Ncg_kGMNl78mDhKng_10_0"></a><a id="Tc_fMd31j9qv0CqgKcZFrlFZA_10_6"></a><a id="Tc_-LmYOh9GGEe5e-LnCi2Mqg_11_0"></a><a id="Tc_3q3PS_0umECi3G8gqXr8VQ_12_0"></a><a id="Tc_77HCzOWsnkqmuNB1_66JWw_13_0"></a><a id="Tc_i-LvyYeTnEOFqNpgoUoD9Q_14_0"></a><a id="Tc_3s9wOSGI6ESDkRCBo8BuIQ_15_0"></a><a id="Tc_MRWxA7_ZCUSBWyEkSZ4RAA_16_0"></a><a id="Tc_FaaBiO3fAUCHwCq0niLeew_17_0"></a><a id="Tc_dQZdSR4o8kWBf2oRvuErTA_18_0"></a><a id="Tc_VRQQNnf0q0aZ9IHJr-_Z3A_18_6"></a><a id="Tc_pBNsgcgjmUKZxXjrFu3xdw_19_0"></a><a id="Tc_1Sle2zgQZE-CLmKlIvFdRg_20_0"></a><a id="Tc_SV0u5AMEnU-nCKV7uMMvbQ_21_0"></a><a id="Tc_GwQbQzh7pEeXncbGT-HQPg_22_0"></a><a id="Tc_MWntQRGVs0errKRwGqgRww_23_0"></a><a id="Tc_DzCZ6x_8xEqFR39PuREzoQ_24_0"></a><a id="Tc_uF3NQZnDBUCgw-J-5BtCNQ_24_6"></a><a id="Tc_lvB4s2YMCEKx764kwfWVBw_25_0"></a><a id="Tc_4cNBFcTw0UaiCKux18z-0A_25_6"></a><ix:continuation id="Tb_0oReTK33YkyuMuX7UCnYuw_cont2" continuedAt="Tb_0oReTK33YkyuMuX7UCnYuw_cont3"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_dLdc34W_p0eqw5XMxnnwew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock option transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price*</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_CwBCmw-Y9U-PphEDQ23cJg_5_2">6,803,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ERa5PBqp20qRzrn716PaYA_5_5">5.20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Sv1Q31fHREmj-hoSZcCozQ_6_2">1,347,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_BqmaQTF2ekaiKyhW0atyDg_6_5">4.55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_fhhO30sd90u579mwv7TQig_7_2">72,910</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_6ogu0SSCAkSLZvrVp2_69w_7_5">4.41</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_a3x27tqSLkerKgxqdWB99A_8_2">175,759</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_3MP3OypQmUyc29JWmSvo1w_8_5">3.60</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_scjeXMwSjkGGVAXgqQHUJA_10_2">7,902,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_xL5JgqqXxUCs_RJT8rD5VA_10_5">5.13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_PMcfdYyVVEeOOrPMnqYLLw_11_2">300,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_r78L6N44dEuwQhAlsYv5RA_11_5">2.97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_28LwqMkdCEaIxhJlXzU5Dw_12_2">89,287</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_IL_HWAs_O0mWAFLsX-TNPQ_12_5">12.27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_CkKKmOvILkucCz_K_OpQUg_14_2">8,112,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_fY3g65T3TE-CM3lVEjdKow_14_5">4.97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance exercisable, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_2ZtPJW10cEOZOwRz3XE_Jg_15_2">6,444,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_-L7ZjH93tUmXYdNFTG-jbg_15_5">4.79</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Options exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">September 30, 2023</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> are translated at current rates to reflect the current weighted average exercise price in U.S. dollars for all outstanding options.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="Tb_PswEBbScoESF-x08XuIblQ" continuedAt="Tb_PswEBbScoESF-x08XuIblQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2023, options were outstanding enabling holders to acquire Common Shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_lVjeFiQ6Ekm7fjJ6XoNSrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_kbyoilkDu0GDrvX_237bWg_4_1">2.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_lVjeFiQ6Ekm7fjJ6XoNSrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_mdHx947PzUCVzpD76k8NUw_4_3">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7PhtjQKMu0GtgpMqe-anoA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_5FhIu2GRNE689EYb4oF8Yw_4_5">8.96</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_sRBNs2Bp202TAd85J0t1Ew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ADSfuBSCm02K5eE3LdV57g_5_1">2.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_sRBNs2Bp202TAd85J0t1Ew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_7gawl_uTrUqAkUNAWF42LQ_5_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_leH9ftDSCk-54cm_qblTEg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_zLIuM1AhwE6TLtpmY2tm1g_5_5">9.59</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_x4LeuRkg3EeVAWxunWBKlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_QmulCNmDN0OY1-B0mzc5lA_6_1">2.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_x4LeuRkg3EeVAWxunWBKlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_N1Ais68jO0ufmfW-gxKnPA_6_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_b7SS3eXxTkaoqtw4IRnCyA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_i9jb_S2Az0mgQWok_RaZtQ_6_5">9.57</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_zjWTpjhz5Emw7U-GDyTvbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_SQIt_6vG702foe9rkcCQ-Q_7_1">2.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_zjWTpjhz5Emw7U-GDyTvbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_T-jZMxxY_0aa2w20bqUJLA_7_3">175,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_nFQt8T1RlESSnCiqvgcN4g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Dqscb0TJHE-NzZqZXOz4yQ_7_5">9.33</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_vIjORgSPqUiUIc9dMJFfFA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_12T676741E6XwYKcXenNvg_8_1">2.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_vIjORgSPqUiUIc9dMJFfFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ULb8ULuqIEitVhUZ96FTRQ_8_3">15,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_tqxeOLNwukiNCCAewkMiEw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Jtc5ZON4zUS0Y5Bf3WxK-w_8_5">9.65</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_O7Jrtq6Zy0mI4nNJSzPGZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_5dyWFqnzPk-E1VZeXR-uuw_9_1">3.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_O7Jrtq6Zy0mI4nNJSzPGZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_LXriLElwekGfrcdG8U64Tw_9_3">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_NQ4IZZb2JUG6Ggr4NZOxqw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_0Jp9ODG58E6b57aRwIrkKQ_9_5">9.69</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_bjAYITQVzEWC4LdXfX0KSg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8fnjo8ctKkeSAum6myL2LA_10_1">3.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_bjAYITQVzEWC4LdXfX0KSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_FIGDoPW6Zk-BEOuVqOXPoA_10_3">3,629,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_pWlgE-YtkE6a1ceHbsbCoA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_IDE3QR8IK0Odr-GfN6pDBA_10_5">6.02</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_tvAsNHy91UG6aiTxFG9cZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ugcRAJ0u_UOjxrbiL6b7SQ_11_1">3.59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_tvAsNHy91UG6aiTxFG9cZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_HKdD0JDHwk-lCGHFIoVfeQ_11_3">26,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_x5J0Bj22GkOSTsuWEuiR0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_AXTrL4HevE2o6jACJ4UETA_11_5">6.05</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_1m2P4O_uf06H8eYherHW9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_EP9KsaiI6EGScllIvbsLsA_12_1">3.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_1m2P4O_uf06H8eYherHW9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zPCKdYlBKUy_5bC3YeUhDg_12_3">910,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_KJWT3GdVH0q0Ytfdkc7bPQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_hwBCxFeNGk6WPBdUK-VY7g_12_5">8.75</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_Mju67xWeg0qPdkvGo74miQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Mf1GiDEFlEu5CPYla8NQ9w_13_1">3.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_Mju67xWeg0qPdkvGo74miQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_AhH_oePHTE27vRjxNoALiw_13_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_r_BXr9FtnkCrKXKU8xDMqg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_FTZblX2HsEKVxafBKEWlrQ_13_5">9.18</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_ovkHbXBRKkiZP-tc8tH0CQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ifNDelPYj0ySwQhin7X7FQ_14_1">3.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_ovkHbXBRKkiZP-tc8tH0CQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_G3gsA0eUTkSP7DrjzVel0w_14_3">185,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_H2lt2rM4EkuRKpzFCmU7bg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Fjt0VSSPJkKVisiokbpB6g_14_5">5.36</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_BBOSnkAiwUSXe9gvqshK1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_uA0D8MmBKkupgsIYEruMEQ_15_1">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_BBOSnkAiwUSXe9gvqshK1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_NpbK9LCDpkGLx5s5gBLXYQ_15_3">539,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_KjLjZYnxOUW1bHNr8qUGxg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_G9fsA_OGEE-oyxfomSj8tg_15_5">4.22</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hvdIRMII4U2RBEiyYCqbEA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ReDimbumNU6rvxOyXebsQw_16_1">4.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hvdIRMII4U2RBEiyYCqbEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_fxJlziJaVEiMbo-QNHtZyA_16_3">168,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_nTVq80JJdEeConndZT7hnw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_dMv9_r-8okGmS9p4zrq1Ag_16_5">6.09</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_45YEp4T3rkaRbQZc8sGXeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_NhgxC9795UGcFOLDx2Gdbg_17_1">5.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_45YEp4T3rkaRbQZc8sGXeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_AJyNzFwfz0-eAcpqsEs3Jw_17_3">190,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_cFCRxahqm0OO2m5OxSVtkQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_jN9KRpeN_k2LThAIiH0QRw_17_5">8.56</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_arlI8eyiaUyFxwbf3MAH1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_g3cD1gCAhEiV7CIK2WXRZA_18_1">7.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_arlI8eyiaUyFxwbf3MAH1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_h6ekHJUjVEec_vBdD-9zAQ_18_3">1,458,646</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_Z8RH8VRQakCIZEbIjDEjqw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_FnzHW5XXwUSTIhOR3xVbIQ_18_5">7.20</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_CiW6XcCB7EaHNCJu_Aq1Bg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8D8ENkdKXkCnjqe8dq3gxg_19_1">8.47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_CiW6XcCB7EaHNCJu_Aq1Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_D7m6VK6v3UC_q6AS4caESQ_19_3">120,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_BVOK3SHXX0WbRyp5MK4RKw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_P0DhOWG-9kOA7E-D9eM1IA_19_5">8.04</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_m_PpxKgTgEO101iOVrfx0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_7aRFLVFsSE21zuEpJvfmig_20_1">9.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_m_PpxKgTgEO101iOVrfx0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_a4t68n3-xkyGqAQcSscj9A_20_3">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_r5PTgGJDcU29voLTSfqxHw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_3VuHfcFH9kOt4v8vJkhCQw_20_5">8.39</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_sGuewVdd5Ei7shCy53nuBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_DtGjxKN-BUG4A3zeAYqxFA_21_1">13.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_sGuewVdd5Ei7shCy53nuBA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_XNLDL1mSOUipbJ6-bfDoUw_21_3">190,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_9BP0mMLtwUiCKPlTHk1SXA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_jgSn8eZT50e5f8iDcPYRHg_21_5">7.29</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_NJOZ1OzFSkq8Ovbj3UzvyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_hsITvQI2a0e0iDRAx3HEsA_22_1">29.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_NJOZ1OzFSkq8Ovbj3UzvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_UWJWR0kFTESFUAYiSLUzJw_22_3">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_iM029G27tEWSaBRh7eMCuA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_f9ISxm93Wk6_yrST4mqTRg_22_5">7.58</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_Pvirta9m-0q0bvKX6IdX9A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_pdXegetXLU62R9sdTuBzKQ_23_1">31.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_Pvirta9m-0q0bvKX6IdX9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_EUm_La_3IkSfcGuE7L59Ag_23_3">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_39z0JsHALEOoxiU3ve-ryw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_2_ZaEWAopEiG1tdeKLCE8Q_23_5">7.67</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_CAD_shares_Mjvk30bxUEexejOIshQtIg" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_FP7VhhSK3kiyjwb8KXwCug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Mkl6dSy990Ouh-7r1dsQMg_24_1">4.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_FP7VhhSK3kiyjwb8KXwCug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_onwt4s_az0KfswnLstUzlA_24_3">124,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_eNYFrBUgOkyeap6Drvlcbw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_5lCVwPQW2EaSci1DPdTpCg_24_5">3.63</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_CAD_shares_Mjvk30bxUEexejOIshQtIg" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_oph37iD120e84jRRKFEFfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_F6riMc9hfkmB5wGybmaFOA_25_1">5.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_oph37iD120e84jRRKFEFfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_8p-xRp7RXUaKpFyC-TR1eA_25_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_1IKX4UL6x02-V0ZkVdX6ew" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_b3-VVNBFaESApATASjwzhA_25_5">5.36</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Bd1k5Bu7FEOifJAvHgoggw_26_3">8,112,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_PH3lrzsVT0GzEr514HBG2A_26_5"> 6.68</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4qyYlMrwq0e0DG3Br4Mq3w" decimals="INF" format="ixt:numdotdecimal" name="epix:Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" scale="0" id="Narr_FnBxv6vLykO3Wy5d7PwwcQ">3,500</ix:nonFraction> options expired unexercised and <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4qyYlMrwq0e0DG3Br4Mq3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_FYrv3G6QqU-WH04GqTYjNA">41,250</ix:nonFraction> options exercised subsequent to September 30, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_64762826_c608_4aa5_8f7c_c5bb41e14e5a"></a><a id="Tc_s4jsq_G6mESTOY0ZwzTzPA_1_2"></a><a id="Tc_REIc72Bj3kCYIdy913a10A_2_2"></a><a id="Tc_0n0AFJuMAkSyWa0ZuleUsQ_3_2"></a><a id="Tc_UHwJRefxeE-E47NSlr-udQ_3_6"></a><a id="Tc_JiN_MSKjikO-P2P6rPCwqQ_5_0"></a><a id="Tc_XKNOa_oeLkO-4inbceScgw_5_2"></a><a id="Tc_OZuAWeKaIUu9SDZXoYsh1A_5_5"></a><a id="Tc_-_wik1slCkqMGBTm0sf8ow_6_0"></a><a id="Tc_yzkiqNx0e0CzUj8ltqQ3xw_7_2"></a><a id="Tc_8aHE8mJn_0CWN1OVMERCFA_7_5"></a><a id="_5196000c_6aba_481d_a841_5f38a8eaae07"></a><a id="Tc_zhaxpNZTqkWqN78DB3N1Tw_1_2"></a><a id="Tc_vlufST57SEis9JjS9gLIbA_1_4"></a><a id="Tc_j6yI46KSa0ifJJPhhayxbA_3_0"></a><a id="Tc_s35u0Q0uBkmBmoywuiyxUw_3_3"></a><a id="Tc_So-pFCBkO0aLyqdeMghSBw_3_5"></a><a id="Tc_eMX90rugmUayqvXjD6HKyA_4_0"></a><a id="Tc_gIOsU-E_LEWuZHQbSufEpg_4_3"></a><a id="Tc_vMgPz0cXcUuHvFTQNC0gHQ_4_5"></a><a id="Tc_s-wv7hgEKEmbq7cqamqvoA_5_0"></a><a id="Tc_bSvgrH7zjUW0vW6AlC91ag_5_3"></a><a id="Tc_D4yhk07FOEm5NIClfI_btQ_5_5"></a><a id="Tc_nawE_zOV3EC6ap1M0yGwGQ_6_0"></a><a id="_8f49fdc1_5d2b_4626_b892_28444bd129ec"></a><a id="Tc__gxoIYHLIUS_O9t4l-SRAw_1_4"></a><a id="Tc_E-Me9Ms7SUmoEOIZK6AAqA_2_2"></a><a id="Tc_PVPg3zQEDUmU1Qq9kh9BVQ_2_4"></a><a id="Tc_7zgBuf-RX0C6vskJE5qUyw_3_2"></a><a id="Tc_XytI1ka6kUW70703wV81eA_3_4"></a><a id="Tc_zZYPV9HBH02Lkh3BE-Ggaw_5_0"></a><a id="Tc_U1_apcbwCkquZ2pvmuKwBQ_5_4"></a><a id="Tc_3mpzAW3KWUO_NOlajepwLw_6_0"></a><a id="Tc_cSN-7M6NcEmj6Sa4fjg3ew_8_0"></a><a id="Tc_m4x_ew4Pckmlzowszmn-qg_8_4"></a><a id="_988edfd2_1d44_415c_ac6d_e2dbb1b08ea5"></a><a id="Tc_mXGw1V5hmEa1IHJ_9vZ6ZA_1_0"></a><a id="Tc_zI3C2d5vmU2Z_Mc-qbYQIw_2_0"></a><a id="Tc_JV-uhkAuM0Og1HIJMqfy7A_2_3"></a><a id="Tc_Nj_WOOQ6zk-0U_HMB3WJJQ_2_6"></a><a id="Tc_w3ggY0Z7fkGstfdP7pnnMA_4_1"></a><a id="Tc_qr0mOOFVDkuHDVzwALMbIA_4_3"></a><a id="Tc_9bjYmOL9XECawVFHpg-0Dg_5_3"></a><ix:continuation id="Tb_0oReTK33YkyuMuX7UCnYuw_cont3"><ix:continuation id="Tb_PswEBbScoESF-x08XuIblQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September 30, 2023, the Company granted a total of <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_R6e8JFTS3kyxk8xBBow3fw">300,000</ix:nonFraction> (2022&#160;&#8211; <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_X9QQ9I4lFUODh1j3ycg1CA">1,347,500</ix:nonFraction>) stock options with a weighted average fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_6Jgr6Ouq60WUgf5lsd1WrA">2.82</ix:nonFraction> per option (2022&#160;&#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Zj0iMuzcVUmBA1ir5jCgjA">3.20</ix:nonFraction>).</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_Yg-RyK_6DEGP1nKtOXARmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2023 and 2022 with allocations to its functional expense as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_b-IPqnYNFUuNriL48L7_JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_N_IKtoIR1EyYZjPncV0WnA_5_3">2,622,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_2u163Nw1DkebtudqKBTvFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_Knva4ssXGEWZxuGlRZ8cqQ_5_6">4,306,463</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_o2_4N6z4yU-LaC4B4CfAIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_sSGfp0m2aUur-o_BbP3yng_6_3">2,372,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_iovEoELo8UyztRr2wxqLXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_okJ74vzPUEOaFxs1z_2Ayg_6_6">3,551,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_p_ipvfu-AUqOngClJ_38RQ_7_3">4,995,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_0Oq2__q_5UOtT5FxYZnkwg_7_6">7,858,142</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_uoqb06zW3kKeFoNtneHwfQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_qEzQgeVBLUmtm7anmwca3g_3_2">3.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_f9P-XIK6NESBYOrRRljdeQ_3_4">2.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_tm8m3qLkQUO__J5PVvmb8Q_4_2"> 10.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_1FxZrIzURk2vla1QEpu-Lg_4_4"> 10.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_zklxTEURm062LxcISxQHaA_5_2">186.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_9Ay3pbY2YEOITIlh_pn1bQ_5_4">79.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_9NqV9hST70mTXgiRuJe0Qw_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_RVJUC42590C7TiPeYLyyxg_6_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Warrants</b></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_dWDIoozQ6E6zs8tPGY7Qiw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021 and September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_QiIM08mxPUy7BLi4ZW6rxQ_5_2">3,234,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_PYAagYyL-E-B2g3AP-k0-g_5_5">4.84</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="INF" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightExpired" scale="0" id="Tc_K3ZG30D6JE6hRqlrICSH5g_6_2">307,273</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="2" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" sign="-" scale="0" id="Tc_BTYxtyPji02Wh_HejdzEng_6_5">49.86</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding and exercisable, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_MUZ80QmZO0qe3XTovz0jZQ_8_2">2,927,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_1h3Z4ruS3kW6NzfZumsciw_8_5">0.11</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" id="Tb_whx_JYPnGkKJ3aaHtpmX7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">At September 30, 2023, warrants were outstanding enabling holders to acquire Common Shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_JPl7VVGk5EKB3wmC98WnMA_4_0">7,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_YqRDi87OT0q6eDwan47iRQ_4_4">42.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Tc_-zvU9yZooUCQh14D6Ck6Rw_4_6">November&#160;18, 2023</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_aT2JbWtE1kWScwUSONqQ0g_5_0">2,920,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ" contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_SrlU-c8K2UyY3Wcm0gvAkQ_5_4">0.0001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Tc_oh0XmiQ9yk23RqjbqZe3hw_5_6">August&#160;23, 2024</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_HCSW3_aas0mzGRpsGpMhBg_6_0">2,927,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_10_1_2023_To_12_12_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hSCrc4kh-k-gCOK-G9Yn7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="0" id="Narr_zX5o1Nv-wkOCOonfy5bmfg">7,477</ix:nonFraction> warrants expired unexercised subsequent to September 30, 2023</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_YkxZcLEByEuyiucrbjavyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Included in accounts payable and accrued liabilities at September 30, 2023, is $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_S2NPPkKazEK7p8VCK-q5Bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Narr_uflT95cSpkOToeOiaNfKNg">98,360</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_diQtzC8i2UykHgFa4IJSIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Narr_cRiTiKrDh0eO8ZHCRcT17Q">81,225</ix:nonFraction>) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_K-L2Fx3cQ0a5mo-hwwMjcQ_1_0"></a><a id="Tc_mMyjcBieFkSWezLLRPBItA_1_2"></a><a id="Tc_AmYl9q7y6kS8-1hX32_l9Q_1_5"></a><a id="Tc_Yz0NlaJeTk6UzFpklUmmXQ_3_0"></a><a id="Tc_F3pUaB_3a0KK7U50QrLuTw_3_2"></a><a id="Tc_yIWprtjD4EuVDJXixqWTqA_3_5"></a><a id="Tc_uC6aAzUR8km9GlNmu69BXA_5_0"></a><a id="Tc_moIZNiA2PUuSotxOteEClg_5_2"></a><a id="Tc_zA0NZ8_u2UiITFMjUP4A8A_5_5"></a><a id="Tc_K50boCj6R0udoUi46cLY5g_6_0"></a><a id="Tc_Fs9L7v4RAUuAU5jL4us96A_7_0"></a><a id="Tc_eH17G-7YjE-m2Q_sZYsJgA_8_0"></a><a id="Tc_zZPdIQJOJUGhDKPPnSmdHQ_9_0"></a><a id="Tc_OHwhV7_OHkiZV2gKoSNnOQ_10_0"></a><a id="Tc_XLxUdaq460Gno1gGfX1Gyg_11_0"></a><a id="Tc_cZlXzRkSqUit5HU7UbEHQw_13_0"></a><a id="Tc_YVRWg0VqZUGntrk-KOuNfQ_13_2"></a><a id="Tc_DyG_d4cH8EyB5AtgrgbRVw_13_5"></a><a id="Tc_pNMGZ2Uhakay1hXGDcR-oQ_1_0"></a><a id="Tc_K3riLFWndU-Sviuavyn-lQ_1_2"></a><a id="Tc_uHLBVhM_CkKtb-psxJxRkg_1_5"></a><a id="Tc_DjCy7NbYukK-zx1fBYE3Ew_3_0"></a><a id="Tc_Qdt6LXLKBU28t3hy-NHVtQ_3_2"></a><a id="Tc_gTP8sNOe6k-MRkdUSDGBaw_3_5"></a><a id="Tc_tZyv69JSbEKwp-jV2SY7gQ_4_0"></a><a id="Tc_tsz6l7OlK0ahFhJL3V2uXg_5_0"></a><a id="Tc_x9SLo9QE1EeJ-qem6fqlAQ_6_0"></a><a id="Tc_xBiv3S-4hUmDm3hXVznY0A_7_0"></a><a id="Tc_EOTzOrNFw0uwt2vSzip37g_8_0"></a><a id="Tc_zlSpDMoTKEimkkZbwGNizQ_11_0"></a><a id="Tc_azYdvA0n-UCaJlPKubee-Q_13_0"></a><a id="Tc_SLc5Kcab90KaTasMDQFvDg_13_2"></a><a id="Tc_2uTAt-44IkSxKVGY_nllMQ_13_5"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_Pj-URnf8sEOaJ_nyCOWtnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_t7g88_PGi0S7e3F-HzdY-w">27.0</ix:nonFraction>% (2022 &#8211; <ix:nonFraction unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_cv_pRwi_20OnoX9kAJ3qRQ">27.0</ix:nonFraction>%) to the tax expense:</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_KPAnhUGotUmdhTPMu5Nz0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">For the&#160;years ended September&#160;30</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss for the&#160;year before income tax</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_-dILJaXHYEagdh5WAlYFKw_3_3">26,580,743</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_ywMh7oqI4UmRdkoAzR8ovw_3_6">35,215,072</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax recovery at statutory income tax rates</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="epix:IncomeTaxReconciliationExpectedIncomeTaxRecovery" scale="0" id="Tc_6-nib1JMjkeOvjNzPBu4Sg_5_3">7,177,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="epix:IncomeTaxReconciliationExpectedIncomeTaxRecovery" scale="0" id="Tc_v2BVY4cul0-e8JLUTuwLng_5_6">9,509,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible share-based payments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="Tc_hljbVqeGyUyeZnsPj6Vmxg_6_3">643,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="Tc_6ayiDNqnMUK9Ck7ZEA67DQ_6_6">963,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxable capital gains</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences including foreign exchange</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" sign="-" scale="0" id="Tc_9Cbpbu_aCkGdx_jg3qNucA_8_3">4,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" sign="-" scale="0" id="Tc_ROBw6uobg0OHS6qdV6atJw_8_6">25,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in statutory, foreign tax, foreign exchange rates and other</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="Tc_zDQTiFjNrU-EMZ_ue6AX8Q_9_3">1,212,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="Tc_JT0nOMfo7Ee1E_LJo4HhaA_9_6">1,288,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="0" id="Tc_WqWCzYEbgkuAq48Kflrjaw_10_3">325,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="0" id="Tc_Rzp5ACrNg0SjHzHTFVyZsQ_10_6">165,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_21wSUxWMjkGqJ3pth-1kSw_11_3">5,003,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_RxIVp5mKlU6YFEXsOtr7Mg_11_6">7,007,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_lmzlcV9vjEWol2ZaLP303g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2,000</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGtoKtsILUiP3lfxWLcxPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (111,000)</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tax attributes are subject to review, and potential adjustment, by tax authorities. The Company has recorded an income tax expense of $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_5bctpm8SSEKI5xHC1Lob0g">2,000</ix:nonFraction> for the&#160;year ended September 30, 2023 (2022&#160;recovery of $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_HocJtCQ_y0aiW3Uavtqtkg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Narr_ehSBlXU9i0CIA2E0F_RDRg">111,000</ix:nonFraction>) in relation to taxable income generated by its U.S. subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the years ended September 30, 2023 and 2022, the Company did not record a provision for income taxes due to a full valuation allowance against our deferred tax assets. The significant components of the Company&#8217;s deferred tax assets that have not been included on the consolidated statement of financial position are as follows:</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_5J5jYmbozkml0O29q5PHLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_i8z8_dNkkUqmvrXLFKQzfA_3_3">43,726,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_Mc4mv5AfcEG81m-l5iWGfQ_3_6">37,710,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsEquipmentAndIntangibleAssets" scale="0" id="Tc_k63zL0p6zEy6GcaKIy0WdA_4_3">77,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsEquipmentAndIntangibleAssets" scale="0" id="Tc_h76vA8YYcUKiuRjwn-4KoA_4_6">77,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="Tc_u6UZYj2jk0egDAU-A2ctrA_5_3">29,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="Tc_nAdXzjyiek-mEwCUDNxNIA_5_6">29,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsFinancingCosts" scale="0" id="Tc_vWtD_-MjJE-jV3-y9eDffQ_6_3">1,191,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsFinancingCosts" scale="0" id="Tc_Fro3J6lMsUGs9VbVEsmkvQ_6_6">2,026,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal R&amp;D credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_irQRvU-GxkC2dmzEIBjj2w_7_3">210,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_1vI7a8GoakGAJ7M06gnvDg_7_6">210,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" sign="-" scale="0" id="Tc_5kMxI8CwlUCjUBVVfAkHzA_8_3">54,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_04anaJLO8Emsd1Zm9cR9sQ_8_6">125,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_rSxtPZt8_EmNCSUUksQ6nA_10_3">45,179,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_GTAWjM9SOkC0JHj-Dp4a1g_10_6">40,177,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_YFJUsOxzrEul12_idoanUQ_11_3">45,179,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_lY7cGbxCwUGxYQBG4qJ5dw_11_6">40,177,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net future tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_UqgadBTN40iO3esfsJ5fzw_13_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_DE2MtbW-N0yC6riyNwBUpA_13_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As at September 30, 2023, the Company has non-capital loss carry-forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ngnJEUWVhEOlVoIyubYBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_5Y3lziNFUkS7DKBc22GAqQ">90,502,000</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_KbenI4q0-UCApoqCAIKAKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_fPlsJJaG60efihift4vfOQ">87,702,000</ix:nonFraction>) available to offset future taxable income in Canada and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_MIfdcUdEqkGqK0TtOwu9JA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_70ggNQgbU0-SFcAvqXO4eg">91,858,000</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2022_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_jv1GtGcpZ0q7yIrUUj3bGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_GlKcPRvPrEytbFxlyYu6lQ">66,812,000</ix:nonFraction>) available to offset future taxable income in the US. These non-capital loss carryforwards begin to expire in 2031.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="Tb_-_5jik8opEOfO5b7buxxTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">12.&#160;&#160;&#160;&#160;SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no significant non-cash financing or investing activities during the year ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxesPaid" scale="0" id="Narr_nkSz_umIOEK-Zn-j3Lm67A"><ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxesPaid" scale="0" id="Narr_oQFpxGmZWUKWO1-Azke5ag">no</ix:nonFraction></ix:nonFraction> amounts paid for taxes and interest in the year ended September 30, 2023 and 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_WD-HIpFdU0GSToU2L0tP7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13.&#160;&#160;&#160;&#160;SEGMENTED INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company works in <ix:nonFraction unitRef="Unit_Standard_segment_4JNQuy2SFUWBUQBeaKqunQ" contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_GK1yg--XG0uG1udFicRBuQ">one</ix:nonFraction> industry being the development of small molecule drugs for prostate cancer. The Company&#8217;s right of use asset is located in the USA.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="Tb_JaO7dojfr0GgMxYJd1ueYA" continuedAt="Tb_JaO7dojfr0GgMxYJd1ueYA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS AND RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using Level 3 inputs (Note 8). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial risk factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s risk exposures and the impact on the Company&#8217;s financial instruments are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. Short-term investments includes investments that may have maturity dates exceeding one year at the date of purchase; however, the Company may liquidate investment positions prior to maturity to implement management strategies. The Company maintains an investment policy which requires certain minimum investment grades over its investment instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023, cash and cash equivalents consisted of cash in Canada and the United States and term deposits in Canada and investments in certain instruments which have a maturity of less than three months at the date of purchase. Balances in cash accounts exceed amounts insured by the Canada Deposit Insurance Corporation for up to C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="epix:CashCanadaDepositInsuranceCorporationInsuredAmount" scale="0" id="Narr_P332y_AL80m-O-aP7PLJgQ">100,000</ix:nonFraction> and by the Federal Deposit Insurance Corporation for up to $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_GxMgAaHsiU-yuPGOkO04sg">250,000</ix:nonFraction>. Amounts due from government agencies are considered to have minimal credit risk.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_7akzkep750C_Xp_qa24X6Q"></a><ix:continuation id="Tb_JaO7dojfr0GgMxYJd1ueYA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Liquidity risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">As at September 30, 2023, the Company had working capital of $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg" decimals="0" format="ixt:numdotdecimal" name="epix:WorkingCapital" scale="0" id="Narr_I3uOV87DAkmVb499vqMkVQ">145,301,807</ix:nonFraction> which will fund budgeted operations past the horizon of the coming year. The Company does not generate revenue and will use available financing options when required to pursue its business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Market risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(a)</span>Interest rate risk</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Over the periods presented, the interest rate environment has changed considerably. The Company has elected to place its cash in instruments which provide a return on funds pending deployment to service business objectives (Note 4). The Company monitors its investments against internal investment criteria which prioritize security of principal. While all investments bear some degree of risk, the Company does not consider interest rate fluctuations to have a significant risk to its financial and operational objectives. The Company does not have any interest-bearing debt.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(b)</span>Foreign currency risk</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company&#8217;s foreign currency risk exposure relates to net monetary assets denominated in Canadian dollars and Euro. The Company maintains its cash and cash equivalents in U.S. dollars and converts on an as needed basis to discharge Canadian and Euro denominated expenditures. A 10% change in the foreign exchange rate between the Canadian, Euro and U.S. dollar in relation to Canadian and Euro dollars held at September 30, 2023 would result in a fluctuation of $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_10_1_2022_To_9_30_2023_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_uQe42TT11ESmRCITPgf7Ag" decimals="0" format="ixt:numdotdecimal" name="epix:ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" sign="-" scale="0" id="Narr_iV3R8IzaKUK8ZvK6Q8nd9Q">2,616</ix:nonFraction> in the net loss recognized for the period. The Company does not currently engage in hedging activities.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_HNmeqSv4a0-kG7nZ1K0NKw_1_0"></a><a id="Tc_t4HWN_vkREGWbM9RMb1LAQ_1_2"></a><a id="Tc_J0h80eF2ekWA5vPaBpqYqg_1_5"></a><a id="Tc_k6dUoIq1LU24kHDA9bzYLA_1_8"></a><a id="Tc_cu6MNIUfAUO-2Xa0xovUmw_1_11"></a><a id="Tc_jYFO4kP-tU6WT17LA_AKCg_1_14"></a><a id="Tc_j_VuWSXSYUu-N5l2VVtk6w_3_0"></a><a id="Tc_Vc3QD4dm-0-oEsr9E0nWig_3_2"></a><a id="Tc_rAaJ5LtN6Eey6Pk_ExsYAw_3_5"></a><a id="Tc_8jSFOR8nHk6dY_WghVXHCg_3_8"></a><a id="Tc_rr7joKbbeE2x5Tt8YqZMyw_3_11"></a><a id="Tc_vCQ_lvxynkSkHz6-zbpLGw_3_14"></a><a id="Tc_RHIDXaMrqE-Ygv5wju9hbA_4_0"></a><a id="Tc_-M3ozA5RFUyuqofgO7uieQ_4_2"></a><a id="Tc_eut3Gxkq70GmilkynmtF0w_4_5"></a><a id="Tc_tWl_u6n1_kSHIOK4v9kpxw_4_8"></a><a id="Tc_LvPBEmUbpUa5kdi2Bsaf-Q_4_11"></a><a id="Tc_5EgIyxQXjkS8_cGi9ySozw_4_14"></a><a id="Tc_ZsOeZ2E9KUOz0JIcMixvpQ_6_0"></a><a id="Tc_pt7a72n29E6j_1bNFnpNPw_6_2"></a><a id="Tc_NsUIokAKME-Naa164tgBNw_6_5"></a><a id="Tc_8Np3RFG6y022RtaeLVRtwQ_6_8"></a><a id="Tc_rfBGloJRyUigJqrQ2jKQ3Q_6_11"></a><a id="Tc_3vpv-UiHSkOtiqE0IuBgkg_6_14"></a><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_vufINS_FVUC5tCJMojQBCw" continuedAt="Tb_vufINS_FVUC5tCJMojQBCw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;&#160;COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The NTD Technology is held under a license agreement signed in fiscal 2010 (the &#8220;License Agreement&#8221;). As consideration for the License Agreement, the Company issued Common Shares of the Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates annual minimum advance royalty payments of C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA" decimals="0" format="ixt:numdotdecimal" name="epix:MinimumAdvanceRoyaltyPayments" scale="0" id="Narr_rGojcGiZy0CKX_YJMoMBig">85,000</ix:nonFraction>. &#160;In addition, there are certain milestone payments for the first compound, to be paid in stages as to C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestoneToBePaidForFilingOfApplication" scale="0" id="Narr_zhPe2gFPF0i6816CWQweDw">20,000</ix:nonFraction> upon filing an Investigational New Drug (IND) Application, C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" scale="0" id="Narr_DqRlPAUPpU-eGBAN3mPwnw">50,000</ix:nonFraction> at the start of a Phase 2 clinical trial, C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" scale="0" id="Narr_jhjR1rzpeUyCsza-do-Geg">900,000</ix:nonFraction> at the start of a Phase 3 clinical trial, C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentsAtApplicationForMarketingApproval" scale="0" id="Narr_NmBoLcXB10CmjNyMhwj-ng">1,450,000</ix:nonFraction> at application for marketing approval, and with further milestone payments on the second and additional compounds. To date, the Company has paid C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentForFilingOfApplication" scale="0" id="Narr_N6Xc-hQ-CEerShI7c-_4OQ">20,000</ix:nonFraction> for filing an IND application for masofaniten (EPI-7386). The next milestone of C$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" scale="0" id="Narr_TUur3J_x0UOSCChyQj54kA">50,000</ix:nonFraction> will be due upon initiation of the Phase 2 clinical trial for masofaniten (EPI-7386).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has the following obligations over the next five&#160;years:</p><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="Tb_kqVVoSf7P0GGVAsHfyYd6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Contractual obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2027</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2028</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minimum annual royalty per License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_GRTRf-zTV0Sfb14DHU0Ijg_3_3">85,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_xfNMvfFukk25Ov4S3pWFVg_3_6">85,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_mmXNC8Ea502DHV2PyVsmMg_3_9">85,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" id="Tc_mf7E03AmeUmyjsz6AWwZkQ_3_12">85,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" id="Tc_Wde5l1Skiku4eLvOPyGi3w_3_15">85,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on CDN office spaces</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_tiybp3dk80u4q3kDIclb2A_4_3">76,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_d-Fd4lalZEO8yBwBVGlckQ_4_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_rNBUKeppxUCHQaAbo3qFQA_4_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" id="Tc_ODe_UhUGNE6K_5tWQIF93Q_4_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" id="Tc_RxYVeqFnH0qPtruWPIWGaA_4_15">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on U.S. office spaces</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_5zKsvUpiRkiFijB79rxEWQ_6_3">81,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_KO3po3_kwUmVAzwJl6DNLA_6_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_bds2VEb990q8LF1_usIFig_6_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" id="Tc_kkyAuuxoNEanHTsz770f1w_6_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" id="Tc_TthJ0HUzAE6sX97qGn2QQw_6_15">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vufINS_FVUC5tCJMojQBCw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Collaborative agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On January 13, 2021, the Company announced a clinical collaboration with Janssen to evaluate masofaniten (EPI-7386) with abiraterone acetate with prednisone as well as the combination of masofaniten (EPI-7386) with apalutamide in patients with mCRPC. Under the terms of the agreement, Janssen may sponsor and conduct up to two Phase 1/2 studies evaluating the safety, tolerability and preliminary efficacy of the combination of </span><span style="font-style:normal;">masofaniten (EPI-7386) </span><span style="font-style:normal;">and apalutamide as well as the combination of masofaniten (EPI-7386) with abiraterone acetate plus prednisone in patients with mCRPC who have failed a current second-generation antiandrogen therapy. Janssen will assume all costs associated with the studies, other than the manufacturing costs associated with the clinical drug supply of masofaniten (EPI-7386). The parties will form a joint oversight committee for the clinical studies. ESSA will retain all rights to masofaniten (EPI-7386). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The combination trial was initiated in March 2022. Enrollment was suspended by Janssen in October 2022 due to operational recruitment challenges. ESSA has announced its intention to revise the collaboration, with ESSA conducting a study of the combinations, potentially in an earlier patient population, and Janssen supplying apalutamide and abiraterone acetate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 25, 2021, the Company announced a clinical collaboration with Astellas Pharma Inc. (&#8220;Astellas&#8221;) to evaluate the combination of masofaniten (EPI-7386) and Astellas/Pfizer&#8217;s androgen receptor inhibitor, enzalutamide, for patients with mCRPC. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of masofaniten (EPI-7386) and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to masofaniten (EPI-7386). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"><span style="font-style:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer Consumer Care AG (&#8220;Bayer&#8221;) to evaluate masofaniten (EPI-7386) in combination with Bayer&#8217;s androgen receptor inhibitor, darolutamide, in patients with mCRPC. &#160;Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of masofaniten (EPI-7386) and darolutamide in mCRPC patients. ESSA will supply masofaniten (EPI-7386) for the trial and will retain all rights to masofaniten (EPI-7386). </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_D_EAvQLxTUKmidNv3d_mPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;&#160;SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oXvRvCbUM0iIVSZ_bqCa7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_A2kt38hCS0enQ2_vsLOn5Q">30,000</ix:nonFraction> common shares for stock options exercised for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g" contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oXvRvCbUM0iIVSZ_bqCa7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_R6J8JmOmk0S2nXOJVOmgKg">96,900</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w" contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kJCtEN0KwUq7roKlGrzIaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_ZnZueVTbIkCu7JJ9p8Ciiw">11,250</ix:nonFraction> common shares for stock options exercised for gross proceeds of CDN$<ix:nonFraction unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw" contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kJCtEN0KwUq7roKlGrzIaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_n2kxARdsNEilkEh7nm529A">55,925</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_4f9a337f_100b_4fc6_8dd7_2024edcdb810"></a><a id="Item9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_48271d38_2edc_46c5_a86f_c6d9971feb2e"></a><a id="Item9A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of end of the period covered by this Annual Report on Form&#160;10-K, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the design and operating effectiveness of our disclosure controls and procedures as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act of 1934 as amended (the &#8220;Exchange Act&#8221;). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms. Any such information is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on our evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were, in design and operation, effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over our financial reporting, defined in Rule&#160;13a-15(f)&#160;and Rule&#160;15d-15(f)&#160;of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute, assurances. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management has assessed the effectiveness of our internal control over financial reporting as at September 30, 2023. In making its assessment, management used the criteria set forth in the internal control&#160;&#8211; integrated framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO framework) to evaluate the effectiveness of our internal control over financial reporting. Based on this evaluation, management has concluded that our internal control over financial reporting was effective as of September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8ffef09d_f510_4ea7_9fac_3570195ca564"></a><a id="Item9B"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;Other Information </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_913c1e4a_7057_4c13_a9af_32ac14af63e0"></a><a id="_51067"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9C.&#160;&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_e9e6d3a4_ae03_4d03_a6a8_f008d3fe397c"></a><a id="PARTIII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;10.</b></span>&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by Item&#160;10. of Form&#160;10-K is incorporated by reference to our proxy statement for the 2024 annual meeting of shareholders (the &#8220;2024 Proxy Statement&#8221;), to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6c42936e_223d_4fa6_8790_ff369fae6393"></a><a id="Item11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;11.</b></span>&#160;&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by Item&#160;11. of Form&#160;10-K is incorporated by reference to our 2024 Proxy Statement (excluding the information under the subheading &#8220;Pay versus Performance&#8221;), to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3e507e49_0361_441d_8251_b4c1e1461ec6"></a><a id="Item12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;12.</b></span>&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by Item&#160;12. of Form&#160;10-K is incorporated by reference to our 2024 Proxy Statement, to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c28ce9a4_0ed7_4fc0_affd_88e11cf71708"></a><a id="Item13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;13.</b></span>&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by Item&#160;13. of Form&#160;10-K is incorporated by reference to our 2024 Proxy Statement, to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8b8119c4_71ea_40e1_bcf5_6a12be491222"></a><a id="Item14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;14.</b></span>&#160;&#160;&#160;Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by Item&#160;14. of Form&#160;10-K is incorporated by reference to our 2024 Proxy Statement, to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_72cff5df_9c19_4c4f_9e66_933c724a8bd7"></a><a id="PARTIV"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;15.</b></span>&#160;&#160;&#160;Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)(1)&#160;Financial Statements&#8212;The financial statements included in Item&#160;8 are filed as part of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)(2)&#160;Financial Statement Schedules&#8212;All schedules have been omitted because they are not applicable or required, or the information required to be set forth therein is included in the consolidated Financial Statements or notes thereto included in Item&#160;8 of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)(3)&#160;Exhibits&#8212;The exhibits required by Item&#160;601 of Regulation S-K are listed in paragraph (b)&#160;below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">(b)&#160;Exhibits&#8212;The exhibits listed on the Exhibit&#160;Index below are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_b86df8ed_7daa_4be3_bc7a_26748261a1f1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBITS INDEX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;No.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001633932/000127956923001206/essa8k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended Articles of Incorporation of ESSA Pharma Inc. (incorporated by reference to Exhibit 3.1 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Current Report on Form 8-K </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(File No.&#160;001-37410), originally filed with the SEC on September 18, 2023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000119312518168196/d587995ds8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen common share certificate (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-225056), originally filed with the SEC on May 18, 2018)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20230930xex4d2.htm">Description of Capital Stock (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on</a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20230930xex4d2.htm">Form 10-K (File No. 001-37410), originally filed with the SEC on December 13, 2022)</a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000095012315003628/filename3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cancer Research Contract between CPRIT and the Company, dated July&#160;9, 2014 (incorporated by reference to Exhibit 4.1 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Registration Statement on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(File No.&#160;377-00939), originally filed with the SEC on February 24, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000095012315004249/filename2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement between the BC Cancer Agency, UBC and the Company, dated December&#160;22, 2010, as amended on February&#160;10, 2011 and May&#160;27, 2014 (incorporated by reference to Exhibit 4.2 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Registration Statement on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(File No.&#160;377-00939), originally filed with the SEC on February 24, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20230930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to License Agreement between the BC Cancer Agency, UBC and the Company, dated May 25, 2021 (Schedules have been omitted pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule upon request)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000095012315004249/filename5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement for David Wood (incorporated by reference to Exhibit 4.9 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Registration Statement on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(File No.&#160;377-00939), originally filed with the SEC on April 7, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956916004844/ex49.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement for David Parkinson (incorporated by reference to Exhibit 4.9 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(File No.&#160;001-37410), originally filed with the SEC on December 14, 2016)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956916004844/ex410.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement for Peter Virsik (incorporated by reference to Exhibit 4.10 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">File (No.&#160;001-37410), originally filed with the SEC on December 14, 2016)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000110465919074530/tm1919820d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement for Alessandra Cesano (incorporated by reference to Exhibit 4.7 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(File No.&#160;001-37410), originally filed with the SEC on December 20, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956918002468/tv507810_ex4-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease for 400 Oyster Point Boulevard, South San Francisco, California, United States dated March&#160;5, 2018 (incorporated by reference to Exhibit 4.12 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(File No.&#160;001-37410), originally filed with the SEC on December 13, 2018)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956922000371/ex991.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Essa Pharma Inc. 2022 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-37410), originally filed with the SEC on March 10, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20230930xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries</span></a>*</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20230930xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Davidson&#160;&amp; Company LLP, an Independent Registered Public Accounting Firm</span></a>*</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20230930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities and Exchange Act of 1934, as amended</span></a>*</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20230930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities and Exchange Act of 1934, as amended</span></a>*</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20230930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350 as added by Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a>**</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20230930xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">The ESSA Pharma Inc. Clawback Policy</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Instance Document &#8211; The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2023 formatted in Inline XBRL (included in Exhibit 101).</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">* Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">** Furnished herewith</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_38bb9f39_d31e_4cdc_af5f_6d08b7d3c4f3"></a><a id="Item16"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;16.</b></span>&#160;&#160;&#160;Form&#160;10-K Summary </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Not applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_06a88d05_3bbc_41a3_9b93_6f973f1c6511"></a><a id="SIGNATURES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Dated: December 12, 2023</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">E</span><span style="font-size:7.5pt;font-style:italic;font-weight:bold;">SSA</span><span style="font-size:10pt;font-style:italic;font-weight:bold;"> P</span><span style="font-size:7.5pt;font-style:italic;font-weight:bold;">HARMA</span><span style="font-size:10pt;font-style:italic;font-weight:bold;">&#160;INC.</span></p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: December 12, 2023</p></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:10pt;">/</span><span style="font-size:7.5pt;">S</span><span style="font-size:10pt;">/ D</span><span style="font-size:7.5pt;">AVID PARKINSON</span></p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Parkinson</p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">David Parkinson</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Parkinson</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">David Wood</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (Principal Financial Officer and</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Wood</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Accounting Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Richard M. Glickman</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard M. Glickman</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Marella Thorell</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marella Thorell</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Alex Martin</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alex Martin</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Sandy Zweifach</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sandy Zweifach</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Franklin Berger</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Franklin Berger</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Scott Requadt</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Scott Requadt</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Gary Sollis</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gary Sollis</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Philip Kantoff</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philip Kantoff</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Lauren Merendino</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lauren Merendino</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>tmb-20230930xex4d2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:08 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following description of the capital stock of ESSA Pharma Inc. (the &#8220;Company,&#8221; &#8220;our&#8221; and &#8220;we&#8221;) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company&#8217;s Articles of Incorporation, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are authorized to issue an unlimited number of common shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Holders of our common shares are entitled to receive notice of any meetings of our shareholders, and to attend and to cast one vote per common share at all such meetings. Holders of common shares are entitled to receive on a pro rata basis such dividends on the common shares, if any, as and when declared by our board of directors at its discretion, from funds legally available therefor, and, upon the liquidation, dissolution or winding up of the Company, are entitled to receive on a pro rata basis the net assets of the Company after payment of debts and other liabilities, in each case subject to the rights, privileges, restrictions and conditions attaching to any other series or class of shares ranking senior in priority to or on a pro rata basis with, the holders of common shares with respect to dividends or liquidation. Our common shares do not carry any pre-emptive, subscription, redemption or conversion rights, nor do they contain any sinking or purchase fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our common shares are listed on the Nasdaq Capital Market under the symbol &#8220;EPIX.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may issue our preferred shares from time to time in one or more series. The terms of each series of preferred shares, including the number of shares, the designation, rights, preferences, privileges, priorities, restrictions, conditions and limitations, will be determined at the time of creation of each such series by our board of directors, without shareholder approval, provided that all preferred shares will rank equally within their class as to dividends and distributions in the event of our dissolution, liquidation or winding-up.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>tmb-20230930xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:09 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"><font style="font-size:12pt;">FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt;"><font style="font-size:12pt;">This Amendment to the Amended and Restated License Agreement (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Amendment</b><font style="font-size:12pt;">&#8221;) is entered into and effective as of May 25, 2021 by and between BC CANCER, part of the Provincial Health Services Authority amalgamated under the Society Act (British Columbia), having an office at Suite 600, West 10</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Avenue, Vancouver, British Columbia, Canada, V5Z 4E6 (&#8220;</font><b style="font-size:12pt;font-weight:bold;">BC CANCER</b><font style="font-size:12pt;">&#8221;) and The University of British Columbia, a corporation continued under the University Act (British Columbia), having its registered office at 103 &#8211; 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3 (&#8220;</font><b style="font-size:12pt;font-weight:bold;">UBC</b><font style="font-size:12pt;">&#8221;) and ESSA Pharma Inc. a corporation incorporated under the laws of the Province of British Columbia located at 999 West Broadway, Suite 720, Vancouver, British Columbia V5Z 1K5 (&#8220;</font><b style="font-size:12pt;font-weight:bold;">ESSA</b><font style="font-size:12pt;">&#8221;) (each, a &#8220;Party&#8221; and collectively, the &#8220;Parties&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WITNESSETH:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS, </b><font style="font-size:12pt;">BC CANCER, UBC and ESSA entered into an Amended and Restated License Agreement effective May 27, 2014 (the &#8220;Agreement&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS, </b><font style="font-size:12pt;">the Parties wish to amend the Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Now therefore, in consideration of the foregoing, of the mutual covenants and undertakings set forth below, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Defined Terms</b><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u><font style="font-size:12pt;"> Words and phrases which are introduced by initial capitals and which are not otherwise defined in this Amendment shall have the same meaning as in the Agreement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Replace Schedule &#8220;A&#8221; Description of &#8220;Technology&#8221; in the Agreement with Schedule &#8220;A&#8221; Description of &#8220;Technology&#8221; attached to this Amendment.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Counterparts. </b><font style="font-size:12pt;">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original of the Party or Parties who executed such counterpart, but all of which together shall constitute one and the same instruments.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Otherwise Unchanged. </b><font style="font-size:12pt;">Except as amended by this Amendment, the Agreement shall remain unchanged, and the Agreement, as amended hereby, is hereby ratified, approved and confirmed in all respects by the Parties and shall remain in full force and effect.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Governing Law</b><font style="font-size:12pt;">. This Amendment shall be governed by, and construed and enforced in accordance with, the laws of the Province of British Columbia, Canada, excluding its conflict of laws.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 180pt;"><font style="font-size:12pt;">(</font><i style="font-size:12pt;font-style:italic;">signature page follows</i><font style="font-size:12pt;">)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 180pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:12pt;">, the Parties have caused this Amendment to be executed as of the date written above by their duly authorized officers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">BC CANCER</b></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Sarah Jane Lee</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Sarah Jane Lee</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Director, Technology Development Office</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">THE UNIVERSITY OF BRITISH COLUMBIA</b></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Brett Sharp</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Brett Sharp</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Associate Director UBC UILO</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ESSA PHARMA INC.</b></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ David Parkinson</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">David Parkinson</font></p></td></tr><tr><td style="vertical-align:top;width:49.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>tmb-20230930xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:08 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;">21</b><b style="font-weight:bold;">.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;width:35.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Abbreviation</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Place of Incorporation</b></p></td></tr><tr><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ESSA Texas</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">State of Texas</p></td></tr><tr><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>tmb-20230930xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:09 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20230930xex23d1002.jpg" alt="Graphic" style="display:inline-block;height:31.8pt;width:540pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the registration statements on Form S-3 (No. 333-250971 and No. 333-250967) and Form S-8 (No. 333-245143, No. 333-239541, No. 333-225056 and No. 333-210217) of ESSA Pharma Inc. of our report dated December 12, 2023, relating to the consolidated financial statements of ESSA Pharma Inc., for the years ended September 30, 2023 and 2022 which appears in the annual report on Form 10-K of ESSA Pharma Inc. dated December 12, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#8220;DAVIDSON &amp; COMPANY LLP&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1.15pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Vancouver, Canada </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Chartered Professional Accountants</p></td></tr><tr style="height:1.15pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:1.15pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">December 12, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20230930xex23d1001.jpg" alt="Graphic" style="display:inline-block;height:81.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:314.25pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>tmb-20230930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:26 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, David Parkinson, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">1. I have reviewed this Annual Report on Form 10-K of ESSA Pharma Corp.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: December 12, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:40%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Parkinson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>tmb-20230930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:26 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, David Wood, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">1. I have reviewed this Annual Report on Form 10-K of ESSA Pharma Corp.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: December 12, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:40%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Wood</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>tmb-20230930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;">32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF CEO AND CFO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the annual report of ESSA Pharma Inc. (the &quot;Registrant&quot;) filed under cover of Form 10-K for the annual period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), David Parkinson as Chief Executive Officer of the Registrant and David Wood as Chief Financial Officer of the Registrant, each hereby certifies, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ David Parkinson</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">David Parkinson</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">December 12, 2023</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ David Wood</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name: </p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">David Wood</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Financial Officer&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">December 12, 2023</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This certification accompanies the Report pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Registrant for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>9
<FILENAME>tmb-20230930xex97.htm
<DESCRIPTION>EX-97
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 12/12/2023 02:45:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 97</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ESSA PHARMA INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CLAWBACK POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Compensation Committee (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u><font style="font-size:12pt;">&#8221;) of the Board of Directors (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="font-size:12pt;">&#8221;) of ESSA Pharma Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:12pt;">&#8221;) believes that it is appropriate for the Company to adopt this Clawback Policy (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="font-size:12pt;">&#8221;) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Definitions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">For purposes of this Policy, the following definitions shall apply:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Group</u><font style="font-size:12pt;">&#8221; means the Company and each of its Subsidiaries, as applicable.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Compensation</u><font style="font-size:12pt;">&#8221; means any Incentive-Based Compensation granted, vested or paid to a person who served as an Executive Officer at any time during the performance period for the Incentive-Based Compensation and that was Received (i) on or after the effective date of the Nasdaq listing standard, (ii) after the person became an Executive Officer and (iii) at a time that the Company had a class of securities listed on a national securities exchange or a national securities association.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:12pt;">&#8221; means November 30, 2023.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneously Awarded Compensation</u><font style="font-size:12pt;">&#8221; means the amount of Covered Compensation granted, vested or paid to a person during the fiscal period when the applicable Financial Reporting Measure relating to such Covered Compensation was attained that exceeds the amount of Covered Compensation that otherwise would have been granted, vested or paid to the person had such amount been determined based on the applicable Restatement, computed without regard to any taxes paid (i.e., on a pre-tax basis). For Covered Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Restatement, the Committee will determine the amount of such Covered Compensation that constitutes Erroneously Awarded Compensation, if any, based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Covered Compensation was granted, vested or paid and the Committee shall maintain documentation of such determination and provide such documentation to the Nasdaq.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u><font style="font-size:12pt;">&#8221; means the U.S. Securities Exchange Act of 1934.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">f)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Executive Officer</u><font style="font-size:12pt;">&#8221; means each &#8220;officer&#8221; of the Company as defined under Rule 16a-1(f) under Section 16 of the Exchange Act, which shall be deemed to include any individuals identified by the Company as executive officers pursuant to Item 401(b) of Regulation S-K under the Exchange Act. Both current and former Executive Officers are subject to the Policy in accordance with its terms.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">g)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Reporting Measure</u><font style="font-size:12pt;">&#8221; means (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures and may consist of GAAP or non-GAAP financial measures (as defined under Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Exchange Act), (ii) stock price or (iii) total shareholder return. Financial Reporting Measures may or may not be filed with the SEC and may be presented outside the Company&#8217;s financial statements, such as in Managements&#8217; Discussion and Analysis of Financial Conditions and Result of Operations or in the performance graph required under Item 201(e) of Regulation S-K under the Exchange Act.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">h)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Home Country</u><font style="font-size:12pt;">&#8221; means the Company&#8217;s jurisdiction of incorporation.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive-Based Compensation</u><font style="font-size:12pt;">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">j)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lookback Period</u><font style="font-size:12pt;">&#8221; means the three completed fiscal years (plus any transition period of less than nine months that is within or immediately following the three completed fiscal years and that results from a change in the Company&#8217;s fiscal year) immediately preceding the date on which the Company is required to prepare a Restatement for a given reporting period, with such date being the earlier of: (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Restatement. Recovery of any Erroneously Awarded Compensation under the Policy is not dependent on if or when the Restatement is actually filed.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">k)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq</u><font style="font-size:12pt;">&#8221; means the Nasdaq Stock Market.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">l)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Received</u><font style="font-size:12pt;">&#8221;: Incentive-Based Compensation is deemed &#8220;Received&#8221; in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in or otherwise relating to the Incentive-Based Compensation award is attained, even if the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">m)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restatement</u><font style="font-size:12pt;">&#8221; means a required accounting restatement of any Company financial statement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including (i) to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as a &#8220;Big R&#8221; restatement) or (ii) to correct an error in previously issued financial statements that is not material to the previously issued financial statements but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as a &#8220;little r&#8221; restatement). Changes to the Company&#8217;s financial statements that do not represent error corrections under the then-current relevant accounting standards will not constitute Restatements. Recovery of any Erroneously Awarded Compensation under the Policy is not dependent on fraud or misconduct by any person in connection with the Restatement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">n)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</u><font style="font-size:12pt;">&#8221; means the U.S. Securities and Exchange Commission.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">o)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</u><font style="font-size:12pt;">&#8221; means any domestic or foreign corporation, partnership, association, joint stock company, joint venture, trust or unincorporated organization &#8220;affiliated&#8221; with the Company, that is, directly or indirectly, through one or more intermediaries, &#8220;controlling&#8221;, &#8220;controlled by&#8221; or &#8220;under common control with&#8221;, the Company. &#8220;Control&#8221; for this purpose means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership of voting securities, contract or otherwise.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Recoupment of Erroneously Awarded Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In the event of a Restatement, any Erroneously Awarded Compensation Received during the Lookback Period prior to the Restatement (a) that is then-outstanding but has not yet been paid shall be automatically and immediately forfeited and (b) that has been paid to any person shall be subject to reasonably prompt repayment to the Company Group in accordance with Section 3 of this Policy. The Committee must pursue (and shall not have the discretion to waive) the forfeiture and/or repayment of such Erroneously Awarded Compensation in accordance with Section 3 of this Policy, except as provided below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Notwithstanding the foregoing, the Committee (or, if the Committee is not a committee of the Board responsible for the Company&#8217;s executive compensation decisions and composed entirely of independent directors, a majority of the independent directors serving on the Board) may determine not to pursue the forfeiture and/or recovery of Erroneously Awarded Compensation from any person if the Committee determines that such forfeiture and/or recovery would be impracticable due to any of the following circumstances: (i) the direct expense paid to a third party (for example, reasonable legal expenses and consulting fees) to assist in enforcing the Policy would exceed the amount to be recovered (following reasonable attempts by the Company Group to recover such Erroneously Awarded Compensation, the documentation of such attempts, and the provision of such documentation to the Nasdaq), (ii) pursuing such recovery would violate the Company&#8217;s Home Country laws adopted prior to November 28, 2022 (provided that the Company obtains an opinion of Home Country counsel acceptable to the Nasdaq that recovery would result in such a violation and provides such opinion to the Nasdaq), or (iii) recovery would likely cause any otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Means of Repayment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In the event that the Committee determines that any person shall repay any Erroneously Awarded Compensation, the Committee shall provide written notice to such person by email or certified mail to the physical address on file with the Company Group for such person, and the person shall satisfy such repayment in a manner and on such terms as required by the Committee, and, subject to applicable law, the Company Group shall be entitled to set off the repayment amount against any amount owed to the person by the Company Group, to require the forfeiture of any award granted by the Company Group to the person, or to take any and all necessary actions to reasonably promptly recoup the repayment amount from the person, in each case, to the fullest extent permitted under applicable law, including without limitation, Section 409A of the U.S. Internal Revenue Code and the regulations and guidance thereunder. If the Committee does not specify a repayment timing in the written notice described above, the applicable person shall be required to repay the Erroneously Awarded Compensation to the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Company Group by wire, cash or cashier&#8217;s check no later than thirty (30) days after receipt of such notice.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">No Indemnification</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">No person shall be indemnified, insured or reimbursed by the Company Group in respect of any loss of compensation by such person in accordance with this Policy, nor shall any person receive any advancement of expenses for disputes related to any loss of compensation by such person in accordance with this Policy, and no person shall be paid or reimbursed by the Company Group for any premiums paid by such person for any third-party insurance policy covering potential recovery obligations under this Policy. For this purpose, &#8220;indemnification&#8221; includes any modification to current compensation arrangements or other means that would amount to </font><i style="font-size:12pt;font-style:italic;">de facto</i><font style="font-size:12pt;"> indemnification (for example, providing the person a new cash award which would be cancelled to effect the recovery of any Erroneously Awarded Compensation). In no event shall the Company Group be required to award any person an additional payment if any Restatement would result in a higher incentive compensation payment.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Miscellaneous</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">This Policy generally will be administered and interpreted by the Committee, provided that the Board may, from time to time, exercise discretion to administer and interpret this Policy, in which case, all references herein to &#8220;Committee&#8221; shall be deemed to refer to the Board.  Any determination by the Committee with respect to this Policy shall be final, conclusive and binding on all interested parties.  Any discretionary determinations of the Committee under this Policy, if any, need not be uniform with respect to all persons, and may be made selectively amongst persons, whether or not such persons are similarly situated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy is intended to satisfy the requirements of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time, and any related rules or regulations promulgated by the SEC or the Nasdaq, including any additional or new requirements that become effective after the Effective Date which upon effectiveness shall be deemed to automatically amend this Policy to the extent necessary to comply with such additional or new requirements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">The provisions in this Policy are intended to be applied to the fullest extent of the law.  To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to applicable law.  The invalidity or unenforceability of any provision of this Policy shall not affect the validity or enforceability of any other provision of this Policy.  Recoupment of Erroneously Awarded Compensation under this Policy is not dependent upon the Company Group satisfying any conditions in this Policy, including any requirements to provide applicable documentation to the Nasdaq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The rights of the Company Group under this Policy to seek forfeiture or reimbursement are in addition to, and not in lieu of, any rights of recoupment, or remedies or rights other than recoupment, that may be available to the Company Group pursuant to the terms of any law, government regulation or stock exchange listing requirement or any other policy, code of conduct, employee handbook, employment agreement, equity award agreement, or other plan or agreement of the Company Group.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Amendment and Termination</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">To the extent permitted by, and in a manner consistent with applicable law, including SEC and Nasdaq rules, the Committee may terminate, suspend or amend this Policy at any time in its discretion.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Successors</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy shall be binding and enforceable against all persons and their respective beneficiaries, heirs, executors, administrators or other legal representatives with respect to any Covered Compensation granted, vested or paid to or administered by such persons or entities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ESSA PHARMA INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CLAWBACK POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ACKNOWLEDGMENT, CONSENT AND AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">I acknowledge that I have received and reviewed a copy of the ESSA Pharma Clawback Policy (as may be amended from time to time, the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="font-size:12pt;white-space:pre-wrap;">&#8221;) and I have been given an opportunity to ask questions about the Policy and review it with my counsel.  I knowingly, voluntarily and irrevocably consent to and agree to be bound by and subject to the Policy&#8217;s terms and conditions, including that I will return any Erroneously Awarded Compensation that is required to be repaid in accordance with the Policy.  I further acknowledge, understand and agree that (i) the compensation that I receive, have received or may become entitled to receive from the Company Group is subject to the Policy, and the Policy may affect such compensation and (ii) I have no right to indemnification, insurance payments or other reimbursement by or from the Company Group for any compensation that is subject to recoupment and/or forfeiture under the Policy. Capitalized terms used but not defined herein have the meanings set forth in the Policy.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:12pt;font-weight:bold;">Signed:</b></p></td><td style="vertical-align:top;width:39.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:39.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:12pt;font-weight:bold;">Print Name:</b></p></td><td style="vertical-align:top;width:39.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:39.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:12pt;font-weight:bold;">Date:</b></p></td><td style="vertical-align:top;width:39.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:39.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tmb-20230930x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20230930x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &8 X\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU6)IN4O=;T7^9]]4445X1[(4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?C_P#]P?^$Y\-_\ 0P:5_P"!L?\ \51_PG/AO_H8-*_\#8__ (JOP^^T2_\
M/1_^^C1]HE_YZ/\ ]]&C^PH_\_/P_P""']LO^3\3]P?^$Y\-_P#0P:5_X&Q_
M_%4?\)SX;_Z&#2O_  -C_P#BJ_#[[1+_ ,]'_P"^C1]HE_YZ/_WT:/["C_S\
M_#_@A_;+_D_$_<'_ (3GPW_T,&E?^!L?_P 51_PG/AO_ *&#2O\ P-C_ /BJ
M_#[[1+_ST?\ [Z-'VB7_ )Z/_P!]&C^PH_\ /S\/^"']LO\ D_$_<'_A.?#?
M_0P:5_X&Q_\ Q5'_  G/AO\ Z&#2O_ V/_XJOP^^T2_\]'_[Z-'VB7_GH_\
MWT:/["C_ ,_/P_X(?VR_Y/Q/W!_X3GPW_P!#!I7_ (&Q_P#Q5'_"<^&_^A@T
MK_P-C_\ BJ_#[[1+_P ]'_[Z-'VB7_GH_P#WT:/["C_S\_#_ ((?VR_Y/Q/W
M!_X3GPW_ -#!I7_@;'_\51_PG/AO_H8-*_\  V/_ .*K\/OM$O\ ST?_ +Z-
M'VB7_GH__?1H_L*/_/S\/^"']LO^3\3]P?\ A.?#?_0P:5_X&Q__ !5'_"<^
M&_\ H8-*_P# V/\ ^*K\/OM$O_/1_P#OHT?:)?\ GH__ 'T:/["C_P _/P_X
M(?VR_P"3\3]P?^$Y\-_]#!I7_@;'_P#%4?\ "<^&_P#H8-*_\#8__BJ_#[[1
M+_ST?_OHT?:)?^>C_P#?1H_L*/\ S\_#_@A_;+_D_$_<'_A.?#?_ $,&E?\
M@;'_ /%4?\)SX;_Z&#2O_ V/_P"*K\/OM$O_ #T?_OHT?:)?^>C_ /?1H_L*
M/_/S\/\ @A_;+_D_$_<'_A.?#?\ T,&E?^!L?_Q5'_"<^&_^A@TK_P #8_\
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M_?1H^T2_\]'_ .^C1_84?^?GX?\ !#^V7_)^)^X/_"<^&_\ H8-*_P# V/\
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M5^'WVB7_ )Z/_P!]&C[1+_ST?_OHT?V%'_GY^'_!#^V7_)^)^X/_  G/AO\
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M.3^-+ T:N&FZ<UHU?377K]X8RK3Q$5.+U3M\NGW'G5%%%>R>4%%%% !1110
M4444 %%%% !1110!^K7[!O\ R;GHW_7Q-_,5]#5\\_L&_P#)N>C?]?$W\Q7T
M-7YGC/\ >:GJS]!PG\"'H@HHHKC.H**** "BBB@ KY\_;O\ ^3;M>_Z[V_\
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MV 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'SM^WI_R;MJW_7Q#_.ORHK]5_P!O
M3_DW;5O^OB'^=?E17W.2_P"[/U?Z'Q^;?QUZ!1117OGB!1110 4444 %>P_
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M\Z\X R0/6OO#X(+IO@#P7\>PNDV^HZ;IMTWEZ=< ^2ZKG"MSDBN'\6_\(_\
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M5H\W/RZ_/T']9J\O+?3Y'TMK'[9-M??%;2/'UE\/M/T[6K6-TNV2\9OMA9<
ML=@QC\?K7(_#3]IW5OAYKGB6271K+7?#OB*9Y=0T*^),3EB3\I['G&2#]*\7
MHI+"4%'EY=-NO0'B:SES<VN_0]P^*'[3LGC+P;!X/\+^%+#P+X5643S6-A(9
M&N'SGYWPN1[8K*^)?[0EW\2=3\'7DVCPV1\.01P1I',6\\(0<G(XSBO)**N.
M&I0MRQVO^.Y,L15E>[W_ $.^^-GQ:N/C1XU?Q%<Z='IDC01P>1%(7&%&,Y(%
M<#116T(1IQ4([(RE)SDY2W844459 4444 %%%% !7ZH_L"_\F_:?_P!?,O\
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M]GXK^3\CXEHK[:_X=BZY_P!#KI__ (#/1_P[%US_ *'73_\ P&>C^T\)_/\
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M "BBB@ HHHH **** "BBB@ HHHH **** /"+W_D];3?^Q,E_]*A7N]>$7O\
MR>MIO_8F2_\ I4*]WKKQ'V/\*_4YJ'V_5A1117(=(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8?CG_ )$O7O\ KPG_ /1;5N5A^.?^1+U[_KPG
M_P#1;5</B1,OA9Y_^R7_ ,FY>!/^O#_VH]>N5Y'^R7_R;EX$_P"O#_VH]>N5
MKB?X\_5_F94/X,/1?D%%%%<YN%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#HI.O_ )1?_$UU5%%UV7W(->[^]G*_\([XO_Z*3K_Y1?\ Q-'_  COB_\
MZ*3K_P"47_Q-=511==E]R#7N_O9RO_".^+_^BDZ_^47_ ,31_P ([XO_ .BD
MZ_\ E%_\37544779?<@U[O[V<I&WQ,\--]ITOQH->*\FRUJV7:X] Z<@^^*]
M+^%GQAM_'\ESI5_9OHGB:R&;G3ICG(_OQM_$I]:Y^N%^)<3^'Y-,\96 :/4M
M&G5V:)<M) 3AT/J,5E.C"LK6L^C1I"M.D[WNCZ@HJOI]XFHV%M=Q@A)XEE4'
MT(S_ %JQ7@'N!1110 4444 %%%% !6'XY_Y$O7O^O"?_ -%M6Y6'XY_Y$O7O
M^O"?_P!%M5P^)$R^%GG_ .R7_P FY>!/^O#_ -J/7KE>1_LE_P#)N7@3_KP_
M]J/7KE:XG^//U?YF5#^##T7Y!1117.;E+6M9LO#VEW.HZA<):V=LADEED. H
M%>!WOQ9\;_$J5W\*+#X6\.$D1ZG>P^9<W*_WDC. H]":O?'Z^_X2OQMX;\#E
MW6Q96U*_0#Y98T/RH3[MVK3CC6*-410B*,*H& !Z5[&'H1C!3DKMGE8BM)R<
M(NR1RJ>'O&9R9?B7KC.>NR.)!^6*=_PCOB__ **3K_Y1?_$UU5%=EUV7W+_(
MY->[^]G*_P#".^+_ /HI.O\ Y1?_ !-'_".^+_\ HI.O_E%_\37544779?<@
MU[O[V<K_ ,([XO\ ^BDZ_P#E%_\ $T?\([XO_P"BDZ_^47_Q-=511==E]R#7
MN_O9RO\ PCOB_P#Z*3K_ .47_P 31_PCOB__ **3K_Y1?_$UU5%%UV7W(->[
M^]G*_P#".^+_ /HI.O\ Y1?_ !-'_".^+_\ HI.O_E%_\37544779?<@U[O[
MV<K_ ,([XO\ ^BDZ_P#E%_\ $T?\([XO_P"BDZ_^47_Q-=511==E]R#7N_O9
MRO\ PCOB_P#Z*3K_ .47_P 31_PCOB__ **3K_Y1?_$UU5%%UV7W(->[^]G*
M_P#".^+_ /HI.O\ Y1?_ !-'_".^+_\ HI.O_E%_\37544779?<@U[O[V<K_
M ,([XO\ ^BDZ_P#E%_\ $T?\([XO_P"BDZ_^47_Q-=511==E]R#7N_O9RO\
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M P/['L__ $2E>R_%;_DF7BO_ +!=S_Z+:O&OA5_R2_P?_P!@:S_]$)7L8/\
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M7&:DBU17B?PS\7:\/&RG7+Z:;3O$4;W&GP3'B#:W"J.@!'-/^+?BK7T\2_\
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M];EOM^9YE[;H[*BN-_X6/<?]"/XV_P#";NO_ (BC_A8]Q_T(_C;_ ,)NZ_\
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M10 4444 %8?CG_D2]>_Z\)__ $6U;E8?CG_D2]>_Z\)__1;5</B1,OA9Y_\
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M;NO_ (BC_A8]Q_T(_C;_ ,)NZ_\ B*.5A='945QO_"Q[C_H1_&W_ (3=U_\
M$4?\+'N/^A'\;?\ A-W7_P 11RL+H[*BN-_X6/<?]"/XV_\ ";NO_B*/^%CW
M'_0C^-O_  F[K_XBCE871V5%<;_PL>X_Z$?QM_X3=U_\11_PL>X_Z$?QM_X3
M=U_\11RL+H[*BN-_X6/<?]"/XV_\)NZ_^(H_X6/<?]"/XV_\)NZ_^(HY6%T=
ME17&_P#"Q[C_ *$?QM_X3=U_\11_PL>X_P"A'\;?^$W=?_$4<K"Z.RHKC?\
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M!/\ KP_]J/7KE:XG^//U?YF5#^##T7Y!1117.;A1110 4444 %%%% !1110
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M#ZW#L_Z^9]!45\^_\)+\6_\ H/\ AS_P6R?_ !='_"2_%O\ Z#_AS_P6R?\
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M\6_^@_X<_P#!;)_\71_PDOQ;_P"@_P"'/_!;)_\ %UK]2G_,OZ^1G];AV?\
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M_L3)?_2H5[O7A%[_ ,GK:;_V)DO_ *5"O=ZZ\1]C_"OU.:A]OU84445R'2>
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M.5HS_"64$C]:\S3]F#P&EQ!(+.[\N.7SVMS=OY4S[MP+KT;FO6$4(H50%4#
M [56(JPJ?"31IRIZ,6BBBN0Z0HHHH **** "BBB@ JW\$/\ D8?&_P#U]P_^
MBZJ5;^"'_(P^-_\ K[A_]%UA7_@R^7YFU#^+'^NAZW1117AGM!1110 4444
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M&;[O# '!]>E-TY+H)3B^IK>(].?5] U&QC;9)<6[Q*V<8)4@5XMX%OO%6C>
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MNI>%Y[VZUFQGT68FVE<OE22/N$=<GTQ6AX3\2>'=7TL)H%_:W-G9J(REN_\
MJ@!P".HXKSG]H:P33]$\/R:;8VYNI-=M6$1Q&LKYX#$ _3.#3/AZUUJ7CGQG
M>ZM9P:)K$%HEN^F6OS(T>"5EW\;\].@QBG[.+I\R%SM3Y6>@Z)\3O"OB._6R
MT[7;.ZNVSMA5\,V.NT'&?PJ?Q)\0?#G@^:*'6=8M;":492*1_G(]<#)Q[UXK
MX-T#6O'?AKP-;Q>'AI-GI=S'>/J\TR%I53/RHJ\_-[XKK_@Y;0:WX@\=ZCJ4
M$<VK#5Y+4F9066!%7RQ@]!C)]Z<J4(W=]@C4E*R[GJ>GZC:ZM90W=E<1W5K,
MNZ.:)@RL/4$58J&RL;?3K9;>UACMX%R5CC4*HR<G@>YJ:N1^1T!1110!4DTF
MSEU.+4'MHVO8HVBCG*_,JG&0#[X%6Z** "BBB@ HHHH *M_!#_D8?&__ %]P
M_P#HNJE6_@A_R,/C?_K[A_\ 1=85_P"#+Y?F;4/XL?ZZ'K=%%%>&>T%%%% !
M1110 4444 %%%% !1110 5YQ^T%_R2W4_P#?B_\ 1BUZ/7G'[07_ "2W4_\
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M-\@D$[L$<>E>@T4>UD'LXGFNH_#/6+@:IIEOJMHF@ZG<"XN$DMR9T.065&#
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M6O\ Q[0_[@_E7GXSX8?/]#OPGQ2^7ZDM%%%>6>D%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'S:G_)POQ-_Z]]*_]%S5UE<[XXA'A3]HF229?+M?
M%.D1B"4]&N;9GW)]3'*"/]TUT5?11=X1:[+\K'@25IR3[O\ S"BBBF(****
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MXO\ GE&3U/JW<UZU117R%2I*K+FD?4TZ<:<>6(4445D:!1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tmb-20230930x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20230930x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $A Z # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKPX4L1A5'$16^VSW\CV)5*&(<J#>V^ZV\SX0^*WP@\=?#GX@>'O!.F_$F_\
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M"3=)I]&U\@HHHKRCT@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^?;^YA]9H?SK[T>V45XG_P -I?!?_H>;;_P#N?\ XU1_PVE\%_\ H>;;_P
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MSI8HX)4*IG&<N@'6O0:PG"5-\LU9^9K&<9J\7=!1114%A1110 4444 %%%%
M!1110 4444 %%%% !117EWC+]IWX8_#[Q!<:'X@\5P:;JMOCS;=[:=RN>G*H
M1^M:0ISJ.T$V_(B<XTU>;MZGJ-%>)_\ #:7P7_Z'FV_\ [G_ .-4?\-I?!?_
M *'FV_\  .Y_^-5M]5Q'_/M_<S+ZS0_G7WH]LHKQ/_AM+X+_ /0\VW_@'<__
M !JC_AM+X+_]#S;?^ =S_P#&J/JN(_Y]O[F'UFA_.OO1[917B?\ PVE\%_\
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M\%_^AYMO_ .Y_P#C5'U7$?\ /M_<P^LT/YU]Z/;**\3_ .&TO@O_ -#S;?\
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M#0;T32_:M'OVN8+^&-2^4=LX8@ ''3-4L?2:3L[6;^[\]NA+P=1-J^M[??\
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M#PE\0;S4-9T;X16;Z+)<I LNMZR;:TMQ@956SEG/6NCZ]!IR4796[=?5G/\
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M2(&0CD$\UX!772J*K'F2M_P#EJ4W2ERMW"BBBMC(**** "BBB@#[!_X)H_\
M)4_$G_8+'_HP5^C]?G!_P31_Y*GXD_[!8_\ 1@K]'Z^!SC_>WZ(^URO_ '9>
MK"BBBO%/6"BBB@ HHHH **** "BBB@ HHHH **** "OR7_;?_P"3CO$O_;/_
M -!K]:*_)?\ ;?\ ^3CO$O\ VS_]!KZ')/\ >)>GZH\/-_X"]3P>BBBOMSY
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M]#II_P"3_P#Q->,>L>HT5Y=_PT_\+/\ H=-/_)__ (FC_AI_X6?]#II_Y/\
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M3U?^9I]:JI\U]?1?Y'T;IO[6ME/>^-[7Q)X+BU_PQXEOVU$:4]X8VMYB>")
MO(X&>!TKBOCK\=8OC-;^&H8?#T'AZ+1;5K5(;:4O&R[B1@$#&!QU->3T4X86
ME"2G%:KS?:Q,L15G%PD]/EZGT'X0_:ETQOA]IGA#XA>!K3QUIVD#;IT[W)MY
MX%_NEMK9& !QC@<YJOX<_::TK3;CQ+I=_P" =/N/!&MLC/H%I.UOY!085DD
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MR*/L\7_/-/\ OD5)10!']GB_YYI_WR*/L\7_ #S3_OD5)10!']GB_P">:?\
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M,/:T_P"9?>=Y]GB_YYI_WR*/L\7_ #S3_OD5P?\ PT%\,?\ HH/AK_P:P_\
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M #S4L1\_^SU]JTKOQYX9T^]FL[KQ%I-M=P_ZR":^B21/]Y2V1^-?(&O?L?\
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M_P &+T?\.^/@_P#] _5?_!B]?2E%'U[$_P#/Q_>'U/#_ ,B^X^:_^'?'P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5G^&_@)X#\(>++WQ-HV@KI^MWL[7-U=174_[^4]7=2^UC]10!Z!129 /6EH
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M:2:==QM(<(K0,"Q]N.:]GF^-EAIFGBRLM9U>_NK>R-NFL3;DGF9I_,(^\64
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M7R^>_P 2'H?19/\ PY^H4445\P?0A1110 4444 %%%% !1110 4444 %%%%
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MGXO_ #/@W_AURW_12Q_X(O\ [IK=\"?\$X6\%>,M&U[_ (6$+S^SKE+C[/\
MV+L\S:<XW?:#CZX-?:M%)YIBY)IS_!?Y#6785.ZA^+_S"BBBO*/2/+OV@_\
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M1 Z!@T*&+>@)^4,./QYK[2_X7!X%_P"AQT+_ ,&,7_Q5'_"X/ O_ $..A?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#4_G7R?7Z1E_^ZT_0^"QW^\S]0HHHKT#A"BBB@ HHHH **** "BBB@ HHHH
M**** .\^ W_)9_!?_85@_P#0Q7[25^+?P&_Y+/X+_P"PK!_Z&*_:2OCL]_B0
M]#ZK)_X<_4****^8/H0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^&Q4,4FX= HHHKB.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/-_$_P#T)NE_^!4G^%']D8O^7\4']IX;^;\&?HA17YW_ /#S?Q/_ -";I?\
MX%2?X4Z/_@IEXJF<+'X*TUV/9;F0G^5']D8O^7\4']IX;^;\&?H=17YZG_@I
M7XO&[/@:P&SEOW\O'U^6HC_P4T\4C;GP7I@W<C_29.?TH_LC%_R_B@_M/#?S
M?@S]#Z*_/5_^"E7B^, MX&L%!. 3/*,_^.TT?\%+O%IE,8\$:<9!_!]HDS^6
MVC^R<7_*OO0?VGAN_P"#&_MQ_!3QYX\^-YU3P[X3U36=/_LV"+[3:6Y=-X9\
MC([C(_.OGS_AF#XL_P#1/M>_\ VKZ$3_ (*8>+)-VWP3IS;?O8N)#CZ_+7UO
M^S7\8KSXX_#:'Q+?:?#IL[SO$8('+J IQG)KUGB<9@*$5.FK+3<\Q8?"XVLW
M";N]=C\Q/^&8/BS_ -$^U[_P#:C_ (9@^+/_ $3[7O\ P#:OV1HKE_MRM_(O
MQ.G^QZ7\S/QN_P"&8/BS_P!$^U[_ , VH_X9@^+/_1/M>_\  -J_9&BC^W*W
M\B_$/['I?S,_&[_AF#XL_P#1/M>_\ VH_P"&8/BS_P!$^U[_ , VK]D:*/[<
MK?R+\0_L>E_,S\;O^&8/BS_T3[7O_ -J/^&8/BS_ -$^U[_P#:OV1HH_MRM_
M(OQ#^QZ7\S/QN_X9@^+/_1/M>_\  -J/^&8/BS_T3[7O_ -J_9&BC^W*W\B_
M$/['I?S,XOX+:5=Z'\)?".GW]O):7MMID$4T$HP\;A "I'8BNTHHKYR4N>3D
M^I[L8\L5'L%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!^9_\ P4?_ .2TZ=_V#4_G7R?7UA_P4?\ ^2TZ=_V#4_G7R?7Z1E_^ZT_0
M^"QW^\S]0HHHKT#A+VAZ%J'B75+?3=*LYK^^G;;%! NYF/TK8MOAKXCNO$-]
MHBZ>(]0L,_:Q-<1116^.IDE9A&H]RV*I>#;5[SQ+I\:7EO8_O5+3W5PL$:@'
M)R[$ <5[T=6T>U\3>.K,7_A;49=6>*>TGO[U7M'0'YE+JX ;O@FN6K5E!VCV
M_4Z:=.,U=GCVD_!_Q7KKW:V&GP77V:4PEDO[?;+(!DI"WF8F;'.V,L:X^6)X
M)7CD4I(A*LK#!!'4&OI6\U3P;J$_AT:'K.EZ/I_AO6Y+RX@EN=BR1EE?= &)
M:3H5 &3TKSSPGXYLM*U+QOK$/V".[N<O8B]MHYN6ES\J2*1G'M40K3DFVOT_
MS]2ITH)I)GE= &2 .M?4&C^*- \=>+'TJ>+09[5+VTFLX;;3H$W81FF/[M 6
M' )SD>HKCOVBII+J#P]-;+:RZ-&TT45["L"O-)OR0RQ*N-H(49["G'$.4U!Q
MM<)4$HN:E<X"^^$OB33HK)IX]-66\,8@M%UFS>Y;S/N9@$ID7.1U48[U#>?"
M[Q/IVJZMIMWIGV2[THH+U;BXBC6#<VU269@N,GJ#@=3Q7J?B_4-*O-?\*ZQ
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M4 %%%% !1110 5\&?\%1?];\-O\ =U'_ -MJ^\Z^#/\ @J+_ *WX;?[NH_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH *@N?X?QHHIH3(****HD**** "BBB@ HHHH **** "K-O\
M<HHI,:):***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tmb-20230930x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20230930x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #P G # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+G+'@<*:_092C"+E)V2/S:$)5)*$%=LY^BOHG_A@/XS_ /0#T[_P:1?XT?\
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M/UJZV-PV'=JM1)^;)H8'%8E7HTW)>2/G"BOI2^_X)[?&"TC9HK31;PCHD.I
M$_\ ?2BO-?&'[-GQ0\!Q23:SX(U:*VC^]<VT0N8@/4M$6P/K6=/,,)5=H58M
M^J+JY=C**O4I22]&>:U8TS4;O1;^&_TZ[GL+Z%@T=S:RM'(A'<,I!%5S\KLI
M&UE."IZ@^A':BN]I25F<";B[K1GV)\!?^"A.N^&)K?2?B,C^(-)X0:Q @%Y
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M[]3]?Z*0-FEK\N/V **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_#?Q?_ ,CAX@_["5U_Z.:OW(K\-_%__(X>(/\
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MFWJM'ZK^KBT445Y![@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:>5MUPTQ^A&U/^!UU86A+%5X48_:9Q8W$QP>'G7E]E?\-^)^='Q/\=W/Q/\
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MT8XF*UCH_1_\'\SZ'A3&>SKRPTGI+5>J_P"!^1]94445^;GZH%%%% !1110
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MH8$$9'O7W+^Q'^UW>?VG8?#GQM?M=13X@T;5KELNK_PV\K'J#T1CSG"GJ,?
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M?BG//NS]Z]C3_E7W&#_P@7AK_H7M)_\  &+_ .)H_P"$"\-?]"]I/_@#%_\
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M[-0NV:W4_P $"_+$OX(J_CFN,K]IRS"_4\)"EUW?JS\'S7&?7L9.MTO9>BV
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M<MI*#W*,5S]#@'\:RJ_I.,E.*E'9G\HRBX2<7NC[7_X)J_%'^S_$/B'P#=S
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M$]^.,VC6TV_3/#,7V! .AN#AIV_/:G_ *ZLDPGUO&Q3VCJ_E_P $Y,_QGU/
MRL_>EHOGO^!\V 8&***#7Z^?B1]/_P#!/CX:GQC\:W\0W$)?3_#5L;D,1\OV
MF3*1#\!YC?\  17VA^V%K%QI?P8N8H'9/MUY!;2$=T)+$?0[ *YW]@KX:?\
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M\$_(^*<9[?%JA%Z0_-[_ *!75_"KP!<?%+XD>'?"EL&SJEXD,KH.8X?O2O\
M@@8URE?;'_!-3X9?VAXA\1>/+N+,5A'_ &78LP_Y:OAI6'T38O\ P,U[F98K
MZGA9UNJ6GJ]CY_+,(\;BZ='HWKZ+<^_-,T^WTG3[6QM(UAM+:)88HU'"(H 4
M#Z "K##-.HK\4W/WM))61\_?&3]D[2?B!J,^LZ%=)H6LS'?.C)FVN&_O$#E6
M/<CKW%>*']C/XA"Z\H/I!BS_ *[[4V/KC;FONO%+7R.,X6RS&U76G!Q;WY7:
M_P O\C[_ "[CC.LMH+#TZBE%:+F5VO1[_?<^>/@]^R1I?@C4H-9\17::[JL#
M!X8$0BVA<=&P>78=B< >E?0JK@=<TH&*6O=P.7X;+:7L<+#E7XOU?4^7S/-<
M;G%?ZQC:CE+IV2[)+1$%[:PWMI-;W$:S6\R&.2-AD,I&"#[$&OQ<^-'P[E^%
M'Q3\2^%9 1%87;"V8_Q6[?/$?^^&7\<U^U)KX(_X*7?#+RKKPUX^M(OE<'2;
MYE'0C+PL?P\Q?^^:^\X<Q7L,7[*3TGI\UL?FW%&#]OA%6CO#\GO^A\,T^"XF
ML[B*XMY&AN(762*1>"CJ<JP]P0#3**_4FD]&?D:=G<_:+X&_$:'XL?"GPUXH
MC(\R^M%^T(,?).ORRK^#JWX8KO*^"O\ @FC\3_+D\2?#^\F !QJVGJQ^B3J/
M_(;?BU?>@Z5^*9EA?J>*G1Z7T]'L?O&58OZ[@Z=;K:S]5O\ YBT445YIZX44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AK\Q_$'[ 'Q<U+
MQ#JUY!;Z)Y-S>33INU'!VM(S#(V<<$5^G%&!7IX',:^7N4J-M>YY&8970S-1
M5>_N[6\S\M_^'>GQ@_Y]]#_\&7_V%'_#O3XP?\^^A_\ @R_^PK]2-HHVUZ_^
MLF._N_=_P3QO]5<O_O??_P  _+?_ (=Z?&#_ )]]#_\ !E_]A1_P[T^,'_/O
MH?\ X,O_ +"OU(VT;:/]9,=_=^[_ ((?ZJY?_>^__@'Y;_\ #O3XP?\ /OH?
M_@R_^PH_X=Z?&#_GWT/_ ,&7_P!A7ZD;:-M'^LF._N_=_P $/]5<O_O??_P#
M\M_^'>GQ@_Y]]#_\&7_V%'_#O3XP?\^^A_\ @R_^PK]2-M&VC_63'?W?N_X(
M?ZJY?_>^_P#X!^6__#O3XP?\^^A_^#+_ .PKZ%_8L_9A\<_ OQ]K^J^*8=.C
ML[W31:Q&SN_-;>)5;D;1@8!YK[#VT8Q7+B<\Q>*I2HU+6?E_P3JPO#V#PE:-
M>G>\?/\ X M%%%?/GTP4444 0W5G!>V\L%Q$D\$JE7BE4,K@]00>"*\(^('[
M#WPF\>R2W T%O#U])G-QH<OV<9]?+YC_ /':]]HKHHXBMAY<U&;B_)G+7PM#
M$KEK04O5'P;XF_X)B8);P[X\8#M%JMAG_P ?C8?^@UPFI?\ !-GXEVN?L>M>
M'+\=LSS1']8S7Z648KVJ>?YA!6<[^J1X-3AO+JFJ@UZ-_K<_,%/^"=/Q;+$&
M3PZH_O'4'Q_Z*K?TO_@FAX\N"IU#Q1H%BIZB$33D?^.K_.OT?Q2UI+B+'O1-
M+Y&4>%\NB]4W\SXS\&_\$S_">G21R^)O%.J:X5Y:WLXULXF/H3\SX^A%?3'P
MZ^#7@OX3V1MO"GAZRT?<NUYXDW3RC_;E;+M^)KM**\G$9ABL5I6J-KMT^Y:'
MM8;+,'@]:%-)]]W][&A<4ZBBO//3"BBB@ HHHH 0KFO./B1^SM\._BQOD\2>
M%[*[O&'_ !_PJ8+D?]M4PQ_$D5Z116E.I.E+FIR:?EH8U:-.M'DJQ4EYZGQ=
MXM_X)F>%[UY9/#?BW5-()Y2"_B2[C!],C8V/J37F6I_\$S_'4#-]@\5>'[U1
MT\Y9H2?P"M_.OT>I",U[=//<PI*WM+^J3/ J\.Y=5=_9V]&S\PI/^"='Q:1L
M++X=D&?O#4''\XJOZ;_P3;^)ET?]+UCPW8KZ_:)I3^D8K]+L48YKH?$>/:W7
MW',N%\O3O:7W_P# /@_PM_P3%&Y7\2^.F9<\PZ38[2?^!R,?_0:^B/AE^Q]\
M+OA;-%=Z?X>34]3CP5U#6&^U2@CNH;Y%/NJBO::*\VOFN-Q*Y:E1V[+3\CU,
M-DV!PKYJ=)7[O7\QH7;TIU%%>4>T%(W2EI* /@#X[?L:_%[XP_%GQ%XJ,OA]
M+:\GV6<4E_(&CMD&V)2/*.#M&3[DUP7_  [G^+7_ #V\.?\ @PD_^-5^GF**
M^CI9_C:,(TX622LM#Y6KPU@:U252?,VW=Z_\ _,+_AW/\6O^>WAS_P &$G_Q
MJOO3]GCX4#X+_"/0/"SF*2^MXS+?2PG*R7#G=(02!D G XZ**])Q17)C<UQ6
M/@J=9JR=]%8[<!DV%RZHZM%.[5M7<6BBBO'/="BBB@ HHHH 0UY_\>/AA'\8
M?A1XA\*-Y27-Y!NM)9ONQ7"$-$Q/4#<!DCL37H-(1FM*<Y4IJ<-T[HRJTXUH
M2ISV:LS\PA_P3G^+6!F7PX#W_P")A)_\:I?^'<_Q:_Y[>'/_  82?_&J_3S%
M%?2?ZQX_NON/E?\ 5;+_ .]]_P#P#\]_@Q^Q=\8?A+\4O#GBN&7P^Z6%T#<1
M1ZC(#+ WRRI_JNZ$X]P*_0A>@HQ2UX^-QU;'S52M:Z5M%8]O 9=1RZ#IT+V;
MOJ[A1117GGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tmb-20230930x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20230930x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3I \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BDS2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 )7P!^VA^TS^T5^R)8VOB*6Y\ Z_X;U?5IK*RC33
M+I+FV7#21+(3*%<E%()&.1TYX_0"OS[_ ."TD:-^SAX48J"R^*(<$]1FVGH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MS]_X+1?\FV^%O^QHA_\ 2:>OT"K\[?\ @M9>F+X"^"+4,1YWB8.1V(6UF_\
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M[EDC+V2$-GKD9S]: /3?@3\7-*^.WPD\,>.M'=3::Q9K.T2MN\B8?++$?=)
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MOY2,P@;GJ %://\ TRKTWX6 -^TY\;P<'_1_#YQ_V[7% '0?L^?'CPI^T_\
M"?3_ !=X>=)K.\0P7VG3$-)9SX_>6\H]1GKT92&'!KR/]GCX0^#O#7[5?QVN
M]-\/6-G)I-WH\>F"*+"V*RZ:&E\@=(]Y=MVW&<UXU\:/!VN_\$\?C9<?&GP%
M827OP<\37*1>,O#%HN%T^1FXN85Z*-S$KT"L2G"NN/>_V7_&FB_$7XX?'3Q-
MX=U"'5=$U2;0+FTO(#E9$;2T_$$<@@\@@@X(H \$_:A^%-S^Q#\6M"_:+^&-
MI=1^%GN4L/&_AZ"5WBDMI& \Y0Q. 2?HL@C(X9J^D/CW\8KOQ!X"\+^&?AAJ
M4=QXO^)48AT+4(P66RL6C#W&I-Z+#$P(SR9'C7!)Q7M/C+PII7CKPIJWAW7+
M./4-'U2VDL[NVE&5DB=2K#\CU[5\,_\ !*#PE;KH'Q!U:[O;K5[[P]K<_@[2
M;B]DWFTTR!O/6*/LH:29G;'4JOH* /LSX/?"G0_@G\.M&\'>'HY%T[38=GFS
MMNFN)"<R32-W=V)8GU.!@ "ODO\ X*V^#]&7]FF^\7)IT$7B:SO[&WAU:)=E
MRL32D&/>,';\S<'CFON>OC#_ (*W'_C#;6O^PKI__HZ@#Z0^!G@?0/ GPRT"
MT\/Z1::1!/8VUQ,MK&%\V4PIEW/5F.!ECDFN._;.\$Z#XK_9O^(=YJ^E6M_=
MZ3X=U&\L+B9/WMK,MNS+)&XY5LJIR#VKTWX<_P#)/O#/_8,M?_1*5Y]^TSKV
MG:W^S-\9TL+V"\>P\.ZK9W0@D#>3,+-F,;8Z, ZG'N* /-_^":G@K0](_9/\
M">(;73+>/7M8LI9+_4]NZXN3]IE #N<D@   9P,<5]+^)_#&D^,=$N-)US3;
M75M,N-OFVEY$)(GPP(RIX." ?J*\$_X)S_\ )E?PL_[!\O\ Z4S5[\-?TV76
MY]%2^MWU:"WCNY;)9 94A=F5)&7J%9D< ]RI]* /SS_X)[? 7P#XXO?C@?$W
MABPU]=*\:7FD6*ZDK3BWMD)VQH&8@#\,\=:U_A-X=O?@9_P4KOOAS\.KN]'P
MXU'PX=5UK0&N9)[72Y"C;&0.Q\LF018']V8CIC$_[ OA >.=/_:"L%US6-!V
M_$R_F%YH5Y]FG.-PVEL'*G/0CL#VK["^%GP.\(_!Y=3E\/V$IU75I?/U/6=0
MN'N]0U"3LTUQ(2[8[+G:.P% '?452U?6]/\ #]DUYJE];:=:*0K3W<RQ1@DX
M +,0.36!_P +9\$_]#AH'_@T@_\ BZ .LHKD_P#A;/@G_H<- _\ !I!_\71_
MPMGP3_T.&@?^#2#_ .+H ZRBN3_X6SX)_P"APT#_ ,&D'_Q='_"V?!/_ $.&
M@?\ @T@_^+H ZRBN3_X6SX)_Z'#0/_!I!_\ %T?\+9\$_P#0X:!_X-(/_BZ
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MOK^SUXO^',WQ$-WK?BRZOKC5O%$^BQEI!=M^_"6XE"H2AVJ0V%Z@< 5]"T4
M?,?PI_9C^*OP7^'FC^"O#/QGTM-#TF-H;07G@M)9E5G9_F<78W'+'G KJ? 7
MP(\=>$=0\<^(=1^)MMXB\;>)(;*UAU6Y\.)#;V$%L92L2VT<XW@F:0Y+@Y;/
M->YT4 ?,W[,'[(_B/]FKQ#XCNX?B/!XBTOQ)J,FK:K93^'EMY'N7#9:*59SY
M8RP^4JW3C&:^F:** /._CS\)=/\ C7\.KOPMJ>E:9K-I<30RM::NTZV[%'#
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M ._^L_\ R51_P[3\#_\ 1./A_P#]_P#6?_DJON&B@#X>_P"':?@?_HG'P_\
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M*H4!<DG QQGFKU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR*PP, +P>,+0!]/+HVG+=7-RMC;"XNEV3S"%=\J],.V,L/8U<1%C0*H"J!@
M#  K\YO%VMV6G+?WUS^TWJ.H>,[3>T,-C#<_8W=<XC5T.WGID#:">F*^M?V2
MOBAJWQ9^#6GZMKK";5;>XFLI[C 4SF,C#D#@$A@#CN">]%@/9J***0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOE0>P)' .*^K](^)WAK7O&FL>$K#4A<>(-(C$M[:""4")3C'SE0A^\. Q/-
M&Q?:_8:?J5EI\TX^W7A/D6Z L[ ?>; Z*.,L< $@9R0#<2YBD,@21&,9PX#
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M;TCPW?3'Q3X>L=2L)K2;%CJ+ZPUK*\)\TX:(HKH'&1E6.<A:\[U3Q[%\((/
MGC&.R2ZDT,?$.>"U"[1+(+\"*+(Y"M(R XZ9S0!^@5007MO<R2QPSQRO$<.J
M."5/N!TZ5YSX(UGQ?XGMO&FCZ_:SZ.+-TMM-\0);_9Q=I):([S)&Q)7RIFD0
M$XR$7KR3\P>$O%OB3P;IMMX4OK.+P3\7=&O/#.@ZK?PP_:+/7M&;4&AAOH/G
M4MYC22"0D[E8E3C<, 'W917RC;?M'?$!9+R]ODT"/3;KQI)X"T^WM+2=[B.\
M74&B-RQ+$.@M4D?;@'S$ ^Z>+L_[1'Q!EUC5O#EMX3N/^$FT/2+G6/[.-BS3
MZM'_ &C+:V(5=^(5GB@DD8L<H2. %((!]0U$UU"DHC:5!(3@*6&2<9QCZ"O*
M/V;O%'B'Q=X;\47_ (AU)+^2/Q5K-E:H+?RFMX(+Z6%(R=[!L*@Y&/QZU\Y_
MM:^&M8\8_M&ZOX>\-Z/=:KXDU;X8S6^ER6C+']AO#JL0BNWD++Y0BZ^8,L ,
M '." ?<4]Y!:F,331Q&1@B!W"[F/0#/4^U35\JZ;I3?$SXZ?&GP]XRD75X?#
M?@_1]+M"045?M<-S+=7" 'Y'=XH_G7##RU / KTW]DOQMJWQ%_9G^&_B+76D
MDUB_T.W>ZFF.7F<+M,I]WV[_ /@5 'J,>L6,UX;6.]MWN02#"LJEP1U^7.>U
M7*_/'Q/8K;?&GXF:K/:KI.AZ7\6?#MY?^)+,*;BR'V2U54V !O+EDD2)W#'"
MS,2C#->Z^'?VA?&7B]/"UYI-MI4=OXYDUVUT)+V%\6DUD9#:F;:X+I-'!*S_
M '2A*@=#D ^F::)%9F4,"R]1GD5Y?^SU\1]8^+?@"W\5:DUI#%=#R!8PVK0R
MVMS"3%=QR$ROG;<)*J@8^5 <G=Q\S?$'6K[PGX/_ &LVTBZFL99O%VDZ?]I1
MR6@BN;338IF!8\?+-(>O&Z@#[C;4+5+,W;7$2VH&XS&0! /7=G%17.M:?9A/
M/O;:'>N]?,F5=R^HR>1[U\SP76I6_C'X^^&=%\,#Q1#I=_IUWI.A9B2W6>YT
MP>:&$I">7E-^P\%FXY;-9>@?!GX.?&/]E_P%?)X4A\50PZ-#H.C77B6!1?VS
M-)Y#(W41NDF\D+D+LXX H ^L4U"VEF2%+B)I7C\U45P69/[P&>1[]*FDD6)=
MSL%7U8X%?/\ \0OAK:7?QF^$-OX>"Z1+X;O)-6U"^A"JRV*VC6<5H6])G:-1
M'T(BD(Y6NP_:F4-^S+\6.A*^$]596ST86DI!![$$ Y[$4 >GQ3).F^-U=<D;
ME.1P<']:?7Q5\!H/'7@C2=5\7V6F'P]X+UG3= MT3560&$PZ>_VO4([<,2[2
MO]G@5!AI&(<@A?F]#\ ?&KQ]\6[;1[3P^NBV.K6OA;P_XAU,WL+F.YEOR7EA
M0!LQJL,4I!R3O=!T5MP![SXD\8:-X2TB74]5OXK2RC+*9#ER2 2P55!9B K$
M@ D!2>@-:&FZE:ZQIUK?V-Q'=V5U$D\%Q"P9)(V 964CJ"""#[U\3^)/%NO6
M$'@K6]!BT+0;K2M?\<3-9QV,L]I<36ZWW[T@S*P,FURW/WI6(  VUZM\+_B_
MXS^*US!9^'(M$TI-!T_PY<:E;S0-LN?ML"W%TD6&_=+' R^7URY(/"\@'T)=
MWMO81>;<SQV\><;Y7"C/U-3 @@$'(-> >);*#Q]^UE>^%->C6_T"P\!"Z@T^
M8!HFFN[V6&>3:<@L([=%!(^42-C[QJIX1^*7B)=5N="\*:2;WPSX:UK_ (1(
MO-"TGEP0::LQO9IP0"/-:*,*H)(W'J05 /HNBOB'5_VB_B3XB^'.IF35-+TK
M4Y]*\&:Y#=:;8R*+=-5U VUQ;X:7+ "+(?*G#LOHU=QXU_:%^(7A"[^(VJ/'
MX<DT#PKJ\?A^&V6WN&N;JZNTL/L,A(; 57NW$BCJ -IH ^IJA:\@3?NFC&S[
MV7''..:X_P"&7B'Q#K:>(;?Q!IL]I_9VJR6=C>SV_D?VC;".-EG$>3M&YW3M
MGR\X ->"^.K"V\,_M3>)?#D]FMYI_P 4O#=D4@G(5)+JSN?)N55CT?[-<(X
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MEC3.6+H#G!R ?6TLT<"[I'5!ZL0*KW.KV-D ;B\MX06VCS)57G&<<GTKY?\
M$&L:W^TQ_P $_P"3Q'=PPV_BF_\ #W]MP+91$JE[;L9HMBG)Y:$#;S]XCH<5
MT&C>&?AG^TG\-Y_'_BGPKHWB3P_?)#JEL+N%9E BM%5V(_OHS3QD<XV&@#Z
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M7Q%FLOB%X'\#PVFHW]GJ-MJ&NZM::3%YES<6EFB;;=5R,B66:,$9^949/XZ
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MC).-KX$?#F\^'^K^,(IO''B_QI9FX@MH7\6:BMV872/?(8MJ)@$RJ#UR4]J
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M; VR#S9EW@?=E<8^Z1[O10 R&%+>)(HT"1H JJHP !P *?110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tmb-20230930xex23d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20230930xex23d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !M :,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BLOQ-XGTKP;H-[K6N7\&F:59QF6>ZN&VI&OO_ " '))P*^._B
M9^WWX9\4Q2:-X4E\0:= SE9-8M[2(.Z_],U>0,H]^#]*Z*-"=:5HH\G,<SH9
M92=2J]>BNKO[VE\V?:^:6OAOP#\,]6^(^@3^)/!/Q&DU/5[8[Y+*1IK:Y1N2
M Q+'!..#]T^M>U?LX?'2[\9RW/A/Q0_E^*+$-L>1=CW"*<,&']]3U]1SV-=5
M7!\D7*$N:V^EFCYO+N*/K5>GA\70='VM^1\RE&5NG-'1/R_6Q[RS!022 !R2
M>U4M$URP\2:3;:GI=W%?:?<KOAN(3E'7ID'\*ROB'"MSX-U.VDU6#1(;A!!-
M?W$@C6&-V"N0QX#;20N?XB*Y[P_X$,'@?Q%H^EZTFH:1JT<K:==;U/E>=&0_
MS1@+MWDL-H_B->:?='H0=6Z,#]#1O7&=PQTSFO'+?X6Z3JC:Q'X7UC3K*Z6>
M2)I]-EWR6D;67D>40I^4^<&D(XR<G[U,M/@+/+H\EKJ$]M*?L]XL$7FLT4$T
ML<2)(@"(%*F-FX7(+9!SDT >O2:E:Q7T%F\Z+<SQO+'&3RRH5#$?0N@_X$*L
M[AG&1D=J\?U_X(2W5PPL(M+^R#[2EM%<>8!9>=#:H98PHY=7@D<#(YDSD'-4
M-<^%$FEWNO:EK7B6VATZ_+(;N^NO)WJ\D;"*3Y1PH0JOSGM@#G(![>6  )(
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MY_90]I\5E?UMJ>=?LW^/])^%<?Q\\3ZRS)86.O%F6(9>1C)*%11W)) KL/\
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M)4P<8.PYX(KV>B@#P+P]^S=9^&V5=5LK?Q+H^EZ7>:1IFE%03-'<7XNP9"V
MC)LA4,#QL+<< :EQ^SV9_@M)X52]AA\0/JR>)?[0V%HAJ:WJWJL1U,8D54]=
M@'>O::* / _"'P US0_BC%XRGNM-B$VOZIK5Q8QEV,:W5G;6RQJ^T!BIMV<D
MA<^81[GF/#7[.7Q%&MQZMXAU;P]<W\NH:9J=Y-:M./.FM8;F%\ I@!UF1@!P
MN"N"%!/U'10!\V#]E?5X_ =]I$>M62W]Y\/[;P=(-K_9S<Q(\0N^F[_5R%<=
M<''O65XY_9-\2^.;758)]6TBU6]U'5=24@2R!'N8K<0J5*C<%DMP6Y^96(&*
M^J** //T\->(['X?/;Z/I_AW0?$$MW#=S65DA%C(/.C:XC+",$F2-9%WE,@N
M.#BO'7_9.UG2;V2'P]=:/I^B3M9W L9#(%LFM];DU(00A5QY6V5HQTP1D+@X
M'U%6;XDTZ[U?0KZQL=0DTF[N(C$E]"H:2#/!= <C<!DC((SC- '@WB_]F.]\
M2K\3=/1- ^S>*+MM7T_6+JW,E[97;0PH86&WF$O;HQ(<$J[*5[UIOX \8>#O
M%"^-=$T;PM97KZ,;"YT6Q\U83<->1R;D9(UWEU,F78+@A<@C+#A_AS^T%J'A
M'PZVJ^)]5U'Q5>Z@^LR1:?M13;VVG7\L#-&(TR\CJ\"!,?,4/(YK6\'_ +0,
M'@(^(-)U/^T-?OAX@URZ"M,\TT5E%J2VZ(@(9G(,H"1C VQMR,#(!Z=X\^%E
MUXO^+O@3Q61IL^G^&[34H7M;U"[R2W(@V.HVD#88!SU^;C&.>,\0_L^Z[XGL
MO&EC=7NG6MKX_&FS^(A:E\6\\,<<-U]G##YEEBAC1=Q!7!)W9Q7*?%#]HN[\
M5^$=>TBSTG4O#6H13+/87<-^H>Y%IKD5C=1DI]S+%>,D,DISC!%=J?VJ].M]
M*:[N]"GA>PM[B\UF-+@.+&"'4GT]G4[1YN9(IG POR1L>N%(!V7Q(\$Z_P#$
M/X2^.?"3RZ9976L6EUIVGS1^88XH)(]B-*,9W@$DA>.!BO,X/V:_$5MX[?QV
M-4TX^(5\JWCTY#)]C$*:;)9ERQ7)E+2*Y.W[L:I_M5J77[66GZ7?:^FI>'KF
MSM-.-Y';7!ND<W4MOJ46GE"H'R!Y;B$J<GAFR!CGI?$GQE:+X+^(?%MA:-;7
MUG--IT*2@M&;D7'V9)%)5=\1<JX; RIZ"@#(^'WP)U?X=^*?!=_8:A9/9Z'H
M,?AB[W[_ #+VRCB1HGQC"RK.)&ZD;)".M/\ B%\!KWXB>/?&FH7MY:0Z'X@\
M&KX75$W&XAD$TTHGQC:0#-]W/\ .><#!UOXQ6/@[XBZY8ZV-0N?#GA%=.TQ9
ME'F*VI7433+-<'=G!!@13@@/*Q.,@C,^'7Q\UDQ06^MZA#+?:UX-TKQ-:O<%
M(HX+FZ>X62)2<#8HB5P#SA'ZYH Z74?A#J<ND^.+.^T.TUR^\>120WUR)4^S
M:?Y=A':0;EDPSAMKL2@)&[&#UKT31/!E]X=L[*"UNDN7TG0XM+T^:[8DO*%P
MTDO?GRX>G/WO:N'\#_%!-7'PBUBQ,PTGQOIC1-;33^<T4R6OVF-BPX+!4G5C
MW)7^[577?B_;V_QGU;3M52Y70=#N=,T:!XP#;KJ=\"\<EQR&VC=;QH0" TK$
MXX( -/X<Z/\ $KP-::78Z^WAK4C>:KLN!HT5S%'#;&&622?,A8M,]Q@L6.TA
MN.<59M?A)JEC\4OB3XS@DTDWGB#3+.STF::$R264L$,R;GRO*LTP)"GHN#G/
M'E?PF\:Z_P#'O1_$>CW7CS6_!6M:+!8OJOV-;9;N&Z#3F::W,D3QO8SJ$,;@
M,#L.""&SUVN?$*\^&OP@\+Z-+XM?6O&FI7VEV+7.HRP_VB(;V_BA,[Q(J@%(
MYB 0@4%10!SG@;]GOXC^#_%>G>*WU#P]>:U#J,]Y<P-//Y=RMW86EO=;G\O.
M]9K**13MPP9U.S@U/XM_9B\4^(U\0!-6T>-M4G\02;F\WY!J-G';)QMZH4+'
MGG( ]:XSQ)^TGXKTFT\<JVHM:W/@Z+4)=.,B+C6GL]3:.2)N/F86PA4A<',Q
M;L,>P7OCJ/XF?$37? NF>(+O0;F?1&N++6='N86FMUCN1%*RQNKKO+@C+*0%
M48'S9H V_A+\/?$OPXUGQ'9S7.FW7AK4=2EU>"1&D^U12S(GFP%2-NT2AV#Y
MR0P7:,9K@_$O[./B>Y\"7_@71=5TNV\-KK5UK]FUVCNS2/=?;(K66,#!C%PT
MA9@22NWY<@UZA\%M$U70_"5Q%JOBG5?&#R:A</!J6L"$3F$-L5?W,:)M^0D8
M7G=UKQ*+XI^*O"VJ^(-=FUV\U2QL_BC!X5?3;E4:/[!=?9X55 J@AXY;A7#9
M)(5@<YX .J\2?L_ZYXAUJSU*UB\/>'HQ;6*2Z=8!Q%')#K$6H2%2(U#;A$5W
M;02SEB/6'PM^S?KMK-:V^L:EIYTR+1?$.A.;,R><T6H7BSI(,@ ,JI@C/5N#
MQSIVW[4EO)X@DTNY\+WFGLMU%:,;J=4>%Y;&:\B69-N8W*P,A3DAF4=SCBO'
M/QSO]4^$/Q&TG3HM5B\36^G^([UY;B_CAETQ+.4QY22!>=LC@1CJ5C.YL]0#
MTOX4^%?$WPWM?"NAW&B^&HE>W-KJU]HT3H\WV>!4AN"=BC+D8*-G:" &;G%;
MXD?!;7=3\=>(/&_@_5K73?$E]X971(([Q6\@3)<>8LS;03NV,Z!L$KD'!Z5#
MHO[2.GW[G3;*P6\U"+5X?#<=L]X$N/MQ\PL)XRI:)/*B,ZOA@Z$$<\54L?VK
MK#5=7\/6]GX<NGLM26P^TW<MRBFTDNKV>R$>P EV2XMV5N0,<@GI0!QUO^RO
MXO-@]M)J6A0+&;];<0M.0$N-:M]27=E<Y40O'WSE3ZBNMT_X&>*+#P_#H!OM
M,ETW0?%3>)=$GWR>=.K7KW)MYQMPN!--&'4MGY&P,$'LM<^-ME_;EMH_A*U@
M\::@]G+J$R:??QA(X(YXH7P_S R;I20G'W&R1QEOPP^.>G?$W4X+2WL9K$7V
MD)KVFR2.&^U6+S/$LA  V-E58KSQ*G.<@ 'E]S^R[XD@FTZ2RU73'>9OM6I-
M/YB[)SKR:NPB !RI(>,9QC"G!R0-6^_9FO+"^TW4-/?2=<_L_P 3:GJL6DZU
M&1:M97T;K);Y"M@HTC.IVD'E3C.1T=C^T2=4M](O;3PU-+I7B"\CL- O6NU"
MWLIFG1MZ[28E6.W:;/S90C^+BL.T_:SAUF:S&C^%+F\@DETNUGDGO8XC#/>W
M%Q:I'M ;=Y<]NRN>."2-V,$ Z/P=X-\2_#3Q)J9M(=)N].\2^)%NYXX%DC-G
M:+IR0X10-H(>VCP"<;7(Z@9YOQO^SMKOC+XB^*M4.J:?9Z+KU_X?NV=/,-Y;
MKIDK3'9QMW2,0H;/R#)^8G%>K_"[QVGQ,\":9XC2R?3C=B19+1Y!(8I(Y7B=
M0P W#<C8.!D8.!TKJJ /&9?AGXUM/%^L>*M-O=(L];\1:=::=J0C,GE6[6UQ
M*T4\65)<F"9T96Q\RH0<9KN="U+Q8?$L-CK-IIGV'^SWGFN; RY6X\\JB#<,
M%3%@^NY6[8KK:* /GR+X,_$+P;X-L?!_@S5]'MM T[4+BXB-XTBRW%I-=B;[
M,2J'RRD;SIY@R3\A 4Y(Y_PM^RYXMT:Q\-6]QJFA@Z+;:+9KY EVR)I^HS70
M;!48+I(J[<_*0>2.:^HZ* /ECPU^SO\ $S2O&-CXOU#5/#E_KMOJ5GJ<R+).
MD=VZ6EU93J3Y?R Q7"R)A2%*A,;1N,WPT_9X^)'A/Q%\.KC5]5\.7NF^$"L<
M,=L9U;RGM)X)]H*8WEI$<$GG&WY0HW?4-% 'G\7PHBA^.US\14NBK3Z!'HTE
MD/NNZ3O(DQ_VE61T!]'-8_Q/^$^K^//A+=>&;:YLK?5KW4X-1N+BX+&+*7B7
M) P,GB,(/08]*]8HH X#X]?#_4?BO\&_%G@[3;BULK[6[![%;F[W&*'>,%B%
M&3@9XXS[5P/Q$_9XU3Q?K'B*>TNK"W@\4MHMQJ7G;F:TN+"=6+Q?+\XDB'EX
M.T@J#G!('OM% 'C/PH^ \_P]UK0'FNH);#PU9ZGI^EF'<))8+N[CG42@\ QK
M&J8&022W'2O9J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&!*D
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M;:\FOX+:2>19[@*'8RS/*0=H X,A XZ 5U%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tmb-20230930xex23d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20230930xex23d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  M OL# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=3N+.TTN&VU--(OA?F9)-!NF6<K'J2;,PQNT<"+<#]V?M&[.U,M;T+X[7_\
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M+;\+] ?^/T=_\_A0![M17A)_;J_9^ /_ !=OPOQD_P#'Z.W^?QI?^&Z/V?\
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M']GKPX_PJ\5?#Z6\U.;0?$L]]<7Q:9/.W7DSS7(1P@P&>20\@XW8'08]0HH
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M\8KV6B@#QK_AE7P=[XQC']EZ;Z8_Y]<4']E7P<1_$#Z_V9IO3T_X]?2O9:*
M/&C^RKX-)/!P>W]EZ;CK_P!>O'X4#]E;P<-I.21USIFF\\YY_P!%Y_'->RT4
M >-#]E7P<!QN]C_9FF\?^2OX\8H_X95\'>^,8Q_9>F^F/^?7%>RT4 >-']E7
MP<1_$#Z_V9IO3T_X]?2@_LJ^#23P<'M_9>FXZ_\ 7KQ^%>RT4 <QX ^'NF?#
@C2KBPTLDPSS&=R;>"$EBH7I#'&IX4<D$^]=/110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>tmb-20230930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/12/2023 2:45:25 AM-->
<!--Modified on: 12/12/2023 2:45:25 AM-->
<xsd:schema targetNamespace="http://www.essapharma.com/20230930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:epix="http://www.essapharma.com/20230930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" id="DisclosurePrepaidsScheduleOfPrepaidExpensesDetails">
        <link:definition>40501 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>40601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails">
        <link:definition>41101 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" id="DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails">
        <link:definition>41102 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" id="StatementConsolidatedStatementOfChangesInShareholdersEquity">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestments" id="DisclosureShortTermInvestments">
        <link:definition>10401 - Disclosure - SHORT-TERM INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosurePrepaids" id="DisclosurePrepaids">
        <link:definition>10501 - Disclosure - PREPAIDS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities" id="DisclosureAccountsPayableAndAccruedLiabilities">
        <link:definition>10601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLease" id="DisclosureOperatingLease">
        <link:definition>10701 - Disclosure - OPERATING LEASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilities" id="DisclosureDerivativeLiabilities">
        <link:definition>10801 - Disclosure - DERIVATIVE LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquity" id="DisclosureShareholdersEquity">
        <link:definition>10901 - Disclosure - SHAREHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11001 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11101 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows" id="DisclosureSupplementalDisclosureWithRespectToCashFlows">
        <link:definition>11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformation" id="DisclosureSegmentedInformation">
        <link:definition>11301 - Disclosure - SEGMENTED INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk" id="DisclosureFinancialInstrumentsAndRisk">
        <link:definition>11401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>11501 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy" id="DisclosureBasisOfPresentationPolicy">
        <link:definition>20202 - Disclosure - BASIS OF PRESENTATION (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy" id="DisclosureSignificantAccountingPoliciesPolicy">
        <link:definition>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationTables" id="DisclosureBasisOfPresentationTables">
        <link:definition>30203 - Disclosure - BASIS OF PRESENTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsTables" id="DisclosureShortTermInvestmentsTables">
        <link:definition>30403 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosurePrepaidsTables" id="DisclosurePrepaidsTables">
        <link:definition>30503 - Disclosure - PREPAIDS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" id="DisclosureAccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>30603 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseTables" id="DisclosureOperatingLeaseTables">
        <link:definition>30703 - Disclosure - OPERATING LEASE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables" id="DisclosureDerivativeLiabilitiesTables">
        <link:definition>30803 - Disclosure - DERIVATIVE LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" id="DisclosureShareholdersEquityTables">
        <link:definition>30903 - Disclosure - SHAREHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31101 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitmentsTables" id="DisclosureCommitmentsTables">
        <link:definition>31503 - Disclosure - COMMITMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" id="DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails">
        <link:definition>40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails" id="DisclosureSignificantAccountingPoliciesChangeInPresentationDetails">
        <link:definition>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" id="DisclosureShortTermInvestmentsNarrativeDetails">
        <link:definition>40401 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails" id="DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails">
        <link:definition>40402 - Disclosure - SHORT-TERM INVESTMENTS - Realized gains and losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" id="DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" id="DisclosureOperatingLeaseNarrativeDetails">
        <link:definition>40702 - Disclosure - OPERATING LEASE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" id="DisclosureDerivativeLiabilitiesNarrativeDetails">
        <link:definition>40801 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" id="DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails">
        <link:definition>40802 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" id="DisclosureShareholdersEquityNarrativeDetails">
        <link:definition>40901 - Disclosure - SHAREHOLDERS EQUITY (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" id="DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails">
        <link:definition>40902 - Disclosure - SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" id="DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails">
        <link:definition>40903 - Disclosure - SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" id="DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>40904 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" id="DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails">
        <link:definition>40905 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" id="DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails">
        <link:definition>40906 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" id="DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails">
        <link:definition>40907 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" id="DisclosureRelatedPartyTransactionsNarrativeDetails">
        <link:definition>41001 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41103 - Disclosure - INCOME TAXES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" id="DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails">
        <link:definition>41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails" id="DisclosureSegmentedInformationNarrativeDetails">
        <link:definition>41301 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" id="DisclosureFinancialInstrumentsAndRiskNarrativeDetails">
        <link:definition>41401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" id="DisclosureCommitmentsNarrativeDetails">
        <link:definition>41501 - Disclosure - COMMITMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" id="DisclosureCommitmentsScheduleOfContractualObligationsDetails">
        <link:definition>41502 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" id="DisclosureSubsequentEventsNarrativeDetails">
        <link:definition>41601 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="epix_FinancingCosts" name="FinancingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" name="IncomeTaxReconciliationExpectedIncomeTaxRecovery" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" name="DeferredTaxAssetsEquipmentAndIntangibleAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="epix_DeferredTaxAssetsFinancingCosts" name="DeferredTaxAssetsFinancingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="epix_FinancialInstrumentsAndRiskAbstract" name="FinancialInstrumentsAndRiskAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_WorkingCapital" name="WorkingCapital" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="epix_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ScheduleOfPrepaidExpensesTableTextBlock" name="ScheduleOfPrepaidExpensesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_NatureAndContinuanceOfOperationsAbstract" name="NatureAndContinuanceOfOperationsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" name="ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_BasisOfPresentationTable" name="BasisOfPresentationTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_EssaPharmaceuticalsCorpMember" name="EssaPharmaceuticalsCorpMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_OperatingLeaseRightOfUseAssetAbstract" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_EmployeeSharePurchasePlanMember" name="EmployeeSharePurchasePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" name="ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" name="ClassOfWarrantOrRightNumberOfWarrantsRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ClassOfWarrantOrRightExpired" name="ClassOfWarrantOrRightExpired" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" name="ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" name="ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" name="ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_PurchaseRightsOfferingTerm" name="PurchaseRightsOfferingTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" name="MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" name="ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_PrepaidExpensesTextBlock" name="PrepaidExpensesTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_ShortTermInvestmentsMaturityTerm" name="ShortTermInvestmentsMaturityTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_MinimumAdvanceRoyaltyPayments" name="MinimumAdvanceRoyaltyPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" name="AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" abstract="false" />
  <xsd:element id="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" name="AmountOfMilestonePaymentsAtApplicationForMarketingApproval" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" abstract="false" />
  <xsd:element id="epix_LeaseOnUsOfficeSpacesMember" name="LeaseOnUsOfficeSpacesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" name="PrepaidPreclinicalAndClinicalExpensesAndDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="epix_OperatingLeaseLiabilitiesAccretionExpenses" name="OperatingLeaseLiabilitiesAccretionExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="epix_FinancingCostsMember" name="FinancingCostsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_OperatingLeasePaymentsFinancingActivities" name="OperatingLeasePaymentsFinancingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="epix_StockOptionPlanMember" name="StockOptionPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_PercentageOfEffectiveInterestInSubsidiaries" name="PercentageOfEffectiveInterestInSubsidiaries" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceOneInUsdMember" name="ExercisePriceOneInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceTwoInUsdMember" name="ExercisePriceTwoInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceThreeInUsdMember" name="ExercisePriceThreeInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceFourInUsdMember" name="ExercisePriceFourInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceFiveInUsdMember" name="ExercisePriceFiveInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceSixInUsdMember" name="ExercisePriceSixInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceOneInCadMember" name="ExercisePriceOneInCadMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceTwoInCadMember" name="ExercisePriceTwoInCadMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_WarrantsExercisePriceTwoMember" name="WarrantsExercisePriceTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_WarrantsExercisePriceFiveMember" name="WarrantsExercisePriceFiveMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceSevenInUsdMember" name="ExercisePriceSevenInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_EquityIncentivePlansMember" name="EquityIncentivePlansMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" name="ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="epix_TenPercentChangeInForeignExchangeRateMember" name="TenPercentChangeInForeignExchangeRateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceEightInUsdMember" name="ExercisePriceEightInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_StockOptionsAndRsuPlanMember" name="StockOptionsAndRsuPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceNineInUsdMember" name="ExercisePriceNineInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_ExercisePriceTenInUsdMember" name="ExercisePriceTenInUsdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" name="CashCanadaDepositInsuranceCorporationInsuredAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" name="GuaranteedInvestmentCertificatesAndTermDepositsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceElevenInUsdMember" id="epix_ExercisePriceElevenInUsdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceTwelveInUsdMember" id="epix_ExercisePriceTwelveInUsdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceThirteenInUsdMember" id="epix_ExercisePriceThirteenInUsdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SouthSanFranciscoOfficeMember" id="epix_SouthSanFranciscoOfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseOnCdnOfficeSpacesMember" id="epix_LeaseOnCdnOfficeSpacesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceFourteenInUsdMember" id="epix_ExercisePriceFourteenInUsdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" id="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" id="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AmountOfMilestoneToBePaidForFilingOfApplication" id="epix_AmountOfMilestoneToBePaidForFilingOfApplication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AmountOfMilestonePaymentForFilingOfApplication" id="epix_AmountOfMilestonePaymentForFilingOfApplication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" id="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ExercisePriceFifteenMember" id="epix_ExercisePriceFifteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice2.91Member" id="epix_ExercisePrice2.91Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice2.70Member" id="epix_ExercisePrice2.70Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice2.71Member" id="epix_ExercisePrice2.71Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice2.97Member" id="epix_ExercisePrice2.97Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice3.05Member" id="epix_ExercisePrice3.05Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperatingInterestIncomeOfShortTermInvestments" id="epix_OperatingInterestIncomeOfShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockOptionExercisedOneMember" id="epix_StockOptionExercisedOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockOptionExercisedTwoMember" id="epix_StockOptionExercisedTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DocumentFinancialStatementErrorCorrectionFlag" id="epix_DocumentFinancialStatementErrorCorrectionFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" id="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LegacyOptionPlanAndRsuPlanMember" id="epix_LegacyOptionPlanAndRsuPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>tmb-20230930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/12/2023 2:45:25 AM-->
<!--Modified on: 12/12/2023 2:45:25 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" />
  <calculationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent_638379459236204117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent_638379459236204117" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638379459236214116" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638379459236214116" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638379459236214116" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638379459236214116" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638379459236214116" xlink:to="us-gaap_ShortTermInvestments_638379459236214116" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638379459236214116" xlink:to="us-gaap_PrepaidExpenseCurrent_638379459236214116" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638379459236214116" xlink:to="us-gaap_ReceivablesNetCurrent_638379459236214116" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638379459236214116" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638379459236214116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638379459236214116" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638379459236214116" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638379459236214116" xlink:to="us-gaap_LiabilitiesCurrent_638379459236224116" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638379459236224116" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638379459236224116" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638379459236224116" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638379459236224116" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638379459236224116" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638379459236224116" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638379459236224116" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638379459236224116" xlink:to="us-gaap_AdditionalPaidInCapital_638379459236224116" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638379459236224116" xlink:to="us-gaap_CommonStockValue_638379459236224116" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638379459236224116" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638379459236224116" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638379459236224116" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638379459236234117" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638379459236234117" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638379459236234117" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638379459236234117" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638379459236234117" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236234117" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236234117" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638379459236234117" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236234117" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236234117" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236234117" xlink:to="us-gaap_InterestAndOtherIncome_638379459236234117" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638379459236234117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236234117" xlink:to="us-gaap_OperatingExpenses_638379459236234117" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCosts" xlink:label="epix_FinancingCosts_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638379459236234117" xlink:to="epix_FinancingCosts_638379459236244124" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638379459236234117" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638379459236244124" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638379459236234117" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638379459236244124" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638379459236244124" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638379459236244124" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeasePaymentsFinancingActivities" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638379459236244124" xlink:to="epix_OperatingLeasePaymentsFinancingActivities_638379459236244124" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638379459236244124" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638379459236244124" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638379459236244124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638379459236244124" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638379459236244124" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638379459236254122" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638379459236254122" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_638379459236254122" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638379459236254122" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638379459236254122" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_ProfitLoss_638379459236254122" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_AccretionExpense_638379459236254122" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236254122" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638379459236254122" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_638379459236254122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_InvestmentIncomeNet_638379459236254122" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638379459236264120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638379459236264120" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638379459236264120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638379459236264120" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638379459236264120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638379459236264120" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638379459236264120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638379459236264120" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638379459236264120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638379459236264120" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638379459236264120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236254122" xlink:to="us-gaap_ShareBasedCompensation_638379459236264120" order="11" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638379459236274122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidInsurance_638379459236274122" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_638379459236274122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_638379459236274122" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_638379459236274122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_638379459236274122" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638379459236274122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_638379459236274122" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638379459236274122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638379459236274122" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638379459236274122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent_638379459236274122" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" xlink:label="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_638379459236274122" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_638379459236274122" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638379459236284124" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638379459236284124" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638379459236284124" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638379459236284124" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_638379459236284124" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638379459236284124" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638379459236284124" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638379459236284124" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638379459236284124" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638379459236284124" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638379459236294123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638379459236284124" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638379459236294123" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_638379459236294123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638379459236284124" xlink:to="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_638379459236294123" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DeferredTaxAssetsFinancingCosts" xlink:label="epix_DeferredTaxAssetsFinancingCosts_638379459236294123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638379459236284124" xlink:to="epix_DeferredTaxAssetsFinancingCosts_638379459236294123" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments_638379459236294123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638379459236284124" xlink:to="us-gaap_DeferredTaxAssetsInvestments_638379459236294123" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638379459236294123" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638379459236284124" xlink:to="us-gaap_DeferredTaxAssetsOther_638379459236294123" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>tmb-20230930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/12/2023 2:45:25 AM-->
<!--Modified on: 12/12/2023 2:45:25 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedStatementOfChangesInShareholdersEquity" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityTables" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSignificantAccountingPoliciesChangeInPresentationDetails" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShortTermInvestmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureOperatingLeaseNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureDerivativeLiabilitiesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureRelatedPartyTransactionsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureFinancialInstrumentsAndRiskNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureCommitmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureCommitmentsScheduleOfContractualObligationsDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.essapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20230930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1" xlink:title="us-gaap_AssetsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_1" xlink:title="us-gaap_ShortTermInvestments_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract_1" xlink:to="us-gaap_ShortTermInvestments_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract_1 To us-gaap_ShortTermInvestments_1" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_1" xlink:title="us-gaap_DerivativeLiabilitiesCurrent_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_DerivativeLiabilitiesCurrent_1" order="3" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_DerivativeLiabilitiesNoncurrent" order="4" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityNoncurrent_2" order="5" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityCurrent_2" order="6" priority="0" />
  </definitionLink>
  <link:definitionLink xlink:role="http://www.essapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" xlink:title="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" xlink:title="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1 To us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - SHAREHOLDERS EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EmployeeSharePurchasePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_StockOptionPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_BasisOfPresentationTable" xlink:label="epix_BasisOfPresentationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="epix_BasisOfPresentationTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="epix_EssaPharmaceuticalsCorpMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_BasisOfPresentationLineItems" xlink:label="epix_BasisOfPresentationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="epix_BasisOfPresentationLineItems" xlink:to="epix_BasisOfPresentationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_BasisOfPresentationLineItems" xlink:to="epix_PercentageOfEffectiveInterestInSubsidiaries" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable" xlink:label="us-gaap_ReclassificationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ReclassificationTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems" xlink:label="us-gaap_ReclassificationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ReclassificationLineItems" xlink:to="us-gaap_ReclassificationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingInterestIncomeOfShortTermInvestments" xlink:label="epix_OperatingInterestIncomeOfShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ReclassificationLineItems" xlink:to="epix_OperatingInterestIncomeOfShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ReclassificationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ReclassificationLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ReclassificationLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" xlink:label="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ShortTermInvestmentsMaturityTerm" xlink:label="epix_ShortTermInvestmentsMaturityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_ShortTermInvestmentsMaturityTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - SHORT-TERM INVESTMENTS - Realized gains and losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" xlink:label="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_GainLossOnSaleOfInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="epix_FinancingCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseRightOfUseAssetAbstract" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="epix_OperatingLeaseRightOfUseAssetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" xlink:label="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract" xlink:to="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xlink:label="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xlink:type="extended" xlink:title="40702 - Disclosure - OPERATING LEASE (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="epix_FinancingCostsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_SouthSanFranciscoOfficeMember" xlink:label="epix_SouthSanFranciscoOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="epix_SouthSanFranciscoOfficeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DerivativeTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHAREHOLDERS EQUITY (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionsAndRsuPlanMember" xlink:label="epix_StockOptionsAndRsuPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="epix_StockOptionsAndRsuPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EquityIncentivePlansMember" xlink:label="epix_EquityIncentivePlansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EquityIncentivePlansMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="epix_EquityIncentivePlansMember" xlink:to="epix_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LegacyOptionPlanAndRsuPlanMember" xlink:label="epix_LegacyOptionPlanAndRsuPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_EquityIncentivePlansMember" xlink:to="epix_LegacyOptionPlanAndRsuPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PurchaseRightsOfferingTerm" xlink:label="epix_PurchaseRightsOfferingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_PurchaseRightsOfferingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_StockOptionPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_StockOptionPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceOneInUsdMember" xlink:label="epix_ExercisePriceOneInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceOneInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.70Member" xlink:label="epix_ExercisePrice2.70Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePrice2.70Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.71Member" xlink:label="epix_ExercisePrice2.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePrice2.71Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.91Member" xlink:label="epix_ExercisePrice2.91Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePrice2.91Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.97Member" xlink:label="epix_ExercisePrice2.97Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePrice2.97Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice3.05Member" xlink:label="epix_ExercisePrice3.05Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePrice3.05Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwoInUsdMember" xlink:label="epix_ExercisePriceTwoInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceTwoInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceElevenInUsdMember" xlink:label="epix_ExercisePriceElevenInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceElevenInUsdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceThreeInUsdMember" xlink:label="epix_ExercisePriceThreeInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceThreeInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFourInUsdMember" xlink:label="epix_ExercisePriceFourInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceFourInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFifteenMember" xlink:label="epix_ExercisePriceFifteenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceFifteenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFiveInUsdMember" xlink:label="epix_ExercisePriceFiveInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceFiveInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceSixInUsdMember" xlink:label="epix_ExercisePriceSixInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceSixInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceSevenInUsdMember" xlink:label="epix_ExercisePriceSevenInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceSevenInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceEightInUsdMember" xlink:label="epix_ExercisePriceEightInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceEightInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceNineInUsdMember" xlink:label="epix_ExercisePriceNineInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceNineInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTenInUsdMember" xlink:label="epix_ExercisePriceTenInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceTenInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwelveInUsdMember" xlink:label="epix_ExercisePriceTwelveInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceTwelveInUsdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceThirteenInUsdMember" xlink:label="epix_ExercisePriceThirteenInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceThirteenInUsdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFourteenInUsdMember" xlink:label="epix_ExercisePriceFourteenInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceFourteenInUsdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceOneInCadMember" xlink:label="epix_ExercisePriceOneInCadMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceOneInCadMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwoInCadMember" xlink:label="epix_ExercisePriceTwoInCadMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceTwoInCadMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" xlink:label="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40907 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WarrantsExercisePriceTwoMember" xlink:label="epix_WarrantsExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_WarrantsExercisePriceTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WarrantsExercisePriceFiveMember" xlink:label="epix_WarrantsExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_WarrantsExercisePriceFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="epix_EssaPharmaceuticalsCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" xlink:label="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAXES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_TenPercentChangeInForeignExchangeRateMember" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_TenPercentChangeInForeignExchangeRateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WorkingCapital" xlink:label="epix_WorkingCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_WorkingCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - COMMITMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_MinimumAdvanceRoyaltyPayments" xlink:label="epix_MinimumAdvanceRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_MinimumAdvanceRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestoneToBePaidForFilingOfApplication" xlink:label="epix_AmountOfMilestoneToBePaidForFilingOfApplication" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestoneToBePaidForFilingOfApplication" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentForFilingOfApplication" xlink:label="epix_AmountOfMilestonePaymentForFilingOfApplication" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestonePaymentForFilingOfApplication" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LeaseOnCdnOfficeSpacesMember" xlink:label="epix_LeaseOnCdnOfficeSpacesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_LeaseOnCdnOfficeSpacesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LeaseOnUsOfficeSpacesMember" xlink:label="epix_LeaseOnUsOfficeSpacesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_LeaseOnUsOfficeSpacesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInFifthYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionExercisedOneMember" xlink:label="epix_StockOptionExercisedOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="epix_StockOptionExercisedOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionExercisedTwoMember" xlink:label="epix_StockOptionExercisedTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="epix_StockOptionExercisedTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>tmb-20230930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/12/2023 2:45:25 AM-->
<!--Modified on: 12/12/2023 2:45:25 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DocumentFinancialStatementErrorCorrectionFlag" xlink:label="epix_DocumentFinancialStatementErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DocumentFinancialStatementErrorCorrectionFlag" xlink:to="epix_DocumentFinancialStatementErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DocumentFinancialStatementErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DocumentFinancialStatementErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments (Note 4)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids (Note 5)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities (Note 6)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities (Note 7)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities with expected life of less than one year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities with expected life greater than one year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares 44,100,838 issued and outstanding (September 30, 2022 - 44,073,076) (Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital (Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSES (Abstract)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCosts" xlink:label="epix_FinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FinancingCosts" xlink:to="epix_FinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of financing costs incurred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_FinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability gain (Note 8)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the year before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the year before taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax recovery (expense) (Note 11)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (recovery) expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on short-term investments (Note 4)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss and comprehensive loss for the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding - Basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding -Diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Items not affecting cash and cash equivalents:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization/(Accretion) of premiums/discounts on short-term investments, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Investment income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized foreign exchange</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in non-cash working capital items:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from short-term investments sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from stock options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment to Acquire Shares through Employee Share Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased through employee share purchase plan</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeasePaymentsFinancingActivities" xlink:label="epix_OperatingLeasePaymentsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeasePaymentsFinancingActivities" xlink:to="epix_OperatingLeasePaymentsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash flow arising out of lease payments during the period, which are classified as financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of foreign exchange on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash and cash equivalents for the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Deficit) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance, in shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance, in shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued through employee share purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued through employee share purchase plan, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_NatureAndContinuanceOfOperationsAbstract" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_NatureAndContinuanceOfOperationsAbstract" xlink:to="epix_NatureAndContinuanceOfOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAIDS</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PrepaidExpensesTextBlock" xlink:label="epix_PrepaidExpensesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PrepaidExpensesTextBlock" xlink:to="epix_PrepaidExpensesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PrepaidExpensesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PrepaidExpensesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PrepaidExpensesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAIDS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DERIVATIVE LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DERIVATIVE LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Supplemental Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEGMENTED INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEGMENTED INFORMATION</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancialInstrumentsAndRiskAbstract" xlink:label="epix_FinancialInstrumentsAndRiskAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FinancialInstrumentsAndRiskAbstract" xlink:to="epix_FinancialInstrumentsAndRiskAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FinancialInstrumentsAndRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FinancialInstrumentsAndRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INSTRUMENTS AND RISK</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INSTRUMENTS AND RISK</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Consolidation and Functional Currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently accounting pronouncements adopted and not yet adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in presentation</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xlink:to="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the functional currency and effective interest in subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Functional Currency and Effective Interest in Subsidiaries [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Functional Currency of Company and its Subsidiaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of available for sale securities reconciliation</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfPrepaidExpensesTableTextBlock" xlink:to="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of information pertaining to prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Prepaid Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Prepaid Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:to="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of operating lease related assets and liabilities and other related information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Operating Lease Balance Sheet Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_EmployeeSharePurchasePlanMember" xlink:to="epix_EmployeeSharePurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Employee Share Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Share Purchase Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockOptionPlanMember" xlink:to="epix_StockOptionPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant outstanding and Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Assumptions for the Valuation of Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Stock Option Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Warrants Activity</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:to="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrants or Rights Outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Income Taxes at Statutory Rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Components of Future Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contractual obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Contractual Obligations</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_BasisOfPresentationTable" xlink:label="epix_BasisOfPresentationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BasisOfPresentationTable" xlink:to="epix_BasisOfPresentationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BasisOfPresentationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BasisOfPresentationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_EssaPharmaceuticalsCorpMember" xlink:to="epix_EssaPharmaceuticalsCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_EssaPharmaceuticalsCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to ESSA Pharmaceuticals Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_EssaPharmaceuticalsCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESSA Pharmaceuticals Corp [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_BasisOfPresentationLineItems" xlink:label="epix_BasisOfPresentationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BasisOfPresentationLineItems" xlink:to="epix_BasisOfPresentationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BasisOfPresentationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BasisOfPresentationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:to="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of effective interest in subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of effective interest in subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable" xlink:label="us-gaap_ReclassificationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationTable" xlink:to="us-gaap_ReclassificationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Reclassification, Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Reclassification, Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems" xlink:label="us-gaap_ReclassificationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationLineItems" xlink:to="us-gaap_ReclassificationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingInterestIncomeOfShortTermInvestments" xlink:label="epix_OperatingInterestIncomeOfShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingInterestIncomeOfShortTermInvestments" xlink:to="epix_OperatingInterestIncomeOfShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingInterestIncomeOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating interest income of short-term investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingInterestIncomeOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Interest Income of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_OperatingInterestIncomeOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest from short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" xlink:label="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" xlink:to="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to guaranteed investment certificates and term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GICs and Term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guaranteed investment certificates, interest rate</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ShortTermInvestmentsMaturityTerm" xlink:label="epix_ShortTermInvestmentsMaturityTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ShortTermInvestmentsMaturityTerm" xlink:to="epix_ShortTermInvestmentsMaturityTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ShortTermInvestmentsMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term investments maturity term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ShortTermInvestmentsMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term investments maturity term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ShortTermInvestmentsMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guaranteed investment certificates, maturity term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Treasury securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Investment Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Investment Income - extensible enumeration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Sale of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains or losses on sales of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:to="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of prepaid preclinical and clinical expenses and deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Preclinical and Clinical Expenses and Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid CMC and clinical expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other deposits and prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FinancingCostsMember" xlink:to="epix_FinancingCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FinancingCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to financing costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FinancingCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseRightOfUseAssetAbstract" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract" xlink:to="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" xlink:label="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" xlink:to="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease, Right-of-Use Asset [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xlink:label="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xlink:to="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liabilities [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, at beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accretion expense on operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities Accretion Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_SouthSanFranciscoOfficeMember" xlink:label="epix_SouthSanFranciscoOfficeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_SouthSanFranciscoOfficeMember" xlink:to="epix_SouthSanFranciscoOfficeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_SouthSanFranciscoOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the South San Francisco office.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_SouthSanFranciscoOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">South San Francisco Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_SouthSanFranciscoOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">South San Francisco Office</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DERIVATIVE LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Ending balance (in dollar per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Beginning balance (in dollar per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free Interest Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Life (in Years) [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Annualized Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Discount [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions to fair value of the derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionsAndRsuPlanMember" xlink:label="epix_StockOptionsAndRsuPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockOptionsAndRsuPlanMember" xlink:to="epix_StockOptionsAndRsuPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockOptionsAndRsuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options and RSU Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockOptionsAndRsuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options and RSU Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EquityIncentivePlansMember" xlink:label="epix_EquityIncentivePlansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_EquityIncentivePlansMember" xlink:to="epix_EquityIncentivePlansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_EquityIncentivePlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity incentive plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_EquityIncentivePlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LegacyOptionPlanAndRsuPlanMember" xlink:label="epix_LegacyOptionPlanAndRsuPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_LegacyOptionPlanAndRsuPlanMember" xlink:to="epix_LegacyOptionPlanAndRsuPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_LegacyOptionPlanAndRsuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Company's amended and restated stock option plan (the "Legacy Option Plan"), and the Amended and Restated Restricted Share Unit Plan (the "RSU Plan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_LegacyOptionPlanAndRsuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legacy Option Plan And RSU Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price percentage of Common Shares granted</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:to="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of contribution by each employee to employee share purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution Per Employee To Employee Share Purchase Plan, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee contribution percentage</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PurchaseRightsOfferingTerm" xlink:label="epix_PurchaseRightsOfferingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PurchaseRightsOfferingTerm" xlink:to="epix_PurchaseRightsOfferingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PurchaseRightsOfferingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of purchase rights offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PurchaseRightsOfferingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Rights, Offering Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PurchaseRightsOfferingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering term</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:to="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common share each employee is eligible under employee share purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Eligible Common Shares Under Employee Share Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligibility to Common Shares amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life of share purchase options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected annualized volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired/forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired/forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceOneInUsdMember" xlink:label="epix_ExercisePriceOneInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceOneInUsdMember" xlink:to="epix_ExercisePriceOneInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceOneInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price one in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceOneInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.39 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.70Member" xlink:label="epix_ExercisePrice2.70Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePrice2.70Member" xlink:to="epix_ExercisePrice2.70Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePrice2.70Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price one in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePrice2.70Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.70 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.71Member" xlink:label="epix_ExercisePrice2.71Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePrice2.71Member" xlink:to="epix_ExercisePrice2.71Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePrice2.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price one in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePrice2.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.71 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.91Member" xlink:label="epix_ExercisePrice2.91Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePrice2.91Member" xlink:to="epix_ExercisePrice2.91Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePrice2.91Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price one in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePrice2.91Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.91 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.97Member" xlink:label="epix_ExercisePrice2.97Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePrice2.97Member" xlink:to="epix_ExercisePrice2.97Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePrice2.97Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price one in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePrice2.97Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.97 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice3.05Member" xlink:label="epix_ExercisePrice3.05Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePrice3.05Member" xlink:to="epix_ExercisePrice3.05Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePrice3.05Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price one in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePrice3.05Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.05 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwoInUsdMember" xlink:label="epix_ExercisePriceTwoInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceTwoInUsdMember" xlink:to="epix_ExercisePriceTwoInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceTwoInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Two in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceTwoInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.23 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceThreeInUsdMember" xlink:label="epix_ExercisePriceThreeInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceThreeInUsdMember" xlink:to="epix_ExercisePriceThreeInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceThreeInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Three in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceThreeInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.59 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFourInUsdMember" xlink:label="epix_ExercisePriceFourInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceFourInUsdMember" xlink:to="epix_ExercisePriceFourInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceFourInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Four in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceFourInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.60 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFifteenMember" xlink:label="epix_ExercisePriceFifteenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceFifteenMember" xlink:to="epix_ExercisePriceFifteenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceFifteenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Fifteen in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceFifteenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.75 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFiveInUsdMember" xlink:label="epix_ExercisePriceFiveInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceFiveInUsdMember" xlink:to="epix_ExercisePriceFiveInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceFiveInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Five in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceFiveInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.81 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceSixInUsdMember" xlink:label="epix_ExercisePriceSixInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceSixInUsdMember" xlink:to="epix_ExercisePriceSixInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceSixInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Six in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceSixInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $4.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceSevenInUsdMember" xlink:label="epix_ExercisePriceSevenInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceSevenInUsdMember" xlink:to="epix_ExercisePriceSevenInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceSevenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Seven in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceSevenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $4.67 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceEightInUsdMember" xlink:label="epix_ExercisePriceEightInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceEightInUsdMember" xlink:to="epix_ExercisePriceEightInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceEightInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Eight in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceEightInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $5.99 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceNineInUsdMember" xlink:label="epix_ExercisePriceNineInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceNineInUsdMember" xlink:to="epix_ExercisePriceNineInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceNineInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Nine in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceNineInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $7.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTenInUsdMember" xlink:label="epix_ExercisePriceTenInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceTenInUsdMember" xlink:to="epix_ExercisePriceTenInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceTenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Ten in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceTenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $8.47 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceElevenInUsdMember" xlink:label="epix_ExercisePriceElevenInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceElevenInUsdMember" xlink:to="epix_ExercisePriceElevenInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceElevenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Eleven in USD [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceElevenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $9.76 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwelveInUsdMember" xlink:label="epix_ExercisePriceTwelveInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceTwelveInUsdMember" xlink:to="epix_ExercisePriceTwelveInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceTwelveInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Twelve in USD [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceTwelveInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $13.96 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceThirteenInUsdMember" xlink:label="epix_ExercisePriceThirteenInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceThirteenInUsdMember" xlink:to="epix_ExercisePriceThirteenInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceThirteenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Thirteen in USD [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceThirteenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $29.63 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFourteenInUsdMember" xlink:label="epix_ExercisePriceFourteenInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceFourteenInUsdMember" xlink:to="epix_ExercisePriceFourteenInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceFourteenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Fourteen in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceFourteenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $31.62 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceOneInCadMember" xlink:label="epix_ExercisePriceOneInCadMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceOneInCadMember" xlink:to="epix_ExercisePriceOneInCadMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceOneInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price One in CAD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceOneInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price C$4.90 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwoInCadMember" xlink:label="epix_ExercisePriceTwoInCadMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceTwoInCadMember" xlink:to="epix_ExercisePriceTwoInCadMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceTwoInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Two in CAD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceTwoInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price C$5.06 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life (years)</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" xlink:label="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" xlink:to="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No of shares options exercised unexpired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedExpiredNumber</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired unexercised</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Number of Warrants [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants, Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants, Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightExpired" xlink:label="epix_ClassOfWarrantOrRightExpired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightExpired" xlink:to="epix_ClassOfWarrantOrRightExpired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of class of warrant or rights expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right Weighted Average Exercise Price, Warrants Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price, warrants expired (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WarrantsExercisePriceTwoMember" xlink:label="epix_WarrantsExercisePriceTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WarrantsExercisePriceTwoMember" xlink:to="epix_WarrantsExercisePriceTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WarrantsExercisePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WarrantsExercisePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price $42.80 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WarrantsExercisePriceFiveMember" xlink:label="epix_WarrantsExercisePriceFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WarrantsExercisePriceFiveMember" xlink:to="epix_WarrantsExercisePriceFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WarrantsExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WarrantsExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price $0.0001 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiry Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related parties</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" xlink:label="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" xlink:to="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expected income tax recovery.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation Expected Income Tax Recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax recovery at statutory income tax rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other permanent differences including foreign exchange</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in statutory, foreign tax, foreign exchange rates and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating losses carried forward</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:to="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equipment and intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Equipment And Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment and intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInvestments" xlink:to="us-gaap_DeferredTaxAssetsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment tax credits</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DeferredTaxAssetsFinancingCosts" xlink:label="epix_DeferredTaxAssetsFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DeferredTaxAssetsFinancingCosts" xlink:to="epix_DeferredTaxAssetsFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DeferredTaxAssetsFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from financing costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DeferredTaxAssetsFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DeferredTaxAssetsFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Credit Carry forwards Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal R&amp;D credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross future tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net future tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canada</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Us</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General corporate income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-capital loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount paid for taxes and interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of industries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_TenPercentChangeInForeignExchangeRateMember" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_TenPercentChangeInForeignExchangeRateMember" xlink:to="epix_TenPercentChangeInForeignExchangeRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ten percent Change in Foreign Exchange Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">10% Change in Foreign Exchange Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:to="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Canada Deposit Insurance Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Canada Deposit Insurance Corporation Insured amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, CDIC insured amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC insured amount</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WorkingCapital" xlink:label="epix_WorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WorkingCapital" xlink:to="epix_WorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount of working capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:to="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk, fluctuation in the net income(loss) reported due to change in exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_LicenseAgreementMember" xlink:to="epix_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to license agreement .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology-based intangible assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_MinimumAdvanceRoyaltyPayments" xlink:label="epix_MinimumAdvanceRoyaltyPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_MinimumAdvanceRoyaltyPayments" xlink:to="epix_MinimumAdvanceRoyaltyPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_MinimumAdvanceRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents amount of minimum annual royalty payments per annum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_MinimumAdvanceRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Advance Royalty Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_MinimumAdvanceRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum advance royalty payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestoneToBePaidForFilingOfApplication" xlink:label="epix_AmountOfMilestoneToBePaidForFilingOfApplication" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestoneToBePaidForFilingOfApplication" xlink:to="epix_AmountOfMilestoneToBePaidForFilingOfApplication_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestoneToBePaidForFilingOfApplication_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments to be paid upon filing an Investigational New Drug (IND) Application.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestoneToBePaidForFilingOfApplication_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Milestone To Be Paid For Filing of Application</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestoneToBePaidForFilingOfApplication_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment to be paid upon filing an Investigational New Drug (IND) Application.</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payment to be made at the start of the Phase II clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Of Milestone Payments At Start Of Second Phase Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment to be made at the start of a Phase II clinical trial</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments to be made at the start of a Phase III clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Of Milestone Payments At Start Of Third Phase Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment to be made at the start of a Phase III clinical trial</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:to="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments made at application for marketing approval and with further milestone payments on the second and additional compounds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Of Milestone Payments At Application For Marketing Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment to be made at application for marketing approval, and with further milestone payments on the second and additional compounds</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentForFilingOfApplication" xlink:label="epix_AmountOfMilestonePaymentForFilingOfApplication" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestonePaymentForFilingOfApplication" xlink:to="epix_AmountOfMilestonePaymentForFilingOfApplication_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestonePaymentForFilingOfApplication_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments made for filing the Investigational New Drug (IND) Application.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestonePaymentForFilingOfApplication_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Milestone Payment For Filing of Application</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestonePaymentForFilingOfApplication_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payment made for filing an Investigational New Drug (IND) Application.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LeaseOnCdnOfficeSpacesMember" xlink:label="epix_LeaseOnCdnOfficeSpacesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_LeaseOnCdnOfficeSpacesMember" xlink:to="epix_LeaseOnCdnOfficeSpacesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_LeaseOnCdnOfficeSpacesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Lease on CDN office spaces.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_LeaseOnCdnOfficeSpacesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease on CDN office spaces [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LeaseOnUsOfficeSpacesMember" xlink:label="epix_LeaseOnUsOfficeSpacesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_LeaseOnUsOfficeSpacesMember" xlink:to="epix_LeaseOnUsOfficeSpacesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_LeaseOnUsOfficeSpacesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Lease on US office spaces.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_LeaseOnUsOfficeSpacesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease on US Office Spaces [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionExercisedOneMember" xlink:label="epix_StockOptionExercisedOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockOptionExercisedOneMember" xlink:to="epix_StockOptionExercisedOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockOptionExercisedOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to stock option exercised one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockOptionExercisedOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Exercised One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_StockOptionExercisedOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Exercised One</label>
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionExercisedTwoMember" xlink:label="epix_StockOptionExercisedTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockOptionExercisedTwoMember" xlink:to="epix_StockOptionExercisedTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockOptionExercisedTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to stock option exercised two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockOptionExercisedTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Exercised Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_StockOptionExercisedTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Exercised Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>tmb-20230930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/12/2023 2:45:25 AM-->
<!--Modified on: 12/12/2023 2:45:25 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.essapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#StatementConsolidatedStatementOfChangesInShareholdersEquity" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureNatureOfOperations" roleURI="http://www.essapharma.com/role/DisclosureNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureBasisOfPresentation" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShortTermInvestments" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosurePrepaids" roleURI="http://www.essapharma.com/role/DisclosurePrepaids" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureAccountsPayableAndAccruedLiabilities" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureOperatingLease" roleURI="http://www.essapharma.com/role/DisclosureOperatingLease" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureDerivativeLiabilities" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquity" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxes" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSupplementalDisclosureWithRespectToCashFlows" roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSegmentedInformation" roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureFinancialInstrumentsAndRisk" roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureCommitments" roleURI="http://www.essapharma.com/role/DisclosureCommitments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSubsequentEvents" roleURI="http://www.essapharma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureBasisOfPresentationPolicy" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSignificantAccountingPoliciesPolicy" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureBasisOfPresentationTables" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShortTermInvestmentsTables" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosurePrepaidsTables" roleURI="http://www.essapharma.com/role/DisclosurePrepaidsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesTables" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureOperatingLeaseTables" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureDerivativeLiabilitiesTables" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityTables" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureCommitmentsTables" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSignificantAccountingPoliciesChangeInPresentationDetails" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShortTermInvestmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureOperatingLeaseNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureDerivativeLiabilitiesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureRelatedPartyTransactionsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSegmentedInformationNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureFinancialInstrumentsAndRiskNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureCommitmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureCommitmentsScheduleOfContractualObligationsDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20230930.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.essapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638379459236784131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638379459236784131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638379459236784131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638379459236784131" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638379459236794138" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638379459236794138" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638379459236794138" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638379459236794138" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638379459236794138" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry_638379459236794138" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638379459236794138" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638379459236794138" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638379459236794138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638379459236794138" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638379459236804133" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638379459236804133" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638379459236804133" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638379459236804133" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638379459236804133" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638379459236804133" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638379459236804133" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638379459236804133" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638379459236804133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638379459236804133" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638379459236814128" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638379459236814128" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638379459236814128" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638379459236814128" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638379459236814128" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638379459236814128" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638379459236814128" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DocumentFinancialStatementErrorCorrectionFlag" xlink:label="epix_DocumentFinancialStatementErrorCorrectionFlag_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="epix_DocumentFinancialStatementErrorCorrectionFlag_638379459236814128" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638379459236814128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638379459236814128" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638379459236824130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638379459236824130" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638379459236824130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638379459236824130" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638379459236824130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638379459236824130" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638379459236824130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638379459236824130" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638379459236824130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638379459236824130" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638379459236824130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638379459236824130" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638379459236824130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638379459236824130" order="36" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638379459236834128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638379459236834128" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638379459236834128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638379459236834128" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638379459236834128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638379459236834128" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638379459236834128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638379459236834128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638379459236834128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638379459236834128" xlink:to="us-gaap_AssetsCurrentAbstract_638379459236834128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638379459236834128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638379459236834128" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638379459236834128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638379459236834128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638379459236834128" xlink:to="us-gaap_ShortTermInvestments_638379459236834128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638379459236834128" xlink:to="us-gaap_ReceivablesNetCurrent_638379459236844128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638379459236834128" xlink:to="us-gaap_PrepaidExpenseCurrent_638379459236844128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638379459236834128" xlink:to="us-gaap_AssetsCurrent_638379459236844128" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638379459236834128" xlink:to="us-gaap_DepositsAssetsNoncurrent_638379459236844128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638379459236834128" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638379459236844128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638379459236834128" xlink:to="us-gaap_Assets_638379459236844128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638379459236844128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638379459236844128" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638379459236844128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638379459236844128" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638379459236844128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638379459236844128" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638379459236844128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638379459236844128" xlink:to="us-gaap_LiabilitiesCurrent_638379459236844128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638379459236844128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638379459236844128" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638379459236844128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638379459236844128" xlink:to="us-gaap_Liabilities_638379459236854128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638379459236844128" xlink:to="us-gaap_StockholdersEquityAbstract_638379459236854128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638379459236854128" xlink:to="us-gaap_CommonStockValue_638379459236854128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638379459236854128" xlink:to="us-gaap_AdditionalPaidInCapital_638379459236854128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638379459236854128" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638379459236854128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638379459236854128" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638379459236854128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638379459236854128" xlink:to="us-gaap_StockholdersEquity_638379459236854128" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638379459236854128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638379459236844128" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638379459236854128" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638379459236864127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638379459236864127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638379459236864127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638379459236864127" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638379459236864127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCosts" xlink:label="epix_FinancingCosts_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638379459236864127" xlink:to="epix_FinancingCosts_638379459236864127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638379459236864127" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638379459236864127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638379459236864127" xlink:to="us-gaap_OperatingExpenses_638379459236864127" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638379459236864127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome_638379459236864127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236864127" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236864127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459236864127" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638379459236874134" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638379459236874134" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_638379459236874134" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_638379459236874134" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638379459236874134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638379459236874134" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638379459236874134" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638379459236874134" xlink:to="us-gaap_EarningsPerShareBasic_638379459236874134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638379459236874134" xlink:to="us-gaap_EarningsPerShareDiluted_638379459236874134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638379459236874134" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638379459236874134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638379459236874134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638379459236874134" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638379459236874134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_ProfitLoss_638379459236884129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638379459236884129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638379459236884129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_AccretionExpense_638379459236884129" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638379459236884129" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_InvestmentIncomeNet_638379459236884129" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638379459236884129" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_ShareBasedCompensation_638379459236884129" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638379459236884129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638379459236884129" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638379459236884129" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638379459236894134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638379459236884129" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638379459236894134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638379459236884129" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638379459236894134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638379459236884129" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638379459236894134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638379459236894134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638379459236894134" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638379459236894134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638379459236894134" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_638379459236894134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638379459236894134" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638379459236894134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638379459236894134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638379459236894134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638379459236894134" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638379459236894134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638379459236904130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638379459236894134" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_638379459236904130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeasePaymentsFinancingActivities" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_638379459236904130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638379459236894134" xlink:to="epix_OperatingLeasePaymentsFinancingActivities_638379459236904130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638379459236904130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638379459236894134" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638379459236904130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638379459236904130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638379459236904130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638379459236904130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638379459236904130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638379459236904130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638379459236904130" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383794592369041301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383794592369041301" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638379459236914128" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459236914128" xlink:to="us-gaap_StatementEquityComponentsAxis_638379459236914128" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638379459236914128" xlink:to="us-gaap_CommonStockMember_638379459236914128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638379459236914128" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638379459236914128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638379459236914128" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638379459236914128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638379459236914128" xlink:to="us-gaap_RetainedEarningsMember_638379459236914128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638379459236914128" xlink:to="us-gaap_EquityComponentDomain_638379459236914128" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459236914128" xlink:to="us-gaap_StatementLineItems_638379459236914128" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_StockholdersEquity_638379459236914128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_SharesOutstanding_638379459236914128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638379459236914128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459236914128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459236914128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638379459236924130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638379459236924130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638379459236924130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638379459236924130" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638379459236924130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638379459236924130" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638379459236924130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638379459236924130" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638379459236924130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_StockholdersEquity_638379459236924130" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638379459236924130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459236914128" xlink:to="us-gaap_SharesOutstanding_638379459236924130" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_NatureAndContinuanceOfOperationsAbstract" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638379459236924130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_NatureAndContinuanceOfOperationsAbstract" xlink:to="us-gaap_NatureOfOperations_638379459236924130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - BASIS OF PRESENTATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638379459236934128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638379459236934128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638379459236934128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638379459236934128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestments" xlink:type="extended" xlink:title="10401 - Disclosure - SHORT-TERM INVESTMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_638379459236934128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_638379459236934128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaids" xlink:type="extended" xlink:title="10501 - Disclosure - PREPAIDS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PrepaidExpensesTextBlock" xlink:label="epix_PrepaidExpensesTextBlock_638379459236934128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="epix_PrepaidExpensesTextBlock_638379459236934128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638379459236934128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638379459236934128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLease" xlink:type="extended" xlink:title="10701 - Disclosure - OPERATING LEASE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638379459236944132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638379459236944132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilities" xlink:type="extended" xlink:title="10801 - Disclosure - DERIVATIVE LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638379459236944132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638379459236944132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquity" xlink:type="extended" xlink:title="10901 - Disclosure - SHAREHOLDERS EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638379459236944132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638379459236944132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11001 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638379459236944132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638379459236944132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11101 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638379459236944132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638379459236944132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows" xlink:type="extended" xlink:title="11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_638379459236954130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_638379459236954130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSegmentedInformation" xlink:type="extended" xlink:title="11301 - Disclosure - SEGMENTED INFORMATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638379459236954130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638379459236954130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk" xlink:type="extended" xlink:title="11401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancialInstrumentsAndRiskAbstract" xlink:label="epix_FinancialInstrumentsAndRiskAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_638379459236954130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_FinancialInstrumentsAndRiskAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_638379459236954130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="11501 - Disclosure - COMMITMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638379459236954130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638379459236954130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11601 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638379459236954130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638379459236954130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy" xlink:type="extended" xlink:title="20202 - Disclosure - BASIS OF PRESENTATION (Policy)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638379459236964130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638379459236964130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates_638379459236964130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy" xlink:type="extended" xlink:title="20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638379459236964130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock_638379459236964130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638379459236964130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638379459236964130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638379459236964130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638379459236964130" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638379459236964130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638379459236964130" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638379459236974131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638379459236974131" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638379459236974131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638379459236974131" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638379459236974131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638379459236974131" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_638379459236974131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_638379459236974131" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationTables" xlink:type="extended" xlink:title="30203 - Disclosure - BASIS OF PRESENTATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_638379459236974131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_638379459236974131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestmentsTables" xlink:type="extended" xlink:title="30403 - Disclosure - SHORT-TERM INVESTMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638379459236974131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638379459236974131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaidsTables" xlink:type="extended" xlink:title="30503 - Disclosure - PREPAIDS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_638379459236974131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="epix_ScheduleOfPrepaidExpensesTableTextBlock_638379459236974131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638379459236984130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638379459236984130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseTables" xlink:type="extended" xlink:title="30703 - Disclosure - OPERATING LEASE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_638379459236984130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_638379459236984130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - DERIVATIVE LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638379459236984130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638379459236984130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - SHAREHOLDERS EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459236984130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459236984130" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638379459236984130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459236984130" xlink:to="us-gaap_PlanNameAxis_638379459236984130" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638379459236984130" xlink:to="us-gaap_PlanNameDomain_638379459236994131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638379459236994131" xlink:to="epix_EmployeeSharePurchasePlanMember_638379459236994131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638379459236994131" xlink:to="epix_StockOptionPlanMember_638379459236994131" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459236984130" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638379459236994131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638379459236994131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638379459236994131" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638379459236994131" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638379459236994131" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_638379459236994131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459236994131" xlink:to="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_638379459236994131" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31101 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638379459237004131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638379459237004131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsTables" xlink:type="extended" xlink:title="31503 - Disclosure - COMMITMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_638379459237004131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_BasisOfPresentationTable" xlink:label="epix_BasisOfPresentationTable_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="epix_BasisOfPresentationTable_638379459237004131" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_BasisOfPresentationTable_638379459237004131" xlink:to="srt_OwnershipAxis_638379459237004131" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638379459237004131" xlink:to="srt_OwnershipDomain_638379459237004131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638379459237004131" xlink:to="epix_EssaPharmaceuticalsCorpMember_638379459237004131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_BasisOfPresentationLineItems" xlink:label="epix_BasisOfPresentationLineItems_638379459237004131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_BasisOfPresentationTable_638379459237004131" xlink:to="epix_BasisOfPresentationLineItems_638379459237004131" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_BasisOfPresentationLineItems_638379459237004131" xlink:to="epix_PercentageOfEffectiveInterestInSubsidiaries_638379459237014130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable" xlink:label="us-gaap_ReclassificationTable_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ReclassificationTable_638379459237014130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationTable_638379459237014130" xlink:to="srt_RestatementAxis_638379459237014130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638379459237014130" xlink:to="srt_RestatementDomain_638379459237014130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638379459237014130" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_638379459237014130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems" xlink:label="us-gaap_ReclassificationLineItems_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationTable_638379459237014130" xlink:to="us-gaap_ReclassificationLineItems_638379459237014130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingInterestIncomeOfShortTermInvestments" xlink:label="epix_OperatingInterestIncomeOfShortTermInvestments_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationLineItems_638379459237014130" xlink:to="epix_OperatingInterestIncomeOfShortTermInvestments_638379459237014130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationLineItems_638379459237014130" xlink:to="us-gaap_NetIncomeLoss_638379459237014130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationLineItems_638379459237014130" xlink:to="us-gaap_EarningsPerShareBasic_638379459237014130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638379459237014130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReclassificationLineItems_638379459237014130" xlink:to="us-gaap_EarningsPerShareDiluted_638379459237014130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_StatementTable_638379459237024130" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237024130" xlink:to="srt_RangeAxis_638379459237024130" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638379459237024130" xlink:to="srt_RangeMember_638379459237024130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638379459237024130" xlink:to="srt_MinimumMember_638379459237024130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638379459237024130" xlink:to="srt_MaximumMember_638379459237024130" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237024130" xlink:to="us-gaap_FinancialInstrumentAxis_638379459237024130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638379459237024130" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237024130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" xlink:label="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237024130" xlink:to="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_638379459237024130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237024130" xlink:to="us-gaap_StatementLineItems_638379459237024130" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237024130" xlink:to="us-gaap_InvestmentInterestRate_638379459237024130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ShortTermInvestmentsMaturityTerm" xlink:label="epix_ShortTermInvestmentsMaturityTerm_638379459237024130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237024130" xlink:to="epix_ShortTermInvestmentsMaturityTerm_638379459237024130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - SHORT-TERM INVESTMENTS - Realized gains and losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_638379459237034127" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_638379459237034127" xlink:to="us-gaap_FinancialInstrumentAxis_638379459237034127" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638379459237034127" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237034127" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_GuaranteedInvestmentCertificatesAndTermDepositsMember" xlink:label="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237034127" xlink:to="epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_638379459237034127" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237034127" xlink:to="us-gaap_USTreasurySecuritiesMember_638379459237034127" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237034127" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638379459237034127" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638379459237034127" xlink:to="us-gaap_CommercialPaperMember_638379459237034127" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_638379459237034127" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638379459237034127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638379459237034127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638379459237044130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638379459237044130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_638379459237044130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_638379459237044130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_638379459237044130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_638379459237044130" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_638379459237044130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638379459237044130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638379459237044130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_638379459237044130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_638379459237044130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments_638379459237044130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_638379459237034127" xlink:to="us-gaap_GainLossOnSaleOfInvestments_638379459237044130" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638379459237134133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance_638379459237134133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_638379459237134133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_638379459237134133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_638379459237134133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_638379459237134133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638379459237134133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_638379459237134133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638379459237134133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccountsPayableCurrent_638379459237134133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638379459237144134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccruedVacationCurrent_638379459237144134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638379459237144134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638379459237144134" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638379459237144134" xlink:to="us-gaap_IncomeStatementLocationAxis_638379459237144134" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638379459237144134" xlink:to="us-gaap_IncomeStatementLocationDomain_638379459237144134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638379459237144134" xlink:to="epix_FinancingCostsMember_638379459237144134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638379459237144134" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638379459237144134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638379459237144134" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638379459237144134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseRightOfUseAssetAbstract" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638379459237144134" xlink:to="epix_OperatingLeaseRightOfUseAssetAbstract_638379459237144134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward" xlink:label="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_638379459237144134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract_638379459237144134" xlink:to="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_638379459237144134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638379459237154134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_638379459237144134" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638379459237154134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638379459237154134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_638379459237144134" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638379459237154134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_6383794592371541341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward_638379459237144134" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_6383794592371541341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638379459237154134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638379459237144134" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638379459237154134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward" xlink:label="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_638379459237154134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638379459237154134" xlink:to="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_638379459237154134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638379459237154134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_638379459237154134" xlink:to="us-gaap_OperatingLeaseLiability_638379459237154134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_638379459237154134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_638379459237154134" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses_638379459237154134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638379459237154134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_638379459237154134" xlink:to="us-gaap_OperatingLeasePayments_638379459237154134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_6383794592371541341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward_638379459237154134" xlink:to="us-gaap_OperatingLeaseLiability_6383794592371541341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_6383794592371541341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability_6383794592371541341" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_6383794592371541341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638379459237144134" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638379459237164133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638379459237144134" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638379459237164133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xlink:type="extended" xlink:title="40702 - Disclosure - OPERATING LEASE (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_StatementTable_638379459237164133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237164133" xlink:to="us-gaap_IncomeStatementLocationAxis_638379459237164133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638379459237164133" xlink:to="us-gaap_IncomeStatementLocationDomain_638379459237164133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638379459237164133" xlink:to="epix_FinancingCostsMember_638379459237164133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237164133" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638379459237164133" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638379459237164133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638379459237164133" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638379459237164133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_SouthSanFranciscoOfficeMember" xlink:label="epix_SouthSanFranciscoOfficeMember_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638379459237164133" xlink:to="epix_SouthSanFranciscoOfficeMember_638379459237174133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237164133" xlink:to="us-gaap_StatementLineItems_638379459237174133" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237174133" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638379459237174133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237174133" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638379459237174133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237174133" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses_638379459237174133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeTable_638379459237174133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_638379459237174133" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638379459237174133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638379459237174133" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638379459237174133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638379459237174133" xlink:to="us-gaap_PrivatePlacementMember_638379459237174133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_638379459237174133" xlink:to="us-gaap_DerivativeLineItems_638379459237174133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638379459237174133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_638379459237174133" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638379459237174133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_638379459237174133" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638379459237184129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeTable_638379459237184129" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_638379459237184129" xlink:to="us-gaap_MeasurementInputTypeAxis_638379459237184129" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638379459237184129" xlink:to="us-gaap_MeasurementInputTypeDomain_638379459237184129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638379459237184129" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638379459237184129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638379459237184129" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638379459237184129" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638379459237184129" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638379459237184129" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638379459237184129" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638379459237184129" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638379459237184129" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_638379459237184129" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_638379459237184129" xlink:to="srt_RangeAxis_638379459237184129" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638379459237184129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638379459237184129" xlink:to="srt_RangeMember_638379459237184129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638379459237184129" xlink:to="srt_WeightedAverageMember_638379459237194133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_638379459237184129" xlink:to="us-gaap_DerivativeLineItems_638379459237194133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_638379459237194133" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638379459237194133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHAREHOLDERS EQUITY (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237194133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237194133" xlink:to="srt_RangeAxis_638379459237194133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638379459237194133" xlink:to="srt_RangeMember_638379459237194133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638379459237194133" xlink:to="srt_MinimumMember_638379459237194133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638379459237194133" xlink:to="srt_MaximumMember_638379459237194133" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237194133" xlink:to="us-gaap_AwardTypeAxis_638379459237194133" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237194133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638379459237194133" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237194133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237194133" xlink:to="us-gaap_EmployeeStockMember_638379459237204131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionsAndRsuPlanMember" xlink:label="epix_StockOptionsAndRsuPlanMember_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237194133" xlink:to="epix_StockOptionsAndRsuPlanMember_638379459237204131" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237194133" xlink:to="us-gaap_PlanNameAxis_638379459237204131" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638379459237204131" xlink:to="us-gaap_PlanNameDomain_638379459237204131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EquityIncentivePlansMember" xlink:label="epix_EquityIncentivePlansMember_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638379459237204131" xlink:to="epix_EquityIncentivePlansMember_638379459237204131" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_EquityIncentivePlansMember_638379459237204131" xlink:to="epix_EmployeeSharePurchasePlanMember_638379459237204131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LegacyOptionPlanAndRsuPlanMember" xlink:label="epix_LegacyOptionPlanAndRsuPlanMember_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_EquityIncentivePlansMember_638379459237204131" xlink:to="epix_LegacyOptionPlanAndRsuPlanMember_638379459237204131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237194133" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638379459237204131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638379459237204131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638379459237204131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638379459237204131" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_638379459237214133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_638379459237214133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_PurchaseRightsOfferingTerm" xlink:label="epix_PurchaseRightsOfferingTerm_638379459237214133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="epix_PurchaseRightsOfferingTerm_638379459237214133" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_638379459237214133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_638379459237214133" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638379459237214133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638379459237214133" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638379459237214133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638379459237214133" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638379459237214133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237204131" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638379459237214133" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237214133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237214133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237214133" xlink:to="us-gaap_PlanNameAxis_638379459237224134" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638379459237224134" xlink:to="us-gaap_PlanNameDomain_638379459237224134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638379459237224134" xlink:to="epix_EmployeeSharePurchasePlanMember_638379459237224134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638379459237224134" xlink:to="epix_StockOptionPlanMember_638379459237224134" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237214133" xlink:to="us-gaap_IncomeStatementLocationAxis_638379459237224134" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638379459237224134" xlink:to="us-gaap_IncomeStatementLocationDomain_638379459237224134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638379459237224134" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638379459237224134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638379459237224134" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638379459237224134" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237214133" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237224134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237224134" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638379459237224134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237224134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237224134" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237224134" xlink:to="us-gaap_PlanNameAxis_638379459237234133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638379459237234133" xlink:to="us-gaap_PlanNameDomain_638379459237234133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638379459237234133" xlink:to="epix_EmployeeSharePurchasePlanMember_638379459237234133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638379459237234133" xlink:to="epix_StockOptionPlanMember_638379459237234133" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237224134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237234133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237234133" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638379459237234133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638379459237234133" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638379459237234133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638379459237234133" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638379459237234133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638379459237234133" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638379459237234133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638379459237234133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638379459237234133" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638379459237234133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40904 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638379459237244132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638379459237244132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459237244132" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638379459237244132" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383794592372441321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383794592372441321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638379459237244132" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638379459237244132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638379459237244132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638379459237244132" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638379459237244132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638379459237244132" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638379459237254133" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638379459237244132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638379459237254133" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237254133" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237254133" xlink:to="us-gaap_SubsequentEventTypeAxis_638379459237254133" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638379459237254133" xlink:to="us-gaap_SubsequentEventTypeDomain_638379459237254133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638379459237254133" xlink:to="us-gaap_SubsequentEventMember_638379459237254133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237254133" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638379459237254133" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638379459237254133" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceOneInUsdMember" xlink:label="epix_ExercisePriceOneInUsdMember_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceOneInUsdMember_638379459237254133" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.70Member" xlink:label="epix_ExercisePrice2.70Member_638379459237254133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePrice2.70Member_638379459237254133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.71Member" xlink:label="epix_ExercisePrice2.71Member_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePrice2.71Member_638379459237264133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.91Member" xlink:label="epix_ExercisePrice2.91Member_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePrice2.91Member_638379459237264133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice2.97Member" xlink:label="epix_ExercisePrice2.97Member_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePrice2.97Member_638379459237264133" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePrice3.05Member" xlink:label="epix_ExercisePrice3.05Member_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePrice3.05Member_638379459237264133" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwoInUsdMember" xlink:label="epix_ExercisePriceTwoInUsdMember_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceTwoInUsdMember_638379459237264133" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceThreeInUsdMember" xlink:label="epix_ExercisePriceThreeInUsdMember_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceThreeInUsdMember_638379459237264133" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFourInUsdMember" xlink:label="epix_ExercisePriceFourInUsdMember_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceFourInUsdMember_638379459237264133" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFifteenMember" xlink:label="epix_ExercisePriceFifteenMember_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceFifteenMember_638379459237264133" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFiveInUsdMember" xlink:label="epix_ExercisePriceFiveInUsdMember_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceFiveInUsdMember_638379459237264133" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceSixInUsdMember" xlink:label="epix_ExercisePriceSixInUsdMember_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceSixInUsdMember_638379459237264133" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceSevenInUsdMember" xlink:label="epix_ExercisePriceSevenInUsdMember_638379459237264133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceSevenInUsdMember_638379459237264133" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceEightInUsdMember" xlink:label="epix_ExercisePriceEightInUsdMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceEightInUsdMember_638379459237274133" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceNineInUsdMember" xlink:label="epix_ExercisePriceNineInUsdMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceNineInUsdMember_638379459237274133" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTenInUsdMember" xlink:label="epix_ExercisePriceTenInUsdMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceTenInUsdMember_638379459237274133" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceElevenInUsdMember" xlink:label="epix_ExercisePriceElevenInUsdMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceElevenInUsdMember_638379459237274133" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwelveInUsdMember" xlink:label="epix_ExercisePriceTwelveInUsdMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceTwelveInUsdMember_638379459237274133" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceThirteenInUsdMember" xlink:label="epix_ExercisePriceThirteenInUsdMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceThirteenInUsdMember_638379459237274133" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceFourteenInUsdMember" xlink:label="epix_ExercisePriceFourteenInUsdMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceFourteenInUsdMember_638379459237274133" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceOneInCadMember" xlink:label="epix_ExercisePriceOneInCadMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceOneInCadMember_638379459237274133" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ExercisePriceTwoInCadMember" xlink:label="epix_ExercisePriceTwoInCadMember_638379459237274133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638379459237254133" xlink:to="epix_ExercisePriceTwoInCadMember_638379459237274133" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237284134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237254133" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237284134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638379459237284134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237284134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638379459237284134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638379459237284134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237284134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638379459237284134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638379459237284134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237284134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638379459237284134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber" xlink:label="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber_638379459237284134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237284134" xlink:to="epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber_638379459237284134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459237284134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237284134" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459237284134" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" xlink:type="extended" xlink:title="40906 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_638379459237294136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_638379459237294136" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638379459237294136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightExpired" xlink:label="epix_ClassOfWarrantOrRightExpired_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_638379459237294136" xlink:to="epix_ClassOfWarrantOrRightExpired_638379459237294136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6383794592372941361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_638379459237294136" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6383794592372941361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_638379459237294136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_638379459237294136" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638379459237294136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_638379459237294136" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_638379459237294136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6383794592372941361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_638379459237294136" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6383794592372941361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40907 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237294136" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638379459237294136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237294136" xlink:to="us-gaap_SubsequentEventTypeAxis_638379459237294136" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638379459237294136" xlink:to="us-gaap_SubsequentEventTypeDomain_638379459237304130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638379459237304130" xlink:to="us-gaap_SubsequentEventMember_638379459237304130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237294136" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638379459237304130" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638379459237304130" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638379459237304130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WarrantsExercisePriceTwoMember" xlink:label="epix_WarrantsExercisePriceTwoMember_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638379459237304130" xlink:to="epix_WarrantsExercisePriceTwoMember_638379459237304130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WarrantsExercisePriceFiveMember" xlink:label="epix_WarrantsExercisePriceFiveMember_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638379459237304130" xlink:to="epix_WarrantsExercisePriceFiveMember_638379459237304130" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638379459237294136" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237304130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237304130" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638379459237304130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237304130" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638379459237304130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237304130" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_638379459237304130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_638379459237304130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638379459237304130" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_638379459237304130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638379459237314132" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638379459237314132" xlink:to="us-gaap_BalanceSheetLocationAxis_638379459237314132" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638379459237314132" xlink:to="us-gaap_BalanceSheetLocationDomain_638379459237314132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638379459237314132" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_638379459237314132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638379459237314132" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638379459237314132" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638379459237314132" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638379459237314132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_638379459237314132" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237314132" xlink:to="srt_OwnershipAxis_638379459237314132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638379459237314132" xlink:to="srt_OwnershipDomain_638379459237314132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember_638379459237314132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638379459237314132" xlink:to="epix_EssaPharmaceuticalsCorpMember_638379459237314132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237314132" xlink:to="us-gaap_StatementLineItems_638379459237324132" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638379459237324132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery" xlink:label="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery_638379459237324132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638379459237324132" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638379459237324132" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_638379459237324132" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_638379459237324132" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638379459237324132" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237324132" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638379459237324132" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638379459237334132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_638379459237334132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="us-gaap_DeferredTaxAssetsInvestments_638379459237334132" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_DeferredTaxAssetsFinancingCosts" xlink:label="epix_DeferredTaxAssetsFinancingCosts_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="epix_DeferredTaxAssetsFinancingCosts_638379459237334132" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638379459237334132" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="us-gaap_DeferredTaxAssetsOther_638379459237334132" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="us-gaap_DeferredTaxAssetsGross_638379459237334132" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638379459237334132" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638379459237324132" xlink:to="us-gaap_DeferredTaxAssetsNet_638379459237334132" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAXES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_638379459237334132" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638379459237334132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237334132" xlink:to="srt_StatementGeographicalAxis_638379459237334132" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638379459237334132" xlink:to="srt_SegmentGeographicalDomain_638379459237344135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638379459237344135" xlink:to="country_US_638379459237344135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237334132" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638379459237344135" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638379459237344135" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638379459237344135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638379459237344135" xlink:to="us-gaap_DomesticCountryMember_638379459237344135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638379459237344135" xlink:to="us-gaap_ForeignCountryMember_638379459237344135" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237334132" xlink:to="us-gaap_StatementLineItems_638379459237344135" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237344135" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638379459237344135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237344135" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638379459237344135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638379459237344135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237344135" xlink:to="us-gaap_OperatingLossCarryforwards_638379459237344135" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid_638379459237354135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_638379459237354135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_FinancialInstrumentsAndRiskAbstract" xlink:label="epix_FinancialInstrumentsAndRiskAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_FinancialInstrumentsAndRiskAbstract" xlink:to="us-gaap_StatementTable_638379459237354135" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237354135" xlink:to="srt_StatementScenarioAxis_638379459237354135" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638379459237354135" xlink:to="srt_ScenarioUnspecifiedDomain_638379459237354135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_TenPercentChangeInForeignExchangeRateMember" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638379459237354135" xlink:to="epix_TenPercentChangeInForeignExchangeRateMember_638379459237354135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638379459237354135" xlink:to="us-gaap_StatementLineItems_638379459237354135" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237354135" xlink:to="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_638379459237354135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_638379459237354135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237354135" xlink:to="us-gaap_CashFDICInsuredAmount_638379459237354135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_WorkingCapital" xlink:label="epix_WorkingCapital_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237354135" xlink:to="epix_WorkingCapital_638379459237364136" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638379459237354135" xlink:to="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_638379459237364136" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - COMMITMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638379459237364136" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638379459237364136" xlink:to="us-gaap_TypeOfArrangementAxis_638379459237364136" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638379459237364136" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237364136" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237364136" xlink:to="epix_LicenseAgreementMember_638379459237364136" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638379459237364136" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638379459237364136" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638379459237364136" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638379459237364136" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638379459237364136" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_638379459237364136" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638379459237364136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638379459237364136" xlink:to="us-gaap_OtherCommitmentsLineItems_638379459237364136" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_MinimumAdvanceRoyaltyPayments" xlink:label="epix_MinimumAdvanceRoyaltyPayments_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237364136" xlink:to="epix_MinimumAdvanceRoyaltyPayments_638379459237374135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestoneToBePaidForFilingOfApplication" xlink:label="epix_AmountOfMilestoneToBePaidForFilingOfApplication_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237364136" xlink:to="epix_AmountOfMilestoneToBePaidForFilingOfApplication_638379459237374135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237364136" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_638379459237374135" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237364136" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial_638379459237374135" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237364136" xlink:to="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_638379459237374135" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_AmountOfMilestonePaymentForFilingOfApplication" xlink:label="epix_AmountOfMilestonePaymentForFilingOfApplication_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237364136" xlink:to="epix_AmountOfMilestonePaymentForFilingOfApplication_638379459237374135" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638379459237374135" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638379459237374135" xlink:to="srt_ProductOrServiceAxis_638379459237374135" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638379459237374135" xlink:to="srt_ProductsAndServicesDomain_638379459237374135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember_638379459237374135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638379459237374135" xlink:to="us-gaap_RoyaltyMember_638379459237374135" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638379459237374135" xlink:to="us-gaap_TypeOfArrangementAxis_638379459237384134" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638379459237384134" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237384134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237384134" xlink:to="epix_LicenseAgreementMember_638379459237384134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LeaseOnCdnOfficeSpacesMember" xlink:label="epix_LeaseOnCdnOfficeSpacesMember_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237384134" xlink:to="epix_LeaseOnCdnOfficeSpacesMember_638379459237384134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_LeaseOnUsOfficeSpacesMember" xlink:label="epix_LeaseOnUsOfficeSpacesMember_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638379459237384134" xlink:to="epix_LeaseOnUsOfficeSpacesMember_638379459237384134" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638379459237374135" xlink:to="us-gaap_OtherCommitmentsLineItems_638379459237384134" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237384134" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_638379459237384134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237384134" xlink:to="us-gaap_ContractualObligationDueInSecondYear_638379459237384134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237384134" xlink:to="us-gaap_ContractualObligationDueInThirdYear_638379459237384134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237384134" xlink:to="us-gaap_ContractualObligationDueInFourthYear_638379459237384134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear_638379459237384134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638379459237384134" xlink:to="us-gaap_ContractualObligationDueInFifthYear_638379459237384134" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638379459237394134" xlink:to="us-gaap_SubsequentEventTypeAxis_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638379459237394134" xlink:to="us-gaap_SubsequentEventTypeDomain_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638379459237394134" xlink:to="us-gaap_SubsequentEventMember_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638379459237394134" xlink:to="us-gaap_StatementEquityComponentsAxis_638379459237394134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638379459237394134" xlink:to="us-gaap_EquityComponentDomain_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638379459237394134" xlink:to="us-gaap_CommonStockMember_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638379459237394134" xlink:to="us-gaap_AwardTypeAxis_638379459237394134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638379459237394134" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionExercisedOneMember" xlink:label="epix_StockOptionExercisedOneMember_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237394134" xlink:to="epix_StockOptionExercisedOneMember_638379459237394134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20230930.xsd#epix_StockOptionExercisedTwoMember" xlink:label="epix_StockOptionExercisedTwoMember_638379459237394134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638379459237394134" xlink:to="epix_StockOptionExercisedTwoMember_638379459237394134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638379459237404141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638379459237394134" xlink:to="us-gaap_SubsequentEventLineItems_638379459237404141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459237404141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638379459237404141" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638379459237404141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638379459237404141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638379459237404141" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638379459237404141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518264544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ESSA Pharma&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1250703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">999 West Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vancouver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V5Z 1K5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">331-0962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_DocumentFinancialStatementErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,142,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001633932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">DAVIDSON & COMPANY LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Vancouver, Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_DocumentFinancialStatementErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_DocumentFinancialStatementErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709516627040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,701,912<span></span>
</td>
<td class="nump">$ 57,076,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 4)</a></td>
<td class="nump">114,374,489<span></span>
</td>
<td class="nump">110,161,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">135,057<span></span>
</td>
<td class="nump">6,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaids (Note 5)</a></td>
<td class="nump">585,420<span></span>
</td>
<td class="nump">1,815,626<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">148,796,878<span></span>
</td>
<td class="nump">169,059,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">257,245<span></span>
</td>
<td class="nump">259,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets (Note 7)</a></td>
<td class="nump">68,008<span></span>
</td>
<td class="nump">186,499<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">149,122,131<span></span>
</td>
<td class="nump">169,505,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities (Note 6)</a></td>
<td class="nump">3,414,743<span></span>
</td>
<td class="nump">2,176,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities (Note 7)</a></td>
<td class="nump">80,328<span></span>
</td>
<td class="nump">133,834<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,495,071<span></span>
</td>
<td class="nump">2,310,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities (Note 7)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,495,071<span></span>
</td>
<td class="nump">2,386,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares 44,100,838 issued and outstanding (September 30, 2022 - 44,073,076) (Note 9)</a></td>
<td class="nump">278,161,537<span></span>
</td>
<td class="nump">278,089,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital (Note 9)</a></td>
<td class="nump">49,047,280<span></span>
</td>
<td class="nump">44,043,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,120,398)<span></span>
</td>
<td class="num">(2,135,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(179,461,359)<span></span>
</td>
<td class="num">(152,879,016)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td>
<td class="nump">145,627,060<span></span>
</td>
<td class="nump">167,118,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 149,122,131<span></span>
</td>
<td class="nump">$ 169,505,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518226176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">44,100,838<span></span>
</td>
<td class="nump">44,073,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">44,100,838<span></span>
</td>
<td class="nump">44,073,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518433264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 21,322,530<span></span>
</td>
<td class="nump">$ 24,415,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_FinancingCosts', window );">Financing costs (Note 7)</a></td>
<td class="nump">6,942<span></span>
</td>
<td class="nump">13,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administration</a></td>
<td class="nump">10,811,574<span></span>
</td>
<td class="nump">12,544,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(32,141,046)<span></span>
</td>
<td class="num">(36,973,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange</a></td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">5,553,774<span></span>
</td>
<td class="nump">1,736,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative liability gain (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss for the year before taxes</a></td>
<td class="num">(26,580,743)<span></span>
</td>
<td class="num">(35,215,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax recovery (expense) (Note 11)</a></td>
<td class="num">(1,600)<span></span>
</td>
<td class="nump">111,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">(26,582,343)<span></span>
</td>
<td class="num">(35,103,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on short-term investments (Note 4)</a></td>
<td class="nump">14,747<span></span>
</td>
<td class="num">(58,666)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Loss and comprehensive loss for the year</a></td>
<td class="num">$ (26,567,596)<span></span>
</td>
<td class="num">$ (35,161,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - Basic (in shares)</a></td>
<td class="nump">44,089,557<span></span>
</td>
<td class="nump">44,038,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding -Diluted (in shares)</a></td>
<td class="nump">44,089,557<span></span>
</td>
<td class="nump">44,038,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_FinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financing costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_FinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518076288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (26,582,343)<span></span>
</td>
<td class="num">$ (35,103,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not affecting cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">118,491<span></span>
</td>
<td class="nump">121,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/(Accretion) of premiums/discounts on short-term investments, net</a></td>
<td class="num">(671,268)<span></span>
</td>
<td class="nump">69,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of lease liability</a></td>
<td class="nump">6,942<span></span>
</td>
<td class="nump">13,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative liability gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Accrued Investment income</a></td>
<td class="nump">374<span></span>
</td>
<td class="num">(189,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange</a></td>
<td class="num">(528)<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payments</a></td>
<td class="nump">5,007,469<span></span>
</td>
<td class="nump">7,888,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(128,846)<span></span>
</td>
<td class="nump">482,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaids</a></td>
<td class="nump">1,232,416<span></span>
</td>
<td class="nump">366,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,235,577<span></span>
</td>
<td class="num">(1,629,065)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,781,716)<span></span>
</td>
<td class="num">(27,999,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(365,203,691)<span></span>
</td>
<td class="num">(296,012,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from short-term investments sold</a></td>
<td class="nump">361,676,542<span></span>
</td>
<td class="nump">242,959,084<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,527,149)<span></span>
</td>
<td class="num">(53,053,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">319,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Shares purchased through employee share purchase plan</a></td>
<td class="nump">68,709<span></span>
</td>
<td class="nump">66,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_OperatingLeasePaymentsFinancingActivities', window );">Lease payments</a></td>
<td class="num">(136,866)<span></span>
</td>
<td class="num">(134,023)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used) provided by financing activities</a></td>
<td class="num">(68,157)<span></span>
</td>
<td class="nump">252,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign exchange on cash and cash equivalents</a></td>
<td class="nump">2,459<span></span>
</td>
<td class="nump">51,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents for the year</a></td>
<td class="num">(23,374,563)<span></span>
</td>
<td class="num">(80,748,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">57,076,475<span></span>
</td>
<td class="nump">137,825,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 33,701,912<span></span>
</td>
<td class="nump">$ 57,076,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeasePaymentsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash flow arising out of lease payments during the period, which are classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeasePaymentsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518433440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 277,415,176<span></span>
</td>
<td class="nump">$ 36,442,620<span></span>
</td>
<td class="num">$ (2,076,479)<span></span>
</td>
<td class="num">$ (117,775,765)<span></span>
</td>
<td class="nump">$ 194,005,552<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, in shares at Sep. 30, 2021</a></td>
<td class="nump">43,984,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 568,854<span></span>
</td>
<td class="num">(249,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">72,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued through employee share purchase plan</a></td>
<td class="nump">$ 105,106<span></span>
</td>
<td class="num">(38,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued through employee share purchase plan, shares</a></td>
<td class="nump">15,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,888,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,888,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Loss and comprehensive loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,666)<span></span>
</td>
<td class="num">(35,103,251)<span></span>
</td>
<td class="num">(35,161,917)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 278,089,136<span></span>
</td>
<td class="nump">44,043,503<span></span>
</td>
<td class="num">(2,135,145)<span></span>
</td>
<td class="num">(152,879,016)<span></span>
</td>
<td class="nump">167,118,478<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, in shares at Sep. 30, 2022</a></td>
<td class="nump">44,073,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued through employee share purchase plan</a></td>
<td class="nump">$ 72,401<span></span>
</td>
<td class="num">(3,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued through employee share purchase plan, shares</a></td>
<td class="nump">27,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,007,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,007,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Loss and comprehensive loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,747<span></span>
</td>
<td class="num">(26,582,343)<span></span>
</td>
<td class="num">(26,567,596)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 278,161,537<span></span>
</td>
<td class="nump">$ 49,047,280<span></span>
</td>
<td class="num">$ (2,120,398)<span></span>
</td>
<td class="num">$ (179,461,359)<span></span>
</td>
<td class="nump">$ 145,627,060<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, in shares at Sep. 30, 2023</a></td>
<td class="nump">44,100,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709526313024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_NatureAndContinuanceOfOperationsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA Pharma&#160;Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the Province of British Columbia on January&#160;6, 2009. The Company&#8217;s head office address is Suite&#160;720&#160;&#8211; 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5. The registered and records office address is Suite 3500, The Stack, 1133 Melville Street, Vancouver, British Columbia, V6E 4E5. The Company is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;EPIX&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has a license to certain patents (the &#8220;NTD Technology&#8221;) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2023, no products are in commercial production or use.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_NatureAndContinuanceOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_NatureAndContinuanceOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709526350720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) on a going concern basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value using the accrual basis of accounting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#8220;$&#8221; are to United States dollars and references to &#8220;C$&#8221; are to Canadian dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Consolidation and Functional Currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Functional Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The functional currency of an entity is the currency of the primary economic environment in which the entity operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The functional currency of the Company and its subsidiary have been determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The liquidation and dissolution process for Realm Therapeutics plc and Realm Therapeutics Inc. were completed as at September 30, 2022. The consolidated financial statements also include the operations of Realm Therapeutics plc and Realm Therapeutics Inc. to the date of dissolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and income taxes. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;9.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709521636048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-term investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s short-term investments consist of guaranteed investment certificates, U.S. treasury securities, corporate debt securities, commercial paper and term deposits with original maturities exceeding three months and less than one year. The investments are carried at fair value plus accrued interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign exchange</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#8217;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8211; quoted prices (unadjusted) in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8211; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;">directly (i.e., as prices) or indirectly (i.e., derived from prices); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8211; inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using level 3 inputs (Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company grants stock options to acquire Common Shares of the Company to directors, officers, employees and consultants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of Common Shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">The Company elected the short-term lease exemption for all leases that qualify; as a result, we will not recognize right-of-use assets or lease liabilities for leases with a term of less than 12 months at inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration. &#160;The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Change in presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, the Company identified a presentation item that required adjustments to be recorded in the historical consolidated statements of cash flows to conform to the presentation required under U.S. GAAP. Interest from short-term investments of $705,020 for the year ended September 30, 2022 has been reclassified from investing activities to operating activities. There were no changes to net loss of the Company or <span style="-sec-ix-hidden:Hidden_ilqp4H9x3UeeSj7zg-kL4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">earnings</span></span> per <span style="-sec-ix-hidden:Hidden_uPwaofhXOUatr_NRDuquTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share</span></span> in the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company believes this reclassification and presentation change in the historical consolidated statement of cash flow for the year ended September 30, 2022 is not material and has reflected this reclassification and presentation change in the comparative period included within these consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709521578576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>SHORT-TERM INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4</b><b style="font-weight:bold;">.&#160;&#160;&#160;&#160;&#160;SHORT-TERM INVESTMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Short-term investments consist of guaranteed investment certificates (&#8220;GICs&#8221;) held at financial institutions purchased in accordance with the Company&#8217;s treasury policy. These GICs and term deposits bear interest at </span><span style="font-size:10pt;">5.15%</span><span style="font-size:10pt;">-</span><span style="font-size:10pt;">5.40%</span><span style="font-size:10pt;"> per annum and have maturities of up to </span><span style="font-size:10pt;">12 months</span><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Short-term investments also consist of U.S. treasury securities, corporate debt securities and commercial paper. The Company has classified these investments as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investment securities as current assets. Those investments with maturity dates of three months or less at the date of purchase are presented as cash equivalents in the accompanying balance sheets. Short-term investments are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss as a component of shareholders&#8217; equity until realized. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_MqSGdzQPEkKOh8Gi7K9I_Q;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;">Accrued</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 72,802,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 301,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 73,061,021</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GICs and Term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,141,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 172,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,313,468</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 113,943,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 473,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 114,374,489</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Kk5qrfMvTE2vUhXl6Q4JEQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;">Accrued</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GICs and Term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89,688,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 90,005,650</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,149,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,149,183</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,034,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,076)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,044,599</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,961,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,961,597</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 109,833,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (58,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 385,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110,161,029</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">As of September 30, 2023, short-term investments have an aggregate fair market value of </span><span style="font-size:9.5pt;">$114.4</span><span style="font-size:9.5pt;"> million (2022 &#8211; </span><span style="font-size:9.5pt;">$110.2</span><span style="font-size:9.5pt;"> million) were in an aggregate gross unrealized loss position of </span><span style="font-size:9.5pt;">$43,248</span><span style="font-size:9.5pt;"> (2022 - </span><span style="font-size:9.5pt;">$58,666</span><span style="font-size:9.5pt;">). The Company considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. These particular investments have been in an unrealized loss position for less than 12 months and it is not more likely than not that the Company will be required to sell any of its securities prior to maturity. Accordingly, </span><span style="font-size:9.5pt;">no</span><span style="font-size:9.5pt;"> allowance for credit losses has been recorded as of September 30, 2023, and </span><span style="font-size:9.5pt;">no</span><span style="font-size:9.5pt;"> realized gains or losses on sales of short-term investments have been recorded through September 30, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709517592208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAIDS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>PREPAIDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_PrepaidExpensesTextBlock', window );">PREPAIDS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;PREPAIDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,611,516</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid CMC and clinical expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 181,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 181,835</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other deposits and prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 378,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,275</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 585,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,815,626</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515643216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,028,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 954,598</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 845,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 807,484</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 540,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 414,483</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,414,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,176,565</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709516601760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>OPERATING LEASE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;OPERATING LEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s operating leases included on the balance sheet are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 308,286</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121,787)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 186,499</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118,491)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 68,008</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 330,970</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,305</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (134,023)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,252</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,942</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (136,866)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ap4efqCYWU2Hbn9_bqvWYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Balance, September&#160;30,&#160;2023</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80,328</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities with expected life of less than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80,328</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities with expected life greater than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company&#8217;s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. At September 30, 2023, the Company&#8217;s incremental borrowing rate was 5.0% and the remaining lease term for the South Francisco office was <span style="-sec-ix-hidden:Hidden_7lRLzzwpXE2PixIFHj_goQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8&#160;months</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion expense of $6,942 (2022 - $13,305) have been recorded in &#8220;financing costs&#8221; in the statement of operations and comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709516603104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;DERIVATIVE LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January&#160;2016, the Company issued, pursuant to a financing, 227,273 warrants (&#8220;Warrants&#8221;) having an exercise price of $66.00 per common share. The holders of the Warrants had the ability to receive a variable number of shares pursuant to exercise terms or receive cash settlement under certain conditions. Pursuant to these conditions, the Warrants were treated as financial liabilities measured at fair value through profit or loss. The Warrants expired unexercised in the year ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valuation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 73.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liquidity discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709526459696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Authorized</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited common shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited preferred shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Omnibus incentive plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 25, 2021, the Company adopted an omnibus incentive plan (&#8220;Omnibus Plan&#8221;) consistent with the policies and rules of Nasdaq. Pursuant to the Omnibus Plan, the Company may issue stock options, share appreciation rights, restricted shares, restricted share units and other share-based awards. As of September 30, 2023, the Company has not issued any instruments other than stock options under the Omnibus Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Prior to the adoption of the Omnibus Plan, the Company issued equity compensation pursuant to the Company&#8217;s amended and restated stock option plan (the &#8220;Legacy Option Plan&#8221;), Amended and Restated Restricted Share Unit Plan (the &#8220;RSU Plan&#8221;) and Employee Stock Purchase Plan. Since the adoption of the Omnibus Plan, no further grants have been made under the Legacy Option Plan or RSU Plan, though existing grants under the Legacy Option Plan will continue in effect in accordance with their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As of September 30, 2023, the Omnibus Plan has a maximum of </span><span style="font-weight:normal;">8,410,907</span><span style="font-weight:normal;"> Common Shares which may be reserved for issuance. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Employee Share Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has adopted an Employee Share Purchase Plan (&#8220;ESPP&#8221;) under which qualifying employees may be granted purchase rights (&#8220;Purchase Rights&#8221;) to the Company&#8217;s Common Shares at not less of 85% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of six-month periods commencing on January&#160;1 and July&#160;1 and ending on June&#160;30 and December&#160;31 of each calendar&#160;year. As at September 30, 2023, the ESPP has a maximum of 208,836 (2022&#160;&#8211;236,598) Common Shares reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $25,000 worth of the Company&#8217;s Common Shares (determined using the lesser of (i)&#160;the market price of a common share on the first day of an applicable purchase period and (ii)&#160;the market price of a common share on the purchase date) for each calendar&#160;year in which a purchase right is outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the&#160;year ended September 30, 2023, the Company issued a total of 27,762 (2022&#160;&#8211;15,820) Common Shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,381</p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,562</p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,943</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of share purchase rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 72.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Legacy Option Plan and Omnibus Plan, options were previously or may be granted, respectively, with expiry terms of up to 10 years, and vesting criteria and periods are approved by the Board at its discretion. The options issued under the Legacy Option Plan and Omnibus Plan are accounted for as equity-settled share-based payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock option transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price*</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,803,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.20</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.55</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72,910)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.41)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (175,759)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.60)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,902,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.13</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.97</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12.27)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,112,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.97</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance exercisable, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,444,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.79</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Options exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">September 30, 2023</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> are translated at current rates to reflect the current weighted average exercise price in U.S. dollars for all outstanding options.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2023, options were outstanding enabling holders to acquire Common Shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 175,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,629,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 910,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 185,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 539,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 190,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,458,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 120,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">13.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 190,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">29.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">31.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 124,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,112,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* 3,500 options expired unexercised and 41,250 options exercised subsequent to September 30, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September 30, 2023, the Company granted a total of 300,000 (2022&#160;&#8211; 1,347,500) stock options with a weighted average fair value of $2.82 per option (2022&#160;&#8211; $3.20).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2023 and 2022 with allocations to its functional expense as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,622,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,306,463</p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,372,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,551,679</p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,995,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,858,142</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 186.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021 and September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,234,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.84</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (307,273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49.86)</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding and exercisable, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,927,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.11</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">At September 30, 2023, warrants were outstanding enabling holders to acquire Common Shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 42.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November&#160;18, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,920,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.0001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;23, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,927,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* 7,477 warrants expired unexercised subsequent to September 30, 2023</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709526459696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Included in accounts payable and accrued liabilities at September 30, 2023, is $98,360 (2022 - $81,225) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709521663184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax rate of 27.0% (2022 &#8211; 27.0%) to the tax expense:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">For the&#160;years ended September&#160;30</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss for the&#160;year before income tax</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,580,743)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,215,072)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax recovery at statutory income tax rates</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,177,000)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,509,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible share-based payments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 643,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 963,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxable capital gains</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences including foreign exchange</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in statutory, foreign tax, foreign exchange rates and other</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,212,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,288,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 325,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 165,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,003,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,007,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_lmzlcV9vjEWol2ZaLP303g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2,000</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGtoKtsILUiP3lfxWLcxPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (111,000)</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tax attributes are subject to review, and potential adjustment, by tax authorities. The Company has recorded an income tax expense of $2,000 for the&#160;year ended September 30, 2023 (2022&#160;recovery of $111,000) in relation to taxable income generated by its U.S. subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the years ended September 30, 2023 and 2022, the Company did not record a provision for income taxes due to a full valuation allowance against our deferred tax assets. The significant components of the Company&#8217;s deferred tax assets that have not been included on the consolidated statement of financial position are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 43,726,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,710,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 77,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 77,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,191,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,026,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal R&amp;D credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (54,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 125,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,179,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40,177,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,179,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,177,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net future tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As at September 30, 2023, the Company has non-capital loss carry-forwards of approximately $90,502,000 (2022 - $87,702,000) available to offset future taxable income in Canada and approximately $91,858,000 (2022 - $66,812,000) available to offset future taxable income in the US. These non-capital loss carryforwards begin to expire in 2031.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518224544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">12.&#160;&#160;&#160;&#160;SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no significant non-cash financing or investing activities during the year ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There were no amounts paid for taxes and interest in the year ended September 30, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518224544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTED INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTED INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13.&#160;&#160;&#160;&#160;SEGMENTED INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company works in one industry being the development of small molecule drugs for prostate cancer. The Company&#8217;s right of use asset is located in the USA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709526459696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_FinancialInstrumentsAndRiskAbstract', window );"><strong>FINANCIAL INSTRUMENTS AND RISK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS AND RISK</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS AND RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using Level 3 inputs (Note 8). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial risk factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s risk exposures and the impact on the Company&#8217;s financial instruments are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. Short-term investments includes investments that may have maturity dates exceeding one year at the date of purchase; however, the Company may liquidate investment positions prior to maturity to implement management strategies. The Company maintains an investment policy which requires certain minimum investment grades over its investment instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023, cash and cash equivalents consisted of cash in Canada and the United States and term deposits in Canada and investments in certain instruments which have a maturity of less than three months at the date of purchase. Balances in cash accounts exceed amounts insured by the Canada Deposit Insurance Corporation for up to C$100,000 and by the Federal Deposit Insurance Corporation for up to $250,000. Amounts due from government agencies are considered to have minimal credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Liquidity risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">As at September 30, 2023, the Company had working capital of $145,301,807 which will fund budgeted operations past the horizon of the coming year. The Company does not generate revenue and will use available financing options when required to pursue its business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Market risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(a)</span>Interest rate risk</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Over the periods presented, the interest rate environment has changed considerably. The Company has elected to place its cash in instruments which provide a return on funds pending deployment to service business objectives (Note 4). The Company monitors its investments against internal investment criteria which prioritize security of principal. While all investments bear some degree of risk, the Company does not consider interest rate fluctuations to have a significant risk to its financial and operational objectives. The Company does not have any interest-bearing debt.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(b)</span>Foreign currency risk</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company&#8217;s foreign currency risk exposure relates to net monetary assets denominated in Canadian dollars and Euro. The Company maintains its cash and cash equivalents in U.S. dollars and converts on an as needed basis to discharge Canadian and Euro denominated expenditures. A 10% change in the foreign exchange rate between the Canadian, Euro and U.S. dollar in relation to Canadian and Euro dollars held at September 30, 2023 would result in a fluctuation of $2,616 in the net loss recognized for the period. The Company does not currently engage in hedging activities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_FinancialInstrumentsAndRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_FinancialInstrumentsAndRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709522515008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;&#160;COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The NTD Technology is held under a license agreement signed in fiscal 2010 (the &#8220;License Agreement&#8221;). As consideration for the License Agreement, the Company issued Common Shares of the Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates annual minimum advance royalty payments of C$85,000. &#160;In addition, there are certain milestone payments for the first compound, to be paid in stages as to C$20,000 upon filing an Investigational New Drug (IND) Application, C$50,000 at the start of a Phase 2 clinical trial, C$900,000 at the start of a Phase 3 clinical trial, C$1,450,000 at application for marketing approval, and with further milestone payments on the second and additional compounds. To date, the Company has paid C$20,000 for filing an IND application for masofaniten (EPI-7386). The next milestone of C$50,000 will be due upon initiation of the Phase 2 clinical trial for masofaniten (EPI-7386).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has the following obligations over the next five&#160;years:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Contractual obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2027</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2028</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minimum annual royalty per License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">85,000</p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on CDN office spaces</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on U.S. office spaces</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Collaborative agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On January 13, 2021, the Company announced a clinical collaboration with Janssen to evaluate masofaniten (EPI-7386) with abiraterone acetate with prednisone as well as the combination of masofaniten (EPI-7386) with apalutamide in patients with mCRPC. Under the terms of the agreement, Janssen may sponsor and conduct up to two Phase 1/2 studies evaluating the safety, tolerability and preliminary efficacy of the combination of </span><span style="font-style:normal;">masofaniten (EPI-7386) </span><span style="font-style:normal;">and apalutamide as well as the combination of masofaniten (EPI-7386) with abiraterone acetate plus prednisone in patients with mCRPC who have failed a current second-generation antiandrogen therapy. Janssen will assume all costs associated with the studies, other than the manufacturing costs associated with the clinical drug supply of masofaniten (EPI-7386). The parties will form a joint oversight committee for the clinical studies. ESSA will retain all rights to masofaniten (EPI-7386). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The combination trial was initiated in March 2022. Enrollment was suspended by Janssen in October 2022 due to operational recruitment challenges. ESSA has announced its intention to revise the collaboration, with ESSA conducting a study of the combinations, potentially in an earlier patient population, and Janssen supplying apalutamide and abiraterone acetate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 25, 2021, the Company announced a clinical collaboration with Astellas Pharma Inc. (&#8220;Astellas&#8221;) to evaluate the combination of masofaniten (EPI-7386) and Astellas/Pfizer&#8217;s androgen receptor inhibitor, enzalutamide, for patients with mCRPC. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of masofaniten (EPI-7386) and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to masofaniten (EPI-7386). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"><span style="font-style:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer Consumer Care AG (&#8220;Bayer&#8221;) to evaluate masofaniten (EPI-7386) in combination with Bayer&#8217;s androgen receptor inhibitor, darolutamide, in patients with mCRPC. &#160;Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of masofaniten (EPI-7386) and darolutamide in mCRPC patients. ESSA will supply masofaniten (EPI-7386) for the trial and will retain all rights to masofaniten (EPI-7386). </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709521565248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;&#160;SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2023, the Company issued 30,000 common shares for stock options exercised for gross proceeds of $96,900.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2023, the Company issued 11,250 common shares for stock options exercised for gross proceeds of CDN$55,925.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518228992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) on a going concern basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value using the accrual basis of accounting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#8220;$&#8221; are to United States dollars and references to &#8220;C$&#8221; are to Canadian dollars.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation and Functional Currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Consolidation and Functional Currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Functional Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The functional currency of an entity is the currency of the primary economic environment in which the entity operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The functional currency of the Company and its subsidiary have been determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The liquidation and dissolution process for Realm Therapeutics plc and Realm Therapeutics Inc. were completed as at September 30, 2022. The consolidated financial statements also include the operations of Realm Therapeutics plc and Realm Therapeutics Inc. to the date of dissolution.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and income taxes. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;9.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515683584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-term investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s short-term investments consist of guaranteed investment certificates, U.S. treasury securities, corporate debt securities, commercial paper and term deposits with original maturities exceeding three months and less than one year. The investments are carried at fair value plus accrued interest.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign exchange</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign exchange</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#8217;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8211; quoted prices (unadjusted) in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8211; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;">directly (i.e., as prices) or indirectly (i.e., derived from prices); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8211; inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using level 3 inputs (Note 8).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company grants stock options to acquire Common Shares of the Company to directors, officers, employees and consultants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of Common Shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">The Company elected the short-term lease exemption for all leases that qualify; as a result, we will not recognize right-of-use assets or lease liabilities for leases with a term of less than 12 months at inception.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration. &#160;The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently accounting pronouncements adopted and not yet adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Change in presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Change in presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, the Company identified a presentation item that required adjustments to be recorded in the historical consolidated statements of cash flows to conform to the presentation required under U.S. GAAP. Interest from short-term investments of $705,020 for the year ended September 30, 2022 has been reclassified from investing activities to operating activities. There were no changes to net loss of the Company or <span style="-sec-ix-hidden:Hidden_ilqp4H9x3UeeSj7zg-kL4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">earnings</span></span> per <span style="-sec-ix-hidden:Hidden_uPwaofhXOUatr_NRDuquTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share</span></span> in the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company believes this reclassification and presentation change in the historical consolidated statement of cash flow for the year ended September 30, 2022 is not material and has reflected this reclassification and presentation change in the comparative period included within these consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709523224224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock', window );">Schedule of Functional Currency of Company and its Subsidiaries</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the functional currency and effective interest in subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709522448528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>SHORT-TERM INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of available for sale securities reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_MqSGdzQPEkKOh8Gi7K9I_Q;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;">Accrued</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 72,802,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 301,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 73,061,021</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GICs and Term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,141,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 172,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,313,468</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 113,943,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 473,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 114,374,489</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Kk5qrfMvTE2vUhXl6Q4JEQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;">Accrued</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GICs and Term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89,688,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 90,005,650</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,149,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,590)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,149,183</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,034,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,076)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,044,599</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,961,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,961,597</p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 109,833,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (58,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 385,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110,161,029</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709615107360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAIDS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>PREPAIDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ScheduleOfPrepaidExpensesTableTextBlock', window );">Schedule of Prepaid Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,611,516</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid CMC and clinical expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 181,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 181,835</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other deposits and prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 378,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,275</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 585,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,815,626</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709521742352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,028,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 954,598</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 845,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 807,484</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 540,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 414,483</p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,414,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,176,565</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709521663952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>OPERATING LEASE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 308,286</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121,787)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 186,499</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118,491)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 68,008</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 330,970</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,305</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (134,023)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,252</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,942</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (136,866)</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ap4efqCYWU2Hbn9_bqvWYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Balance, September&#160;30,&#160;2023</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80,328</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities with expected life of less than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80,328</p></td></tr><tr><td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities with expected life greater than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of operating lease related assets and liabilities and other related information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518572048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 73.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liquidity discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709517575616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock option transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price*</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,803,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.20</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.55</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72,910)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.41)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (175,759)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.60)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,902,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.13</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.97</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12.27)</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,112,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.97</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance exercisable, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,444,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.79</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Options exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">September 30, 2023</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> are translated at current rates to reflect the current weighted average exercise price in U.S. dollars for all outstanding options.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock Option Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2023, options were outstanding enabling holders to acquire Common Shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 175,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,629,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 910,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 185,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 539,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 190,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,458,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 120,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">13.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 190,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">29.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">31.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">4.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 124,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,112,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* 3,500 options expired unexercised and 41,250 options exercised subsequent to September 30, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021 and September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,234,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.84</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (307,273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49.86)</p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding and exercisable, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,927,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.11</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock', window );">Summary of Warrants Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">At September 30, 2023, warrants were outstanding enabling holders to acquire Common Shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 42.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November&#160;18, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,920,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.0001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;23, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:46.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,927,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* 7,477 warrants expired unexercised subsequent to September 30, 2023</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the&#160;year ended September 30, 2023, the Company issued a total of 27,762 (2022&#160;&#8211;15,820) Common Shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,381</p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,562</p></td></tr><tr><td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,943</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions for the Valuation of Stock Options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of share purchase rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 72.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2023 and 2022 with allocations to its functional expense as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,622,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,306,463</p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,372,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,551,679</p></td></tr><tr><td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,995,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,858,142</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions for the Valuation of Stock Options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 186.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709525133632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Taxes at Statutory Rates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">For the&#160;years ended September&#160;30</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss for the&#160;year before income tax</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,580,743)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,215,072)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax recovery at statutory income tax rates</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,177,000)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,509,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible share-based payments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 643,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 963,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxable capital gains</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences including foreign exchange</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in statutory, foreign tax, foreign exchange rates and other</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,212,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,288,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 325,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 165,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,003,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,007,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_lmzlcV9vjEWol2ZaLP303g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2,000</span></span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_hGtoKtsILUiP3lfxWLcxPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (111,000)</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Future Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating losses carried forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 43,726,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,710,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 77,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 77,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,191,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,026,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal R&amp;D credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 210,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (54,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 125,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,179,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40,177,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,179,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,177,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net future tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709521590880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Contractual obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2027</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2028</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minimum annual royalty per License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">85,000</p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on CDN office spaces</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on U.S. office spaces</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709526260032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember', window );">ESSA Pharmaceuticals Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_PercentageOfEffectiveInterestInSubsidiaries', window );">Effective interest</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PercentageOfEffectiveInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of effective interest in subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PercentageOfEffectiveInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515907984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">$ (26,582,343)<span></span>
</td>
<td class="num">$ (35,103,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_OperatingInterestIncomeOfShortTermInvestments', window );">Interest from short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingInterestIncomeOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating interest income of short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingInterestIncomeOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515674624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Narrative) (Details) - GICs and Term deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Guaranteed investment certificates, interest rate</a></td>
<td class="nump">5.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Guaranteed investment certificates, interest rate</a></td>
<td class="nump">5.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ShortTermInvestmentsMaturityTerm', window );">Guaranteed investment certificates, maturity term</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ShortTermInvestmentsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term investments maturity term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ShortTermInvestmentsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=epix_GuaranteedInvestmentCertificatesAndTermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=epix_GuaranteedInvestmentCertificatesAndTermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518531456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS - Realized gains and losses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 113,943,845<span></span>
</td>
<td class="nump">$ 109,833,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(43,248)<span></span>
</td>
<td class="num">(58,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued Investment Income</a></td>
<td class="nump">$ 473,892<span></span>
</td>
<td class="nump">$ 385,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList', window );">Accrued Investment Income - extensible enumeration</a></td>
<td class="text">Short-term investments (Note 4)<span></span>
</td>
<td class="text">Short-term investments (Note 4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 114,374,489<span></span>
</td>
<td class="nump">$ 110,161,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Unrealized loss position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gains or losses on sales of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=epix_GuaranteedInvestmentCertificatesAndTermDepositsMember', window );">GICs and Term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">41,141,314<span></span>
</td>
<td class="nump">89,688,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued Investment Income</a></td>
<td class="nump">172,154<span></span>
</td>
<td class="nump">316,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">41,313,468<span></span>
</td>
<td class="nump">90,005,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">72,802,531<span></span>
</td>
<td class="nump">11,149,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(43,248)<span></span>
</td>
<td class="num">(39,590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued Investment Income</a></td>
<td class="nump">301,738<span></span>
</td>
<td class="nump">39,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 73,061,021<span></span>
</td>
<td class="nump">11,149,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued Investment Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,044,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,961,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,961,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=epix_GuaranteedInvestmentCertificatesAndTermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=epix_GuaranteedInvestmentCertificatesAndTermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709517522736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAIDS (Schedule of Prepaid Expenses) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>PREPAIDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 24,839<span></span>
</td>
<td class="nump">$ 1,611,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits', window );">Prepaid CMC and clinical expenses and deposits</a></td>
<td class="nump">181,835<span></span>
</td>
<td class="nump">181,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Other deposits and prepaid expenses</a></td>
<td class="nump">378,746<span></span>
</td>
<td class="nump">22,275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Balance, end of year</a></td>
<td class="nump">$ 585,420<span></span>
</td>
<td class="nump">$ 1,815,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid preclinical and clinical expenses and deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515674208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 2,028,265<span></span>
</td>
<td class="nump">$ 954,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">845,730<span></span>
</td>
<td class="nump">807,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">540,748<span></span>
</td>
<td class="nump">414,483<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Balance, end of year</a></td>
<td class="nump">$ 3,414,743<span></span>
</td>
<td class="nump">$ 2,176,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515729088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Schedule of Operating Leases) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward', window );"><strong>Increase (Decrease) in Operating Lease, Right-of-Use Asset [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Balance, at beginning of the period</a></td>
<td class="nump">$ 186,499<span></span>
</td>
<td class="nump">$ 308,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization</a></td>
<td class="num">(118,491)<span></span>
</td>
<td class="num">(121,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Balance, at end of the period</a></td>
<td class="nump">68,008<span></span>
</td>
<td class="nump">186,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward', window );"><strong>Increase (Decrease) in Operating Lease Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Balance, at beginning of the period</a></td>
<td class="nump">$ 210,252<span></span>
</td>
<td class="nump">330,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Operating lease liabilities with expected life of less than one year, Operating lease liabilities with expected life greater than one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAccretionExpenses', window );">Accretion</a></td>
<td class="nump">$ 6,942<span></span>
</td>
<td class="nump">13,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="num">(136,866)<span></span>
</td>
<td class="num">(134,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Balance, at end of the period</a></td>
<td class="nump">80,328<span></span>
</td>
<td class="nump">210,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities with expected life of less than one year</a></td>
<td class="nump">80,328<span></span>
</td>
<td class="nump">133,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities with expected life greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward', window );"><strong>Increase (Decrease) in Operating Lease Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAccretionExpenses', window );">Accretion</a></td>
<td class="nump">$ 6,942<span></span>
</td>
<td class="nump">$ 13,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseLiabilitiesAccretionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion expense on operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseLiabilitiesAccretionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709514979088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAccretionExpenses', window );">Accretion expense</a></td>
<td class="nump">$ 6,942<span></span>
</td>
<td class="nump">$ 13,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_SouthSanFranciscoOfficeMember', window );">South San Francisco Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAccretionExpenses', window );">Accretion expense</a></td>
<td class="nump">$ 6,942<span></span>
</td>
<td class="nump">$ 13,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseLiabilitiesAccretionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion expense on operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseLiabilitiesAccretionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_SouthSanFranciscoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_SouthSanFranciscoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518387712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Narrative) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">227,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 66.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515907744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details) - Weighted Average [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0.0355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Life (in Years) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Annualized Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0.733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Liquidity Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709516625984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,347,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">27,762<span></span>
</td>
<td class="nump">15,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_PurchaseRightsOfferingTerm', window );">Offering term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan', window );">Maximum eligibility to Common Shares amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=epix_StockOptionsAndRsuPlanMember', window );">Stock Options and RSU Plan [Member] | Legacy Option Plan And RSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price percentage of Common Shares granted</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Shares reserved for issuance</a></td>
<td class="nump">208,836<span></span>
</td>
<td class="nump">236,598<span></span>
</td>
<td class="nump">208,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage', window );">Employee contribution percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Options and RSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Shares reserved for issuance</a></td>
<td class="nump">8,410,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,410,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of contribution by each employee to employee share purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common share each employee is eligible under employee share purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PurchaseRightsOfferingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of purchase rights offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PurchaseRightsOfferingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=epix_StockOptionsAndRsuPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=epix_StockOptionsAndRsuPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_LegacyOptionPlanAndRsuPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_LegacyOptionPlanAndRsuPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709516492896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">$ 11,548<span></span>
</td>
<td class="nump">$ 29,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">4,517<span></span>
</td>
<td class="nump">16,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member] | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">7,031<span></span>
</td>
<td class="nump">13,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">4,995,921<span></span>
</td>
<td class="nump">7,858,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">2,622,987<span></span>
</td>
<td class="nump">4,306,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member] | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">$ 2,372,934<span></span>
</td>
<td class="nump">$ 3,551,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518379312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">0.94%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of share purchase options</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annualized volatility</a></td>
<td class="nump">72.45%<span></span>
</td>
<td class="nump">89.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.78%<span></span>
</td>
<td class="nump">2.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of share purchase options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annualized volatility</a></td>
<td class="nump">186.50%<span></span>
</td>
<td class="nump">79.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515657824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Summary of Stock Option Activity) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">7,902,061<span></span>
</td>
<td class="nump">6,803,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,347,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options expired/forfeited (in shares) | shares</a></td>
<td class="num">(89,287)<span></span>
</td>
<td class="num">(175,759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">8,112,774<span></span>
</td>
<td class="nump">7,902,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance exercisable (in shares) | shares</a></td>
<td class="nump">6,444,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.97<span></span>
</td>
<td class="nump">4.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired/forfeited (in dollars per share) | $ / shares</a></td>
<td class="num">(12.27)<span></span>
</td>
<td class="num">(3.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">4.97<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709510999200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,112,774<span></span>
</td>
<td class="nump">7,902,061<span></span>
</td>
<td class="nump">8,112,774<span></span>
</td>
<td class="nump">6,803,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInUsdMember', window );">Exercise Price $2.39 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.70Member', window );">Exercise Price $2.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.71Member', window );">Exercise Price $2.71 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.91Member', window );">Exercise Price $2.91 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.97Member', window );">Exercise Price $2.97 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice3.05Member', window );">Exercise Price $3.05 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInUsdMember', window );">Exercise Price $3.23 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThreeInUsdMember', window );">Exercise Price $3.59 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourInUsdMember', window );">Exercise Price $3.60 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFifteenMember', window );">Exercise Price $3.75 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFiveInUsdMember', window );">Exercise Price $3.81 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSixInUsdMember', window );">Exercise Price $4.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSevenInUsdMember', window );">Exercise Price $4.67 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceEightInUsdMember', window );">Exercise Price $5.99 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceNineInUsdMember', window );">Exercise Price $7.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTenInUsdMember', window );">Exercise Price $8.47 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceElevenInUsdMember', window );">Exercise Price $9.76 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwelveInUsdMember', window );">Exercise Price $13.96 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThirteenInUsdMember', window );">Exercise Price $29.63 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourteenInUsdMember', window );">Exercise Price $31.62 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInCadMember', window );">Exercise Price C$4.90 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInCadMember', window );">Exercise Price C$5.06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber', window );">Options expired unexercised</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">41,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No of shares options exercised unexpired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.70Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.70Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.91Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.91Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.97Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice2.97Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice3.05Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePrice3.05Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThreeInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThreeInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFiveInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFiveInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSixInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSixInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSevenInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSevenInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceEightInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceEightInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceNineInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceNineInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTenInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTenInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceElevenInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceElevenInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwelveInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwelveInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThirteenInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThirteenInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourteenInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourteenInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInCadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInCadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInCadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInCadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709515669632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Summary of Warrants Activity) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Beginning balance (in shares) | shares</a></td>
<td class="nump">3,234,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares) | shares</a></td>
<td class="num">(307,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Ending balance (in shares) | shares</a></td>
<td class="nump">2,927,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Beginning balance (in dollar per share) | $ / shares</a></td>
<td class="nump">$ 4.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired', window );">Weighted average exercise price, warrants expired (in dollar per share) | $ / shares</a></td>
<td class="num">(49.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Ending balance (in dollar per share) | $ / shares</a></td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrant or rights expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518536816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,927,477<span></span>
</td>
<td class="nump">3,234,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceTwoMember', window );">Warrants Exercise Price $42.80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 18,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceFiveMember', window );">Warrants Exercise Price $0.0001 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 23,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Warrants Exercise Price $42.80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants Expired</a></td>
<td class="nump">7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518341504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 98,360<span></span>
</td>
<td class="nump">$ 81,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518293120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss for the year before income tax</a></td>
<td class="num">$ (26,580,743)<span></span>
</td>
<td class="num">$ (35,215,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery', window );">Tax recovery at statutory income tax rates</a></td>
<td class="num">(7,177,000)<span></span>
</td>
<td class="num">(9,509,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible share-based payments</a></td>
<td class="nump">643,000<span></span>
</td>
<td class="nump">963,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences including foreign exchange</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Change in statutory, foreign tax, foreign exchange rates and other</a></td>
<td class="nump">1,212,000<span></span>
</td>
<td class="nump">1,288,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">5,003,000<span></span>
</td>
<td class="nump">7,007,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="num">(111,821)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember', window );">ESSA Pharmaceuticals Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="num">$ (111,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expected income tax recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709519656816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Significant Components of Future Tax Assets) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating losses carried forward</a></td>
<td class="nump">$ 43,726,000<span></span>
</td>
<td class="nump">$ 37,710,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_DeferredTaxAssetsEquipmentAndIntangibleAssets', window );">Equipment and intangible assets</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment tax credits</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_DeferredTaxAssetsFinancingCosts', window );">Financing costs</a></td>
<td class="nump">1,191,000<span></span>
</td>
<td class="nump">2,026,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal R&amp;D credit</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross future tax assets</a></td>
<td class="nump">45,179,000<span></span>
</td>
<td class="nump">40,177,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(45,179,000)<span></span>
</td>
<td class="num">(40,177,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net future tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_DeferredTaxAssetsEquipmentAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equipment and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_DeferredTaxAssetsEquipmentAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_DeferredTaxAssetsFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_DeferredTaxAssetsFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709514902256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">General corporate income tax rate</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (recovery) expense</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="num">$ (111,821)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Non-capital loss carry-forwards</a></td>
<td class="nump">90,502,000<span></span>
</td>
<td class="nump">87,702,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Us</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Non-capital loss carry-forwards</a></td>
<td class="nump">$ 91,858,000<span></span>
</td>
<td class="nump">$ 66,812,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709514918512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Amount paid for taxes and interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709528134512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTED INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of industries</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709517462944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details) - 12 months ended Sep. 30, 2023<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CAD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_CashCanadaDepositInsuranceCorporationInsuredAmount', window );">Cash, CDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_WorkingCapital', window );">Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,301,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=epix_TenPercentChangeInForeignExchangeRateMember', window );">10% Change in Foreign Exchange Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate', window );">Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</a></td>
<td class="num">$ (2,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_CashCanadaDepositInsuranceCorporationInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Canada Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_CashCanadaDepositInsuranceCorporationInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_TenPercentChangeInForeignExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_TenPercentChangeInForeignExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709519662576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Narrative) (Details) - License Agreement [Member] - Technology-based intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>CAD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_MinimumAdvanceRoyaltyPayments', window );">Minimum advance royalty payments</a></td>
<td class="nump">$ 85,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_AmountOfMilestoneToBePaidForFilingOfApplication', window );">Milestone payment to be paid upon filing an Investigational New Drug (IND) Application.</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial', window );">Milestone payment to be made at the start of a Phase II clinical trial</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial', window );">Milestone payment to be made at the start of a Phase III clinical trial</a></td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval', window );">Milestone payment to be made at application for marketing approval, and with further milestone payments on the second and additional compounds</a></td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_epix_AmountOfMilestonePaymentForFilingOfApplication', window );">Amount of milestone payment made for filing an Investigational New Drug (IND) Application.</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestonePaymentForFilingOfApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments made for filing the Investigational New Drug (IND) Application.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestonePaymentForFilingOfApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments made at application for marketing approval and with further milestone payments on the second and additional compounds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment to be made at the start of the Phase II clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments to be made at the start of a Phase III clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestoneToBePaidForFilingOfApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments to be paid upon filing an Investigational New Drug (IND) Application.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestoneToBePaidForFilingOfApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_MinimumAdvanceRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents amount of minimum annual royalty payments per annum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_MinimumAdvanceRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709518546560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS (Schedule of Contractual Obligations) (Details) - Sep. 30, 2023<br></strong></div></th>
<th class="th"><div>CAD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=epix_LeaseOnCdnOfficeSpacesMember', window );">Lease on CDN office spaces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 76,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=epix_LeaseOnUsOfficeSpacesMember', window );">Lease on US Office Spaces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2027</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2028</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_LeaseOnCdnOfficeSpacesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_LeaseOnCdnOfficeSpacesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_LeaseOnUsOfficeSpacesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_LeaseOnUsOfficeSpacesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140709519635984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 319,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Common Shares | Stock Option Exercised One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from stock options exercised | $</a></td>
<td class="nump">$ 96,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Common Shares | Stock Option Exercised Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">11,250<span></span>
</td>
<td class="nump">11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=epix_StockOptionExercisedOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=epix_StockOptionExercisedOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=epix_StockOptionExercisedTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=epix_StockOptionExercisedTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>tmb-20230930x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:epix="http://www.essapharma.com/20230930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20230930.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JDmOjRguN0Kdzie1u0Eb5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAmkRE0UfkGBBqBYDyrB1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1GvOZDpc9kurwGwIRX7X8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cE_1p24JbUqJ-xoUjPgBNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_u3RWCPRxEkqwJwigyugqLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dSbYsOwpaE63kePh-8jz7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_33a8zsLaSk-B2UKpI6UonA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_95yfEfIrOESDv0CcRLcCrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iAza1BQ9g06mhs6rTWFHOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YGXbKtAO4kKDSY4O_EsLzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0AhVVm9dOU2bAEoDagZNuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U1nHSjU-9kq6alVsVAiXcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GZadl9A4R0-GCOCxiuNSXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_XLCr0Xj6H0aNDrwxKDqxqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_pWlgE-YtkE6a1ceHbsbCoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_1IKX4UL6x02-V0ZkVdX6ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_9BP0mMLtwUiCKPlTHk1SXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwelveInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_x5J0Bj22GkOSTsuWEuiR0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_iM029G27tEWSaBRh7eMCuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThirteenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_BVOK3SHXX0WbRyp5MK4RKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_KjLjZYnxOUW1bHNr8qUGxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_nTVq80JJdEeConndZT7hnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7PhtjQKMu0GtgpMqe-anoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_eNYFrBUgOkyeap6Drvlcbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_Z8RH8VRQakCIZEbIjDEjqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_39z0JsHALEOoxiU3ve-ryw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourteenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_KJWT3GdVH0q0Ytfdkc7bPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_H2lt2rM4EkuRKpzFCmU7bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_r_BXr9FtnkCrKXKU8xDMqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_r5PTgGJDcU29voLTSfqxHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceElevenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_cFCRxahqm0OO2m5OxSVtkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_NQ4IZZb2JUG6Ggr4NZOxqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice3.05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_tqxeOLNwukiNCCAewkMiEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.97Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_nFQt8T1RlESSnCiqvgcN4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.91Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_b7SS3eXxTkaoqtw4IRnCyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_leH9ftDSCk-54cm_qblTEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.70Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_bjAYITQVzEWC4LdXfX0KSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_oph37iD120e84jRRKFEFfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_sGuewVdd5Ei7shCy53nuBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwelveInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_tvAsNHy91UG6aiTxFG9cZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_NJOZ1OzFSkq8Ovbj3UzvyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThirteenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_CiW6XcCB7EaHNCJu_Aq1Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_BBOSnkAiwUSXe9gvqshK1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hvdIRMII4U2RBEiyYCqbEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_lVjeFiQ6Ekm7fjJ6XoNSrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_FP7VhhSK3kiyjwb8KXwCug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_arlI8eyiaUyFxwbf3MAH1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_Pvirta9m-0q0bvKX6IdX9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourteenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_1m2P4O_uf06H8eYherHW9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_ovkHbXBRKkiZP-tc8tH0CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_Mju67xWeg0qPdkvGo74miQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_m_PpxKgTgEO101iOVrfx0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceElevenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_45YEp4T3rkaRbQZc8sGXeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_O7Jrtq6Zy0mI4nNJSzPGZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice3.05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_vIjORgSPqUiUIc9dMJFfFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.97Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_zjWTpjhz5Emw7U-GDyTvbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.91Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_x4LeuRkg3EeVAWxunWBKlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_sRBNs2Bp202TAd85J0t1Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePrice2.70Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_2_25_2021_To_9_30_2023_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_us-gaap_PlanNameAxis_epix_LegacyOptionPlanAndRsuPlanMember_V6OYcw6z4ky5o49UbZ6MnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionsAndRsuPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:LegacyOptionPlanAndRsuPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_12_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hSCrc4kh-k-gCOK-G9Yn7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_n0-uTgmcUUGkCdF3R77kgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kJCtEN0KwUq7roKlGrzIaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionExercisedTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oXvRvCbUM0iIVSZ_bqCa7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionExercisedOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_MIfdcUdEqkGqK0TtOwu9JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ngnJEUWVhEOlVoIyubYBdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_jv1GtGcpZ0q7yIrUUj3bGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_KbenI4q0-UCApoqCAIKAKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthSanFranciscoOfficeMember_q8gTrDswH0qfe_-3oLWeuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">epix:SouthSanFranciscoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember__JFKnEKGe0C4wTHeLj8ODQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_sSMbCtSnJkqpJVr-Lf7Pqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_HocJtCQ_y0aiW3Uavtqtkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:EssaPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_S2NPPkKazEK7p8VCK-q5Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_diQtzC8i2UykHgFa4IJSIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_oBr_-pywIkaEsKV63Ewtww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ZDv0kj75JkKg3GXnXPe5gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_48y5HKDd8Ue6FoNx1ErTJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_THqCoUiZjkanSO4NpVc-KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_cJ--xfd0e0C0p7RyafiWnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LeaseOnUsOfficeSpacesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LeaseOnCdnOfficeSpacesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ilrzsfU4sEeAns69HPYjLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e_uffl0eK0idHCR6gU0Cig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9cT9Z1eluEyoPr8TmVwHZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AeJ9w5KQP0qIzR5IqHQARw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_FyoK9yWXWUCxMbtsqkJzCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionsAndRsuPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6mUYISo1eEmc_-LnuL2s_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6XCUQP7JO0WguT4GQ8sEbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OlXqQixrvUur2aI9T8N3gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_i33tUz0BdkGB-UPAxwqTtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_b-IPqnYNFUuNriL48L7_JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_M3oeDgOQYE6eQpxPLzjyHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_o2_4N6z4yU-LaC4B4CfAIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_eK7QF44Iy0SInRW3V5Ougw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_2u163Nw1DkebtudqKBTvFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_aDqpgEkao0qTgIxFls48UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_iovEoELo8UyztRr2wxqLXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_wcftaJxSUUSWCXQKbpxAPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NNI3v2338EuRZLbwXgovnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_-Af7YkvMXkif21idoG044w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">epix:GuaranteedInvestmentCertificatesAndTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4qyYlMrwq0e0DG3Br4Mq3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:EssaPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_EfgTWfcorki7QNu4wkVtZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">epix:FinancingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_sF7fPbMdqUqvbTzfsfT_8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">epix:FinancingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_uQe42TT11ESmRCITPgf7Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:TenPercentChangeInForeignExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_S5AnpSsXtEG3ZBTgeWIHtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_pgfyxr43aUaS7J3E2ObeeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_11_2023_mMbu45hweUOoQXPnULm7xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Y_z0MYX-vw9EWUytYjOXmUkg">
        <measure>epix:Y</measure>
    </unit>
    <unit id="Unit_Standard_segment_4JNQuy2SFUWBUQBeaKqunQ">
        <measure>epix:segment</measure>
    </unit>
    <unit id="Unit_Divide_CAD_shares_Mjvk30bxUEexejOIshQtIg">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="2"
      id="Hidden_TrZ4lBb27E2A0GuACyi-aw"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="2"
      id="Hidden_a4Wdv5GQfE61kqdTxTzn1w"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">-0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Hidden_7TlkU0AO20-Mh4JJyOiT2w"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44089557</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Hidden_P17FVeHfbECjABoFyv6khQ"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44038241</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      id="Hidden_ap4efqCYWU2Hbn9_bqvWYg">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Hidden_lmzlcV9vjEWol2ZaLP303g"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Hidden_hGtoKtsILUiP3lfxWLcxPg"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-111821</us-gaap:IncomeTaxExpenseBenefit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_iGTcOO9sPUezKHfYpeV3Bg_2_1">0001633932</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_C3ds3pMhaUqBEvelJWWc6g_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_jDhp5s_xEECqj_5wP52BIg_6_1">false</dei:AmendmentFlag>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      id="Hidden_MqSGdzQPEkKOh8Gi7K9I_Q">http://fasb.org/us-gaap/2022#ShortTermInvestments</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      id="Hidden_Kk5qrfMvTE2vUhXl6Q4JEQ">http://fasb.org/us-gaap/2022#ShortTermInvestments</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="INF"
      id="Hidden_89-NsoVFH0O_N3itcj9uow"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44073076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="INF"
      id="Hidden_HkEK9MjWyUuH6gbj3DHx6g"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44100838</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthSanFranciscoOfficeMember_q8gTrDswH0qfe_-3oLWeuA"
      id="Hidden_7lRLzzwpXE2PixIFHj_goQ">P8M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug"
      decimals="2"
      id="Hidden_ilqp4H9x3UeeSj7zg-kL4w"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug"
      decimals="2"
      id="Hidden_uPwaofhXOUatr_NRDuquTg"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">0.00</us-gaap:EarningsPerShareDiluted>
    <dei:DocumentType
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_FeNMywVaU02dNGLmtpc0Iw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_KPrpPx0j7kiMbOUnQCCZ2Q">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_a61tDkpvj0WuWKcGAN-w7A">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_RwmOim86aEikJSf8rVHAhg">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_nOg9PYe5WkOsg95rbKRBOg">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_NlVmUSP54UiDWq42wdGGrA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_w5kEHuaBKkySzXlr9Nv4Kw">001-37410</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_o3KvpwbapkKSybNWmCMydw">ESSA Pharma&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_SsczzQXtPUKbWRRT1nQlzQ">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_zPxJX4JaN0yCcYkiUdp20w">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_gzY5SJFfqUCe8pA1cZyDCA_1_1">98-1250703</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_kcE2MGqqoEKAlOmOzVujdw">Suite 720</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_KDkxsiXrQkCEqAbmO841lQ">999 West Broadway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_Uj3sUdyA40-5T99lf4M8yg">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_uBy7OwduaE-i9_JtASx3PA">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_WLrFF7JCkEWWdGbWB2FtjQ">V5Z 1K5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_KcBtkjHAGke4H574ugoljg">778</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_wxbkbv9tNUGzqVuD_-I7Og">331-0962</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_6vxGaOnYSUSH6ta6BzYXSQ_2_0">Common Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_wOcr4wspfUaN09ItbdcstA_2_2">EPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_LYocaDNPV0KQGGS2SHvqzA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_5XF9FtYMbUOeO2dlB4sZ8w">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_RMUe0IlqkUS-jqJr8fEnhA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_pAQLpFRpn0atzZl-3gvMUw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_-1CTEsKHRkeZYVbReclWXw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_dwMcQls1WU-oBf_V_fk7Bw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_1CwGW9LLYUCSuqGpQbOTqA_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_9CPSQfESyk-9LTGTxG9A-A_3_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_zlDx2_-NmEGBUx-by2JRUQ">false</dei:IcfrAuditorAttestationFlag>
    <epix:DocumentFinancialStatementErrorCorrectionFlag
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_J9EpuGVQF0izlXXHXiORyA">false</epix:DocumentFinancialStatementErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_XAEErQF8gkqhTk4cbYL1yg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_3_31_2023_pgfyxr43aUaS7J3E2ObeeA"
      decimals="-5"
      id="Narr_Vb_tDBGNrEKco1CxGnn4_Q"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">78800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_11_2023_mMbu45hweUOoQXPnULm7xQ"
      decimals="INF"
      id="Narr_ny9gWW7yVUG_whLBiziAsA"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44142088</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_cxVphLD7j0SOYExZRM2gWA">731</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_Lk0_bpU6fUGyrXJY9J6bTw">DAVIDSON &amp; COMPANY LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Narr_fxytQ5hE8Eii3lc_3jWtZw">Vancouver, Canada</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_YV-MX1Mgzk2Lgf5mmho-UQ_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">33701912</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_OXlE5PRwW0m3tkKJn6r4-w_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">57076475</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_3N1e6JKxiE671c6BiTjsiw_7_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">114374489</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_Ocq-uV0gc0aJDKltWGsaLQ_7_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">110161029</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_MWkZN8Jqg0as9RJ_so_3pg_8_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">135057</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_PfyM3KLqFk27IheWUUczKw_8_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">6211</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_IrmTvOiqj02O0BpoEtu8KA_9_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">585420</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_KE8boZugkU6gFjYs4RQ3GQ_9_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1815626</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_NZtxxy-BhkiwQPY46PTrfg_11_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">148796878</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_nwKrue5gdkiHxvsRTKnmWg_11_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">169059341</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_tBSkTOAPhkOmsRsB4s7j0g_13_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">257245</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_13sTB0pS1EaWwij3E_vw7g_13_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">259455</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_Nfyn0qt2rEyLWnEEji_ELQ_14_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">68008</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_GHXAv5htXkWqGBw7jWPLDA_14_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">186499</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_d_9cevuiFEiKvpoECy57_w_16_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">149122131</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_2RW4F9JznEKyRCyozj9woQ_16_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">169505295</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_usZN87ebFU2FsLGZ-6lbEg_21_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">3414743</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_Nj0L6aO_hEWk_T7AOxsOOQ_21_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2176565</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_CamQWktOSk2Vuw74VYHfCg_22_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">80328</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_KAs-gijJT0egH4z5cGtbjA_22_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">133834</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_16bAMyICzESASw-PkUJdyg_24_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">3495071</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_4x9wUaKjZEam3ALJfggrPw_24_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2310399</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_OI6GR2uXsUSj5R2uMlI1-w_26_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_7pJz5GB2NUGvxTJlXtSSFw_26_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">76418</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_94Z54OS8WkOqXo1j0gGiPw_28_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">3495071</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_fxrMCMcxe0GHqil7QclgBA_28_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2386817</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="INF"
      id="Narr_Y5c6UrmTckOIcy-CpW331w"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44100838</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="INF"
      id="Narr_xP2Uk8sZz0GNrhmznECnuQ"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44073076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_H2Yb9yilfEWTKyZ0BswYAg_34_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">278161537</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_M2inwYoj-UKbdw-1RHmN6A_34_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">278089136</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_7LIoU0HbFEiETSZDavULyQ_35_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">49047280</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_T1_mgO0u1k-wb2TmCC2wxQ_35_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">44043503</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_9x6oeiNS4k-CY12GN25OiA_36_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-2120398</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_q585CLcb3kanl5IWijiohQ_36_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-2135145</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_OcRDsUVrrUKUWwCWC9ALcQ_37_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-179461359</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_JL8-G5HjREWrPttmkFTivw_37_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-152879016</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_0LfhJLzNxEKViK1-o5nYzQ_39_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">145627060</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_ja8mE5o0jkeAunVH40IxBw_39_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">167118478</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_eydg7AsmH0qzTJIObRg2sQ_41_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">149122131</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_9aG7_YTKgUCJStwXGDZiug_41_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">169505295</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_MRHKsU2joEKV3UpcGdBBlg_4_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">21322530</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_9MJPviGEuEWvkvBshuU0mw_4_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">24415246</us-gaap:ResearchAndDevelopmentExpense>
    <epix:FinancingCosts
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_OAyDhZ6-60SZ_rYBoTVbPQ_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">6942</epix:FinancingCosts>
    <epix:FinancingCosts
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_PmHy29vyB0m845rQnifSWQ_5_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">13746</epix:FinancingCosts>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_hhCLTx9uNEaMUWEVDykSkA_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">10811574</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_Dl0X33kcJE-ySEpy1G6CIg_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">12544760</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_V3ttyup_Sk2xT9UhYO_RWw_8_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">32141046</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_Tek0vLzNm0Oe_fvEToslJg_8_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">36973752</us-gaap:OperatingExpenses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_Th_Nbs86zUuUrSuW9RRSSA_10_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">6529</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc__ogGLm31DUODdcWdMATV5A_10_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1687</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_9nh9cIm0akS1xg6u4Y_nUw_11_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">5553774</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_ZUHbWV-QqUmd79PP74289Q_11_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1736641</us-gaap:InterestAndOtherIncome>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_BAG7TqwahUCmBEZYJPrR3g_12_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_GwyDgYJKp0Cqa5WdOD12KQ_12_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">20352</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_MI5B0BzB-k6cGNXjL64icg_14_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-26580743</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_xKkUP_DAGE2awb6CHZ-0zw_14_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-35215072</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_ZI6s_uWBJka7BmciDFYI4w_16_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_f4JBZ1KdU0m6W20EJI13tQ_16_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-111821</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_fXrxH61XwkWAzx3DnWKy1Q_18_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-26582343</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_lBFWaOddS0WfqVPNO0e8lQ_18_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-35103251</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_PVLFlgqNCEegj3A9cotbQQ_21_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">14747</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_TydcJWEHYESTfPuavKB54A_21_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-58666</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_90fEJk6JEUuCLT7mCRlheQ_23_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-26567596</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_ZeAMWuLOREGXluDIAGb1PA_23_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-35161917</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="2"
      id="Tc_4w46MuRmO0a8CQ87GQlmRQ_25_3"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="2"
      id="Tc_aPfYoRbUOkiH_2ihwQXn-Q_25_6"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">-0.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_gxRKiiMpkE6lbCVCSLHyLQ_27_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44089557</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_h0uMJHH5fUqP2U-Iiqpv9w_27_6"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44038241</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_BS0fXrTH8ka7KjQq3J9PjQ_4_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-26582343</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_WXZzPhW5pUmGNKJGbQ66hg_4_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-35103251</us-gaap:ProfitLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_YiDcw_5g3E-j-kvr0oYjTg_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">118491</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_4PpwNfm9qU-zssvv3U_X-g_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">121787</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_cKVRb5bWVkOfhNPFWi3Xkg_7_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">671268</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_DD8FIfESu0uSdWYPYF8GNw_7_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-69653</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_J6w_BPuso06HkqKyZTWYlw_8_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">6942</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_FC0VKoqHiE-IEu8kPGkYjw_8_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">13305</us-gaap:AccretionExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_yoZvg57Ro0mm4w65hb41rQ_9_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_IxWaBw9G5UWoOyZzf52JIA_9_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">20352</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_yBS9LHAEkkenWUi3CWR8rw_10_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-374</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_p7lRLMRPKkeo1LHkuPIY6g_10_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">189213</us-gaap:InvestmentIncomeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_GJuN_5prDECc1WaP3PMBig_11_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">528</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_IhF-cLnh7kyeQGqJAiSxhA_11_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-845</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_BDMfg08dlEq4WEtzbqXG2A_12_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">5007469</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_f38NexbgREaWzlFu_FBFAQ_12_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">7888085</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_u2Qy5q-Fs0qY0xyfethm4Q_15_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">128846</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_48qv4cvtxkOptLqihPz7Ew_15_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-482801</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_A-3XTftIwEWJbGepoRy5wQ_16_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-1232416</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_8_b7kS14IUqpycAAAS5kHQ_16_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-366256</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_VCVKrbCl50KT3ptKsMwgZA_17_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1235577</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_SNIoqeNhtkeP4hvubq0mZA_17_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-1629065</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_zi9GDModREeE3K_B0P6F7A_19_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-19781716</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_Zjxpt251yUe0eoLdRPyfwA_19_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-27999149</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_Nsb_tHpok0yQhyU2Se_JRQ_22_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">365203691</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_y2KterSFoEOLB7G_HHV3sg_22_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">296012498</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_2myFDCbJ4U2VRTeYB7MQ-Q_23_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">361676542</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_2i9RSYRKLk-YTeiqhvpzsA_23_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">242959084</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_k5qxQ5xZ2EWB93OtwhhZtg_25_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-3527149</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_biubL-Yt9km7qGCvupJQGw_25_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-53053414</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_gy-Dd77I0kKwksuGVHBOtg_28_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_CXG5j8tSRkyVgUgETCztrw_28_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">319832</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_NybsPnBvCE-zgt0cNis-GA_29_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">68709</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_7Mc4jVIaIEW857wcQNmfZQ_29_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">66926</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <epix:OperatingLeasePaymentsFinancingActivities
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_3Y0-yDyyWUOQglpTqYlobQ_30_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">136866</epix:OperatingLeasePaymentsFinancingActivities>
    <epix:OperatingLeasePaymentsFinancingActivities
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_25qRWifvyU2GG3Xt3eGPAw_30_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">134023</epix:OperatingLeasePaymentsFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_Or1fQscaYE6XkK0Bj4PWug_32_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-68157</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_zTd67CF8V0emeA-ztgkCIg_32_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">252735</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_dtJTXEhETE2QP0u_lPjtrA_34_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2459</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_ctjKFyu2QkCcTi85BE8EBQ_34_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">51279</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_TbiX-0sxwEiKcUSMfJXwmw_35_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-23374563</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_t8jxsW72K0Spr61ezeyjDA_35_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-80748549</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_kadmN7tBrUevWp-mDCzdQw_36_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">57076475</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ"
      decimals="0"
      id="Tc_teZHVglkjUmn-3utxQWf2g_36_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">137825024</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_9IW6e8Om4kKuSqAkcLTsPw_38_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">33701912</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_XxQq0GXFuEmQKq1m1MNoIA_38_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">57076475</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w"
      decimals="INF"
      id="Tc_eiEJeqNHx0y9uYJilRoiTw_7_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">43984346</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w"
      decimals="0"
      id="Tc_BfGzXkcwckenEpjgcNbDsA_7_5"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">277415176</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YGXbKtAO4kKDSY4O_EsLzw"
      decimals="0"
      id="Tc_udFjEXUpcU6OB6X42J4s7Q_7_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">36442620</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0AhVVm9dOU2bAEoDagZNuQ"
      decimals="0"
      id="Tc_b4s0Apwzm0eBuB9ro5ohlg_7_11"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-2076479</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iAza1BQ9g06mhs6rTWFHOg"
      decimals="0"
      id="Tc_LlU-H19vJUW1ReCMWhWb5g_7_14"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-117775765</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ"
      decimals="0"
      id="Tc_lrWROCa6gk-Ihvp4BbnSJQ_7_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">194005552</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw"
      decimals="INF"
      id="Tc_aYfU9jGkSEKLu6o16PUlqg_8_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">72910</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw"
      decimals="0"
      id="Tc_0ZF_lodnMU-sSjLLbGEeJw_8_5"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">568854</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw"
      decimals="0"
      id="Tc_ZvS2hHtdb0CQdimX61WwHA_8_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-249022</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_QNKcoJKH4Uino4bLN87zaA_8_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">319832</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw"
      decimals="INF"
      id="Tc_-wge2VCcDkaROlWRg71a3A_9_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">15820</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2jnakenDc0i6C0LV-fXVkw"
      decimals="0"
      id="Tc_uVl93BT3PUuEUJbaGyWpyA_9_5"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">105106</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw"
      decimals="0"
      id="Tc_SHqejMynYE2tsPhXx_0ZPw_9_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-38180</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_TCRq0D9oZU6KEHIlXocMWA_9_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">66926</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vX2-URxlvU23fOhP63Wgpw"
      decimals="0"
      id="Tc_o_Chc6-LVU24LO9c-0Mksw_10_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">7888085</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_6yGpMixCBUu74VLQ5g8WGQ_10_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">7888085</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AeJ9w5KQP0qIzR5IqHQARw"
      decimals="0"
      id="Tc_5vyJ3Jzpa0GqPsLnEUDgSw_11_11"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-58666</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9cT9Z1eluEyoPr8TmVwHZA"
      decimals="0"
      id="Tc_959gJ2HXokiH-1PFSgoVEA_11_14"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-35103251</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_TZ9O9RITCEq42VsuzEHI2w_11_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-35161917</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GZadl9A4R0-GCOCxiuNSXQ"
      decimals="INF"
      id="Tc_b1zPhlEQeEeAWScqa3Xf1w_13_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44073076</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GZadl9A4R0-GCOCxiuNSXQ"
      decimals="0"
      id="Tc_kNLH49lJJUm_l3y1HCMfxg_13_5"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">278089136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_33a8zsLaSk-B2UKpI6UonA"
      decimals="0"
      id="Tc_jkwjO-9vrE-AOrZrvwyJSg_13_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">44043503</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_95yfEfIrOESDv0CcRLcCrw"
      decimals="0"
      id="Tc_ZBtMO0UJTU6_-p95lvebnA_13_11"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-2135145</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dSbYsOwpaE63kePh-8jz7Q"
      decimals="0"
      id="Tc_T--6oiEWVEODf8Z9lAfPWQ_13_14"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-152879016</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_gyLXYUcZeUShzxxR12kBSA_13_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">167118478</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAmkRE0UfkGBBqBYDyrB1g"
      decimals="INF"
      id="Tc_sG_YX5fjBk2WycGwYnOKvw_14_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">27762</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAmkRE0UfkGBBqBYDyrB1g"
      decimals="0"
      id="Tc_ZkOjciVM3UCylF_nYVOwyA_14_5"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">72401</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NNI3v2338EuRZLbwXgovnw"
      decimals="0"
      id="Tc_GU70K3JjfkW1MvPf-hxDDw_14_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-3692</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_pKB-jN_9P0qi4xFlEsfZ2Q_14_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">68709</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NNI3v2338EuRZLbwXgovnw"
      decimals="0"
      id="Tc_CR7HBUCGyU2VuSOpSK9W7w_15_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">5007469</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_HVlFF5CACki91_N_l8i4MQ_15_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">5007469</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e_uffl0eK0idHCR6gU0Cig"
      decimals="0"
      id="Tc_q8nKvHnYWk6NK2a66te2ng_16_11"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">14747</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ilrzsfU4sEeAns69HPYjLg"
      decimals="0"
      id="Tc_pf3kofbntkmm46czM-9odw_16_14"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-26582343</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_52WYt9rQ50Kenx-Qs1-fmw_16_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-26567596</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U1nHSjU-9kq6alVsVAiXcQ"
      decimals="INF"
      id="Tc_nnEZDofevU--oCVrUKZp4A_18_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">44100838</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U1nHSjU-9kq6alVsVAiXcQ"
      decimals="0"
      id="Tc_y3htFFlfKkKK00Y93Y1oNw_18_5"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">278161537</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cE_1p24JbUqJ-xoUjPgBNg"
      decimals="0"
      id="Tc_azCoVoCRlUiYiJ6kndtLTg_18_8"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">49047280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_u3RWCPRxEkqwJwigyugqLA"
      decimals="0"
      id="Tc_MtHrLddplkiUr5H9mBqNBg_18_11"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-2120398</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1GvOZDpc9kurwGwIRX7X8A"
      decimals="0"
      id="Tc_xDeWVxhC2UaqblXb3Rq3nQ_18_14"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-179461359</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_l2z-WHppYEmLoMVP8O1gsg_18_17"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">145627060</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_kPHJHrSS30mD_v6ZYEjtwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;&#160;&#160;&#160;&#160;NATURE OF OPERATIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Nature of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ESSA Pharma&#160;Inc. (the &#x201c;Company&#x201d;) was incorporated under the laws of the Province of British Columbia on January&#160;6, 2009. The Company&#x2019;s head office address is Suite&#160;720&#160;&#x2013; 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5. The registered and records office address is Suite 3500, The Stack, 1133 Melville Street, Vancouver, British Columbia, V6E 4E5. The Company is listed on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the symbol &#x201c;EPIX&#x201d;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has a license to certain patents (the &#x201c;NTD Technology&#x201d;) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2023, no products are in commercial production or use.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_OyCICzZzEUOI3PVjH0dMCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;&#160;&#160;&#160;&#160;BASIS OF PRESENTATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) on a going concern basis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value using the accrual basis of accounting. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#x201c;$&#x201d; are to United States dollars and references to &#x201c;C$&#x201d; are to Canadian dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Consolidation and Functional Currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Consolidation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Functional Currency&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of an entity is the currency of the primary economic environment in which the entity operates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The functional currency of the Company and its subsidiary have been determined as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Country of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Functional&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharma&#160;Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharmaceuticals Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;&lt;span style="font-style:normal;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The liquidation and dissolution process for Realm Therapeutics plc and Realm Therapeutics Inc. were completed as at September 30, 2022. The consolidated financial statements also include the operations of Realm Therapeutics plc and Realm Therapeutics Inc. to the date of dissolution.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and income taxes. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Income tax&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based payments and compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;9.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_w3W-gUfGrkOmf9wQ2yxZLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) on a going concern basis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value using the accrual basis of accounting. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#x201c;$&#x201d; are to United States dollars and references to &#x201c;C$&#x201d; are to Canadian dollars.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_o4kjATVRo0Gx5JunlG3RSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Consolidation and Functional Currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Consolidation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Functional Currency&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of an entity is the currency of the primary economic environment in which the entity operates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The functional currency of the Company and its subsidiary have been determined as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Country of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Functional&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharma&#160;Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharmaceuticals Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;&lt;span style="font-style:normal;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The liquidation and dissolution process for Realm Therapeutics plc and Realm Therapeutics Inc. were completed as at September 30, 2022. The consolidated financial statements also include the operations of Realm Therapeutics plc and Realm Therapeutics Inc. to the date of dissolution.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_8cZGhVDv8U2md8nw6p4YJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Country of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Functional&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharma&#160;Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharmaceuticals Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock>
    <epix:PercentageOfEffectiveInterestInSubsidiaries
      contextRef="Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA"
      decimals="2"
      id="Tc_6cgVQF8-eUONqE9hxBQBYQ_5_4"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">1</epix:PercentageOfEffectiveInterestInSubsidiaries>
    <us-gaap:UseOfEstimates
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_1wbXOug6gkuUMlZQXVoIgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and income taxes. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Income tax&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based payments and compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;9.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_Vxmp6MCsJ0qFIMyInZbHAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-term investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s short-term investments consist of guaranteed investment certificates, U.S. treasury securities, corporate debt securities, commercial paper and term deposits with original maturities exceeding three months and less than one year. The investments are carried at fair value plus accrued interest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Foreign exchange&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#x2019;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#160;&#x2013; quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#160;&#x2013; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;"&gt;directly (i.e., as prices) or indirectly (i.e., derived from prices); and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#160;&#x2013; inputs for the asset or liability that are not based on observable market data (unobservable inputs).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using level 3 inputs (Note 8).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share-based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants stock options to acquire Common Shares of the Company to directors, officers, employees and consultants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basic and diluted loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of Common Shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#x201c;if converted&#x201d; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company elected the short-term lease exemption for all leases that qualify; as a result, we will not recognize right-of-use assets or lease liabilities for leases with a term of less than 12 months at inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration. &#160;The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Recently accounting pronouncements adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended September 30, 2023, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Recently accounting pronouncements not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial statement presentation or disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Change in presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended September 30, 2023, the Company identified a presentation item that required adjustments to be recorded in the historical consolidated statements of cash flows to conform to the presentation required under U.S. GAAP. Interest from short-term investments of $705,020 for the year ended September 30, 2022 has been reclassified from investing activities to operating activities. There were no changes to net loss of the Company or &lt;span style="-sec-ix-hidden:Hidden_ilqp4H9x3UeeSj7zg-kL4w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;earnings&lt;/span&gt;&lt;/span&gt; per &lt;span style="-sec-ix-hidden:Hidden_uPwaofhXOUatr_NRDuquTg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;share&lt;/span&gt;&lt;/span&gt; in the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company believes this reclassification and presentation change in the historical consolidated statement of cash flow for the year ended September 30, 2022 is not material and has reflected this reclassification and presentation change in the comparative period included within these consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_6e4IOMAamE-N2hdoasB5Rw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_p0urKmUSnU-h9ZAvNW5Zuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-term investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s short-term investments consist of guaranteed investment certificates, U.S. treasury securities, corporate debt securities, commercial paper and term deposits with original maturities exceeding three months and less than one year. The investments are carried at fair value plus accrued interest.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_MqpsySlwmUq43moaxlznuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Foreign exchange&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_Gv0dYHpII0WPvKGvWco0Dw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_ZCSxY6ewQ02mMbFteSkaGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#x2019;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#160;&#x2013; quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#160;&#x2013; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;"&gt;directly (i.e., as prices) or indirectly (i.e., derived from prices); and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#160;&#x2013; inputs for the asset or liability that are not based on observable market data (unobservable inputs).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using level 3 inputs (Note 8).&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_un7TBWw9ukSAsypovBSCwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share-based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants stock options to acquire Common Shares of the Company to directors, officers, employees and consultants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_cKsgn3k1RUuZNPnwQXJMbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basic and diluted loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of Common Shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#x201c;if converted&#x201d; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_LIEGY1Y4k0qBRF9AkOTQXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company elected the short-term lease exemption for all leases that qualify; as a result, we will not recognize right-of-use assets or lease liabilities for leases with a term of less than 12 months at inception.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_22-3WaosPEaj8PHseQ1ZqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration. &#160;The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_XXU9IvXumUid63YwUh_LUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Recently accounting pronouncements adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended September 30, 2023, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Recently accounting pronouncements not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial statement presentation or disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_QbzhiosBIkOQ6-_yQsaEvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Change in presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended September 30, 2023, the Company identified a presentation item that required adjustments to be recorded in the historical consolidated statements of cash flows to conform to the presentation required under U.S. GAAP. Interest from short-term investments of $705,020 for the year ended September 30, 2022 has been reclassified from investing activities to operating activities. There were no changes to net loss of the Company or &lt;span style="-sec-ix-hidden:Hidden_ilqp4H9x3UeeSj7zg-kL4w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;earnings&lt;/span&gt;&lt;/span&gt; per &lt;span style="-sec-ix-hidden:Hidden_uPwaofhXOUatr_NRDuquTg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;share&lt;/span&gt;&lt;/span&gt; in the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company believes this reclassification and presentation change in the historical consolidated statement of cash flow for the year ended September 30, 2022 is not material and has reflected this reclassification and presentation change in the comparative period included within these consolidated financial statements.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <epix:OperatingInterestIncomeOfShortTermInvestments
      contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug"
      decimals="0"
      id="Narr_uRhwmLNUSkGcomBtGjNEaw"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">705020</epix:OperatingInterestIncomeOfShortTermInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug"
      decimals="0"
      id="Narr_KTv1wIvkbki44-wmiqoEOA"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:NetIncomeLoss>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_zhK3T0rqmU69zudV7htsiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;.&#160;&#160;&#160;&#160;&#160;SHORT-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Short-term investments consist of guaranteed investment certificates (&#x201c;GICs&#x201d;) held at financial institutions purchased in accordance with the Company&#x2019;s treasury policy. These GICs and term deposits bear interest at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.15%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.40%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum and have maturities of up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12 months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Short-term investments also consist of U.S. treasury securities, corporate debt securities and commercial paper. The Company has classified these investments as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investment securities as current assets. Those investments with maturity dates of three months or less at the date of purchase are presented as cash equivalents in the accompanying balance sheets. Short-term investments are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss as a component of shareholders&#x2019; equity until realized. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_MqSGdzQPEkKOh8Gi7K9I_Q;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;"&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investment Income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 72,802,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,248)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 301,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 73,061,021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GICs and Term deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 41,141,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 172,154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 41,313,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 113,943,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,248)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 473,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 114,374,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Kk5qrfMvTE2vUhXl6Q4JEQ;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;"&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investment Income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GICs and Term deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 89,688,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 316,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 90,005,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,149,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,590)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 39,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,149,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,034,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,076)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,044,599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,961,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,961,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 109,833,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (58,666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 385,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 110,161,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;As of September 30, 2023, short-term investments have an aggregate fair market value of &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;$114.4&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; million (2022 &#x2013; &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;$110.2&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; million) were in an aggregate gross unrealized loss position of &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;$43,248&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; (2022 - &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;$58,666&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;). The Company considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. These particular investments have been in an unrealized loss position for less than 12 months and it is not more likely than not that the Company will be required to sell any of its securities prior to maturity. Accordingly, &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; allowance for credit losses has been recorded as of September 30, 2023, and &lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:9.5pt;"&gt; realized gains or losses on sales of short-term investments have been recorded through September 30, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:InvestmentInterestRate
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember__JFKnEKGe0C4wTHeLj8ODQ"
      decimals="4"
      id="Narr_fo_0ShIS60S4iKFiX3cAzA"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.0515</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_sSMbCtSnJkqpJVr-Lf7Pqg"
      decimals="4"
      id="Narr_ca4HkK2TOEizyi7oWKnE7A"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.0540</us-gaap:InvestmentInterestRate>
    <epix:ShortTermInvestmentsMaturityTerm
      contextRef="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_-Af7YkvMXkif21idoG044w"
      id="Narr_XkIE_XX0nkSA10ZVQDrvhg">P12M</epix:ShortTermInvestmentsMaturityTerm>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_FNtG0uoJxUifVfzNCok-Iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_MqSGdzQPEkKOh8Gi7K9I_Q;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;"&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investment Income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 72,802,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,248)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 301,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 73,061,021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GICs and Term deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 41,141,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 172,154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 41,313,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 113,943,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,248)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 473,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 114,374,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:82.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Kk5qrfMvTE2vUhXl6Q4JEQ;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;"&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investment Income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;GICs and Term deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 89,688,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 316,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 90,005,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,149,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,590)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 39,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,149,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,034,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,076)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,044,599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,961,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,961,597&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:14.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 109,833,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (58,666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 385,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 110,161,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw"
      decimals="0"
      id="Tc__gBOlPSHKkeLcyyHeLPYAw_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">72802531</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw"
      decimals="0"
      id="Tc_3l3C1-AObEGKW-6QMtNjjQ_5_9"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">43248</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw"
      decimals="0"
      id="Tc_MDv0p2au9EWTp0RhWraHNQ_5_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">301738</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_3OIoon0QiEqmUTGTdkJEAw"
      decimals="0"
      id="Tc_4vAw7zxqIkKmw9BERiSvzA_5_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">73061021</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A"
      decimals="0"
      id="Tc_pIgYPIPp80eEfF9D5g9rDA_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">41141314</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A"
      decimals="0"
      id="Tc_jOedparnV0apV7coupqVSA_6_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">172154</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_lpgyRDrFKUmnfiwt6-v86A"
      decimals="0"
      id="Tc_sZZcuVg7X0OeiqRJZ2vLwA_6_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">41313468</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_UxfxTzro9EKnvpJPSvFevg_9_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">113943845</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_oZa83lMmikqwirxRqSE0yg_9_9"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">43248</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_bGRmg4LSQkaVp3NQxaw_3Q_9_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">473892</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_K9thhLvMO0OkpO36dYXNUQ_9_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">114374489</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ"
      decimals="0"
      id="Tc_rzqjkTJmREaYcPpSqBhwCg_15_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">89688690</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ"
      decimals="0"
      id="Tc_NWHeT44KGEagJ5UlcEUgPQ_15_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">316960</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember_rQg55_RIeUmlDLHgAs5YAQ"
      decimals="0"
      id="Tc_vHHJNedNCEKyq-Bh6fQvSQ_15_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">90005650</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw"
      decimals="0"
      id="Tc_UHgii78ICUy-laoKa0XrCA_16_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">11149053</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw"
      decimals="0"
      id="Tc_urzh27YYUU6YVmMPj7yAEQ_16_9"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">39590</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw"
      decimals="0"
      id="Tc_hvD3ZfVImkOgfGSYNyA5oQ_16_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">39720</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_LbnI3jXUQUeFwZ7C_1yOFw"
      decimals="0"
      id="Tc_JmjZ_Ip2dU2h1m3bfx581A_16_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">11149183</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ"
      decimals="0"
      id="Tc_sNjUg210CEKz6uoh86jEkw_17_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">3034417</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ"
      decimals="0"
      id="Tc_u7niG12RN02k2eJN_MmcVw_17_9"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">19076</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ"
      decimals="0"
      id="Tc_TPOkXy5jdUqGXfoOtovLlA_17_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">29258</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_sbgdASZBQU2ipTQgkD9KRQ"
      decimals="0"
      id="Tc_7QpCKgnIr0eZmuUA1PBVrg_17_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">3044599</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_i33tUz0BdkGB-UPAxwqTtA"
      decimals="0"
      id="Tc_vw0h5NpBvUWoh_dQt-H1Dw_18_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">5961597</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_i33tUz0BdkGB-UPAxwqTtA"
      decimals="0"
      id="Tc_PsPuNjP4tUWEUkniAj8QWQ_18_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">5961597</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_PGD02kLZSUKSOwsJwa4oEA_20_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">109833757</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_qxyniVNvLUOFmgaeKBx90Q_20_9"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">58666</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_QKCxqtWxAEWkOkhi8C4MGA_20_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">385938</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_LyOGq7YDDk2ZaaJMdJJKwA_20_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">110161029</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="-5"
      id="Narr_CV9MRI4cRkGxyxoY9T6-0g"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">114400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="-5"
      id="Narr_ZrcS4j_ESkCNz6JXv-wVhw"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">110200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Narr_Bpq1Rx08zkW84OARGc6few"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">43248</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Narr_8h7BBi8aF0WusldNbKZt3g"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">58666</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Narr_pUoPKatc5kOhXoSrww0gUQ"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Narr_GUnmvDJ1nkSmzBbehH2gLQ"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:GainLossOnSaleOfInvestments>
    <epix:PrepaidExpensesTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_3Ya-sycOB0ylaArmrU1W6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5.&#160;&#160;&#160;&#160;&#160;PREPAIDS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,611,516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid CMC and clinical expenses and deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 181,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 181,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other deposits and prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 378,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 585,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,815,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</epix:PrepaidExpensesTextBlock>
    <epix:ScheduleOfPrepaidExpensesTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_hJPbnFEQKUKo-YjjJFk_nQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,611,516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid CMC and clinical expenses and deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 181,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 181,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other deposits and prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 378,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 585,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,815,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</epix:ScheduleOfPrepaidExpensesTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_IFjUoANkH0W6Z1tugWtHbQ_4_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">24839</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_0MQH8k6XdES_q7vPtn61Pw_4_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1611516</us-gaap:PrepaidInsurance>
    <epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_vhH5P0DoWk2p6MtQ7GNwRQ_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">181835</epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits>
    <epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_GT6pZhfp_EizDRrGU7Xt3Q_5_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">181835</epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_L7xvUQq5sEaEF5tLyQyaUA_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">378746</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_QyOVxTJPl0KRS_DRqDQG9A_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">22275</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_NYp5l2m3akW3PY-JmF8nnw_8_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">585420</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_FO24ISbv9061wt_5SOQe0g_8_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1815626</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_5yR5mQBX4kSCc2oUKtPg5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6.&#160;&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,028,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 954,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 845,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 807,484&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 540,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 414,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,414,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,176,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_W7hCmDuTjEuTlWbGvHurqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,028,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 954,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 845,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 807,484&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 540,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 414,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,414,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,176,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_Wg2tqy9mskWax00c0ZYqhg_4_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2028265</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_2TRvc-byhE6uzG2WDQHixQ_4_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">954598</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_0rsyOocRC0uP8rxJjqKWrA_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">845730</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_CcIpfPaR6UyVFgNGHJL35Q_5_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">807484</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_snNCeqN-pEOo4iHdIqJrYg_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">540748</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_Csl7YAs5GUCRLDG1WZdQ0w_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">414483</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_JbYmu1JJR0KumYz0XMFh5Q_8_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">3414743</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_9q4qTby8rEObhtH5E6l-JQ_8_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2176565</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_Zar8_jbJJUOxrqgGSm161w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;7.&#160;&#160;&#160;&#160;&#160;OPERATING LEASE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s operating leases included on the balance sheet are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 308,286&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (121,787)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 186,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (118,491)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 68,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 330,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,305&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (134,023)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,252&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (136,866)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ap4efqCYWU2Hbn9_bqvWYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Balance, September&#160;30,&#160;2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities with expected life of less than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities with expected life greater than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company&#x2019;s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. At September 30, 2023, the Company&#x2019;s incremental borrowing rate was 5.0% and the remaining lease term for the South Francisco office was &lt;span style="-sec-ix-hidden:Hidden_7lRLzzwpXE2PixIFHj_goQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8&#160;months&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion expense of $6,942 (2022 - $13,305) have been recorded in &#x201c;financing costs&#x201d; in the statement of operations and comprehensive loss.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_sE3wvdbPx0iXQZGHHheoUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 308,286&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (121,787)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 186,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (118,491)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 68,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 330,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,305&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (134,023)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,252&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (136,866)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ap4efqCYWU2Hbn9_bqvWYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Balance, September&#160;30,&#160;2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities with expected life of less than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities with expected life greater than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ"
      decimals="0"
      id="Tc_21EIvpzflEu9u-kFRAJSrg_2_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">308286</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_DOJWruuDqUaGVAYIFjkzuA_3_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">121787</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_awymHugWfkiEFXlzY7lVzQ_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">186499</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_deKwvJdG1UOi-yThvjrjJg_7_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">118491</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_Ioiwks6rm0CatoRPxR_SJw_9_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">68008</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ"
      decimals="0"
      id="Tc_98vv7IAKrECwF3hCe-IVhw_12_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">330970</us-gaap:OperatingLeaseLiability>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_2ltSlSiPn0GbLdE7S5jV1w_13_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">13305</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_4-T2t9hbaECFOUBNhWKH_Q_14_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">134023</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_Nbfm_H_49EKFrF4jEmHExA_16_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">210252</us-gaap:OperatingLeaseLiability>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_95N2kt0Rr06v4CaYYYZDSQ_18_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">6942</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_Z3_WuSIhiE2DLLzQfUpl-A_19_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">136866</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc__Kbzn_XMEUOXKpKB2ZoQxA_21_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">80328</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_EsAwY1RapEibhKtOw_-Xag_23_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">80328</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_-OtlciBwxkiB97Idvjkxeg_24_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="3"
      id="Narr_qln_1kbV1kmYNNXLpbkyJg"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.050</us-gaap:LesseeOperatingLeaseDiscountRate>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_EfgTWfcorki7QNu4wkVtZg"
      decimals="0"
      id="Narr_yRpmiPxtGkCsYiVqzosyYw"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">6942</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_sF7fPbMdqUqvbTzfsfT_8w"
      decimals="0"
      id="Narr_ayeonbhTUEGOYlzA4PCEOw"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">13305</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_AO3M0kkhv0e5zVcyfdgIhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;&#160;&#160;&#160;&#160;DERIVATIVE LIABILITIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2016, the Company issued, pursuant to a financing, 227,273 warrants (&#x201c;Warrants&#x201d;) having an exercise price of $66.00 per common share. The holders of the Warrants had the ability to receive a variable number of shares pursuant to exercise terms or receive cash settlement under certain conditions. Pursuant to these conditions, the Warrants were treated as financial liabilities measured at fair value through profit or loss. The Warrants expired unexercised in the year ended September 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Valuation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 73.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Liquidity discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JDmOjRguN0Kdzie1u0Eb5A"
      decimals="INF"
      id="Narr_ueKZjFfcD0CVgvitEXAVmA"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">227273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OlXqQixrvUur2aI9T8N3gg"
      decimals="2"
      id="Narr_wLjHU4MZpUqIgnvULyX87Q"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">66.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_jnG08khI0ECvXNkNYZ8bgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 73.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Liquidity discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_oBr_-pywIkaEsKV63Ewtww"
      decimals="4"
      id="Tc_l0ywcv8fAUSf3AEznf1tiA_5_3"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.0355</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_48y5HKDd8Ue6FoNx1ErTJA"
      decimals="2"
      id="Tc_m7y-_2AyOUGs3Ox1lzBiyg_6_3"
      unitRef="Unit_Standard_Y_z0MYX-vw9EWUytYjOXmUkg">0.28</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ZDv0kj75JkKg3GXnXPe5gQ"
      decimals="3"
      id="Tc_wMeOMhFZvEWXeNjyjJ-R1Q_7_3"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.733</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_THqCoUiZjkanSO4NpVc-KQ"
      decimals="4"
      id="Tc_usMr6f1OUkyzHbXrIideCw_8_3"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_cJ--xfd0e0C0p7RyafiWnA"
      decimals="2"
      id="Tc_T3U7fCNd70q4eO-cCcBGUw_9_3"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.20</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_0oReTK33YkyuMuX7UCnYuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9.&#160;&#160;&#160;&#160;&#160;SHAREHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Authorized&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Unlimited common shares, without par value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Unlimited preferred shares, without par value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Omnibus incentive plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 25, 2021, the Company adopted an omnibus incentive plan (&#x201c;Omnibus Plan&#x201d;) consistent with the policies and rules of Nasdaq. Pursuant to the Omnibus Plan, the Company may issue stock options, share appreciation rights, restricted shares, restricted share units and other share-based awards. As of September 30, 2023, the Company has not issued any instruments other than stock options under the Omnibus Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Prior to the adoption of the Omnibus Plan, the Company issued equity compensation pursuant to the Company&#x2019;s amended and restated stock option plan (the &#x201c;Legacy Option Plan&#x201d;), Amended and Restated Restricted Share Unit Plan (the &#x201c;RSU Plan&#x201d;) and Employee Stock Purchase Plan. Since the adoption of the Omnibus Plan, no further grants have been made under the Legacy Option Plan or RSU Plan, though existing grants under the Legacy Option Plan will continue in effect in accordance with their terms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;As of September 30, 2023, the Omnibus Plan has a maximum of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;8,410,907&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; Common Shares which may be reserved for issuance. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Employee Share Purchase Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has adopted an Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) under which qualifying employees may be granted purchase rights (&#x201c;Purchase Rights&#x201d;) to the Company&#x2019;s Common Shares at not less of 85% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of six-month periods commencing on January&#160;1 and July&#160;1 and ending on June&#160;30 and December&#160;31 of each calendar&#160;year. As at September 30, 2023, the ESPP has a maximum of 208,836 (2022&#160;&#x2013;236,598) Common Shares reserved for issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $25,000 worth of the Company&#x2019;s Common Shares (determined using the lesser of (i)&#160;the market price of a common share on the first day of an applicable purchase period and (ii)&#160;the market price of a common share on the purchase date) for each calendar&#160;year in which a purchase right is outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the&#160;year ended September 30, 2023, the Company issued a total of 27,762 (2022&#160;&#x2013;15,820) Common Shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of share purchase rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 72.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 89.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Stock options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Legacy Option Plan and Omnibus Plan, options were previously or may be granted, respectively, with expiry terms of up to 10 years, and vesting criteria and periods are approved by the Board at its discretion. The options issued under the Legacy Option Plan and Omnibus Plan are accounted for as equity-settled share-based payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock option transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,803,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,347,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72,910)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (175,759)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.60)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,902,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89,287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12.27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,112,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance exercisable, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,444,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Options exercisable in Canadian dollars as at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;September 30, 2023&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; are translated at current rates to reflect the current weighted average exercise price in U.S. dollars for all outstanding options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At September 30, 2023, options were outstanding enabling holders to acquire Common Shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 175,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,629,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 26,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 910,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 185,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 539,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 168,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 190,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,458,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 120,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;13.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 190,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;29.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;31.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 124,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,112,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* 3,500 options expired unexercised and 41,250 options exercised subsequent to September 30, 2023&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;year ended September 30, 2023, the Company granted a total of 300,000 (2022&#160;&#x2013; 1,347,500) stock options with a weighted average fair value of $2.82 per option (2022&#160;&#x2013; $3.20).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2023 and 2022 with allocations to its functional expense as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,622,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,306,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,372,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,551,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,995,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,858,142&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 186.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 79.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021 and September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,234,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (307,273)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49.86)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding and exercisable, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,927,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;At September 30, 2023, warrants were outstanding enabling holders to acquire Common Shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 42.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;November&#160;18, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,920,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.0001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August&#160;23, 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,927,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* 7,477 warrants expired unexercised subsequent to September 30, 2023&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_25_2021_To_9_30_2023_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_us-gaap_PlanNameAxis_epix_LegacyOptionPlanAndRsuPlanMember_V6OYcw6z4ky5o49UbZ6MnA"
      decimals="0"
      id="Narr_KP3TXfxJJ0ieGM1HqNu6YA"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_FyoK9yWXWUCxMbtsqkJzCA"
      decimals="INF"
      id="Narr_5KyUU90E1ESw7-8LLnK4Kw"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">8410907</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_XLCr0Xj6H0aNDrwxKDqxqg"
      decimals="2"
      id="Narr_A5PMsOMbgUy9ZL1JdPgs3w"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <epix:PurchaseRightsOfferingTerm
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      id="Narr_WtQ9Lpboq0a2D1JII6If5A">P6M</epix:PurchaseRightsOfferingTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6mUYISo1eEmc_-LnuL2s_w"
      decimals="INF"
      id="Narr_FTd3ziBhZESi3eN2fmWGpg"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">208836</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_6XCUQP7JO0WguT4GQ8sEbA"
      decimals="INF"
      id="Narr_nevKEuYXYUaaKCuSusEhTg"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">236598</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <epix:ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage
      contextRef="Duration_10_1_2022_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_S5AnpSsXtEG3ZBTgeWIHtg"
      decimals="2"
      id="Narr_6LAjL7UCzk-3rPwwhHo3nA"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.15</epix:ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage>
    <epix:MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      decimals="0"
      id="Narr_hjR_jGUn9EemHJ1mOAWy5w"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">25000</epix:MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      id="Tb_A2V56cDu_EmX03MkIvvWaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the&#160;year ended September 30, 2023, the Company issued a total of 27,762 (2022&#160;&#x2013;15,820) Common Shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      decimals="INF"
      id="Narr_Ft1nVoqcvk-VWT9s1oXOAA"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">27762</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw"
      decimals="INF"
      id="Narr_rlX8Utw-0EC06meFCoTdpA"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">15820</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_M3oeDgOQYE6eQpxPLzjyHQ"
      decimals="0"
      id="Tc_5k3RtfR8kUuuMX9TxrA6-w_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">4517</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_aDqpgEkao0qTgIxFls48UQ"
      decimals="0"
      id="Tc_6aru2227rUmkUXtwp0jCuw_5_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">16381</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_eK7QF44Iy0SInRW3V5Ougw"
      decimals="0"
      id="Tc_2DkfN0MD1UG3FIa2WOlX8Q_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">7031</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_wcftaJxSUUSWCXQKbpxAPA"
      decimals="0"
      id="Tc_dNnKnXlNNkqMkZAT2LpErQ_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">13562</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      decimals="0"
      id="Tc_0DhuixKAWkW_UEkhY6FNWQ_7_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">11548</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw"
      decimals="0"
      id="Tc_i_f7RyklvUWqvFmo68cdhg_7_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">29943</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      id="Tb_cJtYMD8VrEezBFk1B3riJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of share purchase rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 72.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 89.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      decimals="4"
      id="Tc_fq3wtrUlSEutQQK75TqVuQ_3_2"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.0490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw"
      decimals="4"
      id="Tc_blyslfZrkUqVYxAE6PqdtQ_3_4"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      id="Tc_r81roVf8ykSiG9nUmsfOoQ_4_2">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw"
      id="Tc_XGZorc4tAE2XXs60o4rpOg_4_4">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      decimals="4"
      id="Tc_M2EbSVDHHk24C_qBoaXpyA_5_2"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.7245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw"
      decimals="4"
      id="Tc_CtXOxluRT0O9oG_cVzc0Nw_5_4"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.8942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg"
      decimals="4"
      id="Tc_niIdvMBtzUOFYbqhLL83ug_6_2"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember__9QdG7XsykaQiTOSBtgQgw"
      decimals="4"
      id="Tc_o-WQqGE0CU6xBYycl0GoLA_6_4"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_n0-uTgmcUUGkCdF3R77kgA"
      id="Narr_zBxJfBQmnkKRfld459LbyA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_dLdc34W_p0eqw5XMxnnwew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock option transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,803,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,347,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72,910)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (175,759)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.60)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,902,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89,287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12.27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,112,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance exercisable, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,444,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Options exercisable in Canadian dollars as at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;September 30, 2023&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; are translated at current rates to reflect the current weighted average exercise price in U.S. dollars for all outstanding options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ"
      decimals="INF"
      id="Tc_CwBCmw-Y9U-PphEDQ23cJg_5_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">6803230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ"
      decimals="2"
      id="Tc_ERa5PBqp20qRzrn716PaYA_5_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="INF"
      id="Tc_Sv1Q31fHREmj-hoSZcCozQ_6_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">1347500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="2"
      id="Tc_BqmaQTF2ekaiKyhW0atyDg_6_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">4.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="INF"
      id="Tc_fhhO30sd90u579mwv7TQig_7_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">72910</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="2"
      id="Tc_6ogu0SSCAkSLZvrVp2_69w_7_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">4.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="INF"
      id="Tc_a3x27tqSLkerKgxqdWB99A_8_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">175759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="2"
      id="Tc_3MP3OypQmUyc29JWmSvo1w_8_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="INF"
      id="Tc_scjeXMwSjkGGVAXgqQHUJA_10_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">7902061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="2"
      id="Tc_xL5JgqqXxUCs_RJT8rD5VA_10_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="INF"
      id="Tc_PMcfdYyVVEeOOrPMnqYLLw_11_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="2"
      id="Tc_r78L6N44dEuwQhAlsYv5RA_11_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">2.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="INF"
      id="Tc_28LwqMkdCEaIxhJlXzU5Dw_12_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">89287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="2"
      id="Tc_IL_HWAs_O0mWAFLsX-TNPQ_12_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">12.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="INF"
      id="Tc_CkKKmOvILkucCz_K_OpQUg_14_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">8112774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="2"
      id="Tc_fY3g65T3TE-CM3lVEjdKow_14_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">4.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="INF"
      id="Tc_2ZtPJW10cEOZOwRz3XE_Jg_15_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">6444885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="2"
      id="Tc_-L7ZjH93tUmXYdNFTG-jbg_15_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">4.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_PswEBbScoESF-x08XuIblQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At September 30, 2023, options were outstanding enabling holders to acquire Common Shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 175,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,629,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 26,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 910,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 185,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 539,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 168,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 190,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,458,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 120,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;13.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 190,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;29.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;31.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 124,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;5.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 8,112,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* 3,500 options expired unexercised and 41,250 options exercised subsequent to September 30, 2023&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_lVjeFiQ6Ekm7fjJ6XoNSrQ"
      decimals="2"
      id="Tc_kbyoilkDu0GDrvX_237bWg_4_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_lVjeFiQ6Ekm7fjJ6XoNSrQ"
      decimals="INF"
      id="Tc_mdHx947PzUCVzpD76k8NUw_4_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7PhtjQKMu0GtgpMqe-anoA"
      id="Tc_5FhIu2GRNE689EYb4oF8Yw_4_5">P8Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_sRBNs2Bp202TAd85J0t1Ew"
      decimals="2"
      id="Tc_ADSfuBSCm02K5eE3LdV57g_5_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">2.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_sRBNs2Bp202TAd85J0t1Ew"
      decimals="INF"
      id="Tc_7gawl_uTrUqAkUNAWF42LQ_5_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.70Member_leH9ftDSCk-54cm_qblTEg"
      id="Tc_zLIuM1AhwE6TLtpmY2tm1g_5_5">P9Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_x4LeuRkg3EeVAWxunWBKlw"
      decimals="2"
      id="Tc_QmulCNmDN0OY1-B0mzc5lA_6_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_x4LeuRkg3EeVAWxunWBKlw"
      decimals="INF"
      id="Tc_N1Ais68jO0ufmfW-gxKnPA_6_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.71Member_b7SS3eXxTkaoqtw4IRnCyA"
      id="Tc_i9jb_S2Az0mgQWok_RaZtQ_6_5">P9Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_zjWTpjhz5Emw7U-GDyTvbQ"
      decimals="2"
      id="Tc_SQIt_6vG702foe9rkcCQ-Q_7_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">2.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_zjWTpjhz5Emw7U-GDyTvbQ"
      decimals="INF"
      id="Tc_T-jZMxxY_0aa2w20bqUJLA_7_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.91Member_nFQt8T1RlESSnCiqvgcN4g"
      id="Tc_Dqscb0TJHE-NzZqZXOz4yQ_7_5">P9Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_vIjORgSPqUiUIc9dMJFfFA"
      decimals="2"
      id="Tc_12T676741E6XwYKcXenNvg_8_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_vIjORgSPqUiUIc9dMJFfFA"
      decimals="INF"
      id="Tc_ULb8ULuqIEitVhUZ96FTRQ_8_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice2.97Member_tqxeOLNwukiNCCAewkMiEw"
      id="Tc_Jtc5ZON4zUS0Y5Bf3WxK-w_8_5">P9Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_O7Jrtq6Zy0mI4nNJSzPGZQ"
      decimals="2"
      id="Tc_5dyWFqnzPk-E1VZeXR-uuw_9_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_O7Jrtq6Zy0mI4nNJSzPGZQ"
      decimals="INF"
      id="Tc_LXriLElwekGfrcdG8U64Tw_9_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePrice3.05Member_NQ4IZZb2JUG6Ggr4NZOxqw"
      id="Tc_0Jp9ODG58E6b57aRwIrkKQ_9_5">P9Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_bjAYITQVzEWC4LdXfX0KSg"
      decimals="2"
      id="Tc_8fnjo8ctKkeSAum6myL2LA_10_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_bjAYITQVzEWC4LdXfX0KSg"
      decimals="INF"
      id="Tc_FIGDoPW6Zk-BEOuVqOXPoA_10_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">3629400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_pWlgE-YtkE6a1ceHbsbCoA"
      id="Tc_IDE3QR8IK0Odr-GfN6pDBA_10_5">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_tvAsNHy91UG6aiTxFG9cZA"
      decimals="2"
      id="Tc_ugcRAJ0u_UOjxrbiL6b7SQ_11_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_tvAsNHy91UG6aiTxFG9cZA"
      decimals="INF"
      id="Tc_HKdD0JDHwk-lCGHFIoVfeQ_11_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">26667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_x5J0Bj22GkOSTsuWEuiR0w"
      id="Tc_AXTrL4HevE2o6jACJ4UETA_11_5">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_1m2P4O_uf06H8eYherHW9w"
      decimals="2"
      id="Tc_EP9KsaiI6EGScllIvbsLsA_12_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_1m2P4O_uf06H8eYherHW9w"
      decimals="INF"
      id="Tc_zPCKdYlBKUy_5bC3YeUhDg_12_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">910000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_KJWT3GdVH0q0Ytfdkc7bPQ"
      id="Tc_hwBCxFeNGk6WPBdUK-VY7g_12_5">P8Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_Mju67xWeg0qPdkvGo74miQ"
      decimals="2"
      id="Tc_Mf1GiDEFlEu5CPYla8NQ9w_13_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_Mju67xWeg0qPdkvGo74miQ"
      decimals="INF"
      id="Tc_AhH_oePHTE27vRjxNoALiw_13_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFifteenMember_r_BXr9FtnkCrKXKU8xDMqg"
      id="Tc_FTZblX2HsEKVxafBKEWlrQ_13_5">P9Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_ovkHbXBRKkiZP-tc8tH0CQ"
      decimals="2"
      id="Tc_ifNDelPYj0ySwQhin7X7FQ_14_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_ovkHbXBRKkiZP-tc8tH0CQ"
      decimals="INF"
      id="Tc_G3gsA0eUTkSP7DrjzVel0w_14_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">185816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_H2lt2rM4EkuRKpzFCmU7bg"
      id="Tc_Fjt0VSSPJkKVisiokbpB6g_14_5">P5Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_BBOSnkAiwUSXe9gvqshK1g"
      decimals="2"
      id="Tc_uA0D8MmBKkupgsIYEruMEQ_15_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_BBOSnkAiwUSXe9gvqshK1g"
      decimals="INF"
      id="Tc_NpbK9LCDpkGLx5s5gBLXYQ_15_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">539518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_KjLjZYnxOUW1bHNr8qUGxg"
      id="Tc_G9fsA_OGEE-oyxfomSj8tg_15_5">P4Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hvdIRMII4U2RBEiyYCqbEA"
      decimals="2"
      id="Tc_ReDimbumNU6rvxOyXebsQw_16_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hvdIRMII4U2RBEiyYCqbEA"
      decimals="INF"
      id="Tc_fxJlziJaVEiMbo-QNHtZyA_16_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">168227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_nTVq80JJdEeConndZT7hnw"
      id="Tc_dMv9_r-8okGmS9p4zrq1Ag_16_5">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_45YEp4T3rkaRbQZc8sGXeA"
      decimals="2"
      id="Tc_NhgxC9795UGcFOLDx2Gdbg_17_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">5.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_45YEp4T3rkaRbQZc8sGXeA"
      decimals="INF"
      id="Tc_AJyNzFwfz0-eAcpqsEs3Jw_17_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_cFCRxahqm0OO2m5OxSVtkQ"
      id="Tc_jN9KRpeN_k2LThAIiH0QRw_17_5">P8Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_arlI8eyiaUyFxwbf3MAH1g"
      decimals="2"
      id="Tc_g3cD1gCAhEiV7CIK2WXRZA_18_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_arlI8eyiaUyFxwbf3MAH1g"
      decimals="INF"
      id="Tc_h6ekHJUjVEec_vBdD-9zAQ_18_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">1458646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_Z8RH8VRQakCIZEbIjDEjqw"
      id="Tc_FnzHW5XXwUSTIhOR3xVbIQ_18_5">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_CiW6XcCB7EaHNCJu_Aq1Bg"
      decimals="2"
      id="Tc_8D8ENkdKXkCnjqe8dq3gxg_19_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">8.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_CiW6XcCB7EaHNCJu_Aq1Bg"
      decimals="INF"
      id="Tc_D7m6VK6v3UC_q6AS4caESQ_19_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_BVOK3SHXX0WbRyp5MK4RKw"
      id="Tc_P0DhOWG-9kOA7E-D9eM1IA_19_5">P8Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_m_PpxKgTgEO101iOVrfx0g"
      decimals="2"
      id="Tc_7aRFLVFsSE21zuEpJvfmig_20_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">9.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_m_PpxKgTgEO101iOVrfx0g"
      decimals="INF"
      id="Tc_a4t68n3-xkyGqAQcSscj9A_20_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceElevenInUsdMember_r5PTgGJDcU29voLTSfqxHw"
      id="Tc_3VuHfcFH9kOt4v8vJkhCQw_20_5">P8Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_sGuewVdd5Ei7shCy53nuBA"
      decimals="2"
      id="Tc_DtGjxKN-BUG4A3zeAYqxFA_21_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">13.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_sGuewVdd5Ei7shCy53nuBA"
      decimals="INF"
      id="Tc_XNLDL1mSOUipbJ6-bfDoUw_21_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwelveInUsdMember_9BP0mMLtwUiCKPlTHk1SXA"
      id="Tc_jgSn8eZT50e5f8iDcPYRHg_21_5">P7Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_NJOZ1OzFSkq8Ovbj3UzvyA"
      decimals="2"
      id="Tc_hsITvQI2a0e0iDRAx3HEsA_22_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">29.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_NJOZ1OzFSkq8Ovbj3UzvyA"
      decimals="INF"
      id="Tc_UWJWR0kFTESFUAYiSLUzJw_22_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThirteenInUsdMember_iM029G27tEWSaBRh7eMCuA"
      id="Tc_f9ISxm93Wk6_yrST4mqTRg_22_5">P7Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_Pvirta9m-0q0bvKX6IdX9A"
      decimals="2"
      id="Tc_pdXegetXLU62R9sdTuBzKQ_23_1"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">31.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_Pvirta9m-0q0bvKX6IdX9A"
      decimals="INF"
      id="Tc_EUm_La_3IkSfcGuE7L59Ag_23_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourteenInUsdMember_39z0JsHALEOoxiU3ve-ryw"
      id="Tc_2_ZaEWAopEiG1tdeKLCE8Q_23_5">P7Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_FP7VhhSK3kiyjwb8KXwCug"
      decimals="2"
      id="Tc_Mkl6dSy990Ouh-7r1dsQMg_24_1"
      unitRef="Unit_Divide_CAD_shares_Mjvk30bxUEexejOIshQtIg">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_FP7VhhSK3kiyjwb8KXwCug"
      decimals="INF"
      id="Tc_onwt4s_az0KfswnLstUzlA_24_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">124500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_eNYFrBUgOkyeap6Drvlcbw"
      id="Tc_5lCVwPQW2EaSci1DPdTpCg_24_5">P3Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_oph37iD120e84jRRKFEFfw"
      decimals="2"
      id="Tc_F6riMc9hfkmB5wGybmaFOA_25_1"
      unitRef="Unit_Divide_CAD_shares_Mjvk30bxUEexejOIshQtIg">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_oph37iD120e84jRRKFEFfw"
      decimals="INF"
      id="Tc_8p-xRp7RXUaKpFyC-TR1eA_25_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_1IKX4UL6x02-V0ZkVdX6ew"
      id="Tc_b3-VVNBFaESApATASjwzhA_25_5">P5Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="INF"
      id="Tc_Bd1k5Bu7FEOifJAvHgoggw_26_3"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">8112774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tc_PH3lrzsVT0GzEr514HBG2A_26_5">P6Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <epix:Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber
      contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4qyYlMrwq0e0DG3Br4Mq3w"
      decimals="INF"
      id="Narr_FnBxv6vLykO3Wy5d7PwwcQ"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">3500</epix:Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4qyYlMrwq0e0DG3Br4Mq3w"
      decimals="INF"
      id="Narr_FYrv3G6QqU-WH04GqTYjNA"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">41250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Narr_R6e8JFTS3kyxk8xBBow3fw"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Narr_X9QQ9I4lFUODh1j3ycg1CA"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">1347500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="2"
      id="Narr_6Jgr6Ouq60WUgf5lsd1WrA"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">2.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="2"
      id="Narr_Zj0iMuzcVUmBA1ir5jCgjA"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"
      id="Tb_Yg-RyK_6DEGP1nKtOXARmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2023 and 2022 with allocations to its functional expense as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,622,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,306,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,372,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,551,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,995,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,858,142&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_b-IPqnYNFUuNriL48L7_JQ"
      decimals="0"
      id="Tc_N_IKtoIR1EyYZjPncV0WnA_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2622987</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_2u163Nw1DkebtudqKBTvFw"
      decimals="0"
      id="Tc_Knva4ssXGEWZxuGlRZ8cqQ_5_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">4306463</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_o2_4N6z4yU-LaC4B4CfAIg"
      decimals="0"
      id="Tc_sSGfp0m2aUur-o_BbP3yng_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2372934</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_iovEoELo8UyztRr2wxqLXg"
      decimals="0"
      id="Tc_okJ74vzPUEOaFxs1z_2Ayg_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">3551679</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"
      decimals="0"
      id="Tc_p_ipvfu-AUqOngClJ_38RQ_7_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">4995921</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ"
      decimals="0"
      id="Tc_0Oq2__q_5UOtT5FxYZnkwg_7_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">7858142</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"
      id="Tb_uoqb06zW3kKeFoNtneHwfQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 186.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 79.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"
      decimals="4"
      id="Tc_qEzQgeVBLUmtm7anmwca3g_3_2"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.0378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ"
      decimals="4"
      id="Tc_f9P-XIK6NESBYOrRRljdeQ_3_4"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.0273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"
      id="Tc_tm8m3qLkQUO__J5PVvmb8Q_4_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ"
      id="Tc_1FxZrIzURk2vla1QEpu-Lg_4_4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"
      decimals="4"
      id="Tc_zklxTEURm062LxcISxQHaA_5_2"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">1.8650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ"
      decimals="4"
      id="Tc_9Ay3pbY2YEOITIlh_pn1bQ_5_4"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.7911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_8X2B7zwAwkitxEsKtz3ewA"
      decimals="4"
      id="Tc_9NqV9hST70mTXgiRuJe0Qw_6_2"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2021_To_9_30_2022_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_m6xSDbadOUKXJAJbEEpJkQ"
      decimals="4"
      id="Tc_RVJUC42590C7TiPeYLyyxg_6_4"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_dWDIoozQ6E6zs8tPGY7Qiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021 and September&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,234,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (307,273)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49.86)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding and exercisable, September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,927,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="INF"
      id="Tc_QiIM08mxPUy7BLi4ZW6rxQ_5_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">3234750</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="2"
      id="Tc_PYAagYyL-E-B2g3AP-k0-g_5_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">4.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <epix:ClassOfWarrantOrRightExpired
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="INF"
      id="Tc_K3ZG30D6JE6hRqlrICSH5g_6_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">307273</epix:ClassOfWarrantOrRightExpired>
    <epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="2"
      id="Tc_BTYxtyPji02Wh_HejdzEng_6_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">-49.86</epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="INF"
      id="Tc_MUZ80QmZO0qe3XTovz0jZQ_8_2"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">2927477</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="2"
      id="Tc_1h3Z4ruS3kW6NzfZumsciw_8_5"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">0.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_whx_JYPnGkKJ3aaHtpmX7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;At September 30, 2023, warrants were outstanding enabling holders to acquire Common Shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 42.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;November&#160;18, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,920,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.0001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August&#160;23, 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,927,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* 7,477 warrants expired unexercised subsequent to September 30, 2023&lt;/p&gt;</epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw"
      decimals="INF"
      id="Tc_JPl7VVGk5EKB3wmC98WnMA_4_0"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">7477</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw"
      decimals="2"
      id="Tc_YqRDi87OT0q6eDwan47iRQ_4_4"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">42.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw"
      id="Tc_-zvU9yZooUCQh14D6Ck6Rw_4_6">2023-11-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ"
      decimals="INF"
      id="Tc_aT2JbWtE1kWScwUSONqQ0g_5_0"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">2920000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ"
      decimals="4"
      id="Tc_SrlU-c8K2UyY3Wcm0gvAkQ_5_4"
      unitRef="Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_7gCJXfs_z0W7PT4iC9iUGQ"
      id="Tc_oh0XmiQ9yk23RqjbqZe3hw_5_6">2024-08-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="INF"
      id="Tc_HCSW3_aas0mzGRpsGpMhBg_6_0"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">2927477</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="Duration_10_1_2023_To_12_12_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hSCrc4kh-k-gCOK-G9Yn7Q"
      decimals="INF"
      id="Narr_zX5o1Nv-wkOCOonfy5bmfg"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">7477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_YkxZcLEByEuyiucrbjavyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10.&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Included in accounts payable and accrued liabilities at September 30, 2023, is $98,360 (2022 - $81,225) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_9_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_S2NPPkKazEK7p8VCK-q5Bg"
      decimals="0"
      id="Narr_uflT95cSpkOToeOiaNfKNg"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">98360</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_diQtzC8i2UykHgFa4IJSIA"
      decimals="0"
      id="Narr_cRiTiKrDh0eO8ZHCRcT17Q"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">81225</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_Pj-URnf8sEOaJ_nyCOWtnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;&#160;INCOME TAXES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax rate of 27.0% (2022 &#x2013; 27.0%) to the tax expense:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;For the&#160;years ended September&#160;30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss for the&#160;year before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,580,743)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,215,072)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax recovery at statutory income tax rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,177,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,509,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 643,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 963,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxable capital gains&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other permanent differences including foreign exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in statutory, foreign tax, foreign exchange rates and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,212,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,288,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 325,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 165,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,003,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,007,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lmzlcV9vjEWol2ZaLP303g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 2,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hGtoKtsILUiP3lfxWLcxPg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; (111,000)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Tax attributes are subject to review, and potential adjustment, by tax authorities. The Company has recorded an income tax expense of $2,000 for the&#160;year ended September 30, 2023 (2022&#160;recovery of $111,000) in relation to taxable income generated by its U.S. subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the years ended September 30, 2023 and 2022, the Company did not record a provision for income taxes due to a full valuation allowance against our deferred tax assets. The significant components of the Company&#x2019;s deferred tax assets that have not been included on the consolidated statement of financial position are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 43,726,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,710,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment and intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,191,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,026,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (54,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 125,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 45,179,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 40,177,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (45,179,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40,177,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net future tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As at September 30, 2023, the Company has non-capital loss carry-forwards of approximately $90,502,000 (2022 - $87,702,000) available to offset future taxable income in Canada and approximately $91,858,000 (2022 - $66,812,000) available to offset future taxable income in the US. These non-capital loss carryforwards begin to expire in 2031.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="2"
      id="Narr_t7g88_PGi0S7e3F-HzdY-w"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.270</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="2"
      id="Narr_cv_pRwi_20OnoX9kAJ3qRQ"
      unitRef="Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA">0.270</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_KPAnhUGotUmdhTPMu5Nz0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;For the&#160;years ended September&#160;30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss for the&#160;year before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,580,743)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,215,072)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax recovery at statutory income tax rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,177,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,509,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 643,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 963,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxable capital gains&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other permanent differences including foreign exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in statutory, foreign tax, foreign exchange rates and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,212,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,288,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 325,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 165,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,003,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,007,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lmzlcV9vjEWol2ZaLP303g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 2,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hGtoKtsILUiP3lfxWLcxPg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; (111,000)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_-dILJaXHYEagdh5WAlYFKw_3_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-26580743</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_ywMh7oqI4UmRdkoAzR8ovw_3_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-35215072</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <epix:IncomeTaxReconciliationExpectedIncomeTaxRecovery
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_6-nib1JMjkeOvjNzPBu4Sg_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">7177000</epix:IncomeTaxReconciliationExpectedIncomeTaxRecovery>
    <epix:IncomeTaxReconciliationExpectedIncomeTaxRecovery
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_v2BVY4cul0-e8JLUTuwLng_5_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">9509000</epix:IncomeTaxReconciliationExpectedIncomeTaxRecovery>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_hljbVqeGyUyeZnsPj6Vmxg_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">643000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_6ayiDNqnMUK9Ck7ZEA67DQ_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">963000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_9Cbpbu_aCkGdx_jg3qNucA_8_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-4000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_ROBw6uobg0OHS6qdV6atJw_8_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-25000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_zDQTiFjNrU-EMZ_ue6AX8Q_9_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1212000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_JT0nOMfo7Ee1E_LJo4HhaA_9_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1288000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_WqWCzYEbgkuAq48Kflrjaw_10_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">325000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_Rzp5ACrNg0SjHzHTFVyZsQ_10_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">165000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Tc_21wSUxWMjkGqJ3pth-1kSw_11_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">5003000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Tc_RxIVp5mKlU6YFEXsOtr7Mg_11_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">7007000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA"
      decimals="0"
      id="Narr_5bctpm8SSEKI5xHC1Lob0g"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2021_To_9_30_2022_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_HocJtCQ_y0aiW3Uavtqtkg"
      decimals="0"
      id="Narr_ehSBlXU9i0CIA2E0F_RDRg"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-111000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_5J5jYmbozkml0O29q5PHLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 43,726,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,710,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment and intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,191,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,026,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (54,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 125,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 45,179,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 40,177,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (45,179,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40,177,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net future tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_i8z8_dNkkUqmvrXLFKQzfA_3_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">43726000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_Mc4mv5AfcEG81m-l5iWGfQ_3_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">37710000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <epix:DeferredTaxAssetsEquipmentAndIntangibleAssets
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_k63zL0p6zEy6GcaKIy0WdA_4_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">77000</epix:DeferredTaxAssetsEquipmentAndIntangibleAssets>
    <epix:DeferredTaxAssetsEquipmentAndIntangibleAssets
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_h76vA8YYcUKiuRjwn-4KoA_4_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">77000</epix:DeferredTaxAssetsEquipmentAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_u6UZYj2jk0egDAU-A2ctrA_5_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">29000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_nAdXzjyiek-mEwCUDNxNIA_5_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">29000</us-gaap:DeferredTaxAssetsInvestments>
    <epix:DeferredTaxAssetsFinancingCosts
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_vWtD_-MjJE-jV3-y9eDffQ_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">1191000</epix:DeferredTaxAssetsFinancingCosts>
    <epix:DeferredTaxAssetsFinancingCosts
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_Fro3J6lMsUGs9VbVEsmkvQ_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">2026000</epix:DeferredTaxAssetsFinancingCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_irQRvU-GxkC2dmzEIBjj2w_7_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">210000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_1vI7a8GoakGAJ7M06gnvDg_7_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">210000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_5kMxI8CwlUCjUBVVfAkHzA_8_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-54000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_04anaJLO8Emsd1Zm9cR9sQ_8_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">125000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_rSxtPZt8_EmNCSUUksQ6nA_10_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">45179000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_GTAWjM9SOkC0JHj-Dp4a1g_10_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">40177000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_YFJUsOxzrEul12_idoanUQ_11_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">45179000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_lY7cGbxCwUGxYQBG4qJ5dw_11_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">40177000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Tc_UqgadBTN40iO3esfsJ5fzw_13_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg"
      decimals="0"
      id="Tc_DE2MtbW-N0yC6riyNwBUpA_13_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ngnJEUWVhEOlVoIyubYBdg"
      decimals="0"
      id="Narr_5Y3lziNFUkS7DKBc22GAqQ"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">90502000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_KbenI4q0-UCApoqCAIKAKw"
      decimals="0"
      id="Narr_fPlsJJaG60efihift4vfOQ"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">87702000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2023_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_MIfdcUdEqkGqK0TtOwu9JA"
      decimals="0"
      id="Narr_70ggNQgbU0-SFcAvqXO4eg"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">91858000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2022_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_jv1GtGcpZ0q7yIrUUj3bGw"
      decimals="0"
      id="Narr_GlKcPRvPrEytbFxlyYu6lQ"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">66812000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_-_5jik8opEOfO5b7buxxTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12.&#160;&#160;&#160;&#160;SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There were no significant non-cash financing or investing activities during the year ended September 30, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;There were no amounts paid for taxes and interest in the year ended September 30, 2023 and 2022.&lt;/p&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA"
      decimals="0"
      id="Narr_nkSz_umIOEK-Zn-j3Lm67A"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="0"
      id="Narr_oQFpxGmZWUKWO1-Azke5ag"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_WD-HIpFdU0GSToU2L0tP7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13.&#160;&#160;&#160;&#160;SEGMENTED INFORMATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company works in one industry being the development of small molecule drugs for prostate cancer. The Company&#x2019;s right of use asset is located in the USA.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      decimals="INF"
      id="Narr_GK1yg--XG0uG1udFicRBuQ"
      unitRef="Unit_Standard_segment_4JNQuy2SFUWBUQBeaKqunQ">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_JaO7dojfr0GgMxYJd1ueYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS AND RISK&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities and derivative liabilities. The fair value of cash and cash equivalents, GICs and term deposits included in short-term investments, receivables, accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The fair value of U.S. treasury securities, corporate debt securities and commercial paper included in short-term investments are measured using Level 2 inputs based on standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers (Note 4). The derivative liabilities are measured using Level 3 inputs (Note 8). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Financial risk factors&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s risk exposures and the impact on the Company&#x2019;s financial instruments are summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Credit risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. Short-term investments includes investments that may have maturity dates exceeding one year at the date of purchase; however, the Company may liquidate investment positions prior to maturity to implement management strategies. The Company maintains an investment policy which requires certain minimum investment grades over its investment instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2023, cash and cash equivalents consisted of cash in Canada and the United States and term deposits in Canada and investments in certain instruments which have a maturity of less than three months at the date of purchase. Balances in cash accounts exceed amounts insured by the Canada Deposit Insurance Corporation for up to C$100,000 and by the Federal Deposit Insurance Corporation for up to $250,000. Amounts due from government agencies are considered to have minimal credit risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Liquidity risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;As at September 30, 2023, the Company had working capital of $145,301,807 which will fund budgeted operations past the horizon of the coming year. The Company does not generate revenue and will use available financing options when required to pursue its business objectives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Market risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(a)&lt;/span&gt;Interest rate risk&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Over the periods presented, the interest rate environment has changed considerably. The Company has elected to place its cash in instruments which provide a return on funds pending deployment to service business objectives (Note 4). The Company monitors its investments against internal investment criteria which prioritize security of principal. While all investments bear some degree of risk, the Company does not consider interest rate fluctuations to have a significant risk to its financial and operational objectives. The Company does not have any interest-bearing debt.&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(b)&lt;/span&gt;Foreign currency risk&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;The Company&#x2019;s foreign currency risk exposure relates to net monetary assets denominated in Canadian dollars and Euro. The Company maintains its cash and cash equivalents in U.S. dollars and converts on an as needed basis to discharge Canadian and Euro denominated expenditures. A 10% change in the foreign exchange rate between the Canadian, Euro and U.S. dollar in relation to Canadian and Euro dollars held at September 30, 2023 would result in a fluctuation of $2,616 in the net loss recognized for the period. The Company does not currently engage in hedging activities.&lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <epix:CashCanadaDepositInsuranceCorporationInsuredAmount
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Narr_P332y_AL80m-O-aP7PLJgQ"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">100000</epix:CashCanadaDepositInsuranceCorporationInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Narr_GxMgAaHsiU-yuPGOkO04sg"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">250000</us-gaap:CashFDICInsuredAmount>
    <epix:WorkingCapital
      contextRef="As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg"
      decimals="0"
      id="Narr_I3uOV87DAkmVb499vqMkVQ"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">145301807</epix:WorkingCapital>
    <epix:ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate
      contextRef="Duration_10_1_2022_To_9_30_2023_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_uQe42TT11ESmRCITPgf7Ag"
      decimals="0"
      id="Narr_iV3R8IzaKUK8ZvK6Q8nd9Q"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">-2616</epix:ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_vufINS_FVUC5tCJMojQBCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15.&#160;&#160;&#160;&#160;COMMITMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The NTD Technology is held under a license agreement signed in fiscal 2010 (the &#x201c;License Agreement&#x201d;). As consideration for the License Agreement, the Company issued Common Shares of the Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates annual minimum advance royalty payments of C$85,000. &#160;In addition, there are certain milestone payments for the first compound, to be paid in stages as to C$20,000 upon filing an Investigational New Drug (IND) Application, C$50,000 at the start of a Phase 2 clinical trial, C$900,000 at the start of a Phase 3 clinical trial, C$1,450,000 at application for marketing approval, and with further milestone payments on the second and additional compounds. To date, the Company has paid C$20,000 for filing an IND application for masofaniten (EPI-7386). The next milestone of C$50,000 will be due upon initiation of the Phase 2 clinical trial for masofaniten (EPI-7386).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company has the following obligations over the next five&#160;years:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Contractual obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2027&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2028&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Minimum annual royalty per License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;85,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease on CDN office spaces&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 76,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease on U.S. office spaces&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Collaborative agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;On January 13, 2021, the Company announced a clinical collaboration with Janssen to evaluate masofaniten (EPI-7386) with abiraterone acetate with prednisone as well as the combination of masofaniten (EPI-7386) with apalutamide in patients with mCRPC. Under the terms of the agreement, Janssen may sponsor and conduct up to two Phase 1/2 studies evaluating the safety, tolerability and preliminary efficacy of the combination of &lt;/span&gt;&lt;span style="font-style:normal;"&gt;masofaniten (EPI-7386) &lt;/span&gt;&lt;span style="font-style:normal;"&gt;and apalutamide as well as the combination of masofaniten (EPI-7386) with abiraterone acetate plus prednisone in patients with mCRPC who have failed a current second-generation antiandrogen therapy. Janssen will assume all costs associated with the studies, other than the manufacturing costs associated with the clinical drug supply of masofaniten (EPI-7386). The parties will form a joint oversight committee for the clinical studies. ESSA will retain all rights to masofaniten (EPI-7386). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The combination trial was initiated in March 2022. Enrollment was suspended by Janssen in October 2022 due to operational recruitment challenges. ESSA has announced its intention to revise the collaboration, with ESSA conducting a study of the combinations, potentially in an earlier patient population, and Janssen supplying apalutamide and abiraterone acetate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 25, 2021, the Company announced a clinical collaboration with Astellas Pharma Inc. (&#x201c;Astellas&#x201d;) to evaluate the combination of masofaniten (EPI-7386) and Astellas/Pfizer&#x2019;s androgen receptor inhibitor, enzalutamide, for patients with mCRPC. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of masofaniten (EPI-7386) and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to masofaniten (EPI-7386). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer Consumer Care AG (&#x201c;Bayer&#x201d;) to evaluate masofaniten (EPI-7386) in combination with Bayer&#x2019;s androgen receptor inhibitor, darolutamide, in patients with mCRPC. &#160;Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of masofaniten (EPI-7386) and darolutamide in mCRPC patients. ESSA will supply masofaniten (EPI-7386) for the trial and will retain all rights to masofaniten (EPI-7386). &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <epix:MinimumAdvanceRoyaltyPayments
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"
      decimals="0"
      id="Narr_rGojcGiZy0CKX_YJMoMBig"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">85000</epix:MinimumAdvanceRoyaltyPayments>
    <epix:AmountOfMilestoneToBePaidForFilingOfApplication
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"
      decimals="0"
      id="Narr_zhPe2gFPF0i6816CWQweDw"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">20000</epix:AmountOfMilestoneToBePaidForFilingOfApplication>
    <epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"
      decimals="0"
      id="Narr_DqRlPAUPpU-eGBAN3mPwnw"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">50000</epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial>
    <epix:AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"
      decimals="0"
      id="Narr_jhjR1rzpeUyCsza-do-Geg"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">900000</epix:AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial>
    <epix:AmountOfMilestonePaymentsAtApplicationForMarketingApproval
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"
      decimals="0"
      id="Narr_NmBoLcXB10CmjNyMhwj-ng"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">1450000</epix:AmountOfMilestonePaymentsAtApplicationForMarketingApproval>
    <epix:AmountOfMilestonePaymentForFilingOfApplication
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"
      decimals="0"
      id="Narr_N6Xc-hQ-CEerShI7c-_4OQ"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">20000</epix:AmountOfMilestonePaymentForFilingOfApplication>
    <epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA"
      decimals="0"
      id="Narr_TUur3J_x0UOSCChyQj54kA"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">50000</epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_kqVVoSf7P0GGVAsHfyYd6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Contractual obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2027&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2028&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Minimum annual royalty per License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;85,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease on CDN office spaces&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 76,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease on U.S. office spaces&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA"
      decimals="0"
      id="Tc_GRTRf-zTV0Sfb14DHU0Ijg_3_3"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">85000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA"
      decimals="0"
      id="Tc_xfNMvfFukk25Ov4S3pWFVg_3_6"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">85000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA"
      decimals="0"
      id="Tc_mmXNC8Ea502DHV2PyVsmMg_3_9"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">85000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA"
      decimals="0"
      id="Tc_mf7E03AmeUmyjsz6AWwZkQ_3_12"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">85000</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="As_Of_9_30_2023_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_Dj3XYMDQ60CJRx7QDlp7wA"
      decimals="0"
      id="Tc_Wde5l1Skiku4eLvOPyGi3w_3_15"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">85000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw"
      decimals="0"
      id="Tc_tiybp3dk80u4q3kDIclb2A_4_3"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">76610</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw"
      decimals="0"
      id="Tc_d-Fd4lalZEO8yBwBVGlckQ_4_6"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">0</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw"
      decimals="0"
      id="Tc_rNBUKeppxUCHQaAbo3qFQA_4_9"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">0</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw"
      decimals="0"
      id="Tc_ODe_UhUGNE6K_5tWQIF93Q_4_12"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">0</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw"
      decimals="0"
      id="Tc_RxYVeqFnH0qPtruWPIWGaA_4_15"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w"
      decimals="0"
      id="Tc_5zKsvUpiRkiFijB79rxEWQ_6_3"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">81509</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w"
      decimals="0"
      id="Tc_KO3po3_kwUmVAzwJl6DNLA_6_6"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w"
      decimals="0"
      id="Tc_bds2VEb990q8LF1_usIFig_6_9"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w"
      decimals="0"
      id="Tc_kkyAuuxoNEanHTsz770f1w_6_12"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_voLeGWjc-UCJ1OikIVX55w"
      decimals="0"
      id="Tc_TthJ0HUzAE6sX97qGn2QQw_6_15"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA"
      id="Tb_D_EAvQLxTUKmidNv3d_mPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16.&#160;&#160;&#160;&#160;SUBSEQUENT EVENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2023, the Company issued 30,000 common shares for stock options exercised for gross proceeds of $96,900.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2023, the Company issued 11,250 common shares for stock options exercised for gross proceeds of CDN$55,925.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oXvRvCbUM0iIVSZ_bqCa7w"
      decimals="INF"
      id="Narr_A2kt38hCS0enQ2_vsLOn5Q"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">30000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oXvRvCbUM0iIVSZ_bqCa7w"
      decimals="0"
      id="Narr_R6J8JmOmk0S2nXOJVOmgKg"
      unitRef="Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g">96900</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kJCtEN0KwUq7roKlGrzIaA"
      decimals="INF"
      id="Narr_ZnZueVTbIkCu7JJ9p8Ciiw"
      unitRef="Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w">11250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kJCtEN0KwUq7roKlGrzIaA"
      decimals="0"
      id="Narr_n2kxARdsNEilkEh7nm529A"
      unitRef="Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw">55925</us-gaap:ProceedsFromStockOptionsExercised>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M'9$KTM&"JB^B[=&YH7$;>QX1,D+$+P25]+3:?5UJ97K2[ENP6Q^[HSLT2/V
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MZD48=^/:ER)1R..!XB%XSS7X!1DPO/.-^O'60T^BA)$.1)]H&$.QT7@@Q.2
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M7LX[%_AL2/(!N<6WF&WDSC725)XY_Z%O;N;G'4LC8@D+E79!X6_-ABQ)M"?
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MZ_&#8=-CA-RJC;\JXY_E;9_X5AMQNS@^9? YD,3_L'G9PSIKQPBVW#+B0IW
MRI3":K2&Y4D+_+MZ.N:J,RBCXSO^82+K9B=NX'D-"HJW$HK;-33O=+V(0M]
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M_ !$ MA5IHI/Y>II=<ARD1\M'#R_Q&?#XJADZZ8XN;FC8A%G$B7L!5Q:IS[
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M\+HUD/\_EJ7X?M.^/>M?X,[^ U!+ P04    "  6.(Q72OY6P;0#   7"
M&    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*56ZV_B.!#_5T99:;4G(?(
M^N(A <OJ>J=25&CW=-],,A!?'3MK.V3Y[V^<!$JO+7?2?2FQ/;_'>.QQ!Z72
MSR9%M/ S$](,O=3:_,;W39QBQDQ;Y2AI9:-TQBP-]=8WN4:65*!,^%$07/@9
MX](;#:JYA1X-5&$%E[C08(HL8WH_0:'*H1=ZAXD'ODVMF_!'@YQM<8GV,5]H
M&OE'EH1G* U7$C1NAMXXO)ET77P5\,2Q-"??X#)9*_7L!K?)T N<(1086\?
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MVIZ<O93'*914HTK\+\5)F%3I*-O]X>2].6W3R@V,MRCC?55;%_8HZ2'0AM?
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MW*=H8-5=TX .AY85Y1<RY7WKJ7<33TEM0@<-= E*27JBD6.8M!3+4J?'6NY
M==BGM=V, G>,VI!W:<Q(8 VOJ)144"IEGQ(MBDHB9SQEVF&[[()"O.]![H@H
M]4'4?6@2#R(+RUT.&4GHF"",_J4J.F!N5!>,;'9NWCD&:>>QT,/'C,P,TT[
MFAW#Y@4]'+:,]/0]?$WU$N/4$Y \JYG(O8FUD6(>P$1PK2_2!)W#0_!H;1Y3
M 1"V>@"Q2E("@:A< GTF2,<^08T+G&WFFW'2DE"?:H#3(R@=GH?@\E><83L,
MLX?2>Z:99T7,YA_4<0XBTT%F@\-Z&];6,#*\=M]ZR:\Q09%0DNU(#9@,^:QV
M^\(ZX\:8JH(1V+7MOL#V54. TY;&7B[TU"2^Y)&U)\'/S*GY>/"["!"]DN'
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M1_/$0R[N?KZ\_$0E<NH=>3)QY/(-9_WY^_/O9N<7YY/R\IAR+GA:QF $R1J
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M:N=TY3]+P>&N1(#UF=9N/: #-@^N5[\!4$L#!!0    ( !8XC%?H#5N9?0(
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MQN'Y:0"ZG<SMQJK:3\.ELC1;_;*DCQG43H#N"Z5LOW$&AL^CV=]02P,$%
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MW7)M2Y;A,*)VL&B>,1J]?=.Y3#Z>4-IKE/9.T?]1Z6E6)VG#<1[<JTQ4]%[
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M5Y7-A80/FIFJ*+C>7D&N-A>]J+<[^"B6*TL'@_EYR9=P#_9S^4$C-6BTI*(
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MEOW >-SF@\[F).8(8BX?(@N?VVPAQOLK0"3#;*6CTBK4E)F5R53M3!4YB!!
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M[V=AD&YC>08,C94W$3T$E5#P8OQR_K*SF;,DO(2IT0%E/ =S5WG@CD< E #
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MI%#6_32(P#03H#&<KD/7+;2C'@[+DH8F&N] YTNMW=[P"=HQG/T!4$L#!!0
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MK]\Y:=,.]04$7V+?^>ZYYWRV+YV%D \J =#D*4MSU;42K8MSQU%1 AE39Z*
M'%>F0F9,HRAGCBHDL+ATRE*'NF[@9(SG5J]3ZD:RUQ%SG?(<1I*H>98Q^3R
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M"J"Q'<!<D'-5L BZ%MX !?(1K-[1)R]P+_;0:]3T&OO0>V.\</$\!2*FY+8
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M X P)L]V=Q<A2%J0E[S@2<H+DH#7<*G0@7@UAHV.ICTOXZ@<(%K44F) DO!
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MU>N-=A F81_808@[IN,?W!^)'T$ZZO3M+F<Z8BQ6(JGA"(;G$+TO)[=E!2>
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M9HY+[QIE$WT:\T_!*%25YKI%HMM.),$<MN0P<@T\"U*KUC5/,K[XM ^AH,P
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M5<MNVS 0_!5"!8H$2*R'7T4J"X@3-\G!:6"[Z9F1UA81D53)E9W\?4C*5EU
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MX-TIE23+Q7ME=3T[!>]^?C]VI(I%(SI)/>['U;BH9UR(P 4KY5R LS*EZ2:
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MJYNOU8MDB^KRZ(9)R8KJ<4Y)2KDV4-_?,B:?7_0 S?WCY%]02P,$%     @
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M&D#PM.M#!V\U(KB16I[M2_)J@D35\L,U53,(XS"L4JP5;-G>H):DOR'IG[;
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M>.#T'+*$%=TD>B9VGV'OIVWX(I$H>R6[/+:%P=%&:9'NP:@@93R_TZ=]'DJ
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M@U=LUYSA3PTH.P'',RG-4\?>LYO?I-X?4$L#!!0    ( !8XC%=:2#R4/04
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MKA;(^TO&Q/M$;5 U#X?_ %!+ P04    "  6.(Q7%LHBA9(#  #"#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RU5VUOVC 0_BM6)DV;M#6OO'6
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M2M=[($R _IYRKMX[IJ*H*\CH+U!+ P04    "  6.(Q7PX[OE^<"  "3"
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6RM5MN.VC 0_14KK2J0"KD
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M:&5E=',O<VAE970U-2YX;6RM5&%OVC 0_2NG;)I::6M"0MN)A4@0J%J)MHC
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M =(ZF/-<"'TR;(+A?Y3\ 5!+ P04    "  6.(Q7;"B)+_@"  #K"0  &0
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M[F AZE%M^QM,+XB:8[_)Q67"EBP9UUTUFU1-SS1,UOH"PBYR6UUN!.-8S(T
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MU1[S6?]+S>P-4$L! A0#%     @ %CB,5P=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  6.(Q7_#MC
MCNT    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  6.(Q7F5R<(Q &  "<)P  $P              @ '+ 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !8XC%?9,%0@U@<  'DT
M   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  6.(Q7#.*6YBX%  "1$P  &               @($8$
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ %CB,5S$S<7HV
M @  O@4  !@              ("!?!4  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( !8XC%=DZS$=- 4  )X2   8              "
M@>@7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  6.(Q7
MQ-FLCH(&  ">&0  &               @(%2'0  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ %CB,5_OR:?=\!0  S!T  !@
M     ("!"B0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M !8XC%=*_E;!M ,  !<(   8              " @;PI  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  6.(Q7[IM2)/D(   <&   &
M            @(&F+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ %CB,5PXD+YV&$   BC   !@              ("!U38  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !8XC%>U-)DGXP8  'P5
M   9              " @9%'  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ %CB,5^@-6YE] @  = 8  !D              ("!JTX
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  6.(Q7@<B/
MM) "  #&!@  &0              @(%?40  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( !8XC%?6"M;[*00  *\+   9
M  " @294  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M%CB,5^]$09_? P  *@D  !D              ("!AE@  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  6.(Q7%QCZ;NT+  "-)@  &0
M            @(&<7   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( !8XC%=HJ4%>I@(  .<%   9              " @<!H  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ %CB,5UO]%:W>!0
MYP\  !D              ("!G6L  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  6.(Q7(,$S W@"  #\!0  &0              @(&R
M<0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !8XC%=*
M'U/A6 (  $H%   9              " @6%T  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ %CB,5V5I;RI3"   (14  !D
M     ("!\'8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M"  6.(Q7(.":B8@'  #A%@  &0              @(%Z?P  >&PO=V]R:W-H
M965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !8XC%>C]G]>6@(  )(%   9
M              " @3F'  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!
M A0#%     @ %CB,5PD%Y9,A"0  ,AD  !D              ("!RHD  'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  6.(Q742Y#O#@1
M   #-@  &0              @($BDP  >&PO=V]R:W-H965T<R]S:&5E=#(T
M+GAM;%!+ 0(4 Q0    ( !8XC%?:EKS?@@(  /D%   9              "
M@9&D  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ %CB,
M5PA?+YG+ P  HPT  !D              ("!2J<  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  6.(Q7U-$F$)4"  "%!@  &0
M        @(%,JP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( !8XC%?N_L%3L (  *\&   9              " @1BN  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ %CB,5Z4EP.WN @  F0@
M !D              ("!_[   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  6.(Q7:]!O< D#   H!P  &0              @($DM
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !8XC%?(R1 Q
M#@D  + B   9              " @62W  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ %CB,5S7)*B)>!   "0P  !D
M ("!J<   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  6
M.(Q7*9Q2@Y "  "6!P  &0              @($^Q0  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !8XC%?;L1UD<@(  (8%   9
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M970S."YX;6Q02P$"% ,4    "  6.(Q7-'P"D;0"   P!P  &0
M    @(&0V0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M !8XC%<839:[0 0  /80   9              " @7O<  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ %CB,5\09]:[/ @  SP@  !D
M             ("!\N   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  6.(Q7OM VA>\"  !;"P  &0              @('XXP  >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !8XC%?+@"$N00,
M #(-   9              " @1[G  !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ %CB,5UI(/)0]!0  9B$  !D              ("!
MENH  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  6.(Q7
M Y&[</@#  !(%   &0              @($*\   >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( !8XC%<6RB*%D@,  ,(-   9
M      " @3GT  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ %CB,5T[V0:GG P  R \  !D              ("! O@  'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  6.(Q7T^E:SV$/   QW@
M&0              @($@_   >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( !8XC%?3AGM _0(  /H(   9              " @;@+ 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ %CB,5_@'=]TC
M!   PA<  !D              ("![ X! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    "  6.(Q7:R.S!6T"   =!@  &0
M@(%&$P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( !8X
MC%<!:GO&^P,  .P+   9              " @>H5 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ %CB,5\Z$9=DX P  30H  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( !8XC%=<E)5>40,  ,@(   9
M  " @<TH 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M%CB,5S_ "S>X P  810  !D              ("!52P! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    "  6.(Q7J-Z;KI$$  !M)   &0
M            @(%$, $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( !8XC%<AC:T>4 ,  +05   -              "  0PU 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ %CB,5Y>*NQS     $P(   L
M     ( !AS@! %]R96QS+RYR96QS4$L! A0#%     @ %CB,5P.(_/43!0
MUR<   \              ( !<#D! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( !8XC%>8&UJ>^P$  ,LC   :              "  ; ^ 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !8XC%=TTL9BW@$  %HC
M   3              "  >-  0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !$ $0 DQ(  /)" 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>129</ContextCount>
  <ElementCount>237</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - SHORT-TERM INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShortTermInvestments</Role>
      <ShortName>SHORT-TERM INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - PREPAIDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosurePrepaids</Role>
      <ShortName>PREPAIDS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - OPERATING LEASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLease</Role>
      <ShortName>OPERATING LEASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - DERIVATIVE LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilities</Role>
      <ShortName>DERIVATIVE LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SHAREHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquity</Role>
      <ShortName>SHAREHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - SEGMENTED INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSegmentedInformation</Role>
      <ShortName>SEGMENTED INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>20202 - Disclosure - BASIS OF PRESENTATION (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy</Role>
      <ShortName>BASIS OF PRESENTATION (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30203 - Disclosure - BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentationTables</Role>
      <ShortName>BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShortTermInvestmentsTables</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShortTermInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30503 - Disclosure - PREPAIDS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosurePrepaidsTables</Role>
      <ShortName>PREPAIDS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosurePrepaids</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30603 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30703 - Disclosure - OPERATING LEASE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLeaseTables</Role>
      <ShortName>OPERATING LEASE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureOperatingLease</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30803 - Disclosure - DERIVATIVE LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables</Role>
      <ShortName>DERIVATIVE LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureDerivativeLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30903 - Disclosure - SHAREHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</Role>
      <ShortName>SHAREHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31101 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31503 - Disclosure - COMMITMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitmentsTables</Role>
      <ShortName>COMMITMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureCommitments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureBasisOfPresentationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40401 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShortTermInvestmentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40402 - Disclosure - SHORT-TERM INVESTMENTS - Realized gains and losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails</Role>
      <ShortName>SHORT-TERM INVESTMENTS - Realized gains and losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40501 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails</Role>
      <ShortName>PREPAIDS (Schedule of Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosurePrepaidsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40701 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASE (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureOperatingLeaseTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40702 - Disclosure - OPERATING LEASE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails</Role>
      <ShortName>OPERATING LEASE (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureOperatingLeaseTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40801 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails</Role>
      <ShortName>DERIVATIVE LIABILITIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40802 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails</Role>
      <ShortName>DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SHAREHOLDERS EQUITY (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails</Role>
      <ShortName>SHAREHOLDERS EQUITY (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40902 - Disclosure - SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails</Role>
      <ShortName>SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40903 - Disclosure - SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails</Role>
      <ShortName>SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40904 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>SHAREHOLDERS EQUITY (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40905 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails</Role>
      <ShortName>SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40906 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails</Role>
      <ShortName>SHAREHOLDERS EQUITY (Summary of Warrants Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40907 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails</Role>
      <ShortName>SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41001 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41101 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails</Role>
      <ShortName>INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41102 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES (Significant Components of Future Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41103 - Disclosure - INCOME TAXES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41301 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails</Role>
      <ShortName>SEGMENTED INFORMATION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureSegmentedInformation</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41501 - Disclosure - COMMITMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails</Role>
      <ShortName>COMMITMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureCommitmentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41502 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails</Role>
      <ShortName>COMMITMENTS (Schedule of Contractual Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureCommitmentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="tmb-20230930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41601 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20230930.xsd</File>
    <File>tmb-20230930_cal.xml</File>
    <File>tmb-20230930_def.xml</File>
    <File>tmb-20230930_lab.xml</File>
    <File>tmb-20230930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="tmb-20230930x10k.htm">tmb-20230930x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tmb-20230930x10k002.jpg</File>
    <File>tmb-20230930x10k003.jpg</File>
    <File>tmb-20230930x10k004.jpg</File>
    <File>tmb-20230930x10k005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="474">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20230930x10k.htm": {
   "nsprefix": "epix",
   "nsuri": "http://www.essapharma.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "tmb-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tmb-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20230930x10k.htm"
     ]
    }
   },
   "keyStandard": 206,
   "keyCustom": 31,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 38,
   "hidden": {
    "total": 17,
    "http://fasb.org/us-gaap/2022": 14,
    "http://xbrl.sec.gov/dei/2022": 3
   },
   "contextCount": 129,
   "entityCount": 1,
   "segmentCount": 65,
   "elementCount": 410,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 474,
    "http://fasb.org/srt/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "report": {
    "R1": {
     "role": "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJOjEf4-C0qZblxK7QIl_w",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.essapharma.com/role/DisclosureNatureOfOperations",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentation",
     "longName": "10201 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.essapharma.com/role/DisclosureShortTermInvestments",
     "longName": "10401 - Disclosure - SHORT-TERM INVESTMENTS",
     "shortName": "SHORT-TERM INVESTMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.essapharma.com/role/DisclosurePrepaids",
     "longName": "10501 - Disclosure - PREPAIDS",
     "shortName": "PREPAIDS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:PrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:PrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities",
     "longName": "10601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.essapharma.com/role/DisclosureOperatingLease",
     "longName": "10701 - Disclosure - OPERATING LEASE",
     "shortName": "OPERATING LEASE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilities",
     "longName": "10801 - Disclosure - DERIVATIVE LIABILITIES",
     "shortName": "DERIVATIVE LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquity",
     "longName": "10901 - Disclosure - SHAREHOLDERS EQUITY",
     "shortName": "SHAREHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.essapharma.com/role/DisclosureRelatedPartyTransactions",
     "longName": "11001 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxes",
     "longName": "11101 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows",
     "longName": "11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS",
     "shortName": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.essapharma.com/role/DisclosureSegmentedInformation",
     "longName": "11301 - Disclosure - SEGMENTED INFORMATION",
     "shortName": "SEGMENTED INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk",
     "longName": "11401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.essapharma.com/role/DisclosureCommitments",
     "longName": "11501 - Disclosure - COMMITMENTS",
     "shortName": "COMMITMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.essapharma.com/role/DisclosureSubsequentEvents",
     "longName": "11601 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy",
     "longName": "20202 - Disclosure - BASIS OF PRESENTATION (Policy)",
     "shortName": "BASIS OF PRESENTATION (Policy)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy",
     "longName": "20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policy)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentationTables",
     "longName": "30203 - Disclosure - BASIS OF PRESENTATION (Tables)",
     "shortName": "BASIS OF PRESENTATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.essapharma.com/role/DisclosureShortTermInvestmentsTables",
     "longName": "30403 - Disclosure - SHORT-TERM INVESTMENTS (Tables)",
     "shortName": "SHORT-TERM INVESTMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.essapharma.com/role/DisclosurePrepaidsTables",
     "longName": "30503 - Disclosure - PREPAIDS (Tables)",
     "shortName": "PREPAIDS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:ScheduleOfPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:ScheduleOfPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables",
     "longName": "30603 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.essapharma.com/role/DisclosureOperatingLeaseTables",
     "longName": "30703 - Disclosure - OPERATING LEASE (Tables)",
     "shortName": "OPERATING LEASE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables",
     "longName": "30803 - Disclosure - DERIVATIVE LIABILITIES (Tables)",
     "shortName": "DERIVATIVE LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
     "longName": "30903 - Disclosure - SHAREHOLDERS EQUITY (Tables)",
     "shortName": "SHAREHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesTables",
     "longName": "31101 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.essapharma.com/role/DisclosureCommitmentsTables",
     "longName": "31503 - Disclosure - COMMITMENTS (Tables)",
     "shortName": "COMMITMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails",
     "longName": "40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)",
     "shortName": "BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA",
      "name": "epix:PercentageOfEffectiveInterestInSubsidiaries",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
       "us-gaap:ConsolidationPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_jGSAlqFHOk6UgXwWX6hUAA",
      "name": "epix:PercentageOfEffectiveInterestInSubsidiaries",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
       "us-gaap:ConsolidationPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails",
     "longName": "40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Change in presentation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2021_To_9_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aFHBiSyjkEyJjqK5ha2_ug",
      "name": "epix:OperatingInterestIncomeOfShortTermInvestments",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
     "longName": "40401 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)",
     "shortName": "SHORT-TERM INVESTMENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember__JFKnEKGe0C4wTHeLj8ODQ",
      "name": "us-gaap:InvestmentInterestRate",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_epix_GuaranteedInvestmentCertificatesAndTermDepositsMember__JFKnEKGe0C4wTHeLj8ODQ",
      "name": "us-gaap:InvestmentInterestRate",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails",
     "longName": "40402 - Disclosure - SHORT-TERM INVESTMENTS - Realized gains and losses (Details)",
     "shortName": "SHORT-TERM INVESTMENTS - Realized gains and losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails",
     "longName": "40501 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)",
     "shortName": "PREPAIDS (Schedule of Prepaid Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfPrepaidExpensesTableTextBlock",
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfPrepaidExpensesTableTextBlock",
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
     "longName": "40601 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
     "longName": "40701 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)",
     "shortName": "OPERATING LEASE (Schedule of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2021_PXrY4DSv7E6zmLrZesp3SQ",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
     "longName": "40702 - Disclosure - OPERATING LEASE (Narrative) (Details)",
     "shortName": "OPERATING LEASE (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
     "longName": "40801 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)",
     "shortName": "DERIVATIVE LIABILITIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JDmOjRguN0Kdzie1u0Eb5A",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
     "longName": "40802 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)",
     "shortName": "DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_oBr_-pywIkaEsKV63Ewtww",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_oBr_-pywIkaEsKV63Ewtww",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
     "longName": "40901 - Disclosure - SHAREHOLDERS EQUITY (Narrative) (Details)",
     "shortName": "SHAREHOLDERS EQUITY (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
     "longName": "40902 - Disclosure - SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details)",
     "shortName": "SHAREHOLDERS EQUITY (Schedule of Share Based Compensation Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails",
     "longName": "40903 - Disclosure - SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)",
     "shortName": "SHAREHOLDERS EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_kaP9Rvn2-k6n5TNhPb-lTg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
     "longName": "40904 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Activity) (Details)",
     "shortName": "SHAREHOLDERS EQUITY (Summary of Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
     "longName": "40905 - Disclosure - SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)",
     "shortName": "SHAREHOLDERS EQUITY (Summary of Stock Option Outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_FTh9bIYjmUm93cvyU9OacQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails",
     "longName": "40906 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Activity) (Details)",
     "shortName": "SHAREHOLDERS EQUITY (Summary of Warrants Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2022_3HGgPp357kCI00c0XbhLPg",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:ClassOfWarrantOrRightExpired",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
     "longName": "40907 - Disclosure - SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details)",
     "shortName": "SHAREHOLDERS EQUITY (Summary of Warrants Outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_sPH4ItMCyEO2eGTLiXgwTw",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
     "longName": "41001 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_S2NPPkKazEK7p8VCK-q5Bg",
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_S2NPPkKazEK7p8VCK-q5Bg",
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
     "longName": "41101 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)",
     "shortName": "INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "epix:IncomeTaxReconciliationExpectedIncomeTaxRecovery",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails",
     "longName": "41102 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)",
     "shortName": "INCOME TAXES (Significant Components of Future Tax Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "41103 - Disclosure - INCOME TAXES (Narrative) (Details)",
     "shortName": "INCOME TAXES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_Aspv5tzrRU-MMKfX1YPoYA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails",
     "longName": "41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)",
     "shortName": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:IncomeTaxesPaid",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:IncomeTaxesPaid",
       "p",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:IncomeTaxesPaid",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:IncomeTaxesPaid",
       "p",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails",
     "longName": "41301 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)",
     "shortName": "SEGMENTED INFORMATION (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_4JNQuy2SFUWBUQBeaKqunQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_UJYTVxFEeEWNDZWF7ZjaXA",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_4JNQuy2SFUWBUQBeaKqunQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails",
     "longName": "41401 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "epix:CashCanadaDepositInsuranceCorporationInsuredAmount",
      "unitRef": "Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_PE1BpvznXkOC6FaYslKAqg",
      "name": "epix:CashCanadaDepositInsuranceCorporationInsuredAmount",
      "unitRef": "Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
     "longName": "41501 - Disclosure - COMMITMENTS (Narrative) (Details)",
     "shortName": "COMMITMENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA",
      "name": "epix:MinimumAdvanceRoyaltyPayments",
      "unitRef": "Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_BnEZ8Phu3UGPRBeDanDLKA",
      "name": "epix:MinimumAdvanceRoyaltyPayments",
      "unitRef": "Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails",
     "longName": "41502 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)",
     "shortName": "COMMITMENTS (Schedule of Contractual Obligations) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_epix_LeaseOnCdnOfficeSpacesMember_9fOMlhg_wkePZDx9IBmQVw",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_CAD_pXehJkRmsUaD0WTybpaeQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
     "longName": "41601 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)",
     "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2021_To_9_30_2022_D4jbdKu220a5zFZ3fD_fSA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_Standard_shares_8YdKzAB16E68jyLo4qkw8w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_2_2023_To_11_2_2023_us-gaap_AwardTypeAxis_epix_StockOptionExercisedOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oXvRvCbUM0iIVSZ_bqCa7w",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "Unit_Standard_USD_81yNZeTxcEy9C5QXb0t-1g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20230930x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding - Basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r182"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, in shares",
        "periodStartLabel": "Beginning Balance, in shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r121",
      "r521"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r609",
      "r611",
      "r614"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "verboseLabel": "Accrued vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r63"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Life (in Years) [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Future Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Annualized Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Schedule of Share Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASE"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r131",
      "r154",
      "r220",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r350",
      "r353",
      "r354",
      "r371",
      "r521",
      "r563",
      "r607",
      "r608"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r60",
      "r116",
      "r471",
      "r476",
      "r521"
     ]
    },
    "us-gaap_ReclassificationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ReclassificationLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Summary of Warrants Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of available for sale securities reconciliation",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity Discount [Member]",
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_ReclassificationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ReclassificationTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification [Table]",
        "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES (Abstract)",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Deficit) [Member]",
        "terseLabel": "Deficit",
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r157",
      "r158",
      "r159",
      "r162",
      "r171",
      "r174",
      "r224",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r365",
      "r467",
      "r469"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r283",
      "r534",
      "r535",
      "r548"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net future tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r490",
      "r491",
      "r513",
      "r523",
      "r566"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Accrued Investment Income - extensible enumeration",
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Income Taxes at Statutory Rates",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "OPERATING LEASE",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Number of Warrants, Ending balance (in shares)",
        "periodStartLabel": "Number of Warrants, Beginning balance (in shares)",
        "terseLabel": "Number of Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "verboseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r152"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "verboseLabel": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "negatedLabel": "Options exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance (in dollar per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance (in dollar per share)",
        "verboseLabel": "Exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r545",
      "r546",
      "r547",
      "r599"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted",
        "verboseLabel": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administration",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Sale of Investments",
        "terseLabel": "Gains or losses on sales of short-term investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Non-capital loss carry-forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of contractual obligations",
        "terseLabel": "Schedule of Contractual Obligations",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares 44,100,838 issued and outstanding (September 30, 2022 - 44,073,076) (Note 9)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r521"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DERIVATIVE LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r235",
      "r236",
      "r239",
      "r265",
      "r277",
      "r355",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r508",
      "r552",
      "r553",
      "r554",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Investment tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS AND RISK",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r125",
      "r145",
      "r146",
      "r147",
      "r157",
      "r158",
      "r159",
      "r162",
      "r171",
      "r174",
      "r184",
      "r224",
      "r280",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r365",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r410",
      "r467",
      "r468",
      "r469"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common Shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative [Table]",
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r355"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "SHAREHOLDERS' EQUITY",
        "verboseLabel": "Warrant outstanding and Exercise price",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Items not affecting cash and cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAIDS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic loss per common share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r176",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r366",
      "r367",
      "r458",
      "r462",
      "r505"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r521"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross future tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r322",
      "r323",
      "r327",
      "r328",
      "r331",
      "r333"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Other deposits and prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTED INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities (Note 6)",
        "totalLabel": "Balance, end of year",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaids (Note 5)",
        "totalLabel": "Balance, end of year",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r240",
      "r241",
      "r501"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted loss per common share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r366",
      "r367",
      "r458",
      "r462",
      "r505"
     ]
    },
    "epix_ExercisePrice2.91Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePrice2.91Member",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price one in USD [Member]",
        "label": "Exercise Price $2.91 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r248",
      "r249",
      "r478",
      "r562"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Operating losses carried forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r596"
     ]
    },
    "epix_ExercisePrice2.70Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePrice2.70Member",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price one in USD [Member]",
        "label": "Exercise Price $2.70 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SupplementalCashFlowInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r509",
      "r557"
     ]
    },
    "epix_ExercisePrice2.71Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePrice2.71Member",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price one in USD [Member]",
        "label": "Exercise Price $2.71 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r417"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r596"
     ]
    },
    "epix_ExercisePrice2.97Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePrice2.97Member",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price one in USD [Member]",
        "label": "Exercise Price $2.97 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid",
        "terseLabel": "Amount paid for taxes and interest",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r38"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r417"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Shares [Member]",
        "terseLabel": "Common Shares",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r599"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "epix_ExercisePrice3.05Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePrice3.05Member",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price one in USD [Member]",
        "label": "Exercise Price $3.05 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Incremental borrowing rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r417"
     ]
    },
    "epix_StockOptionExercisedOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "StockOptionExercisedOneMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock option exercised one.",
        "label": "Stock Option Exercised One [Member]",
        "terseLabel": "Stock Option Exercised One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Interest Rate",
        "verboseLabel": "Guaranteed investment certificates, interest rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551"
     ]
    },
    "epix_OperatingInterestIncomeOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "OperatingInterestIncomeOfShortTermInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating interest income of short-term investments.",
        "label": "Operating Interest Income of Short-term Investments",
        "terseLabel": "Interest from short-term investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Tax Credit Carry forwards Research",
        "verboseLabel": "Federal R&amp;D credit",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r596"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations",
        "terseLabel": "Warrants Expired",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSegmentedInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENTED INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r210"
     ]
    },
    "epix_StockOptionExercisedTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "StockOptionExercisedTwoMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock option exercised two.",
        "label": "Stock Option Exercised Two [Member]",
        "terseLabel": "Stock Option Exercised Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "General corporate income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments to be made at the start of a Phase III clinical trial.",
        "label": "Amount Of Milestone Payments At Start Of Third Phase Clinical Trial",
        "terseLabel": "Milestone payment to be made at the start of a Phase III clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "epix_DocumentFinancialStatementErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "DocumentFinancialStatementErrorCorrectionFlag",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction.",
        "label": "Document Financial Statement Error Correction [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "epix_LegacyOptionPlanAndRsuPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "LegacyOptionPlanAndRsuPlanMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Company's amended and restated stock option plan (the \"Legacy Option Plan\"), and the Amended and Restated Restricted Share Unit Plan (the \"RSU Plan\").",
        "label": "Legacy Option Plan And RSU Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_SouthSanFranciscoOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "SouthSanFranciscoOfficeMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the South San Francisco office.",
        "label": "South San Francisco Office [Member]",
        "terseLabel": "South San Francisco Office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "verboseLabel": "Number of industries",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Price percentage of Common Shares granted",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "epix_LeaseOnCdnOfficeSpacesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "LeaseOnCdnOfficeSpacesMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Lease on CDN office spaces.",
        "label": "Lease on CDN office spaces [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_FinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "FinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financing costs incurred during the reporting period.",
        "label": "Financing Costs",
        "terseLabel": "Financing costs (Note 7)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Non-deductible share-based payments",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r59"
     ]
    },
    "epix_IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesRollForward",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Increase (Decrease) in Operating Lease Liabilities [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_AmountOfMilestonePaymentForFilingOfApplication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "AmountOfMilestonePaymentForFilingOfApplication",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments made for filing the Investigational New Drug (IND) Application.",
        "label": "Amount of Milestone Payment For Filing of Application",
        "terseLabel": "Amount of milestone payment made for filing an Investigational New Drug (IND) Application."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaids",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "epix_ExercisePriceFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceFifteenMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Fifteen in USD [Member]",
        "label": "Exercise Price $3.75 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ClassOfWarrantOrRightExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ClassOfWarrantOrRightExpired",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants expired.",
        "label": "Class of Warrant Or Right, Expired",
        "negatedLabel": "Warrants expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss for the year",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r140",
      "r142",
      "r150",
      "r154",
      "r161",
      "r173",
      "r174",
      "r195",
      "r197",
      "r200",
      "r203",
      "r220",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r348",
      "r351",
      "r352",
      "r367",
      "r371",
      "r459",
      "r507",
      "r518",
      "r519",
      "r541",
      "r563"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life of share purchase options",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Class of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of class of warrant or rights expired.",
        "label": "Class of Warrant Or Right Weighted Average Exercise Price, Warrants Expired",
        "terseLabel": "Weighted average exercise price, warrants expired (in dollar per share)"
       }
      }
     },
     "auth_ref": []
    },
    "epix_Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardacceleratedexpirednumber",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No of shares options exercised unexpired",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedExpiredNumber",
        "terseLabel": "Options expired unexercised"
       }
      }
     },
     "auth_ref": []
    },
    "epix_AmountOfMilestoneToBePaidForFilingOfApplication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "AmountOfMilestoneToBePaidForFilingOfApplication",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments to be paid upon filing an Investigational New Drug (IND) Application.",
        "label": "Amount of Milestone To Be Paid For Filing of Application",
        "terseLabel": "Milestone payment to be paid upon filing an Investigational New Drug (IND) Application."
       }
      }
     },
     "auth_ref": []
    },
    "epix_PurchaseRightsOfferingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "PurchaseRightsOfferingTerm",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of purchase rights offering.",
        "label": "Purchase Rights, Offering Term",
        "terseLabel": "Offering term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "verboseLabel": "Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares issued through employee share purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60"
     ]
    },
    "epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common share each employee is eligible under employee share purchase plan.",
        "label": "Maximum Eligible Common Shares Under Employee Share Purchase Plan",
        "terseLabel": "Maximum eligibility to Common Shares amount"
       }
      }
     },
     "auth_ref": []
    },
    "epix_IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetRollForward",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Increase (Decrease) in Operating Lease, Right-of-Use Asset [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of operating lease related assets and liabilities and other related information.",
        "label": "Schedule Of Operating Lease Balance Sheet Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ExercisePriceFourteenInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceFourteenInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Fourteen in USD [Member]",
        "label": "Exercise Price $31.62 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "auth_ref": []
    },
    "epix_PrepaidExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "PrepaidExpensesTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaids"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses [Text Block]",
        "label": "Prepaid Expenses [Text Block]",
        "terseLabel": "PREPAIDS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Options exercised, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60",
      "r296"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "verboseLabel": "Other permanent differences including foreign exchange",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Loss and comprehensive loss for the year",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r141",
      "r143",
      "r148",
      "r457",
      "r461"
     ]
    },
    "epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of contribution by each employee to employee share purchase plan.",
        "label": "Contribution Per Employee To Employee Share Purchase Plan, Percentage",
        "terseLabel": "Employee contribution percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "epix_WarrantsExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "WarrantsExercisePriceFiveMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price Five [Member]",
        "label": "Warrants Exercise Price $0.0001 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r265",
      "r277",
      "r355",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r552",
      "r553",
      "r554",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ]
    },
    "epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsRollForward",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Class of Warrant Or Right, Number of Warrants [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ScheduleOfWarrantsOrRightsOutstandingTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants outstanding.",
        "label": "Schedule of Warrants or Rights Outstanding [Table Text Block]",
        "terseLabel": "Summary of Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "epix_ExercisePriceSevenInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceSevenInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven in USD [Member]",
        "label": "Exercise Price $4.67 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_DeferredTaxAssetsEquipmentAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "DeferredTaxAssetsEquipmentAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equipment and intangible assets.",
        "label": "Deferred Tax Assets Equipment And Intangible Assets",
        "terseLabel": "Equipment and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "epix_IncomeTaxReconciliationExpectedIncomeTaxRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "IncomeTaxReconciliationExpectedIncomeTaxRecovery",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expected income tax recovery.",
        "label": "Income Tax Reconciliation Expected Income Tax Recovery",
        "negatedLabel": "Tax recovery at statutory income tax rates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r136",
      "r154",
      "r220",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r349",
      "r353",
      "r371",
      "r521",
      "r563",
      "r564",
      "r607"
     ]
    },
    "epix_EquityIncentivePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "EquityIncentivePlansMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plans [Member]",
        "label": "Equity Incentive Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_DeferredTaxAssetsFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "DeferredTaxAssetsFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from financing costs.",
        "label": "Deferred Tax Assets Financing Costs",
        "terseLabel": "Financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments (Note 4)",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139"
     ]
    },
    "epix_ExercisePriceThirteenInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceThirteenInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Thirteen in USD [Member].",
        "label": "Exercise Price $29.63 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r109",
      "r117",
      "r521",
      "r543",
      "r555",
      "r602"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders equity",
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r49",
      "r521",
      "r543",
      "r555",
      "r602"
     ]
    },
    "epix_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of working capital.",
        "label": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "epix_TenPercentChangeInForeignExchangeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "TenPercentChangeInForeignExchangeRateMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ten percent Change in Foreign Exchange Rate [Member]",
        "label": "10% Change in Foreign Exchange Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate",
        "label": "Foreign currency risk, fluctuation in the net income(loss) reported due to change in exchange rate",
        "terseLabel": "Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate"
       }
      }
     },
     "auth_ref": []
    },
    "epix_FinancialInstrumentsAndRiskAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "FinancialInstrumentsAndRiskAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "FINANCIAL INSTRUMENTS AND RISK"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "verboseLabel": "Change in statutory, foreign tax, foreign exchange rates and other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "epix_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to license agreement .",
        "label": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r154",
      "r220",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r350",
      "r353",
      "r354",
      "r371",
      "r506",
      "r563",
      "r607",
      "r608"
     ]
    },
    "epix_ExercisePriceEightInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceEightInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eight in USD [Member]",
        "label": "Exercise Price $5.99 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ContractualObligationDueInFifthYear",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "epix_EmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "EmployeeSharePurchasePlanMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Employee Share Purchase Plan.",
        "label": "Employee Share Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_StockOptionsAndRsuPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "StockOptionsAndRsuPlanMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and RSU Plan [Member]",
        "label": "Stock Options and RSU Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "epix_NatureAndContinuanceOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "NatureAndContinuanceOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ScheduleOfPrepaidExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ScheduleOfPrepaidExpensesTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to prepaid expenses.",
        "label": "Schedule Of Prepaid Expenses [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r153",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r280",
      "r356"
     ]
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ContractualObligationDueInFourthYear",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Change in presentation",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "epix_ExercisePriceNineInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceNineInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Nine in USD [Member]",
        "label": "Exercise Price $7.00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued Investment Income",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ContractualObligationDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the functional currency and effective interest in subsidiaries.",
        "label": "Schedule of Functional Currency and Effective Interest in Subsidiaries [Table Text Block]",
        "terseLabel": "Schedule of Functional Currency of Company and its Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "epix_BasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "BasisOfPresentationTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about basis of presentation.",
        "label": "Basis of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ExercisePriceTenInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceTenInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Ten in USD [Member]",
        "label": "Exercise Price $8.47 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_GuaranteedInvestmentCertificatesAndTermDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "GuaranteedInvestmentCertificatesAndTermDepositsMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to guaranteed investment certificates and term deposits.",
        "label": "GICs and Term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "epix_CashCanadaDepositInsuranceCorporationInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "CashCanadaDepositInsuranceCorporationInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Canada Deposit Insurance Corporation.",
        "label": "Cash Canada Deposit Insurance Corporation Insured amount",
        "terseLabel": "Cash, CDIC insured amount"
       }
      }
     },
     "auth_ref": []
    },
    "epix_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent basis of presentation.",
        "label": "Basis of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ExercisePriceElevenInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceElevenInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eleven in USD [Member].",
        "label": "Exercise Price $9.76 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_EssaPharmaceuticalsCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "EssaPharmaceuticalsCorpMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ESSA Pharmaceuticals Corp.",
        "label": "ESSA Pharmaceuticals Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r59",
      "r60"
     ]
    },
    "epix_OperatingLeaseRightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease, Right-of-Use Asset [Abstract]",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ExercisePriceTwelveInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceTwelveInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twelve in USD [Member].",
        "label": "Exercise Price $13.96 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r232"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment to Acquire Shares through Employee Share Purchase Plan",
        "verboseLabel": "Shares purchased through employee share purchase plan",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r76"
     ]
    },
    "epix_ExercisePriceTwoInCadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceTwoInCadMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two in CAD [Member]",
        "label": "Exercise Price C$5.06 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r183",
      "r225",
      "r226",
      "r337",
      "r361",
      "r365",
      "r366",
      "r367",
      "r397",
      "r409",
      "r410",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-term investments",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r617"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "epix_WarrantsExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "WarrantsExercisePriceTwoMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price Two [Member]",
        "label": "Warrants Exercise Price $42.80 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106"
     ]
    },
    "epix_ExercisePriceOneInCadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceOneInCadMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One in CAD [Member]",
        "label": "Exercise Price C$4.90 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r183",
      "r225",
      "r226",
      "r337",
      "r361",
      "r365",
      "r366",
      "r367",
      "r397",
      "r409",
      "r410",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss for the year",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r35",
      "r113",
      "r119",
      "r129",
      "r140",
      "r142",
      "r147",
      "r154",
      "r161",
      "r165",
      "r166",
      "r168",
      "r169",
      "r173",
      "r174",
      "r179",
      "r195",
      "r197",
      "r200",
      "r203",
      "r220",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r367",
      "r371",
      "r507",
      "r563"
     ]
    },
    "epix_ExercisePriceFiveInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceFiveInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five in USD [Member]",
        "label": "Exercise Price $3.81 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r450",
      "r512",
      "r522",
      "r560",
      "r561",
      "r566",
      "r618"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DueToRelatedPartiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties",
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r264",
      "r413",
      "r544"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Net",
        "negatedTerseLabel": "Accrued Investment income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26"
     ]
    },
    "epix_ExercisePriceSixInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceSixInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six in USD [Member]",
        "label": "Exercise Price $4.00 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Derivative liability gain",
        "verboseLabel": "Derivative liability gain (Note 8)",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r35"
     ]
    },
    "epix_MinimumAdvanceRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "MinimumAdvanceRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents amount of minimum annual royalty payments per annum.",
        "label": "Minimum Advance Royalty Payments",
        "terseLabel": "Minimum advance royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ShortTermInvestmentsMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ShortTermInvestmentsMaturityTerm",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investments maturity term",
        "label": "Short term investments maturity term",
        "terseLabel": "Guaranteed investment certificates, maturity term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r190"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r59",
      "r125",
      "r145",
      "r146",
      "r147",
      "r157",
      "r158",
      "r159",
      "r162",
      "r171",
      "r174",
      "r184",
      "r224",
      "r280",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r365",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r410",
      "r467",
      "r468",
      "r469"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "AmountOfMilestonePaymentsAtApplicationForMarketingApproval",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments made at application for marketing approval and with further milestone payments on the second and additional compounds.",
        "label": "Amount Of Milestone Payments At Application For Marketing Approval",
        "terseLabel": "Milestone payment to be made at application for marketing approval, and with further milestone payments on the second and additional compounds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of foreign exchange on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r326",
      "r327",
      "r332",
      "r338",
      "r340",
      "r342",
      "r343",
      "r344"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment to be made at the start of the Phase II clinical trial.",
        "label": "Amount Of Milestone Payments At Start Of Second Phase Clinical Trial",
        "terseLabel": "Milestone payment to be made at the start of a Phase II clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used) provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r184",
      "r450"
     ]
    },
    "epix_LeaseOnUsOfficeSpacesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "LeaseOnUsOfficeSpacesMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Lease on US office spaces.",
        "label": "Lease on US Office Spaces [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r213",
      "r232",
      "r456"
     ]
    },
    "epix_OperatingLeaseLiabilitiesAccretionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "OperatingLeaseLiabilitiesAccretionExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion expense on operating lease liabilities.",
        "label": "Operating Lease Liabilities Accretion Expenses",
        "terseLabel": "Accretion",
        "verboseLabel": "Accretion expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "PrepaidPreclinicalAndClinicalExpensesAndDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid preclinical and clinical expenses and deposits.",
        "label": "Prepaid Preclinical and Clinical Expenses and Deposits",
        "terseLabel": "Prepaid CMC and clinical expenses and deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss [Member]",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r19",
      "r87",
      "r410",
      "r467",
      "r468",
      "r539",
      "r540",
      "r541",
      "r545",
      "r546",
      "r547"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "epix_FinancingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "FinancingCostsMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to financing costs.",
        "label": "Financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "epix_ExercisePriceFourInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceFourInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four in USD [Member]",
        "label": "Exercise Price $3.60 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r134",
      "r460",
      "r472",
      "r476"
     ]
    },
    "epix_StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "StockOptionPlanMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan [Member]",
        "label": "Stock Options Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_OperatingLeasePaymentsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "OperatingLeasePaymentsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash flow arising out of lease payments during the period, which are classified as financing activities.",
        "label": "Operating Lease Payments, Financing Activities",
        "negatedLabel": "Lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "epix_ExercisePriceOneInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceOneInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price one in USD [Member]",
        "label": "Exercise Price $2.39 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "epix_PercentageOfEffectiveInterestInSubsidiaries": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "PercentageOfEffectiveInterestInSubsidiaries",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of effective interest in subsidiaries",
        "label": "Percentage of effective interest in subsidiaries",
        "terseLabel": "Effective interest"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r283",
      "r534",
      "r548"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r69"
     ]
    },
    "epix_ExercisePriceTwoInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceTwoInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two in USD [Member]",
        "label": "Exercise Price $3.23 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Weighted Average Assumptions for the Valuation of Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "epix_ExercisePriceThreeInUsdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.essapharma.com/20230930",
     "localname": "ExercisePriceThreeInUsdMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three in USD [Member]",
        "label": "Exercise Price $3.59 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign exchange",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "periodEndLabel": "Balance, at end of the period",
        "periodStartLabel": "Balance, at beginning of the period",
        "terseLabel": "Operating lease right-of-use assets (Note 7)",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based payments",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r451",
      "r455"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r186",
      "r187",
      "r188",
      "r189"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Options exercised",
        "verboseLabel": "Gross proceeds from stock options exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r76"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r132",
      "r500"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "negatedLabel": "Lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r403"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Treasury securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r514",
      "r515",
      "r616"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Weighted average assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital (Note 9)",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Balance exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r41",
      "r48"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "localname": "US",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization of right-of-use asset",
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "verboseLabel": "SHORT-TERM INVESTMENTS",
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in non-cash working capital items:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected annualized volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities with expected life greater than one year",
        "verboseLabel": "Operating lease liabilities (Note 7)",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities (Note 7)",
        "verboseLabel": "Operating lease liabilities with expected life of less than one year",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "periodEndLabel": "Balance, at end of the period",
        "periodStartLabel": "Balance, at beginning of the period",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r450",
      "r512",
      "r522",
      "r560",
      "r561",
      "r566",
      "r618"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued through employee share purchase plan, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from short-term investments sold",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate debt securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "terseLabel": "Stock options, Exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Number of options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Assumptions to fair value of the derivative warrant liabilities",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r36",
      "r39"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "OPERATING LEASE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents for the year",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r104"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r513",
      "r523",
      "r566"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r122",
      "r615"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesChangeInPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Reclassification, Adjustment",
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology-based intangible assets",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r281",
      "r282",
      "r312",
      "r313",
      "r314",
      "r425",
      "r449",
      "r464",
      "r488",
      "r489",
      "r511",
      "r516",
      "r524",
      "r558",
      "r565",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation and Functional Currency",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r503"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RangeMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r281",
      "r282",
      "r312",
      "r313",
      "r314",
      "r425",
      "r449",
      "r464",
      "r488",
      "r489",
      "r511",
      "r516",
      "r524",
      "r558",
      "r565",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r115",
      "r133",
      "r154",
      "r195",
      "r198",
      "r201",
      "r220",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r349",
      "r353",
      "r371",
      "r521",
      "r563",
      "r564",
      "r607"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchase of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "negatedLabel": "Options expired/forfeited (in dollars per share)",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative [Line Items]",
        "terseLabel": "DERIVATIVE LIABILITIES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options expired/forfeited (in shares)",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r168",
      "r175",
      "r183",
      "r211",
      "r212",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r317",
      "r318",
      "r319",
      "r334",
      "r335",
      "r336",
      "r337",
      "r345",
      "r346",
      "r347",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r452",
      "r453",
      "r454",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Us",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "OPERATING LEASE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "verboseLabel": "Expiry Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r282",
      "r449",
      "r464",
      "r488",
      "r489",
      "r511",
      "r516",
      "r524",
      "r565",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Compensation Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsRealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Unrealized loss position",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r232",
      "r237",
      "r238"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r282",
      "r449",
      "r464",
      "r488",
      "r489",
      "r511",
      "r516",
      "r524",
      "r565",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based payments",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r285"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Option expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Outstanding",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r75"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently accounting pronouncements adopted and not yet adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss for the year before income tax",
        "totalLabel": "Loss for the year before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r107",
      "r112",
      "r120",
      "r195",
      "r197",
      "r200",
      "r203",
      "r459",
      "r507"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax recovery (expense) (Note 11)",
        "totalLabel": "Total income tax expense",
        "verboseLabel": "Income tax (recovery) expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r173",
      "r174",
      "r194",
      "r324",
      "r339",
      "r341",
      "r463"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign exchange",
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r603",
      "r604"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization/(Accretion) of premiums/discounts on short-term investments, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Expense",
        "terseLabel": "Accretion of lease liability",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r559"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based payments",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r320",
      "r321"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments.",
        "terseLabel": "Short-term investments (Note 4)",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r114",
      "r538"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE LIABILITIES",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r355"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r530"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AuditorName",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and diluted loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHORT-TERM INVESTMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding -Diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r182"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r530"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10A",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12A",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "50",
   "Section": "S99",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(4)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "730",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "60",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "940",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "946",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-06(3))",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "105",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "105",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "105",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "105",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "105",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "15",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "272",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "26",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "34",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "42",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2A",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "11",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "14",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "16",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3A",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3B",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "340",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "340",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "440",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "440",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "80",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "80",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "1D",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "19",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "270",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "19",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "17",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "20",
   "Section": "35",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "17",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "832",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "832",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "910",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "924",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "926",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "926",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "926",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "926",
   "SubTopic": "20",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "928",
   "SubTopic": "340",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "235",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "948",
   "SubTopic": "310",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "440",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "976",
   "SubTopic": "310",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "978",
   "SubTopic": "310",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Footnote": "2",
   "Subsection": "28"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Footnote": "4",
   "Subsection": "29"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column B",
   "Subsection": "28"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column C",
   "Subsection": "28"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column D",
   "Subsection": "28"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column E",
   "Subsection": "28"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column F",
   "Subsection": "28"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column G",
   "Subsection": "28"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column H",
   "Subsection": "28"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Paragraph": "Column I",
   "Subsection": "28"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "340",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "80",
   "Section": "55",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "29F",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "340",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "410",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "912",
   "SubTopic": "730",
   "Section": "25",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4H",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "80",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "303",
   "Paragraph": "(a)",
   "Subparagraph": "(5)"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001558370-23-019732-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-019732-xbrl.zip
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MOR4!IFZN%ZV<3X7I^]YE[VR_*X4F.#7,6PN]2W@C?X%B[BAA_W?T+B[A[RW
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M US[5':+]%';-77(JDC52*K/<K>P'07;+@[?][V P> WQ.[DP:5+J5193/8
M#CJ0<Q'\#,CIR'VJ')0JJ(7_P /^^F&7AEX-;94+ /YK6['XGWB6<T862+YX
M>2V>4_QTPND:AKHG\;>5?$$U6#]TDE<3_PW:GCZOW81"L%<\ZR@M8+^"XG(3
M%IC9.2ZY!SF!B;\A3"SI=Q/93U#WM;2""JVK51:#!NKDXH>Z.D$6XC94'6@L
M==79:U^OIU0L. U$]OZN%"2*X?^+L.ON-/^UN__\9?PE^TRF?"03*L%G ?)R
M+S&7//@9O=\\\FW))Z+F9>3BAZC/\U,H*I%/7:S^T=4R"70YY=_\0$D*'M0M
MDF,_F\M8)E='\.F<G7?./APN2/KMVBI"R"SBK^T;N4*,"R'&Q5EU,8J?G*XH
M0))!E'Q9O<RREZN55ECX0G>7N '?LJEIE(I7DBNUAW26Y(^:(I0\.WY$18@O
MAPJQ>SZ[F@ )?52X>/^[L.#X]78Y*A.O*O\[GB5[R[[/Q?U,0J1/)[FOU'7%
MZ3;PWRR$1A'Y=_D ]/7:]V",Q5[,@*S%J 0DAD$>.-)0R/N9^>$F(:5  IY6
M_@8/3'UG+ADY8?3N1)+V$#T@ PGD@09J!;81VNRC7F+GC2W#.JGD1\)>$A4/
MR/>3*L%FQ-'5PBU9$ 9TV_>PQ-K3)GY-R82!FK<43UY':4D5U,WT8_6/7&=P
MB WD%"FV:CU98S54!+,,D$),8??:KH94H2G00)54UA/'3!-6*LM6J?C-9]\%
M%'A# _&\5*1-[FMC(1I16^SU,Y:,R)0[LGX@+-&C-+50'QA<=>1@ZMJ1#X[_
MQ\$H?0=6'G*>D^?@QO7M[XEVU<DUZ@8)Z:LX4I6&T:-'\DEJ<; S%#AG'JO>
M:U8UZ)O7ME0GH,5S>XL%$;M%"#A] C/[P/32)X]UF+\*S\881MG=:XG>BO3C
M@7>"ZQ6D,SM\(.:KFD"!V#"SE85PA6IIFN;9]8!S/)7!29N$\AE WO?9)NMZ
M=43-],#9\VMRG^]D<<^CT=B^<ZI*W$ $UQO7?R'1OJED6_,4>MT]#+5DS41Q
MYR2WN[]8M&<[M3%+YU_K9&V,&^V[F/.M[+'HXU"@M=-HYKONT&=/F#F)V@?D
M:YY5%RH!8R+*B%K1'8U**=$(^,]!<.^\Q. 9^BH*39'!^+8JFM5YO!%D50HE
M)EL%_7I\-$T==)/>\L?;B5A#I0^2[92PQ%7/_5*G#52V&& LMX.J(WGHJT+0
M_O":R!X2FL (6-BHN&,BT5-)H;#VI/P?KL(=?J;K<#UPJ8S]B,5Y/WK<E]][
MS@Z9'!Z)AL<P:'" K>R2B/1;U[MU:5V/?A"/QG3M^W/\?3T5Z8W1H>CVESLQ
MQ1=7**8:; 6Z1C1;ZHE69SB/PI)F_@MV@Y<I?HG?OHB;IH:HP<W/6(LUG<GB
MCKJ  @B3B&T$%L@%*98(XSM3X4WZ+B@*T[PYH[M XE$<?G+-[ 8O"YB\DH.K
MRMAL7!JM(\$8ZPZS[T0X(?C,_,=*5:7G\'-7BFK5E'2^$^]>],,PPK+$2AS?
M"]LJ29HYYXS=+_QCQV8LHI;QS\0IPZ=;LO$YW;F' _(U-AB?[6!3EX>(:\1)
MLM G%"H.H6AR-'<Y-+NDE37FDK1F6G$6C\0#;56(3S?2,@#5&1K<TZ5.#>?#
M8&6)S81P-T6;+#3+ 5L?5"M+0Z9]F7GZQ -Y[[FS%[]4DC03OHS,\R=?IU:.
MY"VHM6)$BU<!T1M0;>B'3*=9GN8M*"9=@D:Q',T;4,RBSSJ]<B1O0"WI[OI8
MZQ'3)&] +>GNU&KE2)JIUBZTG)4]JYF6Z@TI)]Q#!>TR9,U4+^L=R"/QM"XD
M3]10U>3U&:8GQG  A!CP[DUHE!3-5&KH,T*77K)11NS*&[JA.( FXX3>F 31
MUE-Q]?2,B&W"Q+D-R=Q/;IP?/-ORUPP'V^635^?:X G2G"1K/XGLL?9I%;)V
M4B]+,PTGTX8'8OE(U] +B)JI6FI6*W>J\E Y\RVB::9B&3C&5#\SS-.\ <7F
M^CXG1]),M<2-'WWL80?',4[3XY 17)/8,.;':SGB&W&B(/EV_?J0G(V-GGX.
ML1@,$7$,(EGUZHL3<^(UE$ &@<7:5Q((S@)_:.9&F421.W5S Z<2YYPG/%*9
M_;I1*;.O>#7EYD_$W9LQE\UZ<H3-5VY%8;Q3";M"TB8J:/EAL+*P-Q1.AG+;
MCQ:H<MIIZ)JH6KSFUG>\HD6W_=6[$K(F*I8+O54TRD+2)BH(<PPF4+DET;^F
MI]R8G-GKES[0=S"3=!=:<X/@3ZF0U#+C8951QJ!I%9';4C#W;\@44P<D'H("
MWG*R2.TM2-5 [9Q'#:,.4S[>:U!YH*7>9E&_2C09WTR-R#V!XCH&QT[=HB\C
M<TM)]_#"MR2;2&DL#![;-G!BX@( $NV/]<+]CO#U>6<:6;T]V4?5:L4.ABY$
MIZ'I6K)$3>Q4,O*>GUZ=J35*4[P!=3[V=.KL*-Z".EIT/KXE=*X^:HWMXYM1
MY^*T=ZE6)TW11'6V8Y_=CA 1U!8/O^1WZ::4K)FO,?VE(AR>BXHF0#H3KV 6
MJ*9K(M9%(J=6&Y6JI>B:J-JM;\MK&;8W-5@!C"[$EP%C/NO[C!%YH'KHXF5*
MU9KYTF;\X/LNP3]:;]WX1+\'6\1?"K=@U]@)7LKC[;3K$5EB^V6WT2^_XI$*
M@^A(?W(3B&Y&BVXQ^NW_ 5!+ P04    "  6.(Q7JA;?X$(,   3H   %
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M@:":@ C:A VF8N$1H=_UA;)T3Z)3[3%"SII6IQ)N%Y5-M-=/K-:>(^^KB.F
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M]OB/@?-V!9\OX^@]VB4BV/]QE,#^A]^_S OLSG[0[?FN5!'*V"S"ANR]^UJ
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M0=[W1P0= -SXZ585T4JT,R%ZJ2))"9)JN=U_NDP8N/=)_^__ U!+ P04
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MKG$(-$_.0""*@I;_HY+-^$!0$G"&"MG3)O12Q<&'U1[%&P<9*L1@L9YE8*A
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M$9_^$N'5=A'%[LZ*L>PAT:-&P/U6#*KLJ=46@'U3(JBN11)RU!YS@O <<F#
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M-.5KC1&Z?4;"JX]4IC1Z'H7,<<X:$A5<63L\?W)EU3T/F@!W,Q&@ROF_TO>
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MI0[ 7:<9;-D[Y*T!.X""T+HV_N7-^@W*J*,H)V_$;NFE^8!FU56/KS7=IC[
MK5<)<MF :SL MF$UN77-.*>.'!JTC=OQ;H=#ND9\;>UQV&"_XK;@[;8&8M5>
M!0U!VVF=O/KVF5%%>TH62"X>![O:/.JRX1!_-XK 3;P'==7GY<KD +M+'ZC,
MY.>70Q3Z;>&-\P?+]>@<@6AG;7D'X^)\%Y")_+_I<XQ1S,J92'X #3+ _4Y7
M,65G:TL#L(=I0^G-K7()3H@3G41$!O)9QA=1QF;>9AA=,_6@(40-VTYVB4?R
M8.=32*+<%Y_,[#PJ,8UYIYC\?O0]'3U]*M.>=GQII\(604>-\'0C44M\PX:G
M0AC$I$&%.&S\GZ%;)A%]1Z7?Z/61*]+'=Y1[A_@UDCX/%&-HRGR _4 S1!=A
M0H]D\)W7^9;\5YQ=*J6IG<@#CVY]*U(^A=&G#3C&]0YQH#"WSL(<E2<_DC%#
M%A5)/NTQDZB!46JAK])I%GJ?<](Q;YT5LBF=>[VF)\C<P%\\Q=B/7$+VTHWB
M@7^?5H+\0>)H^Q]GB(BK+L4?(#9K* -6%)^A' )[$3 _D9ZA0-\*'&CA)SMV
MB3TX/IX^K?@_X@\G'2G0"<*%;G&A6Q#+ 866JSI7G('4= <>KMLJHF[>+NL+
M.#2VAC#@[!O&8N!@&EA$L;MC"PL7EANBKY:7@$P?>YP>O\RI<%_3WA<VQ34R
MG4U7[28U;1U&4:7E.(^N6^[3_,9(B/EDN3Y%M?(IXM567C5-K0?P@*$ MQP7
M:IH#=G\5J;7/I!/:Z!6E_AJ160AE0"<HQDIXC84Y0B1>>6SUG.*FT2R2EW4S
MXLK7(=Y;+IEE14E(HY9$4X)FP)U6!JSLJ8=M +NG5%3MES$X0913-.."@^%R
M9;@Z/.G#29/_V*0MK7$U]YVS],_%TY[,_ME-X.P6\ %D71I ':V32HH7?EH2
M@'Z53QM//]5$]ZGU[PO^[ )Y_@^<BL ^-729?G0=93'A^D K&4^T*&OE7'+/
M?MB :%8S9Y_/%.S$9(:2HB?@5_$]#N<DJ9+.-AJZ  VH;0 +LAAA>_@93;W8
M7>TZI<ZLF-%'G('19&<8R!Q>YJH,<38:9,YL9B_"MNGH%%U;SW29Y"P)0S*
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MN1?0Z-$2=GFBT] %\ 1'5?+>$H6<A?'IS'C0>7+@%<>\QDL*2F?+.B8$4DI
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MI*8.0(U6'6P^*ZYM#7TBK";\H/>6Z!(M$P,1.5 N")DM4TE&G@ /JP\13,X
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M@\#ZKPTPLBBG*UUG&SE;O6RH#B1N"=P^:^"),]?+"=3DJ9.VCPSVTG3!G$$
M+FZ67^>;Y=<%NES.3Y>7R\URL3:3]]#!:1E%"7;.DY!6_.%'U>\MHLTK_,B^
MDN;LJIV!>V8[)51R(*6>@/VW)0#M7(CE0)P/XHP0YS1#G-<,T>):G)VI:N%C
M*8/10RYC9,3KSSPKBE;;7ZV09+WQ*F27U!=/.+3=").LP,;YEU'Z;?1.HC1=
M6L!C0B<5E4.$%B' $:,;'EV?85SI;"HE38OM,=HSE/%&C'FI390W&B:B*%UB
M,Z.N7S$E1&+MG(0]ZPX?*(DHS7=H#+[E-\/0*]='3N!Y5DB/'Z"(1JC7)J_"
M 57;:7Y[;GS-*0Q@9K26*VG/'+#02%2CDE'&N<_8BA*^%;OT]TG<<'JVICGP
MT:H):'E DK4%/.8TBJQKNB7"B%%&E+3)A6@1U-H%Z-H.$S1;^8*SO/7$3+>G
M!6:9\9I<:3Z$>^-&OU^$&"_]&!/5LO,UM:O/K0A,S+R;E5%G[O+>$S)_!1#:
MIRX(Z9,MH8TRXNR,F=DU[4/\]*Z@33),>LZDE1\(.T[,_N7@Z^S^N->$[+U&
M>/UTFY-$E^Z69]N_89)KOX9EZ&RV\37PK)B5.&AEZ[*^$S/W6A746;RPXX2,
MOE[^SG8_]_W$\MQ_TX<F<R:PK#^3]=Q]<!WL.ZW3GEH"$_.#9F6HA/_CWA/R
M" 40VIN)*4E8#I"=I[\(PDO+_GVU_6R%O^,X+7C3RA4424W,*=HHJ,X]5.A,
MR%%:P=$^J>[^*W$=.FCDMU'Z=YXHC$N.0_Y5. WYQS^RI>9TI5GH$77M@)I[
M(S1JR])&  VU6=;>-AO '+[*O:WJFQ(75NL)U%XUX,L.:TFZ ;1I'>E[.,Q5
MJG=WM'1I_G#74 J81U&R8Z\H1>P=2LL-T8/E)3@KP.D4&GI,-[<[UA/O' SF
MM$AQPV;981O@#BZ$5';E2@/ 3BN64]LZ*37CFU[L1-0I$<@Y"W:T\AE_8)LZ
MPQU_G/#TN6B3EGIBHA?:\!U:380>YJ^_KS$,*^#6/Z2"*^<A!^ #V!<'A=N'
M2YO<"ESL]E[PC#$[55D[XQ>W!.Y2-?#*'B%H!MB@ZZ3M=O9WE:9 728YDN)+
ME'Y*GGC33910AZJIO53?'JC9*4,M*B_5- 9?>$E%]GX,TO(==+/^0B]!^</6
M&1(Y'DBT^KY("[G%STMBQ3Z=T% ND=P3:UM#]L-FF+D7RIM"]T$%R;6W\AAI
MY&:TT9X2-^1]P^/,:3.W&V(,O,1WEOW,G9SR4!D'%?I ]D%5R+DG-G6 [H_*
M\@]>CY!.=BS_^4]D."$2.]AAPPH]<45K-J.(C3@!?]F<>C9Z17M]QP&D0Q%S
MA>]>SUA7^O6\1.HF(T7_"%VVZ\_F4>B+[\9\\.(TL['LN]<CET(<_-<XUA::
M]S5X=[] %NQV@<]2BS-K[\:6QR^UD=\+AP_8N0C"BR1.0DROS-%[$I+YA@X=
MH$&ILVHJE\;:$@$\I]3'HGU9C''DA3=F*&6:WC-%&5M$(ASBC%'&V<PNA#D%
M<8V$98VX$E6,MPY\6[.>EBZGW1XNIUV3'^7>RN\XE31ZC4.:?-4MX W%$'B@
M&E[91RO#@W #'/I& -WI$OH)8XS*PJ&2=.CV&97;I1(B)N(,94(6%V^K@3<5
MU4Q0!:QZKJX]IT8/?I0TQR/R'=T%UJL-()X?G@4^R:-O$Y:MXC!;YMT$^8(O
M99Q#)\"N<_%$V6]'>D C8V^JRN><78A!GX_V@DW;ARK>8Y=$H4$+6_8]PJD8
M=-::_\TN(Z-]%KGH['3DB:-1M969T_B,,J9H$Q1_\ZEV$=X)LSR:$RD,%.$W
MJK1<+Q4SVTOUH1^F,P#\9OYJN\6T"HV@.G=S:\@AMAEF'D#E3:&'1P7)=0V2
M$J%A+P]C(>-!WP1A3$:.: ,BS6,0ISU#&74#1<2'QII#TRT7+HXIGZTG=Y?L
M%I[+WD!*\UF69W[QG2*6'D50$?PNQ"!'I,Y*R@.6-B7H\:P[,.TZ!YQSZ9U@
MF\^6>#)73?;<".%41)10N2#E?N9UF+$^F' R[K4)H(%8:UY;W)+X_5(RBZCJ
MC)OCM-9)%T][ES\=STL;]KUX(J /-.P/ILI>%CT/B;_$-4XI1H-+FH5,:7G2
MB2U>]J[3=/L9%WK9"_4"XYJ [+1U>OKM$RM\MTQU\RD,(FEEXT$X32$4#J/>
M5G<$VK.!'AX'0FLP4*;2S1"7#[E^7L^9R6@P;@)3=G;R5K*GTXMB5&I;PU<-
MJV7$)FF1F7*A_>KHX-8X^_+<BO&%Y89?Z07047XI%2G^4..2\L\RW)C5*,(?
M9CQ3UP3,L>ZHA@-K@B@$1#$@!N(E#(;#_U*Y+JU4E]6K\D'].#K* $%/Y)'
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M1PN@;D)7?#"N$[5)1>G6:I(';&52DXO=[9$-%,93K]M9#FD6LV,*$94HNRK
M)$++);)3J5!,Q3(=M\?37QK"5^40GG%'\Q@Q_O1K+D&JL$P&Q(2 $,['TY@L
ML@MMS))9V)B!?'/OAKW%<3FQ:8?Q!B6UB.(22M,/XDW !D[%&QP,? P?2GW*
M(9P),)T(/I2^- .XD0A>ROW)1.6S%?Z.:<D5\G$8/+0.X<W4)AK#%=6D$L0;
M2$TXBJLB&RR,9PYF%8*PDER[3!3Z#9.%G0][=.-[M$U"=C1,0"[@QXXCGIC2
M'I;CN.D<V@YV>R**,_;3Z@;UWS0.E/BSI9E< I2) &L8&%I?3>- LYG.>K33
MX8>3#@OM312F.&SH+K/7=I_J\&!JD9WY&G6N=#64.LITEM>'59YH=3WE"'MI
M?2RU'*_V'9K3\(OKXD-(#17?KL/ 2>QX%:YQ^.#:6%)J4-(,:+!M I:5>!.U
M 7A0J%%47?M-B;)$(*4[=L7!5 1Z!R25())6'*QK"]\2Y1 /S/&X(6R;K)&W
M5\,T>3XS/>Q2>P[SL U0DZR%5#Y766D T 3KY=2^@),>.^J_UMTE)@Q6_IGC
MK[9;8M'KO44\IN;.5WU[H.:E#+6X_U73&/HD1DGV'NZ"T<F(_#X8DX).[L_.
MKT@V2@5!$9-D['MA0ZI#CG(X9_T2M?)52?,)N&H=T$-/%;6=B*/6BCZ>GWY9
M0W#30911QLC)HW5W)^V<P-'7K4*+U@GQ5K=>.@<_3S M8O(4;QZQ]X _DS;W
MLJN<K0@ =7A]951J'2KW!IPT:H#0+SV0LT(%KUFZQ$\/?L[0;]@*T<H?N<B/
M 640Q_P16 #@Q[/H+]!:/96NDW7Z8P6HN7O1;Y*.+A!_<!??/ ;07+Q'-1"G
M^PF8<[.3.UJ^7>XY6=<^@J_FV7FW23KVL?3#^S4Q9'"#=W]Z( [W9V".?1'0
M8PY:GEWI.EG7/E: FF\7_2;IW +Q!_=NRA.:<_>H!^)U/T/S;G>KZ]REGM/U
M[4/XBJZ==9NF9Q])/[QCNP_@1NW^U$#\[2]&_'J=W$;X7PGVX\4#+>=HW7J'
MU=4;F@+WW#J 95<5M0/LF[7BZEIA010QJN@;H]OC7LTZ#NS?5WOJ08LG'-IN
MA)V57_-L8%,'H-:G#C;?L:EM#7W/1DWX02MM1E0$%# 9$,Z$0(&/1]ZR&587
MC#KBY%%.GRY(#_OR8?UI3E.8AXU,F\>@760J=YA:9#H"6QN9\M93C$S'PIN(
M3/%C " R]:<+B9<2!M BTQB8(63SEZZ/ES'>R3;*:YH#C5ZJ0&LR^[SM=++[
M8Y'[R_ I;<2(5[SS;S\4<I$FOY,/LX]28O_QOP!02P,$%     @ %CB,5T)X
M-H.'0P  M+@$ !0   !T;6(M,C R,S Y,S!?<')E+GAM;.U]6Y/;.);F^T;L
M?^!X'[;GP78J+[:SHFLFE)+25G2FI):4=M>^5# I2.*8(E6\I#/[UR_ B\0;
M;B1(@I1B9[NJ4@"(<[X/!\#!P<'?__MU9R@OP'9TR_S]7>_#Q3L%F)JUTLW-
M[^\\Y[WJ:+K^[K__ZW__K[__Q_OW_[J;/R@K2_-VP'05S0:J"U;*+]W=*DMK
MOU=-Y1'8MFX8RIVMKS9 47H7'VX^7'SXHKQ_'[9QISJPCF4J?F.7'WJ'7P9A
M>Y;YF]*[_ C_[_+B\DJY_.WZYK?+&Z7_>"CY"#NXUNE%#=W\^1OZGV?X406*
M:CJ_O3KZ[^^VKKO_[>/'7[]^??AU]<&R-[#^1>_COQX?%MH6[-3WNNFXJJF!
M=PHL_YOC__'!TE37UU.L^NNS;40-7'T\? M; OW7^ZC8>_2G][W+]U>]#Z_.
MZEW81?0SPT>BXNA7G5 ^)DM0/M-^J(/>[>WM1__7=U![BO)WVS+ '*P5_V^_
MN6][\/L[1]_M#=26_[>M#=:_OW-WS^\1 !>W5Q=(D/\S##D2_;-OKD:FJ[MO
M8W-MV3M?C>\4U/S3?)SH"G <=;]589D/FK7[B(I\9&O-%XY);1]+2K=P(4]1
M1P:6Z5B&OD*TO5,-I.3%%@#789>-I2V9))NI-OQY"UQ=4PV18J8:;ECFPQ^=
MZ7JZ![;/,0<2;V#M]C;8 M/17\"#Y92%FN=#$NEDH#K;>\/Z)5+\6)NR2 H[
MM57-#7#&Y@** [:6L8*3Y>@O#UH?4:)3/E*?+H:ZHQF6X]E@HKKP?^.,Y+#6
MQ%::D 8N.73(KYD-'*ANWLF'W$P3\BSTC0G7/YH*IT)-LSPX%YJ;&>25IH-"
M0%$:;$3&K66[2V#OQN8+<%S?1!02+;>=)B2"O-FK^JJ0%,>Z3?0\Y 2<HM_4
M9P/ R0G^Q?; ZD%7GW5#=PO2CJW=)B0.+9:Y>0!^R_RRI5MH0HHAL/47V FX
M?B@'%*:A9NQ"\6F8W$H3TLR!@98"<.WKOBUMU714K?!LBV^K"<G&)NPB6*JO
MQ1B7J-X(S[P]+(ZF"]4X_O6'[F[GP-D#S5U:!=; 1=MO1 -@@[H'5L7V[)1V
MFI#H7C?A?E-7C;'IN+;O2D [K;GN_"PB&+&Y)N2#6\:=7GRIE*C>S)A[=L!?
M'NS Z*7P>B_3AB0[#G\Y76BR(C0FW>ZCN)1,S4J"Y1(M5PO1D]"8++NLXL*1
M6FMRQU5<HG0+LNZ^BDO(TWKS.['B<N:W(\VNK+A@Q.;DV*&5L2BXMAK>TQ07
M*:>1AM>*Q67):422&1H=XZX\ TS7]Y[I[X-58^#9-C"UM^D:G:VHYALT=F/7
M02M&?:6K-APW0^"JNB%J9B_;">E6=\$YQ=B,"UE"9<6_)<M:::+:MF][RVB!
MJ5U9))X#U=#_#59?5=T_ID0GDZ7&38&/-+F6/([I\"^CUSTPRZF O6U9UY_'
MGK.4+J&J"CO3_.KVV/'DW\LHC/<+S6M!A$VEM2C-NE^$L(P-2R/SO:K;WU7#
M X\0'%@(F?RQN?=\[RGZ(7"+ &UKZG]YI=@O]OMR[*;$K#GHK<HA[=%B^;_Y
MT:-HY0SG11\F =.O@(_*H:L?0-]L7;#JOT#KMP%]Q_%V>_\,\-ZR#\2&JPO/
MUK:P-W-47*SF2G9!#CTNO-U.M>$6;>%:VL^IW_\^W+^]P-_$\HSE0_+J9 I-
MIJN:*%B\<K7D?4LRS?Q )A2= 59*%>Q7)-5&Y20A?4BFF X1\S9[VPW[1^=
MLTP-+KA">Q_[J>^BR%?/M>RW.12FS/Q3\H,-ZRCF_D*+"\L,PJ#O/10U"TO
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ML'__70C@N-!H^@=S@?*P>YV\PFTF (=$%<P4M=\"M?47?T:,V#TUCW^;8"\
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M*ZGF+]>]R]NV\DJ<_)6D3Y;#'7"OZO9WU?# (U!1(32YCLV]YV^@T _^1Y=
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M.[<0O[61 +YJP6':%$D))/^F2(8E.%:YC)NB.I;=%.T_ZJ:^\_+/ 3*_RX<
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M$D>;)T.\ZK15Z6%1_7Y"&6VA=.LS.8UA'0NX3]+X"DN\$O"YL+OP_$+ ^86
MQN?*QE\(H"^].O5"@ 105PMD#G$X]')"+P1<74"1+Z3++8^%A@E8@IS29)<7
M^D* I"@2<*#B2)!2%@QS5[D$TXPM+Q^6-1MG/LU(F7,_5P2B@2;4D(X0?  Q
M ER]F<YW6QU](,DK/?C[4>0:[4"+R1@7E;9^O%#:+$[ CE5. C&*N%@KVI8[
M"P_UWD^3@2:U;YJJ4:$@GQ[UZ<].'>Q+P;]J^%#RL)\Z";7SDHM<YQ9G^A52
MEZ"S-'E,W2&PV5P%<L=&Y:/J>JA?0]7%^:Y9JY\N]TIIJ.*9M0&O9U&U3RPS
MN(D0G"F,3<>U/7]AY!]]^\T(7SDR??1TJ=V 7NNY\U3MT?$<&"B =:;:[ML2
MZLI1-5_@";(4+MSE<9T6]RXN>NG3XOGHH;\<#959?[[\0UG.^Y-%?[ <3R<+
MY6^'K[3A>!BG*LJ!,;U:8T?(N*[=O25^83HNYF@K.9AZ<#!=-FND6)'-/RPN
M*[F4!\-WJJ&:&EAL 7 ?T!<0&OCC!UQQZ: 6!UN6$EQ*: WJQ',&? 7ID.="
MAPU<@J2RG"/V-<WRX%H&KG@0D^'"'_[%]N#21%>?=4-W=> 0#XC9&V@%X@3(
MLIB7E%T6#F L'<W'3:LF'=Y5VO9"RI#R,'GH@:45$P=R>.#92+<8'N K2,>
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MQ9<EO6)%X1$2@%QF\<0G917A$0)<6CG>OZ$'T/V<5W?Y"Q@OX!&6V>*09F]
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M7L\*>9R_J>3N;PJ)^P=TF_XA*%@F0Z32:::@T]"0#L;A,+_SR- H2S=KV&A
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M#?E;&F+> RJ3VW"H59^IDU8XTJWV:_'(36\40.6K<)5/3/<>2G<3=X/)Y>V
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M8K 7CPP*-3)"JH!G6+;!AD$OTTT:FR<"O:7:T'7AD8PH%13\Q;;K[3&S.&,
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M#N/FM<O/T_7+M,,0*MGW7%5OZERA6K]<,*0/RBRU=KSS7.ZL@I-/HN#C6'?
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M8&%,';>%\95#=QDSX<=#.6*BGH$=^8,E6'#L,(@)))K?+ ,/+%; PNQ^Y"M
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M2-]_[%Z#DGA$CK'?0K!X K2-XAGW*6R\TF#B/7_TB%UU=/W%RC)\9%4V:7N
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MHVF_V14K<1K;=IA^[TN&(A=^&\IG_OC3N*2]M$<?/Q=4IK&F&&M^SP6V]B]
M%368*U<YZU-,A8H^P7!L)41.!*B,L31+Z>8EH[ZY(+\[5P%7"+C"2\(2=V["
MBNM\->)%S4U^$#1")D\%X%A==(90<$1S>,G"$S  6P"V%VWO0[<H%A.3' QY
M=HRAKF"56]H<'T[9]?-<B$ KM];L[^#K!_DK1B.5R+XR$XOG? >;[DWPNG2R
M9 1 #H"\BXKIN+'.3]R#GK43^$W&Z@!D <A> MF:%\>),&32MGL>3K]G@U>L
M#5LR>*]S6+KG>NYA98"U &LO88T?DCD[HN'E9.UB2FFDGG G8G9P-B$\)(!)
MA4[*5I_[D8''-C&XO[%_V_9B-M8V[(6+ON)_49="F0J: 7@#\#X'WFD?L^B
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M(_=X8'(.B)%4=N.G0 @.J8<@0[$WL[HRC@<DW1E ;U HQX5TR;27=#0J5#O
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MDG(X]?Q" ?V;<FB*26=_I5(= X@[A["YQL2X-XU(H8(. 4[LG.\L;91#^C
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MEHKG=<:EE:OD,E\9Q;8&J&(4AS45;J+9^E!EM V*RYEPG"XOSZ2S+CU-("C
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ML M G=QP&U!/)_[<* !JZZ(Y,AULE=]1!J7-:J74F%5M[9+FOGK5<5S&8*V
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ME8+MXLDXA%*/DA:[VUUHS]4N?536K0ROG006'&E-AYK=X@M!/QXV?0Y%A[O
MNR/0<FO+P4SW6)XFN\1FDUYY<I9MW:"T,[X=@.1R9J:DH[;%(PZ4RVJ;,:">
MR[0:KR #7,C974IL3U5K_]QSY)!"P(-@SA6S&N5Q1? /NC?_1=7.42-A!C@:
M^0;R%&;K.NFX(0*T*'OES\E@@^L. URO>&8G^6MUD3.9]7HCIU]R@PB>! 0M
MMEM-/?]?I]!C@ )*F%54BW7H1*0XJJ"MKS_ PV7Z*>F%@L+4-6LLXT=<F)3^
M2 BM.N4!8Y^_!_YEA@1=T];GQ3DP1#7S<8.>U_W-KDT^=</9\FZXD,;8>2]D
M1*^,JZ3#,Q'1;\IVD==H. QL#8#' N1$$**JY]/?27CZ$\.*.*GYBHV?SQP^
MO%$?I_=J$^A0W*'L!'%8TEEL2 (O&420RIT8X'@YLN"R-<H08H\72Z'[&4ZI
M?6ZMTR3>*N0!$4#^E(MA:O#*TJC$MFFJMIXHW1-?_*NBX4?5(>XZBK'0L-L9
M.2%L&Z11F&PE_)]I&#?JQ!Q2U<K"%M!3PXT61&&Y&$-CH!NM[6TD&4]3GU8[
MR2M$UVHE_I^0XA5KV!6B=L(WJG96^>2L%+@=L,1TE6+=XY2%M&*LN*6?K9$C
M$X/?HG3?BXJ;NS:P8VEIZ4B/)6.%/@LF&. R34[41.V,R><;LCGMS_12<2,>
M=3P500&)A7;GR:5*0<8CA.(6)RMJ!> X;-,:4EE?_L\6)YE5C@7A?R]1,YS<
M&P (W.<7E]5%/$"ND:PG$BCR*$+=A7_NG/QJZ9 CAVEW _(KJK"\YW<I%R/-
MV\U_9:MEQ-'(99,_M_\(W_J87J4^+)P_39O'SN7N<M7Q+/O>^ZJVM^K3]F0.
MJZF; 4X_R:0J/PD$Z%/V]W?V'_\QG+Z^SRM%K[<#US5X%R[?V;RZL.6Q?X\N
M:+N>BUM.%]_T2G=8(Q0\"/LJT%KS=I7_*B&+JQ(:_$7Z\$:X?/W_J^F&+5A5
M2YO0SM.'=V3Y^VM.PQP0N*]\[6/Q/]C9>WI'UO]W*OYW1?O\+L7_R<Z39W=D
M_;?BOQ7_+RW^>UOM_ZMMP8-5#>/TAH:H6LZZ&GL[V 1:A&*:6 KH>KOU*^>T
MKA'(^/[%ZQ?O7AX]>/ONS??O#E]Q,&/3]_\\KI,'?[GR:Z\/7[UP@9%?P\K\
M,BO7D[=PEM<5N1O;>;\=Z?KVW>'KX^13A>':E\YO4QC$ZOGM",/1FU=O#U__
M/Q:'>R?WMQ)Q8XG8^XVIAY/WA]]W-,,GWL<.B?'\/R:3/)_-;)5@'EY_B7XE
MN^5%@$[_A!MQ8'9?=/B?Q/YP\UOO;N_A_S"OSR<HK-_Z[NDU=;=W;X <=;N5
MZ^Z7N[V5KS@[ET]_Z9WQ9>6OG\SZ;*[15RILFV+:O]*4)+7XV8S.KW3A-T53
M?Z4I_:TZ*YNJE#K*/V6+Y3>)_NGWOAF;8GMW7('>]FUX4BS;>=Y.\OGH_=:J
MOKY5_45G^1:HB/+TQK?='9"O6S.<O^@L_Y7-T31FNS_7MX:_2FW]10=]7,'&
M_9C/MT;N%[_>RP=;"_?+6[@G65G-"@XO@,2D:IO?^R9L+=M/AY5FX^SGXE,5
MZ&V/_O=AV/XM/U]EY:>HVML>^>_#KA6%O-V>K5G[^0;]+IL6[6*T?W"PM6N_
M^.7^/W2<3ZO?NU5U"Z;MM]GE)V7+?E/KOK5F/SWWM?3,K_<.W[T>/=I]=G]K
MU]Y1N_9%#?:IK5U[5^W:SYI*N^W);&W=.VOK'F=U]0LP:[\I,;H%:_=U.\[_
MO0WD;JW=K;7[=5F[;_/%F#1G\7.[R,9;*_>.6KE_SR]7=;LU<^^LF?LJKR<?
MMKNSM6@_WZ#?S#/T1OL4I?R;$J%;L&9_N"QIZ7_>VK-?WIX]!%?C_^9E/OG=
MK_[6JOWTS%<[^63E>=MC_WU8M._:<9U]TAF_[9'_/@S:HWE%<W/M?;?[M#5M
M/R.(NU@6Y]4*&;953O?]QWR5W3@?L+5S?WGP9]Z>%Y/5%J7PY>W<U]4YFBMO
M8;=WQLA]P&2COWT*Z1LQ-EN[[ 6OF;99'>?S(C_/E? =/4$=J?,Y=WE7=N>&
MQEN#\G=,WEP+IF3T%!=J8G ]3XMIMLK3I.!V%6CC/6OG:)AX7LWQ^,QU4UUI
M3X&V+/[=TB^FQ6R6U]QMB8F%P6:;<;?8'IFT:VRNSS6F<B&^96)AL+5GTI@"
M$T(_!B:/1W=';G6QR#Y( X1Q(?3N]OZ):W7AB=-GH$1WC;F&.R(^3\;S:L*M
M.P[?2><;)1L^*?!0:9O0!$3V;BS3@A[/O1Z*DFG<#]^-7K\_MC[VW .5_K3(
MI\50KU :JY(FQYTBP0=_N<R:1MM+CJ1=B/#_2^/X26Y-U)KDWK1H)BVWYLC&
MU7E^WQI77!K]-?HU9,81#=YNMP]1QS/K<N4:C3@^8GZ@=L_6EI<_?'N\D[R,
MI:4KD=R'#03R=:Z=<+DUA&^]WJSR)>B;+T!3KZ3+?G#]GG([R?LJ;KC^H:PN
MYOGTE 2QK+3A!CTY.ZT@JB81NB\8CZ-=YE:=VLFZTUULJ($FMSNQEAYH7CNQ
MSB/R3A7[G#MC<']=DDH\G)>8%@SS)LFFORB[<]195OK88=I9?9EHDXQ"GC;-
M3^MLFMO*"V._;HI0:4O?#6[O=TBR7V9-FKPL)SM?8^ND_=UMZZ3N)GVIUDGK
M+Y^-9$QOLY7TE@5#2ETMZR)G,7Z'+S5WI$GJ#P6)7H.^<G6>>^7WSV^/7"><
M;X^.#K]DE[GN!%A_XLJC(SF7X4Y9E\S1&Q(=V4G)H-7!)?I-5=-"FJD4#1_^
MI>Q"FEAWN*5MRQ(MLK6+%.8*I3FB2TR[B$@;;F@@G"I5+'0/<PMQ=RG2G;PC
M&K[.9^A=(+J5FRX,C9"EO;$&3MKC_0>;U<NWUE/]-AM@! U#EUDMW;"R1)<^
MR6))80FIZ>@U9_3#>;L8%UER)+<#FA5.+IT@_;/D1D_:0:_WHWN]%:GJ1I?C
M/EJVT@(=YY.<6S+L[Z?)_N[>+O?$RA8P!+@]S7?YN&YQRO 1?6$O35[1E;__
MA/_U4/H[\5\>X2_[>P.O#4Z#O3[5'AWH25!,\R;J+B2-/C_2]=7 O.1N+U!-
MN>TVWU9J<T3M%=!CRG7"<"UV\.Q0)&[UX"VS8@H[EVR!1;N@\9>0Y[JZS.:R
MCT?_^?112C<-SAPML2ST4UEH^J]GTO*"7N;ZZ$IWGLO@J>%C8&9PU]3+/.,>
M&'1+X8I"CU:R*)+OBIJ>=:3G,N&+,S)7HNXFF6^-01\=_>>C77X)QG3TG\]V
MY5\\.C0;PES;965=F<S>RES7C:(,&D>R8E_3VPB]D7(HB'S^Y9IZ#1UF=Y+8
M]*6U0O>T51X*6:#\>?*1*5G0C\G7H7.<)MJ[M_\S/'J<^Z>SS947; .*"L&N
MDDK@!EYHY\5]E,;2*+"Q!LR5_X$J5:A]:Z1""XI75=SJC?:5-A.[9[)'TE5B
MQ:V#O;;A<2?-=;IR!\[I>>>QJ&$<'#[6+]8$3*SCX370 1?!MZ$VY^1%8;EI
M"@V)()J%K&B#?;M"W_"WJQJBUES!D$2?5@G\U>"Q^8S66)0-S7!1P6\5IYA_
MT.3<6%"G/@%AM>]\'6H;;K*(G6PZ[P[VVTV1YPS3'I=MO'PD<FFR)SMT\)#[
M A]5)?.<R<SH")-CE9R<9718X%33%9.WO$/9I3MZI>M*9A?0+,_9Q^)WZP(V
MUYE:W%*)WJA-EH,V;Z::3%2[^Q.T.*+S2XXV^,=TN V='MYSTA&GM%2GV'?6
M;/L[#_'U.69M#;!GK,:F=7OJ @Z^(;F7,W?KEM.UCW^TMQMKSJ8=-S0A]>_Q
M;)5.5G3<!@Z3C/8JF9/E(UWU1M/BE-9&=#R\+=_\S;V8+SF^XTH2L"9#$Z/P
M;&W8!>[N1.98#:>'_!!I!CJ6F4H?*=(WK>LWA(&M\MSZ?PY9K+2)^<<E&F7K
M]2E]T^G!^[M\CY 6P1TB9TX7;EBT=7OX<:Z=UQSM B.#TMQ5YZ#_2A?VI]KU
MD0Y_&9JB;\T4/=&>D[=IVX?FI@]"U#D.'S3_/-"(9DU!S!&GT\Z=&$7>Z$DB
M#3@C#5-);S"+N102,O/G*[.XGW1#FT'PSM>9["Y<:$?77KRJ6[1-XW;TW/0P
MN+2<HV*:1,5&YI#*%:5& DYU4RU8*"U6>87/D4KSTN@$!V_GSI#</AH*8R(]
MY*N+DJSOLV+II-K&N P\51UGY!VQ58"A%K."OR[JN:_N)<0'$UF"F-R65I7C
M=2[1R$0<HQ_>-+\UZ^F0-9KW.';W#S281RO9!+9]9HOFQ4_BSJ(BFN3)7L\;
ME<^P2F0AZX=HK.:_(;U*:U:#)'F37 V$<_0?1%?4)5WZZ#S.?U\KD]SGT@D4
MBYV+38=?)X.AF#4/,C*3J],6LOQV0!(P'KD_U)NVGG!X_9142L:M+\NI6F0K
MM#?']QKY1$5&'WU4X8B)-? > 4ZQ$W4N)38KZ)_,L<KRK!AS![[4W"YMV\D*
M6[XXY5>-\]4%XM+[NP>/\=[]W8<'MVJ)]X3$R4<L'&MV/HY?Q-O"OQ#1P/*N
M:4YO8I!VFQ;R!]9K$?^HB\:R$%<^2[7Q(E^=55,6-S),115@#F$_5_6>\;\K
M-=5;.N]S?^,&&T@^5%:>8ABLZOK;^+5%</>V$=S;BN#>Z*Q^2V,3/6^!JW%=
M9;BS.L=&NXU>)MEJQ69WD,,I%CCGF>;?[&2;!1$< #HO: 7JFI@6D'QG1NN%
MBEP25/+A9$);"B/],HW==$TX)9(4$W<*CG0*BQCG,^ALKWVT;5#HY*QW&8(M
MJRK5LXHAAO97DT_H8QG4)*MA'I=FD< $@T*N6MQ[,T1D3(/HPZ67>CWE8168
MS7'1+%NH:FY.7:-3;>:NB*)$HK!R!@N]] %:/CLCAK-)2'7J%:1FI%N1*%BA
MD43Z8.@*9L?I8X9<4\I]4R6S91G G#ZH+O/<.<1FL79?(1DG/-$/T\_>K?=%
M*8X1_=R98#IK?;)X.O8:+ \G1.?%@J_98"])SF@'. G'"X(HU]36U:[ >) J
MU6@MZR=6V[S=W]#BU@5&WQ7-A^0[>I,/R;J.M(<2$GR70^(Y!DM/(M4R^OM.
M\B,D2M* =*EP+EVLF!(96Q=$IC-,ZLP"KK)]XY\D?M:HT<5>7F@?-GG^P2TJ
MMSC67N46MB]-O+G'[U)V 6<AZ!BL  %Q1XMS,5'(\K3SN_I"SMRF1-(['W1X
M49X7Y+A@I6Z[3;;JJ()[PD^#-M+LQT3*J8>H$+WF4OO:X[KW-;4D:<?><6'^
M<:AM8%PT+4L)]DPC,^:G-=DLAYN4SZ"0$;S\=RL("FZ-38([X;"C<@LFIS">
M>%W16+HE15;;:[IMW%\.F+PI^Y^-M:2&'I]D0;QM_6 U0/+=\2$_^8A.PC1+
M-8?4F:[^S(=5OJLJZ=A\S&\_G*S<G55+7VD?LU)#D<XC.V"6T6 ;K60STSWV
M_=OC'7ZDZ^.=S+,+Y\+AB04GX_4"BUJ()_1?4$]\D=$UD<]:2>63,U"1=SV-
M>Y%KC_$@>!3L?QKL"\)"!8DS&Y8V+/H5MSDO=.<$S0&)*Z"<J^2T8#R-^P'K
M#5(D8>"-5)T[8HVX-S935@^DPJL:0L)Q5'&#)_!HRFE63QL'/9A\_^HM1DQ[
M,L_(]I(CNV07" W'[ZDR_?Z'MRZMQ=I0[QG^I4LD#/SN*/@=#8Z\B'EUX4-0
MP1%,W;KR"P92(U&&0B[8RVA5/H?^OV7]Q!81FK=?W:)>L@4U%J42/XNQ)P5;
M<'Q'!9=8,LNG:/Z>BEN;)@CR2S]Z.DBDNTO^H%T-G$"5K,9\'GAUIC01M\6=
MPW G9 GXB45)@RA$N*5U_0YM13''C_2JFU_ZG(<ZAD@)<$!!7RA!F$Q,!7[X
M5([KRNOR2#YT_5)_=MR*UAI-=9_ 0C'UAOBT#$&BJ5C01@YCQNHVE[QA-D7V
M3]0(V3;TC9_(&A-#DR;,JQ4::5 D#9)&3F'R(Z5-O/..0[=80@33.KL032$C
MXQ&G?,%K7(\S?.Z,G-&EF[)+SGM/'UYD-0O//%^M<C6@)%6UNER*5:@:E!=.
MO^:L>*#MLOD\^$.3%S^WG/185=!:E22]>.HMTEQ-G*KB?]6PZU9U,6X%)U>4
M/[5NF4A(V&.6->(A!9K3 C'\#3H[*WT$/9 TVVD>X,IF!;X%FXD4)X]L0LJU
M*-G=.<>/3P/(! W54@2D(!%O#';'CM5QCLG9._Z&PSOA_98UC&Y>& 3L'-R^
MU<7WWUN[P(^#D_%6SL%M&F"'X2&#(=R]Y(+,GQ,;T@WL:T9)I\$ 'N>)2+@=
MJ'6**+9"3.7: 0*:9\^@9!?$D+Y&$_I*MFSRY_8?WWR&';1H3O 7ZU7,8QC-
MLTMR/Y_/BH_Y=&@Y@UB#149$#.):%/G:P6/YK ,5_T7SZ,+F,43&SI_1XH\:
M\N3RYV6%%L(VUJ<]O/F?_N/9XR?/ONF.JP-*[S52_-0A![FEDJ[U;/Y->%3T
M3W_XBP U39O2O#2C4I+GI8HUY1S'BM_/6"E+D<-:RYWZ#2PGF# NJ>"_D97%
MPJ-2.<[<NZGM!HPN/XN^G+4T\YSSYS38X(7RY,8N\H79Z,V*KJ \NHW(AFL\
M]+T'T=\>BNVA^ M91 NR(S0D8=>B&"(O7Q^;!R;*%MJ5G%584.,<5J2(:0^%
M+5 ;VN>M]&VE;Y/T.6M@?"DH&F?XL2O!OO2X0HF!^9<OWWWK\8ZN. ':CE$E
M3A+);,Y-2.-/6$8-#2:X';(JMI*ZE=1-DKK,:]RVYFYE4[JT+4AXD<_GHR!V
M-*P4,\N+!(K611]#[WO"F#.&F$06R/=';Z/O<9")'.4 .SIH2L2)'!F<"V^I
M1QQ&W,]R\I?.D"'!A+7@J4K(T"$A!!J:*[4X=BF!2@U?6N8!(8@*^8+(AC=$
M##( #(0FTV9[Z+:';N.AJ^&69RY^O]Y8X7>S-WSH@RONTG@M)PV7QE;DMB*W
M2>34Z/"JC)67F"<<,)J>%PW\,&CI8K7*<YC(G00BXTUF@8^WE;JMU&WTPDA?
M-3-.75A!J=W7 &^3.'%) 020;.2EW.8NU3^8VN+4O4]S(:HNKEP@UQ)$]6EH
MSKQ5LY0S-_(=LSX:!-6[00PDDSJQ^]*^WUIFBL-Q0;K-0%B:8X?1I)@]LZD8
MV4$&2FWUU3):7^XQY1#L)5(;=5Z>KL[BS.F2%F)UN3USVS.WT;CP!1QDBM8H
MV=#L*8@'<))8WP=97,@BF1+?X%OKA>MK@_SM;R%_-X?\;37(5H/\I1?3+[D0
M@W; E$9X-X:1>88JO*!OM-ZY>558WM*J7HH 5_'NQ:N3") 1OTBC_[Z (8#L
MK%=5T;ERLH44GC][MULB]#;(J9S('&^S%"@<CBTY3!>R8V"AT+IOGDY1)N<%
M63R8@U4@6$('(1:1B-Q O-6'HB1#<")64S:NYD6SL-UO"B[4K#X6$PW*-R%^
M/<?_UVA5$+#I.#8>[>;02 S$#7 /XFQSV$@R6;T%X,@1Y]:!K WP&0(1U<61
MY'U__4!PY%%GBEKI!;K6G:3O?XB"8O)&0UBYR?JW:KYN59WFG-DW:&=@0$>!
M+]2:7 J4FI8I2R7B=IX5<[X!/&J)/A2P[ JU(+!^>9_F6#4N+.[,FYZT0'67
M@C3.Z,U-:A@\]BRG89 C$YX#GYG924Y0CC6G9XQ0"=N;)3TP=; ORT=B]D*N
M9+"-<QC>H#R R#@;?I+5DZ*D1:+GL:6->+D#MOHZ11J(;J ,^2Z4%;Z4F+[Z
M3W_E>.=[69#;U!U'G7BP$G0)'BH^;RJW$9C%(S7=<?3!6U^NUK1+\IL* ^>P
M6S03MA%[& "$T#L<C_:WEX27PU,F_J)6  W+*Z,X_8^T+&@^'P@PFV*2(+,<
MLEQ@ULI:< $X*Q.=S:2 'E]DT-&D6,K*L+Z\[,36=Y+NVL8Z658'3T>!D.1_
M$!2O)G ]IRCDG/-I63=#C_.VK5$&!=8N69V1=E9>E3'G[%FQT\-0!<:593Y:
MSI Z5M?TO)*]ZKI@K@']N5T"TYWDT W3UTUW\EB6!(C+J>4W3#DB?KFQ1URE
M6_1,TZM9R0!E7$$5"L9FG)/)0XO@QD_FNO0DFX+.3-0"J:&\6(8HJY1V8(Z9
MNHU%6( 9!G0$=5:@#) Q\'7)Z#V:2V-H1"4UXRI&2RX,K ,IVXF"%N6/51E#
MYAB]+"J1-!PJP$R'&0#0=@B#XC4#GA&GE$LIVA4#:@5YJ4/UPMH=$MVMD@7O
M@*:+B->'J<TRSAMER='[0UOZ!_3?T?=L"V<%?Q?[/D'%0&3L8>7>OST6QAD7
M?DROF:[G@5HZB7E)7K[[=B#+&N1IP_/I2RV[R599R0XT6H,[=$.R=/?/M8VZ
MT J?<B)Q+"U<#4""MFT8KM&XB'TC5Y96[-O[R3T-1J "!% D2NB%/6:N]2WN
MB?WAK]<7L8I10Z^G[YR5H0=?%:0<S5J EJ([129L)%*/F@^ABO@L!=;0K6&;
M+ZKD0WZ92$@3U\UL3KIIXLJME-Z IGQ*LF6W52]EJ@>+O^X"F$;_J =,>7",
M%\.DT5$SN)N(7Y:)_7QQ)N:?UV2.O%!O#U?H[XT]2ZA.25F!4<>%-SG1602Y
M3=Y!>AX7*#,I3T#60U^<@Y!Q?IEX>D@N7Y=+?Z*&N\2BR#0KO-VNKS8Q\T-V
M@[2CX"M7&G8'U$.PYV#$(G:P"4VAE)<,OJT+#3#SK>-'[M@IM?BH$=T3 M;!
MIO7EL+&;?4>F/=KSQL%[EJI;]1]U2$.TE<:TZAE5]0 XB*NW:! R2)H%#*VR
MY<I_J=V3<Q%ZDE9C-*7-DMH\02!\A%U?"+Q[3F^4:KVTYWE:1'^:"W&2'$A^
M&@9M-%/="='9$X_Q[@C"_MT3A/ZZ^<TV]R 39>%8;^E@+PWSR113ZV3*BMN]
MU,"YY]3)[-('$)SSIPJ"M8Z8JW71?&BTT#:?,\*^IJ7QPJ6VK$-_9 -Q!2YT
MLWHD(:+-IZ;'!L2+1 M\.R*5=")2NN]6[+SJ)PP7K[CVOYF<Y=-V_EGI-WZ9
MD!W</2'K\KX-"9DOQ(I+U?B:8&6S@-5LDN@E,%0[33M3XES'^^+V&T)8!#4B
MV'SM9HRLGE1J1?688I\?O7M[Q(98D_N 46?05J04CYH]1?P]XQMYX/3077::
MPR18GNERH"@9AT$J_AA#V"3WF,AD)(D47<+[,2#*QW8B5)3W\6P*=C11OJ>L
M(7ED"?+*^3PMRD[8FZ:3.!K3#V;@O-(:8BG=#GA W<6NAI$[5-.ODXSB8)N9
M^BK(*%XBU@&GBS6Z^"!60$B.0 \K&=;9KM51N!/(O1(^[=Y-8Z*.&(D0PKDG
MB>O$[I!X9O2V68$#!@/5A<75C(72(E-((U"U,-H(3WNCP![OT<%S%R4H[$:A
M3@B&*XZP$ATX&@$EF<VX[-*3\=,)OT1E?]-F7(TR*R3 $!7\T?<6>88"OUD[
M-P@^8@*H_Q?#K:A!25?+I4Y_'Q=3!8$HG[VK(C3W17)6$9<YA %%Q%6[0J3'
M,!JR?$%D4@GIF6FTR:'<;=F9-)Z=6:X,YJ?"B5B9CF6_@4=Y%V[M(=C@;5[9
MATW3+MBT<>3\'3R0R_!U@_U!R6<<QO4;-I@1B8JO77(B3I!(C#2?1G=5]^KI
MPG3(.%L@ILW9@Z#JVX-^A#A&_$CR7O/U4=AKYD5>(]BH7OK[M\?1IQXB>N)A
MI!XA>A*6%4CP<;A<T=VR(;(Y1&GY%@.:CJ*'X\/7QTR]2K\O-9KD0W=1.9CS
MIL?55-C&-@SC5NO7L0/J7S1L_9N;<)EX(*7L"PL2*8S'8<18N4XL9.P#91+%
MM:BL+M*3AQ!%\/"X_%.,H9>G6,(S @M[!\-"/\&RNT8K[C)P?1T4CH;?KGSM
M^WFN\Y,-YFAQ=FF"$R+RHP.3Z8NS4F.WMC;8XQDG(92Z@P;#2COM#=/"P#C1
M=AY\7?W@BWU2U'[0F3?;HQ'UAU3>^- V'[6)$-04JVB\;Y@_*E[PHO'!:?_=
MU#V*H\V-E/R@1\KJ;./:,L,R^!?YZ <DCT%1QFFE<0=1=SR!@%Z!5IE.XRN8
M*9( Z#(&XGY=:4C,G4Z56;H@16A),ZW.&N_?&$VKS8])9O".Z/%8 =4SG&7'
MO2RO,)J*B(-ETTC(!,BCH;B7VR9'$U<CAVM=IW&B0(*9M*:!T$1/9MJ&$L'#
MFBNR0TGF?'96,Y&89 $L=AWK,YD'O0!!7FQWF$*9YG+8R##2L$31':(6<8LO
M1%8SU_A[.;LUW?>MG Q1R^HX\]WC6!^<B\V44 K:#;&P77RNMS5=U3OGP8S]
M.;A"I^9.@J_:70TA,%AH%N$YA@C@IJDFTLY(X4JL>_QRAK@*\2,-&MQ!2-PS
M6,&AQ,[?QIQS+TLZJU,."MQGV@?RD;OE0-$#'>$6[ )GS[BB9R9B,UW ZU%6
M*Y=$\EP>2M;(J<9BY56^=4'J0:4=:YU44P=+50^F5X;QSB%N68'/ 7=82(\1
M8V_T2#N#SJ)D9CH<NG,))KWQ52+'"Q.&=D3D0LLDJHYLHO'&$_W^Z/8Z.@AD
MJ#&\$!H0JW&K]Y>?O$)/C(]&A"2XAD#[A"=!^?.=%*QH>-]E$:M-)$V*#$Z#
MA%#^<4(W$4;QG_OIHUW?K"$6,.'G,Q-&, B.W86VV[%<A.]SW+7!Z$+*1FUM
M$::R7!A*FB,8E-ETA,":HSP"G7)P\G/21W.=M[79;^2^'I/OZYR3T*;+/4;2
M [ M^2W4@SW(EE=B YZ/UY(;JR?$!PI,.VD>$+#S*(4.$PUY6U&XF9!JX4\Y
M<=O]A3*W_9PW(7&EF/7J^7?5A(^@(Q4_J8MQ9]9QF#WR0 [7CDY#D.RBMZNY
M:LK<7\P2;>T:=\*D=^GXQZ*SXPU01YI61P,M8#W@+%@V54F2ZMQ9&QV3EQLI
M:-(6@T'N*1JB[^^GED;D(GKZ42NR,2"1F<1.6:A\=73JNJV/[5.K!YMZ UK]
M^+/H/;*B%Q76I6?-23Z85TU;ZETNA7(]6D%A]=])7I"+H/+1F4>D[#JEO#IH
M!+#0Y61^J0T')X+.TILRU$K3BE89=ZXLX:4>+.>G.@13Z*M^G3'GA]N8\]<1
M<W9WA=VHC4\_<ML4"#4GO$V<Y=H-=".+:]OD8:6\_#RB5A1FLN!WJ;&M-1I>
MG62M/) 9)>*>&Z;&?7PK>O@@C#^\PR2L_; ;((=!&*=V9VW-X06MU;/X4*#^
M)#<5L>(%HPFBB&C#FI/JDVZE8FNPN:B0QFAB\L!>4R A76>0B(_#BT:*YA<2
MQL7@$\>^ANQ70+_K^MDN&DV5(=]E#9N V)'X>(R""<C&A$+."(KCZS8.Z%@K
M6 9V0Y1LD:/;VJ>]H_9H@>7!NZPCL#0F+NRA=:8;N[-%"Z9#-!H_S/W4MREP
M@NV$UV&^^>"K[QX(;VSPV./$DW%7AHDK_/QBX2.P#J>O"V%BT_.*) W48T.]
M"T'_M]B-0SMS[X*1WV;H7^AQ0S<_XE/,I\+<K3&5L#:Q1]T+"+ADD\RO=AC(
M 4[?X#0.!]^CO0VC_K#9ZNF'/%_R;Y&"KTC0@!BM:BE <'228"XW_1*31#("
M927='/1XHM&'6IKN64*[HF 53O<+(-0%/]T)[IZ?T('ZA:?'*Z6K#HC4TZP[
M!= RYNHI2$?W*#4?SSRY/JF+\*U+^_68AI_3I*$_&-1]\\3B0&,@:XP8YN0L
M_2\F'=I_[$.RA]$NK=?Q/(YQ2GPDK(:Y-9\RPC"SAQTZY2$UJC%Y&J1DB*6X
M)[ LAR8VRJA=Q]W9A'M:/!E0V,<[X@36"$BE6[5!)WU;DOA$R]%J2Q(/LC\G
M/%@?\>MSFC)B)GRPH RO"FGM)$?Q$1D,F<GX^*Z>.P"HHDBKV2IW8:W@''BR
M+PEE20/LPKIGPZ'IX)=CGNNH'$8U6UU[9Y[)H>FLF7&'(#U/C]-*8HEX;2(P
MLDG+PJS&1W#.'!XWK S@>QC](4;2,#*6*^<ZV4]"MXI;(7::8\0_[[4?%>)E
M+I1(87GEEZDABT!BK:)*&Y%U:'CQ)>-#<$%5) Z+DIMJ\*)X0;C%X,\D]JO)
M:R43"*(0!U^,(CE0V?CVK"?-@4_:,T@\%WHASJRMAURT!2_AF&21E/QDTM9!
MEM&3)&N?>#X64, [R0_<Q8\4!,?<+S5J>0X8!;/2HF-SZ1]MH OGJ#A#N%.%
M!UJ"$E$50;.'4'"Z%CC3:/U.!VH8760[E33#(!/WFM5*-;IC$ _,1B(7W4O3
MW8&2Y.%[0]V,(.3P38?'>HTQ/(  4E<F>"Q#4K]QKH5[9JR@G>,0NA,:@4U0
M26W&]D[RAK_HW00NS^"UY6MA;>G;EE=X2P/@**-"I[4,M(.&/^.C&?N;J8_.
MQD3PH=YQ^68]-1QUB'C;MV0W6QG=)*/*O=_M$D""A+I(%MLX$M71QEOYVLK7
M9ATHC2]\"F^H\07G82,WL@F^-N7/4_F"[S"!:_R\FG1;H_NNTQ8%V<KH5D8W
MLXE&G4TXNI:O!!F=BIR)$'O 'V>,%](S".WWY+]\"W%8HENIVTK=!JD+6N 8
M,CEV7?I-;%S'FCM!W?1)H.!>:*CQ)G$:8KW7QGZ#4Y:X9L/,\#"-C>R=Q"+G
MEUI%3T_@+\TO769O,/UG!$P=(A2UO,WIU2LM=GI]FLA'$UV<+;..9=IQB7_/
MS>FZC;;HD=PKVL JT?2KV6S$+T/HR,*"B:)>9$T*!/5:*:%D% 2)%K>$GU\&
M"Q$]QQ>^# *,YH7FQ>Y&^'8E->]1\%4A,$L!GL;00R<R,:L4'O,V_!G7 ;QR
M3MJA<J&^/7YU:+PW7G*'!N%;*7*$F=,;QD[A>J^1G4URD&HE/VA8R*A>M(L@
M%F4"&K4KC,7$7N?' $H%#?A*S_*=A!L"\S1I"D%4F<7.I\$_82W]W,(P:A!<
M0ZBR9!@A3E);NLPJG:WP?5\G(.31%A!R6X"03\WOOJF7*+$XSJ'8_(EZ\7$R
M;QOT*KV\S3PO-PHF)9Q:!%\ZRZ;2*[B2L<MY#R9@[1-Z!?9T]O_IV+]LYES1
M-EG%471['#@%(BPV\\-9A4(P -=$$U4Z@_PFP-#A7K:2PBI >23W/+Q0BQ<3
MZV2<*=G ++^P@IA]!=+B@CXOIFU0S='I8NOKK+3B%-1A5C*-OR.\CUA]4Y5L
M@2.1,EDYR@31A 8Q5KI",T 6F;2IZZR0HU<9;$7'2MS(6#I4+?&:&)H?F7.R
M?% >@]@>>1UYTXGZW3?H)J=[A8)(RHMTBVQPH9AH:JV'E&8,I=PS\HRA5 L/
M#IF,>=6(T6),VX[VS).3L+FC)5N02Q=!YSS7F_5#=&!"6I7S_%((%:?G-!:P
M.S \-&G.R-'2IN#3-F;%B[(6_6Z[FOFX/?,EQ -)%;*L!7=;U2JU<[4J9D5-
M>Q$E1[LD0Y'XX$-EY5LQZI23^L'JIE'<V!] WEI]=5=^<J\7>QL7?,:'.,AR
MFEJ):S$NS1CN%D"QL9(M@J!V^$=OE@O. $DP0<9>TL5#AQZ@^R6GHR9H\TC_
M:XWF)T4]:1=:LKW##>G)J&,;2?)8,NF0R'M:@*DBJ,[P0^P,)*!BB!<&BQ\N
MCH&BI8UO?SNCJ9,])$".8"3^Q8)W5NZ-.E9$3H=/56MWAA6 >IV@^5Q$-"HN
MOG.3'==5-C5=?($]OLB:\'4TJ8([U4?O"[;9@2XA$$S+1;N@M%RAB'W&@QDZ
MW-P1]1HGU9MVW_OFL^^\L?VF73%AEFJ;6-%CEX7([]=5+_RG@IG!G@]90KM#
MWE+<M'WX]@QF0'Y.[NZCJ!@F:(#<>9Z<[9_:NFBFEO&2WKAKP6.#=,',]>=K
M'^3Z&P+:5*U+=='9OBN+_J.6$ /"3\)^D=NQ[VGR(--_D2M]GWS5+N.".]5Y
M*!_; R&CFE2+*$S)]>YF1PN5<9ZX6:P:X4DT0Z2W^E4'NQH5'%IUA7LXJ5/5
MMOY]U:8#PD&(+&E(-\^SVJ&%I$5]V%4\+EC(XH%>=BJ>03U4:&=?L'5NG'*'
MXU(GKG75>?*B18"$OD$#A])BBKN/[.*FPL Y3)8JY*N\"I<.4UT:-:_V3+/-
M4JH/UK".XH\Y,'RA"$ ]T<PLFO3RW;?< WN9:QPIJ+'&\(0_U,)9O?!5UAME
M#.[HK'383ET@SQ7*VWYE^^GZ9^W]62?<H&%"EBNG>U02'-%XG] B3ANQNF(3
MG(Q.?%A,S .@\[48MW4C G4.+@.!DLFJ"HB&_U/H4L%GDS56+W8%/?P:WF7#
M;@[30/0[[ #F*8PJ&'HY*3A PZ>,3Z#@#J5BVNZ!XQPEVYX7.Y_3*GPH[LY]
M+$S=1]D2CCQ=R0TI_PGX_N^&(!YZ\DRM^N<RJT-!Z[YC8&'*'&;"5T""LA)S
MDT_K1[/+'NTF.6F;ZM+ZS0!R1'9;QJ@OE*7-VOE\Q/S(E?!?RS^X2'+'O\$*
M3+)FE3K[LQ-3J',Q1SVPGZ'3J]Y+\9W163714LPB()IA[5^6"K1T(?(C<4V=
ME@D5B<&K[LK>_0BTZ;S(S[7J!F:%+)$1[:CSR\J:(S-8]Q1+@^]:1%,X$1Q"
M,UNM0'.4)F<%%ENT!R^XYUT'M1-6;[Z3_)A'O^9XC^T,AU'QJH;+&I7'-9^<
MF3;)9C,D';C- G_18^!U3_#E:EZ=\@^*LB1[0NSR"[$O<B[^#W*:ULRT]EG0
MT[JZ8&J :;2?:HDYN>6YV(K"_($7P\$*N%YPM_B_RT;[,'J4(YEZ6<VQ+X1>
M\<UQ5;::W8#$K2ZEOXFRW8' 9_*!E#2]\S77LG>&@NO0,50+?T0FU %)*S>\
MT(Z)8BP!H@R6#AF5BZK^0 M<+1&<O3OJ\(A<K8K)STY6=<LHX;MRG-[[X\]N
M(FVF#78:]"(HX?-J6)&UEO!$T*TYV7',)T%-"W[S+;F)S(IOT^>S<4@7][UO
M804W9_3)O%V,B^P^3N??,E*_=$<^3A%!?"9YN:YJ,CR^ M2E; 7J?$;& /,Q
M U^"3U?)20M[_ !U_?PL,FPG'])D;^_@('F5S\])3?".Y#F=^W_1$:I:$JDT
MZ8XN53<K^=?C%\G#%X^&1T9VXW33.)[LTS">/7M&YXULTF_AI%\@='RM%S_Z
MWV3O[X^^SK3+XVW:Y0[5X5Y?-9Q L2=_:\G0>88CN?<H';06CKC)=7)"&L'<
M1KI+ISZY_SIKIMF_P\XFEPM2HDZ?O'WY/TZ)#)VL^ 7Z[ U/LV?IZ]]7-:U*
M12>]FGQ ZHB+8I)[^$Q_]/[D?UQ'+O80>-;[3VW:Y",4<[JTSG-FZ-Y_R!\\
M@3<7_/6)_#5:);I[YP6SLN,"C&?BL,#T>KTH3[.2)QCP!M"'HW^%TX4JECFG
MP:3="M*0WDQ6%8^(52GT3CBBH.IHU7!5BS&KG9/>*5?"#"WCOF+4HW_=&;LP
MO,A@4E?,#U<Q(\8%"D/ ;5%,"[IA;@GP'_[I5\1T,9QJB^FZ)J8K,&8,+2$&
MRXXCE.2OO,\_9HWGE<P_%E(L[<\EPS/4K>00&O[!/Q-[(;0/Z!/_U$%K8>\
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M:5)!WC-2XK7'<)J/?$I'*C^!^I 06R3]6$F^5T,L G6D#Y7GJ\NH,:)ML+_
M5% W.;!9$ZD)SV,J@H#\VR*FB%@C$Y\01)*@< KVI%$0_ +H>TA8L3ER-R$D
M]APR4M!!3:L0(C0B[3O2SDI <JOQK\8?C3^Q=I.([38P(N9L.]T^C,'L:E&U
MM)PFG/OG*8%'@.?KV'8M*5MI*0@I7;8C5@M<+3!SOW=U>S 966(/:=&<KG<
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MBQ QA<O(L'G.U&Q\]?XEMAT5&'%!G95+'EQ5+,+"1&5)8WJFS9),B:O_XT"
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M0P#_!'?L"JNIV%"(U3A;R+CV/!6:()-GDF +M=J*^3GM7XV;D\I0?WGUIMQ
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MO*Q2=J^B3DB#L [6152M.VTOJLS;I<Y@U(B2Y7PVF<N?)&&T5%T:"WE5EA=
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M!JZJXUH$O RY+G+M_@?CB+/TRR5FWF-34<GNBG8X8O6\/N&X[\HUNUB;]%D
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M\X0F1CDX2DF-:,0)NU/N%GEC_AE]<SHE*[],A+'RFPB*<A1CK*\8LRGQM41
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M+&V'X$7C3"MS%> %*?0(*Z,55LRWR3D[]>6#]9H2(T(F$=/%J88>F:+D1.R
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MY*.'#E^8_VZE\RX[L<WS\<PKN".QPVGV8/C=CW__Q^JWX8<^_=T?GXU7\N>
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M^7J!-"AF[/H OL8<F4OR%Y 1F3A%,5&\=V03[UBT0KL@2\PH%Z]1$B.12K;
M[](Z!DV/9W5@>ZV5;_&*'8<HPSAG\NZ.9]V\A S&-J7]ROS+'HZQP)[T;7A-
M1V+,7!!_M&:-#D&FKLNF)A77SMNQ@H]2?P6KZG,1-([&F!J.Y1\S9VY4I%[A
ML84P5-0NH^H9/U+/"J[P*T_V+[HY[QNJ=4?]>'<Z>V'ZW$!(F51QJOD*%C ,
M$GAB<S:"9R#DG*,O2!2JN/!&0P-S;^,BTH*/Y8IO=!J7'*QP:+EM84G[X2%-
MNR#J!*D7PALQ(ZR(CO8Q:QN#-QVC89(]RV RI6L"K+CC!@J83S%\2F%X<A4Q
M7Z7Y-JA2T4Y9$_70*OM<4GW.&:1R&XK5L/(Z^>+8+XDG>AEEG?20RNJ*2J^I
M#)Z4QA2X.=/:-"E/"8>[D1SH)\EQ6>P1=Y8B79BK4CF%I6Q),06.,Z\,*E3Q
M5%'6N%A ,#O7T[MN8C6=G,X'"6OY_0IK^2!@+6GZ0KZ9+5--F$^JA3 _Z<M6
M"NN/P)0EDI[+JFQZ]E7__Y$HS@4S:NMA/ 8J-;II:B^AJ2KHH</NV?0.OR3]
MF2JA.F3$H:90CHFTU%G.Y"N?HEE96I"(%[+$\X[8T+6KG&5_'IH[,A]I!A$V
M\DY]3Q??41'_NP_!SB#$W<3VRC]9I Q&#.0^CG9ZR_:OWV&X<*Y5LFQ>&F?X
M72XRO01=5;"F0U:VQ)_KUB"L\=CNFO+]\@U51@]CY^) Z?N0 A2( %<@JO-?
M90AJ?QDF7:!2OB(7HFD U@&5S3*41!A DN^CA3@TFLYC#0W>, >O4.C I5&N
M[#C^GZ@5$$RN'R87F+J -0GQFF' ;=/X%MV%X5<*8U;7+"(X--J*5REL1@<%
M^QJ BJVU/K%@8VI$G!FZEZ,"%)?XARZLWEQX)QM[5W*UE)CN:7409]YQ@H"&
M-I7<*+7XYB@&V4>DS+/QF%^)KAE3F@GQF&I09<KU82% AZW(;3*&F8.]N'1N
M^"';-X 3,#W.^#!.#6<!>LR;!Z@<70Y YO+O"1.4?50\)A6/),&)INK@JU$O
M:Z%PZ>P^^7G.D_S0P'7;IVQQ8UI"*&OJ69 ^\59.\IRJ*%0AV:6#@,:APV2S
M1&YE@^GWB;SZO@3?"FLZ_X6YZ@VKM!X@ZOW&,>L[@$YA$N0Q6WB42Y0-CIO@
MQ%\%EB)YC[$/3EN.7^M"14,)'$/>4YZ$%;-QLQ(+2UM//%<2/L% LTPG@E+!
MX!!(-KT>AOX>9^7%7R^P<93Y$)YT5S2E'CQ@K+$S.*6_ZPD YP]E$6@<IIQ=
M$S^3*:YE\!;$!@1!TJ)TA XI;ELS?W.U!DBE^C"!D:76XOQL4OG =')XD/WY
M\&R\Z+M;JS Q0'=O*;I"TZGL$K8]N9E'/5O)HV5\>^<. '5917>=5[<A5Q&A
M3\Y<&X9'VNW-[TYDWL,V(5_/E-3T>98M9"(BKYD J\*+ Z+D3'4Y$EB"Q>"#
MP_F&0MS7X5"H[5X+X911'7:H\77?6^ND!!NEW\"U\_.;="'B&!V85BOV3NV6
M"J)MKR!7^GH<%VH&9XO;+'A+10T(-5@YR.!0(&4K4[WS8G*PR>[Q!BT1,@!"
MG%4)^)2EV7Q?I% 0"H_[EZ<^(=?\R*0J:6WHFH8'X+=_J,]=.*C<A1:))HN#
M5'@N>=TSZ\:3\E1A+OWI##?2])$)"YDH%NA\&'OK3! I+Y(0Y@ 0.7HKB(%I
M.3(,A_=Y.'#5E^5OK(Y,T7TZ2M?)B>[NR;P=W8M.=D8&/Q=%#/'<W@E\DL&"
MA;NH/0%8TE;*XP6N5\ C0.P4,S*3!\Q+J599 *F [/&]Z6NS;%9D24DH9YC.
MG:AIOB0=C? $FLI%,@0Y8]W1?KF/',D7."$VC7*;1/#]&!]E>J5/"&V23JH)
MG2P,O,IY$][^Z%# S[H2\S4]O)[(JE:X,#[K\SYENNS%>[11^ 0TFN#SU1%=
M=!1W_?8,KU]#WGG?P%H>;-!2SV!W=+E>M_A@TT2_ :521Q<[6# 2W.R6]HIJ
M+ERX=:?&P&,<\*$LXSO)[!E0/OECZ>!(O,M?LOK_AM3H@]NE=]9T=)_[AJOI
M77,/I]KP@G1G' M['=;3U\.KGJPFMXL[GY0 ^U2DOMJ=K0_+NC_Q36;Z5?IR
M*(R.&DH4@-TU'%0>VGU#.-*%TZMT*TY'5],U/^027E*;*K)I=YS?)!Z64[YX
M_[HV^@27;,UJP[FAU)ON?+QN!F$V?9\]X.AH[EH^]D0'J1QY*P>.+ 5/9>+.
M0D!/5:]P1H$I[TA.\[8YG+*&6?B"Q%VM$-;2]!W^BMPD\AL:?00^C6;#DL\)
M121O5'T<"I  [:"'9(@*/QY3^BQH)3G!*![SU^%GU07W"5HR:D3==9!9M=,Y
MZJ'S$2:$Y/)^\  QIZNO(<O4*7J!GS'5,BC2YU0.TR!2L"UWG77P)B?LC]GF
MA2?Z>^ITJ'(SZFQ7FHTNW7E]\;XEN&FX<D9JC?WDI. KKWPF>G1T0E))242O
MV0>$8 '&1Z'X-;Z,O4M78EKX%\X8S//L$P73$ZAZN=S"4!%J&")>(!KU@^T7
M)R/4LU:3UL$ME(CY)GX#/_!!M@G_L+8)/X@VH:DZ^\K,DK8F44"ZPI9KVV3Q
MK0-)1/U3:^)(MQ#X)BKX-L^GX_5%H[291'PN0R'4!,/9Y^C\I6U)OO'++UZZ
M&J#/KR\WQ5 ]3,5,^O.0ZIQ*H!^BNIM6,2#JYXP/<3A&KG3)XW#G7R!S?3,
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MS=3FU[A4JU,&OJ/(6?6J%*1]6!!+SCMBN'_,B8P7/::+YY:GHMTL8L*:(:&
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M-HQ#IMC?GL;,7+'7/BWI*Y6?QB$.B>F".QQU#R/P$^[W&3WBR,I454Y<H7Y
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M^U[Q*PQ_4E6QTLR,A)3>'C0""3&H'%4L%RI):R->4U7I50YS='S2 DE]$-[
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MHR. _]9=X8;-%6AA<$&.Y'+5UN3F"GJO[U^(@*N%=_N6#(]-IB#0L> K/%3
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M<$P[9/W@9^GHW?LO)M%JZW44"&I-ESK^6!'?L-DBY+LVP8R^&F.ORZH\P?1
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M0N$<39-B4NP4[*+^$LSG?OJ=#R#PC^ <]3UGYAC41#ST0Y1HP,>,'Q,\P&D
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M+ 1J0PD*6)0H;^32UHN!8YMDU7 F9)/^,ZTS?'"='+[O==JT QETX^=E,Y#
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M*,FVX*' FZ 7T@AD/&1)Y,-<$R+,UKHKZ2Z(G&,+W6L\XT\\&>J^UU_2L1V
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M*3V-8LKX58C$ET:# / .ZN#G048^/Q]V,@%I_AI_#FD6-/N@S$1D%'R VFX
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M7/[\^N"E TA=(G/)2/4'^,D%:5<1>%@*^G3 3L,O49J*18+;E@.+(.=$YU*
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MG2=6J!3BW-WE&P#X['ML'_CG" 4Y0.' )9@R =)1%4>DD^6:P1#C=/S261&
M7QTDUP6<W;&ZT$"!B482'EATRA^FGN91 J)W29PY9A^$"; 39O>8+XZO?"HZ
M@I&4!V>,I0B%V]'A6S[UVPVQ[.XCVP-!@_\*THZY=ZF;@0<AZ)OQ]<5_9'3&
M+HM_ 4-[(L.>>0X-AS#E0=T9BQX-!BP6/?B\+(Q[26CG.?*/*"XF-MGQ@#P.
M\/6[/K8_,-XBJXZ%H3#^P3]B'&701WH ]<A?(M$+^)29SQC!^$BD3\$W,>B
M>1$,R,$:H?:-!R^8D\C$2H&$<UYD29$?(F$*QA.4FNF[O 09QT^&?+9O/  #
M8?!%]D5^1V,K?"V1]Q!B<B$'?%NV;"8/^@;FBF4^0_#'E 1]XW&=+-=!4VY4
M*UP6<)AE@U(C5C\PT  ]DGMC* QHB)K8E-!>%-X)N;<K5 C]$PL8A";]5D+
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MLD6FN$D3,YNDN4.&[T!PH'=:M(,POY DC4/+"0+*HDL9HQDF9$=GV#1+D-P
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MD\YXPJ<W:5Y(E=Z>'*#5U4JLYXR>[QNX[D/+N"OCKN54(6PQ=VV?4Z+I^,:
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MH='$_SFO7C0;0NU B%8FX*4)B;4)L+@ERH;$FKY6'T<N\CS,TI8M *S#_VH
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M(5^;S8FTH+#K^("U#M/UL$BAFV>@;A$CB%0LGLP\I+<C2N/X2EZ++Z8GO)M
M9W2Z+NZF\S;+#0Y*P9X4L@6F!0D4* *I6#J=CA'I1T_H"!^^1\Z-R&RZJU,D
M?,<0D41$$G?U)-SL&![%8G;:&N60 ]^$-\ "B8^C1D9;S9"=]D:Z9'$*)L'6
M1Q_7TN@1@1I>[?X+F]''S7QP9Z+'A$9D)H8' 1_!#'K=4=H6>5':P+M*/\X_
M^D4$^$-I<U'T]K%\J665-V!I:5YT_BVK/DJ\XK&QJ=8^L<8+)K$>$;O]3+06
MJW@+7KL-VPY1Z5@ZGHQ"MJ$DS1 RJ"AD>_MLLM?I^\48;3R]WL3YC;63&[I5
M74N+YB'%;B&A)W_\$T]3L33Q6G^Q1[$Z7?6C:8@Z)PE1;#:<ML 7-BJ_6&PV
MR&]<TCI5]+[(<AB<'G9G5GG+#IZG15'7VOO$%N@63DO#&$53L3@9U"X>@68C
M._PKV>%?7D=X/\VF)].4W"'CY=Y:W_,,PW02<@G1+&S%GTS&J,1K%/OXC@N&
M=QL5ZMP>*E6H_S[G5LAY)?I2Y-6XO5?CSM?Q?K;7(SRW#]^?/7ZR2N/1?-,A
M>485W)+8ZHG>K_#*?JY?,:8Y)4%4NK1N5<S:=CYF)F3*TV\2L43JM>:O#\4Y
M[N \N2-)A)!/ONA<"2_G^ K5>[_)+%[4L#KULK86ZPM+%IOQQ<:>KHF5PS5@
MI5\L265B1#*8(Q?F]@+A(Y9OZ[1Q>8&EZ=^>7[J:5G0@$4U$*'"N0WRU WE@
MM\/I$E^4&V?#RC))Q33O8@H,RO]-Y'*(7 [?R>7P^(D8@*)S@*";AK:1!%'(
M[GN LLOJ\<(9YDC6KQD+!RE3S-<TH0U615<F6:*9+*2 L8"Z"Y*96"I-QE)7
M8BA1AL8CT'P(.6/D9+B#D^%C>,5XN=,M*D'N>R(A:E6AW=S/MHA7P*:%J5@F
MDXF1\6!Y;.19B*RHR(J*/ L1340T$7D6'M2SX-./EK9I2;/]Q7%,S]ZR%:$2
M!=:N"+!(C^F4L$*U,>A@A7:CAI7K?;;3+=>+&)/KEOOE;IGM_.^_IX\:N0PA
MM425' ]:V_=E8!85+(2T8.&#BP+OY=%NV@:_@'?<:;,7+OR-%,\H/_@Q<OH?
MWQO=='L5=C6&7]N2(78@278!1;Y^06_=G$ZLDJ[)Q+ZUV/>HCCAY;K<F%.JX
M1B<3,0#I6#(3K!SZ. ?T]T+U;TC=]\[^?WS_\>]2]YZJ *'<*6ALHYI-%2>E
M4I\VYY"ZH<<XDXP1)!6+9U[MV?PH!O++BHJA@04()C8SM-4+J@IT9 @/:D.$
MD.*C4-P7#=M_L4H!CS44 &?H -[9F+V3L5*K?2&?FS['>U2_W15'V52MA0.U
MB7;4)C*63"5CB5O>.!SQF(C'?,UP_Q<KUOQ]'B-EVIU1NU*5\5%7E-:+C7XP
M&<ACH/(6IV*91"9&I%^[_"MT'J4+"KG0U%ZA%N<97!%G%EI,%/:,PIY1*D"4
M"A#11)0*\-U2 =Y?9.!X.*(B@V]C@41%!E\KK/-"XG#9H^OW)0[+B?6NE=B-
M*7:0S= -:[M8C*WYA$(](.E8@DJ]E3?\4*PBJC$(AWX0JF,* ZNX1XW!+[**
MJ61/J_C(RLBKU+J8V]CZ<ZNXA:PB^>.?!!TCP/]Q,NASB&H,(B,J,J(BQT)$
M$Q%-1(Z%!W4L?&B-0:%<9^JYJ,8@JC&(:@R^FSG\O>@PJC&XE4.[H4/CTL3$
MG6CP$K!G(STS2CI^C)*"Q\N4.XB&)G#FXM4$%DOC99<J68\HK[B1YGL\+Z12
M94*N;&73+O9+V0;T.*>AQQD"FZ3^\Y#W H00T[\A<=^[HN KIZB]D\)SPV)B
MF;8Z;7G?G_?F;#=WL(PMI'!XCP"9B:7IU[)?'\4D?E$UZ2PX TRDNU60 F8M
MP,+F"TQ<Z8JV%T7,A".. S!=X=0'M2!"R $BRR.D-O/CZ3WO9HUET[0YE4<9
MO)#X>ZH@&F7P@6I)&]@G''V<A=P@IZW@32QHH4U ^%=++_=3LZEF-SD6/\PM
M@J]+)EYD)A1J_9=,QU)$,"0?,9"(@7QQU\47UJT^F(&D:GQ\V2]S97:03J2V
M?*N^FHU;D($ %2R9C&6HC[_)Z5[J5E5$.I1;!QM9BG\<;OR:V8G?.[_H)IJ0
MJ(-5'SN5(CKTRM$+D@K8V65NT26;HD<$OL_O]X->HS57].YZI&C3%EPE;'%,
M)V/IY"W[&S\F/M^;5$/(O<Z2 [XKB=]$5_EC$J<2Z_9 FFWV/:I8I(<6+1:;
MS!:N$EYY1,=C@!T]>H^)\%%$9,F])R?[ZZ01W:YV(SJCB)@B8OJ@ZH:O<T:/
MY2(X5C_^!<L?_\9TMQ("F^ZQF:?&W*(0\A%!^[B62>1$>$ GPAM%2M>MC!>+
ME!H&.6N!3T=L<BA7B.PRWAS8\PE-N9$3,A&\E#ER*$0.A0=S*'RQ2,@OT7[@
MGK2ND$SE"ND^(:Y$!C]8<SE71B0/FR$EJ%B*#EZI'#D8(ILHLHDB!T,HSB@B
MIHB8(@?# S@8_J@*DIW-1-Z"=V( O0A\HV+BCE]PZES$@+Z&W!- 27-^$=>V
MM %Z#DIH^,#"R$?$A/"FO]_<W_"=#(R;.A<<VFO,6)?BVIPE-E1H<\#_V1.U
MM473,B3>$@7X!:,*YQ_X1I957K$A2/*2J6LFIQ0!1];!$^!ON%%)M47!C9QJ
M5Y.T!.NY.V07;)>E6DW"GBC-I64P$SH.?154+)ZX89+G8U)%5,_R#1C!33T-
MH60$O+6L%/8VU9)S?%=*)[)LFLVV(". G97(&)5ZC1,\@@/CSUM(.(J2](JB
M!)$ LQ:BPV[V(F=$/24>/"W^V_64>/ 8SA_QT28X+DT W-2 669YT?GWR%W]
M'-OAXJ_%@;I3:8@3YF[+2A6^UZG-GH?;U79"H[Z6%!VC4_%8(OEJYME#\8NH
MD\?W*X=YW*S2\/$+*[W<F8,452$ZNI$DQ8.X7^89R"^ "I8F8JEX.I9XO1'N
MU_-8Y5Y2M6+85 1SJ#!K1IO=2.'Z7OSEWD'X;YP[<W,3ES$GC9F/B=*EXKRI
MTXF4G"L3!$\,IXMJ<WX7)GJM)3@GK.HI*VOTQ,U QU?YW$%H =4I"56G1"I&
MI)*Q>.JUD'IX"3_*HHFR:.Y&^.2D.31&\7QGDV*3AU75&(NF3G=:82%\2QR7
M^G-%7O96*D[;UJXUF%%S2/BH5"<52U.)&$%]_*UB(38N EI1E!!P?X_3EPMV
M1]DU$3%%Q'3W(XJR:[ZDKT($GT9>BEMY*6A $()F3Q7Q+FZ*_[F5A^+S]Q4>
M2X6>-%DRJV\.ZE!NY)(%;F0J%68=&A=%ICQ(BNG&*BY7[,Z:D?EJUVQN)S3J
M(4O3L11!QC+D#:]8_S(NBJ] O=?<#-^9>L/N8!SN6FNB."S8[*I569,KLE;7
MR@RDWN0['8Q(??FWQ0'PWE[.OE.R?LPRG#_A1#\E"V 3?UG43%)'++K0AYRG
M5 A5)>BW^/%/Q]9U182M6S@%@[E)BF;:AHAM)6N!&:*IP^QD2\.0)E50M*V)
M_577+#>?AJ3^/NI-=]AJ4/'Q[_;'/]V%B'$\KZW N#T@;1<RV)L/JF"')@;;
M\7+P4EQ+G!O@>'3.0)G:UD(T14AJ2.7G+'C-P#LG=NO*P62F!1YTF].AAY\^
M\!3?>6:?BL1_3$O_%J3-/_\+?GC/\0K0VZ$D6+B3'_D\?(DG!XA_?9S>[6/G
ML FC:'B[HN*^]@+.%M-)WZK1S__[?_RK/UF4.*\IFO'3$TF^;2T<6J60=)J+
M^-00.1GG9N#-/SEER^U-SQ;+/-&>M/MYE&HT C[Q1"?^A?E^A^<1.,P5M\-]
M1^8*0UP19]9/]S'O,R3)CA]JI@09\4]#5#C8EA+._A*0SE]Q[4D.R8,)E9S.
M>)X0)O1L2DWB5$:<<#-:G,23U)2.<P(YI:9P%]R'\AT_:SQ#5[;38;!FB6G7
M&(?QE>LYAUZ=]>9*3+W(=LKU#AC#EAK5/-ONL*U>N3N:I-*I#)7XT,6>K2W7
MJ'<:U7*>Z;)YK-,%_]38>A=K%#!W55BYCOG7A:Y32/T'<];W@13NX<<QJ&/]
MDO[UXY^_V)T.9(Y[&3G4>L!O'<@H3?"<HG"&^7>8.)*+K%.!%ND$T%0X420G
M<8X 6A>= +B;YKD4QXD<1<]<^'.>NK-2*T9W-*VVV'V^WNWJ[4.^D]E.R E)
M7 Y-ES-TBB:J6;FX%^M=\KFQL0O,A)JD+D?BAVY:97H)1NZTR;$RZ'8E(C\'
M(X.3$@TKSY)2/]O;$]0POQ,2F4H=&$L3ZG+D8<9G:_1N495SS0RQ'(WZBU6Q
M!4;&+T=6=:E>B1\626)PZ)M$RS9W%&S<&%PH:5KL>+H9-%B[LYD\$Y7=6.W.
MP<C@0O?-:7*^$7B.* I$=94EFN5X?#Z)!Q=:(%A\4TC.2\3JN9R@\.=.;]K>
M@I&!A9*-%4W1ZIYC[>4\/4C'LXDN#D<&%KK*SE*;Q:Y7Z^$;RDJ9@P&E<?#M
MP85N%[55MFN.\5Y1;M.3^7,FWJHS<"A].90;I!*=%K63V.28L!,[PJCR S0T
M>3ET/,WT6/59QN4*]ZR,M"5=;C:826H2>#^9Y<;EI9CJL\D2VY03S^5-=M@"
M(P/;+Q5&Y;623I1[5#O.,FFFMIZB.0/;KVOLD%^UK$)O/^#;/-_H,9,BG#.X
M_5&VWZH)I)V6.TGI4!QLU#6OPTF#V]]R,W[0RE42Q(#:M]59H]B8M]#0P/:E
MY*;=KV_;8X(3L[3>*W5,:<%,TL'M,XD1;63'Z6VO44@L:^-1D2&[<"1)7@ZM
M]9]S-/VL;62N)14'G4Q/[DA;.#1P5'N[33*#/8?W.KU9<LL/S6Q39H!1%7A_
MSMSVQ@?%P EIGUOO<SJN')I;,#+X_G%9+AU(A;0)BJ^O:\F=.C#2<S@T\/[9
M0<X>-L4:*:_EU3:US!,9>;R%>7B!!0C-LMR<M&JS7I%N,@HW2:RX 1H:H!0\
MNTFO9:4R)L1<?=ANC@>=.=&"0Q.70_/:0%/65JDA-^:S&7O@1:/$HZ'!?37E
M]7[;,-@60>WV\K2.)\L)>H[&!C:VR&YR>H$GN5XE/=UWFWJ> 08LF#2X,7O=
M']:[59+JY?K+ VWTZO+HT()# QLCIFJ#$TIQBA!W\WJY/S.M<8:!0P,;D_'*
M,DTF:W,9+Z?W='FV[F1;:&@Z@ 3I?E'+X=VT/*@KJ>=RH9=?B>!DZ>!:#]JP
MPEO#]I1=MSCQD.OV=+,YAT,#)R .UV9_S.,$D4SV%JO":&?I208.#9"AHBUJ
M^+ZBCXG.(:^M9L][.=MIP:%!.N13Y?QFC#<%F5M*VVQ#$DA102L($N(>'S#U
MQ:'3(/#*M +L\VT\/D(;"U)BKK8OD<]],'9O3.*XM5"%_ @L-QX\!"*QJ&0S
MVK;4:RA<>C#!._,!CH8&<6:$BPO;UK2JW!$3,ZE2KL\(UAD;)(;AD*Q7,NI:
M;NSEU*@8)T?=+EAN(KB$)6%4>KF=OI7W-2FOM";/AE1KP:$!G-F0=2$NDM:@
MMV\/UNU!3VS."FAH &<X9K8;B;D!1:RI'2T6XQEC^(R&!C>6XY;R@2.J%M%@
MJP6IWF_E1X!SP+&!C0D6)TD\8:< D64W-"]L^%4;C$T&-[9*+<CFC-.'Q" C
M#=8=9MX9<"TX-+"QZG:46>&:,&-QOI!J2FHCF['0T,#&K(TZJ+4*/$54>LO!
M-CV8UZ:M.1P:( ;"2(P2Q<)@0:RJ58 2RJXLPEFOL&2=8!*3O+A6>N*X0\V6
M/5T?#]#0P G4GS/U<FE$FL0^@S_76YO^I%5%0X,R:3+F-A-B);"K:5;.\N6$
ML(LS<&B0&))-?2E9,]N0*_2:*PUQ7<H4G+$!8LAVJ4ZK;79'1*7>QNM-1<H>
M:ELTUB,&Y%LZVF^.:LM#O50WQ9_>+WXM$S::<VTX:/P@[YQJG1M7?LW9L:R"
MUJME>&]U9R,=G?5]@3HJ]91^-5#G,]=\\VM@SIFB;3T5V/L;AV[6GXXIN@6'
M\*8)Z&K_Z,7>4&YJ:HIMB3<QT]\3'B-_(3QV,N'_V-F>?K6 .P+$)P$B_42_
M6D ; 2*BB.\&""(3 2($@,@\D<D($"$ 1,2:0@.(B#6% A"1UA020$2L*32
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M\_M-T@<&,\_I\':4",[OLCT?&-"*9D;4_#;73C^V@,Z+,XF7K C07UT\=[4
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M5UH>1ZJRRLJ]ME"3UUNZ:^?F1+I!P)'QRY$MLJF.JY9L]#K#N=V?'XP$V6#
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M'!WLP,!FAK8"DVBF[Q2>L,YI*"R1!2MPC@^^X]7S\\L@V ?A"$X1-0\%WYN
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M6^?<)/KYWDCS+\5SW9^6\(YC7TB6B(,)>)AD 8_+V^93,AX!(A2 (.@($&$
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M@./FHQ&?B,G%ZIH^[T_D=[<G''^BKZM]_U0F7B*8(J$(O?X,W:S<W+WRX;2
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M+-09T!>()>,8R41\.-(948Q?R'3&'[@'Z<8\71H;!0M1!C.79]%ZJF.-/9U
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M)"TZ9K.^;@JM(KQ4!E@2Q<01Y(+YHB..]$/&''&DB".%F2-]*5!;?[G#'N(
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M4*)0 OK-@@(]^?OX+3CLQS5J%!X(I0262K'V \>(/1Z?)3))O"X\^%__[ZC
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M\Z6,S/ *E36K:Y2SVD7VNT''7U')+YD(9O0F(6#LIL;G;+RV1O5M2MW NR9
M(R-/[^96"1$_AZ&[]@.R[F>M+!J&"]IMP9]+$\9EP.6/R'=$OB/R?3,-[UWL
MZ#RC;_>X06:):%.:+&JE,9[K&;VZ0HX;WTT/\$W>O:HHM<HD.UARW9Y2G6ZF
MQ403A;?_@):G\:?32S\1[PX([_;O1QERQ+@CQAVIY.^2[CV*#OPA[?PB;?+J
M8*J)1JM&5.<=*5%JO.,/>2O_US=5LFM7+&J$UGAML\T/>U8!=#"]$IC/90 +
M$?>.?.-E=>&J,KQA*>\R^43,/&+F[S+S,&1K?*!]8I]A*VM:9; 8M5%%M#3%
M>5;GWM.E8B*Q'LF(@J21.=W<B".U:]S$77.P;;1QGAZEJS*-+ BEEI#24BK'
MKP2ONA-V>B/\47G\/OEE,&^*O,YS&9H,G=>^'.[E8]BE(^# I@C3I#K*>SE7
M$+.IM$LXWM<V;L7MT7S:Z+N[Y!VJX0(-X+S3;I=/\NX96I(?9&AIY=DFEZ^5
M,URSM<MK&.,:?*'=O^"]ZR_T][VD H>/><ZRQ[K.Q+2@__$YT<!5LB,?])$W
M='6F0N?G8<8+.^ZEQ#9=)S87]S?I;]R?N:6,% MFD;A)ETZ7Z)V%'9Y9V#/I
M$W<!@K69H0Y=+\4FV)1@QH"Y+AK/(8.WH<\U(Y95AA;,&!3#2"\? 7J<,$B4
MS;GO!8^99WO\G+IF/Z Z^/ Y?0U0$K9JP_O_?CIU+^^J"=.2*GXN.LOU<C>,
M8E71EL7%2<J2V.%CC[LV$W?YC,!4 ;VV2P !1,(3C9@X!\(BJ7[N5H]H@:_@
MR3W0O\Z! +W^R*-8?N=,\#K+_S0Q%&$*"'$%V);]%&.]/G^01C4V$6TO*:N?
M=2GF)6!ZR9&U>[R72_YH!+N$+J]'_Q2[D&1@GY",M[9JY/,[WFU$N&ZI,*VJ
M+RR>M,+UWN7C>%MX=DNB>#NEEQ%1,6Q?5N:O)/!U4ERP[7J9:CSQ5;Q$B_+1
M NYP 7^[PT99&8O2)E;SOSY$2#S&'CRNN7]<\T4HO<13,4CWO1\>/;?9XH_Q
M!A_"S>:ZN5&4F$<)(*"D"<Q!Z\M0"\+W$Y-UQ41@F("1)VD^7[*JLA!CSW:%
ME]C3&XD_>S#M3=-V82=?F2;PHRI8G)>?^=/N_PY^>_+3#E7K2RMJ2V@;TB22
M_'! 58QW"LG"C+S0]H#7M6W%..%@<#)24%&D#P2*A8E@QI[MD=J\--D5FO5&
MNQM:SDN45##\C&,YR[3/YQDKU?%V;[0N%A%5R570_*+J4L#0^\<P3_-6C5S+
M4S/C?6*J?4K1F2@K!YKF5$1A&J>]@$'P>!F>%#"Y7KV,W?/>?<!*U?5G.@ES
M/0'C1I%@0NJ8*,&$IK 2X_/&H%I^JJM+;>#89\V/+^BTL.?9)Z,\^Z\7Z>,\
M^[L,JB."0I41@PFH2! "00\I@1$I5*!EA1P.DV1RA(FOLW.NU!HSRFA-DIL9
MO-JB@&*6,!::>:];UD:S=F<Z9R9(;9$LT=-&/VEN6:@K7[?,F5M&HU))A-_D
MV:6%3Y3\E!X+^&G+CK(>:M6*D>,4M-.MLX-Y94JSH"7UNN76V;9X*JL:B#JJ
M-T=ZO8%EU;-96==8LDTWB ')*QEQC%))2]E,8<N3M[-4GR\CEE31,)E*LH;5
M3J2R,"*1/,G*VI<57JRMTXBRG!,;M,7TQX/QN?RMB7S.%"4NM]%R6$T74DW6
M:>LK@3Y]>WI:GTRQUHSA9ZSCFLE^>L4*\%SV^.T"03"$3&(R6-Z1)!#R,"D,
MA\Q0D!4<93!*H23RY-EMC%C6^J!_O++,CF:S>8E#\JMSJUH?=6=32E!K6JV9
M<+H=Q 1;; .T/,D-FV;G%NF::@I1\XA>UA1+;E3@JI[,084J#;5LRC*YV<#6
M>IEZ?ZG.S^;:;7202J*-RB*_L(HX/QYU)_E) [0\60%NZLZ22F=<TTK2%&/L
MAEM2%V.!.'U[:L&YU?6VW$/4A#DL&S6AK6U6YR1E22:F=K>MD)R"D?UR9D&M
M,U3#CT@];ME-DY6:-6^L-%5K#YAR;R99M?$Y23%R+BUFQ^1(2V3G3+9 D\I
M:QQ(RALU,=[W87S!XX%=S\?QM=R$)WO9B=_@71/ED.QY=HH(",%:G;DS^*O]
MEO?A2R[/$E_7@#AU4%?\?KYB?U]EC=F-64INNKTNGUY7AHZ]T(K;]!^DC4U[
MGA+OE6EQ#KT%?L98P.05:ZG(6=/*NHYK*3!_+.0]9YD=6=KP?!+A4*ZUHA-,
MN6R4B-+JUS],G$"1>!*AS[BA/[E4,;^'OCUA[TJB0!MZ",M5^)WT2E2HNPX^
MQ2YOS5W34?9B]W@6TY'=<V'7V;>KWWA(>W&IO-?E9\<*UZK7GPT\GV_[B[>
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M]_J\*);2;LNUN4D;+@I.Q<GDZ9V.?[_:.L\SK7M1$PZT4V'LRPM_\(Y.X$>
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MS]YH8D-MUUHI9]P8_X&%\ <3;^D]AG=6"81+(]1,R:;-MCSWR$&<.1.F^IJ
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MN_PX3'4:+\!$'V>XW]W"[EZO[!YS\M'V\2,GY=J"\O62I/[!]>E_0R$"%Z[
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M8X'T>3]]1:H0'(5S7Y(?,-0^'*/_$FB#Q^;IL;C2!;=M\0M6XZML-TM@Y08
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M4FYN,TN1%198RO"DTE",N>'CR:-;:9=V?BX5O_Y^^W[5V;UXD<$S!L\NOM=
MB>(376L\L^ T1=6<]MR(T)G4]'Y:*XI<HMD0X]@\B]XDD[&;),N$T;!00'PD
M7';QO09*0+QBJWU40(SY>2O3E91:I_18%(K=;-8LCLX?+J=K$U84)V*L4W/:
ML=S\Z5D?S?H@(,"RBM\D8HD;)OI6)_2=\J(OJ^X%Q#8([F7VPW?_M^L\XFO]
MGK%OV^[8^^Z56^JN,>G2_/*!&Y50SJ@Z.KJ;]1H7O*7N7=O&]\/W:F](F]W
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M6Y.*HKY(UQX<_515'_>,\I>6/+NVY!GF56.]4$W7*EFJ+3QF6^<RS5\NKSU
M?M%(7&(2+&T)]#R@4 9-ZYD8H/E5@@#*D>:P$#"!9-<S)<!>=^!Y^+&KZO Y
M#?:*HH+*[B'P326-F">F94SA!2I\]-]C.Y+C.H:U@"<MTP 2(>^FR!\PW0=-
M4!/H0!1L<QISEE:S$ZE42B"6G^K&DW")SB<K:LWV>F#"@8N[)MLF["OMA:$
MR#4PY5X$S2+LED'IQ/N)A%C/JW0KCKA<Y&ZI/$5F/WZQ\=M]N_W?ON&.#2&&
M^>?TH&.V0<>*F>BPJY1<E@4C:YE[YGH9L=>Z&.CDJ6@V9RHLK:8;C\F14.0F
MS<9KH/L;6\68?C'M^4;TSY.6MEW'8M?5;0_ON+G#@:^4N2W5!7W0R1M.9ZP,
MVO6*&ZLNZ9-%*E0]X@>HZ-NW[?3-D_3'HY_'*O;Z@4JN9*J()BT,UR__>LS:
MKG'VE@M+O 6EQ!O('6U=6IY_LYQ^B)=+X86.AG@)(%Z86R8LB1A$Q(2"+*!X
M"059(/$2"K(@U7;U#>0+UU1Z"T8YP\)NH1>CP0G?-H5T?)2YU\[L=[/0/B'-
M3[[;-T^:7R\!N5T\ZO>KM&T#@KUEDA>GBR/6VO*RDE[ *222D$A>$ G[1Y78
MWHTW7$*G;._Q=/G9YV20H.2D?\+>O,H]OV?+7>6F0^+^'GO^PL3]FT[ 1>_3
M?*3-<=FP<5.]%PX!U47P'=HZ%ST:FP?L.LJE./]W+JA>$DZ_7:M@G_^#N/5/
MW4*C_CIR#NF?G]]_)O_3.XG%C)^SC/&AP^<4X?[UB2VRLW/'D@!'JBY9BX*#
MQG;5T/$.+$/#K3L+?HHEN#T PO_[$3EPFS>B%,I%Z?'N*2OUE4'L0="><B6<
MX\2!E\#?Q!+T33S*[>>37JOD^;-[?J% "07*)P3*I[-:OH! 6<PJ@[@Q*40[
MXZ8R,H1E,V%,L4#A?_SB8C<L$[NAX^Q; B4,183>6NBM7=9;^Y2@#&,3(;6'
MU'X]P8JW=M_&"=-(QL?2"YR(O4FJWD0E2$:U?:T>0H!B$]?K*02*X[]H9 $7
M"]E<8ME-[L[.\85/I.S\C'GZ@$7/1W2URQ0KPQ&J38?593WE1EOXRA*':VHP
M\?C!JK)AA"!DZ^_.UB?Q[X_%UE,V=?\4E5V-CJ!$L=QIN[.RWO>*029O8G3R
M/;;^>GYZU= C"E)<V JY]X$+#T6ZN/(0Y=\Q/Y[5\AU-E.L0RY?W.3Y?NSF@
M)LC>5=I=<07\N&''K'<5[G#!L+1A[]7! !DVT(;=^PG*+SH+]*S;]2%_/Y[C
M*_]@FO!1[JCE[@/%X4<V0KZ9L/J>''Z&TX;C<S@O+=1,=:)7.J5D>A1_S@I\
M/(.K(& KA7^/PZ\EY$*NJ<J2J3J21O4E50^C*]<=73FV-1-T7^Q21PA7B_8@
M$O7%-/W54O_7<\%KS@!9N*P<O @7F%/47@]92)=A!I44;\0%87!> JR>0G-Y
M@ L%7X7-'GKE7]MFOY9S@7=,=L*A@H+3E$E$[*UDGV2Z:W9=44J/\LI<'/:Y
M2=65<7D\\+^C)SX6N ZROCB'?DOW^UK. H[(RLU::L:[1K=/U^Y:_$2YYR6G
M. -6!D>;C9WF+"!@]FF:V!JX=/0ZJ^%F;8HXTOQFSR[Q,AU(O3D#P_I:_9+0
M*_\.7OEW.7;(>5R\4_LNX_LACHI?LR<=EYE&6\T-JU8GDJT\BR[BA<<$KNX+
MA@YSPS+L:8\:KI8/@LCE89CB>YU1_(8X*+9IO5;I&?$L8K)BN6A$[P:2  OG
MB3A()$YR+G%)IMA8D;A\J6FIAD5Y16I(H5T;$P-LP7;MK910D@N*'-?2[57+
M !6^-GJD \#J/$,S;/N(Z:+?3'1<W(&\IA#/=[& ZIA_GX!]MRY_'1!S#Y.'
M]/(IV^V/7&$2391ZFC649GCE8/9PKWB%5\'(88 G9.2O8+M\D)&;2S,FI*UJ
MGVX-[Y9W[=S]XMDF+4>PP<*_Q\A?)KKSR3(;FX#/5-)<O[41;DJ >T1=J_,6
MH%C.!0NJ!2'6<^GM!TV 7L(2\D1 0<\@\/<LI,   =P1Q[Y?201A)1 .R%66
MF;4Z\X?*<)2?%#G3&42846N&N^2 @82EZHE34 ,F6LY=/"-8$B-(<:-+PREH
MHN42MMF?B9;FO'!OQL8EK<,_Y;*/=LVQXA72^HW'U^YH^O"UNZ\<8PK+:'S3
M$-*W=%&# (60VK_'GJ^)VJ\U&-$VG$VOPJW><-?J+ 0V#A&6Y M*2;X#GL(.
MU41L)$?4><0CF9]WY#^B-EYJ\GUR.LP^&!K[+)7K',WU#]J7?]2(E;QH!>=M
M<]7_"MP:/RW$)^#PZDK(I5?(I6]+]L,\.L@[1LFQ"^6.6N>TWORA+,_KE^'1
MOQB&P6SZ]VM\2@R._Y#^G;]6_K;?I/7XE/42!-XOZT .:WZX8](9C!CO<BHE
M.8ZE=EV2"6LARG:[0R23/!$+354TN_$:,AN.ET]#2>M<DANJZV6)2*XS,"S5
M49%]2^'FT/AJL*0OJ(%DDWIC%NZ$!&#9MX]P.LF_SAR:MBU'K,UT9-D#U13F
MJBWBJBQBUK:E^D "RI*12SC?3AN662'=F\1AOB5HD]Q=;<1W^H^SAT=^T!'^
M/.CDWZI.(1WUU+TKU*1!<:PK.^8XT6IE2X78_"[-E(TNW?_QZW#6XH'"\R\:
M45$<?4-A0'AMH+V!ZZIPY\#'BWC>;^'CSI"+3KHA+FA)?> ZTM29.*/^\?%Q
M..6>( 8-6BGML9-4Z71!8+-T3FQFFGW<O9TYG'&/SRJ]AF\ 5-Q'VK\;[K-%
M'R:U2(]TX"O5L:G.;>L6,Z2M*JID+6[/*!F^E!CSFZ]1!_NN;<@=RS%,<#=D
M\$I&*:I"Z8;CRRE*VDJ)PZRTT\9><1'&FT3U7$T[=.Q,2>1^OT,9K@6DZ(6.
M/1E)@L>>>,1$I?: HG4'&&5L&O@RI8U9;VMAI#M[_!_[T&M@G.2 =)TBLO0N
M0KI__Q*&8=J"UP 'DE,#0E XJP^1_#^8I*?JL%8LRU>]!8GDEW#3"KP1^]P-
MS?=B[(*NE%6)T!?HE%=ZF<>*L>'3N&LL1V.-KK')2:Q^5SY9+_,3,,<9^Y<?
MN5LY$S8M??74X\Q-2S'TUKY7@@GQ$D2\T&'SY2#B!3QV/D1, !%SRX<*)I!X
M"059(/$2"K* =2M_VT"^;.OES+X_^2<MIS]A@ :MD?*IFU!O@^8*FU#_4:?R
M3ZC[H&T]))L_(IL_[EU^8N$:V$S'<TK:H"2 ?,+ZO,H]OV?97>6F3ZT/ KGG
MD+B_TJ9_3VL%+.O';R:J]_TJ#I0L698*GD'/L&:2I1Q-405LWY=B[X"!X;>S
MGO9Y^/L5OQ%LL=;;.O.L9YF4.5WJCZ-:FL])3[96$B:_G8^P=R*Z9E7<$C@-
M;+KP>?30A7$UL4R(2G4TZDS&4^NQG"LUECW!:PL>Y6[B+'_4BXU[JCM@=/YG
MR8TA%W\;+F9%[B[?KYM<+#Y*%VA:IA^[@W+]0EQ<D:/C:4SHR=E\@AE'M)CZ
MD.\U_%[<\9LX0Q_]#N&E/>OLQ%5-DJ:"<W54'=#9)\V^5F'*T''^DK[%\23P
M>5R&0$FE8]D6I/7@GDA:LYR@*X4UPWF_'1!*(YY;EFF37V87?%Z62H4%_: (
M8I2T$WWO4O,7C@@<V8;X9@+H&W+ML6R)HW#M(,Y/A<33D]PIJ6YS.-,CT9*!
MN9;_ -=>1:BCH$_1J@*F-*=D *9Z1(,B8+L- QPG,3N^NW]T\BC'ADL/23&7
M[SP_#=GAB$;]C-")"*SL6(+7RIP]W/ X#&E\1;Z]F(7RW1G\Y &0MQE<%Y3'
MY7"AHE%DG)VE.YGJO%H0O*;F[S+XUXMVY+Q[.'H?,&*'T8TOZU"%T8T V!2'
M_:0UB^$&Q8=$SO3!R8B1RK"8C0SON<@BB3*]7L/K0<[<,,G#-SG#D$:P.# ,
M:7PEZ^ W635G&5R1URIV)V\G[[OW67L\FOK-Q-D;^MU#S:N(8^20@BQ)HYK_
MGS0V_\GX@8PPCA'&,4(W)SAQ#/@C31ASYXRWB6PD6?+@4,:&U6A..Y'\?)1F
ME?$R6T@-A^Q,C)/0QKL'O6%LX^OP<AC;^.+6R_&8GID6XE(B;TBCO%",5VB^
MKT\S?6!Z_B-,__7B';4_:;(:1CFXB]X#.K^1$N B^'N;/WH'ZG.GEV+6?*O!
M=&Q4F1<2Z9G620\[J?O[GC"Z6_J]XF-';A9_S5&22U-UP*1:\%G]^NR4%:^_
M9'$Z*NE2L5Q+9,>VPCR/DW(S:3>\'O+,N^T"KR*Z<@F]'H9=0E?M\JY:P. 0
MQ+A$R!4A5USNZNB7W&KHXG^I8]0PD2'(/GK>,NQ#YZ)6:^[4GYV$F!U7TZU.
M9V0W>%WP^WQ'8S=,_,2YD==!LA?GOC")X2K<Z]?8--\6'H:59*LV2M/%NV$D
M8T8EIN]W\8[2P*;?XB+&_?%Z=8=N](<=ADM'V"Z<W7#I[7^KLX0/-<A]RA4[
M=FV^M+*NQK"BJAB2WFGXO;??,%J.=Z@0,&%Q^JR'2S-!P$1E*"R"8"U]2%AH
M3W$YWYVG9YW\_*F1RD<GQ9@R\[MIOV$Z_1T&7<*@2^CV75/=O2\<J@B).R3N
M;U!4LHH<JN<ZKH5V"LR'+OY97?QK:;#[&Q9[P!KL?H6#B"6R#$6R!^^:Z\#<
M!^SSSJ0O*:EV-4JK-0[9/;L8ZRW!/B<%)TD?0_:?\/I"R.DAIU_<._]#3L]D
MV8K3?8A4Z46:M]1%=9;JF +F=/XCG'[19MQ; ]?C+M?3]O5U7GIE[W7;%6Q*
M<@[TU]UMJXM;?P-V([)DJHZDD0KCI+[X(K*Z&H-[T4JF:1ESH%4':8NC=YY^
MJ1A]:A?7[9X%OW/Y@K2=7OV<@1]AXW(:9(]C+?R.TWI?+V8[#_>#;$V[-PH+
MM_N44GX[$O;Q4K!>$_ G3ENJU5QGU(IG2BF99?/"I/'C5Y*^B=&O= (G[;VI
MR(FAROX95$M=I!>B$SK220NF,4D+A9)0FIT)JKVZ9A>+4IZG44\=J#TG.NW5
M *J)^$W\%:C^34E32=5(ZU[' !+NV3L.SW9#;U6GTI(N*1(I9WM>4L=-U5NK
MKL]Y9/1!O0ZP#B8XD3T<P-L_BKV<82$0";O(JQ1ZBMQ1LI-1?E*BVTYMYB:+
MPIF0%Z?[_6JCW^W0D59.%J:3QUH4]8$EF)M$+'%9EC@+](=3)N_D9?.9GL07
M!:O3&7+=_+E8)Z^5Y'IS6K>R"Z>;FVN+)Y?7@'5X_B;!'(5UL#;IM$C'=!N]
MHDO6JJ2+^O@1@T)S4[7(\Z =F5O/]CB)I?&>GCR24O?Z$&YU6Y0U)%G8AAZ\
M,&(X/.\IVBV^VO^+C:Y<@+7%FTR^[*'XW_^UTRMR;=3C7N>&]7-EN6]MR^]1
MR1(COH\B7BM*J0<S_Y2TF;2P5Q&PY.WZ3M7/M?&/X4 Q]"T7^S>U]3>&QQXP
M<1_U+9#MM%+W']OMIK[Z\IV6F#M(VIWBT),[!+HC63*N1<['<*(0XPF7MK$E
MYSO%I_;]/)=%V8=JYODA%W\>2H_"2^9.@\F?TXQ9RS5-C0@E2<NHM@R<!,QG
MMV&VE&;((]_0[XH1,3941PG#S-9ZM5@WWG7G\S8(/02BP(07.Y:+3D%?ASGI
MK8YR#'O[6D.^5J=>+V<KV6I;*%.90BM=KK4ZS2SU4&C?4<ULJYY-MZEVC4H+
MK3LJ5ZX]M-:MZ;ZUD4_8&:_)YVF0P"!29_@?W2"71-4>*#/=\:6R/:!ZZUIV
MA@7"%U?YPQ^PY)\"N</:%-?"WV"IO@#>H)"N(.6 &T%L)4SGMV?T:;9V>&3+
M8(]_F6W^9<5,=-A52B[+TE)LF7OF>AFQUWK#A(K82,:*'#?FM9'^DM'7=@2R
MZY*J'%3=^JBU%-UQH98M19[UR) KC_FXL)9")]OY!R77"7=N-'+F/#]^?NB4
M'FI,1%B.4$P"DU$W#@0M7MJ.TAA;7S9EPMOQNK#) D3H=ZH TK&=E=GR&0(_
M=QCD@V+FU!JIA?I8#361:5A85&RTT;XR>LA$[@IF3NG0^5;;Z+!EVJD#P9Y&
M&>VIF-?E(L.]KGJR>:QWLAFJ4,W5FA6A7:A53Z59VEMQ%^".D8WI\(/<;'MX
M$*/%:L-=L*U<YR'5::205)JX>N/8' W ^ Q/ _D!YX %LO)-?*IYQ24I,8M^
M)/*8I]T\XRHY56ZF7'!)#!WM<[.J*Z (K 5X#BNUI* IT@RO_XS1HVQ8LD:-
M#0W)+C@FBN7V;<+WX,;;V+<#%T27D44\E!7\20PT_H]-$6L1O\:U_?8UE&J#
MYR+#@\K&O1&^M1#P:_Y)6D$'7+@$M6\)@J)4BRO&L&?1^7YE_E14&!<]"1Z1
MJKJ+%,%Y8YR(AS$!$!O15\5&KE 5JND"F*N%:JO=[& 9TJ*$:H9J%EJE"]I_
M>_3=6Z$.:'F-.XP(6[4)W1.S$*LZ\@>:N.H4.!8&W5#V &1^!%3FV#<5Q][W
M%I(1C.IJ"#Y(LKS2MPL2&2 Q-%D&I"F4IDJ$?%5? 8/_!P]B;VK[)X\S>Y)J
M43"WB]Y95KZ0]MY&5J8@XJEA62IKKN(Q[9%7OHD(VE@>P#I)5 ,+)+)@;#63
M6(GW(YG=6QU\!X^Y.%!T:)>=V]8MY8#;#'RTH$#(XI$J7IQL6*!QL?124-?9
M^LD#BC$&7B=H-8%'K ]LGI+ :!Z3F6"8:^/%E[$DI5@89KHPHBO9\).!I8^G
M=2BC"V0Y]0,^>,R-/Q-^VB(V 3SA6)*"U]RUC!&R_J,@P)1%35S#(6"&]795
MA2S\/R"6C5X/63;U5Q5^IJ)_>V Y3!BOKYE;K=E[30)><RFNRVTPBKTICTH
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M!2Z.'PPX$2M52+@F@'RTM3!\"(+12_[&EJ1A;_DNX";:OD:5-V$<+PRUBFZ
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M7:M4"FV2K_9%PB5E\-YT&U$"]H<P0L]Y*N];Q]5VAFHC>: ;FM%?X. (L<S
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MB @ (D+1%!!$A*(I((B(O]-Z*T1$*)J^%R)"T1001(2B*2"("$530! 1BJ:
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M*B_^E!#M'XZNBIUW<EB^L\,XC'%8GL,DQF$E."S7[Q9XJ[(.$)[?PU$#@_F
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M%<< !P^PL!QD9?EMU,Q/PYB? UAY#_&=O'CU,+^I$]LI7P'%)R]SV"5U2IN
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MW\VNE^$A6-P0Y/0YW?Q;_@.4A/170,-F+^I)/0'(V8'_M^'Y+_H_H:>/%8.
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MS2@JE0J>CB9_HYNTTIH8@*<++<BM"QY0BAB( 0 :4*6UQ1B G(@;#,#7GPP
MI9"J_;L\!KC3#$ 6<XAAHN#/>0P &,Q#.4G[P@ DD< /D'@UXA2-2Q1"/\S,
MB=J8$W6DCYE-_[HS@"&J@.FR&)[&?@7J%G+_5S\Y!KG ;#ZECUJ188ZPKX7.
MCKR/F:6:_#4W?\W-__9STUY%0D0\.I' [7,K7;=?LBX^AGJ@^,Y#174(7J\Q
M+P!V(E$L+>?%0U$UCI>4V+U'9&=:F:8N<=^AK!]NBE1!XS^.7W/$/^_RRE(]
MK#F#JRF:+2M@DS6;K](-42N7EK=]696V]TCOJFOPT3RW0\/UX=9GKDIY-XA<
M[U36@O=O'= 3N/T/ @)[OEL%;O0I/</'&-55Z=U6- 88#GSQAD-S;+I=LFT'
MW[X(,)2?,0,?A&V&DK-I9=2K)!;'QA_UTDCY)'SH(_>GE2MF=O7'!<\/*;P%
M;M#:\QX].ID8FO;^Q7:PU#D3 FS1_6[9QT.R7^8PNE^+W^CP^1:([6979?]I
MVC[\V5J@T5-_G[S?C<0!_).I^^SL:"I_]KXK R!-0$S_&6SS_J0?!.@?NOPG
MQ?R]HV/T4607);L:_%\9C\'OT W^#;FEUWC^Q<3!?S1="'[G'X:N_7>CI46"
M=G<IR":>U51J=LQ^Q)_M&_5GT[6DA/W#T'\W6J23 1V! !%U_YJ;O^;F?^#<
M%%[7='H[<5TRVF[P_8NMZVLSSD@ C+C\CQX,#]&&R\.O>[O&=.@;G$"UFOY!
M0!259>?.L2LG9B4(*1AYY#WTF'1K-K?RF)9TZZ--F(1P6JNWO'5]RNCE\4_!
M'16(K,7:^$9TP=@D[OJ9RNHX0S&TOIDB=Y#P=^#-X\5:YJ-9(T)"7!8^XEB=
M'@%3>S9W4ST!P'^3#N"G*J.?K6FJ[FM24HS<W.=J+"HG"U@/.V7_X*5@9R,1
M1?3)[ UO7!4-KDM=WLAMG)$R=!K;9  D9Y4":;6.5YDUQ \)X7_M6?TRS@9X
MS/O>99:A'RSN:.LJVJO&<Q,V;0$\X<I'SL]=/:5>CE1\^0*QDQ^,?4:]6!2D
M:YEZ<Z1\/UZ1KH YU UT6E_36I89+E!U-P2GO?O8R['Q7-]5P-0V+1+H:2Q+
M/J^ML5">=NZ=<\R#3AVEHV]5=3R+Q>)D2JIL*$8$!H G2+^O330ATL_CK2/P
M&%1[(O'N71<VS9F!&MG7W8HC\C.^O@,WFO0$+/G^)>5FB7C9E!L+H 72$NI-
M5&,Q;@P ][A)(GEII$9:ZJDF:*2AL#&8%H&<'=_RV:.\V8W=$\4HMN4?OS:P
MUO?C<T_M,9\O'#*Y-4=?_'VW$"U"0U--%"+!;AC@>+.-:]8!]Y+H0_"6JA/8
M,DA?=A62^B:P@0%P6&4 MNZ4U)\R:S4WJ:7VWC?R?(I;Z>N6+S?50Z0C0OYM
M?6 9KWJK9GA]=>43P6.MP/>XJ8*5RP_(1\-]:;A]++]<D)CI!BDC*HZTQ6US
MJU@]Y)9A2-GUP0RZ<&7P>:"/Y8"/_WF=4'']$3NY3K'[+VY%.O#D'"ZT^CAE
MH3\6*6!9UW"*W#R"FY\?@ 7)7W672E$LDF%C_:BE)W0P']A/$</WQ6B?]GSH
M01<9N#>\[F)R$?_XP\DPA+/<IQ$&X)Y"+$)\\'WCD";PHRZ,+R580&Z5Y6-S
MJ?*K(O.X&E>I[(^Y^69&Z1>]0B2<]%B!4KSAZA%ZGG?_G93 O>%]8% BD@_1
M1P>%1BF<_@#S:MW0R>"@)J.'03^%Z,;[)@P .@VY);M+792.-OF^HQA%JW,T
MZ-\RU8.K;>/_D#W\UXBM=ZJJ@/JFLI@!@!YC -2I']##R+%!NO&8%?/1SY"9
M" O(^"QFK6^8'MTQ/]7A^(3I&(U!3_[<E94_9O>(+0. M:0'V+[_DN:U?B*Y
MK.+XQ8ZWE[):[++SP2+P0R3^UAV)@XW$Z(3[]:<+QA8O/$^N&8JONXB+?G#3
M*4IILMZ%G#=2ST/BGS$)WPHSL V[)2>F7#5<P2UZ4JE'&B3KU6MX8F]&>8X!
MJ "U3_ 3)A:>2A&7I_0D4O.+,[]67Y6X>R#$*<'@<$W?: $A"D5,)12CGBDO
MGU7XQ"NA>E'&[=GG]FVVC\#IV\T6!8:62+Y;77):\#[ORC/\'Q:+WT"\)CQF
M0[$QX'NH@\L,  ?5M.07@I^D\-1[*RBN$JO>6EQ),@B+[Z9;IOH2HZ<[6M8C
M'#E)J+ASVV_J&N[]G!]IGWXB]7IYR(L%5^Y*RVT47@Q11953 OH$E[&(4U6^
MXFOYHHJMMVZT%U4[&10'&[2;Q#6"2-@F:+2CX."AGT-;PJ/>W_L/Q25>4'G1
M 7Z1?^-R6H6(VFFD5C'=R<SB5$9N4B#5AVY0@QBH O'PDYV(AN4#%>QF0:]_
MM7R?/S-SQA'A+3=K$JG-7DV))_'H$+=K4V!CK_3'ALW57"A<V"^4 L+Z8^T3
MB)X]MJ@*CVT[!2 E6,3K5/AI]S/2J+28WHN+L0M(U^S822!%F7#>I35]!0(1
M_13H)9@J<*RH(-W 2BJ^H49D"?;^J>?MEAZI\9+5/6&K!\6.W.5YS%C%NJ_;
MYH0X.Q8T,[WW:]!VT=8J57C A[OHG<\E6%^OOOJT[SKT]5[DJUJO[;9WO\S<
MI=PGKC>Q'A?= S=-5;FUPGC$K!UA(7UCEQ3*(P+<*TMGFTU.'#O0*:Z&EJ>]
MU33"(T6HIB/*4T<X7V\57Z7_<*E])ODN>IUX9$8-''^.6[3:H];/5CE,&8N>
M%.XN)_&:/Q_6@->&=62:Z@%7LF[_NP"Q5[%_F 'HJODUM4U2W01N*<,W_W0#
MX1;'  1_7.K[\2#[:W0N$_VJ>]_^CG[98&\&8%=E-91>-\8,]$W0J]A_ ;WO
MH/T>L.5N1C5ZVJ0_^Y4%$_%>(^#_#@L"LH\@9]\'N=$Q3)3_4;0E24 ]IDM.
M4%U+L?[(9^G(*$TE/IU!.WM/5S%WED!G25;>)=AFWM>084RTIEN>9VHHO<?#
M/\EP+J[RQ\,'<OU(C_7GMM"V[!@S6 AK:DQ!1>TUP3EX9>=QHG#LAN\E:=OZ
M8'^K$-Q"070QAX5KV%IY \J:TO:(.$7 KFJ <6L^Z*UG7H)JR,]><5^@]C*S
M9^TS0.L</FWKH]@F,I)5'NZ3&^3F2 Q8S<?IDL\[^IW,%)X)Y)'<0E^FO4)<
MH(3B>9YOVV7SMOE7UD8FV>:O)AY.&461'L,PI$<=R&ASJB@)'%Z^"FG%->8$
M^U?Y>J:7N\\'LFG<$IMC*0A9>"5G^I'#?_V;6(CRT*12OA5?II'#U.R>*)*W
MD1]^C**,G^*>#(J^A546-[ =S*N)FAR8?6KU=;RMRC?1!%BZ'_AMNKJ>9]K:
M:VNYLR)ZT"5,\0HE5L-;52YN8T*-&;7>(Y3<08+GJ#P24?(M[GO..'M:X8F(
MH(Z)EN,)6D6AY'!* [/*G&%KX3G2XZ-2[#5S7K17@_=NO\)H+*JQK3:I0SC_
M5KQCB+*LG^HCI/S4R=YB;=O/D8E?JK+]?.A'<'5TF: GUQJOJANA+C$ ;(Y(
MCAU4N 2H@3C5ZG"+UJC8--,R:\].56!E "Y]]XMLJ3GNOP@]0^\""</5B#[M
MN)(\@E/0??D5VZ&PV).2L_N"P$7MHY34_<O42Z1$2H<!LV#-*1[3Z//A[L[M
MF%<)P>_Y38%O](GHOUL:^A+H8=NE0=T3BBQB'XS$]3=6,@#1VHZD(2$K^B4L
M'[FM? Q=V7VWS#?BB/RMJ1;E: >%5K3H-Y)81^UZ3,$3KW=#:UG3S9G\6FQS
ML?-%OTXB+,/Z^ +G W_*Y,9^.1@K\_8/A+% WH'NJJZ"Z8VNOUGM1NV?[WSM
MQ4RD%FK5%]#P>R"#?CT@L>/G(0'3*_]= FD@_I"^82P9 !^3754O.WKC27K
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MNPCX$8BH/H?TT.+4I]@1D?BJ<*?!^X.M@SBF(RRE8MR.^*O.OO/^V:OMK,X
M?%/_E:"HF/X^I9@NV/#=-=(WXDV(':GA$WR0F:L&-_]SF$44(YHP&]XAJC2X
M,;4MC!NJ2?_C^[09\*1G2-G6<6GBR5_AL3(E2A^8T ?XC>06^L8P=.,Z1P:@
MA,P [%V _ C87%B=8@#.3*"1V% D35BNC(V^:3*,<).7H_!ON<T!!4RA[T'9
M_XQ<HEG"Q/:"&?' /H/^5:G&(>]Q X&+<2G2NSPA>\K@.TB^\GM]='X0)[/P
MORFY"?ZL-^^M[B:\G-TBL6U'/A@^ HVK4I#5QYIZE&F54+WY9L(;MV?W,A?B
MY+65H%T%#402S-.,G9I7Z:/DVZYUN2VX0M8RT\:\X+2$99CE.O+'UMGFC+.R
M2<^3)S!HI9<DA:AM$/MR:KIV\?V1],AW46>=$:W(BS85VYBOJ.@RSY"%5@41
MN/E 2<7ZL2!/;)^Z=TU-?=?%IK#1SJTE.2.36B)V59?HUH[+7X^X!.58;A1#
MK0IB:Z4D;ONOQ"GU$9 <$DK)H^V+-BJ5=2N<1[Z79+YI2-K05LEMW" M/*,J
M$".:IMCGRRAA^!YSRQ$O9\.U]946IZ,L#RZFJ.UW* ].79U&<]+[TWT>GT>(
M4WS+T<=&:85D#R_5[^*IEU'2['D_.#KV=8WV58?7:KUAV^)>O;7^88':YXD\
M7VD0 L]CN"FA3F/9+A3,\S88_R9P5U%I8]IE$WV918K'=K]E.GRQ$4"$=GRN
M-6[,>[]893RWB 7LRA=ER/DERD63?*B2#( 8YIX<\[_JTRT?+LISO49KUEH]
MS"@A13&$M_>6UE).7&IY8N*.=V)8R4O%YHZ7ES$A/;3O3+@F0)KG*;X^.=TX
M<FHQTM..,[/V?K.N3_9T4G_-HKU6V/ ,BH42.$78^2IG7:ZEK@';E\&M 2NO
MI+*)V[MP4["Z^$S=9FU)6AX<0DRCBP?=XP;HJ:D:WM,>NFO)%KCY=?DKP 7(
MVU'!63VE/_GMVHI=D[3<63N+QL":W46KK4S9=8>A5?]]=MOYC26]6.%4D4!I
M@!_4%'Z(6#'R5-/W47Z04$OZ4ZM'ZUY",527H-*?/W-+Q50N[,9TW(9AZX,+
M*,@F;06*\HP#N(4N6#=<4=.3/)M^DVU?V^$G;44W[K.6\$C%Q6[^65.,%P1&
MC<-'S$=KI.(77&:6>9ZH?Z6\@Q\I]K1UBPZX9CQH$O: E5>\!M<WJ/QU6=V'
MK%T<[.P6N[ R4.[H+RU#N=R=-8V=0IP8+E\'(<:M)L6&-97S##T*#&0\$-TB
M:S%7KJ8&ZO*.Q6YB(A$<1'0D7(OD0[A7@%\&\]I3D+<3ITP&UH^)N?>N":-O
MT3.KVURY[G_*5RXR'>RI$]*4\OG&EC_9: B2,(5"@Q+&6K++02LS)4&[U+/Y
M0>:MC1*UUCAC49"LW*O+NS<6?NR<J?.)04@2T<WB1GA_=60+ \"])(3K>74D
MV#?LKMC.M<>!CZ]P&8(OLHY@'+')5S<=BAS\(>-]2^E^?J&U&GN_X$)ZH=&K
M*#PWJ DC%L#I<+3YO&)[T*EJP<\RUOUI#P.?#-1KURU:6'JTYR[Y#D7DJ[+]
M8"++4.?O$+-M0#[$ "0AF!G)\CR4QH&1*_KSK7JN9=IH2-Y8-W(2E+,5QD08
MKK#'_XD5L\VJU44FEJT6(;&MX%Z,K-RV&YD4_XZ6&1!>>-T&+RT>M41]CZ[I
M0DYD%]%X4#V8A 9F%HB&DW[/!QO >&2''#I*FXV$CIH>R&E$M8Y@7!,)AC?*
M66!<C]G H5OH"[FY#^+UOIWVMY>6]4E7,)_0--^W7FZ4I9C@42SC'I\[#C\_
M)[\#NSCA7WH\]\L,"TB!MFDR@H2A>2?@7BB"=EJ![2(6><_.T'\A,.5(GDAW
ME6[O>G/]J=@%:UO.E1WJ(Y6@]+[50*J*]@L2:#5&B"J)&T:%-X(6)0X/*5?(
M?5@*-$L[_0+44#;G4*.VC=;$4/ !2*+.-WR+A^_YBHK%!B&ZAWSKRXW5=HT0
M;)KIK<NV%W!:/M@'*:<^[82="UF(90#<&^Q:M<6)9]YXN$@D^^)/TN.#!?+3
MS8Y>E60!+H*)XQ>U<)1P:%0(:Y:6-3R'H+5RU#>>;C6)(<KN>L:F.<D82LWL
M;H_[MED]KTW=0MVGZ.Z;+$&/:EH2XEVL^Z=)GD&)*JC;X4LNO/ ,XE<5MOLN
M^9886HXE$P4*FM)](E<O%<O9-NX[GU,JW3\AW.IYL7.F.&@5Z,-M^.U-J@.8
M.V:OS5+";A$]4[-4&]U!TU_&0Z+J17P*.N[Y:_157OW0<5%1:4%RKOVP=L6O
M,OKHB&V2P:<E)-<E;H-VTEC8:]AF9RLH52R=[QU_PG[1O*VLZ].\\S-3&(?N
MA#.? I&IQBC;0;"[W3[HZ:0<\5JZ<7T7@;.OT@A><KMUU#SRRD542CE=%#&@
M0N>EP!Y-0_F"%#O:0[A209[A&F]2J]SO[KV50CE%8--)LK)9HJ^2C+W7-T]#
M/@JFA\K!49\T1?;UC$BIA([F,,6%EA%1+EL@,8'G\_7FDR(G#N%&VP\^R<#J
MD6#DSU648%)H6Z)-$(M.#2F@'N7A1?!J<[5H/W"79?[.Y7'V:>?&\[DU60>?
M)P8.C%0VK$\15:UQA2J-50U;J]X=6,QG!B!*TRF4)+% B.]9$:0+6=48.]/7
M%BTZVQX=L\C(?OVQBU"O2HZGI"#.P9U(1S''WQL)OEDA(R_*GC!)OK'P]O)Y
M%+FH1]$WCK2HY\6E'O_(IL'+]7UGK^58[H?\_#7J3U,]X,^'?ZA9BJ"??:AO
MLN(9 "@_\B)4%]*'_!QG(K2RD!MM]F[\IKZ!Z4NH#F0^J&\G/>L3C8V3RAYR
M(C=6+FZ)0R;W\=]H=Y.\SL0";RQFN0%#CP-NB<,9@/T G4UZ#_T$[\>'7[YV
MB#_V37)X#=Y)1Q1MJOE"OV;G@:5_Y<;2+E I?T>9WVB<:!*O[!/=*%V*W3)*
M@GT8[92*)[W<DJQ6WHJE3ZB\F%"IXVG.YFZ9N8?RP&+7!=M5[X_6@8GJNS>8
M=6%4OLUD;DV_":]98KG(,@/ @_28 E+$.M0[GI4(3CDZP"3-!]>?;'@+D+\N
M)@S7S3  N$\P!'L=L2!"4^@]A<40$[8S=>=5U_FFK8F*!UJECFQZTI&YL^]G
M"FDJ@TZ?]"PE'+UX["BH?1T'ZK5!31XW%11W(L56*D'5\+D(^<7#AY<7<545
M2%PC V!%Z<^#Z_KPC'7XO1\[_^7G\RB9::Z[E8I@6:*GS%Z%F%TJ9J8ZS+EX
M'3$5U=%($2-78HB:64IG\?$:YL];L5#WZJJ&P*!D$^ONF7DVK:!"I #8HX]B
MK,GB,XTY&J1K3#2)9IURKZXH?='IEE1B=.R"TK;V-G[(;*\8J(UP0#AMI]?7
M9^ DUDL0PU6XJ3AMT/(J?C_H'3%.CNOV\ZA3"RPB+JA48F'6<5J!#S-T+5A0
M,M*!]5@(X;8_.3/\#)&-.R[#9:#^5BS2,C>Y)L1N[F^#[1EA )0F-8'[IAVY
M%)-6"4&20L3]>CM\C]7NML"7K,5IE8TR0?S0W;ALEW6#5AY<[4Z'Z*/PXCO$
MQC=OT9$^AWHR H\23N4)QWWL/<QFOYE.##D;9H52!<MCP%=I]] *Y[=V048P
M4*5QQ4Z;EV3'")2GG*9A6Q$_L)I(>K,:F0HH_7D1U;%LCVHQP3VRH@27!*48
M^L/./VII/)4V-W1)CG#SEG721E9'QMV(+;10;F+S;=.YN4'OA@,$F)J?'PRC
M.ZXM@QC\$O2MZ7,0N)DN\)FH$&EEJCFBPB<BBM_,SB362/S\A(Y!EI^>:LTT
M:<(FN1-'04>O'N=]YR>XV7R,J>!>N2Z9H@315^>_B:,I:S=+@:ZA#0R ;B-E
ME.0Y,V,0#VV%J/N'W(UG?1#,>]W>25\I\="#2Z9V.KP%0/:5N'QI-36C0&;"
M;_/[ C6T$/Q9@?J&G,WT/D4&X)?EK@.T$/KYVOWLLK5TF^L3OF=%UI0<#P?0
M5QI,5^? ZSP_]M29T2U*^^L_N\U_E0@()2H8&@OF@E_%)^ITA=W_QJ]Z]<1N
MTO9!C C5"-^CVZR^NH8JM#/T0+K)Z9XSD^?X?!D]OD3*3LC^4A!.US@0\%'W
M3&K)J55CL\X#)\4C/N([L-DA.XK?FYS$(DTBZ6RHUW>R3I]M(4!C=CGUPB ?
MZ<VJ*0R J!/Q4$'L]*N>=RJ?4LMLOP!RH0I.MSNR=GL"& #BBH,?/=H!S  <
MR&K\.'_9&K<YY5C0\^GP*4AYX);VZ=Q&9K45[;R<O:7.S LH7%O(EM* OCUQ
M?P: >C@D>U53>I..G(60$7*[8$F"K=PJFA(H7\-44@ESCA_W&5 UA.P9@!RL
M"0/PU2UOW^0(E0'(WF7[B_\O_O\$_P@Q.W(;)!H4U:$W4/RNKK$^V3GA,E8J
M,00[6@DBWC36*S%?;;Q<<5UI4_C<Z!N)KY^!6PM?UT=A3<B#+DJ+M[7S/M6N
M)EDT-"6)-Q]HYBG0WNZ!JK8,1I!]TC(%'M9NIJX#7X[")8F*5%6*WUN*/]#C
M7''RZ8#;==E%$EH,0'+ EBF4^ZQ:5[==V8HD4""W\JJ>@,6KW[?VNN&61!VX
M 26 P,.M\:PWSYWX+O+JSU9X038< M&SN(L_?;KVC*G9+86/%"_"%,>2(SOI
M3$[.$KG/X\//[A_?!!Z'LZ]O:5W=4GX)_0P^CG%=/T0-BKPWO#K98AL3V%8X
MZN3:X?H@*("LN<<+E0TJH!\I0N9:>PJ1LY0KJRLKH@R;>^YUK@ -.[@,//<S
MM'VB/P)70>=0*'2*58%T9PDJUAW]"2%(_ZJ.:5V/WI..O4-R2'ZEGB$1,M;E
MO=*IRAMN,%";_0=U.#S\_N!S4EQ!X;9:WN/6KK,R[C2>&'=T)0;_LW:!=K06
M26?1 OTSI!3\76,\^V @-?LEZ3R0C/VC3NGBSTN0/Y8+&(!II7Y:P5,ZLH\:
M\1?W7]Q_Y/ZX@IE^G?[&_D0=J2WW:O;KEGO??Y(//<[;-__-P"(8@),,@)LS
M)FE#6X&X$(VF0DIL/$1=ZR:@#MVG8F7:#:6P*U5-"M$M>&0+-UM+P6$[HP"^
MS\+?7J;08"\H(OLR00K3-ON.V0+I)97?*BHT?G ^&3^5< S1N+T*W!3)NE/J
MI9/=C.'_]9#*WR*M1KW)C.=$U)W_1%;P&Q&?3^UJ>:G26[N06Q\@==BGC@Q
MU[('AGS&B '(UVF8K"6!7*ARVVH?PC!63&AY*'[R/[#M_SM9(]08@)<*S(>B
MCS  6W96<TZ4!?JUAE!ZO30#T.\%X8GA5XC,0NZ?_FUK-(B?7@\FYV%+("_I
M7<@-;T=69CL>VH?MY>02:<KF-C(MF6>ZI1_QV^D9M>K_P*+$?_\8D!!F(P3G
M0XM)9  6;Z,?H=F9:632R"!RY68J W C,K0A@*#=08$L^=W>1WQB*F167>?/
MVUS_'?I,]6, 3CDR'^K(S\PZ*XN[6TA]U)B0'5H0T[9S<24@OC-03DT&@,Q4
M=])#HC0M"+EJ@+9'2]*8(YX=KV=JQ1&T;[J,E;,W(2TL,>L"65!3="[UM[5I
MOP?_$WXQH%D!.;M=/K7/SS21@1S'=4?>4 9 NO@] _ S38&>S+$3LMP:AB*B
MA^9SR#1K9EG<Z1\97-5F$O<BB&,>JS^P8N= LMQ(J1P\Y97#GY-H16>5:-B'
MY$ =.@I&[>V[FYRC5%Z^W@)PI>\^QU\R6R:K9ET>BJ*YM Z\:5[OBAJ3NLJQ
M)W.E0.(=-E PSE-5;04CZ.OL6>NAKU%VXRI)H=6+' ]I9XXE;ORY%M^PCKX6
M9Z,1[W+L(ZIDHP)3 TEHNBF2I#QLZECR7 ^X(_F]/FN5MC*'Q(N3D#2!3.3&
M<P8@)H_..R7$= =#+ ,@@Z&D+WTH"!@-ZU1>HY,?8H@)% P]]A9F5X\!:.UG
M -C7F4U^O6/6Q:^@5., "]._6/^W9'U9U=K'K8KSQXAR!Z'/?+.M="C18BDX
ML4]H4,"[M8LA05U^^=#1QA@"[.2;3'67#-1Z^U1KP4C-'AYQNI4.2KI)2G[L
MOGU>-"#0/?6\%"O^QUZ<E7D>1_=(V:_^=W*WDAK64!]D"O?"")XJ@EC?<+Z@
M%$NV'W$,@&VIXX&U/VQX_Q&2[9*C9[)W^;;7]XC,S$ROPEY;ZF:C8# #L,)$
MM#-STR9[1 8 AW*L<33X$VI;56?/] W3[UF (WCT=IE=V\_/G8?9?"&24_T^
M+ D=@;G=CS)T?3$M YQ^A!&$^Y!D(4B.<]J"1+R4P<?)EGG[<?1.HM+CO!_I
M#:2]?3H?1BS(Y^O<Q'T;.S/,%6T;%]V-'.U57/E,O'.\J< IF>8/PH 02&ET
MCG#3K1NK65:GRC,R3JV\["Z(KK_WT)626J*452<9PS;WK[[HD.J0.H[IG,76
M[8]V,P#-&@0&8.^L.@,PQ_1"?H,_L^MA77=._,7[_R5>8Q^>H)X'SI2T$CG4
M[N+Q6YB40P&O?O/-;]0(Q_5U-RTG4F@[DON][HSP- D4_1"X'<I>7[,:O?,.
ME2/Q#M*X&))?4E%@-V5S*U4EE5TJUKK7\M76J?HH=S."=*P%G_YTD1Q7.,]M
MS]054JAT%%67@&0ITQ@=59_RP-=**?I]!MWK+#EG+-Q]])UE^OARRTABXM/,
M0:V16!GTB>W_1(+ \R]Y2)#>.C6K\@T#X'P7LV<A-[&,YB6#FS'FZ=%CVT[,
M?.KDP,,IH'!!BPE0,5'8(U6*=VS'RU&)F*-#E2<&L;#L2_0Q -?R0Q7:?';/
M.,HQ )\=^NC//4GH2.B&$17$ -R!@6G'DE?N, "1"M ?&[[(5L=H<V:_-MU_
M.),Z3Y>G[.-1AX(29JXUHLS2R9/**2X>]P;>>88(2N:'Z,%[")Q((!3Q0_OB
M%V*]J/^7\<47;1I+1[_J/W6193-?@>7&2:KLUDJ*?O$U>K5=2>G)-0G%7R^G
MX>(QS]X%K:XYWQ%4S)-^ .ZN6]HU:9UB1^*%JBD0_-D*M=;$2?ORG<#H;_>_
MS(5GM51<?1>4@OV:#FV-9[-H&%:X9"36F5MQ?>VUR2:H5DKSL>](55!0E[0Q
M P I32R6J>K%%-GO]<;N*N$SR?DP$G_K)&BP)%NWK/K')$%F8:AQI'+CCM>+
MSI" KD+Z<9+6^N-RL*!'+FX.[NJ5K]PQ-CUD/-S0[';XMF+@YUY/1Y')+C)5
MOZC((6^Y=D$S@,2F2_'-4RDHF7@.@^,M]1=>[,GN*&\N-'E)MRH0P$=@5E6!
M1)S#E8[;?##'T$E!^X5N+7;-:7^T*V69EI+-1;UZ>K?"INTIX><XD+L^!Z\T
MM6A3>P,H(%;CF??J>&+I2!"D=<3Q(I&64E8@!)/KI';&/:\H7=.P*H:/.<T8
MLQG07OL+-%9G+3J<JH*%*?XR4-F8?>K&-LMV?*%"B1P\A/9G .*R9(@;NY4X
M6X\N_TH%)+E)X,W077 _"FC6LGA6_FDAKNV1=G)NK-R+Q=_W$WZCKZ2-*.*]
MS^R=^QH!Q7M-I'5J3&T'+51UHQ#5^I3L5DDQH.LY@.CU> ;@QR'8B,%3Y*PE
M,VXN]X)H *L&^&SCF5#2*#.6F/U^RM(*E("<-<)BEIN1-,'AFC^7&)8MA&O?
M\&[9?ZX@9I%?H-0WJ4_ RRT,@*=6R!PLAJY)@\Z[ZE(N;$%?,!/'7N\@9#S!
MBO)SS4+00?C.'F++LC"B?6K#EAGF/O^VJ-MOCL684'RW--6S6U,_,%ODO/[G
M@F#TO5%0ELUQ*??\M-?3 /7TC5]@#P4VAV6=YHD*SF=QDP;DIU;>(W6;<<&9
MZMBKI/01\@[>+29G,.)-QQ=?X3@\J@3,A>4DLK0C^+]0U-[:]GU<_&'"Q_Z^
M,D6/+WBL%JB9E!%8\EI'_J@7U$[XAD^FGH8$[N@5R9P2M<;3H^@V5J+)J.N^
MB\V;OO*[]W$:+B6P^:+]ZGI3//*9A.Q(O5&P*R%3?N-:::51Y=,KA3^OE-[U
M[B07B2(B?4DF,Z H/.E0VUQR6U]4"BS)XVRLP<G0EWV:HA-.B75)=(RYM$.=
M3-[RDMP,#"RTM$K\UB(J/E+V"/9NG.G(QO5#7 7?[?Q]7G*2V=Y[KI6%JD94
M3#W3!A%[T0%A^,YR4[^&$F;FX?8&5;NKF5UL,NRPBEPB@T8$R=J?L%3=@B#H
MC6RS8?G$WO9C7$G:#VHNKT).5B<0)J3C6W1^B4-+S12YX:D$DRAR_+[R-P*L
MQ\B\<5CAO%--\D*M\Y.J SM^<<Z-,11(WJ*ZPI-+8V%G%M'G<$ _J=0SR-<?
MSJGRA9)7;2SRA?47I^Q$==[ERRD/S(KRM(,Y*6_:DR@N-^M#>VX(XPS<9[1O
M<SS0I\]"O!P/>7UP%WVTJGSOW-K6?JAI7A=HS57/Y )F8IJV[EVQ_C9<40T(
MO/-VN#;W8U?WSAH3V9P]_P!SNO@/+#.5I0E[4DSCQ* A2]$MT%WY6@SMR4EF
MCH4V-:>8;\EGDR270HL%3*':H3G_B;/V_U+;UY_:H9O8,2&L5!%*DP6N;6.?
M[8/PT(\]NJM[G__FJFK0V*F-F_40)G[793.]:0;*@9E-I8#I7T>0>R?E1A%R
MR"Y%$I06OH;<LH/$PV49@$3H- .PSV+#](>G:!<VZMD0>G32<_JI+?5TF=S:
MWMN_U6UO7ZBGR_5NAZ:,T"_^VG-+1_2]M^E"D(YN\)<>V;N;_J'C=<I*R&G@
M3(AJ=$6VT"2EA*P@N*P>-ER2)Z72W_;@)CO0XLE<%GM7$4*0\LTO *^EVC<X
M.UQOH#54>1 W]*P5S=NB)AUI[V=;:Y)7PY&[%-)S;XP",ZK RBL_^Y2#,J^^
M>KSJ*N*1Z0]^>S>JO%&HL9Q-JOE R:55\QLR9P8G]9QU,R3E$E22QF> B 7"
MM5K5J+O# <421D>X8H -Y1#.B]7W]G.L 6H['\E^N@O/U8T-6M+O%7^PACK:
MZ/D&.[>MO@_X=NUZD]RB#19\%*X45)O;DVO3K:PHNNE_9W?6_[Q%_7G2@>WB
MAUY"9@/9!L-\O ]>7EI6[!*YW.G:<6);N$2,<+3BOK9T8W8A)=OFQXJ0B>&I
MYT:)KEQSG5+/FE83*DR?KG][Z"J#(VM,R.$-GE[2/5E*I"77&;'8=G:!%/@#
MS$(CS(,>X0LBJ3)51OGN*2E(#X<D 50J="V#3/X4K]L^T[SX=E'4M:+CF8]/
MCMN3DC7X>__;BC;C=ZNT+J:GVE.2?-\OB08FN;[M^["\8\7$PR03F^1#]2[A
M-KT&CH?5^SU1)727>B&=R4CBFV8)D>&H@OQ?@H&/N@UM<F\"^^Q#[I533:>+
MV=HK25=+%JUJ/UU4F35Z-2ZPU?F)60VG3V3&UY,;^6IK7N8H]AVO,FT]V6'9
MIX'"Q\[.DSYI7R()M1C;F7@XES=D+?C??'#5.@-X>3F<6UDT$=X34WVZ^R76
M#GZ2Z)#U,CB?J563:)-Z6;>JZU=L.&@#!A]Z'(@++6CN('U2R5:8*-:DUAW1
M.ZCS^AY*#6>""/[D8$ZPRLE9&B$M:0O75 RXU=M)#7%W\XF\\2R-0QZYO*"V
MD.]",2'PQ"BC8K+D^Q4NY5[*U,JUGK.Y+2R0E]G!<KX.L&_ZS?3]V."0 NN
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M^=FSQ>,AL5#4[\A-<B%HUJZWB.OH?:D9"'#0L*B*(G2Y<I_0Z#@0=8 5XE)
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MY45AAL49?9VEU#+S%71!^WE'^.5EX-<BPR1V/]7'B#7%W=UU#EF;\**F" D
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MX59Z[F\X+DLS7#$G?XZ=[N6TV]<A0\@Q;U/*4]P;^:BD$_9VI;+I+*C\J[)
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MV"%-8_NNJ?;4:S5^PY#K![-/GC7U5\33\'[W#]EV!>+5/NX-O!'LDV5H;.T
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MTPHA.66J0/VWQ@^%7S'496G,'/9P +-]TM,7&O,R)DWJ+3BJ_20,A#!L,61
M@T/ARV_2-^+O*O+N8:I7#Z=GYYIBA?9F"4ODUQK,*!X&:% ^:2:H!#TLY/9F
M'<KA]A2T^MOY"D68NW@Z'=2) QR?DF)#\V/M%X,P8;)B>--?#3TR-C-%/S[S
MM1@%AC)OIV^[:,I!+"O^S^_64:XS5U!CHN?4+]%-1V\F,B>2?0=-#U1<@:=X
M"SD4JD**T?-,'\<R-!#AC6M#6\<=SN_)1(D SA*I"G2L"[]9ZMJ\R A_I>C/
MD"=J*P1AR9Z)*J2A2&,P$W=%]*P<23AS D5=T_*B>3*I>0=X)WL2GLJ1,61D
MD8(B80P7+6"K2B-RTYSK_01+H+'7W#2@@[:;DFS%N<- Y\FVUQ,#4Q+T10D&
M%S\HRH[QDQG?63,>B @Y[*=&K*450@KT8"K?XN5_5D8X.VUTMT1J/ 5@8VO>
MH03:=%'E'?GR5[NC[G$+OZ=MW">ZTG*\J3H2O<$FWO@#]OEH?>R(6+Y3=(JM
MHZZ]*/EU['W=4 C518>!V =S)&LJ^:CM,0W?:B5==.R%.,U[\?>G_9XH5..G
M'*V;6D&2+J&4@SV7(U6B_GM.W">EQ7H;=,X+-M1<MC;??D5N>0)NLJ8]U:$5
M+P8%1VNYOSPK;\$2C.74(4=!OI1U@P(N25*?CU7.M*^XZ2O>N@6459<0,6^%
MWG;ENRY+,V^PX:2W%64\X*H28"3)PF,[[SPBCFAXCL<+744*=2NY3:).[YR1
MQ^;[?&3/!>R-[/DR"T&:Y\(8QD):8/%S9=(PK+PL(Z/UAZ!TA$,^@=-C=<\M
M5QNWA?/+EY22/B?8IN?-&"#RPA"<0JW"1%/W$T6<"F-;G?AL1!Q.@E!CEK!M
M(Z#T\;VEDHOA0E4GM6UYJ[I[.+(5#'SOUO75M?\AY[E:$G[<(& Z?(0#D%F[
MC3O:!&16I0Z_67I+(,7 K#GK"?J1A!)KDVS B((2"YW5!1\^HJPJ)UI];DY+
M(VTIG&*3E+UV)UGT_0!29V;3E.A^8E=;^>:IZ'@7G>%]!0]*CT4H)&3)]V9;
M_AP$ICV.45W:58.W2X9$G^H*!OC=BM]K3Y[(WDPCEQ8IM+D[I;]5VN_XEP2_
M4D9M4<&HB(1^63@"&"1P_#SG:5X7V[C^D\D6O8AT0QI6+[JN1"4EISVP557*
MB:0RC]\85A1BKCJ\TNBW>7S+//:AN3WY%T+1^3H'1SCET/-E53H(/YOAV&U[
M0$V\9UE,V-&;6]V%1JR55F/* A:V0T:5>/["3&1=UL7864 G_;GLP[VD%;LP
M!W&FM7)O791!6\NFEZ-;CZ/MK<\9AC>L2;#K@ ^<VBOGMP=X\N:&C$Z2EB\)
MM7]6UX4<\8*&@BT/[WWIS$F__P'L-KXFU0=9#X!U/ P$=3XF58ZG@LFQI[;'
MZ!!3&U5,[*9ZB5F&LUH%FT4FJ!&;9HU5F,_^Y=HL-_)"N[]#MP\F< "%;!\V
M, [ -(@#5 -CO6=0YE@Y CSKB6LZE^'9Y#%%GP1=MF *_&F1;>OGC)/J(:8"
MHW%X/Y#WR.\_HLS[&Y83<J&&?G=A8&TP7WK]*(YX2:R*^)W-2-6ADR*-Z6MP
M'@X0V(94N"2HQ_N3?OK@F7?EL,2GK%\46#^\EKK/2OIRZ$0<N/X)>MI</&$0
M$Z.].*,\@P,T2U!R1]EV*O<OV*,Y@IEG2%LL]ZQEN6/.%3*453DPHM3^>&>5
M8)D4<[?/9+YJ,+VW/<0GYE5]%A:!U9$^ D9=X@#(.RM%F.T]O%#OM$5F>GWO
M9^@V%+W!R&Z)K:U%D*I.J ;LT4O1K.95TH<-HC6<S:;3Y(C7! 0[Y[KJY^LB
MKI4[58F@Z;X#A<A\N\N%M?_EH3-,M$/O-@5@*/.W'GWA""%[V-,U &'.*U8P
MK4&QQX,7C4G:#,!2,P=:>P=Z<99O'O+[GE[HE*+J7GY]A;8MX%6&LW)SW/)G
MJ_KB> ZR#%T;%:'U)D3PL2A5C]LNFCNR@GY]]*MG)3B\*YFX^2.>^PQK0*-:
MUQ2_II2.[C- 3H0;MLERUU<UZA>9'(QH!@IPQJHW%F=^_#@@9V6]0.M"+(\=
MO\)XV= PFZI3>=E1JN*1]%,7[CMUM2:TY 8>)/?JGWL4VR1Z#++XJR7VMHZM
MD?((^\<[U5_9X?Y4*Q9<K[^T3P(!K;<Y;P*GRIM/)4-[4Y7T(O603BKFU8PV
M9_=/%_*DAPV9PBU1].JC(F<N=8:JSZ#<YM?B@V_8#C^1T#K#QBJO([ !X%RE
M*RI3?&^^&?;E=MDGZ:T,B,;#2V@[>6*P[6,CB#M&5IZB>1FLIZQ;6BJ2(K'M
MD$YDS<!REYG16CBRUY9C-Y&I_#NXME#(I+['^1VT;/B%Y2PA.\I/"FFEO7G\
M>ETV*!\_Z8C7@Z1O>^5N3CA.S?+(YSEMT6H(Y?+Y=SW7GZ>=8!MV:5#0;D2Y
M^/)5P3XIHO3D;D."M!QIUU$%:905/$6&2W/C:3F3E4?-;55#BGWYM=$2R]_W
MM5U2E+?@ST<[@C[LN?1E^Z\$Q%%2DX9=.8 =YH:H,0,%'LYXXX&UEH<N6%H#
M6=F9K)*U;_$CV9<89(LVU',JM8=\'V_0[66;6]\Q;8W'&!C/&E+XN76Z%3 =
MKTGJMEV"E]("O8UM9?*-]6VFC6!.QO(4/HD^.8+FQ?.0K@83Y.6/IN5^\F9)
MEU2F-.6*X:S $V.YM>?D^1R]=TG4=B*^OZEPR9NJ.#H6.ODZ5:2N4(<NRIZT
MV31W-L]_2C]+J-,8/1CJ_$"<P,VY9UF\0W="5LA*DBHOSWJ?)-/=->?U'%]V
MWI<7V<_M.&0>^5:N>YX&>9N6F"@1GR04SLTK%'0]AI^,&5)6Z7_4BMI;"6"\
M!??<$V8FW!)M9$<'N(HDZ(D(<!K4L)Q6!UEWR=8[:RVI\C3!![.Y8&]M;=+(
M75)D9?B^AQSJ^"@3N-I3I9%^V[U+P/^4A6"-.462F:P#&%9DBYT3UNS/KER?
M?/>!D[#&U\WN>_CDC(EK <0$2WH# IJJERH4;3#+X74[#XQU"&:KJ'O">69V
ML$)TS #:82)#W<A!J!"&J]Z*4R?J>>?J00_(6$U\K+"AKC9:<S_NLBU1=7=R
MH@P]LK0]TZ<W)K!<5INT<W*>7-5A^\Y[$7"V![GV@:L6WME$NE$;E_<&N27V
M:C."ZG"GZH?<)TKBF@C/UY<^!0%I;?,<*+$/%< K1F@['\&=E:J(=9W#5SL(
M<2/&3?_J.,(1@J_&=D%+JLHS6NA8WG&Y5SH)!D/!S(U7 ?7.VUW"LUQ%. !0
MF(VKH>DA/,0;-&T9C"'/FS96$?U:T'<B&@X<^QDKIL"Q=G,-/%C0Z5HD>\+#
M_.F<X 495BK)@_^!!7VFGOGL.K*39ZJ .YBUZ-+&^L:,F1P%B/V?,A-!V%O0
M[K9EZ/E%$-X;'%.&(9]CY9GI\<QG%GC._[,$0^O=)&3#W!%Y/'A<RYE1+S3]
M6S9%.ZHV#FE72T&F&K9X9>'4UM E+/WCM:NDU^BLIWZP%Q=ZQU_(^@YC*9!B
M+=#;&P;A$8VG)Z*IVJTSRG$OB!LBYQD])]*A;69H%NS'1@X<H(6W<M<Z9[J]
M3FN:PE0N[(K:!0/S82OP8E'W_;9&<O(L4^T^#@!8"> ># E)'.G#WD9PG+0B
MW7R-23L&I!YO:'T!1Z&S+UY"P)V-I&GR94,8%7MG5U[%:)--LN=D*<O[$HNZ
M(PB:YF8Y@DG=9.R@8"[:.._+=T:4&P[P(U17WL6GT/9F[39>1&)IP<ZJ!U\=
MM.51;D;(4:0P%ZOJ1M_(_9##/ON[D*#.U/MCB,%C0F/1-I5OAJ6)"_W669V&
MTDC9V.P";]7RP;WURKA>+'HJ_[)J:P!@]B%-2X^Y3R2G/'8'QI)BY^3I'EA\
M'!GDN1?TEH[8I!.K=-^ZFLEBM]MYPR9VO]7TKFS"$IQ=3W9R2M6<+[R[O^8D
MV;G?U2"^TX=4J:X^3-^&^MYTC)B8Z/A29IAX;ZG$.K)?KLA;PQ!.!':>-#39
MG!@7Y&VQ2[^20(/LO2)QHY8\S^=>>/K8%PA^B<G.!].-5N7=KJKY&3A^=]\_
MQLZYZR4(&MI(;7,^GY<+!Z]TD4\9LBHU75GYO))'L\AL,,E,:5OLDA0#*:GP
MD2>$K'?,U<9%D=PXIO_,LAU2ZHP*4BZOKZX"\\D[6CZ4<W6EK!9\ID=$YCR2
MVCRLEC\%-2#.M\_KMED@QJ@@"BX--:K+*H=7$NG-B&MG[4F&&':= (OC1:<?
MCDMH^@I,MZA$I^7:)K.+"@DY8^)!LXS?KD3(WZQTK8ULI_<1 ,$JTE1&J:8]
M0->:#B:Z^>=NSL.70]9'$ %SNR6?7T[;KGU)?+?P!19.)ED]>T.P^A">?4>'
MJ5OB-<R2)]V;&45A,/#5/9?>%F8'\UR;NDTJ*<A581X51MK:(("@"O IW'3C
M^]%!W#$6OJ(+MI>R57JVSI,ZYSDF\QQ1G/1C#DZ/5SQ551FOF,&G1_[7^!W;
MR)I/:9O%<^UD!:VISL/'8)/'M&85M53Q8E'-1(]J.H?5G)YVKQ HU4;;@.@T
M0FS6Q0HQ0-3-X/1QU]M%]W\VC/+OS+W_=#'&\BFL]#6 US=VVEL9^6E>"%F@
M;RBIX$4T9&R8(%3^*QP&F-SQ]!4I0@B034/>#,QO'2FMJ$H:[LMU/UL'P+[#
M/9N9J2JH?*PIUZR%"R:/SKYP"/ L6SU-50"FY]:O6L2U55".>"7T9Z&_=LK>
M'[([+I(DINI2<JLY0-0<)GI4+9I_K)17.B[F6!H/*-[&T@_RS:C"*H9W7+GL
MP\_[#[L)&JDM'M^&<XB,;#%3\Q^EJ*A4^*O639"=:J?VK(:P/F>"+VE6OXU\
M-:IM0H,NYJWDLX._*FL4_6FS;Q4O.),;."LJRG+71UV#^'W-J(OI^ _[V#Z0
M<Q.IMU0Q.JG-X'JF]?B)P;L4# QJK]3H3I]\?2K,'R^LR6P1>D_=.MT*YD95
M5>4ITZ=^F4[9:>!X:'M%\(O:GI.7;A;$7\>_C8FYH8D[C[)"];YFP+43YN!B
MGA9F,@'H$MTX!TJ9U3,BSGLJ>DK^):_8 \)M_\@B=>FUY&B>.,$*PP>AS9)%
MD:T%/DRW^&:T_1P=5V].1[RH0]4Q=GF6(*#$D!_8?=WJLN&B;]L&3C/*97/+
M.P-":4MG03*EQNQ?4?)=H%1#QQ\V;A//9HV?VTO?84((S=U8/F, "00W<@IC
MF4=E6XCGOQ;HJU]5L?>@"])Q)Y FN\4R_[DV?I(N ,;3@5S05A4S",C\T.^:
M)?>.W!X'B N1Z.FZ6F"">3R^/BRB&//,,FY@6OSCUT#(V?UDQ^/B7OM@.N,?
M"3X>W -:G2Z5239$\>_-&8[6<B%0A/%X2>[V^ '$2T.Q8M--@=4JJ'^1P0<'
MJ(=R*^N(_=PECI#J-*#*SH/DM&G<BF[UT6+SUZS45\'N/29Q C"-[8C5JE:E
MY]#3+O.]U^9ZHKCH%;*\BB[/--2;GY^?-#4PFE3^HFK+>\=2:WVU\_8U9G.=
MKLZ&1TK23M9T[5J&DD6]#;78)<.]<L8Y$J^WP]')T2.OU>XUUL5C&3 B%4@*
M,?9'= A]8UB!(+U2-PU[G3*B1/;!U,9I;8%1O\PO!P\5RHI'Q*O)WODY0$'9
MX_ L;]V;VJAKTP$-QT4-Y6U$HD+/KLV;D];><' ^[E )6YM-4-:(K(U4R_A9
M+[!,J$[)-]QVO2.[OV G=7KS62W3W&T:#-BMU#K'PBKE6('Q_X>]K"V$,A]P
M,I]C\#QL:--4R0 'Z*H [I&NFO@*+07!CZ20:12-IGE\%)HF^IO_$=]?^Y=O
M&HCF8)(%VA?.3X>;CHS&QG79TPX<FLBAVPO*^)$XZ^J;RC?2G OT,!&@L[=P
M %$\3;CZEZVE%>9R)._@OAG> @+17F,:(TGY,6--]6AJJCEN_&=X:0=-:^[1
MU<(AA2__+$@WV5MC3*0;SW]E6!3&#)6,E:U94M^&&U<%P*]\I,T/\T@)_KJJ
M*\-4AGF.2.%H=3,%CXO<$KYP<@M*056?7QE-RX;\$F-Z[ 6DN8$*'U0G[NZ<
M"Z@W7&_=;\^Q9X$!0,5!7M1AC3Q6,+JR@EHK)5=;>PZNALB!1<\CRJ;2JJ*-
M=[L"&0JV4!1A2VU\P'I#[?A[RR$+]FE=@5C6R&H%H[27H*!/&*6E.5.5V]]-
MIV>GIG+#LNMP@'R PZTM\1*)R_1"<O4A:2![DKF=7=:$K=X+1[K>LT5!P*60
M_TNTYX1!?(2WI5>!?DL&^*X!6]UF7--C80C;NX5.S-&&8(CO '_:8VJI5ZN6
MWS?2R.MY$%+'92.5,U(%50.3.LC^B+JGG= [:>UI=[TE%L\R@O3'^=ZSQ[Q[
M&(5UDG%X[+AOPK,X1V" 6@BL)[:G#@K\:ID]VP4YKQ]Y8*TC=)!1 A1KY"E!
M2]C>@"%(&;<D8^[U%Q";J&A9:.B_EC/E?7U$TW.:PZT1/G=R:S2FL"XU)V=+
MM+8R1LQ-]]Z<P:^ZS$1VHD*9IY1OTLM*82-%<?/C-+N+1K$1(G<R.3@^[MG8
MK/@J//DKK41+E7W 6(WOZ6XF>#+3*C.YY%>^XQ?2QNN&_Q"1X%YH(3VC\<:O
M'J9_55/6YOWNSXU3X@#^ O%KML_1I=A:)I@<A6Z@U]-_;>/<Q/'B*;2';Q0'
M6 C% >3Y/&4\NG:OXP"LL%<X@*_ )4UE(S/ZY[&\2%.0P/._OF'C@%*[B;V;
M GTR<<P#)]X"49UX)ON!0[UF++YD'O$&Z+DR1M@PFBZ=U#D[%LA9%NC_2"D(
MN'@#?V\@=]\L[.TCA@O_D"-E'E-KONX5A60E9.R$*NIZ,G5WU):L1MBWGH-6
M@,1Z,J)XVY2D6$2\THSRR*%A-4PTMY]6BA;X^;#[I'@K1*8PH(?\%RO:N'#[
MX9Z/I4Y%-'*:+?G&^%P4Y95KY5?;HQT-5)#C9N8(*6A55PKHA:L]+W;?BB#5
M8]-XE\)+_V9Y\*ID6LOE<RT4J_N!R:02A7N4,6O93)W1PUP< %14!_"E+/!"
M'FK7JM_3#[W0S+%Q)W1E,K,7%>MF):^[YKAIXB_'-/YT!^%1G(F$ZU73_4BP
MSY]F]\^;)0S]%#V;,+A"I?VZ^?4NX],.0QP@P.RA-=/#,I51S;SYHE^6?< Z
M#>U=Z<-3<#8J+?CF)VG!7/"-N6)L#Q,.\,#0VO=),S#<<<*46J BB5'+5KWM
MQS384+C)C[.X/=7E?8N#VE#E1QD)IN,L8R6^6S;W/%/B0[TE&SF1_7LQ[PX,
M("=9WRW-_>[ %I^4R")Q@.:SHQ3[MM-3NGPCGXA'YQ_T'.SM=(*5E. TL_+<
M[0M4QQMV]D6&K5;\?+8W,IJW6.RGNN'&:=#(NC"OD:SQ?=D'Z)D+N@FM^B&7
M;=O']&>RG2ULL:NK\IBW !G)1$>=^T5>#\1N2QUSU*)-<U_$N5-)!M0N3(/)
M;1R3/G_K!*G=N4O#L-QH,XBV=IKFAUF<#M&Z,KZTH1\7^G06&[(,W)F@1W&T
M4Z>2H=2BLN? Y^N3F</LJ4H[Y-[#BB4!EG>J%]VE/4?/2X*/K^1 6,$&JWLI
M)S,2V=5I:M?J(R@H$(^<6QBNA(T=]&?MJ2XF@63HNU+OV=-;/]J,=++=273Q
MRM8\5*%+WKE9I291S-$!O2,?9%NT14<4G6^\V6\KDC#'H]P6\UH)SA2;\AT2
MU,'$68U<#SR6VFY@]PKUV.>H#;ZF2_ZLZ'/+\LH;"?&U6B"%3TYS5^LI:9Z)
MC=ZH7&&TD3C_4$]48#-MYTV.Q)CL&YE.:;P3(F&KZ'<(@;MZA"GJ!G[3&.L^
M2YOWBU:M!'Z=3_2BU1XYAOBKHYG=[6WS@^I^5D5?[.  ;"GEK#;FKY56@UF7
MQQO\0N SZNF^O3+J_..-E&#J@RVJJMK*+#K5XU%=)Y:9\I>TC@>!<V$,GCI%
MZDL#,$FTWS1<%U95-MJKG--K+\( N!--?UV1V>#(D]NG, B/4:H$I/S6\(R&
M;MU/F%?/[IK@U$R9?*I^SV(IAVQ-<:0FVE'D*)7%S#/X,C^*>TWHHN';-ER&
MIS8C"&0[2RF>.7 ,#3AU+Y\W-K01?.H"O_:3^G-90:?@(=$!L4836B5_>VC+
MG:XJYYTCU%58J#//YL4M#7-KK2ENWYJ25QD!($699/U?:)8V,K3=]**Z;?:,
MBM!5^02"%SE,==^BP3\R0OIA'&X&(-!_ 6LMM?Q9(0!HE<":X%UG2K%Y[S.;
M#-W:5)J3STLG/^"<R)#ND-S\/7 9IA!"!DK^NH<#_,*OTV]^(\W=8_5\[PJW
MZ4 Y#@RSF\7P&^/-?40,$<<E<L+3DZI&Z[K-B6\42NZ3[8X'BYD"\W?/?,0+
M=YV71(.+]38=XNK*:D;N*EC[O',8,GI1W4D0T?3<.(52V<G@![]>8]!=V;L;
M<#-;6V?'7%-IZM*%RXR]W=785?6ZN#>0$P;0*)9HI%CZI2NBC.W"@)Z#>X6G
M4\V#*7,<9I4^H.[&4&I,M$]J!9JG'2H2[I-IG9ZZRG[X-=+9:.*S+)FUY%J-
M:.GU^9R,+;$[9 A;=M1N?S.C6( XT*1R1E-)36GND:.J?D:@?_HTVED9-E(8
M.SY]]]E9-+5YM!);,&NTDH2(;PBW86-AT=]VB?^,:+UZ&8>2+GND_43_V\G5
ME L1.==<:U]6%%&7Z'151K]US#MV5OJGZQ.I8"(%Y-M+H) -W5CPSNC?(EW_
M$O'Z,S9U'372=NK+CM9!$/+<F')?H3674B'3WFLF^#H,^SY<0'612==3ZZ12
MVJ>I-T\T8882"#B:DZ>>9__HOO*ZX&/@-;?[_AWO)VK'4A(0'*X.?V8)]*$4
M@I90('^/;",E5HW97!"DM/JU?Z=O;&@)1K04=56MW-A(GJW4D*#<_E8Q Y."
M4<AV;OZK&+>WU3DU?;/>P/+J41'"<D=QKWYQZ^),.TJ)LR!&CW,='AP@T&9"
MTF<OMG#!*C$V.V.*OL",_@PE\/2A9%FRZTU:RNDA5365W!K-WJ?(DX4+FR[M
MNJ;:4;NB0I.6\(%A=ET)B_=7X",$TPG?O<4J!IGEN3P<G82S$Z5<X^VN*F$X
M #[S8Q.:"M)UD;$,\!#,W536^K)1ODKZ(GI0V>R#AO)I0[ K2/>ZOGHZY=<"
M"(=&4U);G+N8,YCJ)+[)MK:A_BV(3:$W7?O*Z G#F[I>SE?1Y"%F<A3:5'^^
M#<<%*N"*!O#X#(P#9 XW1N-G=*05=):YM]$"';L&UO6E1_:GS_GDVVB*#F97
M==#;NXEOB!/('A_-*JVVAUX.7G<P=PFC+MEP?WWZ]8CYG](&_E6/YM^;/D"/
M>K64$MDA0)0BNN;!*_ ZUJY0A 8X/C4K,!OEFW)K[S;C=MN>MQF".7!EROOY
MH#W?L$"LMT+6=(]KSFSNQNYJH!7-J2[-@(.C'.76:QL)54TO8-O@86G,L'\^
M[ 77Q5.,N&,:^J5+A<S8ZK3"HKSU G(02 +<<!X&(N]KROD(C'&=6@Y<6OA\
M@;8]P8CC .EP1;P)_ZB $29MBSQG.(K$W*+05,!?97[^Z^(^'A0?T8XXP//4
M*!S@X]5(M!5S$/.1Q"8S^BYG1F3^J[VV;:$=?RS=S:6N2Q)/!>RU.\"E[[X,
MT,'U+.CBDXP0V3SU.M)">!GI/][XQT-#.,^S97=DRV6[__'>S']\*&?F5LS%
MS_\V ^(JNGB"D>%XS\11V1AS.?D^=H_5?(.2(MKJ7QX8.B[+@++LG*(:<JG;
MOP41C#S7V<NF#3PY!M90F'I0G%JT=#TUE;=*%(D/<DE2%5+[R/>^R/S>\SM$
MUS4'->6\4[D+<V35/I][RW"V2O>YF62$\'S>_E?KV>0UMG0^W ^[ZS4D!_ ^
M1>P',CU$FQ>;;)O<&6F">8MY/4@];?OY4VEW!>BI\CZ9X51-:+JF$WV\6"=V
MX&JK;$HR3\($-ZB(&]:6_23Y\8R,,Z/Q*P!;D9@WDK=HKM56L33J_H_ ^QV3
M>(1?:J6Y>:3II[UE_D<8XP#$!,AE;) ,"PYP%6]&CY5])GW^#9 V.TXX>?K[
MS;\]5XY9.V<N:-QRZN;_9E 4/O@Q,?_/D"RG;D&M!(( T.[U+!Q@\4EVZ#)3
M&D+T0LSOJ%^EL];?(>_'M"+?Z,ECM45Y_P6.33G*6"-IKE?.!I/CL=;:B?Y;
MGI:M I\2 X/RU1%P:M7KZR'%(WV*M@>O1Q X0*KFU]%SF+-)I1SE 26W<F%-
MEH^JI&,.DUX A:8^W;_9N\)-_7]02P,$%     @ %CB,5P0A0W\O=   KI(
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M4BN]WD('V"G,<Y8T7EB:4(QBQ 4-"((DOG;VB3/ ]$W6H*/W3$Z6NL+%Q]0
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M?V>$"7%>&.94?1(G43CBKC]=3,.VK]T_)UNTT8^ +GI9)S0%@:S)H:QQ'^D
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MY>%/Y3O%2TN4*0H9M-F=K&^8.32TY2 ]^HDR]GRZI54UP^*%"@^%MW;X4G\
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MG2NY8,>JXKO+D2"1A@3X6@ \OHJ<4,>;X6A)@!N(!CB6B6S5E9A.U, BJ20
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M+WOC)T.7Q) A,LX)!;@9HS*(]S9RA]F,P=V)!_I6S_CE?<#6QD%1SD#6CJ\
MF<2_=%?/5(8\AL/Q#!ID>+9@1*"[2]9C6B19H_)]M;<",9,60T^^?L4$#0\O
M;I5(67\M$VSK@ZU7(V@@,$Y<\,(KB*,07W3/H6Y<@Q!40LRS<?B'TV<5#2ME
MPS,0=A+@_)IY<%B971\)8"\D?&A^HH" 4CQ_NJAHH,+ MJC+^I7G]4-^.GD9
MG2_W*X!69%L+7I2\U7'3SP@RZ46T,T9PP!W&1;*^:=KI^GW24>.!6-NJWY2B
M(.X,6561O=O$PL)TO'/,M'<)=H(O4</#X<7)XQ]16].H]>JBI=XA0R\\KR]=
M<'R+FP4'C9G?($5<>;4JPH6&Z4-R3/&Y)[>UK8WK>3#$L 4Z6N->I."A3')U
M5J:??%W8NQ\J3UV^1G?>UR]NI9+3?W]5LO#J)%[@:Z:A@\/CF>%#>1:R.-H3
MC\4\AK5J<CBD@J[/.3F-PZR#UCA]<K((Z7 'M@"K4?48RR%#XOI=03(TMYNP
MZ;,3I(L-O\"^U^+SB+4G*<L;J-V_*3(@.Z6UUS/$"_U^GY5=)?Q>KUN;,V38
MR1\R2R #V"8,'.+@-"+S^"#?M-D9J/FQXU#/Z-F>0D!O#<UXP)IZK-26N@B\
M1&HX&;6T81;PY2MQ %[ZXCAS.CF5:XAV*VT[E3M[@D[0FBO:JDV\M^/$ >\4
MJJ**J5U?5X_"LEF>(P'*'P]:X X;)@I'\AT]Y*^::8LG?\L\J!TP^S1P/9*I
M:KQFZ<AS^W3]BQ'3_C*_P2?48PF(=MHA7JV9@=)TE?"=;C61$X_+AH7&_N)F
M1XA2!%59UPX]7A!=E)^KY5Q&TRW#LO(I1V^[\[P4X!2.>E/@)8[L&'FT&X#8
M\V3 U4?I=7!$,(A5NS&%@*I-7W8I(</8$C&YWGEP:Q)=,$P:;13L[.F3RE5M
M3R-Z$G@5W!T:V5-WIUZ04(*GX<S'+,S)=SE*ZM1G^\?9=7+Y4!=EN_GM@>T?
MI)H_# IC CC+:WJ.9I[3RY3:'D1-N^GF2@_ELC@E5OQ4".4OXB[X=] I+I!(
M;?3%T;0;^3H"D3T%]G'K1FWVE2;!+'%43.@V/!>1F^R*SY(![$L].$;\Y+VR
M7Z7YB+&I>G30UK(W+KE<*C0B/;;HUSD$C73SH&. (P)'R?<'.?K'JAXD@',O
M,0!9NT1L#=Y#5>*E28 WP&;X/F 8A*;6_D68[N/)'. >K3X) ,@@ >8AAZRA
MH H[$D!A=!HXUD?T.@0&@]"!N$CB2]9LXBFUOS#%<Z!W),#JJ3SX+","KPE;
MT%7%;I( *Q,G32>LP![B IH,3C1K!HKDPB;5-I=;=X3G>=\7;[R^Q<\5M^X]
M^UHBT<'XNDJ@X ]?@, Z L=?JPUJ"U#@C\J(W1^+O7S6),2)C"TLQT]8B6UJ
ML^^@_M %,^7X9GK^Z#:MCS9.'_=M.1:)CS<U1(/DQ"#=CEC5>':*['>Q5S<K
M;&;&)K&*87/#F17AM1:.T;BX%W00!Z[V$OV?9,6$JQ]OAPK,;8RF7G?.5,W%
M,MHWOF'D*B5K2%7WZ[\%^^&0V'9"KK\?&CROF?I^+JQ+UH]%,,[3+$PYMH)A
M'=( FIM%786O\F7!9ZMEL/9+QJ%#PP_+[%;($[B;MVQP4[/1J!JDOXKLHL-Y
MB[0"C\^O(7#"$9%__Z6<V-)\"(;CSXAL.8'L#N$-_^+ZR$US;8]#LE>F^]OU
M:RQ*N8: W*M<A\@NX'^AXCVZS0YT<:U(D;='+4.60ECASZ1NQ?[^3^::R4=O
M8CX$W%:1-;*>A9_"^<TAWQ;*R<]!.0<5^Z&G+HV;J-"+]_*<1/OP[/J-+GOA
MY:XLT!$H]GOQ5U15__0%*\Q7_8M[4&'+@=].4+.(W'VCI>#_NZY?'FU$3<;,
M(\,4>+Q=5(;$.:0W79#S%0EZ#4RA=P'/_8S6A'PJ"S@><>OF0OTX<$X&HFJ5
M+\B*4AGQ]=][>?2_7<[L[A"IKY$ ?!?@FPQD'O)%#2PZ.HA Z](=29&1T9,D
M%P*U^E$$2OT["5 ]N*_ZW1HTS;?^ L:$%EH)*Q /JX'4L+T8%'I6$RV;T-AQ
M*RWNNAB+X//L<BJW6\08=..>)?KG1%%"[MKAWG?]GL&G#@K]K#50/;=7=/*!
M#%M:..B\Q9DFH0*U@K9<#:&I\!%=FLN<P_2M[285EP>YP@V78S$T33 .=%!*
M7*Q+7D->FUN\UQV99JOJ9_YIQ3VSGSW/%#I(&VCF%#4KBFTFAXM<\1<;DKN2
MW083E^50O^;FY,RF[7.^K)(FAF%;N:/UN9%;,COG+09T?NM@ACZ09H.>IZ..
M1R+ZTD:%Y_TV;H?>@7)_#PS-@^%]DQ=;U)W8:8$I_1/3S>D2>A[JSIPD[2FV
MF9C>ZV5(!>D;+3^C!26[&*;&S'U@7FS0.0.!\,-;#_>[U6.='V>ENV9ZY7YO
MFZ6C[_[<6Y@5E",1==9_<LYY6OW)0AS9_QJF!#>]K48_@MVH'!4[.<>;"O$6
MX@U=6HY-/V=V5LJ$$89QK0KV/7!A\^YJJB;;V1-$\89A^<0;+ D@7SXUV'[A
M!!_3"V!(?C59Z+.=A*%O!09AB2QQ>^;?4FEJDF(XWN255UQ7?D<9JW':=2FU
M;4?OO7J,45D9GCI6YKEGW3Y>R1S'5N3M1C0+4-QM/,<]&*,O^33#/ERS@NOI
M><&:5A603#LFOJE_CH--;6AA=+_;<5)_3R[J6?SERO,OC0OZ53RCGY]KYP&J
M[Z#F AQ,(U*0:Q-%,1ZN#@&,HJ:USFD:SYG%/[H/W8Y\M6$.;@$QV2N(#,W7
M]L?KO^)6?BVK,1RN2G'K=DZ2&MY]E*=?ZW%R="+C\ WFV>?[NLJ>R<%;=-^!
M1]=A9$_^51-%?"F *CHS2X>/ E' QWC)C/L>T\SH4ADJ1,00]EX#Y[JOV@T3
M0_-M20;,%VHM-($OX\6S[?6TNNT@[O;O>717@JR@;'Q$"EA9& E O8(EN^BT
MW#D0_DPD"? A?WU=(-.:)[:*[+9>IJ?,Z7NMQ!,I>B.-L,]Q._,[[^II1_$!
M"RZTD#A+($JC+&+J@A[E!1K*\TXO8R+GQ;%,C(;BQ?1(YV>Q-0)L>NFLDDO0
MF9I?!.#'?RM[S2<U%TW7E$@F,OP*U];;/6C5!X:AFUN9NDOWR%NOX-!%6WV_
MDS__XY* Q:9ZZ/O-"K(Y^/SY[W?R'HA(#2(!;F1KD>?.$2YSI%#_E4S4R:)V
M. RB-ED1/?7:R $R"#LTA04W6*.F[=;)'?M2G=/]G_?I_KZ<FO;_A]#X%M3+
MF5T3_!42X*DQ:%\47!J+&=_!7%L-,-3&2Q^3B0_X=L _:^_?*/X;)^:PP>KL
MS64BLX6D2MDPJIRR/V;K3HD/S"@V_(D[XC;Q<1GK7:2X5NIF9Z%Q?V"N?-3^
M8Z8CLF+026)4">>KP41*-2*3"%ZNHF7:*AO/=0S#LM"L=$0K)$$&B>UD'BTR
M'PDZT:;%SP2"%%>1O3?(,_0)5]@4B]9*5@S8-%?;)<!,[?!R,\TDP#[O&AS'
MQ(?3)42%D0DD%3:5[0AU%O9.%YQ" J#WX QDP)>423;M!H@YK4@BM<U\;K(@
MC'K0(M*FZ@-B216K(G($9P1.>+LLXUF..91AO@C<37!8ZR:.];O3$@HN @3'
MI8'0^MJ,[ZO0EI\DW4 #SU;VTT^XK^!1H71;<I)[L L$NC24/)A(_7@>]UUH
M%D)),<L@EP[";8G!&S1J36U$(RD<6N_C@?8QH+@)4(DKO+-^G]RA,PD0R';B
MBF?$K$0J2*;H-]4S#(NG@$XDSM4/.CA;2+[U#X]8X-Y#(D!SGQ0$28!^A5$4
MFC9_]<&OV? NT9ST9\B6F*D+"[FH@!(*<#D1QUO5XA;0$T#Z&0?TVK?:G<NO
MJ80_WVQU@XQX)]N>?F.PEB\D*=<2W+@ D3Q?4^<)$OU3P[_.8WB"(Y/S!R>6
M9#0@@1QG%8@_<:O8%6E>([9EXG_@G7^[(IW($CC?2V#8\B/CF@G4,_OTOUP.
M*EZ#WP6QH?Y%Z_S$GX7X, S=IB_X1V_K#LZ6+@RTKUVV@S_C^&>)L2IDN"D
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M7I$B[6"*#K!0];)P"I"Y.9P09&G^%AUH\J #3GH4+?5Y-@K%&462IP/KRW3
M@C@S1:8#LVQ'PZET('"3\0ID=C\\%40@S,2"=H@?&?>JZ4!Y-DU<E!A*0ZI
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MS6._4Z:<_&USDG\FUE[>[)!ZNZU_E.:F,'N#*F.6S":TKU*Y)6=S:VG"#_(
M]1@:+8T?:>+A7N/K6G2]J[//20?@X,MRZI03[AXD@8 -I#>J29T!@O:( VN"
MSF23NVH^<LSQ,VIA\?R.#!T( *,V,I"QS&D4)]5F*E3XFIM3X2YJ&#VY?=]I
MY-G=](!B4"&M1)[?Q.[&)NM_T)W_B2%%23B:'L\IU*C!&AW04T7^ALWA8NC
M[V=$-FI8"6[7&S;U#$N\=*0X1-F*A43J#=,BC )1Z^9T0%IC%G.TQDB@.0,C
MKV YM![XJ0IL.$HD2!V?X=%+ZQJ<=DQ?[S],#.K[RJ6@ZV\_W3 ARGZO>3C,
M?"*&@G[9:*Q"],F3?I2#P2,[N=]4;F]1M)SF% ]\Z0!%D(>FD$035R*DDAL8
M6-7D1P><X DH1P?4TL^&^7W<1A ;A8:>#M;3"6(P+QXADB%UYA1JMNY_+$S]
MAVIZ^X[JM*"N39[_%^H(_[LZ6&N2+'&K!2*^6VQH0JAI.#,>W%B5OO&+9N8A
M(_3@T>\'OU2?_97&NU1DE#N5[:H1S\<+<3+(2EI'ZV=%R[W:-6:>7PK/)6*;
M4"++56M?\5OZ-9:1GU]RRE :L6V[[IT\=V+Q.+^WCT!K\(29RHXF473(C*#J
MB;EJV;FIAWH- PO,OSDZ%'E*=?_J.#!((Y<(MNGR98I 8854: ^IFEU6-_.2
MICQH&9'!Z$X.L.P:[GB]QV,\BL>@P/\IASY+?9LW;_OR>Y3/K/?0J1,K]\,%
MCE@-/(L$V8L^(3V,<PJ,C+F[G_0.;X6"JC MO3%J^[]&1&*19XC,<_ [PSF\
M$4_QLL8"'7FZ^]A@?=-[,%VNV*O"QC?$/XS,B<H\K2?#?&>A\6 (R=$D2!4_
M!36JOI7@LB3L3LLT6T 9D()@G.U&72<U_2$[8#K UI84;=)VD^9&P<VAQ^\,
MC"SVAC!4=\ZT5C^+)PE]:R!([S0FS=G/ZJ?>T-,[=*!1)W I!#*;Q<C"%+TR
M>:^39LW5++.50R#G,%0C_@=E"-8-^Z&TJY[GNX"E@!J/ZL&H5+R*N08\$T.
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M] <7(1]<S.)$//-.)E9/>LX(4IC8VD 1=E*$BEF>#4WI"'5(DX*R*)*;GR9
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MXB(7SF]BE?Z_6+SIK;L]]LBG#61R5==51ZQ.3<]JF;6+B5+%C3\0W-K6)NC
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M'FU(XX]G@\L_VEX,__S3KR?V756-Q]8I#0OM[VN3L&C0:"_^U-?MT)7CE^E
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M)0T$!/WJ6)PT"=TGZ5AKMFP'TB);5$@*%\MKHO'3NA%X0:L+"0B95:_/VDW
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M"UX@ZCRA=_0CGK;UY^ ?9/@^CCR#HC#_YZWMKT+O)8E19^IH)U"%M:B#!CI
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M+E6K)6=T0YK&)@&B'F]X17I,!@4ID&Q48 &HR"2SH?DFVUN6'I4&)S8_-NB
M5[.^?8K><5NLF318*#"9*!O<UKZC9O2RN<'5)YG\#:7T\?ENGHF.OUX%?]Q
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M,;) 9L#+/[N&_[?]?]K8Z&/_!U!+ P04    "  6.(Q7PP23,^9:   @I0
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M]B85@GMC>]:B197M;.]-!&CQD;XTN:JA_BC92CZ&]]?38G6B%/]:5Q)Z)F7
MM8P]!GI1,.V'*TGDA3/(MJ!WC/%$P&L%)\41O5X%BNSIP)6BPPKC(M1.C;[-
MRKM?GBS=%'Z,=N(43:&\=-MH='!\T2T/OTP$8@8CQEOOU6#&37 -I:@!_S5Z
MCBU9L$4^)\7&F.4][>]!WM]1)$>9"2[I(><70_#^,YWJA!%-_HVFQ\B\C80
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MY^89?-C.AIK<Q-Z#*VW=%.\,B[LADLF<^P2I)"JS\PY0_;1HXMD1:K9 9B#
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M=MO5$/-$"D^-C515+>ZE^L]OKYO^)I2)(\:3&A4<E2OG)LT^V4L-UWD)W$(
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M+M2;B$V ; <E_=V?.6*BD+U=Y50+E!0\1^"QU]9'%&*R;$Q(;]AQ^/"&N-1
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MC6;B^?@@A&5H+!!JPE*\T2X]?EHNEI^Z<TPP.DZM3E.U[0VY:OCSR6ZAO#J
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M\SW*<($J4(W!8AQ-<4 'L'K@LN^R+/Z&.*WYJ DP9UBQ[$I6\(!/E!F1MW*
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M'#%G/;T[\+?F>=OOU$87\@.*>;+CK/4?NUD=N\+T_FH9A>702K9Q?M']"7%
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M,JN'2N@A^4KL=9F0M9[5^GUCNHIVAE.I6$AXY;4$C.>TFG0PLH<OFJ!5J]<
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M)AC&8]N#8*@Z9X;FEJUIT[\N&^*S?P%02P,$%     @ %CB,5Y<>T=^I!
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M;1BV8I#]KQA$LE254)G0NU>Q VM@.+I-JU^5*;R+$POC=Y+7 FL"QI8^'9A
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MLI_Z_M]V4>C97NOF]BU:!?G_9^:;9DJF[&S#W)>AE'JD0<\SU]I;_T_XM1U
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MYS/,D"2YD J)"1J.QWUT KXNP^B(QS;:TF2OOLV$ZIZ2*2T4N%15?M]&$\K
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M3=T$(F"1G-,"*OM9](7$*^X9Q:4FRYVQ6C:0V-_EN>FJ0(]P_'4JQ8PG^M&
MD,$R2:UUPUZ=J(H+'S3&*"=6]7V9UM:[<*N1>A/N>GMOCJ?$*LL0/%%$!OA<
MT*2RT4[']G=6&74YYIJ.X+)MV/0A[_\'4$L#!!0    ( !8XC%>7\*2V P8
M /</   6    =&UB+3(P,C,P.3,P>&5X-&0R+FAT;<57_6_;-A#]5[@475O
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MT#K<=APVO;;[;$LC[;.*6<EG.]0(1HI.%('JM*;60NR(&Z;G[$O*"]+[WEQ
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M8O8\M2Y^<[!C#'5DFLD9\)N+UK(V)O_8H5JUC\8(;4RNI[I@3[(BI$1A=U>
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M %!+ 0(4 Q0    ( !8XC%?S8?7@L1(  (#'   0              "  0
M  !T;6(M,C R,S Y,S N>'-D4$L! A0#%     @ %CB,5ZH6W^!"#   $Z
M !0              ( !WQ(  '1M8BTR,#(S,#DS,%]C86PN>&UL4$L! A0#
M%     @ %CB,5Y=Z:<*O*P  <: " !0              ( !4Q\  '1M8BTR
M,#(S,#DS,%]D968N>&UL4$L! A0#%     @ %CB,5YS<FM+M7P  1RD& !0
M             ( !-$L  '1M8BTR,#(S,#DS,%]L86(N>&UL4$L! A0#%
M  @ %CB,5T)X-H.'0P  M+@$ !0              ( !4ZL  '1M8BTR,#(S
M,#DS,%]P<F4N>&UL4$L! A0#%     @ %CB,5PET]YOP00, 3:0= !0
M         ( !#.\  '1M8BTR,#(S,#DS,'@Q,&LN:'1M4$L! A0#%     @
M%CB,5ZE6]N$K?0  EJ8  !<              ( !+C$$ '1M8BTR,#(S,#DS
M,'@Q,&LP,#(N:G!G4$L! A0#%     @ %CB,5P0A0W\O=   KI(  !<
M         ( !CJX$ '1M8BTR,#(S,#DS,'@Q,&LP,#,N:G!G4$L! A0#%
M  @ %CB,5X?^F7>(.P  4T,  !<              ( !\B(% '1M8BTR,#(S
M,#DS,'@Q,&LP,#0N:G!G4$L! A0#%     @ %CB,5\,$DS/F6@  (*4  !<
M             ( !KUX% '1M8BTR,#(S,#DS,'@Q,&LP,#4N:G!G4$L! A0#
M%     @ %CB,5[/L@X3]"0  [UL  !<              ( !RKD% '1M8BTR
M,#(S,#DS,'AE>#$P9#,N:'1M4$L! A0#%     @ %CB,5YTBOB+Z P  YA\
M !<              ( !_,,% '1M8BTR,#(S,#DS,'AE>#(Q9#$N:'1M4$L!
M A0#%     @ %CB,5Y<>T=^I!   \Q4  !<              ( !*\@% '1M
M8BTR,#(S,#DS,'AE>#(S9#$N:'1M4$L! A0#%     @ %CB,5PO[>^8+"
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9:'1M4$L%!@     2 !( P00  (T$!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
